<SEC-DOCUMENT>0001628280-22-021759.txt : 20220809
<SEC-HEADER>0001628280-22-021759.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809082106
ACCESSION NUMBER:		0001628280-22-021759
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		221146530

	BUSINESS ADDRESS:	
		STREET 1:		1460 BROADWAY
		STREET 2:		SUITE 15044
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		1460 BROADWAY
		STREET 2:		SUITE 15044
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ovid-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:8739d977-ca53-4263-89b1-d9c54849b06c,g:ab39b854-7f58-4138-956d-843b33846298,d:ffb89c91b68044fe89584fa1aa2f8679--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ovid="http://www.ovidrx.com/20220630" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ovid-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF8yLTEtMS0xLTExMQ_85300148-d2f3-417c-85ce-d8b242900ab8">0001636651</ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF8zLTEtMS0xLTExMQ_682efd7d-5101-4e74-a583-7a8b039bf0e8">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF80LTEtMS0xLTExMQ_43205079-8815-4bc8-895f-52fc4730bd24">2022</ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF81LTEtMS0xLTExMQ_0a7bedd9-f182-43cb-91b9-c9399944c017">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF82LTEtMS0xLTExMQ_1c9faf1d-f47d-4a74-a146-19bc6c40124c">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ovid-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if943073443f547b19aee7c55893e79e2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc605709f3a40779864f2d39fb359e4_I20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5514b03ea99548678298804a7de4efdb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i18f3cae6721f43a693142c5e9c86f229_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cef6b081bc54d82a49f3c118a7c65e8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f78e6e5ddd4d44a2471e1fd844f7b4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e89cb3e1f0040f7be63e6cd7f47cf4d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05147c8a6f84aa7bae4e655d515586d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430e4630f3014c55bfe38535a0b3c699_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434929d63dcb494293b5e8e5efadb4c3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99beb7807f764390a9af1caa039963dc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941a78f2412c464899f42108f91b4f35_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad7480407a3f4c48928d4ccbe1dd5c10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d307e57dbc40ff93c2b5995aeba167_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8760fd385cca4d73b7b31af558f982ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0310bbd84f804abea3269f6c899e1a78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fab542d4f974a00912a7939cf326eb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c62b7cade354d0388144a8b711b4722_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31de4bccf32942219f29ef0e07207b80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f72e97f2a064f1c90998ceed128f870_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d18fe72233749f28cfd64f0d70907ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf2fd110a9a4c5ab75eea6d9c720226_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8260726b54e04ea1ad6d0ca24421b805_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56157218fe549b2b3302bac54442c1b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic488d6492f0a4affa4b6e168bc0497a8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e3e29443fb640e1ac31ec6b44140e14_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1269bd94e5ad48d198e0186fcb7d2e2b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9abf6069224ad1b07f06bfe5e710f4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6554df655cdb468099698d2e5466ee5d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e677a4abbe94743a6e30d84324ce7f7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cfbc34d3a114e34912c01fb42a6e923_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0999ec79eeb14fdfb352298d2cb61f83_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb2c95532874480bb6ff7d1bfc14723_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0aab07b1f2e4699bfef8151c47b8a0d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45904026876d4027b04a7d7c2108f617_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8366cf4b4e584ca1933dcff24730eee2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799e74a1e807418187738a7890f11901_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296138c6708441f693c8a9280889de40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336ccea71ae9453b969559eea3a1e540_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0c0dfa04e4b4f4898016afa3ab78e19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658dc49bdacc4997a02fdffb11586100_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c476d2dc2b4b06b06ce5c44e0b513d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab306a7297d4fb1a87a32f3962e910b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd60c60db2c42138469dff255b2cb5c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6c40a93ca044369ee51636d6e0cec8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica40e02a37a64756b88e97b575b776e7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i835c3a4e2d324395a70abe30b2d458bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae07d73b4dae4632a39cea16a19f66e1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44748b4c9e84136a2dba9fcf256ff76_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d44e580ba3462ca1cde50a64e4926c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5c89ad10f2477f8220874a9b49e705_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d00e69252de424aaf5e53c938c8b70d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ef3d8eca944ac4bf14a1496778579c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i681a4f60e7b446d18f13235cf1ab4515_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77147210c23641b5a8af1144e5fa6e04_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1104e8485b1942128c40c3a1a39b0b69_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7ddc6b88a248569b3b27c0b1e3efde_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0fee23ec5d486db1a16b33b9f1ad15_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb5c5087a7345cea587ac586d74b78e_D20140401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd69d41d3fa3410981127bf2969db96f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a67b91f0f784fb39b30c84c6e1e1667_I20220317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ovid:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a543a156421421492ae9ac7e6fdd405_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ovid:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2c1e78e1146d41af95d207583e74eb8f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf80654a79be4240b9b2f9216351b6d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d5fb933c1c4101afc9b43949132d1c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id062c33120f64e1e86eb963d29a355d4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09fdc4f878d749a2a0c510248458b0c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b464c3358e49f08d0e076378fff060_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91752729f23489a9a1fdf7618bd851d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5cc0fd641241a9a8645ff092db348c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0daa1be00e7421584b963e7641737bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa62a7ee26a34283b02d9a020bb48d54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240d93a2ab414f6d8279a85350aa8834_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ovid:Investment</xbrli:measure></xbrli:unit><xbrli:context id="i247b2b8238374cad8df96951a6bae08d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f82c24689c54b7687abc86742065cc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fce33f178a14e88b1785363753aaa5b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87adc2ffe0ba416eb4da45a8b61856c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57c6dc3481c441408bca8588e4b4cd13_I20220310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8a54288182e24aa280eacf76b58680fb_D20220310-20220310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-10</xbrli:startDate><xbrli:endDate>2022-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c97d8b7325e4ee5bfb436d1850897fe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>ovid:vote</xbrli:measure></xbrli:unit><xbrli:context id="i396fded5753344dc9202659aa58b987f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1edfe140f8c433fb25ab41d64b939f4_D20201101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bcc14f90fb4eaba2e1ef18f0fd5335_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide285b55b9334ea5a3d4633e081e2e8b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e9dab21e48412995440424c42b8768_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f1a12100aba4eaaba8e5398cb22d594_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52d16d0decba4c0cb030da72a9ea1c58_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3508026e6a624653b3042497a2e56b5b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02cc5fc3748f41a18d30fe59dd7c68f5_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8940c1997dcf4466957a1a618e9364e2_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10101268c9545129eb922032bed501f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fd80cb6bb741a59d284cc88e7d599f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470e73798de645539193ae88dadc6e89_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86715d6c5277421e8cfe925f1cecc804_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475e7bce27984b60afa0fcb779a15e53_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f12ff0a9fb44b2ba76ca118062f6098_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccabdb8d53a43e0970777c2bff04d2a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056926527a084313881277f409aada39_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29fa1f2702714d129b63abc66f393ba1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7d9406a7aa47ee9442314d3d15d65a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ba85194e42413b99a2652ace7aedca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i572f2349b435422a9a724121d8d55ebb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec14aa7f907a4e77ac1af5c41c07ec9c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9c90a69fca438fbe1136fe21266e47_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107d1ca201584d23b2e52b6528cee3b9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe25102eb24f4ad2918ef4f8234f9dd9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745854a2110948c8b69f1d073bd78059_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492b94210b3a4b7d86d6b2934d8249c4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726e5f3ab7a2403e8a39b4c4299b8f03_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968b13093ea749a08c539d52bb627da8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a49b7682c84becb2480ace83af36da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64ce862122d47ecbb9d8f2a54bceb89_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d6c1d737bc4c51950da33e52888f55_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc43365824f445169eaac324f106070c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3cb23b2f75c46c28a56b7a45b2e8df4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215fc869cefa46228a13075881587aa5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec95a18524b84f6cba11d8e830382e5e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4297c63d08874f919d86d5021b5f608e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d0ce81ed9f94da3af27fc09016adade_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2df3425269455d899f773df3cd67d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f367baf510f4fcaa8c3b3609d892ab8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e4fcf781a84fabbc66e00870f256e2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c156f7edfc44816bd94d9a3facde46d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58c5083745084ba09e6a766ccd66cc65_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06df7810437744ac89df59b3071c4620_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5eb55df39f645e1a8229022112b64af_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a447e8d29e345cca3c8dc8bedfbe959_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1bdd56609e4b82a082d20e67eb1ef3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f5712bd10f4cb4b4c1c3047f7e03c4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15dbdd9413234e60876544ae84047d70_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda6566951b0490fb0253c079cb5f522_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67836ea5c7334cdca1bd28a16693be9e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0fd76e8bb5349d9ab296f99828590c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900ec607f0a344bbbf9a2c6f28d71d29_I20150326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89857dab9c4747b59247c78b1c721361_D20150326-20150326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-26</xbrli:startDate><xbrli:endDate>2015-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trial"><xbrli:measure>ovid:Trial</xbrli:measure></xbrli:unit><xbrli:context id="ia2be4bda75f94fdd83408349ef2a84a4_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f4bf2cb6d44b7f9ec70416be17a531_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0577fed13974cc79c32e75d6afbf552_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>ovid:Product</xbrli:measure></xbrli:unit><xbrli:context id="iff1b6990a524490f93ea31b743af4557_D20211230-20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf2f99c556604fba8747dc92065c5ec1_I20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5e3642cc734de5ac47c8a5ccb0a666_D20211201-20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d5cd62a7c1493a9fde980d2163424c_I20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e38e7a15e34cceafd124f84ef81706_D20211230-20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417dd14e7c28468cbb32aa243f71b4ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e6ce3a5011403898de05a7b8a7950e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5dc9854b22c4401944c1c3f1c81fa35_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4975144823b4b6397ba0954f6522143_I20210329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76ece08d363143b3a4e48d1512b2d3f2_D20210329-20210329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-29</xbrli:startDate><xbrli:endDate>2021-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c8f02f699a46e3be40c5246e96e602_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97b2a2da582483fb06d8288d746a65f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabba1d2cdfc4be9b9d2d6a75d6c5d4d_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dff19c285cc484e915ef6c61e6e770a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9290ae797c984118825406206a94dc50_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23af69e8e97e4050a2c0ce0556ad29df_I20220301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i315b0e5db1654ee59132ac7839cdab6b_D20220301-20220301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:PatentLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8717ce65ce149a596e214e8657b3b6c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44bf255bfaca451db24cb2de86760946_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc5d022a300431fa15d4be1cb81e3e7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd93d38c649e4bcf9dc0997d1f36eb7a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20ea80f44894cb98636c41e3d77bcc1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9fd4d2cf174503b125fdaeeb11c6fc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9467652c06534816ba1aa9bc3a888d71_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03f0f7a1a3d450aad2a50ecf43a159f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660cdfd473c24c05b53a1ce7e820084a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09793674d52f4223a7e62a26166fa5e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iffb89c91b68044fe89584fa1aa2f8679_1"></div><div style="min-height:22.5pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTA5_fe1322c2-9263-4d7e-a31e-523c7ad96266">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEw_54c76a59-75bf-436a-a91d-125f3c355cdf">x</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEx_144c7784-2879-4f28-90f6-3fc207f9037e">June 30, 2022</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE1_f5b38943-1ea3-427e-9a88-51d30aa86043">o</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from ______________________ to ______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE2_ff14f114-a10d-4705-a105-78b23c597dd3">001-38085</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE3_d7ee26b0-9c4c-4b16-9f4c-53627acb3032">Ovid Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________ </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6YTEzNjBiMWNmZGUwNGE0OTk0ZTJhNzJjYzgxYmE4MjAvdGFibGVyYW5nZTphMTM2MGIxY2ZkZTA0YTQ5OTRlMmE3MmNjODFiYTgyMF8wLTAtMS0xLTExMQ_8bc2f146-f8c8-4952-9a97-847e39d2fca3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6YTEzNjBiMWNmZGUwNGE0OTk0ZTJhNzJjYzgxYmE4MjAvdGFibGVyYW5nZTphMTM2MGIxY2ZkZTA0YTQ5OTRlMmE3MmNjODFiYTgyMF8wLTEtMS0xLTExMQ_dc9ab2cd-364f-48b8-8765-15dd836d2059">46-5270895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzU_928c48f0-5447-4a02-a669-8d197063d78c">441 Ninth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzk_aa6d3387-16c0-4805-8cdc-e0e8a8d7fef7">14th Floor</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzEy_9fb38cb9-8f6a-4596-8813-8a9fc2479177">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzE2_8b18ea90-b6c7-4b5b-bafa-793d362671a5">New York</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTEtMS0xLTExMQ_7beac0bc-729a-4b6f-b157-de83aa3bb160">10001</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEy_c26157b1-3060-40bb-9fb2-e9c92f5c5eb1">646</ix:nonNumeric>) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE4_9e5d9599-2ebd-4a4b-8de0-78cf67a4b7fd">661-7661</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5MA_cc08d34c-5ef5-4313-8f8b-d99be46e9df1">1460 Broadway</ix:nonNumeric>, <ix:nonNumeric contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5MQ_9abcddf1-55d3-43a3-a1b7-28be782877e8">Suite 15044</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5Mw_333c113b-09cb-40f7-ac6f-d5a382d81a06">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5NA_46c3419d-93f8-48fa-9445-96619ec9a220">New York</ix:nonNumeric> <ix:nonNumeric contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5Ng_dbffdb8e-79ae-4555-8810-4166e473948b">10036</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:94%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:95%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:95%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:94%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2RmOWQ1ZjRiM2JlNGM3ZThkM2EyZDdkODVmYTVkOGQvdGFibGVyYW5nZTozZGY5ZDVmNGIzYmU0YzdlOGQzYTJkN2Q4NWZhNWQ4ZF8xLTAtMS0xLTExMQ_d79fadc0-f2d2-442e-8dc2-778e60b89f37">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2RmOWQ1ZjRiM2JlNGM3ZThkM2EyZDdkODVmYTVkOGQvdGFibGVyYW5nZTozZGY5ZDVmNGIzYmU0YzdlOGQzYTJkN2Q4NWZhNWQ4ZF8xLTItMS0xLTExMQ_3444305a-cdfe-4fd0-a7f1-c5bbe6de0e44">OVID</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2RmOWQ1ZjRiM2JlNGM3ZThkM2EyZDdkODVmYTVkOGQvdGFibGVyYW5nZTozZGY5ZDVmNGIzYmU0YzdlOGQzYTJkN2Q4NWZhNWQ4ZF8xLTQtMS0xLTExMQ_c736cad9-a44f-4f2d-981b-11d2ed94ac74">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEz_11fa44da-138f-42b7-8e87-1e7ab67b40b6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE5_983f7486-4c04-4a3f-a4b9-dfce22f7eb1b">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2YyNTRiZDI4Yjc0NDdiY2JkNDE2Mjk3Y2U4ZGRlZDYvdGFibGVyYW5nZTozZjI1NGJkMjhiNzQ0N2JjYmQ0MTYyOTdjZThkZGVkNl8wLTItMS0xLTExMQ_18a55283-a0cd-4e33-b186-584e371ac99f">Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2YyNTRiZDI4Yjc0NDdiY2JkNDE2Mjk3Y2U4ZGRlZDYvdGFibGVyYW5nZTozZjI1NGJkMjhiNzQ0N2JjYmQ0MTYyOTdjZThkZGVkNl8xLTMtMS0xLTExMQ_e7c4aa5f-2766-4779-b152-ea7f691a6ed2">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2YyNTRiZDI4Yjc0NDdiY2JkNDE2Mjk3Y2U4ZGRlZDYvdGFibGVyYW5nZTozZjI1NGJkMjhiNzQ0N2JjYmQ0MTYyOTdjZThkZGVkNl8yLTEtMS0xLTExMQ_22b5666c-240c-402b-9be4-d6789247ac6d">x</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityExTransitionPeriod" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE0_020eac0e-b62a-45f7-b589-ee6636fe0539">x</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTA3_f1fea708-612d-4d76-9080-30f0b0a59fcf">x</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;5, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="iadc605709f3a40779864f2d39fb359e4_I20220805" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xMDk5NTExNjMwNDAw_c5107aa8-cd29-46ed-b03a-b538e173e624">70,419,388</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_13">PART I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_22">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_376">Condensed Consolidated Statements of Comprehensive (Loss) Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_376">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_25">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_31">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_73">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_73">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_100">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_103">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_106">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_106">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_109">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_109">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_112">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_112">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_115">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_115">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:none" href="#iffb89c91b68044fe89584fa1aa2f8679_115">59</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_118">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to identify additional novel compounds with significant commercial potential to acquire or in-license; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to successfully acquire or in-license additional drug candidates on reasonable terms; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our estimates regarding expenses, future revenue including any royalty or milestone payments, capital requirements and needs for additional financing; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to obtain regulatory approval of our current and future drug candidates; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our expectations regarding the potential market size and the rate and degree of market acceptance of such drug candidates;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to fund our working capital requirements; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the implementation of our business model and strategic plans for our business and drug candidates; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to maintain and establish collaborations or obtain additional funding; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">statements regarding the impact of the COVID-19 pandemic and its effects on our operations, access to capital, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers, and collaborators with whom we conduct business;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our expectations regarding government and third-party payor coverage and reimbursement; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to compete in the markets we serve; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the impact of government laws and regulations; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">developments relating to our competitors and our industry; and </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the factors that may impact our financial results. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part II, Item 1A, &#8220;Risk Factors,&#8221; herein and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs and consumer products, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources and we have not independently verified the data from third party sources. In some cases, we do not expressly refer to the sources from which these data are derived.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to &#8220;Ovid,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Ovid Therapeutics Inc. and its wholly owned subsidiaries. This Quarterly Report on Form 10-Q also contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">ii</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMy0xLTEtMS0xMTE_87c555f6-bb40-4999-a8ac-119da377a5aa">72,811,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMy0zLTEtMS0xMTE_48acf6ac-567f-4aa0-8ad4-2a2ce529a4fe">187,797,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0xLTEtMS0xNjQy_69f23b00-7938-4674-a030-8d69c9f08db9">79,554,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0zLTEtMS0xNjQy_a7959c37-ec16-4233-8146-213120cf4552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0xLTEtMS0xMTE_101beafa-7dd7-4c12-87b5-18b98f489ea7">2,715,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0zLTEtMS0xMTE_29bdea08-6533-4078-99ee-1e23fc0b2bfc">2,681,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="ovid:NoteReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNS0xLTEtMS0xMTE_5e8eeeeb-8df6-4f21-8bfa-8c745a96c43a">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="ovid:NoteReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNS0zLTEtMS0xMTE_75c49c35-1943-4f1e-836e-9aa966859967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNi0xLTEtMS0xMTE_5b868013-53ab-4188-928f-b650c6effcde">156,080,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNi0zLTEtMS0xMTE_e98d1fe4-9505-4614-bf35-1600fa7c14c1">190,479,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOC0xLTEtMS0xMTE_660fec1a-6577-43f3-9e67-085476e21cfe">2,228,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOC0zLTEtMS0xMTE_0f80cdf2-0a9e-4e1d-8a2c-07e9cf33fe46">1,631,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOS0xLTEtMS0xMTE_e49b1407-df39-4de9-9cc6-acbf33d4fe41">1,930,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOS0zLTEtMS0xMTE_9f919ad3-50fd-4aa9-b17a-848cfb9816dc">1,930,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Security deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTAtMS0xLTEtMTEx_aac00d23-f7b3-45a0-8bb3-c9d83f0ef85b">80,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTAtMy0xLTEtMTEx_8002b799-76da-4971-b0b8-c09f5fbc11f1">96,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTEtMS0xLTEtMTEx_69c20a2f-fb08-49fd-98d0-c3ec3481c8ce">1,243,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTEtMy0xLTEtMTEx_6e050964-0166-49c9-9ae3-0474262fb470">242,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTItMS0xLTEtMTEx_d4903505-4762-4110-bb81-4ad6713a7289">15,437,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTItMy0xLTEtMTEx_fef977b1-5aee-4c0d-8a8d-a9a183c7782e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTMtMS0xLTEtMTEx_17182d7b-b8eb-4523-b6a9-ada053d101ff">328,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTMtMy0xLTEtMTEx_0233c499-0b75-4874-9108-7744fbddd572">164,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTQtMS0xLTEtMTEx_fe949c91-1edf-4959-90ad-bbaf5b439568">177,329,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTQtMy0xLTEtMTEx_1dea5095-9715-4664-933d-9a6412c62353">194,544,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTgtMS0xLTEtMTEx_1fb8093a-a529-4abf-9235-14c4ea01cb54">4,616,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTgtMy0xLTEtMTEx_e6ab12ca-6d8a-4891-8830-bf456ea14ecc">7,127,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTktMS0xLTEtMTEx_76c39983-f43b-4132-b626-3218db31b1f5">4,598,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTktMy0xLTEtMTEx_59101324-8846-4798-a5f6-70558a175620">7,671,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjItMS0xLTEtMTEx_0d52e44e-805d-4b76-b164-5600bd7fdbcb">15,966,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjItMy0xLTEtMTEx_06d34859-bdfa-4fb9-8e01-bd00180ccef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjMtMS0xLTEtMTEx_62ea82b2-e070-4a09-a392-1e5b65155a4b">25,182,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjMtMy0xLTEtMTEx_78222bae-d81e-4a37-9f71-5193a1e989d5">14,798,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMjE_0638f470-6211-4824-98f2-1f0278e6bf03"><ix:nonFraction unitRef="usdPerShare" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMjE_520f64c2-b36e-47bf-9288-54f2ba453067">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMzU_43614acc-23a7-4f65-a888-dcd8b45267c4"><ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMzU_eafe2557-b9c0-447f-aeee-5000d4c3beb9">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; Series A convertible preferred stock, <ix:nonFraction unitRef="shares" contextRef="i18f3cae6721f43a693142c5e9c86f229_I20211231" decimals="0" name="ovid:PreferredStockShareDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfOTU_7844a0b0-8d1e-454c-8a6a-2ea1c4c9a2f2"><ix:nonFraction unitRef="shares" contextRef="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630" decimals="0" name="ovid:PreferredStockShareDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfOTU_d99e6703-78d2-4532-9ef9-2b943e75cc2b">10,000</ix:nonFraction></ix:nonFraction> shares designated, <ix:nonFraction unitRef="shares" contextRef="i18f3cae6721f43a693142c5e9c86f229_I20211231" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_0c595a41-fc6e-49c5-bb31-384649e041fe"><ix:nonFraction unitRef="shares" contextRef="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630" decimals="0" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_365696f0-5b56-4d20-baf0-fcb978a8fc34"><ix:nonFraction unitRef="shares" contextRef="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_707322ef-f049-4922-a25d-0a12545e1e29"><ix:nonFraction unitRef="shares" contextRef="i18f3cae6721f43a693142c5e9c86f229_I20211231" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_dc221365-08ab-4612-8d76-baa94781a527">1,250</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMS0xLTEtMTEx_0002c631-e294-48ee-853b-4697ba74077e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMy0xLTEtMTEx_c0295b8d-aaf3-4452-87c1-ae829b559c85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMTg_17c8700d-dd4a-4171-840d-335c57ac0ef0"><ix:nonFraction unitRef="usdPerShare" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMTg_5e63e1a3-9b76-48b9-8b83-38fe63755689">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMzI_34e6564c-af3a-4f62-91c3-108a1f113c94"><ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMzI_75673604-4203-43d3-845c-650e181c2de7">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNTQ_84248121-65fd-402a-9170-a5ed4545b0ce"><ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNTQ_eca2c63d-af3e-44dd-946c-7ffe8259d94f">70,419,388</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNjE_20502419-7f7b-4936-90ee-315216f5cc53"><ix:nonFraction unitRef="shares" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNjE_406e5899-82ad-4ad9-aa30-8e36aeb2b488">70,364,912</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMS0xLTEtMTEx_0760febd-a117-4465-935b-926e0e5f61b1">70,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMy0xLTEtMTEx_059c4edc-225a-441b-9916-b6aa53a540cf">70,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjctMS0xLTEtMTEx_896d3171-c4d2-4185-a5b1-d45c95c320b3">354,221,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjctMy0xLTEtMTEx_56c0b46d-fee6-48de-a8b6-5e7673962355">351,033,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMS0xLTEtMzk0NQ_91e74268-b3a5-4ac6-8c8a-f63a0f3fda08">90,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMy0xLTEtMzk0NQ_347469bb-0b2b-4d4f-adc8-2a41151015ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjgtMS0xLTEtMTEx_4947edfa-6bce-453b-a502-143a9fa9b2dc">202,053,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjgtMy0xLTEtMTEx_a87b7b0a-d13d-4a66-a46c-54715c244ca6">171,357,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMS0xLTEtMTEx_80948faf-f971-49ba-9836-a54a9497ab75">152,147,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMy0xLTEtMTEx_f8cb17de-0a32-45fd-8852-c605c7e78db4">179,746,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMzAtMS0xLTEtMTEx_617d2326-b3a8-490b-99a8-23366783e9a1">177,329,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMzAtMy0xLTEtMTEx_a8875985-c036-47cc-8eb5-cfcbdbc5cec9">194,544,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:30.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Three Months Ended<br/>June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Three Months Ended<br/>June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cef6b081bc54d82a49f3c118a7c65e8_D20220401-20220630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi0xLTEtMS0xMTE_e41949df-4884-4b49-9965-c307ae7dcaf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f78e6e5ddd4d44a2471e1fd844f7b4_D20210401-20210630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi0zLTEtMS0xMTE_17b96734-01d3-4527-8926-500f28a86a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e89cb3e1f0040f7be63e6cd7f47cf4d_D20220101-20220630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi01LTEtMS0xMTE_4ca141d9-7af8-4a97-98f9-71d806c3818c">1,445,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05147c8a6f84aa7bae4e655d515586d_D20210101-20210630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi03LTEtMS0xMTE_41dcf21d-7b28-440f-ac24-80e06ab83c73">12,382,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License revenue - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430e4630f3014c55bfe38535a0b3c699_D20220401-20220630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy0xLTEtMS0xMTE_d9cb00f3-8201-41b7-9dea-2a1d4580d7f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434929d63dcb494293b5e8e5efadb4c3_D20210401-20210630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy0zLTEtMS0xMTE_72d56e33-7693-4012-9b73-a4ead10111fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99beb7807f764390a9af1caa039963dc_D20220101-20220630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy01LTEtMS0xMTE_5714d7bb-4977-4dec-934e-31d5c857d11c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i941a78f2412c464899f42108f91b4f35_D20210101-20210630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy03LTEtMS0xMTE_1e06e154-bd44-42c7-8113-2dab878297b8">196,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC0xLTEtMS0xMTE_7f03e070-4a90-4e6a-bbc9-f600fbda0085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC0zLTEtMS0xMTE_b155a5bf-db62-4a28-81f8-45b8c97fd534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC01LTEtMS0xMTE_8b48fd08-99df-4f0b-bf66-400d438fa5d8">1,445,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC03LTEtMS0xMTE_c3c85bd3-1b2d-4539-be89-795701083026">208,382,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi0xLTEtMS0xMTE_d6e0b5d9-a397-4063-9810-f5709403c2c2">6,046,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi0zLTEtMS0xMTE_801489bd-7f9d-47a9-a6c0-ff61fa5e0181">7,683,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi01LTEtMS0xMTE_533d5d87-52c5-4c25-9d8b-731851693fb6">13,878,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi03LTEtMS0xMTE_b671709e-49ff-4275-ba45-171d00c145c0">23,932,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy0xLTEtMS0xMTE_b3713013-cbd0-40e6-be20-af8697b4b22a">8,257,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy0zLTEtMS0xMTE_3e6f1615-cfce-48c9-8d82-68b2d5a4ba0a">6,629,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy01LTEtMS0xMTE_6ad1e4a7-0b60-48c7-a68d-cdbee59bcf03">18,137,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy03LTEtMS0xMTE_cab36bc2-097e-4a77-aaf4-f60d3771e97e">22,205,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC0xLTEtMS0xMTE_a342cbde-66b3-4e02-974e-355ece99bbc0">14,304,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC0zLTEtMS0xMTE_1bb8a402-03b7-43bb-a304-3cffd4b9ec05">14,312,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC01LTEtMS0xMTE_a3e39ddf-a8b2-45d8-a56f-0ff50e1ed132">32,016,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC03LTEtMS0xMTE_ddae19a5-2461-4d0a-ae97-22348de34b6e">46,138,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS0xLTEtMS0xMTE_0cda7fed-89db-4ea5-ab6d-5b14ac8626b9">14,304,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS0zLTEtMS0xMTE_ce240060-aee2-4907-bd1f-c19a09eb3c51">14,312,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS01LTEtMS0xMTE_786fccf4-461d-46db-ad81-edca72ce01b9">30,571,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS03LTEtMS0xMTE_6099cd9f-c2bc-4a91-99e0-3e827a8ebbdd">162,244,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtMS0xLTEtMTEx_ba6b6d3c-306c-421a-971c-b5bc454d715d">284,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtMy0xLTEtMTEx_6a1b90e8-a0ab-4bd4-84c7-70632a1d77b9">2,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtNS0xLTEtMTEx_cd115bda-18a9-424b-a794-8eb6c830ddd2">125,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtNy0xLTEtMTEx_d4434581-3099-48f3-8afd-9e2779ab9892">52,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtMS0xLTEtMTEx_4d9ec2ea-f523-4167-9100-586e49b365d3">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtMy0xLTEtMTEx_3ae31bc8-7b88-4a22-94e4-b324ee011ee1">14,315,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtNS0xLTEtMTEx_ed2f311e-07a6-47df-9b91-6092064b962a">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtNy0xLTEtMTEx_5154a025-9b42-4ff6-a15e-6918ca2caa1d">162,192,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItMS0xLTEtMTEx_55679012-4078-4c4c-8335-5eaae77bc8f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItMy0xLTEtMTEx_f2f4ea58-30b2-4244-8ce9-c6cc7e39acae">1,473,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItNS0xLTEtMTEx_6b6daa51-b518-405c-8406-516355e4a555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItNy0xLTEtMTEx_72245c6f-a371-48eb-8a52-b34fb93799de">1,973,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtMS0xLTEtMTEx_26a094ba-30f3-49f3-aea2-92dc8ec04ae3">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtMy0xLTEtMTEx_6b6caa12-fbef-4b37-8db2-bcdd83960170">15,788,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtNS0xLTEtMTEx_de532c45-a728-4ee5-b6c4-ccffa97db4b2">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtNy0xLTEtMTEx_75b1e921-7960-4a16-8445-115f017743f7">160,218,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtMS0xLTEtMTEx_96d848a2-0522-454c-acee-bdea7539f16d">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtMy0xLTEtMTEx_da596662-1e9c-44bf-b072-ede56cb6a9e2">0.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtNS0xLTEtMTEx_319208ce-222e-4111-a374-c668558c2689">0.44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtNy0xLTEtMTEx_e74da05a-aba6-4d4a-aaf8-7c61c6b4b2d8">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtMS0xLTEtMTEx_24566285-e2d1-461b-b32e-71da7ff3efdc">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtMy0xLTEtMTEx_e0b5eb6b-3ee9-4a83-a787-422541516037">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtNS0xLTEtMTEx_b1a924dd-74a1-4e9d-acda-53ef705aa407">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtNy0xLTEtMTEx_3add3066-d2b5-453b-a30b-5879436c9dbf">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtMS0xLTEtMTEx_52bde955-ed14-4c10-bec8-d0f6f851b954">70,391,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtMy0xLTEtMTEx_28fa5eeb-2a3f-4751-a2b3-025baefbaddb">67,818,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtNS0xLTEtMTEx_5013e63b-637b-4224-860f-a87c5380fe3c">70,391,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtNy0xLTEtMTEx_dae71852-5ae7-4c5a-b2e8-ef5948b999b1">66,953,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctMS0xLTEtMTEx_289d4782-1f8e-4d9f-8f61-34d3d0af2751">70,391,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctMy0xLTEtMTEx_5aff4ec9-493d-472c-8d51-6151d6291571">67,818,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctNS0xLTEtMTEx_87b5563b-c56d-411b-8358-8e3aa049e2dc">70,391,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctNy0xLTEtMTEx_f1b3023b-8297-488d-9636-91bf3079f433">67,565,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_376"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive (Loss) Income </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For The Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtMS0xLTEtMzkxNg_26a094ba-30f3-49f3-aea2-92dc8ec04ae3">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtMy0xLTEtMzkxNg_6b6caa12-fbef-4b37-8db2-bcdd83960170">15,788,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtNS0xLTEtMzkxNg_de532c45-a728-4ee5-b6c4-ccffa97db4b2">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtNy0xLTEtMzkxNg_75b1e921-7960-4a16-8445-115f017743f7">160,218,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtMS0xLTEtNDc4NQ_1d69884b-aac8-4002-b001-43a16dc06f2f">90,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtMy0xLTEtNTg5MA_46dc6765-1bdf-48db-a845-6350cce65b35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtNS0xLTEtNTg5NA_0ccbad84-9686-48b7-b410-1380380f1d9c">90,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtNy0xLTEtNTg5Ng_8cd4c19f-91eb-457d-b5e9-06e4be1e3d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtMS0xLTEtNTg5OA_d9f40622-9354-43ed-a725-f4d91036c63b">14,678,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtMy0xLTEtNTkwMQ_e4fe8766-073c-4f3c-8206-2a6247387866">15,788,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtNS0xLTEtNTkwMw_d04547d9-9f5b-472d-a492-31c1f28f2ebc">30,786,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtNy0xLTEtNTkwNQ_edd65229-7bfd-4a12-b2c3-51f033419cf1">160,218,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.998%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A<br/>Convertible<br/>Preferred Stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad7480407a3f4c48928d4ccbe1dd5c10_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xLTEtMS0xMTE_02fbf564-6193-426f-9f89-6b6376db49f4">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7480407a3f4c48928d4ccbe1dd5c10_I20211231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0zLTEtMS0xMTE_dfc0ba58-c736-4b52-b9ff-f32deafde3a3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02d307e57dbc40ff93c2b5995aeba167_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi01LTEtMS0xMTE_c78c0cb4-9e23-4e1c-a6a2-596a7a95cd01">70,364,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d307e57dbc40ff93c2b5995aeba167_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi03LTEtMS0xMTE_6fa38d98-557e-4f62-b201-f01bafb8c155">70,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8760fd385cca4d73b7b31af558f982ad_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi05LTEtMS0xMTE_8ddd722a-90d8-4e8d-a036-1ea4dbf25fe5">351,033,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0310bbd84f804abea3269f6c899e1a78_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xMS0xLTEtMTEx_aadf75a2-3bda-40b1-b417-0d692e7aaeb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fab542d4f974a00912a7939cf326eb2_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xMy0xLTEtNDg0MA_74af6a25-6266-40bb-8d84-2df5d79bf0da">171,357,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xMy0xLTEtMTEx_80bca802-5af1-49e3-a591-15bd0b6766f1">179,746,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c62b7cade354d0388144a8b711b4722_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy05LTEtMS00ODQw_42f57e54-69fb-4629-a21c-9432d752145e">1,324,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy0xNS0xLTEtNDg0MA_1c708604-6cad-49f7-8f83-6108c9ff2298">1,324,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31de4bccf32942219f29ef0e07207b80_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC01LTEtMS00ODQw_11054fae-0328-4634-a0d6-9a779be28234">52,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31de4bccf32942219f29ef0e07207b80_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC03LTEtMS00ODQw_66a80af6-7bac-4896-9c0b-5f9a6b161e7c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c62b7cade354d0388144a8b711b4722_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC05LTEtMS00ODQw_c37b9d48-bac4-4251-b244-a2dbb0999169">33,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC0xNS0xLTEtNDg0MA_f29ce6db-c474-461f-ac7e-412c89628c53">33,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f72e97f2a064f1c90998ceed128f870_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNS0xMy0xLTEtNDg0MA_14399a3c-6000-4f16-9f73-b6e9016d12dc">16,108,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNS0xNS0xLTEtNDg0MA_f58fda63-f55b-43c7-9f4c-8d83a16e2aec">16,108,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d18fe72233749f28cfd64f0d70907ea_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xLTEtMS00ODQw_da9dbda2-8e84-43a3-9363-b682730587b7">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d18fe72233749f28cfd64f0d70907ea_I20220331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0zLTEtMS00ODQw_77c94aa5-6356-49dd-843c-3616dc913a64">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bf2fd110a9a4c5ab75eea6d9c720226_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi01LTEtMS00ODQw_dd55d07b-fa98-43c9-895d-f20c42a5b218">70,417,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf2fd110a9a4c5ab75eea6d9c720226_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi03LTEtMS00ODQw_c139a92d-b6bf-426f-be33-ba3059999d3e">70,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8260726b54e04ea1ad6d0ca24421b805_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi05LTEtMS00ODQw_87251f4c-b158-4e2e-9535-aa9cbb6b4a79">352,391,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56157218fe549b2b3302bac54442c1b_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMS0xLTEtNDg0MA_4503bfa6-e5ad-4929-8105-2a62ffd2e1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic488d6492f0a4affa4b6e168bc0497a8_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMy0xLTEtNDg0MA_e1701d8c-be79-45dc-b801-c646f0bfd8cd">187,465,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3e29443fb640e1ac31ec6b44140e14_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xNS0xLTEtNDg0MA_90b33ca4-778e-4f15-a96b-5ee9c77ea5c7">164,996,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1269bd94e5ad48d198e0186fcb7d2e2b_D20220401-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNy05LTEtMS00ODQw_78982f06-aaa4-40cd-bfac-56c4585e4a24">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNy0xNS0xLTEtNDg0MA_8df96fc0-6258-40f2-a3c4-584824dd3ecd">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f9abf6069224ad1b07f06bfe5e710f4_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy01LTEtMS0xMTE_78881e7b-78e9-4b98-9e09-b80e52a5645c">2,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9abf6069224ad1b07f06bfe5e710f4_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy03LTEtMS0xMTE_daf772c4-4026-4108-87ea-7d1ff63ec25c">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1269bd94e5ad48d198e0186fcb7d2e2b_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy05LTEtMS0xMTE_1436b88e-1f4e-4a4f-8737-04d888cfdeaf">109,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy0xMy0xLTEtMTEx_937658ea-6778-46fc-a180-e465603e997d">109,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6554df655cdb468099698d2e5466ee5d_D20220401-20220630" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC0xMS0xLTEtMTEx_261ebb03-2673-4e2c-9532-cb340acacf85">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC0xMy0xLTEtMTEx_1fbfde3f-24ab-474f-b908-669c2b1d4f05">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e677a4abbe94743a6e30d84324ce7f7_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMTMtMS0xLTQ4NDA_b3f3b7f0-22cb-481b-8f23-85a1c7b3766c">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNS0xMy0xLTEtMTEx_cf2a1a7b-748f-4d88-bd2d-9e86dff17a6c">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cfbc34d3a114e34912c01fb42a6e923_I20220630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xLTEtMS0xMTE_82c93124-a401-4a9e-aa21-7ecc333b28b6">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfbc34d3a114e34912c01fb42a6e923_I20220630" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0zLTEtMS0xMTE_3bb78bd3-29dc-4d06-8e13-00156caa0b1a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0999ec79eeb14fdfb352298d2cb61f83_I20220630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi01LTEtMS0xMTE_9a7d3336-15a1-468a-89f7-a63d0f948f4b">70,419,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0999ec79eeb14fdfb352298d2cb61f83_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi03LTEtMS0xMTE_a621c81c-62ba-45c5-b4a9-e09b8b11d885">70,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb2c95532874480bb6ff7d1bfc14723_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi05LTEtMS0xMTE_9d9de29c-ed07-4060-a5d7-c48c90decb34">354,221,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0aab07b1f2e4699bfef8151c47b8a0d_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMS0xLTEtMTEx_546de829-0e63-472d-b90d-26dcb6afcb7d">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45904026876d4027b04a7d7c2108f617_I20220630" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTEtMTMtMS0xLTQ4NDA_99960309-282a-4c67-9f74-c2894580314b">202,053,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMy0xLTEtMTEx_43f82539-58ab-4e89-8bf6-09cca068fd2f">152,147,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A<br/>Convertible<br/>Preferred Stock </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8366cf4b4e584ca1933dcff24730eee2_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMS0xLTEtMTEx_32c34e97-56e6-4407-93f0-de98afbdc2f4">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8366cf4b4e584ca1933dcff24730eee2_I20201231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMy0xLTEtMTEx_e73215e1-391d-42cb-a2ac-40c22ff1dede">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i799e74a1e807418187738a7890f11901_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtNS0xLTEtMTEx_89d872f6-389a-4296-b024-13f7d60cc344">65,743,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799e74a1e807418187738a7890f11901_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtNy0xLTEtMTEx_036381a8-d8e2-42b4-87a6-496535729ce7">65,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296138c6708441f693c8a9280889de40_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtOS0xLTEtMTEx_3c021ecc-47e5-4175-a22a-bf81c41af9e5">337,758,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i336ccea71ae9453b969559eea3a1e540_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMTEtMS0xLTExMQ_c286115f-04d3-4d9c-b8be-0bc5027ecd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0c0dfa04e4b4f4898016afa3ab78e19_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtMTMtMS0xLTQ4NTI_9dc2558d-9d34-4934-a4aa-2b28ea92e781">294,192,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658dc49bdacc4997a02fdffb11586100_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMTMtMS0xLTExMQ_9296c23d-d041-4b90-9dc2-919aeaac25b9">43,631,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTUtOS0xLTEtNDg1Mg_40dc115b-0af1-4113-8415-ef485e6b84a4">1,320,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTUtMTUtMS0xLTQ4NTI_b8602d24-224d-421c-a34f-afd295d40d19">1,320,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNS0xLTEtNDg1Mg_8be5cc7e-0529-4fd0-a1d2-e34f2e3f60ca">34,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNy0xLTEtNDg1Mg_13b0fc03-d3ec-42ad-8a5e-f3af139bbc8f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtOS0xLTEtNDg1Mg_15dd713d-e4f6-4bf0-981c-087c6fd74892">130,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMTUtMS0xLTQ4NTI_3d09ace9-b88f-4d7d-8668-be5471abe1b7">130,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctNS0xLTEtNDg1Mg_c9ebdae8-6dd5-4e15-afe1-8b7db0bc4d42">10,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctNy0xLTEtNDg1Mg_ea57783c-3d19-48e0-8df0-cb357665bfaf">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctOS0xLTEtNDg1Mg_e8fd9f37-933f-4fe4-a84e-2b6b73940553">20,791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctMTUtMS0xLTQ4NTI_541cb07d-7389-4e08-ae47-90123360d5cb">20,802</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of series A convertible preferred stock to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i10c476d2dc2b4b06b06ce5c44e0b513d_D20210101-20210331" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtMS0xLTEtNDg1Mg_7f2a7013-170a-40e4-8ddb-a5956dbcdea5">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10c476d2dc2b4b06b06ce5c44e0b513d_D20210101-20210331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtMy0xLTEtNDg1Mg_ebb26896-ddcc-460a-b77a-c8a237446645">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtNS0xLTEtNDg1Mg_ca11fde6-fdd5-48b6-8440-4632380639fa">2,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtNy0xLTEtNDg1Mg_5b7f9cf9-2a5c-4486-9be0-721828c9e77e">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtOS0xLTEtNDg1Mg_79365981-ba3c-43da-b138-9388c433c85b">1,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab306a7297d4fb1a87a32f3962e910b_D20210101-20210331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTktMTMtMS0xLTQ4NTI_6e762a34-48e2-466e-a694-a2ac3de41e66">176,007,307</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTEtMTMtMS0xLTExMQ_4e95cc16-b41c-43c9-93ac-92c38c2b496c">176,007,307</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0dd60c60db2c42138469dff255b2cb5c_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMS0xLTEtMTEx_bda4bf43-cd07-40aa-9254-793d4b61cb4b">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd60c60db2c42138469dff255b2cb5c_I20210331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMy0xLTEtMTEx_f2ef441b-b635-4d86-99ff-5f57a76e212a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a6c40a93ca044369ee51636d6e0cec8_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItNS0xLTEtMTEx_666c7738-3035-44b2-abdf-491d174daa86">67,787,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6c40a93ca044369ee51636d6e0cec8_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItNy0xLTEtMTEx_498b7e70-02ff-4acd-9bac-35d01ece9bb2">67,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica40e02a37a64756b88e97b575b776e7_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItOS0xLTEtMTEx_896fc059-d280-447e-aff2-a7e11f945035">339,226,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835c3a4e2d324395a70abe30b2d458bb_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMTEtMS0xLTExMQ_9b3bfa63-8583-4860-a5c2-91dc75bb930c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae07d73b4dae4632a39cea16a19f66e1_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMjAtMTMtMS0xLTQ4NTI_50679124-487f-4fac-94b1-cc30062023e1">118,184,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44748b4c9e84136a2dba9fcf256ff76_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMTMtMS0xLTExMQ_14a21ca6-3e44-4b72-90cb-938c2f982c0b">221,109,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d44e580ba3462ca1cde50a64e4926c_D20210401-20210630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTMtOS0xLTEtMTEx_99c7cc94-0399-4b0f-9ad8-b6c186dfd581">1,257,344</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTMtMTMtMS0xLTExMQ_64ddea53-7965-4ff1-80de-d27ffe0d4aa6">1,257,344</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae5c89ad10f2477f8220874a9b49e705_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtNS0xLTEtMTEx_21525ed4-7ac5-4a74-bcbe-0ef0918cc323">46,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5c89ad10f2477f8220874a9b49e705_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtNy0xLTEtMTEx_b77fe0c8-1550-4ade-a23e-1d5039658afd">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d44e580ba3462ca1cde50a64e4926c_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtOS0xLTEtMTEx_bb7a3eb7-4439-45df-8e7d-21c7f55c18f7">130,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtMTMtMS0xLTExMQ_4b23bcc8-6b6e-4ef3-806f-4a77f6941361">130,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d00e69252de424aaf5e53c938c8b70d_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMjMtMTMtMS0xLTQ4NTI_fba8f474-dfc6-40b8-830f-040f4c705243">15,788,427</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTUtMTMtMS0xLTExMQ_503ce89c-5184-4673-a74a-6110e5e8a6d1">15,788,427</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54ef3d8eca944ac4bf14a1496778579c_I20210630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMS0xLTEtMTEx_36a0e308-ffbd-45b1-a2a2-741536607217">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ef3d8eca944ac4bf14a1496778579c_I20210630" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMy0xLTEtMTEx_3ffeca90-0e94-4999-aadf-8a840363d76a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i681a4f60e7b446d18f13235cf1ab4515_I20210630" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNS0xLTEtMTEx_e749c86b-eebd-4948-b543-a1dc9eb39e3e">67,833,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681a4f60e7b446d18f13235cf1ab4515_I20210630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNy0xLTEtMTEx_141b94a7-1448-4467-8da0-bc4ebafd2fed">67,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77147210c23641b5a8af1144e5fa6e04_I20210630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtOS0xLTEtMTEx_428585d1-b457-471d-834f-26570965f14c">340,614,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1104e8485b1942128c40c3a1a39b0b69_I20210630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMTEtMS0xLTExMQ_28c3a9ec-d2f1-4406-b34f-1eeab2902384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c7ddc6b88a248569b3b27c0b1e3efde_I20210630" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMjQtMTMtMS0xLTQ4NTI_3a7bf8f6-d839-4468-8177-d1b09c14da42">133,973,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0fee23ec5d486db1a16b33b9f1ad15_I20210630" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMTMtMS0xLTExMQ_5dbae1cc-5057-40a3-a48c-5b3ddbc84994">206,709,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, <br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMy0xLTEtMS04MDM2_18ed2cf2-fdba-4d2d-8f9f-e3e860f5dcf7">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMy0zLTEtMS04MDM2_a2cfb441-012a-4db9-9a37-3da349eb4d5d">160,218,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash consideration received in licensing agreement transaction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNS0xLTEtMS0xMTE_2c5dedeb-5797-4534-9e8d-3606acebbfc3">945,366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNS0zLTEtMS0xMTE_4aed0953-09d3-4cbc-bf23-17682e5a17e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on equity investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNi0xLTEtMS0xMTE_5211e409-4159-4de7-83e6-8d7349de542f">348,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNi0zLTEtMS0xMTE_e0d9eaa8-2761-4529-9d59-0ed2cc548014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accrued interest and accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0xLTEtMS01MDE1_40051cad-f147-4588-ac5e-263780c0ce5a">223,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0zLTEtMS01MDE1_96f90507-6d41-42b5-bc6b-3d4f9f2ba1d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0xLTEtMS00Nzk2_4701b261-bacc-4fcf-b02f-9fe07ef03015">3,045,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0zLTEtMS00Nzk2_897823ee-1825-4301-b379-2c17d902fed1">2,577,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOS0xLTEtMS00Nzk2_c2d28787-cc99-4ec1-9217-ffd9e40f67d4">172,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOS0zLTEtMS00Nzk2_eb8000e9-a5bf-4f54-8e3a-e047cf5562e3">127,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0xLTEtMS0xMTE_c39d4e9f-a23a-489d-88e4-47361accd21b">354,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0zLTEtMS0xMTE_1292f27f-71f9-44e4-a8cb-fce767808e9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="ovid:AccretionOfLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTAtMS0xLTEtMTEx_43bf8ab1-485d-492d-a32d-fc7a019740f1">368,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="ovid:AccretionOfLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTAtMy0xLTEtMTEx_827aa615-c50f-4361-86ad-45a2cceeb710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTItMS0xLTEtMTEx_fba40ad3-cc9e-4cd5-9234-52b7e7e309bc">230,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTItMy0xLTEtMTEx_fae7a8c7-b716-4202-b39f-99038e6968ba">1,023,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Security deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:IncreaseDecreaseInSecurityDeposits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTMtMS0xLTEtMTEx_2c92a54d-b72e-401f-8f12-4996aa93b1fa">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInSecurityDeposits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTMtMy0xLTEtMTEx_ff05b71b-a221-4a56-b982-0360e3abf04e">27,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:IncreaseDecreaseDueFromAffiliates" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTQtMS0xLTEtMTEx_738282a3-6359-49ee-a4fc-6b52f9ec6c38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseDueFromAffiliates" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTQtMy0xLTEtMTEx_e48fe786-06d0-4673-aca1-7c66a89c8d64">141,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTUtMS0xLTEtMTEx_3bbeca3d-248c-4585-ac17-eefe00c16c8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTUtMy0xLTEtMTEx_40de10c7-b5ae-47f2-87de-89fb6e2a0271">477,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTYtMS0xLTEtMTEx_0a4eb389-5c11-432b-a124-c722e3efe3a2">2,510,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTYtMy0xLTEtMTEx_9e4af355-a7bf-4a3b-9be4-8828caf7da4f">4,518,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTctMS0xLTEtMTEx_42f9859c-41e7-4bab-a231-304b7ff746d9">3,072,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTctMy0xLTEtMTEx_a8502589-5a71-401e-b23c-13b101cfdd73">1,676,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTgtMS0xLTEtMTEx_e385a2b7-93a7-444c-98d1-bc3dc71a6873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTgtMy0xLTEtMTEx_416414d3-0552-4789-a16f-53727af38185">12,382,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMS0xLTEtNTY2MA_cd93a01c-d74c-4d5c-b3a1-c348717fa69a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMy0xLTEtNTY2MA_76f45b66-1186-412f-a098-3e9e9a6f0a13">2,432,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMS0xLTEtODAzNg_da1a1265-1be1-4c75-b308-b64ac8612cf4">33,375,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMy0xLTEtODAzNg_4bb71243-e683-48aa-86f6-acec087f254a">141,482,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of marketable securities, net of interest earned</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMS0xLTEtNDk2Ng_20b86369-5897-4a5a-8ad5-2270cfb3465b">79,416,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMy0xLTEtNDk2Ng_44893975-ed90-43f8-9408-1a7066fc38b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of convertible short-term note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjItMS0xLTEtMTEx_4e58cd5e-b9e0-4077-b5b1-39d9041cefa5">1,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjItMy0xLTEtMTEx_940b9e01-a8b8-4d93-b269-7008d15b7448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of long-term equity investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMS0xLTEtMTEx_4204432d-b276-49ce-82f6-412ce91478f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMy0xLTEtMTEx_59b91954-34a0-475f-b981-78f0aa2babd8">1,583,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMS0xLTEtNTYyNg_d9218eb9-96e9-4a3c-8f9e-ea6383007e48">1,085,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMy0xLTEtNTYyNg_aad3dc90-a661-4bbd-a1a8-1e54b9122f7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software development and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjctMS0xLTEtMTEx_8a9c35f9-d7c6-4c0c-a7ff-5911fd3825a6">251,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjctMy0xLTEtMTEx_f7b4708d-4f30-4ae1-bc8b-0b88d5ae760e">11,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMS0xLTEtMTEx_bb7fbc7b-cd03-4c23-a3b2-0391757d4caa">81,753,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMy0xLTEtMTEx_d05bd61c-aa77-448e-b09f-3725c81107dd">1,595,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ATM and other offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzAtMS0xLTEtMTEx_f43991ed-ed48-4cee-baa2-c2cf95fcc0f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzAtMy0xLTEtMTEx_218319c4-4dcf-4936-ba87-57383d6ea45a">21,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:ProceedsFromStockPlans" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzUtMS0xLTEtNTYyNg_7caebc48-a032-4bbe-a885-feb7a1717538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzUtMy0xLTEtNTYyNg_13988d84-993e-4042-af24-57a2ab7768c3">115,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzItMS0xLTEtMTEx_1157a720-fb38-451b-9fb5-ab87d18af5e9">142,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzItMy0xLTEtMTEx_5bee8cd7-3440-4f79-976b-22ad3773ec61">151,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzMtMS0xLTEtMTEx_d3274370-bec1-43b0-8d86-453b75c0aa72">142,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzMtMy0xLTEtMTEx_8fbee303-ad21-42f0-9c37-5bd9ebcf4dfe">245,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 49pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzktMS0xLTEtNTYyNg_0cd17c12-5c85-4368-866e-1318a98c5f87">114,985,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzktMy0xLTEtNTYyNg_0cd1302a-23be-4e40-8575-f4e5eb9c144e">140,132,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzgtMS0xLTEtODAzNg_522032af-7d58-49ad-905a-5962c5cacb18">189,728,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658dc49bdacc4997a02fdffb11586100_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzgtMy0xLTEtODAzNg_ccc14ce4-19ac-45c8-8664-4acc6e9d3cca">72,033,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzctMS0xLTEtMTEx_00e6012a-4c56-44bc-83d6-884e1f092568">74,742,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0fee23ec5d486db1a16b33b9f1ad15_I20210630" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzctMy0xLTEtMTEx_881fcf9a-8ed0-4e8d-87e9-b598ee376c13">212,166,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMS0xLTEtNTAyOQ_a1b11148-705b-49cc-98a7-affec1f04aa2">15,791,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMy0xLTEtNTAyOQ_12bf2864-9b28-4552-8466-134250fb4d2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs related to purchase of long-term equity investment in accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDMtMS0xLTEtODAzNg_5b43726a-90a9-4608-b512-648647950fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDMtMy0xLTEtODAzNg_2ea8ede4-51ed-496c-b74c-425c737beed1">24,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercise receivables in prepaid expenses and other current assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="ovid:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDQtMS0xLTEtODAzNg_ff537153-141a-4cb5-b043-86ef8fb1f603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="ovid:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDQtMy0xLTEtODAzNg_2928e801-98e3-4db7-9a01-da6ea3a9fcb1">14,468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMS0xLTEtODAzNg_07f38cb2-87b7-421a-bf5b-5aca8794918b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMy0xLTEtODAzNg_91b16620-5109-4aef-85cf-06bacca571d8">3,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 1 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNTI3OA_49a05a88-2dea-40d9-96a9-2ae586b8dca6" continuedAt="i3e84e39a495846978779ba2b6e3d54c3" escape="true">NATURE OF OPERATIONS</ix:nonNumeric></span></div><ix:continuation id="i3e84e39a495846978779ba2b6e3d54c3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ovid Therapeutics Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the state of Delaware on April 1, 2014 and maintains its principal office in New York, New York. The Company commenced operations on April 1, 2014 (date of inception). The Company is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Historically, the Company&#8217;s major sources of cash have been composed of proceeds from various public and private offerings of its capital stock, revenue from collaboration agreements, option exercises and interest income. As of June&#160;30, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTA5OTUxMTYzMzEzNA_c9826cf9-bab1-4798-8e5e-5c9f9e58269f">152.4</ix:nonFraction> million in cash, cash equivalents and marketable securities. Since inception, the Company has generated $<ix:nonFraction unitRef="usd" contextRef="icdb5c5087a7345cea587ac586d74b78e_D20140401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTM4Mg_28e1b6a8-90d2-4869-97cc-32ace16e2a8e">222.4</ix:nonFraction> million in revenue, primarily pursuant to the Company&#8217;s royalty, license and termination agreement (the &#8220;Takeda License and Termination Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;). Historically, the Company has incurred recurring losses, has experienced negative operating cash flows and requires significant cash resources to execute its business plans. The Company has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNDM5ODA0NjUxNjYwNw_5ea1991a-5a79-4065-80b8-fb351c87a55f">202.1</ix:nonFraction>&#160;million as of June&#160;30, 2022, working capital of $<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="-5" name="ovid:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTgyOA_b5693b39-0a68-4f6e-8b39-1ca10ba79a6b">146.9</ix:nonFraction> million and had cash used in operating activities of $<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTg3Ng_6aaf3fbb-095a-4ba1-a2cd-4922ea0f0070">33.4</ix:nonFraction> million for the six months ended June&#160;30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded net losses of $<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNDM5ODA0NjUxNjYyNQ_802f49af-2e2f-4c23-9ce9-7f763da1fc71">14.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNDM5ODA0NjUxNjY0Mw_a38818ca-bdd9-407c-93d4-3653962659f4">30.7</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2022, respectively, and expects to incur losses in subsequent periods for at least the next several years and is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company&#8217;s existing cash, cash equivalents and marketable securities as of June&#160;30, 2022 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company&#8217;s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the ongoing COVID-19 pandemic impacts the Company's business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for the Company's common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, the extent of sustained or new travel restrictions, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease, including vaccination efforts. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of the Company's product candidates; delays or problems in the supply of the Company's product candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company's business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></div></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_37"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> NOTE 2 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzM_a2fb77b8-c76d-4c03-ac2e-22728cb89070" continuedAt="i5b0768af567f41bf9c77324a17c3a668" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i5b0768af567f41bf9c77324a17c3a668" continuedAt="i4d7372e39953422788a6e1953c47c6c2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 15, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(A) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzQ_9b21aee6-9fce-4d04-9c83-4e0491357b20" continuedAt="i92ab7453b5a04b568fbe9d91c792b0a7" escape="true">Unaudited Interim Condensed Consolidated Financial Statements</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i92ab7453b5a04b568fbe9d91c792b0a7" continuedAt="i48e66078b3154a06bfda857d281f56f7">The interim condensed consolidated balance sheet at June&#160;30, 2022, the condensed consolidated statements of operations, comprehensive (loss) income, cash flows, and stockholders&#8217; equity for the three and six months ended June&#160;30, 2022 and 2021 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. </ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="i4d7372e39953422788a6e1953c47c6c2" continuedAt="ie9cd2ea3e9024623bb1e4f02ddf7e123"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i48e66078b3154a06bfda857d281f56f7">generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2022 and 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2021 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(B) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzU_948c552c-42d9-42d4-a0c4-a3329dfb5597" continuedAt="i07de531ccb47470f989602d4136a45e4" escape="true">Basis of Presentation and Consolidation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i07de531ccb47470f989602d4136a45e4">The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(C) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODA_907b2433-3288-4e4d-a086-7803b6858608" continuedAt="i7d4c43fb200b46a898cc695c3a945fcf" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i7d4c43fb200b46a898cc695c3a945fcf">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(D) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTc1OTIxODYwNTg0MDc_ef70a29d-183d-4d45-8969-27e4e7cdf5c7" continuedAt="i189b588f6dcf44c3baacb6db49a0ed7a" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i189b588f6dcf44c3baacb6db49a0ed7a">Marketable securities consists of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive loss in stockholder's equity.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(E) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODE_0c6dbce7-e479-4d1c-839d-ccea67b8fce1" continuedAt="i7f8b585551ea482a877d3dbe464da4b7" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i7f8b585551ea482a877d3dbe464da4b7">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(F) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODI_d70fc56e-a35b-4873-8381-8eaaf36513d4" continuedAt="iec30fb4ad1f84d25b5baea1cfd8864da" escape="true">Long-Term Equity Investments</ix:nonNumeric></span></div><ix:continuation id="iec30fb4ad1f84d25b5baea1cfd8864da"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term equity investments consist of an equity investment in a private company through preferred shares, which are not considered in-substance common stock, that is accounted for at cost, with adjustments for observable changes in prices or impairments, and is classified within long-term equity investments on our consolidated balance sheets with adjustments recognized in other (expense) income, net on our consolidated statements of operations. The Company has determined that the equity investment does not have a readily determinable fair value and elected the measurement alternative. Therefore, the equity investment&#8217;s carrying amount will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investment is impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investee securities, and other publicly available data. If the investment is impaired, the Company writes it down to its estimated fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the equity investment had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDEyNA_63cd56b4-fe33-4c65-9c4c-5b03618d2a0c"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDEyNA_d8331237-16f9-4bea-9e7a-0fa76d4dde85">1.6</ix:nonFraction></ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. ("Marinus") that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2022, the equity investment in Marinus had a carrying value of approximately $<ix:nonFraction unitRef="usd" contextRef="idd69d41d3fa3410981127bf2969db96f_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDczOA_500d414d-ab92-4b49-b66b-3840ed721fc4">0.6</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(G) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzY_0c793cfc-8b72-4bde-9f27-dec11ff55487" continuedAt="ia8a8899580fd4f7fb202c4ac3bd3289b" escape="true">Note Receivable</ix:nonNumeric></span></div><ix:continuation id="ia8a8899580fd4f7fb202c4ac3bd3289b"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March&#160;17, 2022, the Company issued a convertible promissory note to a related party, in which the Company has a long-term equity investment, with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i1a67b91f0f784fb39b30c84c6e1e1667_I20220317" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDkyMQ_96a474f9-15bb-40da-a256-306c52263f40">1.0</ix:nonFraction> million. The note has certain features that may allow the Company to acquire additional equity or to settle in cash. Either option would result in the Company receiving an amount at least equal to the outstanding principal balance plus accrued and unpaid interest. The Company will receive interest on the convertible promissory note at the rate of <ix:nonFraction unitRef="number" contextRef="i9a543a156421421492ae9ac7e6fdd405_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNTI2NQ_7fbcfed6-8eac-40d8-b252-78895e6891fc">1.5</ix:nonFraction>% per annum payable upon conversion or maturity of the note on March 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has elected to measure the note using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivatives due to changes in the fair value will be reflected in other income (expense), net, in the Company's consolidated statements of operations.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(H) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2Nzc_042ffad6-39c3-4674-905d-47a68ba4ba62" continuedAt="i944f7a1b922a4bb4878718eb5be8171f" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i944f7a1b922a4bb4878718eb5be8171f" continuedAt="ie6026e64ee25465d959e435cdb8b9da2">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent </ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="ie9cd2ea3e9024623bb1e4f02ddf7e123" continuedAt="i3e441e4bc8884652958fe3622d32c4e0"><ix:continuation id="ie6026e64ee25465d959e435cdb8b9da2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i2c1e78e1146d41af95d207583e74eb8f_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNjgxOA_bdaab70c-7d77-47e0-bda2-2ffb089ce6f8">55.6</ix:nonFraction> million as of June&#160;30, 2022. The Company's Level 1 assets consisted of money market funds and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="ibf80654a79be4240b9b2f9216351b6d4_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNjkyMg_8d73b47d-d346-4ccd-a854-4aa23a6d1536">187.6</ix:nonFraction> million as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i23d5fb933c1c4101afc9b43949132d1c_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTA5OTUxMTY0NDg0NQ_3f2d20c8-9be9-454b-96be-24eccb2994e6">94.5</ix:nonFraction> million as of June&#160;30, 2022. The Company had <ix:nonFraction unitRef="usd" contextRef="id062c33120f64e1e86eb963d29a355d4_I20220630" decimals="INF" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_2bce056f-c77f-4b59-8b48-dbc92f921f79"><ix:nonFraction unitRef="usd" contextRef="i09fdc4f878d749a2a0c510248458b0c5_I20211231" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_a4d70b4c-0f79-4575-81d3-1fc9c39ae219"><ix:nonFraction unitRef="usd" contextRef="id062c33120f64e1e86eb963d29a355d4_I20220630" decimals="INF" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_ac887cf4-d7e6-4232-beb7-b7013b7174f3"><ix:nonFraction unitRef="usd" contextRef="i09fdc4f878d749a2a0c510248458b0c5_I20211231" decimals="INF" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_c57fb51e-f146-4a43-89fa-aab4373f4f87">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Level 2 assets or liabilities as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company's Level 3 assets consists of the convertible note receivable totaling $<ix:nonFraction unitRef="usd" contextRef="i70b464c3358e49f08d0e076378fff060_I20220630" decimals="-5" name="ovid:ConvertibleNoteReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzc3NA_00ff9a90-5ae6-4ca9-bc2f-951527cde8cf">1.0</ix:nonFraction> million as of June&#160;30, 2022. There were <ix:nonFraction unitRef="usd" contextRef="if91752729f23489a9a1fdf7618bd851d_I20211231" decimals="0" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzc5OA_0ff5aae6-12ad-47ce-a1fc-6deb76dfe26c"><ix:nonFraction unitRef="usd" contextRef="if91752729f23489a9a1fdf7618bd851d_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzc5OA_da247a41-4739-48d7-822f-257da52a5a23">no</ix:nonFraction></ix:nonFraction> Level 3 assets or liabilities as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2Nzg_8cdd6147-e23f-4dbb-a3a3-68c22c3a4154" continuedAt="i3925a156bd874e418a06d3d26e30d051" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i3925a156bd874e418a06d3d26e30d051">The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use ("ROU") assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period. The Company determined that there was no current lease liability for the period ended June&#160;30, 2022, which is due primarily to the free rental period for the Company's Hudson Commons lease.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(J) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2Nzk_6c1e6f28-6446-4fd2-8ef2-c0b98729e664" continuedAt="i87eb39d6748741bb9ee248ac6cedbe29" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="i87eb39d6748741bb9ee248ac6cedbe29"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="i3e441e4bc8884652958fe3622d32c4e0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(K) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODM_83e08133-f1b7-4722-b4cb-8fb105ac32b2" continuedAt="icd2b72a9e03f41429c39d52a3e356ec3" escape="true">Net (Loss) Income Per Share</ix:nonNumeric></span></div><ix:continuation id="icd2b72a9e03f41429c39d52a3e356ec3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income, basic per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding. The Company applies the two-class method to allocate earnings between common stock and participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income, diluted per share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and preferred stock using the if-converted method.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss, diluted per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(L) <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODQ_60e8287f-ab95-48e9-8789-c80a75275433" continuedAt="i7a3164f5de5a46c1a99c00f5b87c1f40" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i7a3164f5de5a46c1a99c00f5b87c1f40"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.</span></div></ix:continuation></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 3 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMzA5_e64d48b5-2df5-44ea-a764-93b4fa1c05c0" continuedAt="i407cc664934949f0a8e15f1568e58ffe" escape="true">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i407cc664934949f0a8e15f1568e58ffe"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMzEw_36649eb9-59db-4658-ad43-a43a926c1322" escape="true"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMzEw_ff9f8643-701d-40c3-b983-b08abb6b4cdd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5cc0fd641241a9a8645ff092db348c_I20220630" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMi0xLTEtMS0xMTE_fcaa6568-4b6d-4fcc-94f7-b2c7156609f1">2,860,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5cc0fd641241a9a8645ff092db348c_I20220630" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMi03LTEtMS0xMTE_ca2b7899-c2e0-43c3-97c2-c0f3e0038f1d">2,860,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0daa1be00e7421584b963e7641737bb_I20220630" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMy0xLTEtMS0xMTE_e4f88dec-5667-454e-b2e7-11dfeee3efd2">69,951,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0daa1be00e7421584b963e7641737bb_I20220630" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMy03LTEtMS0xMTE_4b3963b9-e47f-4177-9387-cf7baf1fe94b">69,951,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0xLTEtMS0yMDMw_bb930706-d315-4bc9-aa14-fa756babb6f3">79,644,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0zLTEtMS0yMDMw_dc0ecac9-c4f2-4665-b31a-da62f1958a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC01LTEtMS0yMDMw_054c2abf-ecbf-4958-87a2-628f70ab0f2b">90,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC03LTEtMS0yMDMw_6bbcea47-eb6a-4a6b-8273-16516841e54d">79,554,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0xLTEtMS0xMTE_9619e71c-f75d-4fe8-88a3-b72c5f346c43">152,455,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0zLTEtMS0xMTE_7176f5e3-31ad-437d-862a-62521a1ba9c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC01LTEtMS0xMTE_d617d598-ff66-4bce-9597-3f513d49f62f">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC03LTEtMS0xMTE_c79dbd29-d4f9-4e31-8658-e967105f1ebb">152,365,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa62a7ee26a34283b02d9a020bb48d54_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMi0xLTEtMS0xMTE_c1bca75f-d2d1-42b1-824e-56333831eeb7">205,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa62a7ee26a34283b02d9a020bb48d54_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMi03LTEtMS0xMTE_26210127-b07f-442c-870e-df1a830d3762">205,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240d93a2ab414f6d8279a85350aa8834_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMy0xLTEtMS0xMTE_68368353-7e56-4aad-a386-f9a7643c47d1">187,591,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i240d93a2ab414f6d8279a85350aa8834_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMy03LTEtMS0xMTE_bb7dd2b7-619d-46dd-8498-939f79a1564e">187,591,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0xLTEtMS0yMDUy_2a62845b-6a91-4245-90f6-02ddd387ae9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0zLTEtMS0yMDUy_4ffab65d-8ee5-4402-a637-a4beb73ddd77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC01LTEtMS0yMDUy_b24b6a64-3e3b-4155-8eda-7fd81675bb8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC03LTEtMS0yMDUy_734273c5-120b-41d1-9821-fb8050f61322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0xLTEtMS0xMTE_92cfd641-b25d-4d25-a06d-38c15cc3643a">187,797,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0zLTEtMS0xMTE_40a64aca-2d6d-4a1a-a547-0425363dec8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC01LTEtMS0xMTE_4df9435d-3e2d-41d2-b321-62acc78267d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC03LTEtMS0xMTE_044c3d91-cbcf-4633-9216-e9f507108bf7">187,797,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="investment" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMjA2_0e032b73-ea17-4b8a-a42a-f53da4dedee4"><ix:nonFraction unitRef="investment" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMjA2_ca801e91-a538-46cf-8924-4f27496710c7">not</ix:nonFraction></ix:nonFraction> hold any securities that were in an unrealized loss position for more than 12 months as of June&#160;30, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_43"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 4 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDA5_789a6824-9c19-4494-a1c4-56ad3713f98d" continuedAt="iad290c7f5b6d43bb9d65760fcc4ce20f" escape="true">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="iad290c7f5b6d43bb9d65760fcc4ce20f" continuedAt="i781535a66c11412a82b39eaa3cd65005"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDEw_c19b23f9-edc8-4a11-b183-1422531241bd" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247b2b8238374cad8df96951a6bae08d_I20220630" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMS0xLTEtMS0xMTE_db9ba259-f98f-47aa-8a2f-4f7508300cc1">1,303,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f82c24689c54b7687abc86742065cc6_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMS0zLTEtMS0xMTE_c3be110e-958e-499d-b66d-9174b5e6fe27">504,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fce33f178a14e88b1785363753aaa5b_I20220630" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0xLTEtMS0yMDg1_a873fe72-6e10-42f5-a705-8da6dd516268">287,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87adc2ffe0ba416eb4da45a8b61856c8_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0zLTEtMS0yMDg1_36070e25-39ee-42b0-be8c-8754705e5180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0xLTEtMS0xMTE_5df4ad5c-2711-44ea-8e80-3d4dd8614788">347,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0zLTEtMS0xMTE_3e614359-47f1-4775-9122-c18f77da67d0">262,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMy0xLTEtMS0xMTE_e78eb79d-d0e7-422a-8686-36d32526ca6d">1,243,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMy0zLTEtMS0xMTE_f0bdbe75-f2bc-4078-bfef-8f31488f69d3">242,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYxNQ_a2bdc962-aaea-4261-a7b6-b1e42daf4a66">54,631</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYyMQ_dd84408d-c2e3-4ed7-a1f4-674ad77aa694">17,834</ix:nonFraction> for the three months ended June&#160;30, 2022 and 2021, respectively. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYyNw_b449ee02-e9e8-4ab9-bb8b-ddee7ebfea9b">85,470</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYzMw_4e0fb7b6-0e2c-4df3-95c1-220f8537bec4">36,478</ix:nonFraction> for the six months ended June&#160;30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i781535a66c11412a82b39eaa3cd65005">Intangible assets, net of accumulated amortization was $<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMjQ5_0c185f6e-8ac7-4e83-a6e6-ca43b2751dcf">328,797</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMjU2_a3c54746-353a-4481-a117-5aff46bb9651">164,092</ix:nonFraction> as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and are included in other assets. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMzQ5_d5981bb2-d8a8-4d25-aa7b-bb6a2689f08b">32,153</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMzU2_93af33ff-379e-4a2d-b5b9-f0aa060c0cf6">35,381</ix:nonFraction> for the three months ended June&#160;30, 2022 and 2021, respectively. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTY3OQ_705b5ce6-d5fd-495c-9563-96d2f9ca3de4">86,636</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTc0Mg_883a35f4-bb92-4ccd-9c9e-33b8dacff6d2">91,473</ix:nonFraction> for the six months ended June&#160;30, 2022 and 2021, respectively.</ix:continuation></span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 5 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE3OQ_073aa6f3-2b6e-406d-b193-e9df6ddb4105" continuedAt="i438d4a6e2b43483c8efa0d7e3adbc9d8" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i438d4a6e2b43483c8efa0d7e3adbc9d8"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During September 2021, the Company entered into a <ix:nonNumeric contextRef="i57c6dc3481c441408bca8588e4b4cd13_I20220310" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4NjQ_093148e3-7ef7-4908-a258-80aa5777ef4d">10-year</ix:nonNumeric> lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately <ix:nonFraction unitRef="sqft" contextRef="i57c6dc3481c441408bca8588e4b4cd13_I20220310" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4NDI_28a2f3dc-a077-4851-935c-0364d73bd071">19,143</ix:nonFraction> square feet of office space at Hudson Commons in New York, NY. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1NTc_a7a64854-9a52-4cf3-aa31-67e9a5c40ba1">2.3</ix:nonFraction> million per year. Rent payments commence <ix:nonNumeric contextRef="i8a54288182e24aa280eacf76b58680fb_D20220310-20220310" name="ovid:LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4OTQ_31117f7c-79f7-4272-b927-fb9819a1201a">10</ix:nonNumeric> months following the commencement date of the lease, or January 10, 2023, and continue for <ix:nonNumeric contextRef="i57c6dc3481c441408bca8588e4b4cd13_I20220310" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4NTI_faee2b0a-1e1d-43cf-a8c3-3fdcee6049ac">10</ix:nonNumeric> years following the rent commencement date. Rent also includes <ix:nonNumeric contextRef="i8a54288182e24aa280eacf76b58680fb_D20220310-20220310" name="ovid:LesseeOperatingLeaseFreeRentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4Nzk_c1dc9839-1328-4100-89ea-26478e99b394">two months</ix:nonNumeric> of free rent in the 6th and 7th months following the rent commencement date. The Company issued a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1c97d8b7325e4ee5bfb436d1850897fe_I20220630" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ2MDE_b03302f2-9ed5-4ceb-8f93-c2648448ca78">1.9</ix:nonFraction> million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Hudson Commons lease has a remaining lease term of <ix:nonNumeric contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1Njg_91924cd2-bcd8-4bb6-ac1e-92d40d13a8be">10</ix:nonNumeric> years and includes a single renewal option for an additional <ix:nonNumeric contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1Nzg_95a9d3b5-3615-4024-a156-495d4fa5e64e">5</ix:nonNumeric> years. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments is calculated using an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="4" name="ovid:LeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1ODY_3da0fef9-cd05-4d1b-b356-4c310f517ffa">7.02</ix:nonFraction>%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.</span></div><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE4MA_1a54e5df-f039-43aa-beaa-ec3da45c9f7d" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROU asset and lease liabilities related to the Company's operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOjcxZWZhODQ1ZTlmYzQ3MmE5YjlhZTk2NmE2ZDgyOWY3L3RhYmxlcmFuZ2U6NzFlZmE4NDVlOWZjNDcyYTliOWFlOTY2YTZkODI5ZjdfMS0xLTEtMS0xMTE_66048326-bd7a-40eb-8de4-cfac46dcf544">15,437,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Current lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOjcxZWZhODQ1ZTlmYzQ3MmE5YjlhZTk2NmE2ZDgyOWY3L3RhYmxlcmFuZ2U6NzFlZmE4NDVlOWZjNDcyYTliOWFlOTY2YTZkODI5ZjdfMi0xLTEtMS0xMTE_65690727-15ba-49c2-b978-ec7640ddcb82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Long-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOjcxZWZhODQ1ZTlmYzQ3MmE5YjlhZTk2NmE2ZDgyOWY3L3RhYmxlcmFuZ2U6NzFlZmE4NDVlOWZjNDcyYTliOWFlOTY2YTZkODI5ZjdfMy0xLTEtMS0xMTE_96ae383c-ae36-4f24-bc8f-b9be7a4ce71f">15,966,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE3Nw_299b0853-5bd5-42e5-bf54-e761433faef9" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of operating lease cost for the six months ended June&#160;30, 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmZjZGNiYmIwYWUyZjRmNjJhYjNmMDA4NmNjMjQwMTBmL3RhYmxlcmFuZ2U6ZmNkY2JiYjBhZTJmNGY2MmFiM2YwMDg2Y2MyNDAxMGZfMS0xLTEtMS0xMTE_f3cbded5-25cd-496f-9c26-f3cacbc9e23e">722,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmZjZGNiYmIwYWUyZjRmNjJhYjNmMDA4NmNjMjQwMTBmL3RhYmxlcmFuZ2U6ZmNkY2JiYjBhZTJmNGY2MmFiM2YwMDg2Y2MyNDAxMGZfMi0xLTEtMS0xMTE_0629b9ca-14ea-48f8-8181-c4643242375d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmZjZGNiYmIwYWUyZjRmNjJhYjNmMDA4NmNjMjQwMTBmL3RhYmxlcmFuZ2U6ZmNkY2JiYjBhZTJmNGY2MmFiM2YwMDg2Y2MyNDAxMGZfMy0xLTEtMS0xMTE_8c8e89c0-dd90-4237-ac4f-3d34bd6db7df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE3OA_6cff9aff-7a32-4769-a4ae-f690637574d9" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future minimum commitments under the non-cancelable operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMC0xLTEtMS0xMTE_aecb798d-9fd6-4bb7-80f8-475ab364389c">1,672,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMS0xLTEtMS0xMTE_3a43550a-6483-4fa0-819c-72664473e124">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMi0xLTEtMS0xMTE_310f983e-6e89-4599-8db3-9fb2999354bb">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMy0xLTEtMS0xMTE_abf21210-95cd-46b6-900a-abccbae7f795">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfNC0xLTEtMS0xMTE_2ddcaacd-b2bb-4700-8997-71e2a5b8db3f">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfNS0xLTEtMS0xMTE_6d1a0ca2-df0d-4833-b9d7-5731fd785a5c">12,347,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfNi0xLTEtMS0xMTE_20b3bd4a-db7a-46bf-a0b4-dfa3c5f48e68">23,285,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 6 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RleHRyZWdpb246MDhjMWZhNmRkZjU1NDkzMmI1YmJkOGExM2JlYTAxZDlfNzQ_3a440a68-8a74-4745-bc6e-bf158a30de10" continuedAt="i35c0a1645e42493cb595d2bb2d5c298d" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i35c0a1645e42493cb595d2bb2d5c298d"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RleHRyZWdpb246MDhjMWZhNmRkZjU1NDkzMmI1YmJkOGExM2JlYTAxZDlfNzU_a18eb740-62d7-4ff8-bd43-5f302b2bda90" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and bonus accrual</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMS0xLTEtMS0xMTE_bc33cfa9-efe7-46e5-8a50-0cb4afe7f6f1">2,925,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMS0zLTEtMS0xMTE_8922ee44-deac-41ea-be31-0db1cde6ee25">3,764,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="ovid:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMi0xLTEtMS0xMTE_69ce806c-8f33-4c12-b81a-3d2f47ffe6af">771,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="ovid:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMi0zLTEtMS0xMTE_2c61efdf-9674-4174-a102-660aec363cdd">1,795,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMy0xLTEtMS0xMTE_49265732-1f6e-488e-a043-b72aa74562f9">396,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMy0zLTEtMS0xMTE_c2d8f1f8-0d90-4a9a-823f-eee1dba9c54f">1,564,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="ovid:IncomeTaxAccrualCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNS0xLTEtMS0xMTE_5c60c4e2-353a-4fe7-bbda-8b0ef1fac6bc">222,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="ovid:IncomeTaxAccrualCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNS0zLTEtMS0xMTE_d32bf628-ddae-4702-9ded-98d7627c6fb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNi0xLTEtMS0xMTE_00811892-2237-4006-8316-fa10f55fe8e8">283,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNi0zLTEtMS0xMTE_7b4fe2c8-4e49-4610-90b6-c6196674299e">546,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNy0xLTEtMS0xMTE_fdc841f6-f500-464a-b0a6-2e581cd7db9d">4,598,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNy0zLTEtMS0xMTE_2eb83e0d-7fa4-4e9e-bed9-194461099556">7,671,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">12</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 7 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzIzNA_54b7bf3a-d560-44bc-aeb4-0ba524190269" continuedAt="ia8acd907f4464e359af9a03f20db48a6" escape="true">STOCKHOLDERS&#8217; EQUITY AND PREFERRED STOCK</ix:nonNumeric></span></div><ix:continuation id="ia8acd907f4464e359af9a03f20db48a6"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s capital structure consists of common stock and convertible preferred stock ("Preferred Stock"). Pursuant to the Company&#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMjk1_90e7d06c-82a7-48c9-900b-d1266e802ce9">125,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzI1_e873abbf-82f1-42fb-88a6-230be698de8a">10,000,000</ix:nonFraction> shares of Preferred Stock. The Company has designated <ix:nonFraction unitRef="shares" contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630" decimals="INF" name="ovid:PreferredStockShareDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzgy_431b549c-acb9-4ae1-9574-7207ca410420">1,250</ix:nonFraction> of the <ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5NzgyMTc_ffdacf26-819c-467d-839b-43fa0507729d">10,000,000</ix:nonFraction> authorized shares of Preferred Stock as non-voting Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="ovid:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzk0MTA_7b423f48-ba22-4c08-a4dd-374b6f07d55d">one</ix:nonFraction> vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of Preferred Stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of Preferred Stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the Preferred Stock are satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (the &#8220;2020 ATM agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may offer and sell in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i396fded5753344dc9202659aa58b987f_I20201130" decimals="INF" name="ovid:AggregateOfferingPriceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTUxMw_8d7b3d8a-a753-4384-995e-6659f521d355">75.0</ix:nonFraction> million through Cowen acting as sales agent. As of June&#160;30, 2022, the Company has <ix:nonFraction unitRef="shares" contextRef="id1edfe140f8c433fb25ab41d64b939f4_D20201101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU3OQ_6fb7a59e-7eb4-4fcc-9314-cb4d1beeab2e">not</ix:nonFraction> sold any shares of its common stock under the 2020 ATM agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTY1OQ_5574829e-834f-47e9-a8ce-add76bc47aa8"><ix:nonFraction unitRef="shares" contextRef="i25bcc14f90fb4eaba2e1ef18f0fd5335_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTY1OQ_c3677c93-8a73-4db3-a0a0-551b68809bf3">1,250</ix:nonFraction></ix:nonFraction> shares of Series A Preferred Stock outstanding as of June&#160;30, 2022 and December&#160;31, 2021. Each share of Series A Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630" decimals="0" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1NTg_42cb010b-b728-4b19-a854-cf7abcd041e8">1,000</ix:nonFraction> shares of common stock at any time at the holder&#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either <ix:nonFraction unitRef="number" contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630" decimals="4" name="ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1NjY_d21ce643-f848-4d0f-90c1-efba2aaf5014">9.99</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630" decimals="4" name="ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1NzU_bfa76345-bc2d-4000-9186-06fa61fafdc1">14.99</ix:nonFraction>% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to <ix:nonFraction unitRef="number" contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630" decimals="4" name="ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzg4MzA_88fac440-cb2d-4c9f-9de9-ac606c6befc8">19.99</ix:nonFraction>% upon <ix:nonNumeric contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630" name="ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzk0MjM_0c6379fb-7c6d-419e-a1ef-533357597710">61</ix:nonNumeric> days&#8217; notice to the Company; provided, however, that effective <ix:nonNumeric contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630" name="ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzk2MjI_0c6379fb-7c6d-419e-a1ef-533357597710">61</ix:nonNumeric> days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either <ix:nonFraction unitRef="number" contextRef="ide285b55b9334ea5a3d4633e081e2e8b_I20220630" decimals="3" name="ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzg4Mzg_0d83c035-6fee-4021-b7fc-a6e9db720402">10.0</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="i99e9dab21e48412995440424c42b8768_I20220630" decimals="3" name="ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzg4NDU_7646b6ff-f63c-48f7-8742-6fc08e1cee62">15.0</ix:nonFraction>%, as applicable based on the holder&#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630" decimals="3" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMjU2Nw_6d005b5b-3b11-41d5-bbde-a9f1af46ab56">0.001</ix:nonFraction> per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, certain of the Company&#8217;s stockholders elected to convert an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1f1a12100aba4eaaba8e5398cb22d594_D20210301-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1ODM_c9f91b1e-4a21-485c-ae67-85157146188a">2,000</ix:nonFraction> shares of Series A Preferred Stock owned by such holders into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i52d16d0decba4c0cb030da72a9ea1c58_D20210301-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1OTU_7675a195-cc67-44e0-bb1c-ce3723ca14fa">2,000,000</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Holders of Series A preferred stock are entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends (other than dividends in the form of the issuance of common stock) actually paid on shares of common stock. <ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="INF" name="us-gaap:Dividends" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY2MDA_8fd2dffc-aae3-441e-ab65-128d4604f587">No</ix:nonFraction> dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid. Through June&#160;30, 2022, the Company has <ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="INF" name="us-gaap:Dividends" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzIwOQ_8fd2dffc-aae3-441e-ab65-128d4604f587">not</ix:nonFraction> declared any dividends.</span></div></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_55"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 8 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2MA_5b9180d0-6490-44d4-9173-f740a185f7c4" continuedAt="id813cea4d83e4b30ae490781c2f1fd22" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="id813cea4d83e4b30ae490781c2f1fd22" continuedAt="i1d346f637a98453b820e31adfd48cd43"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted and the Company's stockholders approved the 2017 Equity Incentive Plan (&#8220;2017 Plan&#8221;), which became effective immediately on May 4, 2017. The initial reserve of shares of common stock under the 2017 Plan was <ix:nonFraction unitRef="shares" contextRef="i3508026e6a624653b3042497a2e56b5b_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjg3_91765481-eb52-40f9-9158-56d881c01e56">3,052,059</ix:nonFraction> shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company&#8217;s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) <ix:nonFraction unitRef="number" contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfOTcz_003ae004-8260-4002-b1f6-536cdcca8c06">5</ix:nonFraction>% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. On January&#160;1, 2022 and January&#160;1, 2021, respectively, an additional <ix:nonFraction unitRef="shares" contextRef="i02cc5fc3748f41a18d30fe59dd7c68f5_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTIwMA_19ec8342-b3b2-4d99-bd22-7536f4b61e71">1,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8940c1997dcf4466957a1a618e9364e2_D20210101-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTIwNw_3826d7e9-ea69-46d5-bad2-a48e60bb4c91">3,287,158</ix:nonFraction> shares were reserved for issuance under the 2017 Plan. As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i3508026e6a624653b3042497a2e56b5b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTI4Ng_df7b118f-6417-4e0a-b8a3-ca405f7b04fd">2,706,415</ix:nonFraction> shares of the Company&#8217;s common stock reserved and available for issuance under the 2017 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s initial public offering on May 4, 2017. The 2017 ESPP allows employees to purchase common stock of the Company at a <ix:nonFraction unitRef="number" contextRef="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc0Nw_9b8ed03b-650f-4865-8a65-2e6af8ac092f">15</ix:nonFraction>% discount to the market price on designated semi-annual purchase dates. During the three months ended June&#160;30, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="ie10101268c9545129eb922032bed501f_D20210401-20210630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1MzE_60d81594-863e-4b2b-8409-14c26aac3d85"><ix:nonFraction unitRef="shares" contextRef="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1MzE_cafc58d5-4968-44d9-8269-28802d4ab1d4">no</ix:nonFraction></ix:nonFraction> shares were purchased under the 2017 ESPP, and the Company recorded expense of $<ix:nonFraction unitRef="usd" contextRef="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTk1MA_d007b456-06da-4bf7-9449-2dfacff8b6f8">20,176</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie10101268c9545129eb922032bed501f_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTk1Nw_51f4d74b-1a5a-4076-b09b-2ae4e5d8ae73">37,849</ix:nonFraction>, respectively. During the six months ended June&#160;30, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNDM5ODA0NjUxNzkxMA_d7fb4d38-877f-44e3-9cde-b621a3fdb7b0">38,583</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i81fd80cb6bb741a59d284cc88e7d599f_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNDM5ODA0NjUxNzkxOA_0eb23a20-4345-4436-b6b3-6698e026840d">34,256</ix:nonFraction> shares, respectively, were purchased under the 2017 ESPP and the Company recorded expense of $<ix:nonFraction unitRef="usd" contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNTUwMQ_c5ba7947-4e3b-4b6a-92b6-9a690675e21e">41,195</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i81fd80cb6bb741a59d284cc88e7d599f_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNTUwNg_341b75cc-746f-4b96-b06f-cdc160bc74e6">56,636</ix:nonFraction>, respectively. The initial reserve of shares of common stock that may be issued under the 2017 ESPP was <ix:nonFraction unitRef="shares" contextRef="i470e73798de645539193ae88dadc6e89_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjA2NA_2d235b8c-60dc-4360-8777-906ac7a19952">279,069</ix:nonFraction> shares. The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630" decimals="2" name="ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTQ4NDM0MDY5ODQxNDU_a6537041-6b2d-4f21-bd5f-edb8a8f4e87c">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year, (ii) <ix:nonFraction unitRef="shares" contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630" decimals="INF" name="ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTQ4NDM0MDY5ODQxNDk_78c1d51e-b43b-485e-affc-bb9628b6750c">550,000</ix:nonFraction> shares or (iii) such lesser number of shares determined by our Board. The Board acted prior to each of January&#160;1, 2021 and January&#160;1, 2022 to provide that there be <ix:nonFraction unitRef="shares" contextRef="i86715d6c5277421e8cfe925f1cecc804_D20210101-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjU4MQ_0548f70d-ef83-4171-a615-b784dcf00ce3"><ix:nonFraction unitRef="shares" contextRef="i475e7bce27984b60afa0fcb779a15e53_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjU4MQ_3953118d-1a20-4006-ae28-9b3ae6161788">no</ix:nonFraction></ix:nonFraction> increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i470e73798de645539193ae88dadc6e89_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjcwMQ_4735fe89-2ec5-4e2a-97c5-7edc0ac4a2d0">454,479</ix:nonFraction> shares of the Company&#8217;s common stock reserved for issuance under the 2017 ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="i1d346f637a98453b820e31adfd48cd43" continuedAt="i11fd8e978ff24b75b24b032a54ce1fbd"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless specified otherwise in an individual option agreement, stock options granted under the prior plan and the 2017 Plan generally have a <ix:nonNumeric contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2NA_01d96696-eb7f-46a5-89e1-19e5cf452f9a">ten-year</ix:nonNumeric> term and a <ix:nonNumeric contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2NQ_9a4f387f-a6d8-4efc-86b3-3cbf0312af2b">four-year</ix:nonNumeric> graded vesting period. The vesting requirement is generally conditioned upon the grantee&#8217;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for <ix:nonNumeric contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMzI3NA_9f8aae8b-912e-40ec-8e28-42fc7c37e37e">90</ix:nonNumeric> days subsequent to the termination of the option holder&#8217;s service with the Company. In the event of option holder&#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Performance-based option awards generally have similar terms, with vesting commencing on the date the performance condition is achieved and expire in accordance with the specific terms of the agreement. At June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i3f12ff0a9fb44b2ba76ca118062f6098_I20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMzcyOQ_859f150c-741c-4152-8208-e734c2f2cf34">150,000</ix:nonFraction> performance-based options outstanding and unvested that include options to be granted upon the achievement of certain research and development milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require significant assumptions that are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on historical volatility information of peer companies that are publicly available. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be canceled.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="shares" contextRef="i9ccabdb8d53a43e0970777c2bff04d2a_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1NDg_9ce2d89c-67ee-473d-8b8e-b4bd3b67b1b7"><ix:nonFraction unitRef="shares" contextRef="i056926527a084313881277f409aada39_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1NDg_c31220c4-a950-4c2e-a171-f9e34895021a">no</ix:nonFraction></ix:nonFraction>t grant any stock options to nonemployee consultants for services rendered during the three months ended June&#160;30, 2022 and 2021. The Company granted <ix:nonFraction unitRef="shares" contextRef="i29fa1f2702714d129b63abc66f393ba1_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNDkyMA_34cd247c-0d68-497c-b59e-c5f62f695952">no</ix:nonFraction> stock options to nonemployee consultants for services rendered during the six months ended June&#160;30, 2022, and <ix:nonFraction unitRef="shares" contextRef="i2e7d9406a7aa47ee9442314d3d15d65a_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1NDA_08d3e423-ceff-4380-9198-a96755f996e3">170,000</ix:nonFraction> during the six months ended June 30, 2021. There were <ix:nonFraction unitRef="shares" contextRef="ia0ba85194e42413b99a2652ace7aedca_I20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTAzNQ_8db60e5e-52d0-4cae-acdc-ee8d4fea49a7">130,834</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i572f2349b435422a9a724121d8d55ebb_I20210630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTA0Mg_9442fabe-0900-48cb-9fe3-77c9fb6d61bb">191,875</ix:nonFraction> unvested nonemployee options outstanding as of June&#160;30, 2022 and 2021, respectively. Total expense recognized related to nonemployee stock options for the three months ended June&#160;30, 2022 and 2021, was $<ix:nonFraction unitRef="usd" contextRef="i9ccabdb8d53a43e0970777c2bff04d2a_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTIyNQ_81fcc808-6365-4e32-a115-14d7490b59ae">160,337</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i056926527a084313881277f409aada39_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTIzMg_0e0f7b25-aff0-467c-9bee-32ea7925283e">55,310</ix:nonFraction>, respectively. Total expense recognized related to nonemployee stock options for the six months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i29fa1f2702714d129b63abc66f393ba1_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjY5Ng_1d74e512-ede5-4fe2-8bb9-4914cda5550d">355,107</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2e7d9406a7aa47ee9442314d3d15d65a_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjcwMg_8db12a5c-6a85-403c-8125-75f54f155051">91,000</ix:nonFraction>, respectively. Total unrecognized compensation expenses related to the nonemployee stock options was $<ix:nonFraction unitRef="usd" contextRef="ia0ba85194e42413b99a2652ace7aedca_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTMzNg_ca459bae-04c8-4580-a86f-941c6ef9c9bd">1.1</ix:nonFraction> million as of June&#160;30, 2022. The Company did <ix:nonFraction unitRef="usd" contextRef="iec14aa7f907a4e77ac1af5c41c07ec9c_D20220401-20220630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_0486d9d5-ff1c-45f5-a9ea-0ccebda067a4"><ix:nonFraction unitRef="usd" contextRef="i3b9c90a69fca438fbe1136fe21266e47_D20210401-20210630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_5a658daf-16aa-4e42-a971-c52d98f6b6ee"><ix:nonFraction unitRef="usd" contextRef="i107d1ca201584d23b2e52b6528cee3b9_D20210101-20210630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_7b235b32-0dc6-42f0-a77a-72a13847eb86"><ix:nonFraction unitRef="usd" contextRef="ibe25102eb24f4ad2918ef4f8234f9dd9_D20220101-20220630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_cf54aaf4-4c5a-4358-95c2-8009aef8ecd8">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> recognize any expense for nonemployee performance-based option awards during the three months or six months ended June&#160;30, 2022 or 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i745854a2110948c8b69f1d073bd78059_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUwNA_4a84996a-54ca-4392-b7aa-a37ddfbbe3cf">2,426,750</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i492b94210b3a4b7d86d6b2934d8249c4_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUxMg_ba342112-165c-43e1-9476-2e5aa3be2825">363,000</ix:nonFraction> stock options to employees during the three months ended June&#160;30, 2022 and 2021, respectively. The Company granted <ix:nonFraction unitRef="shares" contextRef="i726e5f3ab7a2403e8a39b4c4299b8f03_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUxNg_869ac83a-d804-44ec-9d6c-7e85bffbbc42">4,296,355</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i968b13093ea749a08c539d52bb627da8_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUyMA_f42be184-0f68-474e-91bc-7620d9ea23a1">1,006,600</ix:nonFraction> stock options to employees during the six months ended June&#160;30, 2022 and 2021 respectively. There were <ix:nonFraction unitRef="shares" contextRef="id8a49b7682c84becb2480ace83af36da_I20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTU5MA_996fb280-fba4-450e-907e-3f917e2cc65d">7,354,964</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id64ce862122d47ecbb9d8f2a54bceb89_I20210630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTU5Nw_54b5c4c1-f145-4407-9eeb-b65bb1b5f855">4,749,550</ix:nonFraction> unvested employee options outstanding as of June&#160;30, 2022, and 2021, respectively. Total expense recognized related to the employee stock options for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i745854a2110948c8b69f1d073bd78059_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUzMQ_f6f820ea-6d08-40ca-a231-f459a72f1796">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i492b94210b3a4b7d86d6b2934d8249c4_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUzOA_0672101f-31cb-42b6-bbe7-a34f0ff0b43f">1.2</ix:nonFraction> million, respectively. Total expense recognized related to the employee stock options for the six months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i726e5f3ab7a2403e8a39b4c4299b8f03_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjU0NQ_24b3302b-9365-4419-8375-f47f2ec24c51">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i968b13093ea749a08c539d52bb627da8_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjU1MA_dbbe0576-39b6-44c9-a504-96a0a6e19bc3">2.4</ix:nonFraction> million, respectively. Total unrecognized compensation expense related to employee stock options was $<ix:nonFraction unitRef="usd" contextRef="id8a49b7682c84becb2480ace83af36da_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTg3Mw_aac46b7c-b9e2-41b1-9ee3-d7ce66427254">14.3</ix:nonFraction> million as of June&#160;30, 2022. During the three and six months ended June&#160;30, 2022 and 2021, the Company did <ix:nonFraction unitRef="usd" contextRef="ic5d6c1d737bc4c51950da33e52888f55_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_2d52b2dd-865d-440e-9de5-047227dc971b"><ix:nonFraction unitRef="usd" contextRef="idc43365824f445169eaac324f106070c_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_5c21a48a-920f-4322-b823-22c1874761ff"><ix:nonFraction unitRef="usd" contextRef="ie3cb23b2f75c46c28a56b7a45b2e8df4_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_cbeef085-5973-4c79-a265-6743dcb6341b"><ix:nonFraction unitRef="usd" contextRef="i215fc869cefa46228a13075881587aa5_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_fc53ffa0-a8b3-45aa-9fbb-eae2635c36f4">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> recognize any expense for employee performance-based option awards.</span></div><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2Mw_33abb448-ee13-4127-b193-7ca3b42c5c4e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense was recognized in operating expense as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="iec95a18524b84f6cba11d8e830382e5e_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi0xLTEtMS0xMTE_a09c20ab-64b8-4ac7-b99f-5c8e163a3262">387,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i4297c63d08874f919d86d5021b5f608e_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi0zLTEtMS0xMTE_698259d3-be7e-4cd8-9a4a-77ec834c2810">430,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i1d0ce81ed9f94da3af27fc09016adade_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi01LTEtMS0xMTE_64860c0a-5a7a-4c5a-bbcf-d6ff06cf2369">782,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="ibc2df3425269455d899f773df3cd67d0_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi03LTEtMS0xMTE_c5a11293-9635-4a81-b9ed-65e411734ae8">888,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i3f367baf510f4fcaa8c3b3609d892ab8_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy0xLTEtMS0xMTE_ca2906a8-a17b-4f24-8beb-576160c5b7b6">1,332,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i53e4fcf781a84fabbc66e00870f256e2_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy0zLTEtMS0xMTE_27339b1f-8bc4-4cea-aeee-df1fafed0dbd">826,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i5c156f7edfc44816bd94d9a3facde46d_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy01LTEtMS0xMTE_4249c599-8701-49bc-9241-3149e02ec294">2,262,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i58c5083745084ba09e6a766ccd66cc65_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy03LTEtMS0xMTE_6efa7fa4-c7ee-4e56-953b-728c7ed51271">1,688,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC0xLTEtMS0xMTE_7ca35b15-98dd-4ede-b47a-ef7e493d1a05">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC0zLTEtMS0xMTE_4ee02877-31e5-4351-aeed-afb0bb9232b4">1,257,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC01LTEtMS0xMTE_731c3141-e8fd-4723-b717-dcb41a282cb3">3,045,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC03LTEtMS0xMTE_c1a87200-77fc-4b95-bb9d-31c922850aa8">2,577,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2Ng_ef07d817-5625-4787-9757-e20f7498e483" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06df7810437744ac89df59b3071c4620_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi0xLTEtMS0xMTE_7d413c4b-617f-4e37-b57f-f244bc068740">1,700,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5eb55df39f645e1a8229022112b64af_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi0zLTEtMS0xMTE_51cd7cc0-6fa5-46f6-98fc-6ab822355f06">1,219,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a447e8d29e345cca3c8dc8bedfbe959_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi01LTEtMS0xMTE_5a010e34-7996-4756-995a-ae913ecb8445">3,003,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a1bdd56609e4b82a082d20e67eb1ef3_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi03LTEtMS0xMTE_963855e5-118d-4045-826d-933b2edea175">2,520,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f5712bd10f4cb4b4c1c3047f7e03c4_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy0xLTEtMS0xMTE_296fb217-7f0e-47a8-936b-6395632ca710">20,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dbdd9413234e60876544ae84047d70_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy0zLTEtMS0xMTE_b5ce4df2-27f0-4751-a8b2-df6175984e34">37,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda6566951b0490fb0253c079cb5f522_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy01LTEtMS0xMTE_239b6791-22a4-4273-bb61-11282d87a926">41,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67836ea5c7334cdca1bd28a16693be9e_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy03LTEtMS0xMTE_b79cd270-5fff-4f35-8693-7d2742e24074">56,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC0xLTEtMS0xMTE_27e93f00-778e-4f20-ad1a-259f7c01d860">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC0zLTEtMS0xMTE_24bee972-2f74-4811-ab9e-ccc9863c2ec2">1,257,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC01LTEtMS0xMTE_7dd179f0-3cc0-45e1-9a2a-fe77bbdf7718">3,045,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC03LTEtMS0xMTE_45e22ee0-fa18-42ab-9a6f-48e33dc9997c">2,577,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="i11fd8e978ff24b75b24b032a54ce1fbd"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU1OA_f9d59d90-1228-4e4e-ae89-1dccd36a72b6" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of employee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy0xLTEtMS0xMTE_1c60689b-146d-456c-82cc-ed0dbcb0fe85">87.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy0zLTEtMS0xMTE_e3a8e75f-9cce-4f96-97a2-51605d64790e">86.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy01LTEtMS0xMTE_3173fabd-425a-4c1e-9da5-8d7b4c1831f4">87.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy03LTEtMS0xMTE_cc650d61-094b-48a8-b093-6f1bc8ee4953">81.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC0xLTEtMS0xMTE_fded23a6-d37f-46e3-afde-6bf4fa3c44bd">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC0zLTEtMS0xMTE_f5531443-6d0a-47e8-aafe-3b16c819beed">5.91</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC01LTEtMS0xMTE_924d2f30-32e7-49f1-bb82-8c03760c386c">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC03LTEtMS0xMTE_247fb205-26fb-4997-aafe-a3256cfec3ad">6.04</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS0xLTEtMS0xMTE_8cbf9e69-aa3d-4bdd-8400-302f4dd2fb1b">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS0zLTEtMS0xMTE_215b131e-4a6f-4160-8680-fa9382ee75ac">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS01LTEtMS0xMTE_1087caac-b7b3-4f0b-8f5f-1043deb2cd62">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS03LTEtMS0xMTE_9ceadfed-b276-4920-b282-a4d08cb66f40">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi0xLTEtMS0xMTE_3911094e-c50f-4627-8a78-aa4b02f8fa7b">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi0zLTEtMS0xMTE_6556a4ad-c5f5-47e6-a0a7-f05ee29e536e">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi01LTEtMS0xMTE_8575e5e5-6955-4f7e-bc86-fd451d41045e">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi03LTEtMS0xMTE_c9c869e2-83c0-4ddf-9b58-3c24948f7c80">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy0xLTEtMS0xMTE_7e563618-3b4c-496a-9a27-822da308535d">2.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy0zLTEtMS0xMTE_4db1471e-9196-4811-a0c7-a3d7a215c85e">3.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy01LTEtMS0xMTE_9f68a8d9-8c3e-4ad5-91fc-edba7b57ad5c">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy03LTEtMS0xMTE_6005dd14-8053-42b5-a2de-cc2cd908691d">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of nonemployee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy0xLTEtMS0yNDEx_2daf5c3c-623b-4122-b35c-ddb6829a4c13">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy0zLTEtMS0yNDEx_47ece13d-899b-4b16-baa0-6e6df7254b3e">80.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy01LTEtMS0yNDEx_1d66b13b-347d-4735-9905-1f869baa7dfb">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy03LTEtMS0yNDEx_03354792-9d72-4754-8a85-1712cf998839">80.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC0xLTEtMS0yNDEx_0f1493a7-2fbb-4b63-b1d0-1e3033002087">0.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC0zLTEtMS0yNDEx_82cc7b10-cc91-46de-af18-370776f66676">6.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC01LTEtMS0yNDEx_d2456d7d-a1e1-4e97-b1d5-8b3dcada0db2">0.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC03LTEtMS0yNDEx_8141d1b7-6950-4af2-89ca-e862f1eb8c62">6.23</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS0xLTEtMS0yNDEx_60294358-5b21-4496-aff5-054cec8fc573">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS0zLTEtMS0yNDEx_099e001e-46a8-4b73-bc47-1b5498aeab19">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS01LTEtMS0yNDEx_02dc4507-7219-4da9-a4ac-d4df5b7a8aac">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS03LTEtMS0yNDEx_16482988-db7f-40ab-bb85-f66a0d6bef10">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi0xLTEtMS0yNDEx_38ec55a7-aefc-4136-9c7c-26af81580c16">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi0zLTEtMS0yNDEx_cc6197ba-1123-4989-a7c2-b0ab3f67f690">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi01LTEtMS0yNDEx_06b23c70-be1e-4358-af59-b56745eb0ad4">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi03LTEtMS0yNDEx_48d66202-fe87-4cd8-b856-d4ca0eaa4299">1.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy0xLTEtMS0yNDEx_4fab4a5e-4cb5-40d0-a5ac-e1418eda7963">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy0zLTEtMS0yNDEx_918643ba-9380-49d2-ba32-88dc0804ff51">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy01LTEtMS0yNDEx_d90a4b40-611d-4ffd-80ee-5f90f6bb2eb7">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy03LTEtMS0yNDEx_30f790ea-fc33-4fac-94fd-77c4176b261b">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU1OQ_ea6c4ae7-f5d4-47b4-8f59-5316418efd00" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the number of options outstanding and the weighted average exercise price:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS0xLTEtMS0xMTE_b496d860-8b22-4840-be1f-6f439995e153">10,776,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS0zLTEtMS0xMTE_77239d56-34aa-4b8f-ba4d-bf691104529e">4.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0fd76e8bb5349d9ab296f99828590c8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS01LTEtMS0xMTE_8a4e806e-6d48-428c-88ea-6b836c54c3bb">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS03LTEtMS0xMTE_d8cc91c2-ad35-4a44-b765-20591b8ad7dd">2,389,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMi0xLTEtMS0xMTE_5606ccdb-b547-4c3d-a5b5-7ca83cf4e930">4,296,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMi0zLTEtMS0xMTE_4ad21006-cfc7-4d39-b8bb-084644a43e83">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMi01LTEtMS0xMTE_23ec2054-a71c-46c0-bad7-4844d6d3e78a">9.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMy0xLTEtMS0xMTE_814728ca-2855-4648-b2f4-dfc550284063">15,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMy0zLTEtMS0xMTE_70d7da43-1528-4f61-8bd1-7b52072ceb29">1.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNC0xLTEtMS0xMTE_58f80ff5-9292-46bc-99bd-b1d8f0273324">1,605,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNC0zLTEtMS0xMTE_54dd2004-ec5f-4a13-b801-5fccdadd08f8">5.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS0xLTEtMS0xMTE_511fc59f-d33b-4816-b8e0-231e3162b5a6">13,451,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS0zLTEtMS0xMTE_599bdc74-9366-4ab9-b6f4-14c4a7bd24d3">4.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS01LTEtMS0xMTE_d13e7e0e-b96d-41ea-9e9a-f4210d3405d0">7.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS03LTEtMS0xMTE_e54a1d54-f3ca-40eb-b674-176873ea984a">329,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi0xLTEtMS0xMTE_40b4f299-092b-44b8-806f-fac47f8fe6ee">5,965,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi0zLTEtMS0xMTE_1a101fbd-9a30-432e-8778-f86a43f7064e">5.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi01LTEtMS0xMTE_db3bbd16-badc-485a-b789-b919ed6b57a4">5.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi03LTEtMS0xMTE_9205a50d-b007-4258-9ccf-c9fb1ee87b4f">297,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At June&#160;30, 2022 there was approximately $<ix:nonFraction unitRef="usd" contextRef="i5514b03ea99548678298804a7de4efdb_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjM4Mw_aafe08b9-82b7-490b-ac8b-7f20c7a36ac0">15.4</ix:nonFraction> million of unamortized share&#8211;based compensation expense related to employee and nonemployee grants, which is expected to be recognized over a remaining average vesting period of <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU1Ng_dcfc7aee-233e-476e-85a6-52b5b6924e6b">2.53</ix:nonNumeric> years.</span></div></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_58"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 9 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81OC9mcmFnOmU2OWNmODQzMTZlNzRjZTJiODE0MWY1YTBmOWM5NDVhL3RleHRyZWdpb246ZTY5Y2Y4NDMxNmU3NGNlMmI4MTQxZjVhMGY5Yzk0NWFfMTYyNA_0fa2836d-8086-432d-a386-1fd8e9e5acee" continuedAt="ib85efcc24d2d4bfe9e24cf2547ec6a28" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ib85efcc24d2d4bfe9e24cf2547ec6a28"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of June&#160;30, 2022, the Company was in a pre-tax loss position, and is anticipated to remain so throughout the year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022, the Company did <ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81OC9mcmFnOmU2OWNmODQzMTZlNzRjZTJiODE0MWY1YTBmOWM5NDVhL3RleHRyZWdpb246ZTY5Y2Y4NDMxNmU3NGNlMmI4MTQxZjVhMGY5Yzk0NWFfMTQ4NDM0MDY5NzY3MTM_2194abc8-f01f-42ec-ab38-1747eaf7e0ae"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81OC9mcmFnOmU2OWNmODQzMTZlNzRjZTJiODE0MWY1YTBmOWM5NDVhL3RleHRyZWdpb246ZTY5Y2Y4NDMxNmU3NGNlMmI4MTQxZjVhMGY5Yzk0NWFfMTQ4NDM0MDY5NzY3MTM_735648d1-1712-43e6-b7c7-74a3825fa05c">no</ix:nonFraction></ix:nonFraction>t record a tax provision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of June&#160;30, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 10 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfNzgwNQ_361641af-da39-4396-ad69-04ee05d8dddc" continuedAt="ie7e19ad30c554d22a950571ff9956d96" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="ie7e19ad30c554d22a950571ff9956d96" continuedAt="ib755cec691b24e0bbc7211da403c8f5d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">H. Lundbeck A/S License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 26, 2015, the Company entered into an exclusive agreement with H. Lundbeck A/S (&#8220;Lundbeck&#8221;) for a worldwide perpetual licensing right related to the research, development and commercialization of OV101 (gaboxadol). On May 10, 2019, the parties amended the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the Lundbeck license agreement, as of the first amendment, the Company agreed to make milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i900ec607f0a344bbbf9a2c6f28d71d29_I20150326" decimals="-5" name="ovid:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyMTg_18ba72a7-f3ef-407d-ab68-0e93288f8f27">189.0</ix:nonFraction> million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $<ix:nonFraction unitRef="usd" contextRef="i89857dab9c4747b59247c78b1c721361_D20150326-20150326" decimals="-5" name="ovid:FirstPaymentDueUponCompletionOfFirstPhase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyMzc_dbb36013-6172-4b75-af5b-a82abfc4fd65">1.0</ix:nonFraction> million is due upon the successful completion of the first Phase <ix:nonFraction unitRef="trial" contextRef="i89857dab9c4747b59247c78b1c721361_D20150326-20150326" decimals="0" name="ovid:NumberOfTrial" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfNjU0_4f76d4c4-7314-4857-917e-bc7decd8c366">3</ix:nonFraction> trial for a product in which OV101 is an active ingredient. In addition, the agreement calls for the Company to pay royalties for an initial term based on a low double-digit percentage of sales and provides for the reduction of royalties in certain limited circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter, the Company closed its OV101 program in Angelman syndrome in early 2021. On February 1, 2022, the Company entered into Amendment No. 3 to the Lundbeck agreement, or Amendment No. 3, to permit its performance under the Healx License and Option Agreement. Under the terms of Amendment No. 3, if Healx exercises its option, the Company will owe Lundbeck a share of all milestone and royalty payments received from Healx if the Company chooses not to exercise the Ovid Opt-In Right. If the Company chooses to exercise the Ovid Opt-In Right and to co-develop and co-commercialize the program with Healx, the Company will owe a share of the net profit share to Lundbeck (see further discussion below in Note 11, Healx License and Option Agreement).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Northwestern University License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.  The Company is developing OV329 under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $<ix:nonFraction unitRef="usd" contextRef="ia2be4bda75f94fdd83408349ef2a84a4_D20161201-20161231" decimals="0" name="ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyNTA_cd3b514f-f636-46c2-92ff-da96704633c4">75,000</ix:nonFraction>, and is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i13f4bf2cb6d44b7f9ec70416be17a531_I20161231" decimals="0" name="ovid:AnnualLicenseMaintenanceFeePayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyNjA_eefbfa99-8a03-422e-85eb-a52863d60307">20,000</ix:nonFraction>, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia0577fed13974cc79c32e75d6afbf552_I20161231" decimals="-5" name="ovid:ConsiderationPayableForRightsGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMzczNg_a0b80b61-ddf3-456c-8a7d-78bae7eb8046">5.3</ix:nonFraction>&#160;million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets. The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least <ix:nonFraction unitRef="product" contextRef="ia2be4bda75f94fdd83408349ef2a84a4_D20161201-20161231" decimals="0" name="ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfNDgxMg_3ef38a38-0c80-414a-923c-53949a4947d1">one</ix:nonFraction> product that is covered by the Northwestern Patent Rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#8217;s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company&#8217;s uncured material breach or insolvency.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca AB License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 30, 2021, the Company entered into an exclusive license agreement with AstraZeneca AB, for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="iff1b6990a524490f93ea31b743af4557_D20211230-20211230" decimals="-5" name="ovid:UpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyNzU_805a7f97-3249-45e9-8676-ce24d540c530">5.0</ix:nonFraction> million and issued shares of the Company's common stock in an amount that equaled $<ix:nonFraction unitRef="shares" contextRef="icf2f99c556604fba8747dc92065c5ec1_I20211230" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyOTA_658f8031-bbf4-4324-9711-a12bc18dfd12">7.3</ix:nonFraction> million based on the volume-weighted average price of shares of the Company's common stock for the <ix:nonNumeric contextRef="iff1b6990a524490f93ea31b743af4557_D20211230-20211230" name="ovid:CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTQ4NDM0MDY5ODM1ODY_d8995be7-e8bc-4387-8bc0-8d55ab19669a">30</ix:nonNumeric> business days immediately preceding the execution date of the transaction. Since the intangibles acquired in the AstraZeneca license agreement do not have an alternative future use, all costs incurred were treated as research and development expense. The Company recorded a total of $<ix:nonFraction unitRef="usd" contextRef="i8e5e3642cc734de5ac47c8a5ccb0a666_D20211201-20211230" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEzMDY_9ae864f3-2902-4ac8-aa8c-2420f57946eb">12.3</ix:nonFraction> million as research and development expense related to this agreement during December 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="ib755cec691b24e0bbc7211da403c8f5d"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="id1d5cd62a7c1493a9fde980d2163424c_I20211230" decimals="-5" name="ovid:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEzMzI_ebd748f5-8591-4d10-9b1a-0b8dc91d3d11">203.0</ix:nonFraction> million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $<ix:nonFraction unitRef="usd" contextRef="ib3e38e7a15e34cceafd124f84ef81706_D20211230-20211230" decimals="-5" name="ovid:FirstPaymentDueUponCompletionOfFirstPhase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEzNDc_f6ce67db-a582-43cd-abe3-4059fa538a78">3.0</ix:nonFraction> million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, none of these contingent payments were considered probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of their respective employment agreements, certain of our executive officers are eligible to receive severance payments and benefits upon a termination without &#8220;cause&#8221; or due to &#8220;permanent disability,&#8221; or upon &#8220;resignation for good reason,&#8221; contingent upon the executive officer&#8217;s delivery to the Company of a satisfactory release of claims, and subject to the executive officer&#8217;s compliance with non-competition and non-solicitation restrictive covenants.</span></div></ix:continuation><div id="iffb89c91b68044fe89584fa1aa2f8679_64"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 11 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTM0MjA_0e1e37d4-bd00-486e-87bf-f96454c45d0a" continuedAt="i94c0c40cb817408491ca5bf4d4ded97d" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i94c0c40cb817408491ca5bf4d4ded97d" continuedAt="ia962f441c7cc49c5ac0c3a06c87b0ae3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Angelini Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 9, 2020, the Company entered into the Angelini License Agreement, pursuant to which the Company granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABAA receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey (the &#8220;European Territory&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 29, 2021, the Company received a notice of termination of the Angelini License Agreement. Subsequently, Angelini and the Company mutually agreed to waive the six month termination notice provisions and the Angelini License Agreement terminated effective March 31, 2021. The Company has been released from its performance obligations and will not be entitled to any future milestone payments under the Angelini License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluated the Angelini License Agreement to determine whether it was a collaborative arrangement for purposes of ASC 808. The Company concluded that because Angelini was not the ultimate decision maker or the legal owner of the license, Angelini was not considered an active participant and therefore the Angelini License Agreement was outside of the scope of ASC 808. The Company concluded that Angelini was a customer with regard to the combined license and research and development activities and as such the Angelini License Agreement should be evaluated under ASC 606.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company identified the following material promises under the Angelini License Agreement: (1) licensing of intellectual property with respect to OV101; (2) completion of certain ongoing trials; (3) transfer of a specified amount of compound and related information; (4) potential for funding <ix:nonFraction unitRef="number" contextRef="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630" decimals="2" name="ovid:PotentialFundingCostPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcwNjI_a6d707c4-e939-4224-85cc-16857f3310fe">35</ix:nonFraction>% of the cost for Angelini future trials limited to $<ix:nonFraction unitRef="usd" contextRef="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630" decimals="-5" name="ovid:CostOfAgreementNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcwNzg_217f3550-39cc-416b-9dcb-60e717548715">7.0</ix:nonFraction> million; and (5) completion of the manufacturing process technology transfer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630" decimals="-5" name="ovid:DeferredUpfrontPaymentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcwOTU_584c98c5-ad75-4768-8d1d-dde995098ce2">7.0</ix:nonFraction> million represented a potential payment to a customer and was deferred. The transfer of compound and related information was considered a contingent milestone payment that will be recognized upon acceptance by Angelini of the milestone. The Company further determined that the license and the completion of ongoing trials were distinct from each other, as each had value without the other. As such, for the purposes of ASC 606, the Company determined that these two material promises, represented distinct performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the Angelini License Agreement and during the year ended December 31, 2020, Angelini made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="i417dd14e7c28468cbb32aa243f71b4ee_I20201231" decimals="-5" name="ovid:LicenseAgreementUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxMTE_3c49a874-7f99-4d08-a47c-f80ea2859647">20.0</ix:nonFraction> million. Upon the transfer of the specified amount of compound and related information and acceptance by Angelini, Angelini paid the Company an additional $<ix:nonFraction unitRef="usd" contextRef="i97e6ce3a5011403898de05a7b8a7950e_D20220101-20220630" decimals="-5" name="ovid:AdditionalUpFrontFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxMjY_e91c032d-d23e-4896-94ad-39b31012ed69">5.0</ix:nonFraction> million. This payment was determined to be variable consideration which was constrained and not considered part of the upfront transaction price allocation. The Company determined the transaction price was equal to the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i97e6ce3a5011403898de05a7b8a7950e_D20220101-20220630" decimals="-5" name="ovid:UpFrontFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxNDI_701e92dd-1a02-4e16-8563-35bef9e494e7">20.0</ix:nonFraction> million. The transaction price was allocated based on the standalone selling price of the license and the ongoing trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, no revenue was recognized pursuant to the Angelini License Agreement. During the six months ended June 30, 2021 and effective upon termination of the Angelini License Agreement, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxNTg_dd662136-759e-4456-bef2-cd81654404a7">12.4</ix:nonFraction> million of revenue consisting of $<ix:nonFraction unitRef="usd" contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630" decimals="-5" name="ovid:LicenseRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxNzM_0d4385a7-efd5-40de-8f0e-cac52edd233b">5.4</ix:nonFraction> million of license revenue related to ongoing trials and the $<ix:nonFraction unitRef="usd" contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630" decimals="-5" name="ovid:AmountForPotentialFutureTrials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxODg_8d934300-08af-4abe-a500-31bc13f51c7d">7.0</ix:nonFraction> million related to the potential <ix:nonFraction unitRef="number" contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630" decimals="2" name="ovid:PotentialFundingCostPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxOTQ_1515262f-c4cf-4df5-a264-893640d1ac1b">35</ix:nonFraction>% funding of the cost for Angelini future trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 6, 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company entered into the Takeda License and Termination Agreement, pursuant to which Takeda secured rights to the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="ic5dc9854b22c4401944c1c3f1c81fa35_I20210331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyMTY_d61a40d0-34ef-4546-a077-bb60797c41e6">50</ix:nonFraction>% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company&#8217;s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="ia962f441c7cc49c5ac0c3a06c87b0ae3" continuedAt="i25e3e37f25664798b64918cac84f4ea7"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Takeda License and Termination Agreement, all rights in soticlestat were owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including milestone payments or any future development and commercialization costs. On March 29, 2021 upon the closing of the Takeda License and Termination Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if4975144823b4b6397ba0954f6522143_I20210329" decimals="-5" name="ovid:UpfrontPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyMzM_ac42e12d-4ad9-44b7-9f97-a0e8c908c309">196.0</ix:nonFraction> million and, if soticlestat is successfully developed, will be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="if4975144823b4b6397ba0954f6522143_I20210329" decimals="-5" name="ovid:AgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyNTA_ae8fd6ff-1cbb-4271-961e-f6ee1106ec07">660.0</ix:nonFraction> million upon Takeda achieving developmental, regulatory and sales milestones. In addition, the Company will be entitled to receive tiered royalties beginning in the low double-digits, and up to <ix:nonFraction unitRef="number" contextRef="i76ece08d363143b3a4e48d1512b2d3f2_D20210329-20210329" decimals="2" name="ovid:AdditionalPaymentReceivableOnSalesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyNTY_bc060a06-d332-4ab1-b83e-5f897d9d3eaf">20</ix:nonFraction>% on sales of soticlestat if regulatory approval is achieved. Royalties will be payable on a country-by-country and product-by-product basis for any indications that soticlestat is approved for and sold during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company identified the following material promises under the Takeda License and Termination Agreement: (1) no later than the second business day prior to the closing of the Takeda License and Termination Agreement (the &#8220;Closing Date&#8221;), the Company and Takeda were required to agree on an estimate of the development expenses that accrued, or would accrue, under the original collaboration agreement as of March 31, 2021; (2) on the Closing Date, the Company was required to (i) provide and transfer to Takeda the materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the Takeda License and Termination Agreement, (ii) assign to Takeda certain agreements applicable to the soticlestat program, and (iii) assign to Takeda all of its right, title and interest in, to and under all intellectual property rights developed or created pursuant to the original collaboration agreement and owned jointly by the Company and Takeda as of the Closing Date; (3) within 45 days after March 31, 2021, the Company and Takeda were required to provide a written report to the finance officer designated by the other party setting forth a final total of the development expenses that accrued as of March 31, 2021 and, within 10 business days after receipt of such report, the finance officers shall agree on whether a net settlement payment is due from Takeda to the Company or from the Company to Takeda; and (4) within 75 days after the Closing Date, to the extent not provided on the Closing Date, Ovid shall provide to Takeda (i) any materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the Takeda License and Termination Agreement, (ii) other documents (including all expired agreements and related data developed thereunder) to the extent relating to the soticlestat program that are necessary for the exploitation, development, commercialization and manufacture of soticlestat, as further set forth in the Takeda License and Termination Agreement and (iii) any tangible embodiments of the intellectual property rights controlled by Ovid that are reasonably necessary for, used in or held for use in Takeda&#8217;s exploitation of the soticlestat program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determined the transaction price is equal to the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ie4c8f02f699a46e3be40c5246e96e602_D20220101-20220630" decimals="-5" name="ovid:UpFrontFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyNzM_90e62543-8588-4ba5-a6f5-14c9738fd6b8">196.0</ix:nonFraction> million and is associated with all four performance obligations identified above. It is noted that the incremental effort associated with performance obligations three and four is negligible and not material in the context of the Takeda License and Termination Agreement since all of the information is related to the collaboration period for which the Company already has the information readily available. Therefore, since they are not material in the context of the Takeda License and Termination Agreement, the full upfront fee was allocated to the two performance obligations satisfied at closing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, <ix:nonFraction unitRef="usd" contextRef="ie4c8f02f699a46e3be40c5246e96e602_D20220101-20220630" decimals="INF" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfODQ2Mw_c6a3e087-30d9-4060-b57c-2920e607596f">no</ix:nonFraction> expense was recognized pursuant to the Takeda License and Termination Agreement. During the six months ended June&#160;30, 2021, the Company recognized a credit in research and development expenses of $<ix:nonFraction unitRef="usd" contextRef="id97b2a2da582483fb06d8288d746a65f_D20210101-20210630" decimals="-5" name="ovid:ResearchAndDevelopmentExpenseReimbursementReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfODY1MA_0ae3e87c-1fad-4a72-89f2-5ebde0f63494">2.6</ix:nonFraction> million and recognized $<ix:nonFraction unitRef="usd" contextRef="id97b2a2da582483fb06d8288d746a65f_D20210101-20210630" decimals="-5" name="ovid:GeneralAndAdministrativeExpenseReimbursementReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfODY2OA_883e8b7a-35eb-422e-928c-e10f5d54b949">0.1</ix:nonFraction> million in general and administrative expenses representing costs which were reimbursed to the Company from Takeda. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Healx License and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 1, 2022, the Company entered into the Healx License and Option Agreement. Under the terms of the Healx License and Option Agreement, Healx has secured a one-year option to investigate gaboxadol (OV101) as part of a potential combination therapy for Fragile X syndrome in a Phase 2A clinical trial, as well as a treatment for other indications, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ibabba1d2cdfc4be9b9d2d6a75d6c5d4d_D20220201-20220201" decimals="-5" name="ovid:UpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyODg_57779d46-ea24-4130-91ab-4078ea8a3a4d">0.5</ix:nonFraction> million, and fees to support prosecution and maintenance of our relevant intellectual property rights. At the end of the one-year option period, Healx has the option to secure rights to an exclusive license under our relevant intellectual property rights, in exchange for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="ibabba1d2cdfc4be9b9d2d6a75d6c5d4d_D20220201-20220201" decimals="-5" name="ovid:DevelopmentAndCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMDM_82e89ab0-e35d-4ed9-9d4b-ea1d53c7586a">2.0</ix:nonFraction> million, development and commercial milestone payments, and low to mid-tier double digit royalties. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healx will assume all responsibility for, and costs of, both development and commercialization of gaboxadol following the exercise of the option. The Company will retain the option to co-develop and co-commercialize the program with Healx, or the Ovid Opt-In Right, at the end of a positive readout of clinical phase 2B and would share net profits and losses in lieu of the milestones and royalty payments. If the Ovid-Opt-In Right were exercised, the Company would be required to pay Healx <ix:nonFraction unitRef="number" contextRef="i3dff19c285cc484e915ef6c61e6e770a_D20220101-20220630" decimals="2" name="ovid:PercentageOfDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMDk_60a211e2-fdd5-4feb-a3ec-48b491ca0c9b">50</ix:nonFraction>% of development costs. The Company does not plan to conduct further trials of gaboxadol. The term of the Healx License and Option Agreement will continue until the later of (a) the expiration of all relevant royalty terms, or in the event that Healx does not exercise its option during the option period defined in the Healx License and Option Agreement, or the Option Period, the expiration of such period, or (b) in the event that Healx does exercise its option during the Option Period, and the Company does not exercise the Ovid Opt-In Right during the period of time we have to opt-in, or the Opt-In Period, or the opt-in terms are otherwise terminated, upon the expiration of all payment obligations, or (c) in the event that Healx does exercise the Option during the Option Period, and the Company does exercise the Ovid Opt-In Right during the Opt-In Period, such time as neither Healx nor Ovid is continuing to exploit the gaboxadol. As part of the revised contractual obligations with Lundbeck, Ovid will owe Lundbeck a share of all milestone and royalty payments received from Healx, if we do not </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="i25e3e37f25664798b64918cac84f4ea7" continuedAt="ia5bf75425eed4359a1efe9583804c82f"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">exercise the Ovid Opt-In Right. If we do exercise the Ovid Opt-In Right to co-develop and co-commercialize the program with Healx, we will owe a share of the net profit share to Lundbeck.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9290ae797c984118825406206a94dc50_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTQ4NDM0MDY5ODg4NjI_eae75a64-7487-4856-9e88-3ddb6d946095">No</ix:nonFraction> revenue was recognized relating to this agreement during the three months ended June&#160;30, 2022. During the six months ended June&#160;30, 2022, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i3dff19c285cc484e915ef6c61e6e770a_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTE4MTc_d293a3b7-8a78-48a7-b31b-e5d50ccd1564">0.5</ix:nonFraction> million associated with the Healx License and Option Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Marinus Pharmaceuticals Out-License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 1, 2022, the Company entered into an exclusive patent license agreement with Marinus, or the Marinus License Agreement. Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consist of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory which was received on March 18, 2022, Marinus issued, at the Company's option, <ix:nonFraction unitRef="shares" contextRef="i23af69e8e97e4050a2c0ce0556ad29df_I20220301" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMTk_b17b6d3f-31cd-46ce-bf21-c669c12603b3">123,255</ix:nonFraction> shares of Marinus common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i23af69e8e97e4050a2c0ce0556ad29df_I20220301" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMjg_36195260-2eeb-4806-9998-db642cf593c1">0.001</ix:nonFraction> per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single digits on net sales of each such licensed product sold.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ia5bf75425eed4359a1efe9583804c82f">The Company recorded revenue and an associated investment in equity securities of approximately $<ix:nonFraction unitRef="usd" contextRef="i315b0e5db1654ee59132ac7839cdab6b_D20220301-20220301" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTMwNDg_aab1a5a5-ffc3-41e4-a77f-a0beee51bb24">0.9</ix:nonFraction> million related to the patent license agreement on March 18, 2022, based on the price of Marinus common stock on March&#160;1, 2022. The Company had an unrealized loss on the Marinus common stock of $<ix:nonFraction unitRef="usd" contextRef="ib8717ce65ce149a596e214e8657b3b6c_D20220401-20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMzE_47c122de-d53c-4a8a-8a41-5b53768935cb">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i44bf255bfaca451db24cb2de86760946_D20220101-20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTMyMjY_b94c4ef4-be02-4d6a-9e18-428f9c51c178">0.3</ix:nonFraction> million for the three and six months ended June&#160;30, 2022, which was recorded as an unrealized loss on equity securities and is reflected in other (expense) income, net in the condensed consolidated statements of operation</ix:continuation>s.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_67"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 12 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82Ny9mcmFnOjllMjgzNmU3ODNiYjQ2MjM5NGQ0Mzc1NDBhZDRjYjE3L3RleHRyZWdpb246OWUyODM2ZTc4M2JiNDYyMzk0ZDQzNzU0MGFkNGNiMTdfMjEw_b6208652-4afb-4f21-844e-7d036c0bd7e3" continuedAt="i31800bba4c59434e9e52e1a636ea6ea6" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i31800bba4c59434e9e52e1a636ea6ea6">In March 2021, the Company entered into the Takeda License and Termination Agreement with Takeda. For a description of the Takeda License and Termination Agreement, see Note 11.</ix:continuation></span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 13 &#8211; <ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RleHRyZWdpb246ZDVmMjAzNGYxOGM1NDcxZjgzMzM1NTA1ZjQ5MThmZGZfMjEwOA_a093e884-0f43-471a-9c88-393a96a3bf1d" continuedAt="i5339b90d8356492bb505e77e97ad89c2" escape="true">NET (LOSS) INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i5339b90d8356492bb505e77e97ad89c2" continuedAt="i176738a4cd5c4d08bd8872a4f5286954"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding outstanding stock options that have not yet vested. Diluted net income per share is calculated based upon the weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares outstanding during the period resulting from the assumed exercise of outstanding stock options determined under the treasury stock method and the assumed conversion of preferred stock into common shares determined using the if-converted method. Diluted net loss per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The basic and diluted net (loss) income per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For any period in which the Company records net income, undistributed earnings allocated to the participating securities are subtracted from net income in determining net income attributable to common stockholders. The undistributed earnings have been allocated based on the participation rights of preferred stock and common shares as if the earnings for the year have been distributed. For periods in which the Company recognizes a net loss, undistributed losses are allocated only to common shares as the participating securities do not contractually participate in the Company&#8217;s losses. Basic net (loss) income per share is computed by dividing the net (loss) income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Participating securities are excluded from basic weighted-average common shares outstanding.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><ix:continuation id="i176738a4cd5c4d08bd8872a4f5286954"><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RleHRyZWdpb246ZDVmMjAzNGYxOGM1NDcxZjgzMzM1NTA1ZjQ5MThmZGZfMjEwOQ_a282e849-9c68-4b74-b9fc-ee9e8ed25448" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi0xLTEtMS0xMTE_a42c263c-c781-42f4-afee-a060e2f70e9a">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi0zLTEtMS0xMTE_5d15fa70-755b-4785-906f-4596197c5347">15,788,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi01LTEtMS0xMTE_97f7d0ea-74a7-415f-b77c-395e693a6c52">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi03LTEtMS0xMTE_9be37e70-fec7-4caa-a3d8-10be71d28383">160,218,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy0xLTEtMS0xMTE_23823bab-2eff-4e4f-bdba-06b0c33990ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy0zLTEtMS0xMTE_c663cfb8-334c-4204-b92b-665c870e89e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy01LTEtMS0xMTE_667df96a-029c-4c2b-bf84-768d4556a09e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy03LTEtMS0xMTE_86ed7220-8dc0-4a01-bd32-7f6ab8264bfc">4,824,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC0xLTEtMS0xMTE_a4799c9d-6a0b-44b5-b5c6-e3cea8445993">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC0zLTEtMS0xMTE_f8c47e6f-2c2b-444f-8994-c9fc87e21726">15,788,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC01LTEtMS0xMTE_060d8db7-ba56-409a-8b37-a32066b5a2b9">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC03LTEtMS0xMTE_1cc946c1-3868-4881-853d-597365e00841">155,394,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC0xLTEtMS0xMTE_5b564eb9-a362-453b-9da3-ab2f9865f7f0">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC0zLTEtMS0xMTE_30cd0352-1104-4fef-b683-71c5bcb12b9e">15,788,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC01LTEtMS0xMTE_3dc0dde7-0a5c-4c0e-ad1b-52e65ea48736">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC03LTEtMS0xMTE_80ba5f95-62b7-4bb2-b816-cfa033c722f0">155,394,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in computing net income (loss) per share - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS0xLTEtMS0xMTE_94eafe85-1c1f-4815-9c39-ad73debb0cd5">70,391,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS0zLTEtMS0xMTE_7416b1c0-4b06-4545-a2e8-c2d33222122d">67,818,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS01LTEtMS0xMTE_6f91c0fb-10c2-4694-b5fc-fdaffe59ddee">70,391,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS03LTEtMS0xMTE_e2b593fd-d7cb-4977-a2d7-11dd9b90cf5c">66,953,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in computing net income (loss) per share - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtMS0xLTEtMTEx_e620693d-465f-47e0-8107-32fbc351b100">70,391,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtMy0xLTEtMTEx_9e53e7b2-422d-4e65-8733-dafa6d2ea3b2">67,818,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtNS0xLTEtMTEx_540b0060-b40f-4d01-a7f2-cdb2fbb99a97">70,391,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtNy0xLTEtMTEx_47e93ebc-5fda-45b7-baff-3637a1cfc38c">67,565,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtMS0xLTEtMTEx_a6283d14-7461-4d4f-afae-d33b46d01c84">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtMy0xLTEtMTEx_e4efbe03-bbdc-4d1d-9339-a6eb4508447f">0.23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtNS0xLTEtMTEx_e481b46b-b596-4783-8535-8645a8394507">0.44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtNy0xLTEtMTEx_fb534ce9-3220-46ce-8fb6-a2c7fe438f4e">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItMS0xLTEtMTEx_2ebf5bf8-8722-4c03-b332-b60770743d7f">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItMy0xLTEtMTEx_263bd529-a779-41a8-95a1-632a30f53471">0.23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItNS0xLTEtMTEx_9c1df1b1-8913-40f5-a7c3-b2160cd2c34d">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItNy0xLTEtMTEx_737c63cb-045a-411a-930c-dcdc3f742ca5">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RleHRyZWdpb246ZDVmMjAzNGYxOGM1NDcxZjgzMzM1NTA1ZjQ5MThmZGZfMjEwNw_d63a565a-52b5-4f75-a005-8a0542ddcd67" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bc5d022a300431fa15d4be1cb81e3e7_D20220401-20220630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi0xLTEtMS0xMTE_a6b1abc8-3392-47ac-a85b-f62ebc67c4a6">13,451,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd93d38c649e4bcf9dc0997d1f36eb7a_D20210401-20210630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi0zLTEtMS0xMTE_70cb5a0c-6d04-46bb-b24a-30eb2820b26a">10,352,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id20ea80f44894cb98636c41e3d77bcc1_D20220101-20220630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi01LTEtMS00MTg2_891f8f0d-decf-49a6-9807-82038e69c408">13,103,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff9fd4d2cf174503b125fdaeeb11c6fc_D20210101-20210630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi03LTEtMS00MTg2_15e96e34-11c5-426b-bc11-46eb8ab8ab7f">10,435,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable upon conversion of Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9467652c06534816ba1aa9bc3a888d71_D20220401-20220630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy0xLTEtMS0xMTE_b783c30a-aff1-4542-85c7-4770a5d8f1cf">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia03f0f7a1a3d450aad2a50ecf43a159f_D20210401-20210630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy0zLTEtMS0xMTE_0b9be222-f465-4fce-ba57-f7ffb68baa22">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i660cdfd473c24c05b53a1ce7e820084a_D20220101-20220630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy01LTEtMS00MTg2_a9f70815-2af8-422e-b2a7-cd1bb9e08b1d">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09793674d52f4223a7e62a26166fa5e4_D20210101-20210630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy03LTEtMS00MTg2_8b322d2b-bd6d-469f-ac49-1780749b4b08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">20</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 15, 2022. In addition to historical financial information, the following discussion contains forward-looking statements based upon our current plans, expectations and beliefs that involve risks, uncertainties and assumptions. Our actual results may differ materially from those described in or implied by these forward-looking statements because of many factors, including those set forth under the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A. Such factors may be amplified by the ongoing COVID-19 pandemic and its potential impact on our business and the global economy.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_76"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on drug discovery and development for epilepsies and rare CNS disorders in a manner that is scientifically driven, patient focused and is coupled with an integrated and disciplined approach to research, clinical development and business development. Our team has significant experience and understanding of rare epilepsy and neurological conditions, and we continue to build insight into the way the different molecular mechanisms and pathways underlying these disorders impact the symptoms patients suffer. Ovid has set out to be a leader in the field, and has developed a differentiated pipeline containing novel mechanisms of action to target different causes of epilepsies and seizures. Our knowledge of epilepsy disease biology and pathology, which was acquired through our small molecule development programs, now contributes to our pursuit of additional relevant genetic targets and molecular pathways that are the cause of seizures. Over time, we have built a scalable scientific platform and efficient development capabilities in epilepsies that focus on clear, clinical endpoints. We are initially pursuing therapeutic assets for rare disorders as they can leverage accelerated development programs. If successfully developed and marketed in rare conditions, we intend to explore these assets for broader neurologic indications. Our cohesive focus in epilepsies and seizures reinforces our belief that we can develop and produce multiple novel medicines, scale our infrastructure, and thereby succeed in our mission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since our inception in April 2014, we have devoted substantially all of our efforts to organizing and planning our business, building our management and technical team, acquiring operating assets and raising capital.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following chart sets forth the status and mechanism of action of our drug candidates:</span></div><div style="margin-top:6pt;text-align:justify"><img src="ovid-20220630_g1.jpg" alt="ovid-20220630_g1.jpg" style="height:355px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We have historically funded our business primarily through the sale of capital stock. Through June&#160;30, 2022, we have raised net proceeds of $275.4 million from the sale of our convertible preferred stock and our common stock. As of June&#160;30, 2022, we had $152.4 million in cash, cash equivalents and marketable securities. We have also, in previous periods, generated revenue through our license and collaboration agreements. In July 2022, Takeda provided a corporate update in which it reiterated that the anticipated timeline for regulatory filing of the two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes are expected in Takeda&#8217;s 2024 fiscal year. As of June&#160;30, 2022, we had an accumulated deficit of $202.1 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for at least the next several years. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned clinical trials and expenditures on our other research and development and commercial development activities. We expect our expenses will increase substantially over time as we:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">continue the ongoing and planned preclinical and clinical development of our drug candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">build a portfolio of drug candidates through the development, acquisition or in-license of drugs, drug candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">develop, maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">implement operational, financial and management systems; and attract, hire and retain additional administrative, clinical, regulatory, manufacturing, commercial and scientific personnel.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_79"></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_82"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have implemented business continuity plans designed to address and mitigate the impact of the ongoing COVID-19 pandemic on our employees and our business. We continue to operate normally with the exception of enabling all of our employees to work in a hybrid environment, productively at home or in the office, and by continuing to abide by travel restrictions issued by federal, state and local governments. Our hybrid work environment policy remains fluid as federal, state and local guidelines, rules and regulations continue to change and evolve. </span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have generated revenue under various license and collaboration agreements. We have not generated any revenue from commercial drug sales and we do not expect to generate any further revenue unless or until we obtain regulatory approval and commercialize one or more of our current or future drug candidates. In the future, we may also seek to generate revenue from a combination of research and development payments, license fees and other upfront or milestone payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our product discovery efforts and the development of our product candidates, which include, among other things:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">employee-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">fees paid to consultants for services directly related to our drug development and regulatory effort;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">expenses incurred under agreements with contract research organizations, as well as contract manufacturing organizations and consultants that conduct preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">costs associated with preclinical activities and development activities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">costs associated with technology and intellectual property licenses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">milestone payments and other costs under licensing agreements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">depreciation expense for assets used in research and development activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Costs incurred in connection with research and development activities are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development activities are and will continue to be central to our business model. We expect our research and development expenses to increase over the next several years as we advance our current and future drug candidates through preclinical studies and clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. It is difficult to determine with certainty the duration and costs of any preclinical study or clinical trial that we may conduct. The duration, costs and timing of clinical trial programs and development of our current and future drug candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">number of clinical trials required for approval and any requirement for extension trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">per patient trial costs; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">number of patients who participate in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">number of sites included in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">countries in which the clinical trial is conducted;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">length of time required to enroll eligible patients;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">duration of patient follow-up; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">efficacy and safety profile of the drug candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the probability of success for any of our current or future drug candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidate&#8217;s commercial potential.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits and stock-based compensation expense, related to our executive, finance, business development and support functions. Other general and administrative expenses include costs associated with operating as a public company described below, travel expenses, conferences, and professional fees for auditing, tax and legal services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (expense) income primarily consists of unrealized gains (losses) on long-term equity investments and interest income earned on our cash and cash equivalents maintained in money market funds and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_88"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2022 and 2021, respectively</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License and other revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License revenue - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,637)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,589)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,315)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,589)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No revenue was generated in the three months ended June&#160;30, 2022 and 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical and development expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,502)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,684&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,637)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022, total research and development expenses were $6.0 million compared to $7.7 million for the same period in 2021. The decrease of $1.6 million was primarily due to the decision to discontinue the clinical study of OV101 in Angelman syndrome and Fragile X syndrome and the termination of the Takeda collaboration agreement for OV935.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,258&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,629&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses were $8.3 million for the three months ended June&#160;30, 2022 compared to $6.6 million for the same period in 2021. The increase of $1.6 million was primarily due to straight-line rent expense recognized of approximately $0.5 million, strategic consulting fees of approximately $0.6 million, and increased legal and accounting fees relating to business development and compliance of approximately $0.2 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There was no tax provision recorded for the three months ended June&#160;30, 2022. The tax provision recorded for the three months ended June&#160;30, 2021 was $1.5 million, which related to licensing revenue recognized in the first quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (expense) income, net for the three months ended June&#160;30, 2022 includes unrealized gain (loss) on long-term equity investments and interest earned on marketable securities, and included interest income and other nominal items for the three months ended June&#160;30, 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">24</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2022 and 2021, respectively</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.969%"><tr><td style="width:1.0%"></td><td style="width:39.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,937)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License revenue - related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,383&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206,937)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,054)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,068)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,017&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,138&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,122)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,973)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190,915)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue was $1.4&#160;million during the six months ended June&#160;30, 2022, recorded in connection with the Marinus and Healx License Agreements. Total revenue was $208.4&#160;million for the six months ended June 30, 2021, recorded in connection with the Takeda and Angelini License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change </span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical and development expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,266&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(481)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,932&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,054)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, total research and development expenses were $13.9 million compared to $23.9 million for the same period in 2021. The decrease of $10.0 million was primarily due to the decision to discontinue the clinical study of OV101 in Angelman syndrome and Fragile X syndrome and the termination of the Takeda collaboration agreement for OV935.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June&#160;30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,788)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,068)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expenses were $18.1 million for the six months ended June&#160;30, 2022 compared to $22.2  million for the same period in 2021. The decrease of $4.1 million was primarily due to the discontinuation of certain studies and programs detailed above, as well as reduced administrative headcount.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There was no tax provision recorded for the six months ended June&#160;30, 2022. The tax provision recorded for the six months ended June&#160;30, 2021 was $2.0  million, which related to licensing revenue recognized in the first quarter of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (expense) income for the six months ended June&#160;30, 2022 includes unrealized gain (loss) on long-term equity investments and interest earned on marketable securities, and included interest income and other nominal items for the six months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had total cash, cash equivalents and marketable securities of $152.4 million as compared to $187.8 million as of December 31, 2021. The $35.4 million decrease was due to payments relating to licensing and other agreements of $5.0 million, and operating expenses totaling $32.0 million for the six months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar to other development stage biotechnology companies, we have generated limited revenue, which has been through the Takeda License and Termination Agreement and the Angelini License Agreement. With the exception of the three months ended March 31, 2021, when we received the one-time upfront payment of $196.0 million as part of the Takeda License and Termination Agreement, we have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for the next several years. We recorded net losses of approximately $14.6 million and $15.8 million for the three months ended June&#160;30, 2022 and 2021, respectively.  As of June&#160;30, 2022, we had an accumulated deficit of $202.1 million and working capital of $146.9 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents and marketable securities as of June&#160;30, 2022 are sufficient to fund existing and planned cash requirements through at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses and general overhead costs. We have based our estimates on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. We cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had no long-term debt and no material non-cancelable purchase commitments with service providers, as we have generally contracted on a cancellable, purchase order basis. We cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with AstraZeneca AB, H. Lundbeck A/S, and Northwestern. Pursuant to these license agreements, we have agreed to make milestone payments up to an aggregate of $279.3 million upon the achievement of certain development, regulatory and sales milestones. These potential contingent payments have not been recognized in these financial statements, given that the timing, probability, and amount, if any, of such payments cannot be reasonably estimated at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2021, we entered into a 10-year lease agreement for our corporate headquarters with a term commencing March 10, 2022, for approximately 19,143 square feet of office space at Hudson Commons in New York, NY. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3 million per year. Rent payments commence 10 months following the commencement date of the lease, or January 10, 2023, and continue for 10 years following the rent commencement date. Rent also includes two months of free rent in the 6th and 7th months following the rent commencement date. We issued a letter of credit in the amount of $1.9 million in association with the execution of the lease agreement, which is reflected as restricted cash on the balance sheet. Payment obligations under the lease agreement include approximately $1.1 million in the 12 months subsequent to June&#160;30, 2022 and approximately $23.5 million over the term of the agreement. For additional information see Note 5 of our condensed consolidated financial statements under the heading "Leases".</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any product revenues from product sales to date. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings and additional funding from license and collaboration arrangements. Except for any obligations of our collaborators to reimburse us for research and development expenses or to make milestone or royalty payments under our agreements with them, we will not have any committed external source of liquidity. To the extent that we raise additional capital through future equity offerings or debt financings, ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that such financings will be obtained on terms acceptable to us, if at all. The ongoing COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations. If we raise additional funds through collaborations, strategic alliances or licensing agreements with third </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">parties for one or more of our current or future drug candidates, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (Registration No. 333-250054) that allows us to sell up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities and/or warrants (the &#8220;S-3 Registration Statement&#8221;), which includes a prospectus covering the issuance and sale of up to $75.0 million of common stock pursuant to an at-the-market (&#8220;ATM&#8221;) offering program. As of June&#160;30, 2022, we had $250.0 million available under our S-3 Registration Statement, including $75.0 million available pursuant to our ATM program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, <br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(33,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">141,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(81,753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(1,595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Net (decrease) increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">(114,986)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">140,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Cash (Used In) Provided By Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in operating activities was $33.4 million for the six months ended June&#160;30, 2022, which consisted of a net loss of $30.7 million offset by $3.1 million in stock-based compensation expense, $0.1 million, net, of other noncash transactions and charges, and a decrease in accounts payable and accrued expenses of $5.5 million. Net cash provided by operating activities was $145.1 million for the six months ended June&#160;30, 2021, which resulted from an upfront payment pursuant to the Takeda License and Termination Agreement, offset by operating expenses for the period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used In Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities was $81.8 million for the six months ended June&#160;30, 2022, which was primarily due to the purchases of marketable securities during the period. A nominal amount was used in investing activities for the six months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided By Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the six months ended June&#160;30, 2022 was primarily due to the exercise of options. Net cash provided by financing activities of $0.1 million for the six months ended June&#160;30, 2021 was primarily due to proceeds from exercise of options and purchases of shares under the 2017 employee stock purchase plan.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_94"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Emerging Growth Company Status and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We have taken advantage of reduced reporting requirements in this Quarterly Report on Form 10-Q and will continue to do so until December 31, 2022, the date on which we cease to be an emerging growth company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we will continue to qualify as smaller reporting company as defined in the Exchange Act even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">reduced disclosure about our executive compensation arrangements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">to provide audited financial statements for two fiscal years, in contrast to other reporting companies, which must provide audited financial statements for three fiscal years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of June 30, 2022, in addition to being classified as a &#8220;smaller reporting company,&#8221; we will be classified as an &#8220;accelerated filer&#8221; pursuant to SEC rules and will be required to provide, among other items, an auditor&#8217;s attestation of management&#8217;s assessment of internal control over financial reporting required under Sarbanes-Oxley Act Section 404(b) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">beginning </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">with our annual report for the year ending December 31, 2022.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_97"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, there were no material changes to our critical accounting policies as reported for the year ended December 31, 2021 as part of our Annual Report on Form 10-K, which was filed with the SEC on March 15, 2022. In addition, see Note 2 of our Condensed Financial Statements under the heading &#8220;Recent Accounting Pronouncements&#8221; for new accounting pronouncements or changes to the accounting pronouncements during the six months ended June&#160;30, 2022.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_100"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary objectives of our investment activities are to ensure liquidity and to preserve capital. As of June&#160;30, 2022, we had cash, cash equivalents and marketable securities totaling $152.4 million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and marketable securities in institutional market funds that are comprised of U.S. Treasury and U.S. Treasury-backed repurchase agreements as well as treasury notes and high quality short-term corporate bonds.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_103"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of June&#160;30, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our most recent quarter ended June&#160;30, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">28</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_109"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are not currently subject to any material legal proceedings.</span></div><div id="iffb89c91b68044fe89584fa1aa2f8679_112"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our unaudited condensed financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur. In addition, such risks may be amplified by the COVID-19 pandemic and the current economic environment and the potential impact of such risks on Ovid&#8217;s business and the global economy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Summary of Selected Risks Associated with Our Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. Some of the more significant risks we face include the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We expect to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Our operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We are early in our development efforts of our current drug candidates and all our drug candidates are in preclinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our drug candidates, or successfully develop any other drug candidates, or experience significant delays in doing so, our business will be harmed. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug candidates. If we, or our licensees, are not able to obtain the required regulatory approvals, we, or our licensees, will not be able to commercialize our drug candidates, and our ability to generate revenue will be adversely affected.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Preclinical studies and clinical trials are very expensive, time-consuming and difficult to design and implement and involve uncertain outcomes. Further, we may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy in our preclinical studies and clinical trials to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Under the Takeda License and Termination Agreement, we are entitled to receive royalty and milestone payments in connection with the development and commercialization of soticlestat. If Takeda fails to progress, delays or discontinues the development of soticlestat, we may not receive some or all of such payments, which would materially harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to sell profitably, if approved.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future drug candidates.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">COVID-19 could adversely impact our business, including our preclinical studies, clinical trials and access to capital.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have historically incurred significant operating losses with the exception of net income we reported in 2021 primarily due to a one-time, upfront payment of $196.0 million received pursuant to the royalty, license and termination agreement (the &#8220;Takeda License and Termination Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;). As of June&#160;30, 2022, we had an accumulated deficit of $202.1 million. We expect to incur increasing operating losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and clinical development of our drug candidates, as well as hiring employees and building our infrastructure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have no drugs approved for commercialization and have never generated any revenue from drug sales. All of our drug candidates are still in the preclinical testing stage. It could be several years, if ever, before we have a commercialized drug. We expect to continue to incur significant expenses and operating losses over the next several years, and the net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">continue to advance the ongoing and planned preclinical and clinical development of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">continue to build a portfolio of drug candidates through the acquisition or in-license of drugs, drug candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">experience delays in our preclinical studies and planned clinical studies due to the ongoing COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">develop, maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">implement operational, financial and management systems; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">attract, hire and retain additional administrative, clinical, regulatory and scientific personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing our current and future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception in April 2014, primarily due to organizing and staffing our company, business planning, raising capital, acquiring assets and undertaking the development of our drug candidates. We have not yet demonstrated the ability to obtain marketing approvals, manufacture a commercial-scale drug or conduct sales and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had more experience developing drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We will need to eventually transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect our expenses to increase as we advance our current and future drug candidates through preclinical studies and clinical trials, commercialize our drug candidates, and pursue the acquisition or in-licensing of any additional drug candidates. Our expenses could increase beyond expectations if the FDA or other regulatory authorities require us to perform preclinical studies or clinical trials in addition to those that we currently anticipate. In addition, even if we obtain marketing approval for our drug candidates, they may not achieve commercial success. Our revenue, if any, will be derived from sales of drugs that we do not expect to be commercially available for a number of years, if at all. If we obtain marketing approval for any drug candidates that we develop or otherwise acquire, we expect to incur significant expenses related to manufacturing, marketing, sales and distribution. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our cash, cash equivalents and marketable securities were $152.4 million, and we had an accumulated deficit of $202.1 million.  We believe that our cash, cash equivalents and marketable securities will fund our current operating plans through at least 12 months from the filing of this Quarterly Report on Form 10-Q. However, our operating plans may change because of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will require more capital in order to advance the preclinical and clinical development, obtain regulatory approval and, following regulatory approval, commercialize our current or future drug candidates. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future drug candidates. The ongoing COVID-19 pandemic has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital. If we do not raise additional capital in sufficient amounts, or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will harm our business, operating results and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital or acquiring or licensing assets by issuing equity or debt securities may cause dilution to our stockholders, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Until such time as we can generate substantial revenue from drug sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic alliances, and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we issue additional equity securities, our stockholders may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. In addition, we may issue equity or debt securities as consideration for obtaining rights to additional compounds. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, issuing additional equity, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could negatively impact our ability to conduct our business. If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts, or grant rights to develop and market drug candidates that we would otherwise develop and market ourselves.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards and certain other tax attributes to offset future taxable income may be subject to limitation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our federal NOLs generated in tax years beginning on or before December 31, 2017 are permitted to be carried forward for only 20 years under applicable U.S. tax law. Under the Tax Cuts and Jobs Act, or the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the utilization of such federal NOLs incurred in the taxable year beginning after December 31, 2020 is limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2022, we recorded no U.S. federal or state income tax provision, based on a pre-tax loss of approximately $14.6 million. As of June&#160;30, 2022, we had available approximately $171.3 million of unused NOL carryforwards for federal and New York state income tax purposes and approximately $163.9 million of unused NOL carryforwards for New York City income tax purposes, that may be applied against future taxable income. Our NOL carryforwards are significantly limited such that even if we achieve profitability in future periods, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to the Development and Commercialization of Our Drug Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We are very early in our development efforts and all our drug candidates are in preclinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our drug candidates for these or any other indications, or successfully develop any other drug candidates, or experience significant delays in doing so, our business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are very early in our development efforts and all of the drug candidates (including OV329 and OV350), for which we control developmental and commercial responsibility are still in preclinical development. For example, we previously publicly announced we anticipate filing three investigational new drug (&#8220;IND&#8221;) applications in three years, beginning in 2022, however we cannot guarantee success of pre-clinical development to achieve all such IND applications. Following IND acceptance, each of our drug candidates will need to be progressed through clinical development in order to achieve regulatory approval, and we will also need to address issues relating to manufacture and supply, which may involve building our own capacity and expertise. In order to commercialize any product that achieves regulatory approval, we will need to build a commercial organization or successfully outsource commercialization, all of which will require substantial investment and significant marketing efforts before we have the ability to generate any revenue from drug sales. We do not have any drugs that are approved for commercial sale, and we may never be able to develop or commercialize marketable drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our ability to generate revenue from drug sales and achieve profitability depends on our ability, alone or with any current or future collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our current and future drug candidates. We do not anticipate generating revenue from drug sales for the next several years, if ever. Our ability to generate revenue from drug sales depends heavily on our, or any current or future collaborators&#8217;, success in the following areas, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">timely and successfully completing preclinical and clinical development of our current and future drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">obtaining regulatory approvals for our current and future drug candidates for which we successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">launching and commercializing any drug candidates for which we obtain regulatory approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">qualifying for coverage and adequate reimbursement by government and third-party payors for any drug candidates for which we obtain regulatory approval, both in the United States and internationally;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for our current and future drug candidates that is compliant with current good manufacturing practices (&#8220;cGMP&#8221;);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate amount and quality of drugs and services to support clinical development, as well as the market demand for our current and future drug candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">obtaining market acceptance, if and when approved, of our current or any future drug candidates as a viable treatment option by physicians, patients, third-party payors and others in the medical community;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">effectively addressing any competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">implementing additional internal systems and infrastructure, as needed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations pursuant to such arrangements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">obtaining and maintaining orphan drug exclusivity for any of our current and future drug candidates for which we obtain regulatory approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">avoiding and defending against third-party interference or infringement claims; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">securing appropriate pricing in the United States, the European Union and other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the drug candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any drug candidate we develop, we may not be able to continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug candidates. If we, or our licensees, are not able to obtain the required regulatory approvals, we, or our licensees, will not be able to commercialize our drug candidates, and our ability to generate revenue will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We do not have any drugs that have received regulatory approval. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize our current and future drug candidates in a timely manner. Activities associated with the development and commercialization of our current and future drug candidates are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and similar regulatory authorities outside the United States. Failure to obtain regulatory approval in the United States or other jurisdictions would prevent us from commercializing and marketing our current and future drug candidates. An inability to effectively develop and commercialize our current and future drug candidates, whether due to the impacts of the ongoing COVID-19 pandemic or otherwise, could have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TAK-935, the most advanced compound we helped to develop, is being developed by Takeda and is currently in a pivotal trial program. If the pivotal trials are unsuccessful, or the compound is not approved, we will not receive the milestone payments and royalties from the Takeda License and Termination Agreement. Without those funds, we may need to raise significant additional capital to pursue the development and commercialization of our current and future pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, activities associated with the development and commercialization of our current and future drug candidates are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and similar regulatory authorities outside the United States. Failure to obtain regulatory approval in the United States or other jurisdictions would prevent us from commercializing and marketing our current and future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if we obtain approval from the FDA and comparable foreign regulatory authorities for our current and future drug candidates, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of that drug candidate or any other drug candidate that we may in-license, develop or acquire in the future. In certain circumstances, our third-party licensees are responsible for obtaining regulatory approvals in the countries covered by the license, and we are dependent on their efforts in order to achieve the necessary approvals in order to commercialize our products. If any future licensees fail to perform their obligations to develop and obtain regulatory approvals for the licensed products, we may not be able to commercialize our products in the affected countries, or our ability to do so may be substantially delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, even if we obtain regulatory approval for our current and future drug candidates, we will still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize our current and future drug candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Success in preclinical testing and early clinical trials does not ensure that subsequent clinical trials will generate similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a drug candidate. Frequently, drug candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. For instance, our NEPTUNE trial of OV101, one of our former drug candidates, did not meet its primary endpoints despite earlier encouraging results from our Phase 2 trial STARS, the first clinical trial evaluating efficacy of OV101 in patients with Angelman syndrome. We closed our OV101 program in Angelman syndrome in early 2021. The results from preclinical studies of our current and future drug candidates may not be predictive of the effects of these compounds in later stage clinical trials. If we do not observe favorable results in clinical trials of one of our drug candidates, we may decide to delay or abandon clinical development of that drug candidate. Any such delay or abandonment could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">It is difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval for our gene therapy candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future success depends in part on the successful development of our early-stage gene therapy product candidates. We may experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to internal and external commercial manufacturing sites, which may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other product types, which are better known or more extensively studied to date. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also, before a clinical trial can begin to enroll at a site, each clinical site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. The risk of serious adverse events remains a concern for gene therapy and we cannot assure that it will not occur in any of our future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, even if not ultimately attributable to our product candidates, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, we have and may in the future publish or report preliminary or interim data from our clinical trials. Preliminary or interim data from our clinical trials and those of our partners may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published or reported. As a result, preliminary or interim data should be considered carefully and with caution until final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Preclinical studies and clinical trials are very expensive, time-consuming and difficult to design and implement and involve uncertain outcomes. Further, we may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy in our preclinical studies and clinical trials to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All of our current drug candidates are in preclinical development and their risk of failure is high. We must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that each of our drug candidates are safe and effective for its intended indications before we are prepared to submit a new drug application (&#8220;NDA&#8221;) or Biologics License Application (&#8220;BLA&#8221;) for regulatory approval. We cannot predict with any certainty if or when we might submit an NDA or BLA for any of our product candidates or whether any such application will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous review and regulatory requirements by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. For instance, the FDA may not agree with our proposed endpoints for any future clinical trial of our product candidates, which may delay the commencement of such clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We estimate that the successful completion of clinical trials of our product candidates will take at least several years to complete, if not longer. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Furthermore, failure can occur at any stage and we could encounter problems that cause us to abandon or repeat clinical trials. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our inability to generate sufficient preclinical, toxicology or other data to support the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our inability to develop and validate disease-relevant clinical endpoints;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">delays in reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">delays in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">delays in opening investigational sites;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">delays or difficulty in recruiting and enrollment of suitable patients to participate in our clinical trials, whether as a result of the COVID-19 pandemic or otherwise;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">imposition of a clinical hold by regulatory authorities because of a serious adverse event, concerns with a class of drug candidates or after an inspection of our clinical trial operations or trial sites;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">occurrence of serious adverse events associated with the drug candidate that are viewed to outweigh its potential benefits; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">business interruptions resulting from geo-political actions, including the Russia-Ukraine war or the perception that such hostilities may be imminent, terrorism, natural disasters, or public health epidemics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the ongoing COVID-19 pandemic. Patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, could be limited, which in turn could adversely impact our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned preclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, clinical endpoints for certain diseases we are targeting have not been established, and accordingly we may have to develop new modalities or modify existing endpoints to measure efficacy, which may increase the time it takes for us to commence or complete clinical trials. In addition, we believe investigators in this area may be inexperienced in conducting trials in this area due to the current lack of drugs to treat these disorders, which may result in increased time and expense to train investigators and open clinical sites.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our drug candidates, we may need to conduct additional testing to bridge our modified drug candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our drug candidates, if approved, or allow our competitors to bring comparable drugs to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our drug candidates, we may:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">be delayed in obtaining marketing approval, if at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">be required to perform additional clinical trials to support approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (&#8220;REMS&#8221;);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">be subject to the addition of labeling statements, such as warnings or contraindications;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">be sued; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">experience damage to our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our drug development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, we, the FDA or an IRB may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current Good Clinical Practice (&#8220;GCP&#8221;) regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our IND applications or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our drug candidates could be negatively impacted, and our ability to generate revenues from our drug candidates may be delayed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A key element of our current strategy is to discover, develop and potentially commercialize a portfolio of drug candidates to treat epilepsies, seizure-related disorders, and rare neurological disorders. However, our business development activities and research activities may present attractive opportunities outside of epilepsies and seizure-related disorders and we may choose to pursue drug candidates in other areas of interest including other disorders that we believe would be in the best interest of the Company and our stockholders. We plan to continuously review our strategies and modify as necessary based on attractive areas of interest and assets that we choose to pursue. We intend to develop our portfolio of drug candidates by in-licensing and entering into collaborations with leading biopharmaceutical companies or academic institutions for new drug candidates. Identifying new drug candidates requires substantial technical, financial and human resources, whether or not any drug candidates are ultimately identified. The COVID-19 pandemic could also impact our ability to do in-person due diligence, negotiations and other interactions to identify new opportunities. Even if we identify drug candidates that initially show promise, we may fail to in-license or acquire these assets and may also fail to successfully develop and commercialize such drug candidates for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the research methodology used may not be successful in identifying potential drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">competitors may develop alternatives that render any drug candidate we develop obsolete;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">any drug candidate we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">a drug candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">a drug candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">a drug candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors, even if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have limited financial and management resources and, as a result, we may forego or delay the pursuit of opportunities with other drug candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional drug candidates or are unable to do so, our key growth strategy and business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials is critical to our success. The number of patients suffering from some of the seizure related disorders and rare neurological disorders we are pursuing is small and has not been established with precision. If the actual number of patients with these disorders is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our drug candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial, any such enrollment issues could cause delays or prevent development and approval of our drug candidates. Since we are focused on addressing seizure-related disorders and rare neurological disorders, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our drug candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same drug candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our drug candidates, or could render further development impossible.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In addition, it is possible that as we test our drug candidates in larger, longer and more extensive clinical programs, or as use of these drug candidates becomes more widespread if they receive respective regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. For example, adverse events were reported in certain clinical trials for OV101 and OV935, two of our former drug candidates. If clinical experience indicates that any of our drug candidates causes adverse events or serious or life-threatening adverse events, the development of that drug candidate may fail or be delayed, or, if the drug </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our drug candidates, the commercial prospects of our drug candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, if any of our drug candidates receive marketing approval, the FDA could require us to include a black box warning in our label or adopt REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our drug candidates, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">regulatory authorities may suspend or withdraw approvals of such drug candidate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may be required to change the way a drug candidate is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may need to conduct a recall; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our drug candidates and could significantly harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our drug candidates are smaller than we believe they are, even assuming approval of a drug candidate, our business may suffer. Because the patient populations in the market for our drug candidates may be small or difficult to assess, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We focus our research and drug development on treatments for epilepsies, seizure-related disorders and other rare neurological disorders. Given the small number of patients who have the disorders that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our drug candidates. Our projections of both the number of people who have these disorders, as well as the subset of people with these disorders who have the potential to benefit from treatment with our drug candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these disorders. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our drug candidates may be limited or may not be amenable to treatment with our drug candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates and will face competition with respect to any other drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">More established companies may have a competitive advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts, relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products, and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our drug candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted and cheaper than ours, and may also be more successful than us in manufacturing and marketing their drugs. These appreciable advantages could render our drug candidates obsolete or non-competitive before we can recover the expenses of such drug candidates&#8217; development and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if our current or future drug candidates receive marketing approval, they may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant drug revenue and may not become profitable. The degree of market acceptance of our current or future drug candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the efficacy and potential advantages compared to alternative treatments and therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the safety profile of our drug candidate compared to alternative treatments and therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">effectiveness of sales and marketing efforts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the strength of our relationships with patient communities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our ability to offer such drug for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the convenience and ease of administration compared to alternative treatments and therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the availability of third-party coverage and adequate reimbursement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the prevalence and severity of any side effects; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">any restrictions on the use of the drug together with other medications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our drug candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our drug candidates. Since we expect sales of our drug candidates, if approved, to generate substantially all of our drug revenues for the foreseeable future, the failure of our drugs to find market acceptance would harm our business and could require us to seek additional financing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our current or future drug candidates from the FDA, we may never obtain approval for our current or future drug candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approval of a drug candidate in the United States by the FDA does not ensure approval of such drug candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our current and future drug candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a drug candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, which may require additional preclinical studies or clinical trials. In many countries outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any drug candidates, if approved, is also subject to approval. Obtaining approval for our current and future drug candidates in the European Union from the European Commission following the opinion of the European Medicines Agency, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. The FDA and comparable foreign regulatory authorities have the ability to limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our current and future drug candidates in certain countries. In certain cases, we are dependent on third parties to obtain such foreign regulatory approvals, and any delay or failure of performance of such third parties could delay or prevent our ability to commercialize our products in the affected countries. Due to the ongoing COVID-19 pandemic, it is possible that we could experience delays in the timing of our interactions with regulatory authorities due to absenteeism by governmental employees, inability to conduct planned physical inspections related to regulatory approval, or the diversion of regulatory authority efforts and attention to approval of other therapeutics or other activities related to COVID-19, which could delay anticipated approval decisions and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our drug candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our current and future drug candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we seek approval to commercialize our current or future drug candidates outside of the United States, a variety of risks associated with international operations could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we seek approval of our current or future drug candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">different regulatory requirements for approval of therapies in foreign countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">reduced protection for intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the potential requirement of additional clinical studies in international jurisdictions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">foreign reimbursement, pricing and insurance regimes;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters and public health pandemics, such as COVID-19.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any drug candidate that we may develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our current and any future drug candidates in clinical trials and may face an even greater risk if we commercialize any drug candidate that we may develop. If we cannot successfully defend ourselves against claims that any such drug candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">decreased demand for any drug candidate that we may develop;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">significant time and costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the inability to commercialize any drug candidate that we may develop; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">injury to our reputation and significant negative media attention.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any drug candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Licensing and Collaboration Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Under the Takeda License and Termination Agreement, we are entitled to receive royalty and milestone payments in connection with the development and commercialization of soticlestat. If Takeda fails to progress or discontinues the development of soticlestat, we may not receive some or all of such payments, which would materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, we entered into the Takeda License and Termination Agreement, pursuant to which Takeda secured rights to our 50% global share in soticlestat, which we had originally licensed from Takeda, and we granted to Takeda an exclusive worldwide license under our relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. All rights in soticlestat are now owned by Takeda or exclusively licensed to Takeda by us. Following the closing date of the Takeda License and Termination Agreement, Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and we will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs. Upon closing of the Takeda License and Termination Agreement, we received a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">one-time, upfront payment of $196.0 million and, if soticlestat is successfully developed, we will be eligible to receive up to an additional $660.0 million upon Takeda achieving specified regulatory and sales milestones. In addition, if soticlestat achieves regulatory approval, we will be entitled to receive tiered royalties at percentages ranging from the low double-digits, up to 20% on sales of soticlestat. Royalties will be payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Takeda License and Termination Agreement, Takeda now has sole discretion over the conduct of the development and commercialization of soticlestat. If for any reason, Takeda fails to progress,  or elects to terminate the development of soticlestat as contemplated by the Takeda License and Termination Agreement, or if the development or commercialization of soticlestat is delayed or deprioritized by Takeda, we may not receive some or all of the royalty and milestone payments under such agreement. We are dependent upon Takeda&#8217;s progression of such development and the resulting payments to fund the regulatory development of our current and future drug candidates. If we are unable to find alternative sources of revenue, our inability to receive royalty or milestone payments under the Takeda License and Termination Agreement would negatively impact our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the preclinical and clinical development of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have previously acquired and we may acquire or in-license drug candidates for preclinical or clinical development in the future as we continue to build our pipeline. Such arrangements with third parties may impose, diligence, development and commercialization obligations, milestone payments, royalty payments, indemnification and other obligations on us. Our obligations to pay milestone, royalty and other payments to our licensors may be substantial, and the amount and timing of such payments may impact our ability to progress the development and commercialization of our drug candidates. Our rights to use any licensed intellectual property may be subject to the continuation of and our compliance with the terms of any such agreements. Additionally, disputes may arise regarding our rights to intellectual property licensed to us or acquired by us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the scope of intellectual property rights included in, and rights granted under, any license or other agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the sublicensing of patent and other rights under such agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our compliance with our diligence obligations under any license agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the scope and duration of our payment obligations, and our ability to make such payments when they are owed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our need to acquire additional intellectual property rights from third parties that may impact payments due under such agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the rights of our licensors to terminate any such agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our rights and obligations upon termination of such agreement; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Disputes over intellectual property and other rights that we have licensed or acquired, or may license or acquire in the future, from third parties could prevent or impair our ability to maintain any such arrangements on acceptable terms, result in delays in the commencement or completion of our preclinical studies and clinical trials and impact our ability to successfully develop and commercialize the affected drug candidates. If we fail to comply with our obligations under any future licensing agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be required to relinquish important rights to and control over the development and commercialization of our drug candidates to any future collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our current and future collaborations could subject us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may be required to undertake the expenditure of substantial operational, financial and management resources;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may be required to issue equity securities that would dilute our stockholders&#8217; percentage of ownership;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may be required to assume substantial actual or contingent liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new version of a drug candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators may not commit adequate resources to the marketing and distribution, or even commercial launch  of our drug candidates, limiting our potential revenues from these products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we rely on our current collaborators to manufacture drug substance and drug product and may do so with respect to future collaborators, which could result in disputes or delays;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">disputes may arise between us and our current or future collaborators regarding any termination of any collaboration, license, or other business development arrangement in which we may enter;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators may experience financial difficulties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">business combinations or significant changes in a strategic collaborator&#8217;s business strategy may also adversely affect a strategic collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators could decide to move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may explore additional strategic collaborations that may never materialize or may fail.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business strategy is based on acquiring or in-licensing compounds directed at epilepsies, seizure-related disorders, and rare neurological disorders. As a result, we intend to periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional drug candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them. Further, our business development activities and research activities may present attractive opportunities outside of epilepsies and seizure related disorders and we may choose to pursue drug candidates in other areas of interest including other disorders and diseases that we believe would be in the best interest of the Company and our stockholders. We plan to continuously review our strategies and modify as necessary based on attractive areas of interest and assets that we choose to pursue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;PPACA&#8221;), amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created additional federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Physician Payments Sunshine Act, which is part of the PPACA, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals; and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and/or information regarding drug pricing, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers, state laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, and state and local laws that require the registration of pharmaceutical sales representatives; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to sell profitably, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Market acceptance and sales of any drug candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug candidates that we develop will be made on a payor-by-payor basis. One third-party payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each third-party payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a third-party payor&#8217;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future drug candidates that we develop. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any drug candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the PPACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been executive, judicial, Congressional and executive branch challenges to certain aspects of the PPACA. For example, President Trump signed Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the PPACA such as removing penalties, effective January 1, 2019, for not complying with the PPACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain PPACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the PPACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the PPACA and our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2031 unless additional Congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Congress is also considering additional health reform measures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;), which ended the use of the statutory formula and established a quality payment program, also referred to as the Quality Payment Program. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, the full impact to overall physician reimbursement as a result of the introduction of the Quality Payment Program remains unclear.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. Additionally, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. At the state level, legislatures have increasingly passed and implemented regulations designed to control pharmaceutical and biological product pricing, including pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. For example, based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candidates, which could limit the potential profitability of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation, then the drug is entitled to a period of marketing exclusivity that precludes the applicable regulatory authority from approving another marketing application for the same drug for the same indication for the exclusivity period except in limited situations. For purposes of small molecule drugs, the FDA defines &#8220;same drug&#8221; as a drug that contains the same active moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Obtaining orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult and we may not be successful in doing so. Even if we were to obtain orphan drug designation for a drug candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any drug candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable drug candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for our current or future drug candidates, they will remain subject to ongoing regulatory oversight.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even if we obtain any regulatory approval for our current or future drug candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our current or future drug candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA, BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of our current or future drug candidates, a regulatory authority may:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">issue an untitled letter or warning letter asserting that we are in violation of the law;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">suspend any ongoing clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">refuse to approve a pending NDA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">restrict the marketing or manufacturing of the drug;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">seize or detain the drug or otherwise require the withdrawal of the drug from the market;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">refuse to permit the import or export of drug candidates; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current or future drug candidates and harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could cause changes to or delays in the drug review process, or suspend or restrict regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and drug candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future drug candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and drug candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future drug candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future drug candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any drug candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a drug candidate and companion diagnostic under patent protection could be reduced. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to our development programs and drug candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future drug candidates, it could dissuade companies from collaborating with us to develop drug candidates, and threaten our ability to commercialize future drugs. Any such outcome could have a negative effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On December 16, 2011, the Leahy-Smith America Invents Act (the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future drug candidates, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel or our licensing partners to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">others may be able to make compounds or formulations that are similar to our drug candidates but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable because of legal challenges;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The proprietary map of disease-relevant biological pathways underlying orphan disorders of the brain that we developed would not be appropriate for patent protection and, as a result, we rely on trade secrets to protect this aspect of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our commercial success depends, in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current and any future drug candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future drug candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our drug candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or drug candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our current or any future drug candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. See the section herein titled &#8220;Legal Proceedings&#8221; for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future drug candidates. Such a loss of patent protection could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The United States has recently enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents covering our current and any future drug candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These drugs may compete with our drugs in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we rely on third parties to manufacture or commercialize our current or any future drug candidates, or if we collaborate with additional third parties for the development of our current or any future drug candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any third-party collaborators. A competitor&#8217;s discovery of our trade secrets would harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We do not own or operate, and we do not expect to own or operate, facilities for drug manufacturing, storage and distribution, or testing. We have been in the past, and will continue to be, dependent on third parties to manufacture the clinical supplies of our drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, we also will rely on third-party manufacturers to supply us with sufficient quantities of our drug candidates to be used, if approved, for commercialization. Any significant delay in the supply of a drug candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured drug candidates ourselves including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">inability to meet our drug specifications and quality requirements consistently;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">delay or inability to procure or expand sufficient manufacturing capacity;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">issues related to scale-up of manufacturing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">costs and validation of new equipment and facilities required for scale-up;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">failure to comply with cGMP and similar foreign standards;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">reliance on single sources for drug components;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">carrier disruptions or increased costs that are beyond our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future drug candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We do not currently have the ability to independently conduct any preclinical studies or clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and our CROs will be required to comply with good laboratory practices (&#8220;GLPs&#8221;) and GCPs, which are regulations and guidelines enforced by the FDA and are also required by the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities in the form of International Council for Harmonization guidelines for any of our drug candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While we will have agreements governing their activities, our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any drug candidate that we develop. As a result, our financial results and the commercial prospects for any drug candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If our relationship with these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 could adversely impact our business, including our preclinical studies, clinical trials and access to capital.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease. In response to initial state and local orders across the country directing individuals to shelter at their places of residence, directing businesses and governmental agencies to cease non-essential operations at physical locations, prohibiting certain non-essential gatherings, and ordering cessation of non-essential travel, in March 2020 we implemented work-from-home policies for all employees. In June 2022, we adopted a hybrid work model that incorporates a mixture of in-office and remote work in an employee's schedule. Our current plan is to continue with this hybrid work model and adapt the model as appropriate as the pandemic persists and federal, state and local guidelines, rules and regulations regarding the conduct of in-person business operations continue to change and evolve. The effects of our work policies may negatively impact productivity, introduce cybersecurity risks, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of any applicable restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Any new imposition of quarantines, shelter-in-place and similar government orders related to COVID-19 may adversely impact our business operations and the business operations of our CROs conducting our preclinical studies and clinical trials and our third-party manufacturing facilities in the United States and other countries. In particular, some of our third-party manufacturers which we use for the supply of materials for drug candidates or other materials necessary to manufacture product to conduct preclinical studies and clinical trials are located in countries affected by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these tests and trials. Currently, we expect no material impact on the clinical supply of any of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our previous clinical trials were, and our future clinical trials may be, affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be willing or able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our previous and planned clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a sustained, widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve. The extent to which the COVID-19 pandemic impacts our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate duration of the outbreak, the extent of sustained or new travel restrictions, social distancing requirements and business closures in the United States, Europe and other countries, and the effectiveness of actions taken in the United States, Europe and other countries to contain and treat the disease, including vaccination efforts. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the services of our senior management team, including our Chairman and Chief Executive Officer, Dr. Jeremy Levin, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are highly dependent on our senior management team, including our Chairman and Chief Executive Officer, Dr. Levin. The employment agreements we have with these officers do not prevent such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development, operational, financial and commercialization objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. This risk may be further amplified given the particularly competitive hiring market in New York City, the location of our corporate headquarters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop drug candidates and our business will be limited and we may experience constraints on our development objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our drug candidates, harming future regulatory approvals, sales of our drug candidates and our results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had 44 full-time employees. As our development and commercialization plans and strategies for our current pipeline of product candidates develop, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day operations and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future drug candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, our ability to commercialize drug candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, consultants, distributors, and collaborators may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates the regulations of the FDA and non-U.S. regulators, including those laws requiring the reporting of true, complete and accurate information to such regulators, manufacturing standards, healthcare fraud and abuse laws and regulations in the United States and abroad or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry, including the sale of pharmaceuticals, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Further, because of the work from home policies we implemented due to COVID-19, information that is normally protected, including company confidential information, may be less secure. If actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">our ability to operate our business and our results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. In addition, due to the ongoing COVID-19 pandemic, we have enabled all of our employees to work remotely, which may make us more vulnerable to cyberattacks. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. In addition to the extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There is no way of knowing with certainty whether we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or security incidents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to laws and regulations covering data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. In the U.S., we may be subject to state security breach notification laws, state health information privacy laws and federal and state consumer protections laws which impose requirements for the collection, use, disclosure and transmission of personal information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain individually </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or for aiding and abetting the violation of HIPAA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. For example, in May 2016, the EU formally adopted the General Data Protection Regulation, or GDPR, which applies to all EU member states as of May 25, 2018 and replaces the former EU Data Protection Directive. The regulation introduces new data protection requirements in the EU and imposes substantial fines for breaches of the data protection rules. The GDPR must be implemented into national laws by the EU member states imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data from clinical trials and adverse event reporting. Data protection authorities from different EU member states have interpreted the privacy laws differently, which adds to the complexity of processing personal data in the EU, and guidance on implementation and compliance practices are often updated or otherwise revised. Any failure to comply with the rules arising from the GDPR and related national laws of EU member states could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results. The GDPR will increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with EU data protection rules.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;) legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to Being a Public Company</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to such companies may make our common stock less attractive to investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will remain an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), until December 31, 2022. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. We currently take advantage of some, but not all, of the reduced regulatory and reporting requirements that are available to us. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not an EGC. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we will continue to qualify as a smaller reporting company as defined in the Exchange Act even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies, including but not limited to: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">reduced disclosure obligations regarding executive compensation arrangements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">However, as of June 30, 2022, in addition to being classified as a &#8220;smaller reporting company,&#8221; we will be classified as an &#8220;accelerated filer&#8221; pursuant to SEC rules and will be required to provide, among other items, an auditor&#8217;s attestation of management&#8217;s assessment of internal control over financial reporting required under Sarbanes-Oxley Act Section 404(b) beginning with our annual report for the year ending December 31, 2022.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Effective as of December 31, 2022, we will no longer be an EGC, which will increase our costs and demands on management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will cease to be an EGC on December 31, 2022. In addition, as a result of the market value of our common stock held by non-affiliates as of June 30, 2022, we will also qualify as a smaller reporting company and an accelerated filer as of December 31, 2022.  We are not required to reflect the change in our reporting status and comply with the associated increased disclosure obligations until our annual report for the year ending December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to our exit from EGC status and our qualification as a smaller reporting company that is also classified as an accelerated filer, we will be subject to certain disclosure and compliance requirements that apply to other public companies that did not previously apply to us due to our status as an EGC. These requirements include, but are not limited to:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;); and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the requirement that we hold a non-binding advisory vote on executive compensation and obtain stockholder approval of any golden parachute payments not previously approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect that compliance with the additional requirements will increase our legal and financial compliance costs and may cause management and other personnel to divert attention from operational and other business matters to devote increased time to public company reporting requirements. In addition, if we are not able to comply with changing requirements in a timely manner, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC or other regulatory authorities, which would require additional financial and management resources. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an EGC, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these and other compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. We are required, under Section 404 of the Sarbanes-Oxley Act (&#8220;Section 404&#8221;), to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Section 404 also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While we have been EGC, our independent registered public accounting firm has not been required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. This exemption will no longer apply to us as of December 31, 2022.  Accordingly, beginning with our annual report for the year ending December 31, 2022, we will be required to include an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. Our compliance with Section 404 will require that we incur substantial expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risks Related to the Ownership of Our Common Stock and Other General Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The market price of our common stock has been and likely will remain volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid for the shares. The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">results of clinical trials of our current and any future drug candidates or those of our competitors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the success of competitive drugs or therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the level of expenses related to our current and any future drug candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the results of our efforts to discover, develop, acquire or in-license additional drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our inability to obtain or delays in obtaining adequate drug supply for any approved drug or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">general economic, industry and market conditions; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. Similarly, the Russia-Ukraine war has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">There is no public market for our Series A convertible preferred stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There is no established public trading market for our Series A convertible preferred stock, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Series A convertible preferred stock on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the Series A convertible preferred stock will be limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of revenue from our products, if ever, we expect to finance future cash needs through public or private equity or debt offerings. In November 2020, we filed a shelf registration statement on Form S-3 (Registration No. 333-250054) that allows us to sell up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities and/or warrants (the &#8220;S-3 Registration Statement&#8221;), which includes a prospectus covering the issuance and sale of up to $75.0 million of common stock pursuant to an at-the-market (&#8220;ATM&#8221;) offering program. As of March 31, 2022, we had $250.0 million available under our S-3 Registration Statement, including $75.0 million available pursuant to our ATM program. Financing activities may have an adverse impact on our stockholders&#8217; rights as well as on our operations, and such additional funding may not be available on reasonable terms, if at all. If we raise additional funds through the issuance of additional debt or equity securities, it may result in dilution to our existing stockholders and/or increased fixed payment obligations. Furthermore, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as redeeming our shares, making investments, issuing additional equity, limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, if we seek funds through arrangements with collaborative partners, these arrangements may require </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">us to relinquish rights to some of our technologies or drug candidates or otherwise agree to terms unfavorable to us. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">You will be diluted by any conversions of outstanding Series A convertible preferred stock and exercises of outstanding options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had outstanding options to purchase an aggregate of 13,451,517 shares of our common stock at a weighted average exercise price of $4.21 per share and 1,250,000 shares of common stock issuable upon conversion of outstanding Series A convertible preferred stock for no additional consideration. Such Series A convertible preferred stock is convertible any time at the option of the holder thereof subject to the beneficial ownership limitations described in Note 7 to the financial statements contained in this Quarterly Report on Form 10-Q. The exercise of such options and conversion of the Series A convertible preferred stock for shares of our common stock will result in further dilution of your investment and could negatively affect the market price of our common stock. In addition, you may experience further dilution if we issue common stock, or securities convertible into common stock, in the future. As a result of this dilution, you may receive significantly less than the full purchase price you paid for the shares in the event of liquidation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based upon our shares of our common stock outstanding as of June&#160;30, 2022, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 45% of our outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda, a greater than 5% holder, has agreed to, among other things, (i) a standstill provision, (ii) restrictions on its ability to sell or otherwise transfer it shares of our stock, (iii) vote its shares on certain matters in accordance with the holders of a majority of shares of our common stock and (iv) restrictions on the percentage of our outstanding common stock it may own, in accordance with the terms of the Takeda License and Termination Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power, Takeda standstill provisions, voting obligations and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We do currently have research coverage offered by four industry or financial analysts, although two analysts have withdrawn research coverage in the last twelve months. We do not have any control over these analysts. If additional analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If additional analysts cease to cover our stock or fail to regularly publish reports, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">limit who may call stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, the Takeda standstill provisions and transfer restrictions in the Takeda License and Termination Agreement may delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which we may establish and shares of which we may issue without stockholder approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">prohibiting cumulative voting in the election of directors, which would otherwise allow for less than a majority of stockholders to elect director candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">eliminating the ability of stockholders to call a special meeting of stockholders; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under the DGCL, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change of control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business plan is to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">increased operating expenses and cash requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the assumption of additional indebtedness or contingent liabilities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">the diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">challenges related to integrating acquired businesses or entering into or realizing the benefits of strategic transactions generally; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">risks associated with potential international acquisition transactions, including in countries where we do not currently have a material presence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, if we engage in future acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or drugs that may be important to the development of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Some of the holders of our securities have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares would result in the shares becoming freely tradable without restriction under the Securities Act except for shares held by our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">58</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517166080/d382437dex31.htm">Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 10, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000156459019035235/ovid-ex31_6.htm">Corrected Amended and Restated Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on September 24, 2019).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517166080/d382437dex32.htm">Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 10, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517135563/d286200dex41.htm">Form of Common Stock Certificate of the Company (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-217245), filed with the Commission on April 25, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312519047109/d714860dex41.htm">Form of Series A Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on February 21, 2019).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, by and among the Company and certain of its stockholders, dated January 6, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ovid-20220630xexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ovid-20220630xexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ovid-20220630xexx321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained within Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">59</span></div></div></div><div id="iffb89c91b68044fe89584fa1aa2f8679_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iffb89c91b68044fe89584fa1aa2f8679_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OVID THERAPEUTICS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date: August&#160;9, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jeremy M. Levin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeremy M. Levin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date: August&#160;9, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jeffrey Rona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey Rona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Business and Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ovid-20220630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib269204b68f344c7a09b2721b28ada0b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeremy M. Levin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ovid Therapeutics Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;9, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeremy M. Levin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeremy M. Levin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ovid-20220630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic2d1085533df4250af1f39036da6a582_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey Rona, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ovid Therapeutics Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;9, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Rona</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Rona</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ovid-20220630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if9dfab5e864d41dca8de9282a4731109_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeremy M. Levin, Chief Executive Officer of Ovid Therapeutics Inc. (the &#8220;Company&#8221;), and Jeffrey Rona, Chief Business and Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June&#160;30, 2022, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August&#160;9, 2022</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeremy M. Levin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Rona</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeremy M. Levin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Rona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ovid-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8739d977-ca53-4263-89b1-d9c54849b06c,g:ab39b854-7f58-4138-956d-843b33846298-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ovid="http://www.ovidrx.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.ovidrx.com/role/Coverpage">
        <link:definition>0001001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossIncome" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.ovidrx.com/role/NatureofOperations">
        <link:definition>2101101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecurities" roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities">
        <link:definition>2106103 - Disclosure - Cash, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesTables" roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2307301 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail">
        <link:definition>2408403 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2409404 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentandIntangibleAssets" roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets">
        <link:definition>2110104 - Disclosure - Property and Equipment and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentandIntangibleAssetsTables" roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsTables">
        <link:definition>2311302 - Disclosure - Property and Equipment and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail">
        <link:definition>2412405 - Disclosure - Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail">
        <link:definition>2413406 - Disclosure - Property and Equipment and Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ovidrx.com/role/Leases">
        <link:definition>2114105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ovidrx.com/role/LeasesTables">
        <link:definition>2315303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2416407 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail" roleURI="http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail">
        <link:definition>2417408 - Disclosure - Leases - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofOperatingLeaseCostDetail" roleURI="http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail">
        <link:definition>2418409 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail" roleURI="http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail">
        <link:definition>2419410 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Under the non-cancelable Operating Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.ovidrx.com/role/AccruedExpenses">
        <link:definition>2120106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.ovidrx.com/role/AccruedExpensesTables">
        <link:definition>2321304 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleofAccruedExpensesDetail" roleURI="http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail">
        <link:definition>2422411 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandPreferredStock" roleURI="http://www.ovidrx.com/role/StockholdersEquityandPreferredStock">
        <link:definition>2123107 - Disclosure - Stockholders' Equity and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityandPreferredStockAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail">
        <link:definition>2424412 - Disclosure - Stockholders' Equity and Preferred Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.ovidrx.com/role/StockBasedCompensation">
        <link:definition>2125108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.ovidrx.com/role/StockBasedCompensationTables">
        <link:definition>2326305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2427413 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail" roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail">
        <link:definition>2428414 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" roleURI="http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail">
        <link:definition>2429415 - Disclosure - Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail">
        <link:definition>2430416 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail" roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail">
        <link:definition>2431417 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ovidrx.com/role/IncomeTaxes">
        <link:definition>2132109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2433418 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.ovidrx.com/role/CommitmentsandContingencies">
        <link:definition>2134110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail">
        <link:definition>2435419 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreements" roleURI="http://www.ovidrx.com/role/CollaborationAndLicenseAgreements">
        <link:definition>2136111 - Disclosure - Collaboration And License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>2437420 - Disclosure - Collaboration And License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.ovidrx.com/role/RelatedPartyTransactions">
        <link:definition>2138112 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://www.ovidrx.com/role/NetLossIncomePerShare">
        <link:definition>2139113 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareTables" roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareTables">
        <link:definition>2340306 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails">
        <link:definition>2441421 - Disclosure - Net (Loss) Income Per Share - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail">
        <link:definition>2442422 - Disclosure - Net (Loss) Income Per Share - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ovid_DevelopmentAndCommercialMilestonePayments" abstract="false" name="DevelopmentAndCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_HLundbeckASMember" abstract="true" name="HLundbeckASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_HealxLicenseAndOptionAgreementMember" abstract="true" name="HealxLicenseAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_MarinusPharmaceuticalsIncMember" abstract="true" name="MarinusPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_PatentLicenseAgreementMember" abstract="true" name="PatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" abstract="false" name="AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" abstract="true" name="USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_GeneralAndAdministrativeExpenseReimbursementReceived" abstract="false" name="GeneralAndAdministrativeExpenseReimbursementReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" abstract="false" name="BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_DeferredUpfrontPaymentCosts" abstract="false" name="DeferredUpfrontPaymentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_CostOfAgreementNet" abstract="false" name="CostOfAgreementNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_UpfrontCashPayment" abstract="false" name="UpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AnnualLicenseMaintenanceFeePayable" abstract="false" name="AnnualLicenseMaintenanceFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_NumberOfTrial" abstract="false" name="NumberOfTrial" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ovid_UpFrontPayment" abstract="false" name="UpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_UpfrontPaymentReceivable" abstract="false" name="UpfrontPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" abstract="false" name="ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" abstract="false" name="MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_LicenseAgreementUpfrontPayment" abstract="false" name="LicenseAgreementUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_FirstPaymentDueUponCompletionOfFirstPhase" abstract="false" name="FirstPaymentDueUponCompletionOfFirstPhase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" abstract="true" name="MoneyMarketFundsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_IncomeTaxAccrualCurrent" abstract="false" name="IncomeTaxAccrualCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AngeliniLicenseAgreementMember" abstract="true" name="AngeliniLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_NorthwesternUniversityMember" abstract="true" name="NorthwesternUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" abstract="false" name="ResearchAndDevelopmentExpenseReimbursementReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AdditionalUpFrontFeeAmount" abstract="false" name="AdditionalUpFrontFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" abstract="false" name="MinimumNumberOfProductCoveredUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_NoteReceivable" abstract="false" name="NoteReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_NonemployeePerformanceBasedOptionAwardsMember" abstract="true" name="NonemployeePerformanceBasedOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" abstract="false" name="IncreaseDecreaseInPrepaidExpenseNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AccretionOfLeaseLiability" abstract="false" name="AccretionOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_SummaryOfSignificantAccountingPolicyTable" abstract="true" name="SummaryOfSignificantAccountingPolicyTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" abstract="false" name="RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ovid_CowenAndCompanyLLCMember" abstract="true" name="CowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_EmployeePerformanceBasedOptionAwardsMember" abstract="true" name="EmployeePerformanceBasedOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_ATMAgreementMember" abstract="true" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" abstract="false" name="UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MarinusTherapeuticsIncMember" abstract="true" name="MarinusTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_PercentageOfDevelopmentCosts" abstract="false" name="PercentageOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_PotentialFundingCostPercent" abstract="false" name="PotentialFundingCostPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ovid_NonEmployeeStockOptionsMember" abstract="true" name="NonEmployeeStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_StockOptionsMember" abstract="true" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_AmountForPotentialFutureTrials" abstract="false" name="AmountForPotentialFutureTrials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_UpFrontFeeAmount" abstract="false" name="UpFrontFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" abstract="false" name="AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_LeaseIncrementalBorrowingRate" abstract="false" name="LeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_AggregateOfferingPriceOfCommonStock" abstract="false" name="AggregateOfferingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_RelatedPartyMember" abstract="true" name="RelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_LicenseAgreementMilestonePayments" abstract="false" name="LicenseAgreementMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" abstract="false" name="NoncashConsiderationReceivedInLicensingAgreementTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" abstract="false" name="LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_AgreementMilestonePayments" abstract="false" name="AgreementMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" abstract="false" name="CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_LicenseRevenue" abstract="false" name="LicenseRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" abstract="false" name="MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_MarinusLicenseAgreementMember" abstract="true" name="MarinusLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ovid_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_LesseeOperatingLeaseFreeRentPeriod" abstract="false" name="LesseeOperatingLeaseFreeRentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_CommonStockNumberOfVotesPerShare" abstract="false" name="CommonStockNumberOfVotesPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" abstract="false" name="CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_ConvertibleNoteReceivable" abstract="false" name="ConvertibleNoteReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_SummaryOfSignificantAccountingPolicyLineItems" abstract="true" name="SummaryOfSignificantAccountingPolicyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ovid_AdditionalPaymentReceivableOnSalesPercentage" abstract="false" name="AdditionalPaymentReceivableOnSalesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ovid_ConsiderationPayableForRightsGrant" abstract="false" name="ConsiderationPayableForRightsGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ovid-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8739d977-ca53-4263-89b1-d9c54849b06c,g:ab39b854-7f58-4138-956d-843b33846298-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_871c1227-06b5-4bfe-8c58-44b31eba8b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f18426a-8e4c-4dcf-b235-db8bc92ad96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_871c1227-06b5-4bfe-8c58-44b31eba8b75" xlink:to="loc_us-gaap_Liabilities_5f18426a-8e4c-4dcf-b235-db8bc92ad96b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee9878cc-148d-4847-85aa-681aebe915f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_871c1227-06b5-4bfe-8c58-44b31eba8b75" xlink:to="loc_us-gaap_StockholdersEquity_ee9878cc-148d-4847-85aa-681aebe915f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e358c0ef-7939-48ea-b174-ac0022c79eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_AssetsCurrent_e358c0ef-7939-48ea-b174-ac0022c79eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_19762f84-c0b6-4dae-8e64-c3304932dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_LongTermInvestments_19762f84-c0b6-4dae-8e64-c3304932dee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1b846e88-1105-4f74-ad11-bb1dcb5be415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_RestrictedCash_1b846e88-1105-4f74-ad11-bb1dcb5be415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_59e0144c-58a9-48e3-a005-8699439d43f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_SecurityDeposit_59e0144c-58a9-48e3-a005-8699439d43f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dcdac200-b9d6-411e-9e91-646220657d85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dcdac200-b9d6-411e-9e91-646220657d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_140b6baf-1c28-439c-956f-51d823c20be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_140b6baf-1c28-439c-956f-51d823c20be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_51cb169d-a97b-4e59-99ab-9c0072f0098d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e2c006a-d739-4a0b-a02f-f853be433248" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_51cb169d-a97b-4e59-99ab-9c0072f0098d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_46aaed3b-80fc-42aa-9a9b-beb08cf1374f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d32a82dd-f5c1-4985-8b0b-31ee52a00a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46aaed3b-80fc-42aa-9a9b-beb08cf1374f" xlink:to="loc_us-gaap_PreferredStockValue_d32a82dd-f5c1-4985-8b0b-31ee52a00a4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_648f892d-fa4b-4ce8-8cbf-a9736d17dc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46aaed3b-80fc-42aa-9a9b-beb08cf1374f" xlink:to="loc_us-gaap_CommonStockValue_648f892d-fa4b-4ce8-8cbf-a9736d17dc50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5bb55e72-d5a8-49a2-aadd-36d1b6b48f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46aaed3b-80fc-42aa-9a9b-beb08cf1374f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5bb55e72-d5a8-49a2-aadd-36d1b6b48f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e428b3af-1935-44ae-8d6d-945e96b63ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46aaed3b-80fc-42aa-9a9b-beb08cf1374f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e428b3af-1935-44ae-8d6d-945e96b63ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c4bcecae-2d78-4ada-946b-4f9e4f47d6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_46aaed3b-80fc-42aa-9a9b-beb08cf1374f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c4bcecae-2d78-4ada-946b-4f9e4f47d6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7fdcd407-5804-4691-9380-7d3e12b29884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f2ba0e57-f89f-4268-a97f-3421d61119ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7fdcd407-5804-4691-9380-7d3e12b29884" xlink:to="loc_us-gaap_AccountsPayableCurrent_f2ba0e57-f89f-4268-a97f-3421d61119ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cc8b94bf-362d-41f2-bde0-09f800ec21fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7fdcd407-5804-4691-9380-7d3e12b29884" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cc8b94bf-362d-41f2-bde0-09f800ec21fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ab8c5623-fd59-43b8-9d04-d19781e1aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7fdcd407-5804-4691-9380-7d3e12b29884" xlink:to="loc_us-gaap_OperatingLeaseLiability_ab8c5623-fd59-43b8-9d04-d19781e1aca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6950f2f4-5f24-4657-865c-3c843cb7659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ba890dde-4318-4e17-b8bf-cf555806059b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6950f2f4-5f24-4657-865c-3c843cb7659d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ba890dde-4318-4e17-b8bf-cf555806059b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoteReceivable_be16ebc7-9788-48ab-ad1b-59ae439e27d5" xlink:href="ovid-20220630.xsd#ovid_NoteReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6950f2f4-5f24-4657-865c-3c843cb7659d" xlink:to="loc_ovid_NoteReceivable_be16ebc7-9788-48ab-ad1b-59ae439e27d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d905db13-57ae-4b5d-954a-4e3ecf599981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6950f2f4-5f24-4657-865c-3c843cb7659d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d905db13-57ae-4b5d-954a-4e3ecf599981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5c681bce-97a8-4a62-ab2b-c5dc0adfb95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6950f2f4-5f24-4657-865c-3c843cb7659d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5c681bce-97a8-4a62-ab2b-c5dc0adfb95b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8cf692aa-f5a8-456b-a3eb-080c45d3c313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_755a7e48-1b91-4cd0-ba69-8a153bb0e8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8cf692aa-f5a8-456b-a3eb-080c45d3c313" xlink:to="loc_us-gaap_OperatingIncomeLoss_755a7e48-1b91-4cd0-ba69-8a153bb0e8b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_19683fda-bcda-4533-a65d-524de119a2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8cf692aa-f5a8-456b-a3eb-080c45d3c313" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_19683fda-bcda-4533-a65d-524de119a2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4499dc52-0671-445c-ae57-4550903a9990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e932956f-8b71-494a-9d07-9ad5aad2b91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4499dc52-0671-445c-ae57-4550903a9990" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e932956f-8b71-494a-9d07-9ad5aad2b91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_002f563a-00e9-4143-bab5-26d4c1f23d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4499dc52-0671-445c-ae57-4550903a9990" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_002f563a-00e9-4143-bab5-26d4c1f23d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1d32e901-db0c-49fc-8a51-8dfce5e2bfad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_50009ecb-f940-4758-a825-268cbd634328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1d32e901-db0c-49fc-8a51-8dfce5e2bfad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_50009ecb-f940-4758-a825-268cbd634328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_08430d2e-104b-4437-930b-4698d325010a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1d32e901-db0c-49fc-8a51-8dfce5e2bfad" xlink:to="loc_us-gaap_OperatingExpenses_08430d2e-104b-4437-930b-4698d325010a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c9ba1d6-3fdc-4998-aea1-98231d6051d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0322bbef-9270-4588-8e0d-a77d499cc7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c9ba1d6-3fdc-4998-aea1-98231d6051d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0322bbef-9270-4588-8e0d-a77d499cc7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f9894a1f-edad-4240-9f57-9649c7cc53a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c9ba1d6-3fdc-4998-aea1-98231d6051d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f9894a1f-edad-4240-9f57-9649c7cc53a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d8c9090c-2d54-44b5-bd5b-48cc1eba6da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b79c66e-2cf2-4975-a8c2-5503ed01d4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d8c9090c-2d54-44b5-bd5b-48cc1eba6da7" xlink:to="loc_us-gaap_NetIncomeLoss_8b79c66e-2cf2-4975-a8c2-5503ed01d4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ed7a46d0-4c80-4a7a-9312-cce35d376648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d8c9090c-2d54-44b5-bd5b-48cc1eba6da7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ed7a46d0-4c80-4a7a-9312-cce35d376648" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c1fc21-0bfa-4e16-94ec-f0eefaeab02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_26cef0c2-4256-4216-ae86-c256fb17c94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c1fc21-0bfa-4e16-94ec-f0eefaeab02b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_26cef0c2-4256-4216-ae86-c256fb17c94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b39848dc-f9c3-467d-9d9e-091ec5473f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c1fc21-0bfa-4e16-94ec-f0eefaeab02b" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b39848dc-f9c3-467d-9d9e-091ec5473f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b4cb5bbb-8795-4d6e-afff-0bc1d784658e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c1fc21-0bfa-4e16-94ec-f0eefaeab02b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b4cb5bbb-8795-4d6e-afff-0bc1d784658e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_68372b35-dbba-4570-89bd-d7f9128abb36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_68372b35-dbba-4570-89bd-d7f9128abb36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccretionOfLeaseLiability_e4200d42-0e90-45c5-ab6d-3837a4e1ff81" xlink:href="ovid-20220630.xsd#ovid_AccretionOfLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_ovid_AccretionOfLeaseLiability_e4200d42-0e90-45c5-ab6d-3837a4e1ff81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9805b5c3-7606-427e-955c-a017ed08383a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9805b5c3-7606-427e-955c-a017ed08383a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_bff31636-e8d7-450c-a6a7-62f5d3db0caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_bff31636-e8d7-450c-a6a7-62f5d3db0caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_263344a2-c114-4d9c-aa72-3e056bb094fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_263344a2-c114-4d9c-aa72-3e056bb094fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27969aba-07be-4366-9c2b-031b7f64d00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27969aba-07be-4366-9c2b-031b7f64d00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_0ad0485d-d57f-4471-91f2-ad3b76ae7236" xlink:href="ovid-20220630.xsd#ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_0ad0485d-d57f-4471-91f2-ad3b76ae7236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_9b71c9a6-af0c-4d5b-b9f7-e3e074b120fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_9b71c9a6-af0c-4d5b-b9f7-e3e074b120fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1454ec11-22c2-4563-898f-e12c74a31b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1454ec11-22c2-4563-898f-e12c74a31b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_933339e5-3999-49d9-a955-f3f240195fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_ShareBasedCompensation_933339e5-3999-49d9-a955-f3f240195fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_31657311-0f9a-40e4-ae87-6d3a5670c68b" xlink:href="ovid-20220630.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_31657311-0f9a-40e4-ae87-6d3a5670c68b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromAffiliates_d8f39198-b082-43ee-ad28-79a4cbeb40b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromAffiliates_d8f39198-b082-43ee-ad28-79a4cbeb40b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d1fb60ec-2891-4719-8c4b-3aae4d029bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d1fb60ec-2891-4719-8c4b-3aae4d029bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_632d19b4-e0d9-4e01-b46e-41750afd9b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_632d19b4-e0d9-4e01-b46e-41750afd9b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a11be3ab-c5d5-4122-a72d-a4b8df71f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_NetIncomeLoss_a11be3ab-c5d5-4122-a72d-a4b8df71f52b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eb4a1d9f-278f-49bc-9e97-949a5ffdde70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2ee5c86-a868-49d4-b3ef-d14eb3327e36" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eb4a1d9f-278f-49bc-9e97-949a5ffdde70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9237969d-40c5-4f9a-a5a2-b81daa19838e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f456be1-d056-480a-8829-7b405fd496f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9237969d-40c5-4f9a-a5a2-b81daa19838e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f456be1-d056-480a-8829-7b405fd496f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0140921c-eaf6-40f9-a5d1-cf012ab2ada6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9237969d-40c5-4f9a-a5a2-b81daa19838e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0140921c-eaf6-40f9-a5d1-cf012ab2ada6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8daaa5fa-b8f9-43be-836f-ac041d18b93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9237969d-40c5-4f9a-a5a2-b81daa19838e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8daaa5fa-b8f9-43be-836f-ac041d18b93e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a38b4a31-f776-4f79-8422-0d4f6f0dff42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa6a50fa-141a-479e-a3ef-ef39945733ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a38b4a31-f776-4f79-8422-0d4f6f0dff42" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa6a50fa-141a-479e-a3ef-ef39945733ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_01ffae62-03b9-4eea-b3c8-cb4502e6abdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a38b4a31-f776-4f79-8422-0d4f6f0dff42" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_01ffae62-03b9-4eea-b3c8-cb4502e6abdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_e22bdcc2-efbb-4253-ad60-8d10d824563e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a38b4a31-f776-4f79-8422-0d4f6f0dff42" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_e22bdcc2-efbb-4253-ad60-8d10d824563e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_62957a4b-3742-4e6d-9e84-dbb89e89b65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a38b4a31-f776-4f79-8422-0d4f6f0dff42" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_62957a4b-3742-4e6d-9e84-dbb89e89b65c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_899e76cd-4a12-48e1-a6d1-8b4db4a5a506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a38b4a31-f776-4f79-8422-0d4f6f0dff42" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_899e76cd-4a12-48e1-a6d1-8b4db4a5a506" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_cda77e1f-1eaa-4833-9ba2-7c8ae58dab79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_95c5f99a-3763-4676-aa79-da3b2b1ed210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_cda77e1f-1eaa-4833-9ba2-7c8ae58dab79" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_95c5f99a-3763-4676-aa79-da3b2b1ed210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7979583-94bb-45cb-9c9b-914e267bc1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_cda77e1f-1eaa-4833-9ba2-7c8ae58dab79" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7979583-94bb-45cb-9c9b-914e267bc1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f8ebd0bd-ba05-4df9-a05b-707ad89d5672" xlink:href="ovid-20220630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f6ec29ab-2df2-4445-bd07-b3de96215eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f8ebd0bd-ba05-4df9-a05b-707ad89d5672" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f6ec29ab-2df2-4445-bd07-b3de96215eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb99f3dd-40f7-48da-9483-6c869c99bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f8ebd0bd-ba05-4df9-a05b-707ad89d5672" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb99f3dd-40f7-48da-9483-6c869c99bc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77ce3202-f363-4cd4-9592-2eecb48cf5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5a57bc3b-561f-4b09-9090-e6da7540d5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77ce3202-f363-4cd4-9592-2eecb48cf5b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5a57bc3b-561f-4b09-9090-e6da7540d5e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c449f183-78a5-4cf6-a57d-c484cc8ce21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77ce3202-f363-4cd4-9592-2eecb48cf5b6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c449f183-78a5-4cf6-a57d-c484cc8ce21b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfff9676-1074-497b-bc96-434f4089341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_77ce3202-f363-4cd4-9592-2eecb48cf5b6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfff9676-1074-497b-bc96-434f4089341f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3f0a8cd-d9b2-4659-a458-db86144ed628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_82869d27-9f64-4974-85e8-39084215c699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e3f0a8cd-d9b2-4659-a458-db86144ed628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_82869d27-9f64-4974-85e8-39084215c699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5bda887-8f71-43ae-bdfa-9ef88973086e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e3f0a8cd-d9b2-4659-a458-db86144ed628" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5bda887-8f71-43ae-bdfa-9ef88973086e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a343728b-ae9b-4f7c-a2bf-2d58f04585b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a343728b-ae9b-4f7c-a2bf-2d58f04585b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_db6a6dd3-e644-47f2-8e6a-cc5c355c25b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_db6a6dd3-e644-47f2-8e6a-cc5c355c25b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e931a73-ea6a-4ca0-ab8c-ab039f4e4caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4e931a73-ea6a-4ca0-ab8c-ab039f4e4caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_008d27b1-468d-4995-8a3f-8918d296f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_008d27b1-468d-4995-8a3f-8918d296f8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e970510d-3ff3-403c-8d8c-652f26ea6a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e970510d-3ff3-403c-8d8c-652f26ea6a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_04c0f273-f2dd-46ea-b9aa-1dca28b561f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9543ff29-cca5-4c2a-ab41-5103b018c689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_04c0f273-f2dd-46ea-b9aa-1dca28b561f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#AccruedExpensesScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2fe3beaf-fa5d-478c-85ac-7a7fa080eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4b385ca3-7b62-4539-bb44-966dbdf55aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fe3beaf-fa5d-478c-85ac-7a7fa080eae2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4b385ca3-7b62-4539-bb44-966dbdf55aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccruedResearchAndDevelopment_31ce0946-94a0-4cbb-b067-467c244b878a" xlink:href="ovid-20220630.xsd#ovid_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fe3beaf-fa5d-478c-85ac-7a7fa080eae2" xlink:to="loc_ovid_AccruedResearchAndDevelopment_31ce0946-94a0-4cbb-b067-467c244b878a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_bff14cf6-4fdb-40ae-8b24-df56a762664d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fe3beaf-fa5d-478c-85ac-7a7fa080eae2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_bff14cf6-4fdb-40ae-8b24-df56a762664d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_IncomeTaxAccrualCurrent_261e3d5a-9a3a-4f10-b3cd-61bd2be67cff" xlink:href="ovid-20220630.xsd#ovid_IncomeTaxAccrualCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fe3beaf-fa5d-478c-85ac-7a7fa080eae2" xlink:to="loc_ovid_IncomeTaxAccrualCurrent_261e3d5a-9a3a-4f10-b3cd-61bd2be67cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e7067058-8800-46cb-8082-9aa09758248a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_2fe3beaf-fa5d-478c-85ac-7a7fa080eae2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e7067058-8800-46cb-8082-9aa09758248a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="simple" xlink:href="ovid-20220630.xsd#NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5aefc83c-e85b-4a1c-a428-247ea54a9b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dd579a80-6959-482d-9560-5adf06fafbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5aefc83c-e85b-4a1c-a428-247ea54a9b4f" xlink:to="loc_us-gaap_NetIncomeLoss_dd579a80-6959-482d-9560-5adf06fafbd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_ec79779a-7975-48b9-9500-baf671a3fd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5aefc83c-e85b-4a1c-a428-247ea54a9b4f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_ec79779a-7975-48b9-9500-baf671a3fd47" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ovid-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8739d977-ca53-4263-89b1-d9c54849b06c,g:ab39b854-7f58-4138-956d-843b33846298-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ovidrx.com/role/Coverpage" xlink:type="simple" xlink:href="ovid-20220630.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/Coverpage" xlink:type="extended" id="i3aa7318b76204ca6b4151039dd753fe8_Coverpage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_add88097-41cd-44ea-9dd3-c7d3ec4f72d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentType_add88097-41cd-44ea-9dd3-c7d3ec4f72d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fd5609d9-2219-4a6b-a5ff-50cc90475687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentQuarterlyReport_fd5609d9-2219-4a6b-a5ff-50cc90475687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c7102b36-1299-4c7e-8e20-ed1e93ba2df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentPeriodEndDate_c7102b36-1299-4c7e-8e20-ed1e93ba2df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_91a2cc20-1567-41eb-9454-e07946871130" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentTransitionReport_91a2cc20-1567-41eb-9454-e07946871130" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_04d49b87-041a-4b17-bfdc-58566bbbe659" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityFileNumber_04d49b87-041a-4b17-bfdc-58566bbbe659" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e95fc1d-4e47-40b4-b06d-357ff6383401" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityRegistrantName_1e95fc1d-4e47-40b4-b06d-357ff6383401" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a2f232e5-69a1-4dc4-89ea-f0d73a235bf1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a2f232e5-69a1-4dc4-89ea-f0d73a235bf1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3e685c7e-40c6-440c-bef3-6df5e8bfdeba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityTaxIdentificationNumber_3e685c7e-40c6-440c-bef3-6df5e8bfdeba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ad3a4032-316d-4d76-86e4-9ef5a9bcbb7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressAddressLine1_ad3a4032-316d-4d76-86e4-9ef5a9bcbb7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2a82f331-0193-486e-8672-332e0d81ef88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressAddressLine2_2a82f331-0193-486e-8672-332e0d81ef88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4b235c9f-f116-4c0c-b7b0-64b38ae7ea7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressCityOrTown_4b235c9f-f116-4c0c-b7b0-64b38ae7ea7d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6c735928-68ca-4e6f-b0f1-a0cfc120afe9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressStateOrProvince_6c735928-68ca-4e6f-b0f1-a0cfc120afe9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b3801aa-4e81-49c8-bb70-94be38fbf10c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressPostalZipCode_3b3801aa-4e81-49c8-bb70-94be38fbf10c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bfa8335c-5699-43db-a07a-0670e71a1866" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_CityAreaCode_bfa8335c-5699-43db-a07a-0670e71a1866" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7d66dd57-d1ec-45c0-a647-bda28de6a2a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_LocalPhoneNumber_7d66dd57-d1ec-45c0-a647-bda28de6a2a3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_62486394-a376-4510-8d13-6cfb5ab940f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_Security12bTitle_62486394-a376-4510-8d13-6cfb5ab940f4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22b4a8d8-62a0-444e-9927-24c9eec82e42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_TradingSymbol_22b4a8d8-62a0-444e-9927-24c9eec82e42" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6eba586c-d8c2-421c-9e7c-bb37d66fb678" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_SecurityExchangeName_6eba586c-d8c2-421c-9e7c-bb37d66fb678" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_547b5189-dfa1-42c7-ac03-bd44ec3d864a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityCurrentReportingStatus_547b5189-dfa1-42c7-ac03-bd44ec3d864a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a5e01e73-7ff9-416c-beff-c99e9555f59c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityInteractiveDataCurrent_a5e01e73-7ff9-416c-beff-c99e9555f59c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e8ff9ac9-e86c-47b8-b969-912c9a7d45d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityFilerCategory_e8ff9ac9-e86c-47b8-b969-912c9a7d45d1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c7090015-f4b7-499a-b0eb-b178ddf0a4fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntitySmallBusiness_c7090015-f4b7-499a-b0eb-b178ddf0a4fd" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_32719dcc-8f4c-40fd-94c1-f1ec82c43be5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityEmergingGrowthCompany_32719dcc-8f4c-40fd-94c1-f1ec82c43be5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_67d90f02-5caa-48dc-96c8-6e8ca85420a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityExTransitionPeriod_67d90f02-5caa-48dc-96c8-6e8ca85420a1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f97c560a-5654-4831-a476-331a6910785c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityShellCompany_f97c560a-5654-4831-a476-331a6910785c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0f33fb0a-2c9d-49d2-84fd-7148913c7a15" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0f33fb0a-2c9d-49d2-84fd-7148913c7a15" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_37179254-1106-4b72-bffb-21483ac23d17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityCentralIndexKey_37179254-1106-4b72-bffb-21483ac23d17" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7c55cd78-c68a-4a67-9536-425949b87328" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_CurrentFiscalYearEndDate_7c55cd78-c68a-4a67-9536-425949b87328" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1dd6817a-8ff5-4376-9a2f-f9e143618b5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentFiscalYearFocus_1dd6817a-8ff5-4376-9a2f-f9e143618b5f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6429ff2f-797e-4016-8fa5-7f7ef94dfaa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6429ff2f-797e-4016-8fa5-7f7ef94dfaa3" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0d3b16f4-429e-4d0c-bf2e-656933add726" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_AmendmentFlag_0d3b16f4-429e-4d0c-bf2e-656933add726" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:to="loc_dei_AddressTypeDomain_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_89382436-b811-4a9c-b56b-44c8d996860d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:to="loc_dei_AddressTypeDomain_89382436-b811-4a9c-b56b-44c8d996860d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_ab6d406d-c0c7-4993-a87f-3d16cfeed935" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_FormerAddressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_89382436-b811-4a9c-b56b-44c8d996860d" xlink:to="loc_dei_FormerAddressMember_ab6d406d-c0c7-4993-a87f-3d16cfeed935" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i48e2fbe3f5194e88a7d20e07a36b1d7f_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bfb14157-942d-4518-bb69-0fa67c2b0f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bfb14157-942d-4518-bb69-0fa67c2b0f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e51abd0a-7b09-4161-a117-98455c4a2155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e51abd0a-7b09-4161-a117-98455c4a2155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated_1de40410-536f-40af-b7a4-4b2d082be48a" xlink:href="ovid-20220630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_ovid_PreferredStockShareDesignated_1de40410-536f-40af-b7a4-4b2d082be48a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5a0d2a2f-6aae-46c4-8f9e-d8d95e3d3f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5a0d2a2f-6aae-46c4-8f9e-d8d95e3d3f12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4f4a3223-f1e1-48d8-86b9-fa892d8cd575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4f4a3223-f1e1-48d8-86b9-fa892d8cd575" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_037ca470-990b-4363-aeae-0bcb63495e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_037ca470-990b-4363-aeae-0bcb63495e1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0999d794-4081-4136-ba9f-6919806ff895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0999d794-4081-4136-ba9f-6919806ff895" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6a53c81e-f3a0-4da4-9cfe-cd76b25e8569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6a53c81e-f3a0-4da4-9cfe-cd76b25e8569" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6b5e70e9-9070-486a-a104-f1158f0b90ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockSharesIssued_6b5e70e9-9070-486a-a104-f1158f0b90ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_17a547ef-dae9-438e-804f-1de655482c01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:to="loc_us-gaap_ClassOfStockDomain_17a547ef-dae9-438e-804f-1de655482c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec52c37c-0ee6-4162-925e-b43dc8e7b720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:to="loc_us-gaap_ClassOfStockDomain_ec52c37c-0ee6-4162-925e-b43dc8e7b720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f9f1f8e5-4e8a-4047-812a-ab58f7017771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec52c37c-0ee6-4162-925e-b43dc8e7b720" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f9f1f8e5-4e8a-4047-812a-ab58f7017771" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="ib6860ddc088e49069cb1d63bf7ea61bf_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_35329c61-1ba2-407a-8da2-4cf47ddf8d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_RevenuesAbstract_35329c61-1ba2-407a-8da2-4cf47ddf8d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b0790b77-4fb2-4420-b819-6af567e4a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_35329c61-1ba2-407a-8da2-4cf47ddf8d54" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b0790b77-4fb2-4420-b819-6af567e4a08e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6a128f5a-71a8-4edc-ba23-c453f3ec6570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6a128f5a-71a8-4edc-ba23-c453f3ec6570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_35534cfc-95f5-4b1d-9360-b4f7de4ce95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_35534cfc-95f5-4b1d-9360-b4f7de4ce95a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ba0d4c9d-4c0a-4930-a6a9-27f52b5c6edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:to="loc_us-gaap_OperatingExpenses_ba0d4c9d-4c0a-4930-a6a9-27f52b5c6edd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_490be8d7-29a7-4d97-b0de-735cc59b350b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_OperatingIncomeLoss_490be8d7-29a7-4d97-b0de-735cc59b350b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_50d820e4-3298-48aa-adef-e4b652a177e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_50d820e4-3298-48aa-adef-e4b652a177e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_258e3a97-6887-4637-a747-642b3c7ed55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_258e3a97-6887-4637-a747-642b3c7ed55e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_985324b7-c55a-4866-8904-dd1d528d4a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_985324b7-c55a-4866-8904-dd1d528d4a2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81189899-f22f-4833-a498-947e9891b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_NetIncomeLoss_81189899-f22f-4833-a498-947e9891b5f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7953c079-0dbd-479e-8f68-2de2569396cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_EarningsPerShareBasic_7953c079-0dbd-479e-8f68-2de2569396cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2e3fe403-ae8c-4981-8ff4-fa00017b4023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2e3fe403-ae8c-4981-8ff4-fa00017b4023" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70730df5-c3bf-4b34-8b4e-cc6e85905df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70730df5-c3bf-4b34-8b4e-cc6e85905df0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fe3e247-eb04-43a3-aee0-3d36e3557e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fe3e247-eb04-43a3-aee0-3d36e3557e11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:to="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:to="loc_srt_ProductsAndServicesDomain_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:to="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_82bb43e4-cd29-4fa2-9512-4e2e0b5f5a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:to="loc_us-gaap_LicenseMember_82bb43e4-cd29-4fa2-9512-4e2e0b5f5a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RelatedPartyMember_f6ac9b94-801e-402b-8218-c19cc0b47097" xlink:href="ovid-20220630.xsd#ovid_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:to="loc_ovid_RelatedPartyMember_f6ac9b94-801e-402b-8218-c19cc0b47097" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="icd429c02b9354ee298badc1d9e9d872f_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ac32873-f874-423b-b7f6-688ade0948b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ac32873-f874-423b-b7f6-688ade0948b3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_08b7f2cc-20ee-4cdd-a5c8-2aeecf592203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_SharesIssued_08b7f2cc-20ee-4cdd-a5c8-2aeecf592203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b481c99f-269b-4ca1-a78c-fed2967719ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockholdersEquity_b481c99f-269b-4ca1-a78c-fed2967719ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1a0031d-9df4-49dd-8f66-6f4fc581cded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1a0031d-9df4-49dd-8f66-6f4fc581cded" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae28a2d1-02fa-4764-ae80-280caa192cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae28a2d1-02fa-4764-ae80-280caa192cca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54dbade7-c423-4e5b-a56c-44101a472745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54dbade7-c423-4e5b-a56c-44101a472745" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c65830f5-7996-43a3-bb19-b0b8cac82721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c65830f5-7996-43a3-bb19-b0b8cac82721" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4771675b-99e2-482e-8e5f-c6a7ccbe43c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4771675b-99e2-482e-8e5f-c6a7ccbe43c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_be25d23b-e9a5-48e6-8185-72cbbb0d4597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_be25d23b-e9a5-48e6-8185-72cbbb0d4597" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_fde09a33-9ca4-4b88-b437-fc92bf5b9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_fde09a33-9ca4-4b88-b437-fc92bf5b9df1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_5923a051-6bae-42a6-a2a4-2fc9cc27c326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_5923a051-6bae-42a6-a2a4-2fc9cc27c326" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b65225f8-4560-4913-aa46-65b83e2b7c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_NetIncomeLoss_b65225f8-4560-4913-aa46-65b83e2b7c1a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_366689e0-299a-4712-ab27-b03c755d0b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ec0912ae-314c-4403-bb9d-acd6269888ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3ac32873-f874-423b-b7f6-688ade0948b3" xlink:to="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:to="loc_us-gaap_EquityComponentDomain_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:to="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d83e0177-b00c-4516-b19f-4b06cc97b7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_PreferredStockMember_d83e0177-b00c-4516-b19f-4b06cc97b7d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_386e8834-c8fb-42e5-a0a3-90bb35038dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_CommonStockMember_386e8834-c8fb-42e5-a0a3-90bb35038dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a4dd0589-c949-438f-bdd0-19223fbf6935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a4dd0589-c949-438f-bdd0-19223fbf6935" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_78fe52c4-219e-4991-9c9a-1deccaa1fcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_78fe52c4-219e-4991-9c9a-1deccaa1fcf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e84c1c9f-af13-4704-a1a7-412994ee7862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_RetainedEarningsMember_e84c1c9f-af13-4704-a1a7-412994ee7862" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:to="loc_us-gaap_ClassOfStockDomain_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88415573-eb77-4645-8b3c-830ed7bb3d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:to="loc_us-gaap_ClassOfStockDomain_88415573-eb77-4645-8b3c-830ed7bb3d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_bd7d8d9c-3e5c-4328-a4e8-8a8e841aaa30" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_88415573-eb77-4645-8b3c-830ed7bb3d9c" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_bd7d8d9c-3e5c-4328-a4e8-8a8e841aaa30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="ifb8cae24f5c943d490e21dfbcd5af7d2_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:href="ovid-20220630.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8edf9399-cbdf-4f11-adae-079325145f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_EquityMethodInvestments_8edf9399-cbdf-4f11-adae-079325145f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_5f629c69-6677-48fc-8c35-a16e947d8296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_LongTermInvestments_5f629c69-6677-48fc-8c35-a16e947d8296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d09afca-ef6c-455c-9519-a83e03946eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d09afca-ef6c-455c-9519-a83e03946eb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1ea12e31-7689-47c1-ae32-d97cda3223c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1ea12e31-7689-47c1-ae32-d97cda3223c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4e335caa-6b56-4d16-af37-e044d3dc7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4e335caa-6b56-4d16-af37-e044d3dc7df8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConvertibleNoteReceivable_99aca4a2-494b-4dd2-962e-eaa4f4a42005" xlink:href="ovid-20220630.xsd#ovid_ConvertibleNoteReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_ovid_ConvertibleNoteReceivable_99aca4a2-494b-4dd2-962e-eaa4f4a42005" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:href="ovid-20220630.xsd#ovid_SummaryOfSignificantAccountingPolicyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18481555-4148-4c93-8253-b10807615c01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18481555-4148-4c93-8253-b10807615c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_913ff649-1eac-45e3-8a1f-8461510c7765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_913ff649-1eac-45e3-8a1f-8461510c7765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_00f93676-098c-456d-a1c8-407531931357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_00f93676-098c-456d-a1c8-407531931357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7ec7d2f2-5479-481e-b13b-c3b6929e0951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7ec7d2f2-5479-481e-b13b-c3b6929e0951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2c49728e-2e08-4de7-a229-7bf3e531084b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2c49728e-2e08-4de7-a229-7bf3e531084b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_aa3eacbf-bece-48e5-852d-0d6da644c50c" xlink:href="ovid-20220630.xsd#ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:to="loc_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_aa3eacbf-bece-48e5-852d-0d6da644c50c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_8847ced4-8aca-453e-84a0-413c52fd3fe4" xlink:href="ovid-20220630.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:to="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_8847ced4-8aca-453e-84a0-413c52fd3fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_96fbd56f-ed99-4329-b155-158e27bc9102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_96fbd56f-ed99-4329-b155-158e27bc9102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72c11b33-93fa-4a80-8903-0101a2d88953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72c11b33-93fa-4a80-8903-0101a2d88953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_98bd0236-d25a-4ba3-82c3-19c97623f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72c11b33-93fa-4a80-8903-0101a2d88953" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_98bd0236-d25a-4ba3-82c3-19c97623f498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bb724791-1684-4b6e-be37-e95b826b377d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:to="loc_dei_EntityDomain_bb724791-1684-4b6e-be37-e95b826b377d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6f048295-6b21-40b2-bc13-0c13d0964d12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:to="loc_dei_EntityDomain_6f048295-6b21-40b2-bc13-0c13d0964d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusTherapeuticsIncMember_29d5e138-dbd2-4d9f-a626-35a66ea71c0b" xlink:href="ovid-20220630.xsd#ovid_MarinusTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6f048295-6b21-40b2-bc13-0c13d0964d12" xlink:to="loc_ovid_MarinusTherapeuticsIncMember_29d5e138-dbd2-4d9f-a626-35a66ea71c0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0d86767-2a9b-4e1c-b2d6-272e02a80708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0d86767-2a9b-4e1c-b2d6-272e02a80708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc22ec4c-6e0c-4e95-b8ef-9e1b0e181b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc22ec4c-6e0c-4e95-b8ef-9e1b0e181b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PromissoryNotesMember_b8055de4-a0ee-43e8-9b67-ab6c3b0fe198" xlink:href="ovid-20220630.xsd#ovid_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc22ec4c-6e0c-4e95-b8ef-9e1b0e181b48" xlink:to="loc_ovid_PromissoryNotesMember_b8055de4-a0ee-43e8-9b67-ab6c3b0fe198" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended" id="ie431348d9371463e8c38de5541ac5cf5_CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_811a060c-9c1a-4b23-8962-7fb9e1a7f132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_811a060c-9c1a-4b23-8962-7fb9e1a7f132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4360f16-00e0-4c25-b275-9f2d02088642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4360f16-00e0-4c25-b275-9f2d02088642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9701147-5a79-4c16-8c4a-0a987645c136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9701147-5a79-4c16-8c4a-0a987645c136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da826f8f-fb63-4add-a7cd-e54dcb3e5050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da826f8f-fb63-4add-a7cd-e54dcb3e5050" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60c0f681-5c68-4599-b267-ec34ca755e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60c0f681-5c68-4599-b267-ec34ca755e70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c6ddd82f-32e6-4d7d-9de2-b97e806d1730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c6ddd82f-32e6-4d7d-9de2-b97e806d1730" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_4cebb42f-03bd-4881-bcc9-7be7f75b31fa" xlink:href="ovid-20220630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_4cebb42f-03bd-4881-bcc9-7be7f75b31fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d5dcd1e8-7de3-44d6-a646-795756586141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d5dcd1e8-7de3-44d6-a646-795756586141" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7cac50cc-dbcd-46eb-84ec-a809de205802_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7cac50cc-dbcd-46eb-84ec-a809de205802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_c33fd5c1-469f-4904-92b9-e295dd1f523d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:to="loc_us-gaap_CashMember_c33fd5c1-469f-4904-92b9-e295dd1f523d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7df35ec1-07ff-4425-ac29-7a649d1c6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7df35ec1-07ff-4425-ac29-7a649d1c6dac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" xlink:type="extended" id="i33de2eab300e44b2a8faa382053c2f6e_PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9d66cacd-fe25-4e5e-9b27-8cdfe1d8e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9d66cacd-fe25-4e5e-9b27-8cdfe1d8e7cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94380a0d-927a-4b43-ade4-e783416b5b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94380a0d-927a-4b43-ade4-e783416b5b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c86e0190-1c36-4096-80a5-785598e826df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c86e0190-1c36-4096-80a5-785598e826df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5415ffe0-3934-4435-8692-9a047e695dc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5415ffe0-3934-4435-8692-9a047e695dc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f34f7141-4404-4ccc-9221-d48f0cdc692b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f34f7141-4404-4ccc-9221-d48f0cdc692b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90a636e7-22dc-4519-b7dd-2f5470c0fa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_90a636e7-22dc-4519-b7dd-2f5470c0fa9b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="i8f9f9ccdafb74b68b285dbdea5281f9a_LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_82bc7218-c75c-420e-986d-e681bad6fb17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_82bc7218-c75c-420e-986d-e681bad6fb17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_52a38808-aa09-48d5-bd49-5d398545d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_52a38808-aa09-48d5-bd49-5d398545d7ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_fac0a934-8b2d-428d-98ed-bff61be226c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_PaymentsForRent_fac0a934-8b2d-428d-98ed-bff61be226c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_933c09f8-5e3a-4e34-b298-a36c5450fdf3" xlink:href="ovid-20220630.xsd#ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_933c09f8-5e3a-4e34-b298-a36c5450fdf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseFreeRentPeriod_cc484210-5e8d-4a80-9767-1ea88516e33b" xlink:href="ovid-20220630.xsd#ovid_LesseeOperatingLeaseFreeRentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_ovid_LesseeOperatingLeaseFreeRentPeriod_cc484210-5e8d-4a80-9767-1ea88516e33b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b339fbc6-7364-4b86-b846-f97ed0b20e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_RestrictedCash_b339fbc6-7364-4b86-b846-f97ed0b20e16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_173102cb-e027-40e9-835d-b3dba98ef794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_173102cb-e027-40e9-835d-b3dba98ef794" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f6b78899-2daf-4dc5-905d-cc99dd78e5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f6b78899-2daf-4dc5-905d-cc99dd78e5c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LeaseIncrementalBorrowingRate_8d1f0aba-422f-4160-b0cf-579a86c0c95a" xlink:href="ovid-20220630.xsd#ovid_LeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_ovid_LeaseIncrementalBorrowingRate_8d1f0aba-422f-4160-b0cf-579a86c0c95a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_59f8140b-2e5e-4d14-bcba-aa03c61b598d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_59f8140b-2e5e-4d14-bcba-aa03c61b598d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1d7558ca-cc6f-4ea7-ad71-81352b184470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1d7558ca-cc6f-4ea7-ad71-81352b184470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a57d1032-98b7-4f50-8208-2a849079d7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1d7558ca-cc6f-4ea7-ad71-81352b184470" xlink:to="loc_us-gaap_LetterOfCreditMember_a57d1032-98b7-4f50-8208-2a849079d7f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockholdersEquityandPreferredStockAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail" xlink:type="extended" id="i1af42caadd734a23a9668c3fe163bdd0_StockholdersEquityandPreferredStockAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e87d1619-af6c-4c24-8a6c-34b3443933af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e87d1619-af6c-4c24-8a6c-34b3443933af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2fa6de0d-3b49-4c05-b931-53bef1668542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2fa6de0d-3b49-4c05-b931-53bef1668542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated_ab2160a4-669a-40a7-8689-3a9b732d4c66" xlink:href="ovid-20220630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_PreferredStockShareDesignated_ab2160a4-669a-40a7-8689-3a9b732d4c66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockNumberOfVotesPerShare_7b425221-d8be-4b55-9f12-380beb7bdd7c" xlink:href="ovid-20220630.xsd#ovid_CommonStockNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_CommonStockNumberOfVotesPerShare_7b425221-d8be-4b55-9f12-380beb7bdd7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AggregateOfferingPriceOfCommonStock_094a2480-e5c3-4741-95d3-ae215e88acba" xlink:href="ovid-20220630.xsd#ovid_AggregateOfferingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_AggregateOfferingPriceOfCommonStock_094a2480-e5c3-4741-95d3-ae215e88acba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39294df8-33fa-4bd6-ba73-419f048a3d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39294df8-33fa-4bd6-ba73-419f048a3d14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3a2035cd-7f7d-4c9c-b158-94779ef1e713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3a2035cd-7f7d-4c9c-b158-94779ef1e713" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9bb8380f-65c7-4ed6-bd13-5dd39109d382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9bb8380f-65c7-4ed6-bd13-5dd39109d382" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_6ce7ed5a-13c5-44e9-a233-55d8299a40ab" xlink:href="ovid-20220630.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_6ce7ed5a-13c5-44e9-a233-55d8299a40ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_afdeeedc-200c-40cd-b911-cc54b696f9b1" xlink:href="ovid-20220630.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_afdeeedc-200c-40cd-b911-cc54b696f9b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_bfe341d8-2ac7-43e8-8354-87a12f15c6c2" xlink:href="ovid-20220630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_bfe341d8-2ac7-43e8-8354-87a12f15c6c2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_7eca8f6e-1145-4647-8530-7332047a917d" xlink:href="ovid-20220630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_7eca8f6e-1145-4647-8530-7332047a917d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_602e7be0-4ce6-4b4d-af94-192f173ed241" xlink:href="ovid-20220630.xsd#ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_602e7be0-4ce6-4b4d-af94-192f173ed241" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_9fb6fc2a-2964-408a-b86b-9253026f9038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_9fb6fc2a-2964-408a-b86b-9253026f9038" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_015894b6-f11a-404d-9d33-d39f6b693e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_015894b6-f11a-404d-9d33-d39f6b693e1c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_36d76a2e-aeef-403f-aa3f-d29c13618d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_Dividends_36d76a2e-aeef-403f-aa3f-d29c13618d55" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f49862e4-48ba-46c9-a3e8-23da2659b0fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:to="loc_us-gaap_ClassOfStockDomain_f49862e4-48ba-46c9-a3e8-23da2659b0fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31cac589-c21f-4cbf-b1a4-bd54a2ad5baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:to="loc_us-gaap_ClassOfStockDomain_31cac589-c21f-4cbf-b1a4-bd54a2ad5baa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_65ceec0c-1f83-4fe8-9df1-4c7a23fb076e" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31cac589-c21f-4cbf-b1a4-bd54a2ad5baa" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_65ceec0c-1f83-4fe8-9df1-4c7a23fb076e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0edf0957-577e-409e-bf8b-6a5b2a10783b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0edf0957-577e-409e-bf8b-6a5b2a10783b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ATMAgreementMember_e5763af7-8616-442c-ab6f-11c51f72380b" xlink:href="ovid-20220630.xsd#ovid_ATMAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0edf0957-577e-409e-bf8b-6a5b2a10783b" xlink:to="loc_ovid_ATMAgreementMember_e5763af7-8616-442c-ab6f-11c51f72380b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6c73d12-d84b-48f3-8adc-28d342110123_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:to="loc_srt_RangeMember_d6c73d12-d84b-48f3-8adc-28d342110123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:to="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bf368312-21d3-496f-9a25-e56a666ce8db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:to="loc_srt_MinimumMember_bf368312-21d3-496f-9a25-e56a666ce8db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ebe398d-ddfd-47ea-822b-a7714abd58a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:to="loc_srt_MaximumMember_4ebe398d-ddfd-47ea-822b-a7714abd58a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_df071414-41e4-488c-90d7-07a1ec890efe_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:to="loc_dei_EntityDomain_df071414-41e4-488c-90d7-07a1ec890efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a093c30-bb20-4fa6-8f2b-25746d1f47ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:to="loc_dei_EntityDomain_7a093c30-bb20-4fa6-8f2b-25746d1f47ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CowenAndCompanyLLCMember_3f48066d-7703-43a7-afff-585bc6fc2324" xlink:href="ovid-20220630.xsd#ovid_CowenAndCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7a093c30-bb20-4fa6-8f2b-25746d1f47ef" xlink:to="loc_ovid_CowenAndCompanyLLCMember_3f48066d-7703-43a7-afff-585bc6fc2324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_97a50af1-2825-464d-ae8e-d362aba4436c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:to="loc_us-gaap_EquityComponentDomain_97a50af1-2825-464d-ae8e-d362aba4436c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ae0b3289-d625-4dde-ae9f-77007ee71e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:to="loc_us-gaap_EquityComponentDomain_ae0b3289-d625-4dde-ae9f-77007ee71e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1b8bba84-956e-4676-9862-b3ef89a8fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ae0b3289-d625-4dde-ae9f-77007ee71e14" xlink:to="loc_us-gaap_CommonStockMember_1b8bba84-956e-4676-9862-b3ef89a8fb0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i46ec27e7c8454c78a9f10379076338b0_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fcbbccfb-c6d3-439d-9cc9-16c53315efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fcbbccfb-c6d3-439d-9cc9-16c53315efe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_16d6c682-88aa-479f-a7d2-20fe718387fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_16d6c682-88aa-479f-a7d2-20fe718387fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c018278a-cc51-43fd-9060-bf9e6c1f3071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c018278a-cc51-43fd-9060-bf9e6c1f3071" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ff59a0c-6716-41f3-bbd2-50fdb84ff961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ff59a0c-6716-41f3-bbd2-50fdb84ff961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3dbbccf0-932b-40f4-af36-389a7463c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3dbbccf0-932b-40f4-af36-389a7463c5e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_4b7b6139-70f9-4d50-b84f-1a31558fd44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_4b7b6139-70f9-4d50-b84f-1a31558fd44d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_45c16e2a-515a-4d91-a617-4f4dd2141db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_45c16e2a-515a-4d91-a617-4f4dd2141db9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_c4e746ff-d999-4791-90fa-41cee447b6b0" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_c4e746ff-d999-4791-90fa-41cee447b6b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_7970475a-82ef-4ea9-ae28-a9676d2eeb4d" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_7970475a-82ef-4ea9-ae28-a9676d2eeb4d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cd3dbee7-44f6-4ce3-946a-af5ccf58ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cd3dbee7-44f6-4ce3-946a-af5ccf58ad96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_787b5454-892b-4822-9425-c84bcf0a5e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_787b5454-892b-4822-9425-c84bcf0a5e46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0fdb194b-0b98-49ab-96a7-9bc95a992bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0fdb194b-0b98-49ab-96a7-9bc95a992bf6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_95e3771b-509f-49fb-9920-ae8ef80ef635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_95e3771b-509f-49fb-9920-ae8ef80ef635" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be79c20a-c284-440f-ae0d-162e8c3a6089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be79c20a-c284-440f-ae0d-162e8c3a6089" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54cbbe3f-a4e0-461a-bb21-61dd5a165bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54cbbe3f-a4e0-461a-bb21-61dd5a165bef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_51f6f51b-fcf7-4d87-b287-75057db695df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_51f6f51b-fcf7-4d87-b287-75057db695df" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88240127-74b1-4ceb-8874-b759e89fb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88240127-74b1-4ceb-8874-b759e89fb14a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:to="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:to="loc_us-gaap_PlanNameDomain_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:to="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_5122de60-be48-4f92-9695-5a442381c789" xlink:href="ovid-20220630.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:to="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_5122de60-be48-4f92-9695-5a442381c789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_cf58e5dc-c6ea-4e7c-9d0a-2595b0d96f66" xlink:href="ovid-20220630.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:to="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_cf58e5dc-c6ea-4e7c-9d0a-2595b0d96f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:to="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2304d840-1bca-4083-a9e1-f0875c87decb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2304d840-1bca-4083-a9e1-f0875c87decb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c7d8e9e4-9aac-4ec3-9731-6e4c56c47448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_us-gaap_PerformanceSharesMember_c7d8e9e4-9aac-4ec3-9731-6e4c56c47448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonEmployeeStockOptionsMember_7ef11f34-ada4-45ca-98bc-0275006a8fda" xlink:href="ovid-20220630.xsd#ovid_NonEmployeeStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_ovid_NonEmployeeStockOptionsMember_7ef11f34-ada4-45ca-98bc-0275006a8fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_a2d79666-ce8d-486e-8862-ca143d89b7aa" xlink:href="ovid-20220630.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_a2d79666-ce8d-486e-8862-ca143d89b7aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec6585e6-3efb-4c8f-bd07-5b8d73c815bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec6585e6-3efb-4c8f-bd07-5b8d73c815bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_3767b659-3963-4436-a6e5-0a30e1f9ed8d" xlink:href="ovid-20220630.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_3767b659-3963-4436-a6e5-0a30e1f9ed8d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail" xlink:type="extended" id="iad165dd5330a49e2a5e29c893fa07f48_StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b5f72ac-9687-4fb1-adc2-d230299f8c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7fab3d48-7a33-4950-ac56-33e341a099ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b5f72ac-9687-4fb1-adc2-d230299f8c4d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7fab3d48-7a33-4950-ac56-33e341a099ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b5f72ac-9687-4fb1-adc2-d230299f8c4d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_280219bf-ef9f-438e-8d75-20dd70195952_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_280219bf-ef9f-438e-8d75-20dd70195952_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_998f8502-616a-4cf0-a464-0de2a1da4832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_998f8502-616a-4cf0-a464-0de2a1da4832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c7fb825-3ee6-4043-ab1b-facfecac55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c7fb825-3ee6-4043-ab1b-facfecac55d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="extended" id="id1187017cfa14356aec0b4b5e3653f02_StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84e0406-f8ba-4856-a8b2-69ac1cc7d639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec736e59-840d-4c20-81be-e87108b0a263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84e0406-f8ba-4856-a8b2-69ac1cc7d639" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec736e59-840d-4c20-81be-e87108b0a263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84e0406-f8ba-4856-a8b2-69ac1cc7d639" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:to="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9eee8f73-87e0-449a-865a-24b23cd14c34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9eee8f73-87e0-449a-865a-24b23cd14c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_StockOptionsMember_d82ca6f4-0e77-4268-8dce-811f8ac65ca9" xlink:href="ovid-20220630.xsd#ovid_StockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:to="loc_ovid_StockOptionsMember_d82ca6f4-0e77-4268-8dce-811f8ac65ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeeStockPurchasePlanMember_b07c0f2d-cd63-48fb-b91e-bcda49ba3d56" xlink:href="ovid-20220630.xsd#ovid_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:to="loc_ovid_EmployeeStockPurchasePlanMember_b07c0f2d-cd63-48fb-b91e-bcda49ba3d56" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="extended" id="ib1e6757b9b9c474eb6036cdc07007fd0_StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82d5b596-f0d7-4ce7-930b-ed4b884620cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82d5b596-f0d7-4ce7-930b-ed4b884620cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ed6b44d-2cf9-4b5d-afae-c3b275fa3b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ed6b44d-2cf9-4b5d-afae-c3b275fa3b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d2726e23-ff24-4dfd-b03f-7c084a70f77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d2726e23-ff24-4dfd-b03f-7c084a70f77a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81b1a791-df10-415e-9887-7a4fb6e716a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81b1a791-df10-415e-9887-7a4fb6e716a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b545d9d-85b2-4baa-98e5-9b244dee2afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b545d9d-85b2-4baa-98e5-9b244dee2afc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:to="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_115b3a4d-8f12-4b5a-b192-747e22477ce3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_115b3a4d-8f12-4b5a-b192-747e22477ce3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2d894a8-ce3a-4735-aa3f-12aa6ebb42dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2d894a8-ce3a-4735-aa3f-12aa6ebb42dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94116268-84de-4def-bfaa-79cf5a5c02cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2d894a8-ce3a-4735-aa3f-12aa6ebb42dd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94116268-84de-4def-bfaa-79cf5a5c02cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:to="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:to="loc_us-gaap_GranteeStatusDomain_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:to="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3a4f0ab0-df96-420b-9328-62062bffa1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3a4f0ab0-df96-420b-9328-62062bffa1be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fccf9a8-7f5b-4b01-8628-cf90ae0b95c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fccf9a8-7f5b-4b01-8628-cf90ae0b95c8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CommitmentandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i7b52b4a94b75436b96442a2c41ee1f56_CommitmentandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMilestonePayments_485c356c-bc7a-4b29-bc81-f5f97c00f1cf" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_LicenseAgreementMilestonePayments_485c356c-bc7a-4b29-bc81-f5f97c00f1cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_44693f3d-16c4-4098-ad10-491a2ce01f1c" xlink:href="ovid-20220630.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_44693f3d-16c4-4098-ad10-491a2ce01f1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NumberOfTrial_04eb77da-65e9-495e-b571-40f7683b1223" xlink:href="ovid-20220630.xsd#ovid_NumberOfTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_NumberOfTrial_04eb77da-65e9-495e-b571-40f7683b1223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_6ae0602e-4114-400c-9711-bd36be9dda09" xlink:href="ovid-20220630.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_6ae0602e-4114-400c-9711-bd36be9dda09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AnnualLicenseMaintenanceFeePayable_53fe5d65-fa42-4cac-b7c0-7c558fb403e2" xlink:href="ovid-20220630.xsd#ovid_AnnualLicenseMaintenanceFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_AnnualLicenseMaintenanceFeePayable_53fe5d65-fa42-4cac-b7c0-7c558fb403e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConsiderationPayableForRightsGrant_05297392-2d74-4b81-a940-162533134486" xlink:href="ovid-20220630.xsd#ovid_ConsiderationPayableForRightsGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_ConsiderationPayableForRightsGrant_05297392-2d74-4b81-a940-162533134486" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_be90b076-c48e-45eb-8770-8888733afe3a" xlink:href="ovid-20220630.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_be90b076-c48e-45eb-8770-8888733afe3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontCashPayment_68b156d1-eeb7-4723-980c-d0dd9fdc03a5" xlink:href="ovid-20220630.xsd#ovid_UpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_UpfrontCashPayment_68b156d1-eeb7-4723-980c-d0dd9fdc03a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d2486af5-4af0-4920-bcf1-ca95fbf8fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_us-gaap_CommonStockSharesIssued_d2486af5-4af0-4920-bcf1-ca95fbf8fa26" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_a4895f59-113e-4726-983c-d54aec0dbafd" xlink:href="ovid-20220630.xsd#ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_a4895f59-113e-4726-983c-d54aec0dbafd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_34f78454-80cb-4a16-bacb-c2313d075c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_34f78454-80cb-4a16-bacb-c2313d075c65" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5391fae-a3cf-4ec2-a617-1d61c82ca91f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5391fae-a3cf-4ec2-a617-1d61c82ca91f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HLundbeckASMember_62b5dd24-8b13-4446-b1c8-c62616f49c24" xlink:href="ovid-20220630.xsd#ovid_HLundbeckASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:to="loc_ovid_HLundbeckASMember_62b5dd24-8b13-4446-b1c8-c62616f49c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NorthwesternUniversityMember_4d822fcb-1508-40e2-a1d3-33d5057250a8" xlink:href="ovid-20220630.xsd#ovid_NorthwesternUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:to="loc_ovid_NorthwesternUniversityMember_4d822fcb-1508-40e2-a1d3-33d5057250a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AstrazenecaMember_db7e7094-80f6-49de-a820-b892f09f9d3c" xlink:href="ovid-20220630.xsd#ovid_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:to="loc_ovid_AstrazenecaMember_db7e7094-80f6-49de-a820-b892f09f9d3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27bc3786-35c3-4f3a-8380-1aaf8bdc646d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_27bc3786-35c3-4f3a-8380-1aaf8bdc646d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8352a83-7607-4ab6-9671-b24f1c9a6505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8352a83-7607-4ab6-9671-b24f1c9a6505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember_f69b1ebb-7a13-44ca-bbba-83af6d37c675" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8352a83-7607-4ab6-9671-b24f1c9a6505" xlink:to="loc_ovid_LicenseAgreementMember_f69b1ebb-7a13-44ca-bbba-83af6d37c675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_714fa88d-2ecf-4256-a673-223a7bc45741_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:to="loc_srt_RangeMember_714fa88d-2ecf-4256-a673-223a7bc45741_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2db5839e-0e1a-4dfc-83a8-c47826729c96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:to="loc_srt_RangeMember_2db5839e-0e1a-4dfc-83a8-c47826729c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a14539f-a1c6-4ca6-987b-c2d6c358d419" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2db5839e-0e1a-4dfc-83a8-c47826729c96" xlink:to="loc_srt_MaximumMember_3a14539f-a1c6-4ca6-987b-c2d6c358d419" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CollaborationAndLicenseAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="extended" id="i97b2a79b1dce4d9aa2ddfe33f2f96404_CollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PotentialFundingCostPercent_a6d5787e-a127-4efb-8a97-de0d5c9afd17" xlink:href="ovid-20220630.xsd#ovid_PotentialFundingCostPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_PotentialFundingCostPercent_a6d5787e-a127-4efb-8a97-de0d5c9afd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CostOfAgreementNet_1898406d-d544-4ec7-bf2c-02a4d3b351ad" xlink:href="ovid-20220630.xsd#ovid_CostOfAgreementNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_CostOfAgreementNet_1898406d-d544-4ec7-bf2c-02a4d3b351ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DeferredUpfrontPaymentCosts_85e630d6-736e-4781-aceb-fed72db101eb" xlink:href="ovid-20220630.xsd#ovid_DeferredUpfrontPaymentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_DeferredUpfrontPaymentCosts_85e630d6-736e-4781-aceb-fed72db101eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementUpfrontPayment_b790cdb4-2bfc-40e0-be1d-b77440ed5ada" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_LicenseAgreementUpfrontPayment_b790cdb4-2bfc-40e0-be1d-b77440ed5ada" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalUpFrontFeeAmount_f11b6808-5c2b-4358-9088-ac9dd55cdbf4" xlink:href="ovid-20220630.xsd#ovid_AdditionalUpFrontFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AdditionalUpFrontFeeAmount_f11b6808-5c2b-4358-9088-ac9dd55cdbf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontFeeAmount_8d5316e9-990a-49d8-9437-48508ecef988" xlink:href="ovid-20220630.xsd#ovid_UpFrontFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_UpFrontFeeAmount_8d5316e9-990a-49d8-9437-48508ecef988" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e59762b1-74f0-4248-9fdb-60af7bbd1a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e59762b1-74f0-4248-9fdb-60af7bbd1a61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseRevenue_4acfe974-094b-492c-8497-f49412cc430a" xlink:href="ovid-20220630.xsd#ovid_LicenseRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_LicenseRevenue_4acfe974-094b-492c-8497-f49412cc430a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AmountForPotentialFutureTrials_71f07fae-1518-4bae-99e0-0c02c2ac18b5" xlink:href="ovid-20220630.xsd#ovid_AmountForPotentialFutureTrials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AmountForPotentialFutureTrials_71f07fae-1518-4bae-99e0-0c02c2ac18b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b039a3b6-6dde-41f9-85e2-7249a69b76cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b039a3b6-6dde-41f9-85e2-7249a69b76cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontPaymentReceivable_f551e465-e7cc-4c59-be78-53f27872da66" xlink:href="ovid-20220630.xsd#ovid_UpfrontPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_UpfrontPaymentReceivable_f551e465-e7cc-4c59-be78-53f27872da66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AgreementMilestonePayments_348a63d5-316e-473e-a0f4-f00457485e2f" xlink:href="ovid-20220630.xsd#ovid_AgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AgreementMilestonePayments_348a63d5-316e-473e-a0f4-f00457485e2f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_ec5b0841-71f6-491f-aa9e-99d522c55fab" xlink:href="ovid-20220630.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_ec5b0841-71f6-491f-aa9e-99d522c55fab" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca5cde3c-17dd-47bb-b8f4-f7dbf366bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca5cde3c-17dd-47bb-b8f4-f7dbf366bf73" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_3ad39c74-bc51-468a-ade9-950bcd0a83cb" xlink:href="ovid-20220630.xsd#ovid_ResearchAndDevelopmentExpenseReimbursementReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_3ad39c74-bc51-468a-ade9-950bcd0a83cb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_d6cfeb70-6963-4be7-aec1-d01b505a1e91" xlink:href="ovid-20220630.xsd#ovid_GeneralAndAdministrativeExpenseReimbursementReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_d6cfeb70-6963-4be7-aec1-d01b505a1e91" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontPayment_04026e78-87f2-4875-add2-49d5f464a3be" xlink:href="ovid-20220630.xsd#ovid_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_UpFrontPayment_04026e78-87f2-4875-add2-49d5f464a3be" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DevelopmentAndCommercialMilestonePayments_81b3c84f-a268-4258-961c-480e40208a6b" xlink:href="ovid-20220630.xsd#ovid_DevelopmentAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_DevelopmentAndCommercialMilestonePayments_81b3c84f-a268-4258-961c-480e40208a6b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PercentageOfDevelopmentCosts_be63f5fe-5dd8-4817-b16d-208ec5fecf2b" xlink:href="ovid-20220630.xsd#ovid_PercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_PercentageOfDevelopmentCosts_be63f5fe-5dd8-4817-b16d-208ec5fecf2b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cfa21c4b-8780-4bab-b742-bfb4fbd65c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_CommonStockSharesIssued_cfa21c4b-8780-4bab-b742-bfb4fbd65c77" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_073080bb-1582-4e84-90cf-98881c8134b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_073080bb-1582-4e84-90cf-98881c8134b4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_9390f930-e778-4eec-8565-9fe6c69c4125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_9390f930-e778-4eec-8565-9fe6c69c4125" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97875851-1492-4535-acc0-cd043070f42d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97875851-1492-4535-acc0-cd043070f42d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_865fa515-94f9-4732-86d1-e01365a94c9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_865fa515-94f9-4732-86d1-e01365a94c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AngeliniLicenseAgreementMember_d0694f13-eabe-4825-998d-67fcc0fc1a6f" xlink:href="ovid-20220630.xsd#ovid_AngeliniLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_865fa515-94f9-4732-86d1-e01365a94c9f" xlink:to="loc_ovid_AngeliniLicenseAgreementMember_d0694f13-eabe-4825-998d-67fcc0fc1a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19fa880b-c229-4084-bfbc-87a3d79db62e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19fa880b-c229-4084-bfbc-87a3d79db62e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember_2b65adb8-d390-4a01-b5d4-b3d9b7205d3b" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_LicenseAgreementMember_2b65adb8-d390-4a01-b5d4-b3d9b7205d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8d446116-6cd3-442a-9f7e-60f67badeeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8d446116-6cd3-442a-9f7e-60f67badeeaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HealxLicenseAndOptionAgreementMember_6793084a-821f-47e8-86c4-d6b8707f8f34" xlink:href="ovid-20220630.xsd#ovid_HealxLicenseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_HealxLicenseAndOptionAgreementMember_6793084a-821f-47e8-86c4-d6b8707f8f34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusLicenseAgreementMember_2e5283ec-3c01-49ae-9b6b-8697a9384837" xlink:href="ovid-20220630.xsd#ovid_MarinusLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_MarinusLicenseAgreementMember_2e5283ec-3c01-49ae-9b6b-8697a9384837" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PatentLicenseAgreementMember_8a4838a3-1888-41ee-af85-05bb0d2f4958" xlink:href="ovid-20220630.xsd#ovid_PatentLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_PatentLicenseAgreementMember_8a4838a3-1888-41ee-af85-05bb0d2f4958" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_38721e80-79e0-4c9a-a070-cc4fec900766_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:to="loc_dei_EntityDomain_38721e80-79e0-4c9a-a070-cc4fec900766_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:to="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1013e996-184b-4a38-9e95-a679bb6bfa98" xlink:href="ovid-20220630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1013e996-184b-4a38-9e95-a679bb6bfa98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember_48e22889-7116-40f6-af0d-f2cc76e0ffc2" xlink:href="ovid-20220630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:to="loc_ovid_MarinusPharmaceuticalsIncMember_48e22889-7116-40f6-af0d-f2cc76e0ffc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_610c93fa-737e-421e-881b-df7dc3e5a39a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_610c93fa-737e-421e-881b-df7dc3e5a39a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_15305687-b895-4187-89d8-0def256cce68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_15305687-b895-4187-89d8-0def256cce68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_62541a01-2120-404b-a229-188155b8c9f5" xlink:href="ovid-20220630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_15305687-b895-4187-89d8-0def256cce68" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_62541a01-2120-404b-a229-188155b8c9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:to="loc_srt_RangeMember_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37852b32-17e9-48c6-b41d-f89c00146eb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:to="loc_srt_RangeMember_37852b32-17e9-48c6-b41d-f89c00146eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9fbab07e-f261-4cb2-bbd2-e9eb69326e47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37852b32-17e9-48c6-b41d-f89c00146eb6" xlink:to="loc_srt_MaximumMember_9fbab07e-f261-4cb2-bbd2-e9eb69326e47" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="extended" id="ibb8c17aaa13b429cb7b038aacedd24b5_NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2721379-7d08-4afb-9b3e-8f02cd28e522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_815ba93e-a026-44f9-bc03-0863eae65e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2721379-7d08-4afb-9b3e-8f02cd28e522" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_815ba93e-a026-44f9-bc03-0863eae65e8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2721379-7d08-4afb-9b3e-8f02cd28e522" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_464b621b-d7c4-4015-a9bf-cfe42411d235_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_464b621b-d7c4-4015-a9bf-cfe42411d235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_62f1033d-ba7c-4f89-9de7-6e14b5abc0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:to="loc_us-gaap_EmployeeStockOptionMember_62f1033d-ba7c-4f89-9de7-6e14b5abc0ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_5b7d3930-49dd-4f52-be7f-b6bbac5d0e6d" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_5b7d3930-49dd-4f52-be7f-b6bbac5d0e6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ovid-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8739d977-ca53-4263-89b1-d9c54849b06c,g:ab39b854-7f58-4138-956d-843b33846298-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f1f5c378-b106-4462-8f6d-80443bed2595_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d33cd916-df03-4bed-8722-8d2ce92a39c9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease, liability, to be paid</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_91a65a3f-b054-44bd-9cc8-3ab0d695bbad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3f6c9007-ffc2-40df-a433-8f4c474442fd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PercentageOfDevelopmentCosts_a17c461f-ec01-46e1-824b-186850c616b6_terseLabel_en-US" xlink:label="lab_ovid_PercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs</link:label>
    <link:label id="lab_ovid_PercentageOfDevelopmentCosts_label_en-US" xlink:label="lab_ovid_PercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Development Costs</link:label>
    <link:label id="lab_ovid_PercentageOfDevelopmentCosts_documentation_en-US" xlink:label="lab_ovid_PercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PercentageOfDevelopmentCosts" xlink:href="ovid-20220630.xsd#ovid_PercentageOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PercentageOfDevelopmentCosts" xlink:to="lab_ovid_PercentageOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb3185bb-cfea-4e19-9ecc-0bf60c1294e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c8797611-43ce-4709-b1b1-1665a7712758_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_314f0d87-33e0-49e0-b1af-85fe7d88532a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6c0afaa8-c8ea-46bf-8f53-d59d17ef819c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_47555ae3-825e-4f1e-83bf-4cdf07bea60e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_46e6fad6-7d91-42aa-8fec-e11d4b785754_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction expenses recognized</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2a54918f-b7d5-4fa8-918f-d8be5610209d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_644050bc-4e97-420b-b43b-5d0f8b810c28_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4bc9391c-fd3c-4837-a6a6-b99cebbfc62c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c7c3cc49-49b5-4941-852d-59f4a820e840_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_4be71b64-98b7-4275-bbd4-132454107c1c_terseLabel_en-US" xlink:label="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership limitations, percentage of issued and outstanding common stock</link:label>
    <link:label id="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_label_en-US" xlink:label="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock</link:label>
    <link:label id="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_documentation_en-US" xlink:label="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:href="ovid-20220630.xsd#ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:to="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_96b1c080-b7f9-442f-9913-96482d9402e8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d1c6e58e-703b-4db1-868d-d5cd65cd81b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cd592161-c2f8-471c-b8b2-4a175e3c7420_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_ac3d0e13-3c53-4bd0-b2d1-f5a46f30efe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_719901f4-549a-4d3f-9d52-c81826de790a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of interest received on convertible promissory note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34c7c6ff-8f32-4b18-8f34-30350961dcba_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c0d5f03d-98a5-4134-8144-30b87c221dc5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of series A convertible preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ff89fe98-cd7c-45bd-a41e-f59220ca7d82_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_125c4c93-0322-4c4b-9b37-c9b30ddbf956_terseLabel_en-US" xlink:label="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum number of product covered under license agreement</link:label>
    <link:label id="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_label_en-US" xlink:label="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Number Of Product Covered Under License Agreement</link:label>
    <link:label id="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_documentation_en-US" xlink:label="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum number of product covered under license agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:href="ovid-20220630.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:to="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember_dc9d3eed-b15c-46bf-95ee-101c0cd98e20_terseLabel_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="ovid-20220630.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_82128c56-61ad-4abf-b629-fcaf5566dff3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2363a239-3cbb-484e-a2e2-46bdfd8cebe8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_05753d43-76c1-4ff7-a01b-ecf83e481355_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b0f60e7-6106-4db9-afde-6976284302b4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d7f5fc4c-c4a1-4f50-bd90-23925457f3c0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_90451aed-161d-469f-a22b-2179ed87390a_terseLabel_en-US" xlink:label="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront non-creditable one-time license issuance fee payment</link:label>
    <link:label id="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_label_en-US" xlink:label="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Non Creditable One Time License Issuance Fee Payment</link:label>
    <link:label id="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_documentation_en-US" xlink:label="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront non-creditable one-time license issuance fee payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:href="ovid-20220630.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:to="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_88e14476-4018-4d32-bca4-c062a12c3e5c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_07779a28-2da9-4297-a783-b816ec1b3e32_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_18aecb88-0dea-4b69-8d47-fd25bde7693a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NoteReceivable_0cd631af-f5e6-4c99-b4b2-c21216aa951b_terseLabel_en-US" xlink:label="lab_ovid_NoteReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable</link:label>
    <link:label id="lab_ovid_NoteReceivable_label_en-US" xlink:label="lab_ovid_NoteReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable</link:label>
    <link:label id="lab_ovid_NoteReceivable_documentation_en-US" xlink:label="lab_ovid_NoteReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The sum of amounts of notes currently receivable from customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoteReceivable" xlink:href="ovid-20220630.xsd#ovid_NoteReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NoteReceivable" xlink:to="lab_ovid_NoteReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a9f88bfb-0f92-4e02-a296-4743255f2643_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_63ee657d-8da6-4ca7-bff1-2076b85a31d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_DevelopmentAndCommercialMilestonePayments_3150a212-61b2-49f9-a634-36c57e4e2149_terseLabel_en-US" xlink:label="lab_ovid_DevelopmentAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercial milestone payments</link:label>
    <link:label id="lab_ovid_DevelopmentAndCommercialMilestonePayments_label_en-US" xlink:label="lab_ovid_DevelopmentAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercial Milestone Payments</link:label>
    <link:label id="lab_ovid_DevelopmentAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_ovid_DevelopmentAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DevelopmentAndCommercialMilestonePayments" xlink:href="ovid-20220630.xsd#ovid_DevelopmentAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_DevelopmentAndCommercialMilestonePayments" xlink:to="lab_ovid_DevelopmentAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_78660ddc-f073-43d2-ba5d-89ae745bccf9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_df410917-3f8c-47de-9ac8-a2d5293b54cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c69c90fb-e583-4f3c-a081-c841843883dd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_84f48763-4a01-45f1-b963-e90a27e85f89_terseLabel_en-US" xlink:label="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Days immediately preceding the execution date</link:label>
    <link:label id="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_label_en-US" xlink:label="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuance , Period Immediately Preceding Execution Date</link:label>
    <link:label id="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_documentation_en-US" xlink:label="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuance , Period Immediately Preceding Execution Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:href="ovid-20220630.xsd#ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:to="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2dc864e4-0405-4881-9290-502fe3416274_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_06a9a0f6-381a-40cc-b41d-f497bbbd6d4d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AdditionalUpFrontFeeAmount_b2f1306e-b9e6-4105-b5b4-4a2ef6c77825_terseLabel_en-US" xlink:label="lab_ovid_AdditionalUpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional up front fee amount</link:label>
    <link:label id="lab_ovid_AdditionalUpFrontFeeAmount_label_en-US" xlink:label="lab_ovid_AdditionalUpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Up Front Fee Amount</link:label>
    <link:label id="lab_ovid_AdditionalUpFrontFeeAmount_documentation_en-US" xlink:label="lab_ovid_AdditionalUpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdditionalUpFrontFeeAmount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalUpFrontFeeAmount" xlink:href="ovid-20220630.xsd#ovid_AdditionalUpFrontFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AdditionalUpFrontFeeAmount" xlink:to="lab_ovid_AdditionalUpFrontFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c6775eaa-3650-4ee5-aac4-fa89d22e4c9b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementMilestonePayments_f0bb0eb0-c649-4261-9199-f2ec5c92fd8a_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement milestone payments</link:label>
    <link:label id="lab_ovid_LicenseAgreementMilestonePayments_label_en-US" xlink:label="lab_ovid_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payments</link:label>
    <link:label id="lab_ovid_LicenseAgreementMilestonePayments_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercial and regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMilestonePayments" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementMilestonePayments" xlink:to="lab_ovid_LicenseAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_873f07cb-4c71-4121-aa2a-c539b28e26c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d9754a8c-b797-41b8-80c4-8195a26b9f08_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_352ebe43-8c01-451a-ba05-ee76540ab4fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_e440dc36-567d-4793-8678-e945ca5faa54_terseLabel_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable voting right percentage of outstanding common stock holders upon notice of days</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_label_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_documentation_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:href="ovid-20220630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:to="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6bb155c8-11b3-4e54-85e4-fd446b916c54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5005c9c1-0ca5-4087-80b7-bfe3ae427380_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6bd1ece0-769e-4ba5-a05e-7d28b64977d2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_251156d6-98e4-4606-b5cf-02c75e43e4ad_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6d18a63a-bbda-4a39-9402-6dfb330b3bd6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_febd2a66-f3d2-4ce5-9611-0bf0f7f37cc4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PotentialFundingCostPercent_adfc5b76-55fe-45d2-bac5-7fb11c36d797_terseLabel_en-US" xlink:label="lab_ovid_PotentialFundingCostPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential funding cost percent</link:label>
    <link:label id="lab_ovid_PotentialFundingCostPercent_label_en-US" xlink:label="lab_ovid_PotentialFundingCostPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Funding Cost Percent</link:label>
    <link:label id="lab_ovid_PotentialFundingCostPercent_documentation_en-US" xlink:label="lab_ovid_PotentialFundingCostPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential funding cost percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PotentialFundingCostPercent" xlink:href="ovid-20220630.xsd#ovid_PotentialFundingCostPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PotentialFundingCostPercent" xlink:to="lab_ovid_PotentialFundingCostPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f24a9183-f808-47d7-a45b-922159199c5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b40266fc-083a-44c4-aba4-0de3fc138e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_60e6b62d-cd73-44c3-b6cd-458622eb2638_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_b990a9d6-8c83-4105-a78b-31a52a0f1375_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1976a375-a2eb-40c6-8dcd-5eb02c96bf18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_30099864-a20f-4ce9-8765-1aa8477919b8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd8a210b-bc3a-48b4-8993-ba5854ef0ca9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ccaca6b3-d094-4a28-a034-e54b56b2da82_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AmountForPotentialFutureTrials_d2aea7f3-0466-4b8b-9728-495642eaf4aa_terseLabel_en-US" xlink:label="lab_ovid_AmountForPotentialFutureTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount for potential future trials</link:label>
    <link:label id="lab_ovid_AmountForPotentialFutureTrials_label_en-US" xlink:label="lab_ovid_AmountForPotentialFutureTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount For Potential Future Trials</link:label>
    <link:label id="lab_ovid_AmountForPotentialFutureTrials_documentation_en-US" xlink:label="lab_ovid_AmountForPotentialFutureTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount for potential future trials.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AmountForPotentialFutureTrials" xlink:href="ovid-20220630.xsd#ovid_AmountForPotentialFutureTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AmountForPotentialFutureTrials" xlink:to="lab_ovid_AmountForPotentialFutureTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9c69e046-7edc-4e26-b6bb-59373c812141_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6e9b3df9-c585-4e02-b257-07fbbbbeb3c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_75b123f3-e064-48d4-a0e6-e490db970e8b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MarinusTherapeuticsIncMember_907a77db-6436-46e1-8c93-0e12326f96c9_terseLabel_en-US" xlink:label="lab_ovid_MarinusTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Therapeutics, Inc</link:label>
    <link:label id="lab_ovid_MarinusTherapeuticsIncMember_label_en-US" xlink:label="lab_ovid_MarinusTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ovid_MarinusTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ovid_MarinusTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus therapeutics inc member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusTherapeuticsIncMember" xlink:href="ovid-20220630.xsd#ovid_MarinusTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MarinusTherapeuticsIncMember" xlink:to="lab_ovid_MarinusTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f9aa92f9-6e05-460a-b407-9ba7f8da0227_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_feb851c4-1aa4-4c21-badc-9a50bb45da20_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_161317f6-be2f-4fe6-a774-248b5d266227_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_693d1f3c-337a-41ba-91d6-2e511bbf9f6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_7cacd160-7989-4781-bd43-7d70bb3e03c5_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land subject to ground leases (sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f4cce03c-ce73-43f3-bae4-94935ebb2fb2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0da6ee98-f2a2-4552-b915-c186d5a7c932_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3b2f0155-e783-438c-88ac-a4bb94b263d5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4a65ee75-d1ae-4980-b76d-8f9c0287a053_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_5e4f99db-6331-4e95-bd35-b5eba42bbb50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of convertible short-term note</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8e60890-6207-4924-819a-0b658ad9664e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d8ff2893-49e8-4076-84ea-459241b3e4fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase_5d390104-7dc2-4187-b223-0a6f4d0b303e_terseLabel_en-US" xlink:label="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First payment due upon completion of first phase</link:label>
    <link:label id="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase_label_en-US" xlink:label="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Payment Due Upon Completion Of First Phase</link:label>
    <link:label id="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase_documentation_en-US" xlink:label="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First payment due upon completion of first phase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:href="ovid-20220630.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:to="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_215af634-c08f-4d2f-a84a-12aaff743aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_55141066-0045-48c3-a74b-322c9cb972eb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_db4c5bb1-4167-4b81-8703-b949b56d7e46_totalLabel_en-US" xlink:label="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_label_en-US" xlink:label="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost</link:label>
    <link:label id="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:href="ovid-20220630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:to="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MarinusLicenseAgreementMember_6a1b6843-7ff3-42bb-9753-c910f34631bd_terseLabel_en-US" xlink:label="lab_ovid_MarinusLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus License Agreement</link:label>
    <link:label id="lab_ovid_MarinusLicenseAgreementMember_label_en-US" xlink:label="lab_ovid_MarinusLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus License Agreement [Member]</link:label>
    <link:label id="lab_ovid_MarinusLicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_MarinusLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">marinus license agreement member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusLicenseAgreementMember" xlink:href="ovid-20220630.xsd#ovid_MarinusLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MarinusLicenseAgreementMember" xlink:to="lab_ovid_MarinusLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AngeliniLicenseAgreementMember_d4462492-dd12-4ea7-ae06-a22727aec839_terseLabel_en-US" xlink:label="lab_ovid_AngeliniLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Angelini License Agreement</link:label>
    <link:label id="lab_ovid_AngeliniLicenseAgreementMember_label_en-US" xlink:label="lab_ovid_AngeliniLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Angelini License Agreement [Member]</link:label>
    <link:label id="lab_ovid_AngeliniLicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_AngeliniLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Angelini License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AngeliniLicenseAgreementMember" xlink:href="ovid-20220630.xsd#ovid_AngeliniLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AngeliniLicenseAgreementMember" xlink:to="lab_ovid_AngeliniLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b505a296-92a3-4917-ad89-6fb4403a276f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a3f0e9e6-ffa5-4e68-b40b-5d27660bddea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInSecurityDeposits_d58fbfd1-9923-4ff5-95d8-1d823bf5b046_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInSecurityDeposits_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Security Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4dd14636-01c7-452d-9045-603eb612678d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_16d1e0f2-2ae6-4c9f-abbc-593bae308a1d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_33bef2b4-2b39-48bb-892a-d2fa40c25b57_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based Option Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_0675b473-0b90-40ef-aa2a-2ea3a33eaaca_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_1b667c1c-1f94-43aa-8974-ae25799cef49_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5a94cebb-f103-4dad-ab86-64d6324c681b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3d448267-4573-4100-be7d-23046d7e887b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpfrontCashPayment_da42bc8c-d761-4517-bbef-46d2c44181ea_terseLabel_en-US" xlink:label="lab_ovid_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_ovid_UpfrontCashPayment_label_en-US" xlink:label="lab_ovid_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Cash Payment</link:label>
    <link:label id="lab_ovid_UpfrontCashPayment_documentation_en-US" xlink:label="lab_ovid_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontCashPayment" xlink:href="ovid-20220630.xsd#ovid_UpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpfrontCashPayment" xlink:to="lab_ovid_UpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_cd8fe1ab-121e-4ac1-b3bd-c7299d52f71f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation preference per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_us-gaap_PreferredStockLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_84d1ea8e-4c0b-44b0-9a34-3390ac0943c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c4e4a600-3fa3-419c-b4d3-1fb7ea44a809_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9026b709-7f58-4448-ae3e-58c99cb53d49_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_16c43138-84c3-4b68-b77c-7ef3d65be8db_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_58cd73cc-ed96-4459-85a4-075b0bb4d767_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term equity investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d65a0556-6c37-489f-83b5-19dc667a74bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and bonus accrual</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_9ac95aff-9acc-4256-ac73-28d4cb241577_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_061483f2-90f4-4f70-9805-7c0301fca127_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6c4aec18-afdf-4632-9c93-fe9b946be2ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c7a6804e-ed10-4ca2-972e-55235126720c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f5075067-dd23-451c-98f9-9548ba0add54_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e26f00a-1473-4eab-aca0-4be495c22d41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assumptions Used to Compute Fair Value of Employee Option Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseDueFromAffiliates_8932b828-2c5c-4d0f-9f00-7afa4061d800_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseDueFromAffiliates_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Due from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:to="lab_us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f0e76a9-acc6-4d80-b917-22edfe47a524_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_392926dc-2baf-49b5-98e8-92c525f4ce7d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ce0d541f-4b92-4b10-a1ff-89dce876bc2c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fed78ca3-a459-4013-8613-8c4c2412f668_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_f65fb716-aedb-47b4-8611-a1c833342b93_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_7f52bdbf-bc15-4548-9789-0977f9d11125_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_18a1d6a2-b92a-4608-b4e2-45fe77a59fca_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d62a2293-af1b-49ef-993f-26bcd19b4430_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpfrontPaymentReceivable_99fd6261-a3f6-4c1c-9c11-42902feaa65b_terseLabel_en-US" xlink:label="lab_ovid_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment under royalty and termination agreement</link:label>
    <link:label id="lab_ovid_UpfrontPaymentReceivable_label_en-US" xlink:label="lab_ovid_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Receivable</link:label>
    <link:label id="lab_ovid_UpfrontPaymentReceivable_documentation_en-US" xlink:label="lab_ovid_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontPaymentReceivable" xlink:href="ovid-20220630.xsd#ovid_UpfrontPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpfrontPaymentReceivable" xlink:to="lab_ovid_UpfrontPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0a183750-e230-4714-bfaf-5e0d5a4755dc_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpFrontFeeAmount_0f47ec0b-16d0-4f63-bf3b-43087f717cd1_terseLabel_en-US" xlink:label="lab_ovid_UpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front fee</link:label>
    <link:label id="lab_ovid_UpFrontFeeAmount_label_en-US" xlink:label="lab_ovid_UpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Fee Amount</link:label>
    <link:label id="lab_ovid_UpFrontFeeAmount_documentation_en-US" xlink:label="lab_ovid_UpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front fee amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontFeeAmount" xlink:href="ovid-20220630.xsd#ovid_UpFrontFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpFrontFeeAmount" xlink:to="lab_ovid_UpFrontFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_093ec62a-1d81-41d1-b3b4-9b4fe6be3ed3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fa6fca1d-df15-4624-b7ec-d5760eff1f5a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_7ead40a4-4c46-43b7-8c4b-3f99482ce518_terseLabel_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable voting right percentage of outstanding common stock holders</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_label_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_documentation_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:href="ovid-20220630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:to="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_db9e0824-4715-43b3-a2e1-1ad9280b64b3_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7968aa8b-a312-47d3-beed-0f5f6bb71b77_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_85dabc50-c77a-442a-9088-fb7affba8bdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5c0eacb4-47c6-4ef0-b622-42b769295c08_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_265db9a5-54d9-4560-bc91-585aa736755f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e81472eb-fb08-45c3-8153-0481dcce67f7_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MarinusPharmaceuticalsIncMember_d1c3dc87-1b73-478e-a7e0-bac762007201_terseLabel_en-US" xlink:label="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Pharmaceuticals, Inc</link:label>
    <link:label id="lab_ovid_MarinusPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_ovid_MarinusPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus pharmaceuticals, inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember" xlink:href="ovid-20220630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MarinusPharmaceuticalsIncMember" xlink:to="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9cce1444-4aeb-46ca-bb0b-0925def0de49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f0ff045d-ac7e-449e-92b0-b2d9fd391016_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7b674279-2799-4dea-939f-76bd80e45cf4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33649d51-023b-432b-a2b0-280a9468275d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementMember_e62ee2fc-a7bc-4620-bf09-a203054dc3cd_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_ovid_LicenseAgreementMember_label_en-US" xlink:label="lab_ovid_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_ovid_LicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementMember" xlink:to="lab_ovid_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AstrazenecaMember_d4362b94-eb92-4a04-8681-b19ce6a4c9e6_terseLabel_en-US" xlink:label="lab_ovid_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ovid_AstrazenecaMember_label_en-US" xlink:label="lab_ovid_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ovid_AstrazenecaMember_documentation_en-US" xlink:label="lab_ovid_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AstrazenecaMember" xlink:href="ovid-20220630.xsd#ovid_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AstrazenecaMember" xlink:to="lab_ovid_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseRevenue_2f4527ee-9fd5-454f-8c96-d998306930f4_terseLabel_en-US" xlink:label="lab_ovid_LicenseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_ovid_LicenseRevenue_label_en-US" xlink:label="lab_ovid_LicenseRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue</link:label>
    <link:label id="lab_ovid_LicenseRevenue_documentation_en-US" xlink:label="lab_ovid_LicenseRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseRevenue" xlink:href="ovid-20220630.xsd#ovid_LicenseRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseRevenue" xlink:to="lab_ovid_LicenseRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bf2a5648-a222-4bfc-b283-48b61a0d7f1c_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e010e0a2-4371-4132-b9af-83dba1264cf1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5af03e7b-e28e-459b-b311-da8ff9980f50_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_7f76b7b5-ca59-41d9-a573-9fb1bab21ede_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a923e2bb-a6f7-479e-8a17-9d1be6c114be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3af064a3-83ad-4424-8213-2f477c654995_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_b3837f36-7c98-45d6-8e01-74f28cba1e49_negatedLabel_en-US" xlink:label="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash consideration received in licensing agreement transaction</link:label>
    <link:label id="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_label_en-US" xlink:label="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Consideration Received in Licensing Agreement Transaction</link:label>
    <link:label id="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_documentation_en-US" xlink:label="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash consideration received in licensing agreement transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:href="ovid-20220630.xsd#ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:to="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AnnualLicenseMaintenanceFeePayable_357977f7-f4ea-42b8-8606-f9fd525bc5f9_terseLabel_en-US" xlink:label="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee payable</link:label>
    <link:label id="lab_ovid_AnnualLicenseMaintenanceFeePayable_label_en-US" xlink:label="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual License Maintenance Fee Payable</link:label>
    <link:label id="lab_ovid_AnnualLicenseMaintenanceFeePayable_documentation_en-US" xlink:label="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AnnualLicenseMaintenanceFeePayable" xlink:href="ovid-20220630.xsd#ovid_AnnualLicenseMaintenanceFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AnnualLicenseMaintenanceFeePayable" xlink:to="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8efca106-a399-43e5-a3ae-168e84578a35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance based options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dfb37c80-2b01-4671-8055-a53668e641b7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_525ad1da-9148-4e4d-aef0-7612a3692499_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f6e37748-d94f-4c6a-8dd9-9c947101c80d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares reserved for issuance under the plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_2c299eaf-f078-48a6-b341-bb9ca5a5a280_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in an unrealized loss position for more than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_eb951dac-4c0c-4883-bcaf-aa4f7c9f86ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AggregateOfferingPriceOfCommonStock_70487fb0-747c-4602-a79c-51ab927b97cb_terseLabel_en-US" xlink:label="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from offering, value</link:label>
    <link:label id="lab_ovid_AggregateOfferingPriceOfCommonStock_label_en-US" xlink:label="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Offering Price Of Common Stock</link:label>
    <link:label id="lab_ovid_AggregateOfferingPriceOfCommonStock_documentation_en-US" xlink:label="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AggregateOfferingPriceOfCommonStock" xlink:href="ovid-20220630.xsd#ovid_AggregateOfferingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AggregateOfferingPriceOfCommonStock" xlink:to="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ddc92699-176a-4eaa-8cee-a7b652a2a51a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c7578454-d201-4e71-a09c-dd0651dbe5bd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd41d951-d61c-44f7-9684-b0c6b56304aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CommonStockNumberOfVotesPerShare_6b7ef983-1c23-448a-b06b-02270fb20f1d_terseLabel_en-US" xlink:label="lab_ovid_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_ovid_CommonStockNumberOfVotesPerShare_label_en-US" xlink:label="lab_ovid_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes Per Share</link:label>
    <link:label id="lab_ovid_CommonStockNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_ovid_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockNumberOfVotesPerShare" xlink:href="ovid-20220630.xsd#ovid_CommonStockNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CommonStockNumberOfVotesPerShare" xlink:to="lab_ovid_CommonStockNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c8760fd3-a29b-4372-b847-34bc4e6f441f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_d19f7158-e793-4609-8b26-090b4c4be457_terseLabel_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase, outstanding stock maximum</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_label_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_documentation_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:to="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5ddb14ff-a3d6-4573-90a4-e2ee6421160b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_257d34f3-9c8e-4d0d-bf2b-787bf3b6842f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_91c12c75-e5c9-4ebc-87fd-b0237fff0139_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9b00c548-157f-499d-9abe-74b4a7124a08_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpFrontPayment_8583b7d3-7b74-4cb3-a141-48dc86b4c3f0_terseLabel_en-US" xlink:label="lab_ovid_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_ovid_UpFrontPayment_label_en-US" xlink:label="lab_ovid_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Payment</link:label>
    <link:label id="lab_ovid_UpFrontPayment_documentation_en-US" xlink:label="lab_ovid_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up front Payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontPayment" xlink:href="ovid-20220630.xsd#ovid_UpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpFrontPayment" xlink:to="lab_ovid_UpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ConsiderationPayableForRightsGrant_d74c9c3a-ae17-4ec7-8265-505f5f3c7e80_terseLabel_en-US" xlink:label="lab_ovid_ConsiderationPayableForRightsGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration payable for rights grant</link:label>
    <link:label id="lab_ovid_ConsiderationPayableForRightsGrant_label_en-US" xlink:label="lab_ovid_ConsiderationPayableForRightsGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Payable For Rights Grant</link:label>
    <link:label id="lab_ovid_ConsiderationPayableForRightsGrant_documentation_en-US" xlink:label="lab_ovid_ConsiderationPayableForRightsGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration payable for rights grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConsiderationPayableForRightsGrant" xlink:href="ovid-20220630.xsd#ovid_ConsiderationPayableForRightsGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ConsiderationPayableForRightsGrant" xlink:to="lab_ovid_ConsiderationPayableForRightsGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3a6bcc5a-123a-4e5f-b43f-01d9dc402e06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5f7f987e-c2b8-4d4d-9250-cff3cdfc59cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_eb8ca514-61cd-4464-a635-24eee98fe441_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PromissoryNotesMember_f51df6e1-ddc4-4ec4-a001-bd2a5e806336_terseLabel_en-US" xlink:label="lab_ovid_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory notes</link:label>
    <link:label id="lab_ovid_PromissoryNotesMember_label_en-US" xlink:label="lab_ovid_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_ovid_PromissoryNotesMember_documentation_en-US" xlink:label="lab_ovid_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PromissoryNotesMember" xlink:href="ovid-20220630.xsd#ovid_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PromissoryNotesMember" xlink:to="lab_ovid_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ca972a86-6943-438d-bcb1-e82dda9fcdba_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_7843fb96-01f3-4425-a54f-550ffc7128dd_terseLabel_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, reserved for future issuance increase</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_label_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_documentation_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:to="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_cae8bc3a-807a-4df5-83a8-0b707c45abbc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRent_9b0cbc97-b92a-4b71-b3e1-e337ead0b45e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent lease</link:label>
    <link:label id="lab_us-gaap_PaymentsForRent_label_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6c3f3050-f364-4758-9d49-960bebbdaab4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d038bcfd-7e53-4bda-9684-5fe660fadcd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Recognized Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0014dc37-b7f9-4c19-a199-21d6e19e9c87_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Operating Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb59e9f7-e85f-4181-9d08-538fc7937232_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of company's common stock reserved for issuance under the plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ee3c475d-1ad7-40de-9099-399e2ee22bbc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_48be0654-3313-4f07-8915-39641f62b563_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_f2ed4023-9396-40be-a358-045bbe73e07f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e2d9ade6-8bcb-4a2a-b166-245de3ae8224_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_56986cbc-4717-4670-a75b-7cfa30817ece_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_93c9f416-f1e1-4583-9995-68b64be875bf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_b550f5ce-fa76-48a6-8672-7ff856f32290_terseLabel_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:href="ovid-20220630.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:to="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ba0ef4f9-de6d-43a5-80e2-6e918da4e00c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_89f080e9-617d-4ec7-8959-920c644eb8ff_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_HLundbeckASMember_07439176-7fe2-4fc2-84e0-08cf069950a2_terseLabel_en-US" xlink:label="lab_ovid_HLundbeckASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lundbeck</link:label>
    <link:label id="lab_ovid_HLundbeckASMember_label_en-US" xlink:label="lab_ovid_HLundbeckASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H Lundbeck A S [Member]</link:label>
    <link:label id="lab_ovid_HLundbeckASMember_documentation_en-US" xlink:label="lab_ovid_HLundbeckASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H. Lundbeck A/S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HLundbeckASMember" xlink:href="ovid-20220630.xsd#ovid_HLundbeckASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_HLundbeckASMember" xlink:to="lab_ovid_HLundbeckASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_a964d804-5815-4eca-b5ae-bb66cee10985_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4e3e5cc6-7020-4254-8c32-cd035020ec17_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5e04f114-5066-4960-9149-53aa236c8f0a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c5ca4e46-52fb-4920-9d6c-3c5cdaa77439_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1ba12313-e061-4d58-9806-c22a5fab74e0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4107b9d9-aa76-4eb0-a38e-b146619f2fba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to purchase of long-term equity investment in accrued expenses</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_be5e762d-2d43-46e2-aa47-af5b775061d2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_14f6d789-ae3a-4c45-9d66-c5f472c17f86_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e1b7768b-56c6-4262-8ff5-7c7a35ba8d4c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9784febc-fca2-4cc4-8b5e-e87082ea4eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for each share of convertible preferred stock that is converted</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ATMAgreementMember_9dbef979-0711-40db-832e-854ff1963915_terseLabel_en-US" xlink:label="lab_ovid_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_ovid_ATMAgreementMember_label_en-US" xlink:label="lab_ovid_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A T M Agreement [Member]</link:label>
    <link:label id="lab_ovid_ATMAgreementMember_documentation_en-US" xlink:label="lab_ovid_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ATMAgreementMember" xlink:href="ovid-20220630.xsd#ovid_ATMAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ATMAgreementMember" xlink:to="lab_ovid_ATMAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_ec2972f7-220b-4db4-a954-6ae24c7d3fed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, number of shares purchased</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_135ca4f5-2310-46e5-b2b4-21eb7e5d993d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b75b34f4-a0d0-4181-af96-372f4fb1e1a4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f4678cf8-7b1b-43e6-a95f-0ffa0264c96a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_867deb37-51d7-4e9d-a8a4-651adca44ce3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a749607c-6261-47ba-b6c1-a6153b965e4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NonEmployeeStockOptionsMember_c01cf0ee-74df-4668-9bf9-c152fe7fd530_terseLabel_en-US" xlink:label="lab_ovid_NonEmployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Stock Options</link:label>
    <link:label id="lab_ovid_NonEmployeeStockOptionsMember_label_en-US" xlink:label="lab_ovid_NonEmployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Options [Member]</link:label>
    <link:label id="lab_ovid_NonEmployeeStockOptionsMember_documentation_en-US" xlink:label="lab_ovid_NonEmployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonEmployeeStockOptionsMember" xlink:href="ovid-20220630.xsd#ovid_NonEmployeeStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NonEmployeeStockOptionsMember" xlink:to="lab_ovid_NonEmployeeStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_DeferredUpfrontPaymentCosts_9cd1943f-44f4-4be1-8fbb-398fb1b95881_terseLabel_en-US" xlink:label="lab_ovid_DeferredUpfrontPaymentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred upfront payment costs</link:label>
    <link:label id="lab_ovid_DeferredUpfrontPaymentCosts_label_en-US" xlink:label="lab_ovid_DeferredUpfrontPaymentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Upfront Payment Costs</link:label>
    <link:label id="lab_ovid_DeferredUpfrontPaymentCosts_documentation_en-US" xlink:label="lab_ovid_DeferredUpfrontPaymentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred upfront payment costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DeferredUpfrontPaymentCosts" xlink:href="ovid-20220630.xsd#ovid_DeferredUpfrontPaymentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_DeferredUpfrontPaymentCosts" xlink:to="lab_ovid_DeferredUpfrontPaymentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8142736d-186e-43a5-9c62-1f2250a446d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7e128d82-3ace-4773-91ff-812c5ca948dd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_f3dbc6c0-d059-4b11-9b61-e2d6b77c4174_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_986031c1-3a30-4fab-923d-8385037110f0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8b7fbd46-eb77-42d1-ba88-9aeadb66167e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_c14f4049-c741-4cde-9045-bc5f872e63c0_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af715678-7bed-4a06-be42-6b26ad844cad_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_ceacf210-b892-43b6-88ca-b13986dfbaa6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_59598635-dcd2-48ee-b832-d4088418e326_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_66235b0d-375b-4667-affb-d07298f46a4a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f58fbd40-f6fb-493c-8efc-f47d663eec4a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_733e8f39-8ae4-4e89-9883-4489edb12a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Outstanding and Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_612ae5f1-84f7-4e2e-8ebf-2db5e20ab825_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e5863d2a-2e48-4126-8224-b4650c672908_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_29eefc21-e44a-4310-8a20-4e3a92dcf096_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3b416e23-30c9-439f-b95d-7f4d8594c84d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_a508cb94-ce69-43b8-9be8-5a9cc6a96d10_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56a2d24-1936-47c1-83f5-7d9a57cd7684_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9563706c-2a21-4f57-9bd9-8b8e057c4d48_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_c28a8e45-e804-4ae8-8d19-583d02e83e66_terseLabel_en-US" xlink:label="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds and Short-term Investments</link:label>
    <link:label id="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds And Short Term Investments [Member]</link:label>
    <link:label id="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds and short-term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:href="ovid-20220630.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:to="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ee5dd8b4-1cc7-409c-a226-44dbaa71ceed_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_175f5eb9-50a4-43a0-a6b3-8d4d7d1761d0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1e4b416f-df11-4692-863c-461cae6cc021_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d9e26681-ce2a-487d-b85c-bc60bd914ead_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_fb91879e-4e77-4ffd-86a7-a2532497ab30_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_39710338-3a3d-42ae-adf4-300047d8a0d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1009c4d3-bcbe-4259-9aef-05e4a40768fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_9e2f7441-c3fa-46c8-8589-245077c7baf8_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ade6f2bf-f837-4454-8363-52dc608fbc53_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_04660790-6339-4fce-bb3c-4387689cb8b0_terseLabel_en-US" xlink:label="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease</link:label>
    <link:label id="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_label_en-US" xlink:label="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset and Lease Liabilities Operating Lease [Table Text Block]</link:label>
    <link:label id="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_documentation_en-US" xlink:label="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset and lease liabilities operating lease table text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:href="ovid-20220630.xsd#ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:to="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6df1579e-d193-49a1-af4f-99367f688bb4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_EmployeeStockPurchasePlanMember_246fe167-1882-44f8-b6ab-04961a8c67b8_terseLabel_en-US" xlink:label="lab_ovid_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_ovid_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ovid_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ovid_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ovid_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeeStockPurchasePlanMember" xlink:href="ovid-20220630.xsd#ovid_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_EmployeeStockPurchasePlanMember" xlink:to="lab_ovid_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dad05b7-2924-4793-b3e5-d6f286363807_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_242e4578-0f3a-49fb-9a04-4aa444a93aa4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding used in computing net income (loss) per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74b381f7-c278-4246-a35e-fbfb2c75cc23_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LesseeOperatingLeaseFreeRentPeriod_14ede1a2-ec53-48c1-a010-3a55bc488446_terseLabel_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseFreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free rent period</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseFreeRentPeriod_label_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseFreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Free Rent Period</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseFreeRentPeriod_documentation_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseFreeRentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Free Rent Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseFreeRentPeriod" xlink:href="ovid-20220630.xsd#ovid_LesseeOperatingLeaseFreeRentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LesseeOperatingLeaseFreeRentPeriod" xlink:to="lab_ovid_LesseeOperatingLeaseFreeRentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e81bd57a-cc32-4d5c-936a-46d6b56309db_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_26799c28-d2a2-4033-af79-5edcf4534f88_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289568a-af0f-461b-a635-d2175947d220_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_5e755ba9-cf22-4c86-8d28-28bef845519f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Co-promotion</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_e3b391db-d63f-46ff-b1aa-31ebaf551653_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized; 70,419,388 and 70,364,912 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8b31efe8-6896-457c-b0d9-24989bb1534c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_6f59a7f1-94fa-4f19-ba77-3bf4dbd8225e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NorthwesternUniversityMember_4f4dcc5f-bba7-4f35-9d14-490879754488_terseLabel_en-US" xlink:label="lab_ovid_NorthwesternUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Northwestern University</link:label>
    <link:label id="lab_ovid_NorthwesternUniversityMember_label_en-US" xlink:label="lab_ovid_NorthwesternUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Northwestern University [Member]</link:label>
    <link:label id="lab_ovid_NorthwesternUniversityMember_documentation_en-US" xlink:label="lab_ovid_NorthwesternUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Northwestern University.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NorthwesternUniversityMember" xlink:href="ovid-20220630.xsd#ovid_NorthwesternUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NorthwesternUniversityMember" xlink:to="lab_ovid_NorthwesternUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_IncomeTaxAccrualCurrent_778f22b2-c1ed-424f-b11d-058183f48a35_terseLabel_en-US" xlink:label="lab_ovid_IncomeTaxAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_ovid_IncomeTaxAccrualCurrent_label_en-US" xlink:label="lab_ovid_IncomeTaxAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Accrual, Current</link:label>
    <link:label id="lab_ovid_IncomeTaxAccrualCurrent_documentation_en-US" xlink:label="lab_ovid_IncomeTaxAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax accrual, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_IncomeTaxAccrualCurrent" xlink:href="ovid-20220630.xsd#ovid_IncomeTaxAccrualCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_IncomeTaxAccrualCurrent" xlink:to="lab_ovid_IncomeTaxAccrualCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d301fc90-e05c-442a-979b-1010252cdda4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c1801c70-f179-4082-bae8-1edad4511b40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_3000f8bb-2b54-4f92-a189-ba79097f28d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_bfa986a1-67d1-4cdd-b09e-77c74e8463b7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3a94e2a7-5014-4593-ac1c-4442aa940e7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2343432-0665-4897-931b-959df6d4d8f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_15dad453-646d-42e1-9cad-72efa3d82d57_terseLabel_en-US" xlink:label="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense reimbursement received</link:label>
    <link:label id="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_label_en-US" xlink:label="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Reimbursement Received</link:label>
    <link:label id="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_documentation_en-US" xlink:label="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense reimbursement received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:href="ovid-20220630.xsd#ovid_ResearchAndDevelopmentExpenseReimbursementReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:to="lab_ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5090f539-4c86-4020-a2e5-9986a9d94473_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c5b83c66-3cd2-455b-b8ac-1e887c2ad40a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4ba315cd-3f35-457c-ad87-3459563db6e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c5f94556-640b-4281-8f5a-9b73213bbbab_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d4b58684-194e-410a-95ab-28ea2cd40996_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ce8c9a25-c1a7-4952-bc17-a4b90803579c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_2e98f3bf-80e3-43bc-b903-425e3320356c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5564e5f3-93ab-451c-8f8c-d87f84bc6047_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_13836a09-71c8-4a74-8469-c9ef16d68020_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_b08abbfb-f18a-406c-939c-d24495aedecd_terseLabel_en-US" xlink:label="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Consolidated Financial Statements</link:label>
    <link:label id="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Statements Policy [Policy Text Block]</link:label>
    <link:label id="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited interim financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:href="ovid-20220630.xsd#ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:to="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_34ab03df-3aa6-420f-9769-cb7a549f7fe6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Intangible Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8213e8fe-095e-436e-8db1-5de5bb565f56_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_facc00e7-70cf-4b8f-87a2-4a2d958301b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8e506f63-5eb7-4c42-9f11-9c9b7c5838b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_dd945b32-3273-4ef6-9e56-6361cffda2a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542ec8c0-08ee-4972-a52e-98b92ca65ac4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a60d9dcd-825d-440a-805b-1640bec39667_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c968c210-7238-48a7-9a88-7f58b6bdeb1c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a79da77f-2af2-472e-8830-f1b87a40d922_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_WorkingCapital_e9c1616e-8f06-46ed-a334-b8b9b7cd6541_terseLabel_en-US" xlink:label="lab_ovid_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ovid_WorkingCapital_label_en-US" xlink:label="lab_ovid_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ovid_WorkingCapital_documentation_en-US" xlink:label="lab_ovid_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_WorkingCapital" xlink:href="ovid-20220630.xsd#ovid_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_WorkingCapital" xlink:to="lab_ovid_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_HealxLicenseAndOptionAgreementMember_87c420a5-c616-4020-bc9d-d8cdeb9485a9_terseLabel_en-US" xlink:label="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healx License and Option Agreement</link:label>
    <link:label id="lab_ovid_HealxLicenseAndOptionAgreementMember_label_en-US" xlink:label="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healx License and Option Agreement [Member].</link:label>
    <link:label id="lab_ovid_HealxLicenseAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healx License and Option Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HealxLicenseAndOptionAgreementMember" xlink:href="ovid-20220630.xsd#ovid_HealxLicenseAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_HealxLicenseAndOptionAgreementMember" xlink:to="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b93e4e89-dc15-4d05-9f51-96ce4f50a5dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f73f6ca0-cb60-4b56-bea6-9cfeeaece497_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b4aa9a54-1b94-4879-87f0-0a17d8a5e637_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_85d9ede6-e25e-4389-97f2-c98b9eace7c5_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_37dc10e1-776c-4765-b3a6-19b90660070a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in accrued interest and accretion of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b2a0dd62-2697-4693-b99f-487890552005_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1886339b-fcb7-4d60-a705-1ddd0fc34a0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2df92b05-9598-4c38-809c-305551325006_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52f7cd31-036b-43dc-ba30-9f193428afb9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e488605c-379a-46dd-85ff-f9b5e377549d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0c7e7454-5085-4dc5-b70b-49c2c4ef075d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_18d87bff-1f01-4520-b6e6-22e47bb200b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_de415dc2-6840-489d-b5c9-422297de8832_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage_2c32a570-25fa-4be5-bec1-da289f1af8dc_terseLabel_en-US" xlink:label="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment on sales percentage</link:label>
    <link:label id="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage_label_en-US" xlink:label="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payment Receivable On Sales Percentage</link:label>
    <link:label id="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage_documentation_en-US" xlink:label="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment receivable on sales percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:href="ovid-20220630.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:to="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cc5e304b-8dca-4840-a719-0b74a2e124d5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c309ecd3-ae89-4478-a992-8a9256841da3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f1d5c6e3-85ce-4d0f-97e8-6309724a24c3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_f56c5592-ffec-4a0a-988c-9f2a8b4acffd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1fafc6de-778a-441a-9a40-1cb1ced64a88_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cf871e6e-a207-4399-bfaa-62f9d56e8f5a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d1647194-6105-49b1-927b-f35bda3eef9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_38518ea9-07eb-4524-85a9-19c95549c02d_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d07781a4-6ce1-453d-9ad5-508e47daa441_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0cf89f06-25f4-411d-9443-c961f2a57b33_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_06f2081a-d691-4af0-b5fb-2a4dc3cb9fd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_66f0edc7-2da3-4e1c-ae72-45671f8db27a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4580c09a-d59b-4f4f-b066-a0fbea9e0523_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba66e57e-6457-4e2d-beb3-bab5df6f1bee_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_3954d66e-6f57-4158-b0b9-637fde826124_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5689aea6-5b41-4fc3-99d6-1269e41bbc28_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a04fe734-716d-41bc-8a16-c60568cafbb9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_145b51fc-30c6-45c5-92aa-f2045455f748_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, Amortized cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_99a8f8a2-be49-47aa-8059-17bc710c386e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d1358eec-1521-4b70-9b00-4861ec66b4b7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_35d7bdcf-fcb0-495c-8b6f-9d573567802d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6520bdbe-d48e-4761-b423-e85b0be183f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b7aead31-5d0b-429c-a8d9-064553e7197e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1275817f-0521-4828-aa02-8f07c8f4e580_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1422f251-1aad-4cb3-9688-8667936042b9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_1b3f653f-0d1d-4058-9e79-ac5f6cb339f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1419aa64-55dc-494e-a4d0-0af238fd82f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities, net of interest earned</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_80636227-c3da-40d6-a10e-f546ab7069fd_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e7d031f9-8c46-4881-8830-5c2d88f9841d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3cee98fa-513c-4feb-9add-71437dbe8e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyTable_180fa677-5d44-440f-ad46-88fe3af330ae_terseLabel_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policy [Table]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyTable_label_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policy [Table]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyTable_documentation_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:href="ovid-20220630.xsd#ovid_SummaryOfSignificantAccountingPolicyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AccruedResearchAndDevelopment_30236bfb-4caf-4bea-aaf1-d3145b071f59_terseLabel_en-US" xlink:label="lab_ovid_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development accrual</link:label>
    <link:label id="lab_ovid_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_ovid_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_ovid_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_ovid_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccruedResearchAndDevelopment" xlink:href="ovid-20220630.xsd#ovid_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AccruedResearchAndDevelopment" xlink:to="lab_ovid_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db028eec-a6af-4a1a-8c7c-54827e52e406_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8280126-aeb3-49a6-b063-6b3c34c6dd06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_4cca92c0-a01a-477d-a81b-a754a9c99d57_terseLabel_en-US" xlink:label="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities</link:label>
    <link:label id="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_label_en-US" xlink:label="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities [Member]</link:label>
    <link:label id="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_documentation_en-US" xlink:label="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" xlink:href="ovid-20220630.xsd#ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" xlink:to="lab_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6caa836a-3e61-4f1f-9eaa-0e2ecf98421d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_e26c2d28-341f-4a5f-8b13-33d948386680_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_00502340-0be3-4bc2-95ad-ea902fd71242_terseLabel_en-US" xlink:label="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable voting right percentage of outstanding common stock holders</link:label>
    <link:label id="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_label_en-US" xlink:label="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders</link:label>
    <link:label id="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_documentation_en-US" xlink:label="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable voting right percentage of outstanding common stock holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:href="ovid-20220630.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:to="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_af02481e-1843-408c-9253-c2bd563529b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember_37942b47-6feb-4948-bed1-48f235435125_terseLabel_en-US" xlink:label="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="ovid-20220630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b45c0f88-4d23-4f54-b7af-2923c51e3b1f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e1e3f682-7302-4630-a195-7c98ae7d3e00_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6ac03a29-d988-42e4-90ed-6ea3f1ade479_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_RelatedPartyMember_563bfa51-2419-45ea-af6a-024d915a586d_terseLabel_en-US" xlink:label="lab_ovid_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue - related party</link:label>
    <link:label id="lab_ovid_RelatedPartyMember_label_en-US" xlink:label="lab_ovid_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:label id="lab_ovid_RelatedPartyMember_documentation_en-US" xlink:label="lab_ovid_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RelatedPartyMember" xlink:href="ovid-20220630.xsd#ovid_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_RelatedPartyMember" xlink:to="lab_ovid_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e7d43ada-dbb0-4e8b-9dfc-b0778cd47c9a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PreferredStockShareDesignated_18028fd0-1f13-43ab-9ea7-7f9bdf42d561_terseLabel_en-US" xlink:label="lab_ovid_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, share designated (in shares)</link:label>
    <link:label id="lab_ovid_PreferredStockShareDesignated_label_en-US" xlink:label="lab_ovid_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_ovid_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_ovid_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated" xlink:href="ovid-20220630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PreferredStockShareDesignated" xlink:to="lab_ovid_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34127a33-df6d-4387-aebc-c63733ff82c2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_08980ad8-008a-4c9d-8352-6994b20fccff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c82d1aed-9833-4cdb-bd8a-9e25ed9b49b1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2336d624-12af-4962-9ba9-b45833b14719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_39422d19-756f-4319-b6fd-d0db0e1c809e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_01277262-eb87-4e17-bb3e-6969dedac5d2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_44834ec1-d381-4d58-970b-eedd62695538_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0282815d-441d-44d0-9512-6298e1806e09_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding used in computing net income (loss) per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_fb40adab-94e5-4c29-b7a3-d026941488d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_7046ae71-6a5e-4839-83c2-a1aad765f8eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement ownership share</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_55fad608-b4ba-4503-8acd-ed5ea40f0597_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5bfca15a-45f2-4351-9975-0081b6e9ad53_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NumberOfTrial_75367a2f-65c7-4d0a-b9ae-92d9bd62c9d1_terseLabel_en-US" xlink:label="lab_ovid_NumberOfTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trial</link:label>
    <link:label id="lab_ovid_NumberOfTrial_label_en-US" xlink:label="lab_ovid_NumberOfTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Trial</link:label>
    <link:label id="lab_ovid_NumberOfTrial_documentation_en-US" xlink:label="lab_ovid_NumberOfTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trial.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NumberOfTrial" xlink:href="ovid-20220630.xsd#ovid_NumberOfTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NumberOfTrial" xlink:to="lab_ovid_NumberOfTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7ee5b410-fe8c-4a6a-9806-6af50ad4a67d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24d3ceda-7acb-4192-8d6b-8f2713c4e8bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8589c968-e25f-4534-97c6-429734806e8c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_0127b663-1d48-440d-98a8-5f946e109140_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ee257b58-302a-41cc-af69-274fa7fa6c3d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PatentLicenseAgreementMember_c463816d-217a-4e73-a29b-eeec8baf334c_terseLabel_en-US" xlink:label="lab_ovid_PatentLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent License Agreement</link:label>
    <link:label id="lab_ovid_PatentLicenseAgreementMember_label_en-US" xlink:label="lab_ovid_PatentLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent License Agreement [Member]</link:label>
    <link:label id="lab_ovid_PatentLicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_PatentLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent license agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PatentLicenseAgreementMember" xlink:href="ovid-20220630.xsd#ovid_PatentLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PatentLicenseAgreementMember" xlink:to="lab_ovid_PatentLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_67ba4d77-9c74-4ecf-9323-c3c06ee66a75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_96c03b07-356c-40ed-a5bb-b6137160d027_terseLabel_en-US" xlink:label="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercise receivables in prepaid expenses and other current assets</link:label>
    <link:label id="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ovid-20220630.xsd#ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_e32774e0-6914-44e4-b814-92d2d8b6ae02_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AccretionOfLeaseLiability_f541eabe-5993-4b19-a08b-aa5821d27ddb_terseLabel_en-US" xlink:label="lab_ovid_AccretionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of lease liability</link:label>
    <link:label id="lab_ovid_AccretionOfLeaseLiability_label_en-US" xlink:label="lab_ovid_AccretionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of Lease Liability</link:label>
    <link:label id="lab_ovid_AccretionOfLeaseLiability_documentation_en-US" xlink:label="lab_ovid_AccretionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of lease liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccretionOfLeaseLiability" xlink:href="ovid-20220630.xsd#ovid_AccretionOfLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AccretionOfLeaseLiability" xlink:to="lab_ovid_AccretionOfLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2d31cdd9-b3b3-4bbe-8d38-ad5bfbe77012_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series A convertible preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_18186886-b322-4306-b2d0-d8b341a201a9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of common stock to series A convertible preferred stock, Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_FormerAddressMember_26b1e42f-988c-44fe-a05f-24efd0d6b08d_terseLabel_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address</link:label>
    <link:label id="lab_dei_FormerAddressMember_label_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_FormerAddressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_FormerAddressMember" xlink:to="lab_dei_FormerAddressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3b10822e-99a7-4d77-a188-3093f409cfdc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_9a35b49a-a7f0-4c88-9482-08068e12016b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6d70b256-cb73-4ac7-8686-9c9709a23b7b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_23912482-b39d-45c4-83b9-0b714d35844e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_27f4a92c-93e4-42f0-a01c-b96d41575058_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_2a93e663-9b0d-46ff-9801-ac77dc6674a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of long-term equity investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_f1a63bb4-fea7-4884-8e36-534559b91185_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of number of shares of common stock outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0ab8fa38-66b7-4614-ba0a-df8913edb4cc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_10722f89-93ab-4900-ae33-b993d6d3070a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Stock-based Compensation Expense by Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_ff1b9978-c45f-4dfb-adf5-a2534f089e04_terseLabel_en-US" xlink:label="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Granted</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_label_en-US" xlink:label="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation By Share Based Payment Award Options Granted Contractual Life</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_documentation_en-US" xlink:label="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation by share based payment award options granted contractual life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:to="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CostOfAgreementNet_5b045eba-cefa-4bc3-a713-afe702e6151b_terseLabel_en-US" xlink:label="lab_ovid_CostOfAgreementNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future cost of agreement</link:label>
    <link:label id="lab_ovid_CostOfAgreementNet_label_en-US" xlink:label="lab_ovid_CostOfAgreementNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Agreement Net</link:label>
    <link:label id="lab_ovid_CostOfAgreementNet_documentation_en-US" xlink:label="lab_ovid_CostOfAgreementNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of agreement net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CostOfAgreementNet" xlink:href="ovid-20220630.xsd#ovid_CostOfAgreementNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CostOfAgreementNet" xlink:to="lab_ovid_CostOfAgreementNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e5965edb-69b6-477d-a816-44a9120dbdbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ed76cfc3-a70c-42e4-9fc1-8b7b7d6027e8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e69584df-fa6f-4588-898e-2255e241e132_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ConvertibleNoteReceivable_11b6aaf9-41d8-4f5e-a199-48a11ece00fe_terseLabel_en-US" xlink:label="lab_ovid_ConvertibleNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note receivable</link:label>
    <link:label id="lab_ovid_ConvertibleNoteReceivable_label_en-US" xlink:label="lab_ovid_ConvertibleNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note Receivable</link:label>
    <link:label id="lab_ovid_ConvertibleNoteReceivable_documentation_en-US" xlink:label="lab_ovid_ConvertibleNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConvertibleNoteReceivable" xlink:href="ovid-20220630.xsd#ovid_ConvertibleNoteReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ConvertibleNoteReceivable" xlink:to="lab_ovid_ConvertibleNoteReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2621af91-ed07-4a26-a446-f42df0fd26c1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_dc946983-9ffe-4d7b-8dbb-8a8d6140e78d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e610e007-37a9-49b9-a490-96002a253d66_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d9b7a13a-cdb9-445e-84fc-61e993036412_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AgreementMilestonePayments_7268cb1b-3bae-45b7-a036-e2bbc28ef07b_terseLabel_en-US" xlink:label="lab_ovid_AgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestone payments</link:label>
    <link:label id="lab_ovid_AgreementMilestonePayments_label_en-US" xlink:label="lab_ovid_AgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Milestone Payments</link:label>
    <link:label id="lab_ovid_AgreementMilestonePayments_documentation_en-US" xlink:label="lab_ovid_AgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AgreementMilestonePayments" xlink:href="ovid-20220630.xsd#ovid_AgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AgreementMilestonePayments" xlink:to="lab_ovid_AgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_StockOptionsMember_89e31d9d-39de-4777-b8a5-c78f0d7d9a0e_terseLabel_en-US" xlink:label="lab_ovid_StockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_ovid_StockOptionsMember_label_en-US" xlink:label="lab_ovid_StockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:label id="lab_ovid_StockOptionsMember_documentation_en-US" xlink:label="lab_ovid_StockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_StockOptionsMember" xlink:href="ovid-20220630.xsd#ovid_StockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_StockOptionsMember" xlink:to="lab_ovid_StockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fd505e34-8e1a-472d-8655-e5bd2ff12d2a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_efe756f1-0495-4fbb-9027-84aea1cc4638_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e223e27-6f0e-496d-a7d8-76c134d8b053_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, graded vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_fa06b6e8-5ef2-48a7-abe5-2fa2fd62fd7a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM and other offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f81c91c9-0f2a-4066-865b-f36614dc64c7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember_96eaefe9-cd65-4244-a7fe-e989496552f8_terseLabel_en-US" xlink:label="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Performance Based Option Awards</link:label>
    <link:label id="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember_label_en-US" xlink:label="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Performance Based Option Awards [Member]</link:label>
    <link:label id="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember_documentation_en-US" xlink:label="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee performance based option awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:href="ovid-20220630.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:to="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_99f7a17b-2cb0-4bc2-8146-a8b3e1165e99_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LeaseIncrementalBorrowingRate_a793eae2-c1de-41a9-9400-72751077a4ae_terseLabel_en-US" xlink:label="lab_ovid_LeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incremental borrowing rate</link:label>
    <link:label id="lab_ovid_LeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_ovid_LeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incremental Borrowing Rate</link:label>
    <link:label id="lab_ovid_LeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_ovid_LeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LeaseIncrementalBorrowingRate" xlink:href="ovid-20220630.xsd#ovid_LeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LeaseIncrementalBorrowingRate" xlink:to="lab_ovid_LeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_de34709a-6d40-4135-8a31-c4caad264b14_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_2480d720-4e5b-4a24-b7a3-ff3ce2e66a04_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software development and other costs</link:label>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Develop Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToDevelopSoftware" xlink:to="lab_us-gaap_PaymentsToDevelopSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5ca7c559-7554-4cac-a79f-a9aba13f37ce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, term of plan</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_EmployeePerformanceBasedOptionAwardsMember_6ee0ae41-1034-4b86-80d6-cdf243b51705_terseLabel_en-US" xlink:label="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Performance Based Option Awards</link:label>
    <link:label id="lab_ovid_EmployeePerformanceBasedOptionAwardsMember_label_en-US" xlink:label="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Performance Based Option Awards [Member]</link:label>
    <link:label id="lab_ovid_EmployeePerformanceBasedOptionAwardsMember_documentation_en-US" xlink:label="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee performance based option awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:href="ovid-20220630.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:to="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e6d1cce8-58d1-4fa5-995b-207b90e4579c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3de95059-76d2-413d-817a-c08ee8d86a76_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a25cafe3-8a78-4701-9bde-48603da796d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Commitments Under the non-cancelable Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ff325887-7010-4d74-9a32-e1786420a98f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_35465022-d07b-4500-b52d-54eb6b8f0410_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_d9179de3-0b33-43b9-a2c7-982f05ea43a0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems_8718a368-b9d3-4779-985a-28c92879bdec_terseLabel_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policy [Line Items]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems_label_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policy [Line Items]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems_documentation_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:href="ovid-20220630.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_34f33dda-84a3-4de9-8a3b-2df93a6247dc_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3beeb58f-1d34-4ff3-b22a-3fa20eac1f41_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_72d5745a-4a4b-4c56-83ba-d3204e61e9be_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_1613ee62-0fc6-44a1-8517-17f8b73d8e45_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_4e74fe4f-fb41-4387-8895-d56c38bbdefa_terseLabel_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_fc137ad3-53f9-4c22-9c38-82b28233aa1c_verboseLabel_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuable upon conversion of Series A convertible preferred stock</link:label>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_SeriesAConvertiblePreferredStockMember" xlink:to="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_3491b1f7-7058-42a1-835b-fa128d02e0e9_terseLabel_en-US" xlink:label="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable owning percentage of outstanding common stock by associates or affiliates</link:label>
    <link:label id="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_label_en-US" xlink:label="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:label id="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_documentation_en-US" xlink:label="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable owning percentage of outstanding common stock by associates or affiliates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:href="ovid-20220630.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:to="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_32560ae5-b6d0-4294-a292-78dad1845b45_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_37c1c6f1-71f1-41e6-a20d-ad19447ea7eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_fd49ddf2-fc46-4185-9f72-3eb8e4f3547d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_bc5becd7-54ca-43fd-ba2b-c381d64b9081_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9a9ff443-3628-4f01-8a79-8064507e3590_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_9b21752b-2ebb-4c67-be75-275cb6415b19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, percentage of discount from market price on purchase date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CowenAndCompanyLLCMember_5cc330d5-38f9-42bd-997e-8a2306dc3a25_terseLabel_en-US" xlink:label="lab_ovid_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen And Company, LLC</link:label>
    <link:label id="lab_ovid_CowenAndCompanyLLCMember_label_en-US" xlink:label="lab_ovid_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen And Company L L C [Member]</link:label>
    <link:label id="lab_ovid_CowenAndCompanyLLCMember_documentation_en-US" xlink:label="lab_ovid_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen and Company, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CowenAndCompanyLLCMember" xlink:href="ovid-20220630.xsd#ovid_CowenAndCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CowenAndCompanyLLCMember" xlink:to="lab_ovid_CowenAndCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_0756be9c-1573-45b3-a327-02e0e1d16c36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_bd31f198-869a-441a-965e-2562743cd7db_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_26075e93-3eab-49ee-a3f8-796fd7734995_negatedLabel_en-US" xlink:label="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term prepaid expenses</link:label>
    <link:label id="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Prepaid Expense Noncurrent</link:label>
    <link:label id="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_documentation_en-US" xlink:label="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in prepaid expense, noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:href="ovid-20220630.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:to="lab_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f33eb37d-6db9-4435-823e-bd6081b4f38c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_e3fa2b8e-8df5-4084-9cef-c5820a6630dc_terseLabel_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent payments commencement following this period</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_label_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Payments Commencement Following This Period</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_documentation_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Payments Commencement Following This Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:href="ovid-20220630.xsd#ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:to="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a1603ae7-e662-4bc9-916d-3a7029e456bd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6e5dee9e-f4ba-4785-b537-a1e6677df457_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_09b968a1-1b18-4193-9007-33ae346549d8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277774d2-372d-4130-96ea-d174d41cc352_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d6c3843f-7019-479d-a124-a3b39faba392_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_899b0835-e34e-4b15-9063-84795d49e770_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2d4cd19b-4a2b-4243-ae1c-11f2933e77a9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_fb64af8b-4d19-44c4-8030-4a67e292fa0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees accrual</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a2fcb392-771c-438f-aca2-baf2d5d3d752_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3e83d97e-bab6-4396-bdbd-dae17f8922cc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_a6efa2fa-4b7d-4603-b4b4-013bf9a867b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested stock options, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_63c0434e-ccc3-4541-8624-c8e238cd40d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_97788b75-2cec-45c4-b5db-cdb9fe926ccf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bd6d1fae-4a9f-4cb3-bfaa-26b12927d19d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_8a1effdb-291a-405e-ad70-e2ff37ba7f17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3290c503-1d1c-4f4e-ade1-57d95766fdbf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9f250982-33ae-4494-90e4-a8ffb7a7e298_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73764c8d-c360-4c69-87ca-91be1780db17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_7a447bb5-4673-4511-96f4-545fcf5e3e00_terseLabel_en-US" xlink:label="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense reimbursement received</link:label>
    <link:label id="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_label_en-US" xlink:label="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense Reimbursement Received</link:label>
    <link:label id="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_documentation_en-US" xlink:label="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense reimbursement received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GeneralAndAdministrativeExpenseReimbursementReceived" xlink:href="ovid-20220630.xsd#ovid_GeneralAndAdministrativeExpenseReimbursementReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_GeneralAndAdministrativeExpenseReimbursementReceived" xlink:to="lab_ovid_GeneralAndAdministrativeExpenseReimbursementReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1b9d27ed-5321-496b-9075-5bd6be13f37d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a054b277-6e78-41bc-ab68-4296a14d8de3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3754ba6a-c7bd-40c0-8e8d-dcc33fc5692e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementUpfrontPayment_d54f8847-c509-4bb3-8666-4e56c919a525_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment under license agreement</link:label>
    <link:label id="lab_ovid_LicenseAgreementUpfrontPayment_label_en-US" xlink:label="lab_ovid_LicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Upfront Payment</link:label>
    <link:label id="lab_ovid_LicenseAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementUpfrontPayment" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementUpfrontPayment" xlink:to="lab_ovid_LicenseAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ea0a0a43-0092-454c-9585-bbf3a614fc84_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ovid-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:8739d977-ca53-4263-89b1-d9c54849b06c,g:ab39b854-7f58-4138-956d-843b33846298-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/Coverpage" xlink:type="simple" xlink:href="ovid-20220630.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2dd90ca4-f2e6-47bf-ab6b-7e3226198383" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2dd90ca4-f2e6-47bf-ab6b-7e3226198383" xlink:to="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_89382436-b811-4a9c-b56b-44c8d996860d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_3fecd3e3-4b3a-40f5-824d-b5d4aeefe611" xlink:to="loc_dei_AddressTypeDomain_89382436-b811-4a9c-b56b-44c8d996860d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_ab6d406d-c0c7-4993-a87f-3d16cfeed935" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_FormerAddressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_89382436-b811-4a9c-b56b-44c8d996860d" xlink:to="loc_dei_FormerAddressMember_ab6d406d-c0c7-4993-a87f-3d16cfeed935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_610a1a11-b3dc-4a0b-b037-65b837376089" xlink:to="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_add88097-41cd-44ea-9dd3-c7d3ec4f72d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentType_add88097-41cd-44ea-9dd3-c7d3ec4f72d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fd5609d9-2219-4a6b-a5ff-50cc90475687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentQuarterlyReport_fd5609d9-2219-4a6b-a5ff-50cc90475687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c7102b36-1299-4c7e-8e20-ed1e93ba2df5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentPeriodEndDate_c7102b36-1299-4c7e-8e20-ed1e93ba2df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_91a2cc20-1567-41eb-9454-e07946871130" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentTransitionReport_91a2cc20-1567-41eb-9454-e07946871130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_04d49b87-041a-4b17-bfdc-58566bbbe659" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityFileNumber_04d49b87-041a-4b17-bfdc-58566bbbe659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e95fc1d-4e47-40b4-b06d-357ff6383401" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityRegistrantName_1e95fc1d-4e47-40b4-b06d-357ff6383401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a2f232e5-69a1-4dc4-89ea-f0d73a235bf1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a2f232e5-69a1-4dc4-89ea-f0d73a235bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3e685c7e-40c6-440c-bef3-6df5e8bfdeba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityTaxIdentificationNumber_3e685c7e-40c6-440c-bef3-6df5e8bfdeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ad3a4032-316d-4d76-86e4-9ef5a9bcbb7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressAddressLine1_ad3a4032-316d-4d76-86e4-9ef5a9bcbb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2a82f331-0193-486e-8672-332e0d81ef88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressAddressLine2_2a82f331-0193-486e-8672-332e0d81ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4b235c9f-f116-4c0c-b7b0-64b38ae7ea7d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressCityOrTown_4b235c9f-f116-4c0c-b7b0-64b38ae7ea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6c735928-68ca-4e6f-b0f1-a0cfc120afe9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressStateOrProvince_6c735928-68ca-4e6f-b0f1-a0cfc120afe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b3801aa-4e81-49c8-bb70-94be38fbf10c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityAddressPostalZipCode_3b3801aa-4e81-49c8-bb70-94be38fbf10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bfa8335c-5699-43db-a07a-0670e71a1866" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_CityAreaCode_bfa8335c-5699-43db-a07a-0670e71a1866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7d66dd57-d1ec-45c0-a647-bda28de6a2a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_LocalPhoneNumber_7d66dd57-d1ec-45c0-a647-bda28de6a2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_62486394-a376-4510-8d13-6cfb5ab940f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_Security12bTitle_62486394-a376-4510-8d13-6cfb5ab940f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22b4a8d8-62a0-444e-9927-24c9eec82e42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_TradingSymbol_22b4a8d8-62a0-444e-9927-24c9eec82e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6eba586c-d8c2-421c-9e7c-bb37d66fb678" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_SecurityExchangeName_6eba586c-d8c2-421c-9e7c-bb37d66fb678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_547b5189-dfa1-42c7-ac03-bd44ec3d864a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityCurrentReportingStatus_547b5189-dfa1-42c7-ac03-bd44ec3d864a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a5e01e73-7ff9-416c-beff-c99e9555f59c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityInteractiveDataCurrent_a5e01e73-7ff9-416c-beff-c99e9555f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e8ff9ac9-e86c-47b8-b969-912c9a7d45d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityFilerCategory_e8ff9ac9-e86c-47b8-b969-912c9a7d45d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c7090015-f4b7-499a-b0eb-b178ddf0a4fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntitySmallBusiness_c7090015-f4b7-499a-b0eb-b178ddf0a4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_32719dcc-8f4c-40fd-94c1-f1ec82c43be5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityEmergingGrowthCompany_32719dcc-8f4c-40fd-94c1-f1ec82c43be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_67d90f02-5caa-48dc-96c8-6e8ca85420a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityExTransitionPeriod_67d90f02-5caa-48dc-96c8-6e8ca85420a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f97c560a-5654-4831-a476-331a6910785c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityShellCompany_f97c560a-5654-4831-a476-331a6910785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0f33fb0a-2c9d-49d2-84fd-7148913c7a15" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0f33fb0a-2c9d-49d2-84fd-7148913c7a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_37179254-1106-4b72-bffb-21483ac23d17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_EntityCentralIndexKey_37179254-1106-4b72-bffb-21483ac23d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7c55cd78-c68a-4a67-9536-425949b87328" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_CurrentFiscalYearEndDate_7c55cd78-c68a-4a67-9536-425949b87328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1dd6817a-8ff5-4376-9a2f-f9e143618b5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentFiscalYearFocus_1dd6817a-8ff5-4376-9a2f-f9e143618b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6429ff2f-797e-4016-8fa5-7f7ef94dfaa3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6429ff2f-797e-4016-8fa5-7f7ef94dfaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0d3b16f4-429e-4d0c-bf2e-656933add726" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_7c95b632-d49d-4f8b-8775-82e2f11bf4a2" xlink:to="loc_dei_AmendmentFlag_0d3b16f4-429e-4d0c-bf2e-656933add726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ad500aed-c396-4460-afff-1018fd6ba097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ad500aed-c396-4460-afff-1018fd6ba097" xlink:to="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51842485-5556-42cd-8653-7885c94d1c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_51842485-5556-42cd-8653-7885c94d1c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79d2231e-b02b-4c74-bf88-b750ef3b31cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79d2231e-b02b-4c74-bf88-b750ef3b31cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9f8ba23-3258-411e-a4e1-a17310b29c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c9f8ba23-3258-411e-a4e1-a17310b29c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoteReceivable_96adf9ba-abd8-465b-8d08-3313356b0142" xlink:href="ovid-20220630.xsd#ovid_NoteReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:to="loc_ovid_NoteReceivable_96adf9ba-abd8-465b-8d08-3313356b0142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d45c6ce-dd5f-4812-b3ac-4ae1a31b0ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f9990703-c208-4acd-a073-6ec5c9391580" xlink:to="loc_us-gaap_AssetsCurrent_0d45c6ce-dd5f-4812-b3ac-4ae1a31b0ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_90d19f10-5d5e-4e29-8f03-8cc6e98c3d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_LongTermInvestments_90d19f10-5d5e-4e29-8f03-8cc6e98c3d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fc041bba-6764-4e94-a073-3b9d8a102b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_RestrictedCash_fc041bba-6764-4e94-a073-3b9d8a102b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_a61b2958-88ff-4f1c-9557-559d99599d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_SecurityDeposit_a61b2958-88ff-4f1c-9557-559d99599d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d0fccc97-9b60-49ad-9c11-11fa5c31bf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d0fccc97-9b60-49ad-9c11-11fa5c31bf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bac31138-d063-483d-83d4-129f52520aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bac31138-d063-483d-83d4-129f52520aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c35237ca-9399-4f5a-970c-307a6f64dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c35237ca-9399-4f5a-970c-307a6f64dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7655b362-9107-4f20-b0ae-db7d4a2d5631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cc5b5dce-5b36-4d18-b286-42d3e9b63aee" xlink:to="loc_us-gaap_Assets_7655b362-9107-4f20-b0ae-db7d4a2d5631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ad500aed-c396-4460-afff-1018fd6ba097" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_936d79ba-7159-4716-bc53-974b9550963f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_936d79ba-7159-4716-bc53-974b9550963f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1091086d-8deb-4ff6-9e43-b367db7bec8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_936d79ba-7159-4716-bc53-974b9550963f" xlink:to="loc_us-gaap_AccountsPayableCurrent_1091086d-8deb-4ff6-9e43-b367db7bec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ea68689b-cc6d-4190-a2ff-134db86a0304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_936d79ba-7159-4716-bc53-974b9550963f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ea68689b-cc6d-4190-a2ff-134db86a0304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_708deba9-4e78-4bab-a4e3-020a3993b96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_708deba9-4e78-4bab-a4e3-020a3993b96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_67dc8c13-d06f-4aca-91e9-6d291d01f6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_708deba9-4e78-4bab-a4e3-020a3993b96f" xlink:to="loc_us-gaap_OperatingLeaseLiability_67dc8c13-d06f-4aca-91e9-6d291d01f6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40f6a58a-ccc2-4bf2-987a-bd731d1a03a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:to="loc_us-gaap_Liabilities_40f6a58a-ccc2-4bf2-987a-bd731d1a03a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_69769464-e7f2-40e6-b447-16bc2529129b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:to="loc_us-gaap_PreferredStockValue_69769464-e7f2-40e6-b447-16bc2529129b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4db7a2e7-ca78-4c1f-8020-f8bec12a8c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:to="loc_us-gaap_CommonStockValue_4db7a2e7-ca78-4c1f-8020-f8bec12a8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_79d31989-d394-4734-ad59-63addca98f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_79d31989-d394-4734-ad59-63addca98f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0eb1cb21-3bbb-4187-ba49-f5f7daf4de3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0eb1cb21-3bbb-4187-ba49-f5f7daf4de3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b5f1730a-1f1f-465f-8b00-722a058e3695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b5f1730a-1f1f-465f-8b00-722a058e3695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4bc45f5-97d3-42f2-b8ba-c60002151c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b3676fd-e970-4692-b8e9-5c7e1f6c64bd" xlink:to="loc_us-gaap_StockholdersEquity_d4bc45f5-97d3-42f2-b8ba-c60002151c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bca6b09a-7246-47d9-9971-a1edabbcaf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4dfefbee-c53b-4b43-975d-4de943f97e93" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_bca6b09a-7246-47d9-9971-a1edabbcaf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e86687c5-23d9-4338-bc1e-4c60aa04e137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e86687c5-23d9-4338-bc1e-4c60aa04e137" xlink:to="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec52c37c-0ee6-4162-925e-b43dc8e7b720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_17a547ef-dae9-438e-804f-1de655482c01" xlink:to="loc_us-gaap_ClassOfStockDomain_ec52c37c-0ee6-4162-925e-b43dc8e7b720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_f9f1f8e5-4e8a-4047-812a-ab58f7017771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec52c37c-0ee6-4162-925e-b43dc8e7b720" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_f9f1f8e5-4e8a-4047-812a-ab58f7017771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c90b7052-dc77-47f9-8ad0-5182d6ea875c" xlink:to="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bfb14157-942d-4518-bb69-0fa67c2b0f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bfb14157-942d-4518-bb69-0fa67c2b0f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e51abd0a-7b09-4161-a117-98455c4a2155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e51abd0a-7b09-4161-a117-98455c4a2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated_1de40410-536f-40af-b7a4-4b2d082be48a" xlink:href="ovid-20220630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_ovid_PreferredStockShareDesignated_1de40410-536f-40af-b7a4-4b2d082be48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5a0d2a2f-6aae-46c4-8f9e-d8d95e3d3f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5a0d2a2f-6aae-46c4-8f9e-d8d95e3d3f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4f4a3223-f1e1-48d8-86b9-fa892d8cd575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4f4a3223-f1e1-48d8-86b9-fa892d8cd575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_037ca470-990b-4363-aeae-0bcb63495e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_037ca470-990b-4363-aeae-0bcb63495e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0999d794-4081-4136-ba9f-6919806ff895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0999d794-4081-4136-ba9f-6919806ff895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6a53c81e-f3a0-4da4-9cfe-cd76b25e8569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6a53c81e-f3a0-4da4-9cfe-cd76b25e8569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6b5e70e9-9070-486a-a104-f1158f0b90ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f73ff73-9a06-4d63-a0bc-af9dc752c475" xlink:to="loc_us-gaap_CommonStockSharesIssued_6b5e70e9-9070-486a-a104-f1158f0b90ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b366735-a1cb-4880-ba74-cb3d6df55949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b366735-a1cb-4880-ba74-cb3d6df55949" xlink:to="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:to="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8c5babfa-a8f9-4fc4-93fa-0705ce45ee17" xlink:to="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_82bb43e4-cd29-4fa2-9512-4e2e0b5f5a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:to="loc_us-gaap_LicenseMember_82bb43e4-cd29-4fa2-9512-4e2e0b5f5a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RelatedPartyMember_f6ac9b94-801e-402b-8218-c19cc0b47097" xlink:href="ovid-20220630.xsd#ovid_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fbc4b7cf-2201-4281-bb25-e57102557869" xlink:to="loc_ovid_RelatedPartyMember_f6ac9b94-801e-402b-8218-c19cc0b47097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c4c8ca9a-5392-4b0f-ab52-a32462d32542" xlink:to="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_35329c61-1ba2-407a-8da2-4cf47ddf8d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_RevenuesAbstract_35329c61-1ba2-407a-8da2-4cf47ddf8d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b0790b77-4fb2-4420-b819-6af567e4a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_35329c61-1ba2-407a-8da2-4cf47ddf8d54" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b0790b77-4fb2-4420-b819-6af567e4a08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6a128f5a-71a8-4edc-ba23-c453f3ec6570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6a128f5a-71a8-4edc-ba23-c453f3ec6570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_35534cfc-95f5-4b1d-9360-b4f7de4ce95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_35534cfc-95f5-4b1d-9360-b4f7de4ce95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ba0d4c9d-4c0a-4930-a6a9-27f52b5c6edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca1801e3-1186-477c-bedb-2016a7720e8a" xlink:to="loc_us-gaap_OperatingExpenses_ba0d4c9d-4c0a-4930-a6a9-27f52b5c6edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_490be8d7-29a7-4d97-b0de-735cc59b350b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_OperatingIncomeLoss_490be8d7-29a7-4d97-b0de-735cc59b350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_50d820e4-3298-48aa-adef-e4b652a177e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_50d820e4-3298-48aa-adef-e4b652a177e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_258e3a97-6887-4637-a747-642b3c7ed55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_258e3a97-6887-4637-a747-642b3c7ed55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_985324b7-c55a-4866-8904-dd1d528d4a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_985324b7-c55a-4866-8904-dd1d528d4a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81189899-f22f-4833-a498-947e9891b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_NetIncomeLoss_81189899-f22f-4833-a498-947e9891b5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7953c079-0dbd-479e-8f68-2de2569396cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_EarningsPerShareBasic_7953c079-0dbd-479e-8f68-2de2569396cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2e3fe403-ae8c-4981-8ff4-fa00017b4023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2e3fe403-ae8c-4981-8ff4-fa00017b4023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70730df5-c3bf-4b34-8b4e-cc6e85905df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_70730df5-c3bf-4b34-8b4e-cc6e85905df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fe3e247-eb04-43a3-aee0-3d36e3557e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_de7ce7b4-5eed-4fac-b11c-272e117fcc4c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fe3e247-eb04-43a3-aee0-3d36e3557e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_198879f9-0072-4d50-a91f-7558df99f875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e805618f-a1d5-4f73-ba3a-a98799e6b3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_198879f9-0072-4d50-a91f-7558df99f875" xlink:to="loc_us-gaap_NetIncomeLoss_e805618f-a1d5-4f73-ba3a-a98799e6b3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a2cf3647-4f03-4da6-8bf4-4e881718bad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_198879f9-0072-4d50-a91f-7558df99f875" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a2cf3647-4f03-4da6-8bf4-4e881718bad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c637d3e1-0bde-4d6f-a206-50b395dc504c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a2cf3647-4f03-4da6-8bf4-4e881718bad3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c637d3e1-0bde-4d6f-a206-50b395dc504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_83cd4c09-f177-4300-95c9-7801bf5be957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_198879f9-0072-4d50-a91f-7558df99f875" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_83cd4c09-f177-4300-95c9-7801bf5be957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a55e185a-545f-43b3-8a12-bc3570c58848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a55e185a-545f-43b3-8a12-bc3570c58848" xlink:to="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_62f7f0f1-07d4-4997-ad9b-8bfdeb29968a" xlink:to="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d83e0177-b00c-4516-b19f-4b06cc97b7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_PreferredStockMember_d83e0177-b00c-4516-b19f-4b06cc97b7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_386e8834-c8fb-42e5-a0a3-90bb35038dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_CommonStockMember_386e8834-c8fb-42e5-a0a3-90bb35038dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a4dd0589-c949-438f-bdd0-19223fbf6935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a4dd0589-c949-438f-bdd0-19223fbf6935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_78fe52c4-219e-4991-9c9a-1deccaa1fcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_78fe52c4-219e-4991-9c9a-1deccaa1fcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e84c1c9f-af13-4704-a1a7-412994ee7862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cbb5e8f3-131b-406e-986c-1d4e5c80789c" xlink:to="loc_us-gaap_RetainedEarningsMember_e84c1c9f-af13-4704-a1a7-412994ee7862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_88415573-eb77-4645-8b3c-830ed7bb3d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7fa36e1e-a0e9-4feb-a29b-cd5a2a16d176" xlink:to="loc_us-gaap_ClassOfStockDomain_88415573-eb77-4645-8b3c-830ed7bb3d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_bd7d8d9c-3e5c-4328-a4e8-8a8e841aaa30" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_88415573-eb77-4645-8b3c-830ed7bb3d9c" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_bd7d8d9c-3e5c-4328-a4e8-8a8e841aaa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ac32873-f874-423b-b7f6-688ade0948b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38bec6bc-1d47-429f-9d65-56e50003ff29" xlink:to="loc_us-gaap_StatementLineItems_3ac32873-f874-423b-b7f6-688ade0948b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ac32873-f874-423b-b7f6-688ade0948b3" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_08b7f2cc-20ee-4cdd-a5c8-2aeecf592203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_SharesIssued_08b7f2cc-20ee-4cdd-a5c8-2aeecf592203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b481c99f-269b-4ca1-a78c-fed2967719ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockholdersEquity_b481c99f-269b-4ca1-a78c-fed2967719ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1a0031d-9df4-49dd-8f66-6f4fc581cded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1a0031d-9df4-49dd-8f66-6f4fc581cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae28a2d1-02fa-4764-ae80-280caa192cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ae28a2d1-02fa-4764-ae80-280caa192cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54dbade7-c423-4e5b-a56c-44101a472745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_54dbade7-c423-4e5b-a56c-44101a472745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c65830f5-7996-43a3-bb19-b0b8cac82721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c65830f5-7996-43a3-bb19-b0b8cac82721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4771675b-99e2-482e-8e5f-c6a7ccbe43c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4771675b-99e2-482e-8e5f-c6a7ccbe43c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_be25d23b-e9a5-48e6-8185-72cbbb0d4597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_be25d23b-e9a5-48e6-8185-72cbbb0d4597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_fde09a33-9ca4-4b88-b437-fc92bf5b9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_fde09a33-9ca4-4b88-b437-fc92bf5b9df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_5923a051-6bae-42a6-a2a4-2fc9cc27c326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_5923a051-6bae-42a6-a2a4-2fc9cc27c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b65225f8-4560-4913-aa46-65b83e2b7c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_NetIncomeLoss_b65225f8-4560-4913-aa46-65b83e2b7c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_366689e0-299a-4712-ab27-b03c755d0b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_StockholdersEquity_366689e0-299a-4712-ab27-b03c755d0b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_ec0912ae-314c-4403-bb9d-acd6269888ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e49ac71-de99-42a3-b15b-f9a42644292e" xlink:to="loc_us-gaap_SharesIssued_ec0912ae-314c-4403-bb9d-acd6269888ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ovid-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5a06fb-373b-4138-9b2c-33e5d24ef891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5a06fb-373b-4138-9b2c-33e5d24ef891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be5e76f5-1967-4e86-9956-6534537c72cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5a06fb-373b-4138-9b2c-33e5d24ef891" xlink:to="loc_us-gaap_NetIncomeLoss_be5e76f5-1967-4e86-9956-6534537c72cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5a06fb-373b-4138-9b2c-33e5d24ef891" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_d0831fa4-1dbf-49df-bbcc-88f833536351" xlink:href="ovid-20220630.xsd#ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_d0831fa4-1dbf-49df-bbcc-88f833536351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c666d8eb-b8a9-4307-9610-413d0c97e28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c666d8eb-b8a9-4307-9610-413d0c97e28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_53e9dda9-392a-44af-8a36-f4f9844cbee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_53e9dda9-392a-44af-8a36-f4f9844cbee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_680dbbb0-e6ab-4720-9a22-cc97412dfe55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_us-gaap_ShareBasedCompensation_680dbbb0-e6ab-4720-9a22-cc97412dfe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_46498128-0ba2-4840-b4df-a7150a53db26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_46498128-0ba2-4840-b4df-a7150a53db26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7419052b-8646-4b96-93d6-77dc841a917b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7419052b-8646-4b96-93d6-77dc841a917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccretionOfLeaseLiability_9bb4e852-13da-4246-aca9-aeaa319df4dd" xlink:href="ovid-20220630.xsd#ovid_AccretionOfLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0becb3e6-3e36-48b9-9e39-5345e5f800d3" xlink:to="loc_ovid_AccretionOfLeaseLiability_9bb4e852-13da-4246-aca9-aeaa319df4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5a06fb-373b-4138-9b2c-33e5d24ef891" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7d77c133-eacc-48ef-972f-e179a7a8d8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7d77c133-eacc-48ef-972f-e179a7a8d8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_797357a9-d2d1-4093-adbc-76dac2fc17b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_797357a9-d2d1-4093-adbc-76dac2fc17b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseDueFromAffiliates_8968424c-3ccb-4226-a27a-69b8486abcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseDueFromAffiliates_8968424c-3ccb-4226-a27a-69b8486abcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_9f62251e-627f-4275-ba8e-13441d964285" xlink:href="ovid-20220630.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_9f62251e-627f-4275-ba8e-13441d964285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_99da69dc-ac9b-4f32-9e4a-ca0cccbc7bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_99da69dc-ac9b-4f32-9e4a-ca0cccbc7bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6d73c9da-d735-48ec-a598-a1b4f7447257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_6d73c9da-d735-48ec-a598-a1b4f7447257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4210cd22-0d71-4dc0-84dc-ad5205072216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4210cd22-0d71-4dc0-84dc-ad5205072216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_7f20c87f-616b-45e5-a982-ec8fa99a4ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_180c6191-31b8-4602-99c7-62eae19f6e1c" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_7f20c87f-616b-45e5-a982-ec8fa99a4ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8328732d-fb7a-47ea-8b7e-a6e440735ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a5a06fb-373b-4138-9b2c-33e5d24ef891" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8328732d-fb7a-47ea-8b7e-a6e440735ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f7d45cfa-40cb-4a4d-b61d-39044787f3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f7d45cfa-40cb-4a4d-b61d-39044787f3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_cd9b4176-6a6c-4e03-9348-7eacbc3cd3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_cd9b4176-6a6c-4e03-9348-7eacbc3cd3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_0c13b873-0f16-44c0-b6bf-146598973f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_0c13b873-0f16-44c0-b6bf-146598973f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a9b55d7-dc0e-4bc8-aa92-f955ea02b3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a9b55d7-dc0e-4bc8-aa92-f955ea02b3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_0749a7d8-1159-4573-ba8e-a3272205a942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_0749a7d8-1159-4573-ba8e-a3272205a942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_120c1c0a-1b90-4306-a7a3-5b4ca315fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_55d9d7ce-2aac-4df0-aff0-f99e43ac1136" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_120c1c0a-1b90-4306-a7a3-5b4ca315fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6469feaa-94ea-4b0f-8aba-1230849205fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6469feaa-94ea-4b0f-8aba-1230849205fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b33aa81b-4525-4034-950c-193e4d6f9ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6469feaa-94ea-4b0f-8aba-1230849205fe" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b33aa81b-4525-4034-950c-193e4d6f9ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f18a3768-ef12-4d4f-b87b-76940cb73e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6469feaa-94ea-4b0f-8aba-1230849205fe" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f18a3768-ef12-4d4f-b87b-76940cb73e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c96b0fa7-f350-4a1b-9a8e-0dfa66d30c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6469feaa-94ea-4b0f-8aba-1230849205fe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c96b0fa7-f350-4a1b-9a8e-0dfa66d30c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99605378-c839-4a07-b346-4dabaec95668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6469feaa-94ea-4b0f-8aba-1230849205fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99605378-c839-4a07-b346-4dabaec95668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1855352f-6bcf-4eea-87df-885549338d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1855352f-6bcf-4eea-87df-885549338d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b24632a6-053f-4be1-b43a-a7c1f1825d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b24632a6-053f-4be1-b43a-a7c1f1825d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e703a3f-a490-441e-a68c-f066afbe76f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e703a3f-a490-441e-a68c-f066afbe76f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d513b88a-1618-4ce3-b195-e34f774d51db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dbc43194-1fa1-4364-b754-99405799db37" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d513b88a-1618-4ce3-b195-e34f774d51db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_31af4094-c481-42f5-8c6d-694e6204a5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d513b88a-1618-4ce3-b195-e34f774d51db" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_31af4094-c481-42f5-8c6d-694e6204a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bd61ef54-7af4-4423-80af-b76850ea0ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d513b88a-1618-4ce3-b195-e34f774d51db" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bd61ef54-7af4-4423-80af-b76850ea0ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_e28c2d90-24d5-4a0d-8a67-d77bd5ad9abd" xlink:href="ovid-20220630.xsd#ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d513b88a-1618-4ce3-b195-e34f774d51db" xlink:to="loc_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets_e28c2d90-24d5-4a0d-8a67-d77bd5ad9abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_84113261-dab1-4cd8-a68c-60fe325dd65d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d513b88a-1618-4ce3-b195-e34f774d51db" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_84113261-dab1-4cd8-a68c-60fe325dd65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NatureofOperations" xlink:type="simple" xlink:href="ovid-20220630.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd2d0eae-2fb0-4e74-887e-c207f6c55b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a88ce44e-4628-46df-8e14-addbf9ef86a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd2d0eae-2fb0-4e74-887e-c207f6c55b15" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a88ce44e-4628-46df-8e14-addbf9ef86a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#NatureofOperationsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7cc9e575-7c2a-49ed-ade5-4ebd82b7125b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7cc9e575-7c2a-49ed-ade5-4ebd82b7125b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_22d0ec4a-2361-43a4-9ec3-470a67afe2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_22d0ec4a-2361-43a4-9ec3-470a67afe2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83c593d1-21fc-46cb-8829-284647152275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83c593d1-21fc-46cb-8829-284647152275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_WorkingCapital_34c1de2b-813c-4d60-952d-f36021ccc827" xlink:href="ovid-20220630.xsd#ovid_WorkingCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:to="loc_ovid_WorkingCapital_34c1de2b-813c-4d60-952d-f36021ccc827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc7b322c-311f-43a3-ad7f-e6d34c61ef16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc7b322c-311f-43a3-ad7f-e6d34c61ef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f24099a7-c9eb-4858-9f85-f7d9e5e9671a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a658ca7-187d-4891-89e9-50fc2a1ee7a6" xlink:to="loc_us-gaap_NetIncomeLoss_f24099a7-c9eb-4858-9f85-f7d9e5e9671a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ovid-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dc9728af-a62c-4df9-ab13-0a05cf00c323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_dd105846-23b4-414e-a821-38c22301399a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dc9728af-a62c-4df9-ab13-0a05cf00c323" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_dd105846-23b4-414e-a821-38c22301399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ovid-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_0b18e087-e191-4e44-a3c7-936161391a54" xlink:href="ovid-20220630.xsd#ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_0b18e087-e191-4e44-a3c7-936161391a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e4502a7c-3e64-4d1f-8294-afe9b80db0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e4502a7c-3e64-4d1f-8294-afe9b80db0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3bf9a64c-16de-4f34-b6ae-0816379b80e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_UseOfEstimates_3bf9a64c-16de-4f34-b6ae-0816379b80e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_16ff2ca9-c174-45c0-b728-e1f2dd46f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_16ff2ca9-c174-45c0-b728-e1f2dd46f3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_12b11f96-5c01-476a-98a8-242b7f0b2661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_12b11f96-5c01-476a-98a8-242b7f0b2661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_4cc0b911-c3e3-41b0-bcfa-d09da7048732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_4cc0b911-c3e3-41b0-bcfa-d09da7048732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_dd3ecd97-96d3-427d-97a9-4540e2b3f2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_dd3ecd97-96d3-427d-97a9-4540e2b3f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bf4527ea-0d77-4660-8f2f-9b39843f3ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bf4527ea-0d77-4660-8f2f-9b39843f3ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2cbb83c1-a268-4bd5-b836-f0cff2559739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2cbb83c1-a268-4bd5-b836-f0cff2559739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_bda0ab4c-1b31-4178-a861-88fccc082772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_bda0ab4c-1b31-4178-a861-88fccc082772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a195af22-d31e-496a-ba2c-c1438a7e4804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a195af22-d31e-496a-ba2c-c1438a7e4804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_967a4de5-ff1d-4056-a023-7c72ed672e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_45f9d624-2f6c-4780-9535-d2b66cb08b3b" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_967a4de5-ff1d-4056-a023-7c72ed672e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2690e0f5-3c61-4e44-9299-3ff83a4705d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:href="ovid-20220630.xsd#ovid_SummaryOfSignificantAccountingPolicyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2690e0f5-3c61-4e44-9299-3ff83a4705d4" xlink:to="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18481555-4148-4c93-8253-b10807615c01" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_913ff649-1eac-45e3-8a1f-8461510c7765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_913ff649-1eac-45e3-8a1f-8461510c7765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_00f93676-098c-456d-a1c8-407531931357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_00f93676-098c-456d-a1c8-407531931357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7ec7d2f2-5479-481e-b13b-c3b6929e0951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c62204b4-d261-4042-b388-bb978fc78136" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7ec7d2f2-5479-481e-b13b-c3b6929e0951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2c49728e-2e08-4de7-a229-7bf3e531084b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_aa3eacbf-bece-48e5-852d-0d6da644c50c" xlink:href="ovid-20220630.xsd#ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:to="loc_ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember_aa3eacbf-bece-48e5-852d-0d6da644c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_8847ced4-8aca-453e-84a0-413c52fd3fe4" xlink:href="ovid-20220630.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c518cea9-6731-4773-b239-6fed33fe6efb" xlink:to="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_8847ced4-8aca-453e-84a0-413c52fd3fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72c11b33-93fa-4a80-8903-0101a2d88953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_96fbd56f-ed99-4329-b155-158e27bc9102" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72c11b33-93fa-4a80-8903-0101a2d88953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_98bd0236-d25a-4ba3-82c3-19c97623f498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_72c11b33-93fa-4a80-8903-0101a2d88953" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_98bd0236-d25a-4ba3-82c3-19c97623f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6f048295-6b21-40b2-bc13-0c13d0964d12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bb724791-1684-4b6e-be37-e95b826b377d" xlink:to="loc_dei_EntityDomain_6f048295-6b21-40b2-bc13-0c13d0964d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusTherapeuticsIncMember_29d5e138-dbd2-4d9f-a626-35a66ea71c0b" xlink:href="ovid-20220630.xsd#ovid_MarinusTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6f048295-6b21-40b2-bc13-0c13d0964d12" xlink:to="loc_ovid_MarinusTherapeuticsIncMember_29d5e138-dbd2-4d9f-a626-35a66ea71c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc22ec4c-6e0c-4e95-b8ef-9e1b0e181b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c0d86767-2a9b-4e1c-b2d6-272e02a80708" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc22ec4c-6e0c-4e95-b8ef-9e1b0e181b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PromissoryNotesMember_b8055de4-a0ee-43e8-9b67-ab6c3b0fe198" xlink:href="ovid-20220630.xsd#ovid_PromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc22ec4c-6e0c-4e95-b8ef-9e1b0e181b48" xlink:to="loc_ovid_PromissoryNotesMember_b8055de4-a0ee-43e8-9b67-ab6c3b0fe198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:href="ovid-20220630.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_be43cd6b-110c-4490-a028-5d38c48370b8" xlink:to="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8edf9399-cbdf-4f11-adae-079325145f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_EquityMethodInvestments_8edf9399-cbdf-4f11-adae-079325145f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_5f629c69-6677-48fc-8c35-a16e947d8296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_LongTermInvestments_5f629c69-6677-48fc-8c35-a16e947d8296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d09afca-ef6c-455c-9519-a83e03946eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d09afca-ef6c-455c-9519-a83e03946eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1ea12e31-7689-47c1-ae32-d97cda3223c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1ea12e31-7689-47c1-ae32-d97cda3223c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4e335caa-6b56-4d16-af37-e044d3dc7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4e335caa-6b56-4d16-af37-e044d3dc7df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConvertibleNoteReceivable_99aca4a2-494b-4dd2-962e-eaa4f4a42005" xlink:href="ovid-20220630.xsd#ovid_ConvertibleNoteReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_d84260bd-144d-427f-a698-aa68f5699880" xlink:to="loc_ovid_ConvertibleNoteReceivable_99aca4a2-494b-4dd2-962e-eaa4f4a42005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="ovid-20220630.xsd#CashCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_3a7912a2-ebd9-4dd3-829d-eebe09f05824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_fe4e8ead-f322-426d-aa1e-15c1f193f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_3a7912a2-ebd9-4dd3-829d-eebe09f05824" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_fe4e8ead-f322-426d-aa1e-15c1f193f2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="ovid-20220630.xsd#CashCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0a8452ab-a6ea-4653-a936-4a751e3df9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2dbfc11d-4859-43e4-8e29-093bfec4f098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0a8452ab-a6ea-4653-a936-4a751e3df9f2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2dbfc11d-4859-43e4-8e29-093bfec4f098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b51af119-d7a5-4da3-a127-93892a86e9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0a8452ab-a6ea-4653-a936-4a751e3df9f2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b51af119-d7a5-4da3-a127-93892a86e9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_cf7a103b-2d9b-444c-bf44-d8cc3bfe043d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cf7a103b-2d9b-444c-bf44-d8cc3bfe043d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7cac50cc-dbcd-46eb-84ec-a809de205802" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_c33fd5c1-469f-4904-92b9-e295dd1f523d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:to="loc_us-gaap_CashMember_c33fd5c1-469f-4904-92b9-e295dd1f523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7df35ec1-07ff-4425-ac29-7a649d1c6dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_99ed057e-e4ee-4e2b-8247-c4cf2a109cd9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7df35ec1-07ff-4425-ac29-7a649d1c6dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_ece12016-0cca-4398-9a7d-64fe99c5ba10" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_811a060c-9c1a-4b23-8962-7fb9e1a7f132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_811a060c-9c1a-4b23-8962-7fb9e1a7f132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4360f16-00e0-4c25-b275-9f2d02088642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4360f16-00e0-4c25-b275-9f2d02088642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9701147-5a79-4c16-8c4a-0a987645c136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d9701147-5a79-4c16-8c4a-0a987645c136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da826f8f-fb63-4add-a7cd-e54dcb3e5050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_da826f8f-fb63-4add-a7cd-e54dcb3e5050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60c0f681-5c68-4599-b267-ec34ca755e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60c0f681-5c68-4599-b267-ec34ca755e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c6ddd82f-32e6-4d7d-9de2-b97e806d1730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c6ddd82f-32e6-4d7d-9de2-b97e806d1730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_4cebb42f-03bd-4881-bcc9-7be7f75b31fa" xlink:href="ovid-20220630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_4cebb42f-03bd-4881-bcc9-7be7f75b31fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d5dcd1e8-7de3-44d6-a646-795756586141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_b95d358a-4e38-4c4a-88f8-8165c0915323" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_d5dcd1e8-7de3-44d6-a646-795756586141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5ee78362-27cd-4cdb-94e0-00a93816320d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7e55ab31-a47f-4786-9cb7-bb67359b8197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5ee78362-27cd-4cdb-94e0-00a93816320d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_7e55ab31-a47f-4786-9cb7-bb67359b8197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets" xlink:type="simple" xlink:href="ovid-20220630.xsd#PropertyandEquipmentandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_962cb618-bbed-4cf2-abff-eed8a5238d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_12ab645c-d1e8-498c-9218-121c5a1d1c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_962cb618-bbed-4cf2-abff-eed8a5238d5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_12ab645c-d1e8-498c-9218-121c5a1d1c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsTables" xlink:type="simple" xlink:href="ovid-20220630.xsd#PropertyandEquipmentandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_884d658b-6570-4e0a-9026-8e5634a0e00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_728e674b-59e3-4907-b1d1-017c11085392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_884d658b-6570-4e0a-9026-8e5634a0e00d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_728e674b-59e3-4907-b1d1-017c11085392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_29390d35-986a-4935-8056-f69f599ad2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_29390d35-986a-4935-8056-f69f599ad2ee" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5415ffe0-3934-4435-8692-9a047e695dc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f34f7141-4404-4ccc-9221-d48f0cdc692b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f34f7141-4404-4ccc-9221-d48f0cdc692b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90a636e7-22dc-4519-b7dd-2f5470c0fa9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_712e13ec-9ce3-4882-92cf-42fce2264c85" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_90a636e7-22dc-4519-b7dd-2f5470c0fa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_59c7039f-3675-4c8d-a556-fe77987ba2da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9d66cacd-fe25-4e5e-9b27-8cdfe1d8e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9d66cacd-fe25-4e5e-9b27-8cdfe1d8e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94380a0d-927a-4b43-ade4-e783416b5b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_94380a0d-927a-4b43-ade4-e783416b5b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c86e0190-1c36-4096-80a5-785598e826df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1d98bd15-6b51-4115-bed1-34cafdc383d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c86e0190-1c36-4096-80a5-785598e826df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b07da330-bca2-46fc-b40d-2967a0e6df40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_aa261236-d5cb-4e0e-b5a9-177e7f6847de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b07da330-bca2-46fc-b40d-2967a0e6df40" xlink:to="loc_us-gaap_Depreciation_aa261236-d5cb-4e0e-b5a9-177e7f6847de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cff8358c-051c-40f8-9bca-ce38a92c7611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b07da330-bca2-46fc-b40d-2967a0e6df40" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cff8358c-051c-40f8-9bca-ce38a92c7611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_de75fd27-3387-462f-9abc-e06d92d771c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b07da330-bca2-46fc-b40d-2967a0e6df40" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_de75fd27-3387-462f-9abc-e06d92d771c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/Leases" xlink:type="simple" xlink:href="ovid-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_63e22afd-b161-4b4d-8299-27c8d2e11591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_875098b2-01e1-4f6a-97af-5d69799e97af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_63e22afd-b161-4b4d-8299-27c8d2e11591" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_875098b2-01e1-4f6a-97af-5d69799e97af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesTables" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7ed20c42-278d-48ee-9fbf-07ee946e858f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_8b8abde7-57b1-491e-916f-dfb432c68811" xlink:href="ovid-20220630.xsd#ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ed20c42-278d-48ee-9fbf-07ee946e858f" xlink:to="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_8b8abde7-57b1-491e-916f-dfb432c68811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_4a48a400-ea2a-449a-941f-72a4f08b636e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ed20c42-278d-48ee-9fbf-07ee946e858f" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_4a48a400-ea2a-449a-941f-72a4f08b636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a0ceded6-343e-4f11-9d16-faec137380b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ed20c42-278d-48ee-9fbf-07ee946e858f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a0ceded6-343e-4f11-9d16-faec137380b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0594ce62-c956-4610-8449-6bf4b1957684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0594ce62-c956-4610-8449-6bf4b1957684" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1d7558ca-cc6f-4ea7-ad71-81352b184470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_59f8140b-2e5e-4d14-bcba-aa03c61b598d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1d7558ca-cc6f-4ea7-ad71-81352b184470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a57d1032-98b7-4f50-8208-2a849079d7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1d7558ca-cc6f-4ea7-ad71-81352b184470" xlink:to="loc_us-gaap_LetterOfCreditMember_a57d1032-98b7-4f50-8208-2a849079d7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7ad8f210-6f64-4c96-bb2b-3f95766b8122" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_82bc7218-c75c-420e-986d-e681bad6fb17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_82bc7218-c75c-420e-986d-e681bad6fb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_52a38808-aa09-48d5-bd49-5d398545d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_52a38808-aa09-48d5-bd49-5d398545d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_fac0a934-8b2d-428d-98ed-bff61be226c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_PaymentsForRent_fac0a934-8b2d-428d-98ed-bff61be226c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_933c09f8-5e3a-4e34-b298-a36c5450fdf3" xlink:href="ovid-20220630.xsd#ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_933c09f8-5e3a-4e34-b298-a36c5450fdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseFreeRentPeriod_cc484210-5e8d-4a80-9767-1ea88516e33b" xlink:href="ovid-20220630.xsd#ovid_LesseeOperatingLeaseFreeRentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_ovid_LesseeOperatingLeaseFreeRentPeriod_cc484210-5e8d-4a80-9767-1ea88516e33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b339fbc6-7364-4b86-b846-f97ed0b20e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_RestrictedCash_b339fbc6-7364-4b86-b846-f97ed0b20e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_173102cb-e027-40e9-835d-b3dba98ef794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_173102cb-e027-40e9-835d-b3dba98ef794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f6b78899-2daf-4dc5-905d-cc99dd78e5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f6b78899-2daf-4dc5-905d-cc99dd78e5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LeaseIncrementalBorrowingRate_8d1f0aba-422f-4160-b0cf-579a86c0c95a" xlink:href="ovid-20220630.xsd#ovid_LeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fcf673d4-72a0-4b13-9a05-067b29007122" xlink:to="loc_ovid_LeaseIncrementalBorrowingRate_8d1f0aba-422f-4160-b0cf-579a86c0c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c26ff10a-83ea-4228-841d-c05808afb426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_38560f50-b10d-4a45-8666-4819f129f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c26ff10a-83ea-4228-841d-c05808afb426" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_38560f50-b10d-4a45-8666-4819f129f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eef1ea79-cef9-475e-bcf9-7af3745eff71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c26ff10a-83ea-4228-841d-c05808afb426" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eef1ea79-cef9-475e-bcf9-7af3745eff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b867a3c3-8042-42e6-a019-ccc1f1f91ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c26ff10a-83ea-4228-841d-c05808afb426" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b867a3c3-8042-42e6-a019-ccc1f1f91ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesScheduleofComponentsofOperatingLeaseCostDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3244f7b3-75b3-41f5-af91-0ac84bf5be44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_24d5b449-538b-4220-944d-164d28db34bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3244f7b3-75b3-41f5-af91-0ac84bf5be44" xlink:to="loc_us-gaap_OperatingLeaseCost_24d5b449-538b-4220-944d-164d28db34bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_27ddc2a4-faf4-4c02-97fe-f7377788f4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3244f7b3-75b3-41f5-af91-0ac84bf5be44" xlink:to="loc_us-gaap_VariableLeaseCost_27ddc2a4-faf4-4c02-97fe-f7377788f4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_579536ab-3286-4be8-a010-ca71c4cefe55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3244f7b3-75b3-41f5-af91-0ac84bf5be44" xlink:to="loc_us-gaap_ShortTermLeaseCost_579536ab-3286-4be8-a010-ca71c4cefe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e9cd68f8-95f1-4ae7-b149-a75f84e10f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e9cd68f8-95f1-4ae7-b149-a75f84e10f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3da81e9-324f-4923-8ef4-02e687432162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3da81e9-324f-4923-8ef4-02e687432162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a9d5062-930f-4df5-b135-4228a947b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a9d5062-930f-4df5-b135-4228a947b0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_502cbf19-70c0-4c38-a656-d813137bb532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_502cbf19-70c0-4c38-a656-d813137bb532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_684c9cc0-3a91-48c7-9814-d59434ed438e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_684c9cc0-3a91-48c7-9814-d59434ed438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c925a5b6-f531-4af1-a567-fb1bd599dc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c925a5b6-f531-4af1-a567-fb1bd599dc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_146b5a00-5b0e-4e28-b57f-35b4fee01d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07a444fd-8217-47fe-b208-31ffd76780b3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_146b5a00-5b0e-4e28-b57f-35b4fee01d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="ovid-20220630.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_32820bdf-c704-431e-8006-d2579ea40460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0c8a591b-d9d5-4d4c-bc37-90c7f027e9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_32820bdf-c704-431e-8006-d2579ea40460" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0c8a591b-d9d5-4d4c-bc37-90c7f027e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="ovid-20220630.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b89ce496-7003-4538-8c46-254a2d6c4229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a1b2c903-6b63-4431-b3bc-8f677eabc6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b89ce496-7003-4538-8c46-254a2d6c4229" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a1b2c903-6b63-4431-b3bc-8f677eabc6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#AccruedExpensesScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ac3b975-7987-4ea6-93fa-de0b12e10293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ac3b975-7987-4ea6-93fa-de0b12e10293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccruedResearchAndDevelopment_946f407a-fccc-4691-badb-275994287cd0" xlink:href="ovid-20220630.xsd#ovid_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:to="loc_ovid_AccruedResearchAndDevelopment_946f407a-fccc-4691-badb-275994287cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a7a4c382-6051-493e-a1f0-68c0474d2647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a7a4c382-6051-493e-a1f0-68c0474d2647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_IncomeTaxAccrualCurrent_9a8d21dc-fdf9-4469-8f15-dc96e07cec1d" xlink:href="ovid-20220630.xsd#ovid_IncomeTaxAccrualCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:to="loc_ovid_IncomeTaxAccrualCurrent_9a8d21dc-fdf9-4469-8f15-dc96e07cec1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_089d94f5-2074-40bd-b551-54e5d17faa73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_089d94f5-2074-40bd-b551-54e5d17faa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8506234e-c01f-494d-9bf5-88816c64ea25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_db90deb9-4198-4a98-92ca-3955249e1b4a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8506234e-c01f-494d-9bf5-88816c64ea25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockholdersEquityandPreferredStock" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockholdersEquityandPreferredStock"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockholdersEquityandPreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c758a282-55e8-4872-ba49-07263d033463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bc5a665b-2662-482d-a3de-cf609df5a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c758a282-55e8-4872-ba49-07263d033463" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bc5a665b-2662-482d-a3de-cf609df5a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockholdersEquityandPreferredStockAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7c2353dc-47c2-4185-a83e-1c64f613486b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7c2353dc-47c2-4185-a83e-1c64f613486b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31cac589-c21f-4cbf-b1a4-bd54a2ad5baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f49862e4-48ba-46c9-a3e8-23da2659b0fd" xlink:to="loc_us-gaap_ClassOfStockDomain_31cac589-c21f-4cbf-b1a4-bd54a2ad5baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_65ceec0c-1f83-4fe8-9df1-4c7a23fb076e" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31cac589-c21f-4cbf-b1a4-bd54a2ad5baa" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_65ceec0c-1f83-4fe8-9df1-4c7a23fb076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0edf0957-577e-409e-bf8b-6a5b2a10783b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5f8eff6a-fbf5-405e-a1c4-bf0cdef06e0c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0edf0957-577e-409e-bf8b-6a5b2a10783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ATMAgreementMember_e5763af7-8616-442c-ab6f-11c51f72380b" xlink:href="ovid-20220630.xsd#ovid_ATMAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0edf0957-577e-409e-bf8b-6a5b2a10783b" xlink:to="loc_ovid_ATMAgreementMember_e5763af7-8616-442c-ab6f-11c51f72380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d6c73d12-d84b-48f3-8adc-28d342110123" xlink:to="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bf368312-21d3-496f-9a25-e56a666ce8db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:to="loc_srt_MinimumMember_bf368312-21d3-496f-9a25-e56a666ce8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4ebe398d-ddfd-47ea-822b-a7714abd58a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bfc7548e-cb93-41f7-b3df-3e12369043e2" xlink:to="loc_srt_MaximumMember_4ebe398d-ddfd-47ea-822b-a7714abd58a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a093c30-bb20-4fa6-8f2b-25746d1f47ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_df071414-41e4-488c-90d7-07a1ec890efe" xlink:to="loc_dei_EntityDomain_7a093c30-bb20-4fa6-8f2b-25746d1f47ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CowenAndCompanyLLCMember_3f48066d-7703-43a7-afff-585bc6fc2324" xlink:href="ovid-20220630.xsd#ovid_CowenAndCompanyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7a093c30-bb20-4fa6-8f2b-25746d1f47ef" xlink:to="loc_ovid_CowenAndCompanyLLCMember_3f48066d-7703-43a7-afff-585bc6fc2324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ae0b3289-d625-4dde-ae9f-77007ee71e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97a50af1-2825-464d-ae8e-d362aba4436c" xlink:to="loc_us-gaap_EquityComponentDomain_ae0b3289-d625-4dde-ae9f-77007ee71e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1b8bba84-956e-4676-9862-b3ef89a8fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ae0b3289-d625-4dde-ae9f-77007ee71e14" xlink:to="loc_us-gaap_CommonStockMember_1b8bba84-956e-4676-9862-b3ef89a8fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0d746471-9391-4b84-a3ca-d72fe2c16bd4" xlink:to="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e87d1619-af6c-4c24-8a6c-34b3443933af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e87d1619-af6c-4c24-8a6c-34b3443933af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2fa6de0d-3b49-4c05-b931-53bef1668542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2fa6de0d-3b49-4c05-b931-53bef1668542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated_ab2160a4-669a-40a7-8689-3a9b732d4c66" xlink:href="ovid-20220630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_PreferredStockShareDesignated_ab2160a4-669a-40a7-8689-3a9b732d4c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockNumberOfVotesPerShare_7b425221-d8be-4b55-9f12-380beb7bdd7c" xlink:href="ovid-20220630.xsd#ovid_CommonStockNumberOfVotesPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_CommonStockNumberOfVotesPerShare_7b425221-d8be-4b55-9f12-380beb7bdd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AggregateOfferingPriceOfCommonStock_094a2480-e5c3-4741-95d3-ae215e88acba" xlink:href="ovid-20220630.xsd#ovid_AggregateOfferingPriceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_AggregateOfferingPriceOfCommonStock_094a2480-e5c3-4741-95d3-ae215e88acba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39294df8-33fa-4bd6-ba73-419f048a3d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_39294df8-33fa-4bd6-ba73-419f048a3d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3a2035cd-7f7d-4c9c-b158-94779ef1e713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3a2035cd-7f7d-4c9c-b158-94779ef1e713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9bb8380f-65c7-4ed6-bd13-5dd39109d382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9bb8380f-65c7-4ed6-bd13-5dd39109d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_6ce7ed5a-13c5-44e9-a233-55d8299a40ab" xlink:href="ovid-20220630.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_6ce7ed5a-13c5-44e9-a233-55d8299a40ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_afdeeedc-200c-40cd-b911-cc54b696f9b1" xlink:href="ovid-20220630.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_afdeeedc-200c-40cd-b911-cc54b696f9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_bfe341d8-2ac7-43e8-8354-87a12f15c6c2" xlink:href="ovid-20220630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_bfe341d8-2ac7-43e8-8354-87a12f15c6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_7eca8f6e-1145-4647-8530-7332047a917d" xlink:href="ovid-20220630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_7eca8f6e-1145-4647-8530-7332047a917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_602e7be0-4ce6-4b4d-af94-192f173ed241" xlink:href="ovid-20220630.xsd#ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_602e7be0-4ce6-4b4d-af94-192f173ed241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_9fb6fc2a-2964-408a-b86b-9253026f9038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_9fb6fc2a-2964-408a-b86b-9253026f9038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_015894b6-f11a-404d-9d33-d39f6b693e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_015894b6-f11a-404d-9d33-d39f6b693e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_36d76a2e-aeef-403f-aa3f-d29c13618d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_bd8d2c06-3d31-4160-a478-cd6aba608713" xlink:to="loc_us-gaap_Dividends_36d76a2e-aeef-403f-aa3f-d29c13618d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e94cc3e-3035-4c6c-9175-41a0bc57255d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637e8c35-7dc9-4384-b568-bf377ece853b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e94cc3e-3035-4c6c-9175-41a0bc57255d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637e8c35-7dc9-4384-b568-bf377ece853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd68f25a-af88-4511-9e16-e51af6c291d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4488eea9-ceae-45b3-9223-24124554fa9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd68f25a-af88-4511-9e16-e51af6c291d5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4488eea9-ceae-45b3-9223-24124554fa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_833c20b6-99a7-4ebc-8f06-bd1ad6ae404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd68f25a-af88-4511-9e16-e51af6c291d5" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_833c20b6-99a7-4ebc-8f06-bd1ad6ae404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7f877998-7b47-4e8c-b5b1-9281d2a7f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd68f25a-af88-4511-9e16-e51af6c291d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7f877998-7b47-4e8c-b5b1-9281d2a7f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a1deb58-07a3-41e4-9e8b-fbd926cf6734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd68f25a-af88-4511-9e16-e51af6c291d5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a1deb58-07a3-41e4-9e8b-fbd926cf6734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9c94f2e-afe0-482c-b839-c6c005e14de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9c94f2e-afe0-482c-b839-c6c005e14de7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:to="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_27b98ae7-4b96-4d5a-8d94-4f99007cdbf9" xlink:to="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_5122de60-be48-4f92-9695-5a442381c789" xlink:href="ovid-20220630.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:to="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_5122de60-be48-4f92-9695-5a442381c789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_cf58e5dc-c6ea-4e7c-9d0a-2595b0d96f66" xlink:href="ovid-20220630.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0891b052-b176-49bf-97d9-4e193c014c93" xlink:to="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_cf58e5dc-c6ea-4e7c-9d0a-2595b0d96f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:to="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2304d840-1bca-4083-a9e1-f0875c87decb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c7d8e9e4-9aac-4ec3-9731-6e4c56c47448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_us-gaap_PerformanceSharesMember_c7d8e9e4-9aac-4ec3-9731-6e4c56c47448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonEmployeeStockOptionsMember_7ef11f34-ada4-45ca-98bc-0275006a8fda" xlink:href="ovid-20220630.xsd#ovid_NonEmployeeStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_ovid_NonEmployeeStockOptionsMember_7ef11f34-ada4-45ca-98bc-0275006a8fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_a2d79666-ce8d-486e-8862-ca143d89b7aa" xlink:href="ovid-20220630.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_a2d79666-ce8d-486e-8862-ca143d89b7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec6585e6-3efb-4c8f-bd07-5b8d73c815bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec6585e6-3efb-4c8f-bd07-5b8d73c815bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_3767b659-3963-4436-a6e5-0a30e1f9ed8d" xlink:href="ovid-20220630.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62282443-5cfc-4041-a7f0-80fa495875b4" xlink:to="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_3767b659-3963-4436-a6e5-0a30e1f9ed8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6286c26a-2526-4508-a3ff-551463272c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fcbbccfb-c6d3-439d-9cc9-16c53315efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fcbbccfb-c6d3-439d-9cc9-16c53315efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_16d6c682-88aa-479f-a7d2-20fe718387fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_16d6c682-88aa-479f-a7d2-20fe718387fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c018278a-cc51-43fd-9060-bf9e6c1f3071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c018278a-cc51-43fd-9060-bf9e6c1f3071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ff59a0c-6716-41f3-bbd2-50fdb84ff961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ff59a0c-6716-41f3-bbd2-50fdb84ff961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3dbbccf0-932b-40f4-af36-389a7463c5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3dbbccf0-932b-40f4-af36-389a7463c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_4b7b6139-70f9-4d50-b84f-1a31558fd44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_4b7b6139-70f9-4d50-b84f-1a31558fd44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_45c16e2a-515a-4d91-a617-4f4dd2141db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_45c16e2a-515a-4d91-a617-4f4dd2141db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_c4e746ff-d999-4791-90fa-41cee447b6b0" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_c4e746ff-d999-4791-90fa-41cee447b6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_7970475a-82ef-4ea9-ae28-a9676d2eeb4d" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_7970475a-82ef-4ea9-ae28-a9676d2eeb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cd3dbee7-44f6-4ce3-946a-af5ccf58ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cd3dbee7-44f6-4ce3-946a-af5ccf58ad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_787b5454-892b-4822-9425-c84bcf0a5e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_787b5454-892b-4822-9425-c84bcf0a5e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0fdb194b-0b98-49ab-96a7-9bc95a992bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0fdb194b-0b98-49ab-96a7-9bc95a992bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_95e3771b-509f-49fb-9920-ae8ef80ef635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_95e3771b-509f-49fb-9920-ae8ef80ef635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be79c20a-c284-440f-ae0d-162e8c3a6089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be79c20a-c284-440f-ae0d-162e8c3a6089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54cbbe3f-a4e0-461a-bb21-61dd5a165bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_54cbbe3f-a4e0-461a-bb21-61dd5a165bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_51f6f51b-fcf7-4d87-b287-75057db695df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_51f6f51b-fcf7-4d87-b287-75057db695df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88240127-74b1-4ceb-8874-b759e89fb14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e00ae995-6808-4d40-a70c-fc1fd1d5bc5d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_88240127-74b1-4ceb-8874-b759e89fb14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4991917-0776-4781-87a3-235830c055b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4991917-0776-4781-87a3-235830c055b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_280219bf-ef9f-438e-8d75-20dd70195952" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_998f8502-616a-4cf0-a464-0de2a1da4832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_998f8502-616a-4cf0-a464-0de2a1da4832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c7fb825-3ee6-4043-ab1b-facfecac55d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3d35c817-5dc1-485b-af9b-f84ef4941c83" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5c7fb825-3ee6-4043-ab1b-facfecac55d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b5f72ac-9687-4fb1-adc2-d230299f8c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4cd20bcd-660d-4452-b08f-7cba98f7fbb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b5f72ac-9687-4fb1-adc2-d230299f8c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7fab3d48-7a33-4950-ac56-33e341a099ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b5f72ac-9687-4fb1-adc2-d230299f8c4d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7fab3d48-7a33-4950-ac56-33e341a099ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cffa8de-dcd1-4dbf-8b2e-820be57943c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8cffa8de-dcd1-4dbf-8b2e-820be57943c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:to="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9eee8f73-87e0-449a-865a-24b23cd14c34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_StockOptionsMember_d82ca6f4-0e77-4268-8dce-811f8ac65ca9" xlink:href="ovid-20220630.xsd#ovid_StockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:to="loc_ovid_StockOptionsMember_d82ca6f4-0e77-4268-8dce-811f8ac65ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeeStockPurchasePlanMember_b07c0f2d-cd63-48fb-b91e-bcda49ba3d56" xlink:href="ovid-20220630.xsd#ovid_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96a6dcf6-8bbf-40de-91f7-6103a60878b7" xlink:to="loc_ovid_EmployeeStockPurchasePlanMember_b07c0f2d-cd63-48fb-b91e-bcda49ba3d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84e0406-f8ba-4856-a8b2-69ac1cc7d639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6614abcc-a244-4d0e-a11e-54bdea4eead7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84e0406-f8ba-4856-a8b2-69ac1cc7d639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec736e59-840d-4c20-81be-e87108b0a263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d84e0406-f8ba-4856-a8b2-69ac1cc7d639" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ec736e59-840d-4c20-81be-e87108b0a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4d9cb9e-a797-4a47-8024-51c601e65def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4d9cb9e-a797-4a47-8024-51c601e65def" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:to="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2d894a8-ce3a-4735-aa3f-12aa6ebb42dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_115b3a4d-8f12-4b5a-b192-747e22477ce3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2d894a8-ce3a-4735-aa3f-12aa6ebb42dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94116268-84de-4def-bfaa-79cf5a5c02cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e2d894a8-ce3a-4735-aa3f-12aa6ebb42dd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94116268-84de-4def-bfaa-79cf5a5c02cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:to="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_ba9d5812-d4ad-4027-9442-ad42d6a5bc2e" xlink:to="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3a4f0ab0-df96-420b-9328-62062bffa1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3a4f0ab0-df96-420b-9328-62062bffa1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fccf9a8-7f5b-4b01-8628-cf90ae0b95c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_0f9f5ac8-1625-470a-aca5-293ec6bf47a6" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8fccf9a8-7f5b-4b01-8628-cf90ae0b95c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ba56b38d-7a6e-41d1-a68a-636b40e3f64b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82d5b596-f0d7-4ce7-930b-ed4b884620cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82d5b596-f0d7-4ce7-930b-ed4b884620cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ed6b44d-2cf9-4b5d-afae-c3b275fa3b39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1ed6b44d-2cf9-4b5d-afae-c3b275fa3b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d2726e23-ff24-4dfd-b03f-7c084a70f77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d2726e23-ff24-4dfd-b03f-7c084a70f77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81b1a791-df10-415e-9887-7a4fb6e716a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81b1a791-df10-415e-9887-7a4fb6e716a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b545d9d-85b2-4baa-98e5-9b244dee2afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183af0b6-a8a3-41fe-8cb6-8c4e1103d834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b545d9d-85b2-4baa-98e5-9b244dee2afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_caea3bed-86f5-49f3-8ec3-93cbbe8702f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_caea3bed-86f5-49f3-8ec3-93cbbe8702f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a19ec219-9675-49dd-bc65-a3125cd32962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a19ec219-9675-49dd-bc65-a3125cd32962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a84d352c-0f3a-4791-8e32-f3ed89f332ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a84d352c-0f3a-4791-8e32-f3ed89f332ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ad9a993-b0d1-4b08-b71c-f4cd3ea76ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ad9a993-b0d1-4b08-b71c-f4cd3ea76ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_dc9b70ae-2f29-4d0b-9a3b-bb44383e881a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_dc9b70ae-2f29-4d0b-9a3b-bb44383e881a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_04995770-af9b-4731-b9d4-1db2c4670c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_33a8ddfa-7e6b-4ce5-8e64-5760a1a8a18e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_04995770-af9b-4731-b9d4-1db2c4670c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_af4a6c80-29d3-41fc-aa55-c6f46a526c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_caea3bed-86f5-49f3-8ec3-93cbbe8702f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_af4a6c80-29d3-41fc-aa55-c6f46a526c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_caea3bed-86f5-49f3-8ec3-93cbbe8702f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f1d303e4-1c48-40b6-801c-4a7b2d38e7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f1d303e4-1c48-40b6-801c-4a7b2d38e7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_93a46cc8-816c-483a-946f-73547bbb32be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_93a46cc8-816c-483a-946f-73547bbb32be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_022eb4ad-12f4-4727-914d-ed9d53870959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_022eb4ad-12f4-4727-914d-ed9d53870959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2e7f3c0c-1f95-4110-bfd9-43fbd664b076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2e7f3c0c-1f95-4110-bfd9-43fbd664b076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e822b936-0a0f-4acc-91bc-25e8a72b4645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d7c92c5d-2d53-48f5-bad8-4a33cfc80ada" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e822b936-0a0f-4acc-91bc-25e8a72b4645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0efed0f1-d7ea-44ac-a4e4-5476f338e413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_caea3bed-86f5-49f3-8ec3-93cbbe8702f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0efed0f1-d7ea-44ac-a4e4-5476f338e413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_caea3bed-86f5-49f3-8ec3-93cbbe8702f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ee3d47f9-7c3d-4025-a478-0d731db921e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ee3d47f9-7c3d-4025-a478-0d731db921e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_ccddb470-a61a-44c7-a4c4-84b0a87d4f6e" xlink:href="ovid-20220630.xsd#ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:to="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_ccddb470-a61a-44c7-a4c4-84b0a87d4f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_baa32539-44ee-4462-bedd-b909a888f05d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_baa32539-44ee-4462-bedd-b909a888f05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07afe1ed-8499-4525-9976-49725b55171f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07afe1ed-8499-4525-9976-49725b55171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e5294d80-3dd3-455e-865a-35d3f9f0022c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9ee2ebfe-7708-46a4-ac62-2d43092f72b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e5294d80-3dd3-455e-865a-35d3f9f0022c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ovid-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1c14640d-5e2b-46ee-8064-590f007ea678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c866927e-157f-4e52-9b35-d0fe30b42f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1c14640d-5e2b-46ee-8064-590f007ea678" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c866927e-157f-4e52-9b35-d0fe30b42f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c27f5436-17b8-4d9e-be2b-c1c8bfb3a5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ba5f840a-0bd8-4250-80ae-3414b4242fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c27f5436-17b8-4d9e-be2b-c1c8bfb3a5dd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ba5f840a-0bd8-4250-80ae-3414b4242fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ovid-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_788b2766-2874-45b1-a623-109186cf3d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a60fb5b1-2072-490e-af25-da052da8c5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_788b2766-2874-45b1-a623-109186cf3d76" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a60fb5b1-2072-490e-af25-da052da8c5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CommitmentandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_148f223a-f654-43fe-9f58-d80cb064eb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_148f223a-f654-43fe-9f58-d80cb064eb52" xlink:to="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f5391fae-a3cf-4ec2-a617-1d61c82ca91f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HLundbeckASMember_62b5dd24-8b13-4446-b1c8-c62616f49c24" xlink:href="ovid-20220630.xsd#ovid_HLundbeckASMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:to="loc_ovid_HLundbeckASMember_62b5dd24-8b13-4446-b1c8-c62616f49c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NorthwesternUniversityMember_4d822fcb-1508-40e2-a1d3-33d5057250a8" xlink:href="ovid-20220630.xsd#ovid_NorthwesternUniversityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:to="loc_ovid_NorthwesternUniversityMember_4d822fcb-1508-40e2-a1d3-33d5057250a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AstrazenecaMember_db7e7094-80f6-49de-a820-b892f09f9d3c" xlink:href="ovid-20220630.xsd#ovid_AstrazenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd41085-7203-4d3a-a6dd-834fe5e78de9" xlink:to="loc_ovid_AstrazenecaMember_db7e7094-80f6-49de-a820-b892f09f9d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8352a83-7607-4ab6-9671-b24f1c9a6505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_27bc3786-35c3-4f3a-8380-1aaf8bdc646d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8352a83-7607-4ab6-9671-b24f1c9a6505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember_f69b1ebb-7a13-44ca-bbba-83af6d37c675" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f8352a83-7607-4ab6-9671-b24f1c9a6505" xlink:to="loc_ovid_LicenseAgreementMember_f69b1ebb-7a13-44ca-bbba-83af6d37c675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2db5839e-0e1a-4dfc-83a8-c47826729c96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_714fa88d-2ecf-4256-a673-223a7bc45741" xlink:to="loc_srt_RangeMember_2db5839e-0e1a-4dfc-83a8-c47826729c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a14539f-a1c6-4ca6-987b-c2d6c358d419" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2db5839e-0e1a-4dfc-83a8-c47826729c96" xlink:to="loc_srt_MaximumMember_3a14539f-a1c6-4ca6-987b-c2d6c358d419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7c92577-b4a8-4ac8-834b-a614d40ce70f" xlink:to="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMilestonePayments_485c356c-bc7a-4b29-bc81-f5f97c00f1cf" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_LicenseAgreementMilestonePayments_485c356c-bc7a-4b29-bc81-f5f97c00f1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_44693f3d-16c4-4098-ad10-491a2ce01f1c" xlink:href="ovid-20220630.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_44693f3d-16c4-4098-ad10-491a2ce01f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NumberOfTrial_04eb77da-65e9-495e-b571-40f7683b1223" xlink:href="ovid-20220630.xsd#ovid_NumberOfTrial"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_NumberOfTrial_04eb77da-65e9-495e-b571-40f7683b1223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_6ae0602e-4114-400c-9711-bd36be9dda09" xlink:href="ovid-20220630.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_6ae0602e-4114-400c-9711-bd36be9dda09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AnnualLicenseMaintenanceFeePayable_53fe5d65-fa42-4cac-b7c0-7c558fb403e2" xlink:href="ovid-20220630.xsd#ovid_AnnualLicenseMaintenanceFeePayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_AnnualLicenseMaintenanceFeePayable_53fe5d65-fa42-4cac-b7c0-7c558fb403e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConsiderationPayableForRightsGrant_05297392-2d74-4b81-a940-162533134486" xlink:href="ovid-20220630.xsd#ovid_ConsiderationPayableForRightsGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_ConsiderationPayableForRightsGrant_05297392-2d74-4b81-a940-162533134486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_be90b076-c48e-45eb-8770-8888733afe3a" xlink:href="ovid-20220630.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_be90b076-c48e-45eb-8770-8888733afe3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontCashPayment_68b156d1-eeb7-4723-980c-d0dd9fdc03a5" xlink:href="ovid-20220630.xsd#ovid_UpfrontCashPayment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_UpfrontCashPayment_68b156d1-eeb7-4723-980c-d0dd9fdc03a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d2486af5-4af0-4920-bcf1-ca95fbf8fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_us-gaap_CommonStockSharesIssued_d2486af5-4af0-4920-bcf1-ca95fbf8fa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_a4895f59-113e-4726-983c-d54aec0dbafd" xlink:href="ovid-20220630.xsd#ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_a4895f59-113e-4726-983c-d54aec0dbafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_34f78454-80cb-4a16-bacb-c2313d075c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e29b0164-4af2-41a6-a6ec-71eaddcb3a21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_34f78454-80cb-4a16-bacb-c2313d075c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CollaborationAndLicenseAgreements" xlink:type="simple" xlink:href="ovid-20220630.xsd#CollaborationAndLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CollaborationAndLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12f75d0f-984e-4e13-bc1e-e7360e9437a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1d2d0236-721b-412f-afdd-fc026bb417db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12f75d0f-984e-4e13-bc1e-e7360e9437a7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1d2d0236-721b-412f-afdd-fc026bb417db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#CollaborationAndLicenseAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67fe659b-7312-4459-b5bd-79d79e5b70ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67fe659b-7312-4459-b5bd-79d79e5b70ca" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_865fa515-94f9-4732-86d1-e01365a94c9f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_97875851-1492-4535-acc0-cd043070f42d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_865fa515-94f9-4732-86d1-e01365a94c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AngeliniLicenseAgreementMember_d0694f13-eabe-4825-998d-67fcc0fc1a6f" xlink:href="ovid-20220630.xsd#ovid_AngeliniLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_865fa515-94f9-4732-86d1-e01365a94c9f" xlink:to="loc_ovid_AngeliniLicenseAgreementMember_d0694f13-eabe-4825-998d-67fcc0fc1a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19fa880b-c229-4084-bfbc-87a3d79db62e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember_2b65adb8-d390-4a01-b5d4-b3d9b7205d3b" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_LicenseAgreementMember_2b65adb8-d390-4a01-b5d4-b3d9b7205d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8d446116-6cd3-442a-9f7e-60f67badeeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8d446116-6cd3-442a-9f7e-60f67badeeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HealxLicenseAndOptionAgreementMember_6793084a-821f-47e8-86c4-d6b8707f8f34" xlink:href="ovid-20220630.xsd#ovid_HealxLicenseAndOptionAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_HealxLicenseAndOptionAgreementMember_6793084a-821f-47e8-86c4-d6b8707f8f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusLicenseAgreementMember_2e5283ec-3c01-49ae-9b6b-8697a9384837" xlink:href="ovid-20220630.xsd#ovid_MarinusLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_MarinusLicenseAgreementMember_2e5283ec-3c01-49ae-9b6b-8697a9384837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PatentLicenseAgreementMember_8a4838a3-1888-41ee-af85-05bb0d2f4958" xlink:href="ovid-20220630.xsd#ovid_PatentLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ccb516a-accc-4ae8-a6f4-d4bb36d2d633" xlink:to="loc_ovid_PatentLicenseAgreementMember_8a4838a3-1888-41ee-af85-05bb0d2f4958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_38721e80-79e0-4c9a-a070-cc4fec900766" xlink:to="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1013e996-184b-4a38-9e95-a679bb6bfa98" xlink:href="ovid-20220630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1013e996-184b-4a38-9e95-a679bb6bfa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember_48e22889-7116-40f6-af0d-f2cc76e0ffc2" xlink:href="ovid-20220630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66336b35-ef7c-460e-b3bb-641190c4c10f" xlink:to="loc_ovid_MarinusPharmaceuticalsIncMember_48e22889-7116-40f6-af0d-f2cc76e0ffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_15305687-b895-4187-89d8-0def256cce68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_610c93fa-737e-421e-881b-df7dc3e5a39a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_15305687-b895-4187-89d8-0def256cce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_62541a01-2120-404b-a229-188155b8c9f5" xlink:href="ovid-20220630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_15305687-b895-4187-89d8-0def256cce68" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_62541a01-2120-404b-a229-188155b8c9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37852b32-17e9-48c6-b41d-f89c00146eb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c6fbf04f-3fdf-4a7d-ad0a-fba3791ffe39" xlink:to="loc_srt_RangeMember_37852b32-17e9-48c6-b41d-f89c00146eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9fbab07e-f261-4cb2-bbd2-e9eb69326e47" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37852b32-17e9-48c6-b41d-f89c00146eb6" xlink:to="loc_srt_MaximumMember_9fbab07e-f261-4cb2-bbd2-e9eb69326e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee75ad86-96a7-4623-9fa6-45a8410c630d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PotentialFundingCostPercent_a6d5787e-a127-4efb-8a97-de0d5c9afd17" xlink:href="ovid-20220630.xsd#ovid_PotentialFundingCostPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_PotentialFundingCostPercent_a6d5787e-a127-4efb-8a97-de0d5c9afd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CostOfAgreementNet_1898406d-d544-4ec7-bf2c-02a4d3b351ad" xlink:href="ovid-20220630.xsd#ovid_CostOfAgreementNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_CostOfAgreementNet_1898406d-d544-4ec7-bf2c-02a4d3b351ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DeferredUpfrontPaymentCosts_85e630d6-736e-4781-aceb-fed72db101eb" xlink:href="ovid-20220630.xsd#ovid_DeferredUpfrontPaymentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_DeferredUpfrontPaymentCosts_85e630d6-736e-4781-aceb-fed72db101eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementUpfrontPayment_b790cdb4-2bfc-40e0-be1d-b77440ed5ada" xlink:href="ovid-20220630.xsd#ovid_LicenseAgreementUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_LicenseAgreementUpfrontPayment_b790cdb4-2bfc-40e0-be1d-b77440ed5ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalUpFrontFeeAmount_f11b6808-5c2b-4358-9088-ac9dd55cdbf4" xlink:href="ovid-20220630.xsd#ovid_AdditionalUpFrontFeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AdditionalUpFrontFeeAmount_f11b6808-5c2b-4358-9088-ac9dd55cdbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontFeeAmount_8d5316e9-990a-49d8-9437-48508ecef988" xlink:href="ovid-20220630.xsd#ovid_UpFrontFeeAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_UpFrontFeeAmount_8d5316e9-990a-49d8-9437-48508ecef988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e59762b1-74f0-4248-9fdb-60af7bbd1a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e59762b1-74f0-4248-9fdb-60af7bbd1a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseRevenue_4acfe974-094b-492c-8497-f49412cc430a" xlink:href="ovid-20220630.xsd#ovid_LicenseRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_LicenseRevenue_4acfe974-094b-492c-8497-f49412cc430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AmountForPotentialFutureTrials_71f07fae-1518-4bae-99e0-0c02c2ac18b5" xlink:href="ovid-20220630.xsd#ovid_AmountForPotentialFutureTrials"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AmountForPotentialFutureTrials_71f07fae-1518-4bae-99e0-0c02c2ac18b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b039a3b6-6dde-41f9-85e2-7249a69b76cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b039a3b6-6dde-41f9-85e2-7249a69b76cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontPaymentReceivable_f551e465-e7cc-4c59-be78-53f27872da66" xlink:href="ovid-20220630.xsd#ovid_UpfrontPaymentReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_UpfrontPaymentReceivable_f551e465-e7cc-4c59-be78-53f27872da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AgreementMilestonePayments_348a63d5-316e-473e-a0f4-f00457485e2f" xlink:href="ovid-20220630.xsd#ovid_AgreementMilestonePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AgreementMilestonePayments_348a63d5-316e-473e-a0f4-f00457485e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_ec5b0841-71f6-491f-aa9e-99d522c55fab" xlink:href="ovid-20220630.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_ec5b0841-71f6-491f-aa9e-99d522c55fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca5cde3c-17dd-47bb-b8f4-f7dbf366bf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ca5cde3c-17dd-47bb-b8f4-f7dbf366bf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_3ad39c74-bc51-468a-ade9-950bcd0a83cb" xlink:href="ovid-20220630.xsd#ovid_ResearchAndDevelopmentExpenseReimbursementReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_ResearchAndDevelopmentExpenseReimbursementReceived_3ad39c74-bc51-468a-ade9-950bcd0a83cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_d6cfeb70-6963-4be7-aec1-d01b505a1e91" xlink:href="ovid-20220630.xsd#ovid_GeneralAndAdministrativeExpenseReimbursementReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_GeneralAndAdministrativeExpenseReimbursementReceived_d6cfeb70-6963-4be7-aec1-d01b505a1e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontPayment_04026e78-87f2-4875-add2-49d5f464a3be" xlink:href="ovid-20220630.xsd#ovid_UpFrontPayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_UpFrontPayment_04026e78-87f2-4875-add2-49d5f464a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DevelopmentAndCommercialMilestonePayments_81b3c84f-a268-4258-961c-480e40208a6b" xlink:href="ovid-20220630.xsd#ovid_DevelopmentAndCommercialMilestonePayments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_DevelopmentAndCommercialMilestonePayments_81b3c84f-a268-4258-961c-480e40208a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PercentageOfDevelopmentCosts_be63f5fe-5dd8-4817-b16d-208ec5fecf2b" xlink:href="ovid-20220630.xsd#ovid_PercentageOfDevelopmentCosts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_ovid_PercentageOfDevelopmentCosts_be63f5fe-5dd8-4817-b16d-208ec5fecf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cfa21c4b-8780-4bab-b742-bfb4fbd65c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_CommonStockSharesIssued_cfa21c4b-8780-4bab-b742-bfb4fbd65c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_073080bb-1582-4e84-90cf-98881c8134b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_073080bb-1582-4e84-90cf-98881c8134b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_9390f930-e778-4eec-8565-9fe6c69c4125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a42d1c6c-3e4b-4581-8955-fc0cdfd9dff6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_9390f930-e778-4eec-8565-9fe6c69c4125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ovid-20220630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2870c4bc-ce0a-45f2-beaf-7bcc1100b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_45e5db0c-c79f-4ad0-a4ae-51b67ac696d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2870c4bc-ce0a-45f2-beaf-7bcc1100b33e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_45e5db0c-c79f-4ad0-a4ae-51b67ac696d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="ovid-20220630.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ff0c27b2-ff10-4a8b-ae98-6a93c57a1f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7476c3a0-672c-42f1-a3ad-dd9d922b7265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff0c27b2-ff10-4a8b-ae98-6a93c57a1f24" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7476c3a0-672c-42f1-a3ad-dd9d922b7265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="ovid-20220630.xsd#NetLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NetLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0235246d-e71b-48a5-a7da-92aed45ee2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_411c5194-6629-4dcd-91b8-6178516b6c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0235246d-e71b-48a5-a7da-92aed45ee2ba" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_411c5194-6629-4dcd-91b8-6178516b6c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0abfe97e-ed0a-4df9-9532-b5204992c5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0235246d-e71b-48a5-a7da-92aed45ee2ba" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0abfe97e-ed0a-4df9-9532-b5204992c5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="simple" xlink:href="ovid-20220630.xsd#NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dca7deb6-4d22-4979-993a-ce90fb19916e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_NetIncomeLoss_dca7deb6-4d22-4979-993a-ce90fb19916e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e18ad290-397a-42f7-9442-186272ca294a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_e18ad290-397a-42f7-9442-186272ca294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_32d9a282-6911-4cd1-b670-c5a2f3f9c8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_32d9a282-6911-4cd1-b670-c5a2f3f9c8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e0e97670-72c5-4842-93b1-2a4237109a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e0e97670-72c5-4842-93b1-2a4237109a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c678936-be62-48b5-ba92-0e7033bb0c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2c678936-be62-48b5-ba92-0e7033bb0c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac68a064-df95-4e31-84d9-5df25eee4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac68a064-df95-4e31-84d9-5df25eee4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0f05fdae-d908-4666-ab41-d256cae5e9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_EarningsPerShareBasic_0f05fdae-d908-4666-ab41-d256cae5e9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_71c1dc6c-4828-43d3-9279-ab8cb19111bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_51b87bb4-49f0-4f97-9132-d55e35eae05a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_71c1dc6c-4828-43d3-9279-ab8cb19111bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="ovid-20220630.xsd#NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_97b4d2f8-f649-440d-a4b4-8de3c78e45e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97b4d2f8-f649-440d-a4b4-8de3c78e45e8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_464b621b-d7c4-4015-a9bf-cfe42411d235" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_62f1033d-ba7c-4f89-9de7-6e14b5abc0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:to="loc_us-gaap_EmployeeStockOptionMember_62f1033d-ba7c-4f89-9de7-6e14b5abc0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_5b7d3930-49dd-4f52-be7f-b6bbac5d0e6d" xlink:href="ovid-20220630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cfced8b1-288e-4ac3-abd3-4cf5afd931ed" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_5b7d3930-49dd-4f52-be7f-b6bbac5d0e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2721379-7d08-4afb-9b3e-8f02cd28e522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_359069a1-98e8-4743-b11e-23115e875a9c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2721379-7d08-4afb-9b3e-8f02cd28e522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_815ba93e-a026-44f9-bc03-0863eae65e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2721379-7d08-4afb-9b3e-8f02cd28e522" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_815ba93e-a026-44f9-bc03-0863eae65e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ovid-20220630_g1.jpg
<TEXT>
begin 644 ovid-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MN:6=H="P@
M0VAE   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  !+ &X :0!G &@ =  L "  0P!H &4   #_X0ID:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[
MOR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB
M83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(O/CQR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W
M-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX\9&,Z8W)E871O<CX\<F1F.E-E<2!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z
M;&D^2VYI9VAT+"!#:&4\+W)D9CIL:3X\+W)D9CI397$^#0H)"0D\+V1C.F-R
M96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO>#IX;7!M971A
M/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^
M_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=
M)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ_\  $0@"- 06 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           !
M @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-1
M80<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$
M149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;G
MZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*
M"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"
MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F
MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V
M]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Q?%^HW&D^%+R]LI/*GBV;7V@XRZ@\'
MCH:\>N_BAXGBSLU3'_;O%_\ $UZA\3I/*^'.J/Z>5_Z-2OF:_O\ KS7KX&E"
M=-N2OJ2SVGX6>.M=\3>+[FQU>_\ M%O'9/*J>3&F&#H <JH/1C7;ZIXBU1?$
M4VB^'=*M;ZZM;2.[N#>WS6JA9&=4$>V*0N<Q/G(4#Y>22<>+?L_7/G?$>_'7
M&ER'_P BQ5ZMXYT^]U69HK#PS=3ZE# QTK7;2[AB^QS.K+\Y,BR! =I95616
M7JK'Y:Y<;",*UHJPT=#<^+/#MEJATR\U_2[>_!"FTEO(UER0& V$YZ$'IT(H
MB\6>'9]&FU>#7]+DTRW?RYKU+R,PQMQ\K.#M!^9>"?XAZUQGB;P7J.J>'?&E
MNNFP7-WK&IV4L9^1?M,,4=H&SN;A0T<V%8^N,YR5UW1/$D'C#6=2T73W:WO9
M+ ^?:K;/< 1QSB1X1.P02 F)-S_PLV 2,5Q#-K7/B#9:;!;7.E+;ZO:7.GWU
M['<VUTIC;[,JDJ&4,#DDC.>,=#6]_;5G!H,.K:G<0:?:O%'(\EQ,$2/?C +'
M ZL![DBO);7P-XKDT^]^TZ?<-).NN&/[3/;>:?M4<?E;_*(0,S!\[?E!SSC!
M/H.NZ%<ZGX$T[26M$N'2YTTW$#E2ICBN87ESDX("(QQWQ@9S0!=@\;>%;E[9
M+;Q-H\K7<GE6RQW\3&9\@;4PWS') P.>15F?Q-H-KK$>D76MZ=#J4A4)927<
M:S.6Z (3N.>W'-<)XC\&:M?1_$=[/38Y)M;2T^P-OC!G:*%1U)XVL#C=CU%+
MJ/A_6V\/>(_"\/AS[0^LZA<7$6L">$0()I Z2R N)1)$, !48?NH\'GY0#JK
M+QMI;:;?7^MW-IHUO:ZG/IXEN[M421HW*@[FP 6VD[>?QJ]?^*- TJSMKO5-
M<TVRMKM=UO-<7<<:3# .49B PP0>/45YW/X0\26>LPZM;0:B/)U/56":9)9&
MX5+B5'CE47(,>"L94\JXWC'&X5?T#0+_ ,%ZI!>6/AS5-7M9M+6V4//9"\L7
M%Q+*\;#>D6Q_.7_5L0/*4$8"X ._35M.DMC<1W]J\(F%N95F4J)2X01YSC<6
M(7'7) ZUEV_C'2DT1]4UR\L]&MQJ%U8J]Y=+&C-#/+$,,V!EA$6V]N>N,UR,
MFC^);?[9HD.@27%O/XI@U0:DMU"L2VWVN*X;Y2_F%UVLI7: 0"02< UI/"GB
M6PUJWU6W&KA4DU1!%I,EBTL8GOWF1\70*;7C*YVD,"J@CK@ ]4CD26-9(F5T
M<!E93D,#T(-.K)\+:4FA^%--TR+[6([:W5%2]=&FC&.$8Q_)E?N_+\HQQQ6M
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH7.!GH,3WO@>TOK[4YY=2U!(-3N+>ZGM$:+RA-"82CKE"P)$"*1NP1G@'!
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MFW+B,"-^-VXKP< '(Q6%\/K.Q^*$FJ:'KNEV-G)&JW=M?Z;8Q6S0?O%4Q$H
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M!PP'RL.">,@9Q6?:0Z=KWQ7U[P5J&AZ:-.EDN([:>TL(K>6Q,89E821J"1P
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MAH,=K%HVD:5:06M^VH1PJL[CS3"82"6E)QM.<9Z^W%)T:GL^7KW ZF70-/\
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MLA2BODDFFDT_[._O?A_P0N?70I17R"33":/[/_O?A_P0N?80I17QT33":?\
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M5!]N;9;+9ZG9E@2@^>1W>10IW,/.;RV#$?*%!4N!Z/%-',I:&1) K%"48'#
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M 4444 %%%% !1110!S-I6Y:=!6':5N6G05O4$6J***P&%%%% !1110 4444
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M+-66*/)&^1I&))))9F)9B22222222:6H%FBBBF 4444 %%%% !1110 4444
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M_P!^W_\ BZ?U*KV"Y[0+N7U7_OD4HNI?5?\ OD5XK_PMW7A_RZ:=_P!^I/\
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MO%-MK]WX?EA\)7UO8:F70QSW*;D"AAN&-K=1GL?PZC;3.T;B"V.2!C-:<J[
M71?S^J?]\#_"GB]F]5_[X%>/Z&]QH/A[[38:9I^E7DND0RQ/;OA;U2R![B4^
M7]^,'<?D?;YF<OG%:EKX@NCH]B=7\865G9S2S#^V+*[M[@.RA-D)E:!8MQW2
MG C!Q&!G.28T[ >GB\F]5_[X%/%W+ZK_ -\BO-(/&=Q;Z1 -3U..._O-.LI[
M5'B$;SN[,)"D9&3P 2.=@Y.!S537_$=WH=D?[.U);&X6[O[@1S3Q1I=!9CE
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MA!1115@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"&SL8A%;PKM1<D\>I)Y)/4D\DY)YJQ110 4444 %%%% !1110 4444 %%%%
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M&QZL0 >2 >C4AI:0U(PHHHH YWQ!>26-]'-"%+;%&&''5JI?\)EJ &/)MO\
MOEO_ (JI?%W^NC_W5_\ 9JY@FO8P=&G.E>2,YMW.@/C/4/\ GC:_]\M_\533
MXUU'_GC:_P#?#?\ Q5<\34;-77]7I?RDW9T1\;ZB/^6-K_WPW_Q51MXZU(?\
ML+3_ +X;_P"*KG&:H'>CZO2_E"[.F;Q]J8Z06G_?#?\ Q51-\0M4'_+O9_\
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M3*$/&"-K,3GZXV8I4GA26([DD4,IQC(/(H 4T4&BD 4AI:0TAA6GH7_'\_\
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M.6Y""4;X9%8;414SYDFX$ <,V>1SJZ;T%:5:1V(>YR+>&=1CMC:VXM#%+:O
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MQAU>&S$VHRQQS3+=IY,6W>%;(#?+@[@@R#L&/4O)?_9_[[%'DO\ [/\ WV*
M/)+G4K?^Q7/A?Q)J%W?OITK:FS7SS-;/L&'>-B1;R^8<",!/XQMPF%]/L+*/
M3[*.UADGD1,X>XG>9SDDG+N23R?7@<#  %7/)?\ V?\ OL4>2_\ L_\ ?8H
MCHJ3R7_V?^^Q1Y+_ .S_ -]B@".BI/)?_9_[[%'DO_L_]]B@".BI/)?_ &?^
M^Q1Y+_[/_?8H CHJ3R7_ -G_ +[%'DO_ +/_ 'V* (Z*D\E_]G_OL4>2_P#L
M_P#?8H CHJ3R7_V?^^Q1Y+_[/_?8H CHJ3R7_P!G_OL4>2_^S_WV* (Z*D\E
M_P#9_P"^Q1Y+_P"S_P!]B@#SBQZUT5ET%9]CH-[L5\V^& (Q<(?ZUNVFEW*8
MW>5^$JG^M901<A:*L_8)O^F?_?P4?8)_^F?_ '\%:D%6BK/]GS_],_\ OX*/
M[/G_ .F?_?P4#*U)5K^SY_\ IG_W\%']GS_],_\ OX*0%2BK7]GS_P#3/_OX
M/\:/[/G_ .F?_?P?XT 5:*M?V?/_ -,_^_@_QH_L^?\ Z9_]_!_C2 J45:_L
MZ?\ Z9_]_!_C1_9T_P#TS_[^#_&@"K15K^SI_P#IG_W\'^-']G3_ /3/_OX/
M\: *M)5O^SY_^F?_ '\'^-)_9T__ $S_ ._@_P :0RK15K^SI_\ IG_W\'^-
M']G3_P#3/_OX/\: *M%6O[.G_P"F?_?P?XT?V=/_ -,_^_B_XT 5:0U;_LZ?
M_IG_ -_%_P :/[.G_P"F?_?Q?\: *E%6O[.G_P"F?_?Q?\:/[.G_ .F?_?Q?
M\:0%6D-6_P"SI_\ IG_W\7_&C^S;C_IG_P!_%_QHL!4HJW_9MQ_TS_[^+_C1
M_9MQ_P!,_P#OXO\ C189S]W_ ,AJ/_KD/YFMM?NCZ54N=&NWU5)!Y.T1@<S+
MGJ>V:U!I\^T?ZOI_ST%.(F5J0U:_L^?_ *9_]_!0=/G_ .F?_?P50BI0:M?V
M?/\ ],_^_@_QH_L^?_IG_P!_!_C2 J4AJW_9T_\ TS_[^#_&C^SI_P#IG_W\
M'^- RI0:M?V=/_TS_P"_@_QH_LZ?_IG_ -_%_P :0%2D-6_[.G_Z9_\ ?Q?\
M:/[.G_Z9_P#?Q?\ &E8##UK_ (]8?^NP_D:O6'_'N*-4T>ZGMXU3R<B0$YF4
M=C[U;L],N(X &\O/M(I_K1'<'L--%63I\_\ TS_[^"C^SY_^F?\ W\%:"*II
M*M?V?/\ ],_^_@H_L^?_ *9_]_!_C2 JFDJW_9\__3/_ +^#_&D_LZ?_ *9_
M]_!_C2 JFDJW_9T__3/_ +^#_&D_LZ?_ *9_]_!_C2&5:0U;_LZ?_IG_ -_%
M_P :/[.G_P"F?_?Q?\: *E(:M_V=/_TS_P"_B_XT?V;<?],_^_B_XT@,?5O^
M07+]5_\ 0A4NE?\ 'O5G4=)N9K"1$\K)*]95'<>]/T_2KF*'#^5GVE4_UH6X
MWL.-%6CI\_\ TS_[^"D_L^?_ *9_]_!6A)5-)5LZ?/\ ],_^_@I/[/G_ .F?
M_?P?XT@*II*M_P!GS_\ 3/\ [^#_ !I/[.G_ .F?_?P?XT@*II*M_P!G3_\
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M*X;X/:S>ZW\-;*34YWN;JUEEM7G?[T@C<A2?4[<<UW- !1110 4444 %%%%
M!1110 4444 %%%% !1110!YY8]:Z*RZ"N=L>M=%9=!64"Y%ZBBBM2!****0P
MI*6DH 2BBB@ HHHI )1110 4444 %)2TE(84444 %%%% !2&EI#2 **** "D
M-+2&D,**** ,J[_Y#4?_ %R'\S6VOW1]*Q+O_D-1_P#7(?S-;:_='TJHBD%(
M:6D-4(2@T4&D E(:6D-(84&B@T@$I#2TAH&9VM?\>L/_ %V'\C5ZP_X]Q5'6
MO^/6'_KL/Y&KUA_Q[BB.X/8LFB@T59(AI*4TE  :2E-)2 #24II*0PI#2TAI
M %(:6D- REJW_(+E^J_^A"I=*_X]ZBU;_D%R_5?_ $(5+I7_ ![T+<'L7C10
M:*LD0TE*:2@ -)2FDI !I*4TE(84AI:0T@"D-+2&@93U;_D&2_5?_0A4VF?\
M>HJ'5O\ D&2_5?\ T(5-IG_'J*([@]BX:*#15DC:#10: $HHHI )1112&!I*
M4TE(!*R-<_UUK_P+^E:]9&N?ZZU_X%_2I>Q2+FF]!6E6;IO05I5I'8A[B&B@
MT4P"D-+2&@!****  TE*:2D 4444#$HHHI %%%% "&B@T4@"D-+2&D,*T]"_
MX_G_ .N9_F*S*T]"_P"/Y_\ KF?YBFMP>QOT445H05K[_4#_ 'OZ&L36-*M=
M=T6\TK4$+VMY"T,H4X.UA@X/8UMWW^H'^]_0UAZQJ/\ 9.ERWGE>;Y90;-VW
M.Y@O7!]: .1TO2?'V@: NAV%SHE_%;((;/4KN25)4C PN^)4(=@,#.\9QS4]
MI\.+2U^&6H>%)+AKJ748YGNKR50#+<2<F4@=,-C [!1UK2'BLSVIN[&Q-U:W
M$JP:8RRA6OY,,6901A8@%+!\G<JLP!&TNY];UFRM0-4TBS%]<2B&QMK*_:83
M/M9CO=XH]BJ%))PW . 3A2 87PY\$:OX*\'7L-W=VEYX@O9GGEN69WB9@ L:
MDD!BH '88R:DO_#7B+Q/XBT&\\0)I>GVFBW/VP)8W$EQ)/*!@#+1H$7N1\V?
MUK>%YXG%@S/HNE_;#(%2)-5D,6S!)9G, (/&  C9SU%-?Q,+?P7<:]=64JO;
M1R&6VA#3?.C%&"E5)9=RG#[?N_,0.< &#XN\/^+?&.CW?AZY_L>QTR[GQ)>1
M3RR3^0'#!1$8PH?  )WD=<#TC/@[Q!X=\3ZOJ?@F73F@U>UBCD@U"61/LTT2
M[$E7:C;QMZJ=N3WKH;;QGH]P\$1DN8KB6V%T89+*=6BB.\;WR@V+F-QEL#@?
MWERG_";:$+.2XFN+BW6.5(6CN;&>&7>X.P"-T#G=@A<#YB,#)XH /!'A>/P;
MX/L=$CG-RUNI,L[#F61F+.WYD_A6_6$/&>BM:0SQR7DIF=XU@BT^X>=2A ?=
M"$,B $KDLH'S+_>&5/C'0QJAT_[5(9EN!:NXM93%',2 (WEV[%8DC + G<N,
M[AD W**Q8_%VBRZ@;-+F7?O>-96M95AD= 2R),5\MV&ULJK$_*W'RG%"#Q_I
M-[J^FV>GQ7US#J"LT=TNGW(C.-NTAO+VLIW_ '\[1CDT =316"OC;0&@N9VO
MFB@ME#M--;RQQR(6"^9&S*!*F2/G0LHW*<X()OMK-HFC?VI(+I+; .UK242\
MG 'E%?,R3P!MR?2@"_16(WC#1ET^&[\ZY99I&B2!+*=K@LOWAY 3S!CJ<KP"
M#T(JE%XXM;G4+VTAM;F(VEU;P&2[M;B!'$KQIPQBQNS( %_BZY5<L #J**RW
M\2:7'8VUV;AC%=1--#MA=F957<?E W CI@C.2%QD@5E77C_2X'L!!!J$_P!K
MO#:2(-.N1);L(R_SQ^7N!(VX! R&+#(4T =316/%XKTB;5CIT=Q*9O-: 2&U
ME$#2KG=&LQ7RV<88%0Q(*L,9!Q/HNNZ?XAL%O=(EDGM6 *2M!)&L@(!!4NHW
M#GJ,C.1U!% &C1110 4444 >>6/6NBLN@KG;'K716705E N1>HHHK4@2BBBD
M,*2EI* $HHIDDT4.SS9$3>P1-S ;F/8>I]J 'T444@$HHHH **** "DILTT5
MO$9)Y$BC&,L[  9.!R?>G4AA12.ZQHSNP55&2Q. !ZTB.DL:R1LKHP#*RG((
M/0@T .HHHH *0TM(:0!1110 4AI:0TAA1110!E7?_(:C_P"N0_F:VU^Z/I7'
M^+O]='_NK_[-7,,U>AA\)[6'->Q$I69ZO2&O(W>J\DE='U#^]^'_  2>8]CH
M->)224RUU2XTR]2ZLY"DJ'CT(]#ZBI> =M)?@/F/;Z0UC^&_$MKXBLM\1$=Q
M&/WT)/*GU'J/>M@UYLXN#Y9%H*#10:@!*0TM(:!F=K7_ !ZP_P#78?R-7K#_
M (]Q5'6O^/6'_KL/Y&KUA_Q[BB.X/8LFB@T59(AI*4TE  :2E-)2 #24II*0
MPI#2TAI %(:6D- REJW_ ""Y?JO_ *$*ETK_ (]ZBU;_ )!<OU7_ -"%2Z5_
MQ[T+<'L7C10:*LD0TE*:2@ -)2FDI !I*4TE(84AI:0T@"D-+2&@93U;_D&2
M_5?_ $(5-IG_ !ZBH=6_Y!DOU7_T(5-IG_'J*([@]BX:*#15DC:#10: $HHH
MI )1112&!I*4TE(!*R-<_P!=:_\  OZ5KUD:Y_KK7_@7]*E[%(N:;T%:59NF
M]!6E6D=B'N(:*#13 *0TM(: $HHHH #24II*0!1110,2BBBD 4444 (:*#12
M *0TM(:0PK3T+_C^?_KF?YBLRM/0O^/Y_P#KF?YBFMP>QOT445H05K[_ % _
MWOZ&N=\1Z4=;\/W.G!8F$^T,LPRC*&!((P<@@$=*Z*^_U _WOZ&N;\27D]AH
M;W%I)Y<HF@4-M!X:5%/7V)% &5)X>UB"-(+"ZMGBTV<76E/=,S,OR,C02<<K
MM=E60$L PRK%<O+<VGB3488+J:UTNPU"PG$ULD=Y)<13@HRNCL8D*9#<, V#
M@X.-I</%>Q/+BLKK5+R2ZN8X[:SB2-MD,A1F)DD"  [1DL-Q(PHZ"<>*(O[1
M%NVG7RV_FK;R7Q$?DQS-@"(_/N)RRKN52NXXW9!P 4-4@\6ZIIT43Z?I<'[_
M #/;PZS,HGBVGY3*+8,OS8) '(&-V"0=7[!=7OA*73KFVM-.GFM9+<0VDIEA
MA!!5=I*(2 ,<;1CIVS63:_$*PN+!+Z;3=2M+.:R:\MY[B- LZJ%+*H#DAAN'
MW@H/)4D<U?E\2SQ06X/A[5&OI]Y73U:W,H1< R%O.\L+EE'W\G/3K@ J6VC:
MX%U&[WV=AJ-UI$%G"T$IG6&:)K@A\M&N1^]0\KUW#! YR])\&:K!K#7U[Y,:
MM+:/Y3:I<7S*(3.6_>3*#SYJD   <\=S8\2>.O*\+ZG=^'K._NVATYKC[;!"
MA2T9HB\9=78,3@JQ4*V 1N S6CXUU34=-TNV32;>]DFN[J. RV7D>9$">2!,
MP3) P,@CGF@#.U?PQK$MS>3:6MFMQ<7CSP7QO98);/,,*!@%0B4;HRS1,0C;
M4SGM%9V&L:G+J=A&E@NE3:N\DUR97$Z!75B@CVE6)*@;]ZX#?=.WYM*#QI%+
M:,\&E:I<$7+6=N-D(>\F1G60)EP!M\MF+-M7'0D\4K^-8Q);VT6B:K-J$S2H
MU@BPB2)HPC,&8R",?+(K AR"#UR0" 5(?#NN?9;/1I_L"Z7I[%HKI)W,\X4,
M(U:,H F-PW-O;.T_*-WRVCX?OH;?P_'"+:06-H;*Z4S-'A&1%9XR$.2-G"D+
MG/48I=-\;Q:M&CV6BZL4N+=Y[-I(XH_M00J&50T@*L"P_P!8$!P2"1S734 >
M>Z=X#U"&S^SW<43301Q0PWCZW>7(D198W?\ <2@K%N$0.%9L$ 9QS77>([34
M;[19(-(E6.X9TRK3M!YB;AO3S55FCRN1N4;AVP>1J44 <)I/A;7]"D34+-+&
MYO/-N UK=:E.ZB*80G_CX='=F5H0,E<,#_#@ :%WH.KW5]=G99)!=W5A>L_V
MARR/!+"SQA?+P1MC)#9&20"HZUU=% ')R^&M5@DU:33;J"(N"--7<5,0DD$M
MP&?:=N]^ 0&V@*<'&*S]-\):WIX-VJVK7(U-+U+:;5+BX 00&$J;B5&<GYBP
M^7'\/'6NS?4+:.[6V:4>:W 7%6:SA4A-M1:=M'Y%.,HVNMSD[;0M:0VVE3?8
M1I%I>"Y2Z29S<2JLAD2,Q[-JD-M!?><A3\HW?+M>&]-ET;PKI.EW!C:6RLH;
M=S$3M+(@4XR!QD>@K2HK0D**** "BBB@#SRQZUS;V*GQAJ-[)I6GJG]LVL;:
MR6S=6O[BW(4#8#M8X3/F<>:25*@@])8]:V[:QM)H9XIK6&2.ZYG1XP1-\H7Y
MA_%P .>P K*!<CF+36/$^H:E<7%C!=B'S[FW/VDV@LH1'O5&^5_/W;T3=G(P
M7^4<$.MKV^,MM ;J>;5(9+E&.L0V^ZWD^SAD&Z% NP@JV5).&()XVCIY] T-
MKZ;4[G2=/-W)&5FNY+9/,9-NTAG(R1MXY/3CI45E8>'HU_LK3K"P2-(?/$$-
MLHC\N7<N1@;<-M8''4=>M:D'*^7>WU_H$<^N:S'=VVL/'<1W,5GO1C9RN!F.
M+805Z$$\2-G# ;:U_P"*=6MY+Z2PO;V2&YTR[N[.:\AMEBRFTHT*I^]VC=@^
M:#GCGU[A/#NBQ:>EA%H]@EG'()4MEM4$:N#D,%Q@'/?K4&GZ/X<F6ZNM.TG3
MQ]HEEAN9$LU0RLKLD@;Y06^96!SU]Z!G+>(8-6\V72[CQ!>2*MSI=RDRP0*Z
M-)>;"H_=D;055ER"01RS D5O>*M0O]-L=-M=/-Y+->7 MVFM1;^?Q&SY7SBL
M>X[.X/&<#.,;=UIUC>I,EY9V]PL\8BE66)7$B DA6R.1DDX/J:AFM-*U*SFT
MJXM[.[MH@B2V;HCHF,,H9#P/X2 1Z&D!RMI<^(-0U&#3-0U:YT61;*2=@8[5
MKF0+,55VX>,?(5W[1C)&-O2JUAJ,^J3V-U=+#YLMQ8NTD403S"8Y/FSUP>H!
M)P#C-=%+X,T.XN(Q<:7I\MA# (HK![-&BC(9CN52, _,1P.Y]:V&L[9YO->W
MB:3<K;R@)RN0#GU&3CZT >>)XE\3OX<NM:V7MM#+823^;>"S-O:N "OE^6YD
M('((DR>/X<$5K7<NNVU[-IEAK,^I226T=T6"6R3PC>05BRHC.]0VWS ?N-EC
MVV;_ ,)Z3<PZ@]I86=E?7\31S7L5J@E8,03N88+<@'D]JF'AC0!I\MB-#TT6
M<\GFRVXM(_+D?^\RXP3P.30!R-UKMQ;R7,FF27%S+/::="+DPVZ7)9Y[A&R6
MV(7^7:H;Y QR%.2&GEO_ !%;:>D^J2ZK86-I)*UQ/BR:\,05&6615#1^6/WP
M;RQO^6/"G+5UYTG3FM7MFL+4P20+;O$85VM$N=L9&,%1N;"]!D^M55\*^'DC
MMHTT'3%2T<R6RBSC A<D$L@Q\I)4'(]!Z4 0>)[JXBAMK:PGU!+N9RR1Z;'
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M_5?_ $(5+I7_ ![U%JW_ ""Y?JO_ *$*ETK_ (]Z%N#V+QHH-%62(:2E-)0
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M<-%!HJR1M!HH- "4444@$HHHI# TE*:2D E9&N?ZZU_X%_2M>LC7/]=:_P#
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MA05(8QJ1SD@'UQ5SP%;7NG^&[Y;RUN8I_P"T+F5([G&]@S[@21P<YZCBM/\
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M@_I?_@9'_C0!K&DK)_X2SP[_ -!_2_\ P,C_ ,:/^$L\._\ 0?TO_P #(_\
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M_ R/_&C_ (2OP[_T'M+_ / R/_&D,UC25DGQ7X=_Z#VF?^!D?^-'_"5^'?\
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M45D_\)7X=_Z#VE_^!D?^-'_"5^'?^@]I?_@9'_C0!JFBLD^*_#O_ $'M,_\
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M16SS,8XSY2\JI. >3T]30!P%%%% !1110 4444 %%%% !1110 4444 %%%%
M!17I_@2::W^$OB:2WU@Z*XO+;_30TJ^6,C/,8+<].!WYKMO[9B\4:<+CPKK
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MS*X<''#-QG /%>2#4=3O?&=O=:-?7^L7XE3[)/?0AYG< 8RC-(.#TY/0'CL
M8%%>A>.M9?\ X1*RT#7=3&K^(K>^>YN9@PD%FK)S;B3H3G!(7*@KC/RBO/:
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MK:U9V]I?W0^R6V?)M8(4@A0DDDB.,*N<L><9YKZ<_P"$.\,_]"YI/_@#%_\
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MP[_T -+_ / ./_"BXSYCHKZ<_P"$4\._] #2_P#P#C_PH_X13P[_ - #2_\
MP#C_ ,*+@?,=%?3G_"*>'?\ H :7_P" <?\ A1_PBGAW_H :7_X!Q_X47 ^8
MZ*^G/^$4\._] #2__ ./_"D_X13P[_T =,_\ X_\*7,!\R45]-_\(IX=_P"@
M#IG_ (!Q_P"%'_"*>'?^@#IG_@''_A1S ?,E%?3?_"*>'?\ H Z9_P" <?\
MA2?\(IX>_P"@#IG_ (!Q_P"%',%CYEHKZ:_X13P]_P! '3/_  #C_P */^$4
M\/?] '3/_ ./_"CF"Q\RT5]#_P#"-:%_;,J?V+IVP%<+]D3 ^4>U;'_")^',
M?\@#2_\ P"C_ ,*:=P>A\WV^N:C:Z'=Z/!<;;"\=))X=BG>RG*G)&1CV-+%K
MNI0:*NE0W31V:78O51% *S!=H<-C<#CWQ7T?_P (GX<_Z &E_P#@%'_A1_PB
M?AW_ * &E_\ @%'_ (4Q'A%W\1_$U_&\=_=6=W')+YS)<:9;2 R;0N[#1GG:
M ,U5@\::W!IYL!/;2V7G-.MM<6,$T43MG)1'0A!R>% ')XKZ _X1/P[_ - #
M2_\ P#C_ ,*0^$_#O_0 TO\ \ X_\*5P/ YO'.N7%G#:W+:?/!;AA#'+I5JX
MB#')"9C^49[#&./2HM6\9:]KEO=0:I?^?'=W"W,Z^3&N^14"*WRJ,?* ,#BO
MH'_A$_#O_0 TO_P#C_PH_P"$4\._] #2_P#P#C_PHN!X(/'WB8:3'IO]IL;2
M*SDL4C:&,X@D #)DKGHH&<Y&.,5&OC36_P"SK6QGFM;NWLT\NW6]L(+DQ+_=
M5I$8@=.,\  =J]^_X13P[_T -+_\ X_\*/\ A%/#O_0 TO\ \ X_\*+C/GR;
MQ=KEQXGC\0RZ@QU6,J4N BC;M&  H&W&.V,'GUJUJ7CS7]8C":I+97>(S$KS
M:9;,Z*<\*WEY7J>A&*]X/A3P[_T =,_\ X_\*/\ A%/#O_0!TS_P#C_PI<P'
MS)17TT?"GAW_ * .F?\ @''_ (54U/POH$>G2-'H>FJP*X*VD8/WA[4<P6/G
M"BOI33O"WA][?+Z%IK'U-G&?Z5;/A/PY_P! #2__  "C_P *H1\P5H:=KNHZ
M3:7UKI]QY,.H0^3<KL5O,3TR02/J,5]'_P#")^'/^@!I?_@%'_A2?\(GX=_Z
M &E_^ <?^% 'S=:ZQ?V6DW^F6T^RSU#R_M4>Q3YGEL63DC(P2>A'O6E:^./$
M-EX<.A6VH>7IK120F$01D[)#EQN*[N3[U[__ ,(GX=_Z &E_^ <?^%)_PB?A
MW_H :7_X!Q_X4K@?/^C>-->T#2Y]-TN]2.RN'+S026T4JN2NTY#J>"O!'2K2
M_$7Q.JL@OX?):W^S&W-E 81%G.T1;-@&3S@<\9Z"O=O^$3\._P#0 TO_ , X
M_P#"D_X13P[_ - #2_\ P#C_ ,*+@?-NH:A-J5R)[E+9'"A<6UK' N/]V-5&
M>>N,U/K6O:EXANXKG6+G[1-%"L"-Y:IA%S@84 =SSUKZ+_X13P[_ - #2_\
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M6Y]./VPYN0=)M,3G=NR_[KYCN&><\\U7F\9Z_/?WEY+J!::]LC83'RD"FW(
M\M5VX0<#[H'?U->_?\(IX>_Z .F?^ <?^%'_  BGA[_H Z9_X!Q_X4<P6/ M
M-\9ZYI6GP6-I=1-;6TWGP1W-K%.('Z[D\Q6V<\\8YR>]0:GXIUK6;)K75+][
MJ%KIKMA(JDF4KM+;L9Z #&<#' KZ$_X13P]_T =,_P# ./\ PH_X13P]_P!
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M TE<MX:\3?:=ECJ+_OND<I/W_8^_\_KUZFO$JTI4I<LC]&P>,I8RDJM)_P#
M\F(:IZM_R#)?JO\ Z$*N&J>K?\@R7ZK_ .A"L7L=J)=+_P"/85=-4M+_ ./8
M5=-:+8CJ%)2TE "4E+24@"DI:2D,**** $H-%!I )67H/^K%:E9>@_ZL4EN/
MH;1HH-%:$B&DI324 )1112 0T4&BD,*2EI*0 :2E-)2&8^A]!6\:P=#Z"MXU
M<-A2W"D-+2&F(2BBB@!****0"&B@T4AA2&EI#2 *0TM(:!E+6/\ D%2_5?\
MT(53TWM5S6/^05+]5_\ 0A5/3>U0]RNALT4451(4444 %%%% !1110 4444
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M'@7(QNV,>AR7C59_%,5O',=MY'$NDW C/"7<A_TO'H8XHG(/H_O0!Z317!Z
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M+' K8F\-:V_W;/\ \BI_C4'_  B>M_\ /E_Y%3_&O4C4I+[2^\^2J8/&R?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH *T]"_X_G_ZYG^8K,K3T+_C^?\
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M4[?+N91V/M6)!H_B*Y-]=7=E?DFUMUC@NGM$8M'-YACC$)VA,<+O<G.02.I
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MD E9>@_ZL5J5EZ#_ *L4EN/H;1HH-%:$B&DI324 )1112 0T4&BD,*2EI*0
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M?]^Q6A!5HJS]OE_N1?\ ?L4?;Y?[D7_?L4AE:DJU]OE_N1?]^Q1]OE_N1?\
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M5R/E)(!XK7\\_P#/./\ [XH\\_\ /./_ +XH HC3K%8GC6SMQ&Y5G01+ABH
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M5R!_='I3K:U@LK9+>S@CMX(QA(HD"JH]@.!5KSS_ ,\X_P#OBCSS_P \X_\
MOB@"*BI?//\ SSC_ .^*///_ #SC_P"^* /-['M71V5;JVUFOW;"S'T@7_"I
M%\I?NVUN/I$*B,;%-W,NBM;>G_/"'_OV*-Z?\\(?^_8JR3(HK7W)_P \(?\
MOV*-R?\ /"'_ +]B@9D4E;&Y/^>$/_?L4;D_YX0_]^Q2 QJ*V=R?\^\'_?L4
M;D_Y]X/^_8H QJ*V=R?\^\'_ '[%&Y/^?>#_ +]BBP&+16SN3_GW@_[]BC<G
M_/O!_P!^Q18#&HK9W)_S[P?]^Q1N3_GW@_[]BBP&-25M;D_Y]X/^_8HW1_\
M/O!_W[%*P7,6BMK='_S[P?\ ?L4;H_\ GW@_[]BBP7,6BMK='_S[P?\ ?L4;
MH_\ GW@_[]BBP7,6DK;W1_\ /O!_W[%&8_\ GW@_[]BCE"YB45MYC_Y]X/\
MOV*,Q_\ /O!_W[%'*%S$I*W,Q_\ /O!_W[%&8_\ GW@_[]BERCN8=%;F8_\
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M?>W_ ._0K1;$]2M25:^W'_GWM_\ OT*3[<?^?>W_ ._0H JTE6_MQ_Y][?\
M[]"D^W'_ )][?_OT*0%6DJW]N/\ S[V__?H4?;S_ ,^]M_WZ%(94HJU]O/\
MS[VW_?H4?;S_ ,^]M_WZ% %2@U:^WG_GWMO^_0H-^?\ GVMO^_0I 5*R]!_U
M8K?^WG_GVMO^_0K/TC56F09L[)/]R "CJ/H6S15HWI_Y][?_ +]"D^W'_GWM
M_P#OT*T)*II*MF^/_/O;_P#?H4GVX_\ /O;_ /?H4@*E%6OMQ_Y][?\ []"C
M[<?^?>W_ ._0I 5#15O[>?\ GWMO^_0I/MY_Y][;_OT*0RK25;^WG_GWMO\
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MDMQ]#<I#2TAK4S"BBBD,0TE*:2@ I*6DI %%%%  :2E-)2&%%%%  :2E-)2
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MF;_X[1_PT'XH_P"@7HO_ 'YF_P#CM']GUPN?0M%?/7_#0?BC_H%Z+_WYF_\
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M'_#0?BC_ *!>B_\ ?F;_ ..T?V?7"Y]"T5\]?\-!^*/^@7HO_?F;_P".T?\
M#0?BC_H%Z+_WYF_^.T?V?7"Y]"T5\]?\-!^*/^@7HO\ WYF_^.T?\-!^*/\
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M_P +X\0_] ?1?^_<_P#\=H_X7QXA_P"@/HO_ '[G_P#CM']FU_(.9'LNK_\
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M]"__ .3MO_\ '*/K%'^9?>@.#HKO/^%)?$'_ *%__P G;?\ ^.4?\*2^(/\
MT+__ ).V_P#\<H^L4?YE]Z X.BN\_P"%)?$'_H7_ /R=M_\ XY1_PI+X@_\
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MR%@GWNL0Y%86G:_;2Z3K\NJZAJ6N6%S)9VMQ/J" 7"H1-RH+R8*-AE^;DC'
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M0.GH*98_##XL:7:S6VF6E[9P3_ZV*WU6*-9.,?,!* >..:?-1Y?BC?U0'.>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911621064208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ovid Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">441 Ninth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1460 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 15044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620526432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,811,755<span></span>
</td>
<td class="nump">$ 187,797,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">79,554,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,715,134<span></span>
</td>
<td class="nump">2,681,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_NoteReceivable', window );">Note receivable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">156,080,929<span></span>
</td>
<td class="nump">190,479,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">2,228,547<span></span>
</td>
<td class="nump">1,631,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,930,753<span></span>
</td>
<td class="nump">1,930,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">80,114<span></span>
</td>
<td class="nump">96,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,243,128<span></span>
</td>
<td class="nump">242,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">15,437,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">328,797<span></span>
</td>
<td class="nump">164,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">177,329,852<span></span>
</td>
<td class="nump">194,544,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,616,543<span></span>
</td>
<td class="nump">7,127,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,598,843<span></span>
</td>
<td class="nump">7,671,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">15,966,970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,182,356<span></span>
</td>
<td class="nump">14,798,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 70,419,388 and 70,364,912 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">70,414<span></span>
</td>
<td class="nump">70,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">354,221,191<span></span>
</td>
<td class="nump">351,033,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(90,127)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(202,053,983)<span></span>
</td>
<td class="num">(171,357,513)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">152,147,496<span></span>
</td>
<td class="nump">179,746,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 177,329,852<span></span>
</td>
<td class="nump">$ 194,544,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_NoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts of notes currently receivable from customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_NoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620224016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">70,419,388<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">70,419,388<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PreferredStockShareDesignated', window );">Preferred stock, share designated (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620557328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,445,366<span></span>
</td>
<td class="nump">$ 208,382,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,046,670<span></span>
</td>
<td class="nump">7,683,668<span></span>
</td>
<td class="nump">13,878,939<span></span>
</td>
<td class="nump">23,932,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,257,617<span></span>
</td>
<td class="nump">6,629,158<span></span>
</td>
<td class="nump">18,137,820<span></span>
</td>
<td class="nump">22,205,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,304,287<span></span>
</td>
<td class="nump">14,312,826<span></span>
</td>
<td class="nump">32,016,759<span></span>
</td>
<td class="nump">46,138,288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(14,304,287)<span></span>
</td>
<td class="num">(14,312,826)<span></span>
</td>
<td class="num">(30,571,393)<span></span>
</td>
<td class="nump">162,244,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (expense) income, net</a></td>
<td class="num">(284,127)<span></span>
</td>
<td class="num">(2,517)<span></span>
</td>
<td class="num">(125,076)<span></span>
</td>
<td class="num">(52,250)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before provision for income taxes</a></td>
<td class="num">(14,588,414)<span></span>
</td>
<td class="num">(14,315,343)<span></span>
</td>
<td class="num">(30,696,470)<span></span>
</td>
<td class="nump">162,192,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,473,084<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,973,361<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (15,788,427)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="nump">$ 160,218,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">70,391,458<span></span>
</td>
<td class="nump">67,818,366<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
<td class="nump">66,953,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">70,391,458<span></span>
</td>
<td class="nump">67,818,366<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
<td class="nump">67,565,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,445,366<span></span>
</td>
<td class="nump">$ 12,382,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ovid_RelatedPartyMember', window );">License revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 196,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ovid_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ovid_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620204400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (15,788,427)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="nump">$ 160,218,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(90,127)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (14,678,541)<span></span>
</td>
<td class="num">$ (15,788,427)<span></span>
</td>
<td class="num">$ (30,786,597)<span></span>
</td>
<td class="nump">$ 160,218,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911617158192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">65,743,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 43,631,656<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 65,743<span></span>
</td>
<td class="nump">$ 337,758,007<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (294,192,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,320,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,320,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">20,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">20,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from employee stock purchase plan</a></td>
<td class="nump">130,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">130,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of series A convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="num">(1,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">176,007,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,007,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">221,109,940<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 67,788<span></span>
</td>
<td class="nump">339,226,941<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(118,184,790)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">67,787,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">65,743,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">43,631,656<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 65,743<span></span>
</td>
<td class="nump">337,758,007<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(294,192,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">160,218,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">206,709,513<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 67,834<span></span>
</td>
<td class="nump">340,614,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(133,973,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">67,833,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">67,787,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">221,109,940<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 67,788<span></span>
</td>
<td class="nump">339,226,941<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(118,184,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,257,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A convertible preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of series A convertible preferred stock to common stock</a></td>
<td class="nump">130,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">130,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(15,788,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,788,427)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">206,709,513<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 67,834<span></span>
</td>
<td class="nump">340,614,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(133,973,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">67,833,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">179,746,436<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,359<span></span>
</td>
<td class="nump">351,033,589<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(171,357,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,324,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">33,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">33,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(16,108,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,108,056)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">164,996,271<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,373<span></span>
</td>
<td class="nump">352,391,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(187,465,569)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">70,417,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 179,746,436<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,359<span></span>
</td>
<td class="nump">351,033,589<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(171,357,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="nump">15,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">152,147,496<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,414<span></span>
</td>
<td class="nump">354,221,191<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="num">(202,053,983)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">70,417,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">164,996,271<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,373<span></span>
</td>
<td class="nump">352,391,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(187,465,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,720,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">109,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">109,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(90,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(14,588,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,588,414)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 152,147,496<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,414<span></span>
</td>
<td class="nump">$ 354,221,191<span></span>
</td>
<td class="num">$ (90,127)<span></span>
</td>
<td class="num">$ (202,053,983)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619702496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="nump">$ 160,218,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction', window );">Non-cash consideration received in licensing agreement transaction</a></td>
<td class="num">(945,366)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity investment</a></td>
<td class="nump">348,812<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Change in accrued interest and accretion of discount on marketable securities</a></td>
<td class="num">(223,649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,045,029<span></span>
</td>
<td class="nump">2,577,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">172,105<span></span>
</td>
<td class="nump">127,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">354,185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AccretionOfLeaseLiability', window );">Accretion of lease liability</a></td>
<td class="nump">368,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(230,877)<span></span>
</td>
<td class="num">(1,023,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="nump">15,920<span></span>
</td>
<td class="num">(27,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromAffiliates', window );">Related party receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">141,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">477,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(2,510,503)<span></span>
</td>
<td class="num">(4,518,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(3,072,434)<span></span>
</td>
<td class="num">(1,676,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,382,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Related party payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,432,192)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(33,375,022)<span></span>
</td>
<td class="nump">141,482,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities, net of interest earned</a></td>
<td class="num">(79,416,203)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Issuance of convertible short-term note</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of long-term equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,583,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,085,840)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Software development and other costs</a></td>
<td class="num">(251,340)<span></span>
</td>
<td class="num">(11,515)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(81,753,383)<span></span>
</td>
<td class="num">(1,595,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">ATM and other offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">142,628<span></span>
</td>
<td class="nump">151,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">142,628<span></span>
</td>
<td class="nump">245,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(114,985,777)<span></span>
</td>
<td class="nump">140,132,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">189,728,285<span></span>
</td>
<td class="nump">72,033,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">74,742,508<span></span>
</td>
<td class="nump">212,166,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">15,791,769<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Transaction costs related to purchase of long-term equity investment in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets', window );">Stock option exercise receivables in prepaid expenses and other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment in accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AccretionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of lease liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AccretionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in prepaid expense, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash consideration received in licensing agreement transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911627865120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Operations</a></td>
<td class="text">NATURE OF OPERATIONS<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ovid Therapeutics Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the state of Delaware on April 1, 2014 and maintains its principal office in New York, New York. The Company commenced operations on April 1, 2014 (date of inception). The Company is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Historically, the Company&#8217;s major sources of cash have been composed of proceeds from various public and private offerings of its capital stock, revenue from collaboration agreements, option exercises and interest income. As of June&#160;30, 2022, the Company had approximately $152.4 million in cash, cash equivalents and marketable securities. Since inception, the Company has generated $222.4 million in revenue, primarily pursuant to the Company&#8217;s royalty, license and termination agreement (the &#8220;Takeda License and Termination Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;). Historically, the Company has incurred recurring losses, has experienced negative operating cash flows and requires significant cash resources to execute its business plans. The Company has an accumulated deficit of $202.1&#160;million as of June&#160;30, 2022, working capital of $146.9 million and had cash used in operating activities of $33.4 million for the six months ended June&#160;30, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded net losses of $14.6&#160;million and $30.7&#160;million during the three and six months ended June&#160;30, 2022, respectively, and expects to incur losses in subsequent periods for at least the next several years and is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company&#8217;s existing cash, cash equivalents and marketable securities as of June&#160;30, 2022 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company&#8217;s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the ongoing COVID-19 pandemic impacts the Company's business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for the Company's common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, the extent of sustained or new travel restrictions, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease, including vaccination efforts. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of the Company's product candidates; delays or problems in the supply of the Company's product candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company's business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911627660304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 15, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(A) Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interim condensed consolidated balance sheet at June&#160;30, 2022, the condensed consolidated statements of operations, comprehensive (loss) income, cash flows, and stockholders&#8217; equity for the three and six months ended June&#160;30, 2022 and 2021 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2022 and 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2021 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(B) Basis of Presentation and Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(C) Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(D) Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities consists of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive loss in stockholder's equity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(E) Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(F) Long-Term Equity Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term equity investments consist of an equity investment in a private company through preferred shares, which are not considered in-substance common stock, that is accounted for at cost, with adjustments for observable changes in prices or impairments, and is classified within long-term equity investments on our consolidated balance sheets with adjustments recognized in other (expense) income, net on our consolidated statements of operations. The Company has determined that the equity investment does not have a readily determinable fair value and elected the measurement alternative. Therefore, the equity investment&#8217;s carrying amount will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investment is impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investee securities, and other publicly available data. If the investment is impaired, the Company writes it down to its estimated fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the equity investment had a carrying value of $1.6 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. ("Marinus") that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2022, the equity investment in Marinus had a carrying value of approximately $0.6 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(G) Note Receivable</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March&#160;17, 2022, the Company issued a convertible promissory note to a related party, in which the Company has a long-term equity investment, with a principal amount of $1.0 million. The note has certain features that may allow the Company to acquire additional equity or to settle in cash. Either option would result in the Company receiving an amount at least equal to the outstanding principal balance plus accrued and unpaid interest. The Company will receive interest on the convertible promissory note at the rate of 1.5% per annum payable upon conversion or maturity of the note on March 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has elected to measure the note using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivatives due to changes in the fair value will be reflected in other income (expense), net, in the Company's consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(H) Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling approximately $55.6 million as of June&#160;30, 2022. The Company's Level 1 assets consisted of money market funds and short-term investments of $187.6 million as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills totaling approximately $94.5 million as of June&#160;30, 2022. The Company had no Level 2 assets or liabilities as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company's Level 3 assets consists of the convertible note receivable totaling $1.0 million as of June&#160;30, 2022. There were no Level 3 assets or liabilities as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I) Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use ("ROU") assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period. The Company determined that there was no current lease liability for the period ended June&#160;30, 2022, which is due primarily to the free rental period for the Company's Hudson Commons lease. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(J) Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(K) Net (Loss) Income Per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income, basic per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding. The Company applies the two-class method to allocate earnings between common stock and participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income, diluted per share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and preferred stock using the if-converted method.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss, diluted per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(L) Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622783392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,860,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,860,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,951,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,951,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,644,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,554,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,455,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,365,795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,591,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,591,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of June&#160;30, 2022 and December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622783392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">Property and Equipment and Intangible Assets</a></td>
<td class="text">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,243,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense was $54,631 and $17,834 for the three months ended June&#160;30, 2022 and 2021, respectively. Depreciation expense was $85,470 and $36,478 for the six months ended June&#160;30, 2022 and 2021, respectively.</span></div>Intangible assets, net of accumulated amortization was $328,797 and $164,092 as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and are included in other assets. Amortization expense was $32,153 and $35,381 for the three months ended June&#160;30, 2022 and 2021, respectively. Amortization expense was $86,636 and $91,473 for the six months ended June&#160;30, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911627806944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,143 square feet of office space at Hudson Commons in New York, NY. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3 million per year. Rent payments commence 10 months following the commencement date of the lease, or January 10, 2023, and continue for 10 years following the rent commencement date. Rent also includes two months of free rent in the 6th and 7th months following the rent commencement date. The Company issued a letter of credit in the amount of $1.9 million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Hudson Commons lease has a remaining lease term of 10 years and includes a single renewal option for an additional 5 years. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments is calculated using an incremental borrowing rate of 7.02%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROU asset and lease liabilities related to the Company's operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">15,437,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Current lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Long-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">15,966,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of operating lease cost for the six months ended June&#160;30, 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future minimum commitments under the non-cancelable operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,347,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,285,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911624387312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and bonus accrual</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,925,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,764,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,564,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,598,843&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,671,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622646272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Preferred Stock</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY AND PREFERRED STOCK<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s capital structure consists of common stock and convertible preferred stock ("Preferred Stock"). Pursuant to the Company&#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of Preferred Stock. The Company has designated 1,250 of the 10,000,000 authorized shares of Preferred Stock as non-voting Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of Preferred Stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of Preferred Stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the Preferred Stock are satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (the &#8220;2020 ATM agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may offer and sell in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Cowen acting as sales agent. As of June&#160;30, 2022, the Company has not sold any shares of its common stock under the 2020 ATM agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were 1,250 shares of Series A Preferred Stock outstanding as of June&#160;30, 2022 and December&#160;31, 2021. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, certain of the Company&#8217;s stockholders elected to convert an aggregate of 2,000 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,000,000 shares of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Holders of Series A preferred stock are entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends (other than dividends in the form of the issuance of common stock) actually paid on shares of common stock. No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid. Through June&#160;30, 2022, the Company has not declared any dividends.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622676992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted and the Company's stockholders approved the 2017 Equity Incentive Plan (&#8220;2017 Plan&#8221;), which became effective immediately on May 4, 2017. The initial reserve of shares of common stock under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company&#8217;s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. On January&#160;1, 2022 and January&#160;1, 2021, respectively, an additional 1,000,000 and 3,287,158 shares were reserved for issuance under the 2017 Plan. As of June&#160;30, 2022, there were 2,706,415 shares of the Company&#8217;s common stock reserved and available for issuance under the 2017 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 Employee Stock Purchase Plan (the &#8220;2017 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#8217;s initial public offering on May 4, 2017. The 2017 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated semi-annual purchase dates. During the three months ended June&#160;30, 2022 and 2021, no shares were purchased under the 2017 ESPP, and the Company recorded expense of $20,176 and $37,849, respectively. During the six months ended June&#160;30, 2022 and 2021, 38,583 and 34,256 shares, respectively, were purchased under the 2017 ESPP and the Company recorded expense of $41,195 and $56,636, respectively. The initial reserve of shares of common stock that may be issued under the 2017 ESPP was 279,069 shares. The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board. The Board acted prior to each of January&#160;1, 2021 and January&#160;1, 2022 to provide that there be no increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of June&#160;30, 2022, there were 454,479 shares of the Company&#8217;s common stock reserved for issuance under the 2017 ESPP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless specified otherwise in an individual option agreement, stock options granted under the prior plan and the 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&#8217;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#8217;s service with the Company. In the event of option holder&#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Performance-based option awards generally have similar terms, with vesting commencing on the date the performance condition is achieved and expire in accordance with the specific terms of the agreement. At June&#160;30, 2022, there were 150,000 performance-based options outstanding and unvested that include options to be granted upon the achievement of certain research and development milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require significant assumptions that are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on historical volatility information of peer companies that are publicly available. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be canceled.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company did not grant any stock options to nonemployee consultants for services rendered during the three months ended June&#160;30, 2022 and 2021. The Company granted no stock options to nonemployee consultants for services rendered during the six months ended June&#160;30, 2022, and 170,000 during the six months ended June 30, 2021. There were 130,834 and 191,875 unvested nonemployee options outstanding as of June&#160;30, 2022 and 2021, respectively. Total expense recognized related to nonemployee stock options for the three months ended June&#160;30, 2022 and 2021, was $160,337 and $55,310, respectively. Total expense recognized related to nonemployee stock options for the six months ended June&#160;30, 2022 and 2021 was $355,107 and $91,000, respectively. Total unrecognized compensation expenses related to the nonemployee stock options was $1.1 million as of June&#160;30, 2022. The Company did not recognize any expense for nonemployee performance-based option awards during the three months or six months ended June&#160;30, 2022 or 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company granted 2,426,750 and 363,000 stock options to employees during the three months ended June&#160;30, 2022 and 2021, respectively. The Company granted 4,296,355 and 1,006,600 stock options to employees during the six months ended June&#160;30, 2022 and 2021 respectively. There were 7,354,964 and 4,749,550 unvested employee options outstanding as of June&#160;30, 2022, and 2021, respectively. Total expense recognized related to the employee stock options for the three months ended June&#160;30, 2022 and 2021 was $1.5 million and $1.2 million, respectively. Total expense recognized related to the employee stock options for the six months ended June&#160;30, 2022 and 2021 was $2.6 million and $2.4 million, respectively. Total unrecognized compensation expense related to employee stock options was $14.3 million as of June&#160;30, 2022. During the three and six months ended June&#160;30, 2022 and 2021, the Company did not recognize any expense for employee performance-based option awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense was recognized in operating expense as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">387,384&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">430,638&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">782,876&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">888,673&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,332,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">826,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2,262,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,688,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,257,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2,577,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,003,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,520,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,577,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of employee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">86.13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">81.72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">5.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.04</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">3.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of nonemployee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">80.43&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">80.43&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the number of options outstanding and the weighted average exercise price:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,776,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,296,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,605,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,451,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,965,719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At June&#160;30, 2022 there was approximately $15.4 million of unamortized share&#8211;based compensation expense related to employee and nonemployee grants, which is expected to be recognized over a remaining average vesting period of 2.53 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622701248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of June&#160;30, 2022, the Company was in a pre-tax loss position, and is anticipated to remain so throughout the year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022, the Company did not record a tax provision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of June&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622791712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">H. Lundbeck A/S License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 26, 2015, the Company entered into an exclusive agreement with H. Lundbeck A/S (&#8220;Lundbeck&#8221;) for a worldwide perpetual licensing right related to the research, development and commercialization of OV101 (gaboxadol). On May 10, 2019, the parties amended the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the Lundbeck license agreement, as of the first amendment, the Company agreed to make milestone payments totaling up to $189.0 million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $1.0 million is due upon the successful completion of the first Phase 3 trial for a product in which OV101 is an active ingredient. In addition, the agreement calls for the Company to pay royalties for an initial term based on a low double-digit percentage of sales and provides for the reduction of royalties in certain limited circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter, the Company closed its OV101 program in Angelman syndrome in early 2021. On February 1, 2022, the Company entered into Amendment No. 3 to the Lundbeck agreement, or Amendment No. 3, to permit its performance under the Healx License and Option Agreement. Under the terms of Amendment No. 3, if Healx exercises its option, the Company will owe Lundbeck a share of all milestone and royalty payments received from Healx if the Company chooses not to exercise the Ovid Opt-In Right. If the Company chooses to exercise the Ovid Opt-In Right and to co-develop and co-commercialize the program with Healx, the Company will owe a share of the net profit share to Lundbeck (see further discussion below in Note 11, Healx License and Option Agreement).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Northwestern University License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.  The Company is developing OV329 under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3&#160;million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets. The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#8217;s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company&#8217;s uncured material breach or insolvency.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca AB License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 30, 2021, the Company entered into an exclusive license agreement with AstraZeneca AB, for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $5.0 million and issued shares of the Company's common stock in an amount that equaled $7.3 million based on the volume-weighted average price of shares of the Company's common stock for the 30 business days immediately preceding the execution date of the transaction. Since the intangibles acquired in the AstraZeneca license agreement do not have an alternative future use, all costs incurred were treated as research and development expense. The Company recorded a total of $12.3 million as research and development expense related to this agreement during December 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $203.0 million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $3.0 million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, none of these contingent payments were considered probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of their respective employment agreements, certain of our executive officers are eligible to receive severance payments and benefits upon a termination without &#8220;cause&#8221; or due to &#8220;permanent disability,&#8221; or upon &#8220;resignation for good reason,&#8221; contingent upon the executive officer&#8217;s delivery to the Company of a satisfactory release of claims, and subject to the executive officer&#8217;s compliance with non-competition and non-solicitation restrictive covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622679424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration And License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Angelini Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 9, 2020, the Company entered into the Angelini License Agreement, pursuant to which the Company granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABAA receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey (the &#8220;European Territory&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 29, 2021, the Company received a notice of termination of the Angelini License Agreement. Subsequently, Angelini and the Company mutually agreed to waive the six month termination notice provisions and the Angelini License Agreement terminated effective March 31, 2021. The Company has been released from its performance obligations and will not be entitled to any future milestone payments under the Angelini License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluated the Angelini License Agreement to determine whether it was a collaborative arrangement for purposes of ASC 808. The Company concluded that because Angelini was not the ultimate decision maker or the legal owner of the license, Angelini was not considered an active participant and therefore the Angelini License Agreement was outside of the scope of ASC 808. The Company concluded that Angelini was a customer with regard to the combined license and research and development activities and as such the Angelini License Agreement should be evaluated under ASC 606.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company identified the following material promises under the Angelini License Agreement: (1) licensing of intellectual property with respect to OV101; (2) completion of certain ongoing trials; (3) transfer of a specified amount of compound and related information; (4) potential for funding 35% of the cost for Angelini future trials limited to $7.0 million; and (5) completion of the manufacturing process technology transfer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determined that the $7.0 million represented a potential payment to a customer and was deferred. The transfer of compound and related information was considered a contingent milestone payment that will be recognized upon acceptance by Angelini of the milestone. The Company further determined that the license and the completion of ongoing trials were distinct from each other, as each had value without the other. As such, for the purposes of ASC 606, the Company determined that these two material promises, represented distinct performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the Angelini License Agreement and during the year ended December 31, 2020, Angelini made an upfront payment to the Company of $20.0 million. Upon the transfer of the specified amount of compound and related information and acceptance by Angelini, Angelini paid the Company an additional $5.0 million. This payment was determined to be variable consideration which was constrained and not considered part of the upfront transaction price allocation. The Company determined the transaction price was equal to the upfront fee of $20.0 million. The transaction price was allocated based on the standalone selling price of the license and the ongoing trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, no revenue was recognized pursuant to the Angelini License Agreement. During the six months ended June 30, 2021 and effective upon termination of the Angelini License Agreement, the Company recognized $12.4 million of revenue consisting of $5.4 million of license revenue related to ongoing trials and the $7.0 million related to the potential 35% funding of the cost for Angelini future trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 6, 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company entered into the Takeda License and Termination Agreement, pursuant to which Takeda secured rights to the Company&#8217;s 50% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company&#8217;s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Takeda License and Termination Agreement, all rights in soticlestat were owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including milestone payments or any future development and commercialization costs. On March 29, 2021 upon the closing of the Takeda License and Termination Agreement, the Company received an upfront payment of $196.0 million and, if soticlestat is successfully developed, will be eligible to receive up to an additional $660.0 million upon Takeda achieving developmental, regulatory and sales milestones. In addition, the Company will be entitled to receive tiered royalties beginning in the low double-digits, and up to 20% on sales of soticlestat if regulatory approval is achieved. Royalties will be payable on a country-by-country and product-by-product basis for any indications that soticlestat is approved for and sold during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company identified the following material promises under the Takeda License and Termination Agreement: (1) no later than the second business day prior to the closing of the Takeda License and Termination Agreement (the &#8220;Closing Date&#8221;), the Company and Takeda were required to agree on an estimate of the development expenses that accrued, or would accrue, under the original collaboration agreement as of March 31, 2021; (2) on the Closing Date, the Company was required to (i) provide and transfer to Takeda the materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the Takeda License and Termination Agreement, (ii) assign to Takeda certain agreements applicable to the soticlestat program, and (iii) assign to Takeda all of its right, title and interest in, to and under all intellectual property rights developed or created pursuant to the original collaboration agreement and owned jointly by the Company and Takeda as of the Closing Date; (3) within 45 days after March 31, 2021, the Company and Takeda were required to provide a written report to the finance officer designated by the other party setting forth a final total of the development expenses that accrued as of March 31, 2021 and, within 10 business days after receipt of such report, the finance officers shall agree on whether a net settlement payment is due from Takeda to the Company or from the Company to Takeda; and (4) within 75 days after the Closing Date, to the extent not provided on the Closing Date, Ovid shall provide to Takeda (i) any materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the Takeda License and Termination Agreement, (ii) other documents (including all expired agreements and related data developed thereunder) to the extent relating to the soticlestat program that are necessary for the exploitation, development, commercialization and manufacture of soticlestat, as further set forth in the Takeda License and Termination Agreement and (iii) any tangible embodiments of the intellectual property rights controlled by Ovid that are reasonably necessary for, used in or held for use in Takeda&#8217;s exploitation of the soticlestat program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determined the transaction price is equal to the upfront fee of $196.0 million and is associated with all four performance obligations identified above. It is noted that the incremental effort associated with performance obligations three and four is negligible and not material in the context of the Takeda License and Termination Agreement since all of the information is related to the collaboration period for which the Company already has the information readily available. Therefore, since they are not material in the context of the Takeda License and Termination Agreement, the full upfront fee was allocated to the two performance obligations satisfied at closing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, no expense was recognized pursuant to the Takeda License and Termination Agreement. During the six months ended June&#160;30, 2021, the Company recognized a credit in research and development expenses of $2.6 million and recognized $0.1 million in general and administrative expenses representing costs which were reimbursed to the Company from Takeda. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Healx License and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 1, 2022, the Company entered into the Healx License and Option Agreement. Under the terms of the Healx License and Option Agreement, Healx has secured a one-year option to investigate gaboxadol (OV101) as part of a potential combination therapy for Fragile X syndrome in a Phase 2A clinical trial, as well as a treatment for other indications, for an upfront payment of $0.5 million, and fees to support prosecution and maintenance of our relevant intellectual property rights. At the end of the one-year option period, Healx has the option to secure rights to an exclusive license under our relevant intellectual property rights, in exchange for an additional payment of $2.0 million, development and commercial milestone payments, and low to mid-tier double digit royalties. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Healx will assume all responsibility for, and costs of, both development and commercialization of gaboxadol following the exercise of the option. The Company will retain the option to co-develop and co-commercialize the program with Healx, or the Ovid Opt-In Right, at the end of a positive readout of clinical phase 2B and would share net profits and losses in lieu of the milestones and royalty payments. If the Ovid-Opt-In Right were exercised, the Company would be required to pay Healx 50% of development costs. The Company does not plan to conduct further trials of gaboxadol. The term of the Healx License and Option Agreement will continue until the later of (a) the expiration of all relevant royalty terms, or in the event that Healx does not exercise its option during the option period defined in the Healx License and Option Agreement, or the Option Period, the expiration of such period, or (b) in the event that Healx does exercise its option during the Option Period, and the Company does not exercise the Ovid Opt-In Right during the period of time we have to opt-in, or the Opt-In Period, or the opt-in terms are otherwise terminated, upon the expiration of all payment obligations, or (c) in the event that Healx does exercise the Option during the Option Period, and the Company does exercise the Ovid Opt-In Right during the Opt-In Period, such time as neither Healx nor Ovid is continuing to exploit the gaboxadol. As part of the revised contractual obligations with Lundbeck, Ovid will owe Lundbeck a share of all milestone and royalty payments received from Healx, if we do not </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">exercise the Ovid Opt-In Right. If we do exercise the Ovid Opt-In Right to co-develop and co-commercialize the program with Healx, we will owe a share of the net profit share to Lundbeck.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No revenue was recognized relating to this agreement during the three months ended June&#160;30, 2022. During the six months ended June&#160;30, 2022, the Company recorded revenue of $0.5 million associated with the Healx License and Option Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Marinus Pharmaceuticals Out-License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 1, 2022, the Company entered into an exclusive patent license agreement with Marinus, or the Marinus License Agreement. Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consist of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory which was received on March 18, 2022, Marinus issued, at the Company's option, 123,255 shares of Marinus common stock, par value $0.001 per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single digits on net sales of each such licensed product sold.</span></div>The Company recorded revenue and an associated investment in equity securities of approximately $0.9 million related to the patent license agreement on March 18, 2022, based on the price of Marinus common stock on March&#160;1, 2022. The Company had an unrealized loss on the Marinus common stock of $0.6&#160;million and $0.3 million for the three and six months ended June&#160;30, 2022, which was recorded as an unrealized loss on equity securities and is reflected in other (expense) income, net in the condensed consolidated statements of operation<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622673264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">RELATED PARTY TRANSACTIONSIn March 2021, the Company entered into the Takeda License and Termination Agreement with Takeda. For a description of the Takeda License and Termination Agreement, see Note 11.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619609216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">NET (LOSS) INCOME PER SHARE<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding outstanding stock options that have not yet vested. Diluted net income per share is calculated based upon the weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares outstanding during the period resulting from the assumed exercise of outstanding stock options determined under the treasury stock method and the assumed conversion of preferred stock into common shares determined using the if-converted method. Diluted net loss per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The basic and diluted net (loss) income per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For any period in which the Company records net income, undistributed earnings allocated to the participating securities are subtracted from net income in determining net income attributable to common stockholders. The undistributed earnings have been allocated based on the participation rights of preferred stock and common shares as if the earnings for the year have been distributed. For periods in which the Company recognizes a net loss, undistributed losses are allocated only to common shares as the participating securities do not contractually participate in the Company&#8217;s losses. Basic net (loss) income per share is computed by dividing the net (loss) income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Participating securities are excluded from basic weighted-average common shares outstanding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,218,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,824,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,394,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,394,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in computing net income (loss) per share - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,818,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,953,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in computing net income (loss) per share - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,818,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,565,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,451,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,352,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,103,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,435,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable upon conversion of Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619664640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock', window );">Unaudited Interim Condensed Consolidated Financial Statements</a></td>
<td class="text">Unaudited Interim Condensed Consolidated Financial StatementsThe interim condensed consolidated balance sheet at June&#160;30, 2022, the condensed consolidated statements of operations, comprehensive (loss) income, cash flows, and stockholders&#8217; equity for the three and six months ended June&#160;30, 2022 and 2021 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2022 and 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2021 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">Basis of Presentation and ConsolidationThe accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesMarketable securities consists of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive loss in stockholder's equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashThe Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Long-Term Equity Investments</a></td>
<td class="text">Long-Term Equity Investments<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term equity investments consist of an equity investment in a private company through preferred shares, which are not considered in-substance common stock, that is accounted for at cost, with adjustments for observable changes in prices or impairments, and is classified within long-term equity investments on our consolidated balance sheets with adjustments recognized in other (expense) income, net on our consolidated statements of operations. The Company has determined that the equity investment does not have a readily determinable fair value and elected the measurement alternative. Therefore, the equity investment&#8217;s carrying amount will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investment is impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investee securities, and other publicly available data. If the investment is impaired, the Company writes it down to its estimated fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the equity investment had a carrying value of $1.6 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. ("Marinus") that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2022, the equity investment in Marinus had a carrying value of approximately $0.6 million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Note Receivable</a></td>
<td class="text">Note Receivable<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March&#160;17, 2022, the Company issued a convertible promissory note to a related party, in which the Company has a long-term equity investment, with a principal amount of $1.0 million. The note has certain features that may allow the Company to acquire additional equity or to settle in cash. Either option would result in the Company receiving an amount at least equal to the outstanding principal balance plus accrued and unpaid interest. The Company will receive interest on the convertible promissory note at the rate of 1.5% per annum payable upon conversion or maturity of the note on March 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has elected to measure the note using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivatives due to changes in the fair value will be reflected in other income (expense), net, in the Company's consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial InstrumentsFinancial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling approximately $55.6 million as of June&#160;30, 2022. The Company's Level 1 assets consisted of money market funds and short-term investments of $187.6 million as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills totaling approximately $94.5 million as of June&#160;30, 2022. The Company had no Level 2 assets or liabilities as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company's Level 3 assets consists of the convertible note receivable totaling $1.0 million as of June&#160;30, 2022. There were no Level 3 assets or liabilities as of December&#160;31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use ("ROU") assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period. The Company determined that there was no current lease liability for the period ended June&#160;30, 2022, which is due primarily to the free rental period for the Company's Hudson Commons lease.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">Net (Loss) Income Per Share<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income, basic per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding. The Company applies the two-class method to allocate earnings between common stock and participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income, diluted per share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and preferred stock using the if-converted method.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss, diluted per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622786064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-Sale</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,860,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,860,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,951,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,951,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,644,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,554,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,455,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,365,795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,591,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,591,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,860,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,860,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,951,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,951,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,644,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,554,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,455,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,365,795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized<br/>cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrealized<br/>holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,591,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,591,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,797,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622679424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">287,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(347,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(262,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,243,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620079008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock', window );">Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ROU asset and lease liabilities related to the Company's operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">15,437,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Current lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Long-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">15,966,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Operating Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of operating lease cost for the six months ended June&#160;30, 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722,411&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Commitments Under the non-cancelable Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future minimum commitments under the non-cancelable operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,347,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,285,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset and lease liabilities operating lease table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622766432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and bonus accrual</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,925,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,764,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,795,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,564,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,598,843&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,671,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911623291264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense was recognized in operating expense as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">387,384&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">430,638&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">782,876&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">888,673&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,332,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">826,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2,262,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,688,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1,257,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2,577,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Allocation of Stock-based Compensation Expense by Plan</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,219,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,003,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,520,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,577,346&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Compute Fair Value of Employee Option Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of employee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">86.13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">81.72&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">5.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.04</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">3.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of nonemployee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%">Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">80.43&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">80.43&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">6.23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">1.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options Outstanding and Weighted Average Exercise Price</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the number of options outstanding and the weighted average exercise price:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,776,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,296,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,605,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,451,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,965,719&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.44&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622676288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160,218,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,824,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,394,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,788,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,394,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in computing net income (loss) per share - basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,818,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,953,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in computing net income (loss) per share - diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,818,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,565,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,451,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,352,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,103,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,435,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issuable upon conversion of Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619724752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">99 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="nump">$ 152,365,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,365,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,365,795<span></span>
</td>
<td class="nump">$ 187,797,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445,366<span></span>
</td>
<td class="nump">$ 208,382,779<span></span>
</td>
<td class="nump">222,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(202,053,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,053,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,053,983)<span></span>
</td>
<td class="num">$ (171,357,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_WorkingCapital', window );">Working capital</a></td>
<td class="nump">146,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,375,022)<span></span>
</td>
<td class="nump">141,482,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (16,108,056)<span></span>
</td>
<td class="num">$ (15,788,427)<span></span>
</td>
<td class="nump">$ 176,007,307<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="nump">$ 160,218,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911615935056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">$ 2,228,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,631,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ovid_PromissoryNotesMember', window );">Promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Rate of interest received on convertible promissory note</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ovid_MarinusTherapeuticsIncMember', window );">Marinus Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">55,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds and Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | US Treasury Bill Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">94,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ConvertibleNoteReceivable', window );">Convertible note receivable</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ConvertibleNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible note receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ConvertibleNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ovid_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ovid_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_MarinusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_MarinusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620142080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">$ 72,811,755<span></span>
</td>
<td class="nump">$ 187,797,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized cost</a></td>
<td class="nump">79,644,167<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(90,127)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, Fair value</a></td>
<td class="nump">79,554,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost', window );">Amortized cost</a></td>
<td class="nump">152,455,922<span></span>
</td>
<td class="nump">187,797,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Fair value</a></td>
<td class="nump">152,365,795<span></span>
</td>
<td class="nump">187,797,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">2,860,631<span></span>
</td>
<td class="nump">205,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair value</a></td>
<td class="nump">2,860,631<span></span>
</td>
<td class="nump">205,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, Amortized cost</a></td>
<td class="nump">69,951,125<span></span>
</td>
<td class="nump">187,591,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair value</a></td>
<td class="nump">$ 69,951,125<span></span>
</td>
<td class="nump">$ 187,591,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911622670160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail) - Investment<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in an unrealized loss position for more than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911617091536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">$ (347,678)<span></span>
</td>
<td class="num">$ (262,208)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">1,243,128<span></span>
</td>
<td class="nump">242,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,303,094<span></span>
</td>
<td class="nump">504,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 287,712<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620211328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 54,631<span></span>
</td>
<td class="nump">$ 17,834<span></span>
</td>
<td class="nump">$ 85,470<span></span>
</td>
<td class="nump">$ 36,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">328,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 32,153<span></span>
</td>
<td class="nump">$ 35,381<span></span>
</td>
<td class="nump">$ 86,636<span></span>
</td>
<td class="nump">$ 91,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619790576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 10, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Land subject to ground leases (sqft) | ft&#178;</a></td>
<td class="nump">19,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod', window );">Rent payments commencement following this period</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LesseeOperatingLeaseFreeRentPeriod', window );">Free rent period</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,930,753<span></span>
</td>
<td class="nump">$ 1,930,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LeaseIncrementalBorrowingRate', window );">Lease incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease incremental borrowing rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LesseeOperatingLeaseFreeRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Free Rent Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LesseeOperatingLeaseFreeRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Payments Commencement Following This Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911714569504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">$ 15,437,584<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">$ 15,966,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619659456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Operating Lease Cost (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 722,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911617125872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Commitments Under Under the non-cancelable Operating Lease (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,672,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">12,347,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease, liability, to be paid</a></td>
<td class="nump">$ 23,285,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620779504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and bonus accrual</a></td>
<td class="nump">$ 2,925,196<span></span>
</td>
<td class="nump">$ 3,764,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AccruedResearchAndDevelopment', window );">Research and development accrual</a></td>
<td class="nump">771,066<span></span>
</td>
<td class="nump">1,795,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees accrual</a></td>
<td class="nump">396,563<span></span>
</td>
<td class="nump">1,564,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeTaxAccrualCurrent', window );">Accrued taxes</a></td>
<td class="nump">222,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">283,482<span></span>
</td>
<td class="nump">546,464<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,598,843<span></span>
</td>
<td class="nump">$ 7,671,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_IncomeTaxAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax accrual, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_IncomeTaxAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911617527920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Preferred Stock - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">46,121<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember', window );">ATM Agreement | Cowen And Company, LLC | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember', window );">ATM Agreement | Maximum | Cowen And Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AggregateOfferingPriceOfCommonStock', window );">Net proceeds from offering, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PreferredStockShareDesignated', window );">Preferred stock, share designated (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each share of convertible preferred stock that is converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates', window );">Maximum allowable owning percentage of outstanding common stock by associates or affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders', window );">Maximum allowable voting right percentage of outstanding common stock holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates', window );">Allowable voting right percentage of outstanding common stock holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod', window );">Allowable voting right percentage of outstanding common stock holders upon notice of days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock', window );">Beneficial ownership limitations, percentage of issued and outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock', window );">Beneficial ownership limitations, percentage of issued and outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum allowable owning percentage of outstanding common stock by associates or affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum allowable voting right percentage of outstanding common stock holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911621146080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,720,217<span></span>
</td>
<td class="nump">$ 1,257,345<span></span>
</td>
<td class="nump">$ 3,045,029<span></span>
</td>
<td class="nump">$ 2,577,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,296,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Option Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Performance based options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember', window );">Nonemployee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,337<span></span>
</td>
<td class="nump">$ 55,310<span></span>
</td>
<td class="nump">$ 355,107<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,834<span></span>
</td>
<td class="nump">191,875<span></span>
</td>
<td class="nump">130,834<span></span>
</td>
<td class="nump">191,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember', window );">Non-employee Performance Based Option Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,426,750<span></span>
</td>
<td class="nump">363,000<span></span>
</td>
<td class="nump">4,296,355<span></span>
</td>
<td class="nump">1,006,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354,964<span></span>
</td>
<td class="nump">4,749,550<span></span>
</td>
<td class="nump">7,354,964<span></span>
</td>
<td class="nump">4,749,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember', window );">Employee Performance Based Option Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,052,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,052,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance under the plan</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,287,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of company's common stock reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,706,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,706,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, graded vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share based compensation, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance under the plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of company's common stock reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Share based compensation, percentage of discount from market price on purchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share based compensation, number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,583<span></span>
</td>
<td class="nump">34,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,176<span></span>
</td>
<td class="nump">$ 37,849<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 56,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease', window );">Percentage increase, outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum', window );">Common stock, reserved for future issuance increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620178240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">$ 1,720,217<span></span>
</td>
<td class="nump">$ 1,257,345<span></span>
</td>
<td class="nump">$ 3,045,029<span></span>
</td>
<td class="nump">$ 2,577,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">387,384<span></span>
</td>
<td class="nump">430,638<span></span>
</td>
<td class="nump">782,876<span></span>
</td>
<td class="nump">888,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">$ 1,332,833<span></span>
</td>
<td class="nump">$ 826,707<span></span>
</td>
<td class="nump">$ 2,262,153<span></span>
</td>
<td class="nump">$ 1,688,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620463824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 1,720,217<span></span>
</td>
<td class="nump">$ 1,257,345<span></span>
</td>
<td class="nump">$ 3,045,029<span></span>
</td>
<td class="nump">$ 2,577,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_StockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">1,700,041<span></span>
</td>
<td class="nump">1,219,496<span></span>
</td>
<td class="nump">3,003,834<span></span>
</td>
<td class="nump">2,520,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 20,176<span></span>
</td>
<td class="nump">$ 37,849<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="nump">$ 56,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911615864672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">87.20%<span></span>
</td>
<td class="nump">86.13%<span></span>
</td>
<td class="nump">87.20%<span></span>
</td>
<td class="nump">81.72%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">5 years 10 months 28 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.78%<span></span>
</td>
<td class="nump">0.99%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
<td class="nump">0.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">80.43%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">80.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.03%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 2.49<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 2.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911615836832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">10,776,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">4,296,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(15,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(1,605,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">13,451,517<span></span>
</td>
<td class="nump">10,776,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable, ending balance | shares</a></td>
<td class="nump">5,965,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">5.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="nump">$ 4.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years, Options outstanding</a></td>
<td class="text">7 years 6 months 10 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife', window );">Weighted Average Remaining Contractual Life in Years, Granted</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life in Years, Vested and exercisable</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 329,651<span></span>
</td>
<td class="nump">$ 2,389,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable | $</a></td>
<td class="nump">$ 297,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment award options granted contractual life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911623188000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,473,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,973,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911621259584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 26, 2015 </div>
<div>USD ($) </div>
<div>Trial</div>
</th>
<th class="th">
<div>Dec. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementMilestonePayments', window );">License agreement milestone payments</a></td>
<td class="nump">$ 203,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,046,670<span></span>
</td>
<td class="nump">$ 7,683,668<span></span>
</td>
<td class="nump">$ 13,878,939<span></span>
</td>
<td class="nump">$ 23,932,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember', window );">Lundbeck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase', window );">First payment due upon completion of first phase</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember', window );">Lundbeck | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase', window );">First payment due upon completion of first phase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_NumberOfTrial', window );">Number of trial | Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember', window );">Lundbeck | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementMilestonePayments', window );">License agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember', window );">Northwestern University | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment', window );">Upfront non-creditable one-time license issuance fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AnnualLicenseMaintenanceFeePayable', window );">Annual license maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement', window );">Minimum number of product covered under license agreement | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember', window );">Northwestern University | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ConsiderationPayableForRightsGrant', window );">Consideration payable for rights grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_AstrazenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares) | shares</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate', window );">Days immediately preceding the execution date</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AnnualLicenseMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AnnualLicenseMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuance , Period Immediately Preceding Execution Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ConsiderationPayableForRightsGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration payable for rights grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ConsiderationPayableForRightsGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First payment due upon completion of first phase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_FirstPaymentDueUponCompletionOfFirstPhase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global commercial and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of product covered under license agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_NumberOfTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_NumberOfTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront non-creditable one-time license issuance fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_HLundbeckASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911616680800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration And License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">99 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,445,366<span></span>
</td>
<td class="nump">$ 208,382,779<span></span>
</td>
<td class="nump">$ 222,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Agreement ownership share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpFrontFeeAmount', window );">Up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpfrontPaymentReceivable', window );">Upfront payment under royalty and termination agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AgreementMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ResearchAndDevelopmentExpenseReimbursementReceived', window );">Research and development expense reimbursement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_GeneralAndAdministrativeExpenseReimbursementReceived', window );">General and administrative expense reimbursement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AdditionalPaymentReceivableOnSalesPercentage', window );">Additional payment on sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_HealxLicenseAndOptionAgreementMember', window );">Healx License and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_DevelopmentAndCommercialMilestonePayments', window );">Development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_MarinusLicenseAgreementMember', window );">Marinus License Agreement | Marinus Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">123,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_PatentLicenseAgreementMember', window );">Patent License Agreement | Marinus Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember', window );">Angelini License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PotentialFundingCostPercent', window );">Potential funding cost percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_CostOfAgreementNet', window );">Future cost of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_DeferredUpfrontPaymentCosts', window );">Deferred upfront payment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseRevenue', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AmountForPotentialFutureTrials', window );">Amount for potential future trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember', window );">Angelini License Agreement | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementUpfrontPayment', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AdditionalUpFrontFeeAmount', window );">Additional up front fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpFrontFeeAmount', window );">Up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AdditionalPaymentReceivableOnSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment receivable on sales percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AdditionalPaymentReceivableOnSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AdditionalUpFrontFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdditionalUpFrontFeeAmount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AdditionalUpFrontFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AmountForPotentialFutureTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for potential future trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AmountForPotentialFutureTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CostOfAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of agreement net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CostOfAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DeferredUpfrontPaymentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred upfront payment costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DeferredUpfrontPaymentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DevelopmentAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DevelopmentAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_GeneralAndAdministrativeExpenseReimbursementReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and administrative expense reimbursement received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_GeneralAndAdministrativeExpenseReimbursementReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PotentialFundingCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential funding cost percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PotentialFundingCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ResearchAndDevelopmentExpenseReimbursementReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense reimbursement received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ResearchAndDevelopmentExpenseReimbursementReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpFrontFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front fee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpFrontFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up front Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_HealxLicenseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_HealxLicenseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_MarinusLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_MarinusLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_MarinusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_MarinusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911620118640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (16,108,056)<span></span>
</td>
<td class="num">$ (15,788,427)<span></span>
</td>
<td class="nump">$ 176,007,307<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="nump">$ 160,218,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income attributable to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,824,587)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">(14,588,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,788,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,696,470)<span></span>
</td>
<td class="nump">155,394,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income attributable to common stockholders</a></td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,788,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
<td class="nump">$ 155,394,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding used in computing net income (loss) per share - basic (in shares)</a></td>
<td class="nump">70,391,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,818,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
<td class="nump">66,953,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in computing net income (loss) per share - diluted (in shares)</a></td>
<td class="nump">70,391,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,818,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
<td class="nump">67,565,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139911619766592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">13,451,517<span></span>
</td>
<td class="nump">10,352,559<span></span>
</td>
<td class="nump">13,103,587<span></span>
</td>
<td class="nump">10,435,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Common stock issuable upon conversion of Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ovid_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ovid_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>ovid-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ovid="http://www.ovidrx.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ovid-20220630.xsd" xlink:type="simple"/>
    <context id="i416200c53b644f6288c0fb09b2680206_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if943073443f547b19aee7c55893e79e2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iadc605709f3a40779864f2d39fb359e4_I20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="i5514b03ea99548678298804a7de4efdb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id6a06c63bc824ec19efb5af5e13b7f53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18f3cae6721f43a693142c5e9c86f229_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7cef6b081bc54d82a49f3c118a7c65e8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i49f78e6e5ddd4d44a2471e1fd844f7b4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8e89cb3e1f0040f7be63e6cd7f47cf4d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia05147c8a6f84aa7bae4e655d515586d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i430e4630f3014c55bfe38535a0b3c699_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i434929d63dcb494293b5e8e5efadb4c3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i99beb7807f764390a9af1caa039963dc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i941a78f2412c464899f42108f91b4f35_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ovid:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iad7480407a3f4c48928d4ccbe1dd5c10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02d307e57dbc40ff93c2b5995aeba167_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8760fd385cca4d73b7b31af558f982ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0310bbd84f804abea3269f6c899e1a78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fab542d4f974a00912a7939cf326eb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c62b7cade354d0388144a8b711b4722_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i31de4bccf32942219f29ef0e07207b80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4f72e97f2a064f1c90998ceed128f870_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2d18fe72233749f28cfd64f0d70907ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2bf2fd110a9a4c5ab75eea6d9c720226_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8260726b54e04ea1ad6d0ca24421b805_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if56157218fe549b2b3302bac54442c1b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic488d6492f0a4affa4b6e168bc0497a8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4e3e29443fb640e1ac31ec6b44140e14_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1269bd94e5ad48d198e0186fcb7d2e2b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f9abf6069224ad1b07f06bfe5e710f4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6554df655cdb468099698d2e5466ee5d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6e677a4abbe94743a6e30d84324ce7f7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6cfbc34d3a114e34912c01fb42a6e923_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0999ec79eeb14fdfb352298d2cb61f83_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2fb2c95532874480bb6ff7d1bfc14723_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0aab07b1f2e4699bfef8151c47b8a0d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i45904026876d4027b04a7d7c2108f617_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8366cf4b4e584ca1933dcff24730eee2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i799e74a1e807418187738a7890f11901_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i296138c6708441f693c8a9280889de40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i336ccea71ae9453b969559eea3a1e540_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0c0dfa04e4b4f4898016afa3ab78e19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i658dc49bdacc4997a02fdffb11586100_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i10c476d2dc2b4b06b06ce5c44e0b513d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaab306a7297d4fb1a87a32f3962e910b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0dd60c60db2c42138469dff255b2cb5c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0a6c40a93ca044369ee51636d6e0cec8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ica40e02a37a64756b88e97b575b776e7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i835c3a4e2d324395a70abe30b2d458bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae07d73b4dae4632a39cea16a19f66e1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie44748b4c9e84136a2dba9fcf256ff76_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i37d44e580ba3462ca1cde50a64e4926c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae5c89ad10f2477f8220874a9b49e705_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d00e69252de424aaf5e53c938c8b70d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i54ef3d8eca944ac4bf14a1496778579c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i681a4f60e7b446d18f13235cf1ab4515_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i77147210c23641b5a8af1144e5fa6e04_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1104e8485b1942128c40c3a1a39b0b69_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9c7ddc6b88a248569b3b27c0b1e3efde_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0e0fee23ec5d486db1a16b33b9f1ad15_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icdb5c5087a7345cea587ac586d74b78e_D20140401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2014-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idd69d41d3fa3410981127bf2969db96f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a67b91f0f784fb39b30c84c6e1e1667_I20220317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ovid:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-17</instant>
        </period>
    </context>
    <context id="i9a543a156421421492ae9ac7e6fdd405_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ovid:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c1e78e1146d41af95d207583e74eb8f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibf80654a79be4240b9b2f9216351b6d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23d5fb933c1c4101afc9b43949132d1c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id062c33120f64e1e86eb963d29a355d4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i09fdc4f878d749a2a0c510248458b0c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70b464c3358e49f08d0e076378fff060_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if91752729f23489a9a1fdf7618bd851d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a5cc0fd641241a9a8645ff092db348c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0daa1be00e7421584b963e7641737bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifa62a7ee26a34283b02d9a020bb48d54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i240d93a2ab414f6d8279a85350aa8834_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i247b2b8238374cad8df96951a6bae08d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7f82c24689c54b7687abc86742065cc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fce33f178a14e88b1785363753aaa5b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i87adc2ffe0ba416eb4da45a8b61856c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57c6dc3481c441408bca8588e4b4cd13_I20220310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="i8a54288182e24aa280eacf76b58680fb_D20220310-20220310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="i1c97d8b7325e4ee5bfb436d1850897fe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i396fded5753344dc9202659aa58b987f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="id1edfe140f8c433fb25ab41d64b939f4_D20201101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25bcc14f90fb4eaba2e1ef18f0fd5335_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide285b55b9334ea5a3d4633e081e2e8b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i99e9dab21e48412995440424c42b8768_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1f1a12100aba4eaaba8e5398cb22d594_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52d16d0decba4c0cb030da72a9ea1c58_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3508026e6a624653b3042497a2e56b5b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i02cc5fc3748f41a18d30fe59dd7c68f5_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i8940c1997dcf4466957a1a618e9364e2_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie10101268c9545129eb922032bed501f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i81fd80cb6bb741a59d284cc88e7d599f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i470e73798de645539193ae88dadc6e89_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i86715d6c5277421e8cfe925f1cecc804_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i475e7bce27984b60afa0fcb779a15e53_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i3f12ff0a9fb44b2ba76ca118062f6098_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ccabdb8d53a43e0970777c2bff04d2a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i056926527a084313881277f409aada39_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29fa1f2702714d129b63abc66f393ba1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2e7d9406a7aa47ee9442314d3d15d65a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia0ba85194e42413b99a2652ace7aedca_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i572f2349b435422a9a724121d8d55ebb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec14aa7f907a4e77ac1af5c41c07ec9c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b9c90a69fca438fbe1136fe21266e47_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i107d1ca201584d23b2e52b6528cee3b9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe25102eb24f4ad2918ef4f8234f9dd9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i745854a2110948c8b69f1d073bd78059_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i492b94210b3a4b7d86d6b2934d8249c4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i726e5f3ab7a2403e8a39b4c4299b8f03_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i968b13093ea749a08c539d52bb627da8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id8a49b7682c84becb2480ace83af36da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id64ce862122d47ecbb9d8f2a54bceb89_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic5d6c1d737bc4c51950da33e52888f55_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc43365824f445169eaac324f106070c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie3cb23b2f75c46c28a56b7a45b2e8df4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i215fc869cefa46228a13075881587aa5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iec95a18524b84f6cba11d8e830382e5e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4297c63d08874f919d86d5021b5f608e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1d0ce81ed9f94da3af27fc09016adade_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibc2df3425269455d899f773df3cd67d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3f367baf510f4fcaa8c3b3609d892ab8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53e4fcf781a84fabbc66e00870f256e2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5c156f7edfc44816bd94d9a3facde46d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i58c5083745084ba09e6a766ccd66cc65_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06df7810437744ac89df59b3071c4620_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5eb55df39f645e1a8229022112b64af_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4a447e8d29e345cca3c8dc8bedfbe959_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5a1bdd56609e4b82a082d20e67eb1ef3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i99f5712bd10f4cb4b4c1c3047f7e03c4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i15dbdd9413234e60876544ae84047d70_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idda6566951b0490fb0253c079cb5f522_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i67836ea5c7334cdca1bd28a16693be9e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic0fd76e8bb5349d9ab296f99828590c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i900ec607f0a344bbbf9a2c6f28d71d29_I20150326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-26</instant>
        </period>
    </context>
    <context id="i89857dab9c4747b59247c78b1c721361_D20150326-20150326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-26</startDate>
            <endDate>2015-03-26</endDate>
        </period>
    </context>
    <context id="ia2be4bda75f94fdd83408349ef2a84a4_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i13f4bf2cb6d44b7f9ec70416be17a531_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ia0577fed13974cc79c32e75d6afbf552_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="iff1b6990a524490f93ea31b743af4557_D20211230-20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="icf2f99c556604fba8747dc92065c5ec1_I20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="i8e5e3642cc734de5ac47c8a5ccb0a666_D20211201-20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="id1d5cd62a7c1493a9fde980d2163424c_I20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="ib3e38e7a15e34cceafd124f84ef81706_D20211230-20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i417dd14e7c28468cbb32aa243f71b4ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97e6ce3a5011403898de05a7b8a7950e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5dc9854b22c4401944c1c3f1c81fa35_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if4975144823b4b6397ba0954f6522143_I20210329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="i76ece08d363143b3a4e48d1512b2d3f2_D20210329-20210329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="ie4c8f02f699a46e3be40c5246e96e602_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id97b2a2da582483fb06d8288d746a65f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibabba1d2cdfc4be9b9d2d6a75d6c5d4d_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="i3dff19c285cc484e915ef6c61e6e770a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9290ae797c984118825406206a94dc50_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i23af69e8e97e4050a2c0ce0556ad29df_I20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="i315b0e5db1654ee59132ac7839cdab6b_D20220301-20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:PatentLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="ib8717ce65ce149a596e214e8657b3b6c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i44bf255bfaca451db24cb2de86760946_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4bc5d022a300431fa15d4be1cb81e3e7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibd93d38c649e4bcf9dc0997d1f36eb7a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id20ea80f44894cb98636c41e3d77bcc1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff9fd4d2cf174503b125fdaeeb11c6fc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9467652c06534816ba1aa9bc3a888d71_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia03f0f7a1a3d450aad2a50ecf43a159f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i660cdfd473c24c05b53a1ce7e820084a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09793674d52f4223a7e62a26166fa5e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>ovid:Investment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>ovid:vote</measure>
    </unit>
    <unit id="trial">
        <measure>ovid:Trial</measure>
    </unit>
    <unit id="product">
        <measure>ovid:Product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF8yLTEtMS0xLTExMQ_85300148-d2f3-417c-85ce-d8b242900ab8">0001636651</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF8zLTEtMS0xLTExMQ_682efd7d-5101-4e74-a583-7a8b039bf0e8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF80LTEtMS0xLTExMQ_43205079-8815-4bc8-895f-52fc4730bd24">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF81LTEtMS0xLTExMQ_0a7bedd9-f182-43cb-91b9-c9399944c017">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80L2ZyYWc6ODAwMjM0ODk0ZDY5NDhlMDgxMWJlOTljNTczZjQ5NjcvdGFibGU6OGFkNjdmYjc2ZDg3NDM5ZTk3OWNlYWFlOTQ4YTRiZDAvdGFibGVyYW5nZTo4YWQ2N2ZiNzZkODc0MzllOTc5Y2VhYWU5NDhhNGJkMF82LTEtMS0xLTExMQ_1c9faf1d-f47d-4a74-a146-19bc6c40124c">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTA5_fe1322c2-9263-4d7e-a31e-523c7ad96266">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEw_54c76a59-75bf-436a-a91d-125f3c355cdf">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEx_144c7784-2879-4f28-90f6-3fc207f9037e">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE1_f5b38943-1ea3-427e-9a88-51d30aa86043">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE2_ff14f114-a10d-4705-a105-78b23c597dd3">001-38085</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE3_d7ee26b0-9c4c-4b16-9f4c-53627acb3032">Ovid Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6YTEzNjBiMWNmZGUwNGE0OTk0ZTJhNzJjYzgxYmE4MjAvdGFibGVyYW5nZTphMTM2MGIxY2ZkZTA0YTQ5OTRlMmE3MmNjODFiYTgyMF8wLTAtMS0xLTExMQ_8bc2f146-f8c8-4952-9a97-847e39d2fca3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6YTEzNjBiMWNmZGUwNGE0OTk0ZTJhNzJjYzgxYmE4MjAvdGFibGVyYW5nZTphMTM2MGIxY2ZkZTA0YTQ5OTRlMmE3MmNjODFiYTgyMF8wLTEtMS0xLTExMQ_dc9ab2cd-364f-48b8-8765-15dd836d2059">46-5270895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzU_928c48f0-5447-4a02-a669-8d197063d78c">441 Ninth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzk_aa6d3387-16c0-4805-8cdc-e0e8a8d7fef7">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzEy_9fb38cb9-8f6a-4596-8813-8a9fc2479177">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTAtMS0xLTExMS90ZXh0cmVnaW9uOjU4NWE2NmY1OGE5MzQzNzBiYzgxNjUxZGI0NzNkZWNjXzE2_8b18ea90-b6c7-4b5b-bafa-793d362671a5">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6ZGFiNWJmOGIyNjlhNGJkMmI3ODQ2ZTNmODkzYjI4YzgvdGFibGVyYW5nZTpkYWI1YmY4YjI2OWE0YmQyYjc4NDZlM2Y4OTNiMjhjOF8wLTEtMS0xLTExMQ_7beac0bc-729a-4b6f-b157-de83aa3bb160">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEy_c26157b1-3060-40bb-9fb2-e9c92f5c5eb1">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE4_9e5d9599-2ebd-4a4b-8de0-78cf67a4b7fd">661-7661</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5MA_cc08d34c-5ef5-4313-8f8b-d99be46e9df1">1460 Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5MQ_9abcddf1-55d3-43a3-a1b7-28be782877e8">Suite 15044</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5Mw_333c113b-09cb-40f7-ac6f-d5a382d81a06">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5NA_46c3419d-93f8-48fa-9445-96619ec9a220">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if943073443f547b19aee7c55893e79e2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xNDg0MzQwNjk3ODA5Ng_dbffdb8e-79ae-4555-8810-4166e473948b">10036</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2RmOWQ1ZjRiM2JlNGM3ZThkM2EyZDdkODVmYTVkOGQvdGFibGVyYW5nZTozZGY5ZDVmNGIzYmU0YzdlOGQzYTJkN2Q4NWZhNWQ4ZF8xLTAtMS0xLTExMQ_d79fadc0-f2d2-442e-8dc2-778e60b89f37">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2RmOWQ1ZjRiM2JlNGM3ZThkM2EyZDdkODVmYTVkOGQvdGFibGVyYW5nZTozZGY5ZDVmNGIzYmU0YzdlOGQzYTJkN2Q4NWZhNWQ4ZF8xLTItMS0xLTExMQ_3444305a-cdfe-4fd0-a7f1-c5bbe6de0e44">OVID</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2RmOWQ1ZjRiM2JlNGM3ZThkM2EyZDdkODVmYTVkOGQvdGFibGVyYW5nZTozZGY5ZDVmNGIzYmU0YzdlOGQzYTJkN2Q4NWZhNWQ4ZF8xLTQtMS0xLTExMQ_c736cad9-a44f-4f2d-981b-11d2ed94ac74">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTEz_11fa44da-138f-42b7-8e87-1e7ab67b40b6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE5_983f7486-4c04-4a3f-a4b9-dfce22f7eb1b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2YyNTRiZDI4Yjc0NDdiY2JkNDE2Mjk3Y2U4ZGRlZDYvdGFibGVyYW5nZTozZjI1NGJkMjhiNzQ0N2JjYmQ0MTYyOTdjZThkZGVkNl8wLTItMS0xLTExMQ_18a55283-a0cd-4e33-b186-584e371ac99f">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2YyNTRiZDI4Yjc0NDdiY2JkNDE2Mjk3Y2U4ZGRlZDYvdGFibGVyYW5nZTozZjI1NGJkMjhiNzQ0N2JjYmQ0MTYyOTdjZThkZGVkNl8xLTMtMS0xLTExMQ_e7c4aa5f-2766-4779-b152-ea7f691a6ed2">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGFibGU6M2YyNTRiZDI4Yjc0NDdiY2JkNDE2Mjk3Y2U4ZGRlZDYvdGFibGVyYW5nZTozZjI1NGJkMjhiNzQ0N2JjYmQ0MTYyOTdjZThkZGVkNl8yLTEtMS0xLTExMQ_22b5666c-240c-402b-9be4-d6789247ac6d">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTE0_020eac0e-b62a-45f7-b589-ee6636fe0539">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8yNTA3_f1fea708-612d-4d76-9080-30f0b0a59fcf">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iadc605709f3a40779864f2d39fb359e4_I20220805"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xL2ZyYWc6MjEwNWFjZmY5NTRmNGY4NGE2YmY3YzNkOTMzMTU3YTgvdGV4dHJlZ2lvbjoyMTA1YWNmZjk1NGY0Zjg0YTZiZjdjM2Q5MzMxNTdhOF8xMDk5NTExNjMwNDAw_c5107aa8-cd29-46ed-b03a-b538e173e624"
      unitRef="shares">70419388</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMy0xLTEtMS0xMTE_87c555f6-bb40-4999-a8ac-119da377a5aa"
      unitRef="usd">72811755</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMy0zLTEtMS0xMTE_48acf6ac-567f-4aa0-8ad4-2a2ce529a4fe"
      unitRef="usd">187797532</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0xLTEtMS0xNjQy_69f23b00-7938-4674-a030-8d69c9f08db9"
      unitRef="usd">79554040</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0zLTEtMS0xNjQy_a7959c37-ec16-4233-8146-213120cf4552"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0xLTEtMS0xMTE_101beafa-7dd7-4c12-87b5-18b98f489ea7"
      unitRef="usd">2715134</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNC0zLTEtMS0xMTE_29bdea08-6533-4078-99ee-1e23fc0b2bfc"
      unitRef="usd">2681597</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ovid:NoteReceivable
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNS0xLTEtMS0xMTE_5e8eeeeb-8df6-4f21-8bfa-8c745a96c43a"
      unitRef="usd">1000000</ovid:NoteReceivable>
    <ovid:NoteReceivable
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNS0zLTEtMS0xMTE_75c49c35-1943-4f1e-836e-9aa966859967"
      unitRef="usd">0</ovid:NoteReceivable>
    <us-gaap:AssetsCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNi0xLTEtMS0xMTE_5b868013-53ab-4188-928f-b650c6effcde"
      unitRef="usd">156080929</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfNi0zLTEtMS0xMTE_e98d1fe4-9505-4614-bf35-1600fa7c14c1"
      unitRef="usd">190479129</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOC0xLTEtMS0xMTE_660fec1a-6577-43f3-9e67-085476e21cfe"
      unitRef="usd">2228547</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOC0zLTEtMS0xMTE_0f80cdf2-0a9e-4e1d-8a2c-07e9cf33fe46"
      unitRef="usd">1631992</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCash
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOS0xLTEtMS0xMTE_e49b1407-df39-4de9-9cc6-acbf33d4fe41"
      unitRef="usd">1930753</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfOS0zLTEtMS0xMTE_9f919ad3-50fd-4aa9-b17a-848cfb9816dc"
      unitRef="usd">1930753</us-gaap:RestrictedCash>
    <us-gaap:SecurityDeposit
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTAtMS0xLTEtMTEx_aac00d23-f7b3-45a0-8bb3-c9d83f0ef85b"
      unitRef="usd">80114</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTAtMy0xLTEtMTEx_8002b799-76da-4971-b0b8-c09f5fbc11f1"
      unitRef="usd">96034</us-gaap:SecurityDeposit>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTEtMS0xLTEtMTEx_69c20a2f-fb08-49fd-98d0-c3ec3481c8ce"
      unitRef="usd">1243128</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTEtMy0xLTEtMTEx_6e050964-0166-49c9-9ae3-0474262fb470"
      unitRef="usd">242757</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTItMS0xLTEtMTEx_d4903505-4762-4110-bb81-4ad6713a7289"
      unitRef="usd">15437584</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTItMy0xLTEtMTEx_fef977b1-5aee-4c0d-8a8d-a9a183c7782e"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTMtMS0xLTEtMTEx_17182d7b-b8eb-4523-b6a9-ada053d101ff"
      unitRef="usd">328797</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTMtMy0xLTEtMTEx_0233c499-0b75-4874-9108-7744fbddd572"
      unitRef="usd">164092</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTQtMS0xLTEtMTEx_fe949c91-1edf-4959-90ad-bbaf5b439568"
      unitRef="usd">177329852</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTQtMy0xLTEtMTEx_1dea5095-9715-4664-933d-9a6412c62353"
      unitRef="usd">194544757</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTgtMS0xLTEtMTEx_1fb8093a-a529-4abf-9235-14c4ea01cb54"
      unitRef="usd">4616543</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTgtMy0xLTEtMTEx_e6ab12ca-6d8a-4891-8830-bf456ea14ecc"
      unitRef="usd">7127046</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTktMS0xLTEtMTEx_76c39983-f43b-4132-b626-3218db31b1f5"
      unitRef="usd">4598843</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMTktMy0xLTEtMTEx_59101324-8846-4798-a5f6-70558a175620"
      unitRef="usd">7671275</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjItMS0xLTEtMTEx_0d52e44e-805d-4b76-b164-5600bd7fdbcb"
      unitRef="usd">15966970</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjItMy0xLTEtMTEx_06d34859-bdfa-4fb9-8e01-bd00180ccef3"
      unitRef="usd">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:Liabilities
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjMtMS0xLTEtMTEx_62ea82b2-e070-4a09-a392-1e5b65155a4b"
      unitRef="usd">25182356</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjMtMy0xLTEtMTEx_78222bae-d81e-4a37-9f71-5193a1e989d5"
      unitRef="usd">14798321</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMjE_0638f470-6211-4824-98f2-1f0278e6bf03"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMjE_520f64c2-b36e-47bf-9288-54f2ba453067"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMzU_43614acc-23a7-4f65-a888-dcd8b45267c4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMzU_eafe2557-b9c0-447f-aeee-5000d4c3beb9"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <ovid:PreferredStockShareDesignated
      contextRef="i18f3cae6721f43a693142c5e9c86f229_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfOTU_7844a0b0-8d1e-454c-8a6a-2ea1c4c9a2f2"
      unitRef="shares">10000</ovid:PreferredStockShareDesignated>
    <ovid:PreferredStockShareDesignated
      contextRef="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfOTU_d99e6703-78d2-4532-9ef9-2b943e75cc2b"
      unitRef="shares">10000</ovid:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i18f3cae6721f43a693142c5e9c86f229_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_0c595a41-fc6e-49c5-bb31-384649e041fe"
      unitRef="shares">1250</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_365696f0-5b56-4d20-baf0-fcb978a8fc34"
      unitRef="shares">1250</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6e8f1074ec4740e28381a1ef9c5ad4d2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_707322ef-f049-4922-a25d-0a12545e1e29"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i18f3cae6721f43a693142c5e9c86f229_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMC0xLTEtMTExL3RleHRyZWdpb246NDU0MTczODEzY2YzNDg0ZDhhMTJmMjk2YzRlOGI3NmJfMTE3_dc221365-08ab-4612-8d76-baa94781a527"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMS0xLTEtMTEx_0002c631-e294-48ee-853b-4697ba74077e"
      unitRef="usd">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjUtMy0xLTEtMTEx_c0295b8d-aaf3-4452-87c1-ae829b559c85"
      unitRef="usd">1</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMTg_17c8700d-dd4a-4171-840d-335c57ac0ef0"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMTg_5e63e1a3-9b76-48b9-8b83-38fe63755689"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMzI_34e6564c-af3a-4f62-91c3-108a1f113c94"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfMzI_75673604-4203-43d3-845c-650e181c2de7"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNTQ_84248121-65fd-402a-9170-a5ed4545b0ce"
      unitRef="shares">70419388</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNTQ_eca2c63d-af3e-44dd-946c-7ffe8259d94f"
      unitRef="shares">70419388</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNjE_20502419-7f7b-4936-90ee-315216f5cc53"
      unitRef="shares">70364912</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMC0xLTEtMTExL3RleHRyZWdpb246MWRhZjVmMDc4NjhjNDgwZGFmY2Q4YzBhYWZkOGRkYmZfNjE_406e5899-82ad-4ad9-aa30-8e36aeb2b488"
      unitRef="shares">70364912</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMS0xLTEtMTEx_0760febd-a117-4465-935b-926e0e5f61b1"
      unitRef="usd">70414</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjYtMy0xLTEtMTEx_059c4edc-225a-441b-9916-b6aa53a540cf"
      unitRef="usd">70359</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjctMS0xLTEtMTEx_896d3171-c4d2-4185-a5b1-d45c95c320b3"
      unitRef="usd">354221191</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjctMy0xLTEtMTEx_56c0b46d-fee6-48de-a8b6-5e7673962355"
      unitRef="usd">351033589</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMS0xLTEtMzk0NQ_91e74268-b3a5-4ac6-8c8a-f63a0f3fda08"
      unitRef="usd">-90127</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMy0xLTEtMzk0NQ_347469bb-0b2b-4d4f-adc8-2a41151015ca"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjgtMS0xLTEtMTEx_4947edfa-6bce-453b-a502-143a9fa9b2dc"
      unitRef="usd">-202053983</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjgtMy0xLTEtMTEx_a87b7b0a-d13d-4a66-a46c-54715c244ca6"
      unitRef="usd">-171357513</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMS0xLTEtMTEx_80948faf-f971-49ba-9836-a54a9497ab75"
      unitRef="usd">152147496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMjktMy0xLTEtMTEx_f8cb17de-0a32-45fd-8852-c605c7e78db4"
      unitRef="usd">179746436</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMzAtMS0xLTEtMTEx_617d2326-b3a8-490b-99a8-23366783e9a1"
      unitRef="usd">177329852</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8xOS9mcmFnOmFhN2I4YTVlMGNmODQ0ZWViYjhjZWZkYjY1Y2NjM2ZkL3RhYmxlOmYyMmRlMzY4MGIzODRmOGM5NTMwMGY2NzdhOTA2MzZhL3RhYmxlcmFuZ2U6ZjIyZGUzNjgwYjM4NGY4Yzk1MzAwZjY3N2E5MDYzNmFfMzAtMy0xLTEtMTEx_a8875985-c036-47cc-8eb5-cfcbdbc5cec9"
      unitRef="usd">194544757</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7cef6b081bc54d82a49f3c118a7c65e8_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi0xLTEtMS0xMTE_e41949df-4884-4b49-9965-c307ae7dcaf9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i49f78e6e5ddd4d44a2471e1fd844f7b4_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi0zLTEtMS0xMTE_17b96734-01d3-4527-8926-500f28a86a5f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8e89cb3e1f0040f7be63e6cd7f47cf4d_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi01LTEtMS0xMTE_4ca141d9-7af8-4a97-98f9-71d806c3818c"
      unitRef="usd">1445366</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia05147c8a6f84aa7bae4e655d515586d_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMi03LTEtMS0xMTE_41dcf21d-7b28-440f-ac24-80e06ab83c73"
      unitRef="usd">12382779</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i430e4630f3014c55bfe38535a0b3c699_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy0xLTEtMS0xMTE_d9cb00f3-8201-41b7-9dea-2a1d4580d7f6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i434929d63dcb494293b5e8e5efadb4c3_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy0zLTEtMS0xMTE_72d56e33-7693-4012-9b73-a4ead10111fc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i99beb7807f764390a9af1caa039963dc_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy01LTEtMS0xMTE_5714d7bb-4977-4dec-934e-31d5c857d11c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i941a78f2412c464899f42108f91b4f35_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMy03LTEtMS0xMTE_1e06e154-bd44-42c7-8113-2dab878297b8"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC0xLTEtMS0xMTE_7f03e070-4a90-4e6a-bbc9-f600fbda0085"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC0zLTEtMS0xMTE_b155a5bf-db62-4a28-81f8-45b8c97fd534"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC01LTEtMS0xMTE_8b48fd08-99df-4f0b-bf66-400d438fa5d8"
      unitRef="usd">1445366</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNC03LTEtMS0xMTE_c3c85bd3-1b2d-4539-be89-795701083026"
      unitRef="usd">208382779</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi0xLTEtMS0xMTE_d6e0b5d9-a397-4063-9810-f5709403c2c2"
      unitRef="usd">6046670</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi0zLTEtMS0xMTE_801489bd-7f9d-47a9-a6c0-ff61fa5e0181"
      unitRef="usd">7683668</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi01LTEtMS0xMTE_533d5d87-52c5-4c25-9d8b-731851693fb6"
      unitRef="usd">13878939</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNi03LTEtMS0xMTE_b671709e-49ff-4275-ba45-171d00c145c0"
      unitRef="usd">23932581</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy0xLTEtMS0xMTE_b3713013-cbd0-40e6-be20-af8697b4b22a"
      unitRef="usd">8257617</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy0zLTEtMS0xMTE_3e6f1615-cfce-48c9-8d82-68b2d5a4ba0a"
      unitRef="usd">6629158</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy01LTEtMS0xMTE_6ad1e4a7-0b60-48c7-a68d-cdbee59bcf03"
      unitRef="usd">18137820</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfNy03LTEtMS0xMTE_cab36bc2-097e-4a77-aaf4-f60d3771e97e"
      unitRef="usd">22205707</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC0xLTEtMS0xMTE_a342cbde-66b3-4e02-974e-355ece99bbc0"
      unitRef="usd">14304287</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC0zLTEtMS0xMTE_1bb8a402-03b7-43bb-a304-3cffd4b9ec05"
      unitRef="usd">14312826</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC01LTEtMS0xMTE_a3e39ddf-a8b2-45d8-a56f-0ff50e1ed132"
      unitRef="usd">32016759</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOC03LTEtMS0xMTE_ddae19a5-2461-4d0a-ae97-22348de34b6e"
      unitRef="usd">46138288</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS0xLTEtMS0xMTE_0cda7fed-89db-4ea5-ab6d-5b14ac8626b9"
      unitRef="usd">-14304287</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS0zLTEtMS0xMTE_ce240060-aee2-4907-bd1f-c19a09eb3c51"
      unitRef="usd">-14312826</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS01LTEtMS0xMTE_786fccf4-461d-46db-ad81-edca72ce01b9"
      unitRef="usd">-30571393</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfOS03LTEtMS0xMTE_6099cd9f-c2bc-4a91-99e0-3e827a8ebbdd"
      unitRef="usd">162244491</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtMS0xLTEtMTEx_ba6b6d3c-306c-421a-971c-b5bc454d715d"
      unitRef="usd">-284127</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtMy0xLTEtMTEx_6a1b90e8-a0ab-4bd4-84c7-70632a1d77b9"
      unitRef="usd">-2517</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtNS0xLTEtMTEx_cd115bda-18a9-424b-a794-8eb6c830ddd2"
      unitRef="usd">-125076</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTAtNy0xLTEtMTEx_d4434581-3099-48f3-8afd-9e2779ab9892"
      unitRef="usd">-52250</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtMS0xLTEtMTEx_4d9ec2ea-f523-4167-9100-586e49b365d3"
      unitRef="usd">-14588414</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtMy0xLTEtMTEx_3ae31bc8-7b88-4a22-94e4-b324ee011ee1"
      unitRef="usd">-14315343</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtNS0xLTEtMTEx_ed2f311e-07a6-47df-9b91-6092064b962a"
      unitRef="usd">-30696470</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTEtNy0xLTEtMTEx_5154a025-9b42-4ff6-a15e-6918ca2caa1d"
      unitRef="usd">162192241</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItMS0xLTEtMTEx_55679012-4078-4c4c-8335-5eaae77bc8f5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItMy0xLTEtMTEx_f2f4ea58-30b2-4244-8ce9-c6cc7e39acae"
      unitRef="usd">1473084</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItNS0xLTEtMTEx_6b6daa51-b518-405c-8406-516355e4a555"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTItNy0xLTEtMTEx_72245c6f-a371-48eb-8a52-b34fb93799de"
      unitRef="usd">1973361</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtMS0xLTEtMTEx_26a094ba-30f3-49f3-aea2-92dc8ec04ae3"
      unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtMy0xLTEtMTEx_6b6caa12-fbef-4b37-8db2-bcdd83960170"
      unitRef="usd">-15788427</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtNS0xLTEtMTEx_de532c45-a728-4ee5-b6c4-ccffa97db4b2"
      unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTMtNy0xLTEtMTEx_75b1e921-7960-4a16-8445-115f017743f7"
      unitRef="usd">160218880</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtMS0xLTEtMTEx_96d848a2-0522-454c-acee-bdea7539f16d"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtMy0xLTEtMTEx_da596662-1e9c-44bf-b072-ede56cb6a9e2"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtNS0xLTEtMTEx_319208ce-222e-4111-a374-c668558c2689"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTQtNy0xLTEtMTEx_e74da05a-aba6-4d4a-aaf8-7c61c6b4b2d8"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtMS0xLTEtMTEx_24566285-e2d1-461b-b32e-71da7ff3efdc"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtMy0xLTEtMTEx_e0b5eb6b-3ee9-4a83-a787-422541516037"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtNS0xLTEtMTEx_b1a924dd-74a1-4e9d-acda-53ef705aa407"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTUtNy0xLTEtMTEx_3add3066-d2b5-453b-a30b-5879436c9dbf"
      unitRef="usdPerShare">2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtMS0xLTEtMTEx_52bde955-ed14-4c10-bec8-d0f6f851b954"
      unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtMy0xLTEtMTEx_28fa5eeb-2a3f-4751-a2b3-025baefbaddb"
      unitRef="shares">67818366</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtNS0xLTEtMTEx_5013e63b-637b-4224-860f-a87c5380fe3c"
      unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTYtNy0xLTEtMTEx_dae71852-5ae7-4c5a-b2e8-ef5948b999b1"
      unitRef="shares">66953431</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctMS0xLTEtMTEx_289d4782-1f8e-4d9f-8f61-34d3d0af2751"
      unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctMy0xLTEtMTEx_5aff4ec9-493d-472c-8d51-6151d6291571"
      unitRef="shares">67818366</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctNS0xLTEtMTEx_87b5563b-c56d-411b-8358-8e3aa049e2dc"
      unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yMi9mcmFnOjAxM2ZmMjY3Nzc5YTQ3MDlhM2Q1M2M3NjFmMTNmMWFjL3RhYmxlOmU3MGI4NjllMzUzNzQ2MTE5YmEwM2Y3NTk4NTFiNzI4L3RhYmxlcmFuZ2U6ZTcwYjg2OWUzNTM3NDYxMTliYTAzZjc1OTg1MWI3MjhfMTctNy0xLTEtMTEx_f1b3023b-8297-488d-9636-91bf3079f433"
      unitRef="shares">67565761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtMS0xLTEtMzkxNg_26a094ba-30f3-49f3-aea2-92dc8ec04ae3"
      unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtMy0xLTEtMzkxNg_6b6caa12-fbef-4b37-8db2-bcdd83960170"
      unitRef="usd">-15788427</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtNS0xLTEtMzkxNg_de532c45-a728-4ee5-b6c4-ccffa97db4b2"
      unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzEtNy0xLTEtMzkxNg_75b1e921-7960-4a16-8445-115f017743f7"
      unitRef="usd">160218880</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtMS0xLTEtNDc4NQ_1d69884b-aac8-4002-b001-43a16dc06f2f"
      unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtMy0xLTEtNTg5MA_46dc6765-1bdf-48db-a845-6350cce65b35"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtNS0xLTEtNTg5NA_0ccbad84-9686-48b7-b410-1380380f1d9c"
      unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzMtNy0xLTEtNTg5Ng_8cd4c19f-91eb-457d-b5e9-06e4be1e3d6d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtMS0xLTEtNTg5OA_d9f40622-9354-43ed-a725-f4d91036c63b"
      unitRef="usd">-14678541</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtMy0xLTEtNTkwMQ_e4fe8766-073c-4f3c-8206-2a6247387866"
      unitRef="usd">-15788427</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtNS0xLTEtNTkwMw_d04547d9-9f5b-472d-a492-31c1f28f2ebc"
      unitRef="usd">-30786597</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNzYvZnJhZzoxOGQxOTI4MzkxYjg0MTQ1OWY0OTc5MDc3ODdkMTY3ZC90YWJsZTo4YjFiYmFmYWNmMmE0ZTIyYjA4NWRmZGRhYTgyMjQzMy90YWJsZXJhbmdlOjhiMWJiYWZhY2YyYTRlMjJiMDg1ZGZkZGFhODIyNDMzXzQtNy0xLTEtNTkwNQ_edd65229-7bfd-4a12-b2c3-51f033419cf1"
      unitRef="usd">160218880</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="iad7480407a3f4c48928d4ccbe1dd5c10_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xLTEtMS0xMTE_02fbf564-6193-426f-9f89-6b6376db49f4"
      unitRef="shares">1250</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="iad7480407a3f4c48928d4ccbe1dd5c10_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0zLTEtMS0xMTE_dfc0ba58-c736-4b52-b9ff-f32deafde3a3"
      unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i02d307e57dbc40ff93c2b5995aeba167_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi01LTEtMS0xMTE_c78c0cb4-9e23-4e1c-a6a2-596a7a95cd01"
      unitRef="shares">70364912</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i02d307e57dbc40ff93c2b5995aeba167_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi03LTEtMS0xMTE_6fa38d98-557e-4f62-b201-f01bafb8c155"
      unitRef="usd">70359</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8760fd385cca4d73b7b31af558f982ad_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi05LTEtMS0xMTE_8ddd722a-90d8-4e8d-a036-1ea4dbf25fe5"
      unitRef="usd">351033589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0310bbd84f804abea3269f6c899e1a78_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xMS0xLTEtMTEx_aadf75a2-3bda-40b1-b417-0d692e7aaeb6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fab542d4f974a00912a7939cf326eb2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xMy0xLTEtNDg0MA_74af6a25-6266-40bb-8d84-2df5d79bf0da"
      unitRef="usd">-171357513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMi0xMy0xLTEtMTEx_80bca802-5af1-49e3-a591-15bd0b6766f1"
      unitRef="usd">179746436</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c62b7cade354d0388144a8b711b4722_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy05LTEtMS00ODQw_42f57e54-69fb-4629-a21c-9432d752145e"
      unitRef="usd">1324812</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy0xNS0xLTEtNDg0MA_1c708604-6cad-49f7-8f83-6108c9ff2298"
      unitRef="usd">1324812</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i31de4bccf32942219f29ef0e07207b80_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC01LTEtMS00ODQw_11054fae-0328-4634-a0d6-9a779be28234"
      unitRef="shares">52333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i31de4bccf32942219f29ef0e07207b80_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC03LTEtMS00ODQw_66a80af6-7bac-4896-9c0b-5f9a6b161e7c"
      unitRef="usd">14</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0c62b7cade354d0388144a8b711b4722_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC05LTEtMS00ODQw_c37b9d48-bac4-4251-b244-a2dbb0999169"
      unitRef="usd">33065</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC0xNS0xLTEtNDg0MA_f29ce6db-c474-461f-ac7e-412c89628c53"
      unitRef="usd">33079</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i4f72e97f2a064f1c90998ceed128f870_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNS0xMy0xLTEtNDg0MA_14399a3c-6000-4f16-9f73-b6e9016d12dc"
      unitRef="usd">-16108056</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a7d37d308434df9a7af18206ca4189b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNS0xNS0xLTEtNDg0MA_f58fda63-f55b-43c7-9f4c-8d83a16e2aec"
      unitRef="usd">-16108056</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i2d18fe72233749f28cfd64f0d70907ea_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xLTEtMS00ODQw_da9dbda2-8e84-43a3-9363-b682730587b7"
      unitRef="shares">1250</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2d18fe72233749f28cfd64f0d70907ea_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0zLTEtMS00ODQw_77c94aa5-6356-49dd-843c-3616dc913a64"
      unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i2bf2fd110a9a4c5ab75eea6d9c720226_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi01LTEtMS00ODQw_dd55d07b-fa98-43c9-895d-f20c42a5b218"
      unitRef="shares">70417245</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2bf2fd110a9a4c5ab75eea6d9c720226_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi03LTEtMS00ODQw_c139a92d-b6bf-426f-be33-ba3059999d3e"
      unitRef="usd">70373</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8260726b54e04ea1ad6d0ca24421b805_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi05LTEtMS00ODQw_87251f4c-b158-4e2e-9535-aa9cbb6b4a79"
      unitRef="usd">352391466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if56157218fe549b2b3302bac54442c1b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMS0xLTEtNDg0MA_4503bfa6-e5ad-4929-8105-2a62ffd2e1a3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic488d6492f0a4affa4b6e168bc0497a8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMy0xLTEtNDg0MA_e1701d8c-be79-45dc-b801-c646f0bfd8cd"
      unitRef="usd">-187465569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e3e29443fb640e1ac31ec6b44140e14_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xNS0xLTEtNDg0MA_90b33ca4-778e-4f15-a96b-5ee9c77ea5c7"
      unitRef="usd">164996271</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1269bd94e5ad48d198e0186fcb7d2e2b_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNy05LTEtMS00ODQw_78982f06-aaa4-40cd-bfac-56c4585e4a24"
      unitRef="usd">1720217</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNy0xNS0xLTEtNDg0MA_8df96fc0-6258-40f2-a3c4-584824dd3ecd"
      unitRef="usd">1720217</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1f9abf6069224ad1b07f06bfe5e710f4_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy01LTEtMS0xMTE_78881e7b-78e9-4b98-9e09-b80e52a5645c"
      unitRef="shares">2143</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1f9abf6069224ad1b07f06bfe5e710f4_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy03LTEtMS0xMTE_daf772c4-4026-4108-87ea-7d1ff63ec25c"
      unitRef="usd">41</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1269bd94e5ad48d198e0186fcb7d2e2b_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy05LTEtMS0xMTE_1436b88e-1f4e-4a4f-8737-04d888cfdeaf"
      unitRef="usd">109507</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMy0xMy0xLTEtMTEx_937658ea-6778-46fc-a180-e465603e997d"
      unitRef="usd">109548</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i6554df655cdb468099698d2e5466ee5d_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC0xMS0xLTEtMTEx_261ebb03-2673-4e2c-9532-cb340acacf85"
      unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNC0xMy0xLTEtMTEx_1fbfde3f-24ab-474f-b908-669c2b1d4f05"
      unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6e677a4abbe94743a6e30d84324ce7f7_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMTMtMS0xLTQ4NDA_b3f3b7f0-22cb-481b-8f23-85a1c7b3766c"
      unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNS0xMy0xLTEtMTEx_cf2a1a7b-748f-4d88-bd2d-9e86dff17a6c"
      unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i6cfbc34d3a114e34912c01fb42a6e923_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xLTEtMS0xMTE_82c93124-a401-4a9e-aa21-7ecc333b28b6"
      unitRef="shares">1250</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i6cfbc34d3a114e34912c01fb42a6e923_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0zLTEtMS0xMTE_3bb78bd3-29dc-4d06-8e13-00156caa0b1a"
      unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i0999ec79eeb14fdfb352298d2cb61f83_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi01LTEtMS0xMTE_9a7d3336-15a1-468a-89f7-a63d0f948f4b"
      unitRef="shares">70419388</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0999ec79eeb14fdfb352298d2cb61f83_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi03LTEtMS0xMTE_a621c81c-62ba-45c5-b4a9-e09b8b11d885"
      unitRef="usd">70414</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2fb2c95532874480bb6ff7d1bfc14723_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi05LTEtMS0xMTE_9d9de29c-ed07-4060-a5d7-c48c90decb34"
      unitRef="usd">354221191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0aab07b1f2e4699bfef8151c47b8a0d_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMS0xLTEtMTEx_546de829-0e63-472d-b90d-26dcb6afcb7d"
      unitRef="usd">-90127</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45904026876d4027b04a7d7c2108f617_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTEtMTMtMS0xLTQ4NDA_99960309-282a-4c67-9f74-c2894580314b"
      unitRef="usd">-202053983</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfNi0xMy0xLTEtMTEx_43f82539-58ab-4e89-8bf6-09cca068fd2f"
      unitRef="usd">152147496</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i8366cf4b4e584ca1933dcff24730eee2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMS0xLTEtMTEx_32c34e97-56e6-4407-93f0-de98afbdc2f4"
      unitRef="shares">3250</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8366cf4b4e584ca1933dcff24730eee2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMy0xLTEtMTEx_e73215e1-391d-42cb-a2ac-40c22ff1dede"
      unitRef="usd">3</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i799e74a1e807418187738a7890f11901_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtNS0xLTEtMTEx_89d872f6-389a-4296-b024-13f7d60cc344"
      unitRef="shares">65743170</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i799e74a1e807418187738a7890f11901_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtNy0xLTEtMTEx_036381a8-d8e2-42b4-87a6-496535729ce7"
      unitRef="usd">65743</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i296138c6708441f693c8a9280889de40_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtOS0xLTEtMTEx_3c021ecc-47e5-4175-a22a-bf81c41af9e5"
      unitRef="usd">337758007</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i336ccea71ae9453b969559eea3a1e540_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMTEtMS0xLTExMQ_c286115f-04d3-4d9c-b8be-0bc5027ecd03"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0c0dfa04e4b4f4898016afa3ab78e19_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtMTMtMS0xLTQ4NTI_9dc2558d-9d34-4934-a4aa-2b28ea92e781"
      unitRef="usd">-294192097</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i658dc49bdacc4997a02fdffb11586100_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTAtMTMtMS0xLTExMQ_9296c23d-d041-4b90-9dc2-919aeaac25b9"
      unitRef="usd">43631656</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTUtOS0xLTEtNDg1Mg_40dc115b-0af1-4113-8415-ef485e6b84a4"
      unitRef="usd">1320002</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTUtMTUtMS0xLTQ4NTI_b8602d24-224d-421c-a34f-afd295d40d19"
      unitRef="usd">1320002</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNS0xLTEtNDg1Mg_8be5cc7e-0529-4fd0-a1d2-e34f2e3f60ca"
      unitRef="shares">34256</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNy0xLTEtNDg1Mg_13b0fc03-d3ec-42ad-8a5e-f3af139bbc8f"
      unitRef="usd">34</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtOS0xLTEtNDg1Mg_15dd713d-e4f6-4bf0-981c-087c6fd74892"
      unitRef="usd">130139</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMTUtMS0xLTQ4NTI_3d09ace9-b88f-4d7d-8668-be5471abe1b7"
      unitRef="usd">130173</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctNS0xLTEtNDg1Mg_c9ebdae8-6dd5-4e15-afe1-8b7db0bc4d42"
      unitRef="shares">10400</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctNy0xLTEtNDg1Mg_ea57783c-3d19-48e0-8df0-cb357665bfaf"
      unitRef="usd">11</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctOS0xLTEtNDg1Mg_e8fd9f37-933f-4fe4-a84e-2b6b73940553"
      unitRef="usd">20791</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTctMTUtMS0xLTQ4NTI_541cb07d-7389-4e08-ae47-90123360d5cb"
      unitRef="usd">20802</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i10c476d2dc2b4b06b06ce5c44e0b513d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtMS0xLTEtNDg1Mg_7f2a7013-170a-40e4-8ddb-a5956dbcdea5"
      unitRef="shares">-2000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i10c476d2dc2b4b06b06ce5c44e0b513d_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtMy0xLTEtNDg1Mg_ebb26896-ddcc-460a-b77a-c8a237446645"
      unitRef="usd">-2</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtNS0xLTEtNDg1Mg_ca11fde6-fdd5-48b6-8440-4632380639fa"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0163d8ad92ba486892aa8c006e2f8ba5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtNy0xLTEtNDg1Mg_5b7f9cf9-2a5c-4486-9be0-721828c9e77e"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3d54a63153d44c33b5addb59c59d45e4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTgtOS0xLTEtNDg1Mg_79365981-ba3c-43da-b138-9388c433c85b"
      unitRef="usd">-1998</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="iaab306a7297d4fb1a87a32f3962e910b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTktMTMtMS0xLTQ4NTI_6e762a34-48e2-466e-a694-a2ac3de41e66"
      unitRef="usd">176007307</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTEtMTMtMS0xLTExMQ_4e95cc16-b41c-43c9-93ac-92c38c2b496c"
      unitRef="usd">176007307</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i0dd60c60db2c42138469dff255b2cb5c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMS0xLTEtMTEx_bda4bf43-cd07-40aa-9254-793d4b61cb4b"
      unitRef="shares">1250</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0dd60c60db2c42138469dff255b2cb5c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMy0xLTEtMTEx_f2ef441b-b635-4d86-99ff-5f57a76e212a"
      unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i0a6c40a93ca044369ee51636d6e0cec8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItNS0xLTEtMTEx_666c7738-3035-44b2-abdf-491d174daa86"
      unitRef="shares">67787826</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i0a6c40a93ca044369ee51636d6e0cec8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItNy0xLTEtMTEx_498b7e70-02ff-4acd-9bac-35d01ece9bb2"
      unitRef="usd">67788</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica40e02a37a64756b88e97b575b776e7_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItOS0xLTEtMTEx_896fc059-d280-447e-aff2-a7e11f945035"
      unitRef="usd">339226941</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i835c3a4e2d324395a70abe30b2d458bb_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMTEtMS0xLTExMQ_9b3bfa63-8583-4860-a5c2-91dc75bb930c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iae07d73b4dae4632a39cea16a19f66e1_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMjAtMTMtMS0xLTQ4NTI_50679124-487f-4fac-94b1-cc30062023e1"
      unitRef="usd">-118184790</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie44748b4c9e84136a2dba9fcf256ff76_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTItMTMtMS0xLTExMQ_14a21ca6-3e44-4b72-90cb-938c2f982c0b"
      unitRef="usd">221109940</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i37d44e580ba3462ca1cde50a64e4926c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTMtOS0xLTEtMTEx_99c7cc94-0399-4b0f-9ad8-b6c186dfd581"
      unitRef="usd">1257344</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTMtMTMtMS0xLTExMQ_64ddea53-7965-4ff1-80de-d27ffe0d4aa6"
      unitRef="usd">1257344</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iae5c89ad10f2477f8220874a9b49e705_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtNS0xLTEtMTEx_21525ed4-7ac5-4a74-bcbe-0ef0918cc323"
      unitRef="shares">46121</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iae5c89ad10f2477f8220874a9b49e705_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtNy0xLTEtMTEx_b77fe0c8-1550-4ade-a23e-1d5039658afd"
      unitRef="usd">46</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i37d44e580ba3462ca1cde50a64e4926c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtOS0xLTEtMTEx_bb7a3eb7-4439-45df-8e7d-21c7f55c18f7"
      unitRef="usd">130610</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTQtMTMtMS0xLTExMQ_4b23bcc8-6b6e-4ef3-806f-4a77f6941361"
      unitRef="usd">130656</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="i6d00e69252de424aaf5e53c938c8b70d_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMjMtMTMtMS0xLTQ4NTI_fba8f474-dfc6-40b8-830f-040f4c705243"
      unitRef="usd">-15788427</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTUtMTMtMS0xLTExMQ_503ce89c-5184-4673-a74a-6110e5e8a6d1"
      unitRef="usd">-15788427</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i54ef3d8eca944ac4bf14a1496778579c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMS0xLTEtMTEx_36a0e308-ffbd-45b1-a2a2-741536607217"
      unitRef="shares">1250</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i54ef3d8eca944ac4bf14a1496778579c_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMy0xLTEtMTEx_3ffeca90-0e94-4999-aadf-8a840363d76a"
      unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i681a4f60e7b446d18f13235cf1ab4515_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNS0xLTEtMTEx_e749c86b-eebd-4948-b543-a1dc9eb39e3e"
      unitRef="shares">67833947</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i681a4f60e7b446d18f13235cf1ab4515_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtNy0xLTEtMTEx_141b94a7-1448-4467-8da0-bc4ebafd2fed"
      unitRef="usd">67834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77147210c23641b5a8af1144e5fa6e04_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtOS0xLTEtMTEx_428585d1-b457-471d-834f-26570965f14c"
      unitRef="usd">340614895</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1104e8485b1942128c40c3a1a39b0b69_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMTEtMS0xLTExMQ_28c3a9ec-d2f1-4406-b34f-1eeab2902384"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c7ddc6b88a248569b3b27c0b1e3efde_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMjQtMTMtMS0xLTQ4NTI_3a7bf8f6-d839-4468-8177-d1b09c14da42"
      unitRef="usd">-133973217</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e0fee23ec5d486db1a16b33b9f1ad15_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yNS9mcmFnOmQ0MDIwM2I2N2ZjZjQ1ODVhMmZlYTVkNDM5ZTM4YzI0L3RhYmxlOmE1NTI2NjZlNjBlODRmMjBhZTNmOWVkOTIwYzNhYjI4L3RhYmxlcmFuZ2U6YTU1MjY2NmU2MGU4NGYyMGFlM2Y5ZWQ5MjBjM2FiMjhfMTYtMTMtMS0xLTExMQ_5dbae1cc-5057-40a3-a48c-5b3ddbc84994"
      unitRef="usd">206709513</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMy0xLTEtMS04MDM2_18ed2cf2-fdba-4d2d-8f9f-e3e860f5dcf7"
      unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMy0zLTEtMS04MDM2_a2cfb441-012a-4db9-9a37-3da349eb4d5d"
      unitRef="usd">160218880</us-gaap:NetIncomeLoss>
    <ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNS0xLTEtMS0xMTE_2c5dedeb-5797-4534-9e8d-3606acebbfc3"
      unitRef="usd">945366</ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction>
    <ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNS0zLTEtMS0xMTE_4aed0953-09d3-4cbc-bf23-17682e5a17e2"
      unitRef="usd">0</ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNi0xLTEtMS0xMTE_5211e409-4159-4de7-83e6-8d7349de542f"
      unitRef="usd">-348812</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNi0zLTEtMS0xMTE_e0d9eaa8-2761-4529-9d59-0ed2cc548014"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0xLTEtMS01MDE1_40051cad-f147-4588-ac5e-263780c0ce5a"
      unitRef="usd">223649</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0zLTEtMS01MDE1_96f90507-6d41-42b5-bc6b-3d4f9f2ba1d5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0xLTEtMS00Nzk2_4701b261-bacc-4fcf-b02f-9fe07ef03015"
      unitRef="usd">3045029</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0zLTEtMS00Nzk2_897823ee-1825-4301-b379-2c17d902fed1"
      unitRef="usd">2577346</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOS0xLTEtMS00Nzk2_c2d28787-cc99-4ec1-9217-ffd9e40f67d4"
      unitRef="usd">172105</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOS0zLTEtMS00Nzk2_eb8000e9-a5bf-4f54-8e3a-e047cf5562e3"
      unitRef="usd">127950</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0xLTEtMS0xMTE_c39d4e9f-a23a-489d-88e4-47361accd21b"
      unitRef="usd">354185</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfOC0zLTEtMS0xMTE_1292f27f-71f9-44e4-a8cb-fce767808e9d"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <ovid:AccretionOfLeaseLiability
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTAtMS0xLTEtMTEx_43bf8ab1-485d-492d-a32d-fc7a019740f1"
      unitRef="usd">368226</ovid:AccretionOfLeaseLiability>
    <ovid:AccretionOfLeaseLiability
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTAtMy0xLTEtMTEx_827aa615-c50f-4361-86ad-45a2cceeb710"
      unitRef="usd">0</ovid:AccretionOfLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTItMS0xLTEtMTEx_fba40ad3-cc9e-4cd5-9234-52b7e7e309bc"
      unitRef="usd">230877</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTItMy0xLTEtMTEx_fae7a8c7-b716-4202-b39f-99038e6968ba"
      unitRef="usd">1023996</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTMtMS0xLTEtMTEx_2c92a54d-b72e-401f-8f12-4996aa93b1fa"
      unitRef="usd">15920</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTMtMy0xLTEtMTEx_ff05b71b-a221-4a56-b982-0360e3abf04e"
      unitRef="usd">-27100</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseDueFromAffiliates
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTQtMS0xLTEtMTEx_738282a3-6359-49ee-a4fc-6b52f9ec6c38"
      unitRef="usd">0</us-gaap:IncreaseDecreaseDueFromAffiliates>
    <us-gaap:IncreaseDecreaseDueFromAffiliates
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTQtMy0xLTEtMTEx_e48fe786-06d0-4673-aca1-7c66a89c8d64"
      unitRef="usd">-141763</us-gaap:IncreaseDecreaseDueFromAffiliates>
    <ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTUtMS0xLTEtMTEx_3bbeca3d-248c-4585-ac17-eefe00c16c8e"
      unitRef="usd">0</ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent>
    <ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTUtMy0xLTEtMTEx_40de10c7-b5ae-47f2-87de-89fb6e2a0271"
      unitRef="usd">-477171</ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTYtMS0xLTEtMTEx_0a4eb389-5c11-432b-a124-c722e3efe3a2"
      unitRef="usd">-2510503</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTYtMy0xLTEtMTEx_9e4af355-a7bf-4a3b-9be4-8828caf7da4f"
      unitRef="usd">-4518374</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTctMS0xLTEtMTEx_42f9859c-41e7-4bab-a231-304b7ff746d9"
      unitRef="usd">-3072434</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTctMy0xLTEtMTEx_a8502589-5a71-401e-b23c-13b101cfdd73"
      unitRef="usd">-1676476</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTgtMS0xLTEtMTEx_e385a2b7-93a7-444c-98d1-bc3dc71a6873"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMTgtMy0xLTEtMTEx_416414d3-0552-4789-a16f-53727af38185"
      unitRef="usd">-12382779</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMS0xLTEtNTY2MA_cd93a01c-d74c-4d5c-b3a1-c348717fa69a"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMy0xLTEtNTY2MA_76f45b66-1186-412f-a098-3e9e9a6f0a13"
      unitRef="usd">-2432192</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMS0xLTEtODAzNg_da1a1265-1be1-4c75-b308-b64ac8612cf4"
      unitRef="usd">-33375022</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjEtMy0xLTEtODAzNg_4bb71243-e683-48aa-86f6-acec087f254a"
      unitRef="usd">141482193</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMS0xLTEtNDk2Ng_20b86369-5897-4a5a-8ad5-2270cfb3465b"
      unitRef="usd">79416203</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMy0xLTEtNDk2Ng_44893975-ed90-43f8-9408-1a7066fc38b3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjItMS0xLTEtMTEx_4e58cd5e-b9e0-4077-b5b1-39d9041cefa5"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjItMy0xLTEtMTEx_940b9e01-a8b8-4d93-b269-7008d15b7448"
      unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMS0xLTEtMTEx_4204432d-b276-49ce-82f6-412ce91478f1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjQtMy0xLTEtMTEx_59b91954-34a0-475f-b981-78f0aa2babd8"
      unitRef="usd">1583893</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMS0xLTEtNTYyNg_d9218eb9-96e9-4a3c-8f9e-ea6383007e48"
      unitRef="usd">1085840</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMy0xLTEtNTYyNg_aad3dc90-a661-4bbd-a1a8-1e54b9122f7d"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjctMS0xLTEtMTEx_8a9c35f9-d7c6-4c0c-a7ff-5911fd3825a6"
      unitRef="usd">251340</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjctMy0xLTEtMTEx_f7b4708d-4f30-4ae1-bc8b-0b88d5ae760e"
      unitRef="usd">11515</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMS0xLTEtMTEx_bb7fbc7b-cd03-4c23-a3b2-0391757d4caa"
      unitRef="usd">-81753383</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMjgtMy0xLTEtMTEx_d05bd61c-aa77-448e-b09f-3725c81107dd"
      unitRef="usd">-1595408</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzAtMS0xLTEtMTEx_f43991ed-ed48-4cee-baa2-c2cf95fcc0f3"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzAtMy0xLTEtMTEx_218319c4-4dcf-4936-ba87-57383d6ea45a"
      unitRef="usd">21314</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzUtMS0xLTEtNTYyNg_7caebc48-a032-4bbe-a885-feb7a1717538"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzUtMy0xLTEtNTYyNg_13988d84-993e-4042-af24-57a2ab7768c3"
      unitRef="usd">115705</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzItMS0xLTEtMTEx_1157a720-fb38-451b-9fb5-ab87d18af5e9"
      unitRef="usd">142628</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzItMy0xLTEtMTEx_5bee8cd7-3440-4f79-976b-22ad3773ec61"
      unitRef="usd">151458</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzMtMS0xLTEtMTEx_d3274370-bec1-43b0-8d86-453b75c0aa72"
      unitRef="usd">142628</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzMtMy0xLTEtMTEx_8fbee303-ad21-42f0-9c37-5bd9ebcf4dfe"
      unitRef="usd">245849</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzktMS0xLTEtNTYyNg_0cd17c12-5c85-4368-866e-1318a98c5f87"
      unitRef="usd">-114985777</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzktMy0xLTEtNTYyNg_0cd1302a-23be-4e40-8575-f4e5eb9c144e"
      unitRef="usd">140132634</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzgtMS0xLTEtODAzNg_522032af-7d58-49ad-905a-5962c5cacb18"
      unitRef="usd">189728285</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i658dc49bdacc4997a02fdffb11586100_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzgtMy0xLTEtODAzNg_ccc14ce4-19ac-45c8-8664-4acc6e9d3cca"
      unitRef="usd">72033930</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzctMS0xLTEtMTEx_00e6012a-4c56-44bc-83d6-884e1f092568"
      unitRef="usd">74742508</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e0fee23ec5d486db1a16b33b9f1ad15_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfMzctMy0xLTEtMTEx_881fcf9a-8ed0-4e8d-87e9-b598ee376c13"
      unitRef="usd">212166564</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMS0xLTEtNTAyOQ_a1b11148-705b-49cc-98a7-affec1f04aa2"
      unitRef="usd">15791769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMy0xLTEtNTAyOQ_12bf2864-9b28-4552-8466-134250fb4d2f"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDMtMS0xLTEtODAzNg_5b43726a-90a9-4608-b512-648647950fcc"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDMtMy0xLTEtODAzNg_2ea8ede4-51ed-496c-b74c-425c737beed1"
      unitRef="usd">24054</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <ovid:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDQtMS0xLTEtODAzNg_ff537153-141a-4cb5-b043-86ef8fb1f603"
      unitRef="usd">0</ovid:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets>
    <ovid:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDQtMy0xLTEtODAzNg_2928e801-98e3-4db7-9a01-da6ea3a9fcb1"
      unitRef="usd">14468</ovid:StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMS0xLTEtODAzNg_07f38cb2-87b7-421a-bf5b-5aca8794918b"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8yOC9mcmFnOjJkYTkwNTkxNTdmNjQzZGE5ZmI5NTY3MDFkY2RmOTZlL3RhYmxlOjg4ZmM4ZmU0Yzk3NDRiMzBiYTgxODlhYThhYzA5MDZjL3RhYmxlcmFuZ2U6ODhmYzhmZTRjOTc0NGIzMGJhODE4OWFhOGFjMDkwNmNfNDUtMy0xLTEtODAzNg_91b16620-5109-4aef-85cf-06bacca571d8"
      unitRef="usd">3005</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNTI3OA_49a05a88-2dea-40d9-96a9-2ae586b8dca6">NATURE OF OPERATIONS&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ovid Therapeutics Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the state of Delaware on April 1, 2014 and maintains its principal office in New York, New York. The Company commenced operations on April 1, 2014 (date of inception). The Company is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Historically, the Company&#x2019;s major sources of cash have been composed of proceeds from various public and private offerings of its capital stock, revenue from collaboration agreements, option exercises and interest income. As of June&#160;30, 2022, the Company had approximately $152.4 million in cash, cash equivalents and marketable securities. Since inception, the Company has generated $222.4 million in revenue, primarily pursuant to the Company&#x2019;s royalty, license and termination agreement (the &#x201c;Takeda License and Termination Agreement&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;). Historically, the Company has incurred recurring losses, has experienced negative operating cash flows and requires significant cash resources to execute its business plans. The Company has an accumulated deficit of $202.1&#160;million as of June&#160;30, 2022, working capital of $146.9 million and had cash used in operating activities of $33.4 million for the six months ended June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recorded net losses of $14.6&#160;million and $30.7&#160;million during the three and six months ended June&#160;30, 2022, respectively, and expects to incur losses in subsequent periods for at least the next several years and is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company&#x2019;s existing cash, cash equivalents and marketable securities as of June&#160;30, 2022 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company&#x2019;s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the ongoing COVID-19 pandemic impacts the Company's business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for the Company's common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, the extent of sustained or new travel restrictions, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease, including vaccination efforts. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of the Company's product candidates; delays or problems in the supply of the Company's product candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company's business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTA5OTUxMTYzMzEzNA_c9826cf9-bab1-4798-8e5e-5c9f9e58269f"
      unitRef="usd">152400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="icdb5c5087a7345cea587ac586d74b78e_D20140401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTM4Mg_28e1b6a8-90d2-4869-97cc-32ace16e2a8e"
      unitRef="usd">222400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNDM5ODA0NjUxNjYwNw_5ea1991a-5a79-4065-80b8-fb351c87a55f"
      unitRef="usd">-202100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <ovid:WorkingCapital
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTgyOA_b5693b39-0a68-4f6e-8b39-1ca10ba79a6b"
      unitRef="usd">146900000</ovid:WorkingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfMTg3Ng_6aaf3fbb-095a-4ba1-a2cd-4922ea0f0070"
      unitRef="usd">-33400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNDM5ODA0NjUxNjYyNQ_802f49af-2e2f-4c23-9ce9-7f763da1fc71"
      unitRef="usd">-14600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNC9mcmFnOjNlOWJjMGMwNmU3NzQ3NWZhNDQzZGQ4MjQ2NjNlMDBmL3RleHRyZWdpb246M2U5YmMwYzA2ZTc3NDc1ZmE0NDNkZDgyNDY2M2UwMGZfNDM5ODA0NjUxNjY0Mw_a38818ca-bdd9-407c-93d4-3653962659f4"
      unitRef="usd">-30700000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzM_a2fb77b8-c76d-4c03-ac2e-22728cb89070">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 2, &#x201c;Summary of Significant Accounting Policies,&#x201d; in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 15, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(A) Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The interim condensed consolidated balance sheet at June&#160;30, 2022, the condensed consolidated statements of operations, comprehensive (loss) income, cash flows, and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2022 and 2021 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2022 and 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2021 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of and for the year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(B) Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(C) Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(D) Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Marketable securities consists of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive loss in stockholder's equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(E) Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(F) Long-Term Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term equity investments consist of an equity investment in a private company through preferred shares, which are not considered in-substance common stock, that is accounted for at cost, with adjustments for observable changes in prices or impairments, and is classified within long-term equity investments on our consolidated balance sheets with adjustments recognized in other (expense) income, net on our consolidated statements of operations. The Company has determined that the equity investment does not have a readily determinable fair value and elected the measurement alternative. Therefore, the equity investment&#x2019;s carrying amount will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investment is impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investee securities, and other publicly available data. If the investment is impaired, the Company writes it down to its estimated fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the equity investment had a carrying value of $1.6 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. ("Marinus") that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2022, the equity investment in Marinus had a carrying value of approximately $0.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(G) Note Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March&#160;17, 2022, the Company issued a convertible promissory note to a related party, in which the Company has a long-term equity investment, with a principal amount of $1.0 million. The note has certain features that may allow the Company to acquire additional equity or to settle in cash. Either option would result in the Company receiving an amount at least equal to the outstanding principal balance plus accrued and unpaid interest. The Company will receive interest on the convertible promissory note at the rate of 1.5% per annum payable upon conversion or maturity of the note on March 17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has elected to measure the note using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivatives due to changes in the fair value will be reflected in other income (expense), net, in the Company's consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(H) Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#x2019;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling approximately $55.6 million as of June&#160;30, 2022. The Company's Level 1 assets consisted of money market funds and short-term investments of $187.6 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills totaling approximately $94.5 million as of June&#160;30, 2022. The Company had no Level 2 assets or liabilities as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company's Level 3 assets consists of the convertible note receivable totaling $1.0 million as of June&#160;30, 2022. There were no Level 3 assets or liabilities as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(I) Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use ("ROU") assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period. The Company determined that there was no current lease liability for the period ended June&#160;30, 2022, which is due primarily to the free rental period for the Company's Hudson Commons lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(J) Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(K) Net (Loss) Income Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income, basic per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding. The Company applies the two-class method to allocate earnings between common stock and participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income, diluted per share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and preferred stock using the if-converted method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss, diluted per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(L) Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzQ_9b21aee6-9fce-4d04-9c83-4e0491357b20">Unaudited Interim Condensed Consolidated Financial StatementsThe interim condensed consolidated balance sheet at June&#160;30, 2022, the condensed consolidated statements of operations, comprehensive (loss) income, cash flows, and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2022 and 2021 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2022 and 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2021 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of and for the year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K.</ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzU_948c552c-42d9-42d4-a0c4-a3329dfb5597">Basis of Presentation and ConsolidationThe accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODA_907b2433-3288-4e4d-a086-7803b6858608">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTc1OTIxODYwNTg0MDc_ef70a29d-183d-4d45-8969-27e4e7cdf5c7">Marketable SecuritiesMarketable securities consists of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive loss in stockholder's equity.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODE_0c6dbce7-e479-4d1c-839d-ccea67b8fce1">Restricted CashThe Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODI_d70fc56e-a35b-4873-8381-8eaaf36513d4">Long-Term Equity Investments&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term equity investments consist of an equity investment in a private company through preferred shares, which are not considered in-substance common stock, that is accounted for at cost, with adjustments for observable changes in prices or impairments, and is classified within long-term equity investments on our consolidated balance sheets with adjustments recognized in other (expense) income, net on our consolidated statements of operations. The Company has determined that the equity investment does not have a readily determinable fair value and elected the measurement alternative. Therefore, the equity investment&#x2019;s carrying amount will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investment is impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investee securities, and other publicly available data. If the investment is impaired, the Company writes it down to its estimated fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the equity investment had a carrying value of $1.6 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. ("Marinus") that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2022, the equity investment in Marinus had a carrying value of approximately $0.6 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestments
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDEyNA_63cd56b4-fe33-4c65-9c4c-5b03618d2a0c"
      unitRef="usd">1600000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDEyNA_d8331237-16f9-4bea-9e7a-0fa76d4dde85"
      unitRef="usd">1600000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="idd69d41d3fa3410981127bf2969db96f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDczOA_500d414d-ab92-4b49-b66b-3840ed721fc4"
      unitRef="usd">600000</us-gaap:EquityMethodInvestments>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2NzY_0c793cfc-8b72-4bde-9f27-dec11ff55487">Note Receivable&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March&#160;17, 2022, the Company issued a convertible promissory note to a related party, in which the Company has a long-term equity investment, with a principal amount of $1.0 million. The note has certain features that may allow the Company to acquire additional equity or to settle in cash. Either option would result in the Company receiving an amount at least equal to the outstanding principal balance plus accrued and unpaid interest. The Company will receive interest on the convertible promissory note at the rate of 1.5% per annum payable upon conversion or maturity of the note on March 17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has elected to measure the note using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivatives due to changes in the fair value will be reflected in other income (expense), net, in the Company's consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="i1a67b91f0f784fb39b30c84c6e1e1667_I20220317"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNDkyMQ_96a474f9-15bb-40da-a256-306c52263f40"
      unitRef="usd">1000000</us-gaap:LongTermInvestments>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a543a156421421492ae9ac7e6fdd405_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNTI2NQ_7fbcfed6-8eac-40d8-b252-78895e6891fc"
      unitRef="number">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2Nzc_042ffad6-39c3-4674-905d-47a68ba4ba62">Fair Value of Financial InstrumentsFinancial Accounting Standards Board (&#x201c;FASB&#x201d;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#x2019;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling approximately $55.6 million as of June&#160;30, 2022. The Company's Level 1 assets consisted of money market funds and short-term investments of $187.6 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills totaling approximately $94.5 million as of June&#160;30, 2022. The Company had no Level 2 assets or liabilities as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:32.85pt"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company's Level 3 assets consists of the convertible note receivable totaling $1.0 million as of June&#160;30, 2022. There were no Level 3 assets or liabilities as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c1e78e1146d41af95d207583e74eb8f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNjgxOA_bdaab70c-7d77-47e0-bda2-2ffb089ce6f8"
      unitRef="usd">55600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf80654a79be4240b9b2f9216351b6d4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNjkyMg_8d73b47d-d346-4ccd-a854-4aa23a6d1536"
      unitRef="usd">187600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i23d5fb933c1c4101afc9b43949132d1c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTA5OTUxMTY0NDg0NQ_3f2d20c8-9be9-454b-96be-24eccb2994e6"
      unitRef="usd">94500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id062c33120f64e1e86eb963d29a355d4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_2bce056f-c77f-4b59-8b48-dbc92f921f79"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i09fdc4f878d749a2a0c510248458b0c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_a4d70b4c-0f79-4575-81d3-1fc9c39ae219"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id062c33120f64e1e86eb963d29a355d4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_ac887cf4-d7e6-4232-beb7-b7013b7174f3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i09fdc4f878d749a2a0c510248458b0c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzM2NQ_c57fb51e-f146-4a43-89fa-aab4373f4f87"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <ovid:ConvertibleNoteReceivable
      contextRef="i70b464c3358e49f08d0e076378fff060_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzc3NA_00ff9a90-5ae6-4ca9-bc2f-951527cde8cf"
      unitRef="usd">1000000</ovid:ConvertibleNoteReceivable>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if91752729f23489a9a1fdf7618bd851d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzc5OA_0ff5aae6-12ad-47ce-a1fc-6deb76dfe26c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if91752729f23489a9a1fdf7618bd851d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfNzc5OA_da247a41-4739-48d7-822f-257da52a5a23"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2Nzg_8cdd6147-e23f-4dbb-a3a3-68c22c3a4154">LeasesThe Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use ("ROU") assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period. The Company determined that there was no current lease liability for the period ended June&#160;30, 2022, which is due primarily to the free rental period for the Company's Hudson Commons lease.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2Nzk_6c1e6f28-6446-4fd2-8ef2-c0b98729e664">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODM_83e08133-f1b7-4722-b4cb-8fb105ac32b2">Net (Loss) Income Per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income, basic per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding. The Company applies the two-class method to allocate earnings between common stock and participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net income, diluted per share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and preferred stock using the if-converted method.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss, diluted per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV8zNy9mcmFnOjg2NzY5NWRkZDE3OTQ3ZWI4NjNkZDQ4ZDdkYmZhNzNkL3RleHRyZWdpb246ODY3Njk1ZGRkMTc5NDdlYjg2M2RkNDhkN2RiZmE3M2RfMTI2ODQ_60e8287f-ab95-48e9-8789-c80a75275433">Recent Accounting Pronouncements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMzA5_e64d48b5-2df5-44ea-a764-93b4fa1c05c0">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,860,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,860,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,951,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,951,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,644,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,554,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,455,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,365,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,797,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,797,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of June&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMzEw_36649eb9-59db-4658-ad43-a43a926c1322">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,860,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,860,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,951,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,951,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,644,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,554,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,455,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,365,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,797,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,797,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMzEw_ff9f8643-701d-40c3-b983-b08abb6b4cdd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,860,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,860,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,951,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,951,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,644,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,554,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,455,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(90,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;152,365,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,591,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,797,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,797,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6a5cc0fd641241a9a8645ff092db348c_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMi0xLTEtMS0xMTE_fcaa6568-4b6d-4fcc-94f7-b2c7156609f1"
      unitRef="usd">2860631</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a5cc0fd641241a9a8645ff092db348c_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMi03LTEtMS0xMTE_ca2b7899-c2e0-43c3-97c2-c0f3e0038f1d"
      unitRef="usd">2860631</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0daa1be00e7421584b963e7641737bb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMy0xLTEtMS0xMTE_e4f88dec-5667-454e-b2e7-11dfeee3efd2"
      unitRef="usd">69951125</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic0daa1be00e7421584b963e7641737bb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfMy03LTEtMS0xMTE_4b3963b9-e47f-4177-9387-cf7baf1fe94b"
      unitRef="usd">69951125</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0xLTEtMS0yMDMw_bb930706-d315-4bc9-aa14-fa756babb6f3"
      unitRef="usd">79644167</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0zLTEtMS0yMDMw_dc0ecac9-c4f2-4665-b31a-da62f1958a94"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC01LTEtMS0yMDMw_054c2abf-ecbf-4958-87a2-628f70ab0f2b"
      unitRef="usd">90127</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC03LTEtMS0yMDMw_6bbcea47-eb6a-4a6b-8273-16516841e54d"
      unitRef="usd">79554040</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0xLTEtMS0xMTE_9619e71c-f75d-4fe8-88a3-b72c5f346c43"
      unitRef="usd">152455922</ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC0zLTEtMS0xMTE_7176f5e3-31ad-437d-862a-62521a1ba9c1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC01LTEtMS0xMTE_d617d598-ff66-4bce-9597-3f513d49f62f"
      unitRef="usd">90127</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjNiNWJmNzQ2OGE4ODQyYWRiMzQ1MDIzZWI4NDBlYWQxL3RhYmxlcmFuZ2U6M2I1YmY3NDY4YTg4NDJhZGIzNDUwMjNlYjg0MGVhZDFfNC03LTEtMS0xMTE_c79dbd29-d4f9-4e31-8658-e967105f1ebb"
      unitRef="usd">152365795</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifa62a7ee26a34283b02d9a020bb48d54_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMi0xLTEtMS0xMTE_c1bca75f-d2d1-42b1-824e-56333831eeb7"
      unitRef="usd">205555</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifa62a7ee26a34283b02d9a020bb48d54_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMi03LTEtMS0xMTE_26210127-b07f-442c-870e-df1a830d3762"
      unitRef="usd">205555</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i240d93a2ab414f6d8279a85350aa8834_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMy0xLTEtMS0xMTE_68368353-7e56-4aad-a386-f9a7643c47d1"
      unitRef="usd">187591977</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i240d93a2ab414f6d8279a85350aa8834_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfMy03LTEtMS0xMTE_bb7dd2b7-619d-46dd-8498-939f79a1564e"
      unitRef="usd">187591977</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0xLTEtMS0yMDUy_2a62845b-6a91-4245-90f6-02ddd387ae9d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0zLTEtMS0yMDUy_4ffab65d-8ee5-4402-a637-a4beb73ddd77"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC01LTEtMS0yMDUy_b24b6a64-3e3b-4155-8eda-7fd81675bb8e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC03LTEtMS0yMDUy_734273c5-120b-41d1-9821-fb8050f61322"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0xLTEtMS0xMTE_92cfd641-b25d-4d25-a06d-38c15cc3643a"
      unitRef="usd">187797532</ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC0zLTEtMS0xMTE_40a64aca-2d6d-4a1a-a547-0425363dec8c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC01LTEtMS0xMTE_4df9435d-3e2d-41d2-b321-62acc78267d4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RhYmxlOjM5ZTkxMDlkMTE0ODQ2NzY5NGQ4ZGFjYWRhYTI0ODE1L3RhYmxlcmFuZ2U6MzllOTEwOWQxMTQ4NDY3Njk0ZDhkYWNhZGFhMjQ4MTVfNC03LTEtMS0xMTE_044c3d91-cbcf-4633-9216-e9f507108bf7"
      unitRef="usd">187797532</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMjA2_0e032b73-ea17-4b8a-a42a-f53da4dedee4"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80MC9mcmFnOmU2YWFhZDk4NjcxMjQzZDZhYzAxMjhiNmY0MmMxYjg5L3RleHRyZWdpb246ZTZhYWFkOTg2NzEyNDNkNmFjMDEyOGI2ZjQyYzFiODlfMjA2_ca801e91-a538-46cf-8924-4f27496710c7"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDA5_789a6824-9c19-4494-a1c4-56ad3713f98d">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property and equipment is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;504,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(347,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(262,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,243,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $54,631 and $17,834 for the three months ended June&#160;30, 2022 and 2021, respectively. Depreciation expense was $85,470 and $36,478 for the six months ended June&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;Intangible assets, net of accumulated amortization was $328,797 and $164,092 as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and are included in other assets. Amortization expense was $32,153 and $35,381 for the three months ended June&#160;30, 2022 and 2021, respectively. Amortization expense was $86,636 and $91,473 for the six months ended June&#160;30, 2022 and 2021, respectively.</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDEw_c19b23f9-edc8-4a11-b183-1422531241bd">&lt;div style="margin-top:6pt;text-align:justify;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property and equipment is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;504,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;287,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(347,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(262,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,243,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i247b2b8238374cad8df96951a6bae08d_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMS0xLTEtMS0xMTE_db9ba259-f98f-47aa-8a2f-4f7508300cc1"
      unitRef="usd">1303094</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f82c24689c54b7687abc86742065cc6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMS0zLTEtMS0xMTE_c3be110e-958e-499d-b66d-9174b5e6fe27"
      unitRef="usd">504965</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4fce33f178a14e88b1785363753aaa5b_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0xLTEtMS0yMDg1_a873fe72-6e10-42f5-a705-8da6dd516268"
      unitRef="usd">287712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i87adc2ffe0ba416eb4da45a8b61856c8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0zLTEtMS0yMDg1_36070e25-39ee-42b0-be8c-8754705e5180"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0xLTEtMS0xMTE_5df4ad5c-2711-44ea-8e80-3d4dd8614788"
      unitRef="usd">347678</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMi0zLTEtMS0xMTE_3e614359-47f1-4775-9122-c18f77da67d0"
      unitRef="usd">262208</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMy0xLTEtMS0xMTE_e78eb79d-d0e7-422a-8686-36d32526ca6d"
      unitRef="usd">1243128</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RhYmxlOmM0ZmMzNWQ3NWM5ODQyYTNiMjlhNTkxODA5MDMwNTIwL3RhYmxlcmFuZ2U6YzRmYzM1ZDc1Yzk4NDJhM2IyOWE1OTE4MDkwMzA1MjBfMy0zLTEtMS0xMTE_f0bdbe75-f2bc-4078-bfef-8f31488f69d3"
      unitRef="usd">242757</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYxNQ_a2bdc962-aaea-4261-a7b6-b1e42daf4a66"
      unitRef="usd">54631</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYyMQ_dd84408d-c2e3-4ed7-a1f4-674ad77aa694"
      unitRef="usd">17834</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYyNw_b449ee02-e9e8-4ab9-bb8b-ddee7ebfea9b"
      unitRef="usd">85470</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTYzMw_4e0fb7b6-0e2c-4df3-95c1-220f8537bec4"
      unitRef="usd">36478</us-gaap:Depreciation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMjQ5_0c185f6e-8ac7-4e83-a6e6-ca43b2751dcf"
      unitRef="usd">328797</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMjU2_a3c54746-353a-4481-a117-5aff46bb9651"
      unitRef="usd">164092</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMzQ5_d5981bb2-d8a8-4d25-aa7b-bb6a2689f08b"
      unitRef="usd">32153</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfMzU2_93af33ff-379e-4a2d-b5b9-f0aa060c0cf6"
      unitRef="usd">35381</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTY3OQ_705b5ce6-d5fd-495c-9563-96d2f9ca3de4"
      unitRef="usd">86636</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80My9mcmFnOjNlYjY1NzA2OWQ3ODQzYzg5YTdlYWE1NzU0MGZlMjc0L3RleHRyZWdpb246M2ViNjU3MDY5ZDc4NDNjODlhN2VhYTU3NTQwZmUyNzRfNDM5ODA0NjUxMTc0Mg_883a35f4-bb92-4ccd-9c9e-33b8dacff6d2"
      unitRef="usd">91473</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE3OQ_073aa6f3-2b6e-406d-b193-e9df6ddb4105">LEASES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,143 square feet of office space at Hudson Commons in New York, NY. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3 million per year. Rent payments commence 10 months following the commencement date of the lease, or January 10, 2023, and continue for 10 years following the rent commencement date. Rent also includes two months of free rent in the 6th and 7th months following the rent commencement date. The Company issued a letter of credit in the amount of $1.9 million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Hudson Commons lease has a remaining lease term of 10 years and includes a single renewal option for an additional 5 years. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments is calculated using an incremental borrowing rate of 7.02%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ROU asset and lease liabilities related to the Company's operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;15,437,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Current lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;15,966,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The components of operating lease cost for the six months ended June&#160;30, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;722,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Future minimum commitments under the non-cancelable operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,347,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,285,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i57c6dc3481c441408bca8588e4b4cd13_I20220310"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4NjQ_093148e3-7ef7-4908-a258-80aa5777ef4d">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i57c6dc3481c441408bca8588e4b4cd13_I20220310"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4NDI_28a2f3dc-a077-4851-935c-0364d73bd071"
      unitRef="sqft">19143</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:PaymentsForRent
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1NTc_a7a64854-9a52-4cf3-aa31-67e9a5c40ba1"
      unitRef="usd">2300000</us-gaap:PaymentsForRent>
    <ovid:LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod
      contextRef="i8a54288182e24aa280eacf76b58680fb_D20220310-20220310"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4OTQ_31117f7c-79f7-4272-b927-fb9819a1201a">P10M</ovid:LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i57c6dc3481c441408bca8588e4b4cd13_I20220310"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4NTI_faee2b0a-1e1d-43cf-a8c3-3fdcee6049ac">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ovid:LesseeOperatingLeaseFreeRentPeriod
      contextRef="i8a54288182e24aa280eacf76b58680fb_D20220310-20220310"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTQ4NDM0MDY5NzY4Nzk_c1dc9839-1328-4100-89ea-26478e99b394">P2M</ovid:LesseeOperatingLeaseFreeRentPeriod>
    <us-gaap:RestrictedCash
      contextRef="i1c97d8b7325e4ee5bfb436d1850897fe_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ2MDE_b03302f2-9ed5-4ceb-8f93-c2648448ca78"
      unitRef="usd">1900000</us-gaap:RestrictedCash>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1Njg_91924cd2-bcd8-4bb6-ac1e-92d40d13a8be">P10Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1Nzg_95a9d3b5-3615-4024-a156-495d4fa5e64e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ovid:LeaseIncrementalBorrowingRate
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTU5NDI5MTg2MDQ1ODY_3da0fef9-cd05-4d1b-b356-4c310f517ffa"
      unitRef="number">0.0702</ovid:LeaseIncrementalBorrowingRate>
    <ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE4MA_1a54e5df-f039-43aa-beaa-ec3da45c9f7d">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ROU asset and lease liabilities related to the Company's operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;15,437,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Current lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;15,966,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOjcxZWZhODQ1ZTlmYzQ3MmE5YjlhZTk2NmE2ZDgyOWY3L3RhYmxlcmFuZ2U6NzFlZmE4NDVlOWZjNDcyYTliOWFlOTY2YTZkODI5ZjdfMS0xLTEtMS0xMTE_66048326-bd7a-40eb-8de4-cfac46dcf544"
      unitRef="usd">15437584</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOjcxZWZhODQ1ZTlmYzQ3MmE5YjlhZTk2NmE2ZDgyOWY3L3RhYmxlcmFuZ2U6NzFlZmE4NDVlOWZjNDcyYTliOWFlOTY2YTZkODI5ZjdfMi0xLTEtMS0xMTE_65690727-15ba-49c2-b978-ec7640ddcb82"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOjcxZWZhODQ1ZTlmYzQ3MmE5YjlhZTk2NmE2ZDgyOWY3L3RhYmxlcmFuZ2U6NzFlZmE4NDVlOWZjNDcyYTliOWFlOTY2YTZkODI5ZjdfMy0xLTEtMS0xMTE_96ae383c-ae36-4f24-bc8f-b9be7a4ce71f"
      unitRef="usd">15966970</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE3Nw_299b0853-5bd5-42e5-bf54-e761433faef9">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The components of operating lease cost for the six months ended June&#160;30, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;722,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmZjZGNiYmIwYWUyZjRmNjJhYjNmMDA4NmNjMjQwMTBmL3RhYmxlcmFuZ2U6ZmNkY2JiYjBhZTJmNGY2MmFiM2YwMDg2Y2MyNDAxMGZfMS0xLTEtMS0xMTE_f3cbded5-25cd-496f-9c26-f3cacbc9e23e"
      unitRef="usd">722411</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmZjZGNiYmIwYWUyZjRmNjJhYjNmMDA4NmNjMjQwMTBmL3RhYmxlcmFuZ2U6ZmNkY2JiYjBhZTJmNGY2MmFiM2YwMDg2Y2MyNDAxMGZfMi0xLTEtMS0xMTE_0629b9ca-14ea-48f8-8181-c4643242375d"
      unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmZjZGNiYmIwYWUyZjRmNjJhYjNmMDA4NmNjMjQwMTBmL3RhYmxlcmFuZ2U6ZmNkY2JiYjBhZTJmNGY2MmFiM2YwMDg2Y2MyNDAxMGZfMy0xLTEtMS0xMTE_8c8e89c0-dd90-4237-ac4f-3d34bd6db7df"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RleHRyZWdpb246ZTU4ZmI2ZGI3N2IxNGUxNGJkYTZhNTMzZjQyZjljNjdfMTE3OA_6cff9aff-7a32-4769-a4ae-f690637574d9">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Future minimum commitments under the non-cancelable operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,347,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,285,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMC0xLTEtMS0xMTE_aecb798d-9fd6-4bb7-80f8-475ab364389c"
      unitRef="usd">1672886</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMS0xLTEtMS0xMTE_3a43550a-6483-4fa0-819c-72664473e124"
      unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMi0xLTEtMS0xMTE_310f983e-6e89-4599-8db3-9fb2999354bb"
      unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfMy0xLTEtMS0xMTE_abf21210-95cd-46b6-900a-abccbae7f795"
      unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfNC0xLTEtMS0xMTE_2ddcaacd-b2bb-4700-8997-71e2a5b8db3f"
      unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfNS0xLTEtMS0xMTE_6d1a0ca2-df0d-4833-b9d7-5731fd785a5c"
      unitRef="usd">12347235</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80Ni9mcmFnOmU1OGZiNmRiNzdiMTRlMTRiZGE2YTUzM2Y0MmY5YzY3L3RhYmxlOmRkMTQ4NDg2MmI5ZTQ4NDg4OWViMzg2YjI4OGEzMGVmL3RhYmxlcmFuZ2U6ZGQxNDg0ODYyYjllNDg0ODg5ZWIzODZiMjg4YTMwZWZfNi0xLTEtMS0xMTE_20b3bd4a-db7a-46bf-a0b4-dfa3c5f48e68"
      unitRef="usd">23285333</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RleHRyZWdpb246MDhjMWZhNmRkZjU1NDkzMmI1YmJkOGExM2JlYTAxZDlfNzQ_3a440a68-8a74-4745-bc6e-bf158a30de10">ACCRUED EXPENSES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payroll and bonus accrual&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,925,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,764,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,795,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,564,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;546,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,598,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,671,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RleHRyZWdpb246MDhjMWZhNmRkZjU1NDkzMmI1YmJkOGExM2JlYTAxZDlfNzU_a18eb740-62d7-4ff8-bd43-5f302b2bda90">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payroll and bonus accrual&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,925,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,764,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,795,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,564,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;546,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,598,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,671,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMS0xLTEtMS0xMTE_bc33cfa9-efe7-46e5-8a50-0cb4afe7f6f1"
      unitRef="usd">2925196</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMS0zLTEtMS0xMTE_8922ee44-deac-41ea-be31-0db1cde6ee25"
      unitRef="usd">3764666</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ovid:AccruedResearchAndDevelopment
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMi0xLTEtMS0xMTE_69ce806c-8f33-4c12-b81a-3d2f47ffe6af"
      unitRef="usd">771066</ovid:AccruedResearchAndDevelopment>
    <ovid:AccruedResearchAndDevelopment
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMi0zLTEtMS0xMTE_2c61efdf-9674-4174-a102-660aec363cdd"
      unitRef="usd">1795190</ovid:AccruedResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMy0xLTEtMS0xMTE_49265732-1f6e-488e-a043-b72aa74562f9"
      unitRef="usd">396563</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfMy0zLTEtMS0xMTE_c2d8f1f8-0d90-4a9a-823f-eee1dba9c54f"
      unitRef="usd">1564955</us-gaap:AccruedProfessionalFeesCurrent>
    <ovid:IncomeTaxAccrualCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNS0xLTEtMS0xMTE_5c60c4e2-353a-4fe7-bbda-8b0ef1fac6bc"
      unitRef="usd">222536</ovid:IncomeTaxAccrualCurrent>
    <ovid:IncomeTaxAccrualCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNS0zLTEtMS0xMTE_d32bf628-ddae-4702-9ded-98d7627c6fb1"
      unitRef="usd">0</ovid:IncomeTaxAccrualCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNi0xLTEtMS0xMTE_00811892-2237-4006-8316-fa10f55fe8e8"
      unitRef="usd">283482</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNi0zLTEtMS0xMTE_7b4fe2c8-4e49-4610-90b6-c6196674299e"
      unitRef="usd">546464</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNy0xLTEtMS0xMTE_fdc841f6-f500-464a-b0a6-2e581cd7db9d"
      unitRef="usd">4598843</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV80OS9mcmFnOjA4YzFmYTZkZGY1NTQ5MzJiNWJiZDhhMTNiZWEwMWQ5L3RhYmxlOjk2MmRjNjNkYjI0MjRlMzdhNDJiY2NjYTY1YTM0NmI0L3RhYmxlcmFuZ2U6OTYyZGM2M2RiMjQyNGUzN2E0MmJjY2NhNjVhMzQ2YjRfNy0zLTEtMS0xMTE_2eb83e0d-7fa4-4e9e-bed9-194461099556"
      unitRef="usd">7671275</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzIzNA_54b7bf3a-d560-44bc-aeb4-0ba524190269">STOCKHOLDERS&#x2019; EQUITY AND PREFERRED STOCK&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s capital structure consists of common stock and convertible preferred stock ("Preferred Stock"). Pursuant to the Company&#x2019;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of Preferred Stock. The Company has designated 1,250 of the 10,000,000 authorized shares of Preferred Stock as non-voting Series A Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of Preferred Stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of Preferred Stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the Preferred Stock are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (the &#x201c;2020 ATM agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may offer and sell in &#x201c;at the market offerings,&#x201d; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Cowen acting as sales agent. As of June&#160;30, 2022, the Company has not sold any shares of its common stock under the 2020 ATM agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There were 1,250 shares of Series A Preferred Stock outstanding as of June&#160;30, 2022 and December&#160;31, 2021. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&#x2019;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#x2019;s election to any other number less than or equal to 19.99% upon 61 days&#x2019; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&#x2019;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2021, certain of the Company&#x2019;s stockholders elected to convert an aggregate of 2,000 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,000,000 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Holders of Series A preferred stock are entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends (other than dividends in the form of the issuance of common stock) actually paid on shares of common stock. No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid. Through June&#160;30, 2022, the Company has not declared any dividends.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMjk1_90e7d06c-82a7-48c9-900b-d1266e802ce9"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzI1_e873abbf-82f1-42fb-88a6-230be698de8a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <ovid:PreferredStockShareDesignated
      contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzgy_431b549c-acb9-4ae1-9574-7207ca410420"
      unitRef="shares">1250</ovid:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5NzgyMTc_ffdacf26-819c-467d-839b-43fa0507729d"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <ovid:CommonStockNumberOfVotesPerShare
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzk0MTA_7b423f48-ba22-4c08-a4dd-374b6f07d55d"
      unitRef="vote">1</ovid:CommonStockNumberOfVotesPerShare>
    <ovid:AggregateOfferingPriceOfCommonStock
      contextRef="i396fded5753344dc9202659aa58b987f_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTUxMw_8d7b3d8a-a753-4384-995e-6659f521d355"
      unitRef="usd">75000000</ovid:AggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id1edfe140f8c433fb25ab41d64b939f4_D20201101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU3OQ_6fb7a59e-7eb4-4fcc-9314-cb4d1beeab2e"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTY1OQ_5574829e-834f-47e9-a8ce-add76bc47aa8"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i25bcc14f90fb4eaba2e1ef18f0fd5335_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTY1OQ_c3677c93-8a73-4db3-a0a0-551b68809bf3"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1NTg_42cb010b-b728-4b19-a854-cf7abcd041e8"
      unitRef="shares">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates
      contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1NjY_d21ce643-f848-4d0f-90c1-efba2aaf5014"
      unitRef="number">0.0999</ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates>
    <ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders
      contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1NzU_bfa76345-bc2d-4000-9186-06fa61fafdc1"
      unitRef="number">0.1499</ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders>
    <ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates
      contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzg4MzA_88fac440-cb2d-4c9f-9de9-ac606c6befc8"
      unitRef="number">0.1999</ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates>
    <ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod
      contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzk0MjM_0c6379fb-7c6d-419e-a1ef-533357597710">P61D</ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod>
    <ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod
      contextRef="i103968bbbbdf4c41b3076a44566672aa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzk2MjI_0c6379fb-7c6d-419e-a1ef-533357597710">P61D</ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod>
    <ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock
      contextRef="ide285b55b9334ea5a3d4633e081e2e8b_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzg4Mzg_0d83c035-6fee-4021-b7fc-a6e9db720402"
      unitRef="number">0.100</ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock>
    <ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock
      contextRef="i99e9dab21e48412995440424c42b8768_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTQ4NDM0MDY5Nzg4NDU_7646b6ff-f63c-48f7-8742-6fc08e1cee62"
      unitRef="number">0.150</ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="ia05d6c2203a4462ea3a7a5ce859fa6f0_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMjU2Nw_6d005b5b-3b11-41d5-bbde-a9f1af46ab56"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1f1a12100aba4eaaba8e5398cb22d594_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1ODM_c9f91b1e-4a21-485c-ae67-85157146188a"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i52d16d0decba4c0cb030da72a9ea1c58_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY1OTU_7675a195-cc67-44e0-bb1c-ce3723ca14fa"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:Dividends
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMTU5NDI5MTg2MDY2MDA_8fd2dffc-aae3-441e-ab65-128d4604f587"
      unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81Mi9mcmFnOjc2NjcwNzA0ZWJmNDQwNmRhODBjNmM4YzE2MWRkZjdlL3RleHRyZWdpb246NzY2NzA3MDRlYmY0NDA2ZGE4MGM2YzhjMTYxZGRmN2VfMzIwOQ_8fd2dffc-aae3-441e-ab65-128d4604f587"
      unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2MA_5b9180d0-6490-44d4-9173-f740a185f7c4">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors adopted and the Company's stockholders approved the 2017 Equity Incentive Plan (&#x201c;2017 Plan&#x201d;), which became effective immediately on May 4, 2017. The initial reserve of shares of common stock under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company&#x2019;s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. On January&#160;1, 2022 and January&#160;1, 2021, respectively, an additional 1,000,000 and 3,287,158 shares were reserved for issuance under the 2017 Plan. As of June&#160;30, 2022, there were 2,706,415 shares of the Company&#x2019;s common stock reserved and available for issuance under the 2017 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 Employee Stock Purchase Plan (the &#x201c;2017 ESPP&#x201d;), which became effective immediately prior to the execution of the underwriting agreement related to the Company&#x2019;s initial public offering on May 4, 2017. The 2017 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated semi-annual purchase dates. During the three months ended June&#160;30, 2022 and 2021, no shares were purchased under the 2017 ESPP, and the Company recorded expense of $20,176 and $37,849, respectively. During the six months ended June&#160;30, 2022 and 2021, 38,583 and 34,256 shares, respectively, were purchased under the 2017 ESPP and the Company recorded expense of $41,195 and $56,636, respectively. The initial reserve of shares of common stock that may be issued under the 2017 ESPP was 279,069 shares. The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#x2019;s common stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board. The Board acted prior to each of January&#160;1, 2021 and January&#160;1, 2022 to provide that there be no increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of June&#160;30, 2022, there were 454,479 shares of the Company&#x2019;s common stock reserved for issuance under the 2017 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unless specified otherwise in an individual option agreement, stock options granted under the prior plan and the 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&#x2019;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#x2019;s service with the Company. In the event of option holder&#x2019;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Performance-based option awards generally have similar terms, with vesting commencing on the date the performance condition is achieved and expire in accordance with the specific terms of the agreement. At June&#160;30, 2022, there were 150,000 performance-based options outstanding and unvested that include options to be granted upon the achievement of certain research and development milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require significant assumptions that are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on historical volatility information of peer companies that are publicly available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be canceled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company did not grant any stock options to nonemployee consultants for services rendered during the three months ended June&#160;30, 2022 and 2021. The Company granted no stock options to nonemployee consultants for services rendered during the six months ended June&#160;30, 2022, and 170,000 during the six months ended June 30, 2021. There were 130,834 and 191,875 unvested nonemployee options outstanding as of June&#160;30, 2022 and 2021, respectively. Total expense recognized related to nonemployee stock options for the three months ended June&#160;30, 2022 and 2021, was $160,337 and $55,310, respectively. Total expense recognized related to nonemployee stock options for the six months ended June&#160;30, 2022 and 2021 was $355,107 and $91,000, respectively. Total unrecognized compensation expenses related to the nonemployee stock options was $1.1 million as of June&#160;30, 2022. The Company did not recognize any expense for nonemployee performance-based option awards during the three months or six months ended June&#160;30, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company granted 2,426,750 and 363,000 stock options to employees during the three months ended June&#160;30, 2022 and 2021, respectively. The Company granted 4,296,355 and 1,006,600 stock options to employees during the six months ended June&#160;30, 2022 and 2021 respectively. There were 7,354,964 and 4,749,550 unvested employee options outstanding as of June&#160;30, 2022, and 2021, respectively. Total expense recognized related to the employee stock options for the three months ended June&#160;30, 2022 and 2021 was $1.5 million and $1.2 million, respectively. Total expense recognized related to the employee stock options for the six months ended June&#160;30, 2022 and 2021 was $2.6 million and $2.4 million, respectively. Total unrecognized compensation expense related to employee stock options was $14.3 million as of June&#160;30, 2022. During the three and six months ended June&#160;30, 2022 and 2021, the Company did not recognize any expense for employee performance-based option awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense was recognized in operating expense as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;387,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;430,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;782,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;888,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,332,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;826,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2,262,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,688,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,257,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2,577,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,219,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,003,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,520,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,257,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,577,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of employee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;86.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;81.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of nonemployee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;80.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;80.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,776,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,389,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,296,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,605,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,451,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,965,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022 there was approximately $15.4 million of unamortized share&#x2013;based compensation expense related to employee and nonemployee grants, which is expected to be recognized over a remaining average vesting period of 2.53 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3508026e6a624653b3042497a2e56b5b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjg3_91765481-eb52-40f9-9158-56d881c01e56"
      unitRef="shares">3052059</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfOTcz_003ae004-8260-4002-b1f6-536cdcca8c06"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i02cc5fc3748f41a18d30fe59dd7c68f5_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTIwMA_19ec8342-b3b2-4d99-bd22-7536f4b61e71"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i8940c1997dcf4466957a1a618e9364e2_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTIwNw_3826d7e9-ea69-46d5-bad2-a48e60bb4c91"
      unitRef="shares">3287158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i3508026e6a624653b3042497a2e56b5b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTI4Ng_df7b118f-6417-4e0a-b8a3-ca405f7b04fd"
      unitRef="shares">2706415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc0Nw_9b8ed03b-650f-4865-8a65-2e6af8ac092f"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="ie10101268c9545129eb922032bed501f_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1MzE_60d81594-863e-4b2b-8409-14c26aac3d85"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1MzE_cafc58d5-4968-44d9-8269-28802d4ab1d4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48b2fd655d9c4320b8cc314462b196e1_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTk1MA_d007b456-06da-4bf7-9449-2dfacff8b6f8"
      unitRef="usd">20176</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie10101268c9545129eb922032bed501f_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTk1Nw_51f4d74b-1a5a-4076-b09b-2ae4e5d8ae73"
      unitRef="usd">37849</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNDM5ODA0NjUxNzkxMA_d7fb4d38-877f-44e3-9cde-b621a3fdb7b0"
      unitRef="shares">38583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="i81fd80cb6bb741a59d284cc88e7d599f_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNDM5ODA0NjUxNzkxOA_0eb23a20-4345-4436-b6b3-6698e026840d"
      unitRef="shares">34256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNTUwMQ_c5ba7947-4e3b-4b6a-92b6-9a690675e21e"
      unitRef="usd">41195</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81fd80cb6bb741a59d284cc88e7d599f_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNTUwNg_341b75cc-746f-4b96-b06f-cdc160bc74e6"
      unitRef="usd">56636</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i470e73798de645539193ae88dadc6e89_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjA2NA_2d235b8c-60dc-4360-8777-906ac7a19952"
      unitRef="shares">279069</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease
      contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTQ4NDM0MDY5ODQxNDU_a6537041-6b2d-4f21-bd5f-edb8a8f4e87c"
      unitRef="number">0.01</ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease>
    <ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum
      contextRef="i7dbb292a8460413d8d992c125a9913b5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTQ4NDM0MDY5ODQxNDk_78c1d51e-b43b-485e-affc-bb9628b6750c"
      unitRef="shares">550000</ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i86715d6c5277421e8cfe925f1cecc804_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjU4MQ_0548f70d-ef83-4171-a615-b784dcf00ce3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i475e7bce27984b60afa0fcb779a15e53_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjU4MQ_3953118d-1a20-4006-ae28-9b3ae6161788"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i470e73798de645539193ae88dadc6e89_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMjcwMQ_4735fe89-2ec5-4e2a-97c5-7edc0ac4a2d0"
      unitRef="shares">454479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2NA_01d96696-eb7f-46a5-89e1-19e5cf452f9a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2NQ_9a4f387f-a6d8-4efc-86b3-3cbf0312af2b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic6177283fa574d389030abaddc54c6f1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMzI3NA_9f8aae8b-912e-40ec-8e28-42fc7c37e37e">P90D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i3f12ff0a9fb44b2ba76ca118062f6098_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMzcyOQ_859f150c-741c-4152-8208-e734c2f2cf34"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9ccabdb8d53a43e0970777c2bff04d2a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1NDg_9ce2d89c-67ee-473d-8b8e-b4bd3b67b1b7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i056926527a084313881277f409aada39_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1NDg_c31220c4-a950-4c2e-a171-f9e34895021a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i29fa1f2702714d129b63abc66f393ba1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNDkyMA_34cd247c-0d68-497c-b59e-c5f62f695952"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2e7d9406a7aa47ee9442314d3d15d65a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTc1OTIxODYwNTM1NDA_08d3e423-ceff-4380-9198-a96755f996e3"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="ia0ba85194e42413b99a2652ace7aedca_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTAzNQ_8db60e5e-52d0-4cae-acdc-ee8d4fea49a7"
      unitRef="shares">130834</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i572f2349b435422a9a724121d8d55ebb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTA0Mg_9442fabe-0900-48cb-9fe3-77c9fb6d61bb"
      unitRef="shares">191875</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ccabdb8d53a43e0970777c2bff04d2a_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTIyNQ_81fcc808-6365-4e32-a115-14d7490b59ae"
      unitRef="usd">160337</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i056926527a084313881277f409aada39_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTIzMg_0e0f7b25-aff0-467c-9bee-32ea7925283e"
      unitRef="usd">55310</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29fa1f2702714d129b63abc66f393ba1_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjY5Ng_1d74e512-ede5-4fe2-8bb9-4914cda5550d"
      unitRef="usd">355107</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e7d9406a7aa47ee9442314d3d15d65a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjcwMg_8db12a5c-6a85-403c-8125-75f54f155051"
      unitRef="usd">91000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia0ba85194e42413b99a2652ace7aedca_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTMzNg_ca459bae-04c8-4580-a86f-941c6ef9c9bd"
      unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec14aa7f907a4e77ac1af5c41c07ec9c_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_0486d9d5-ff1c-45f5-a9ea-0ccebda067a4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b9c90a69fca438fbe1136fe21266e47_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_5a658daf-16aa-4e42-a971-c52d98f6b6ee"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i107d1ca201584d23b2e52b6528cee3b9_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_7b235b32-0dc6-42f0-a77a-72a13847eb86"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe25102eb24f4ad2918ef4f8234f9dd9_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTM2NQ_cf54aaf4-4c5a-4358-95c2-8009aef8ecd8"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i745854a2110948c8b69f1d073bd78059_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUwNA_4a84996a-54ca-4392-b7aa-a37ddfbbe3cf"
      unitRef="shares">2426750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i492b94210b3a4b7d86d6b2934d8249c4_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUxMg_ba342112-165c-43e1-9476-2e5aa3be2825"
      unitRef="shares">363000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i726e5f3ab7a2403e8a39b4c4299b8f03_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUxNg_869ac83a-d804-44ec-9d6c-7e85bffbbc42"
      unitRef="shares">4296355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i968b13093ea749a08c539d52bb627da8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUyMA_f42be184-0f68-474e-91bc-7620d9ea23a1"
      unitRef="shares">1006600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="id8a49b7682c84becb2480ace83af36da_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTU5MA_996fb280-fba4-450e-907e-3f917e2cc65d"
      unitRef="shares">7354964</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="id64ce862122d47ecbb9d8f2a54bceb89_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTU5Nw_54b5c4c1-f145-4407-9eeb-b65bb1b5f855"
      unitRef="shares">4749550</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i745854a2110948c8b69f1d073bd78059_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUzMQ_f6f820ea-6d08-40ca-a231-f459a72f1796"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i492b94210b3a4b7d86d6b2934d8249c4_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjUzOA_0672101f-31cb-42b6-bbe7-a34f0ff0b43f"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i726e5f3ab7a2403e8a39b4c4299b8f03_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjU0NQ_24b3302b-9365-4419-8375-f47f2ec24c51"
      unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i968b13093ea749a08c539d52bb627da8_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfMTA5OTUxMTYzNjU1MA_dbbe0576-39b6-44c9-a504-96a0a6e19bc3"
      unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id8a49b7682c84becb2480ace83af36da_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTg3Mw_aac46b7c-b9e2-41b1-9ee3-d7ce66427254"
      unitRef="usd">14300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic5d6c1d737bc4c51950da33e52888f55_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_2d52b2dd-865d-440e-9de5-047227dc971b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc43365824f445169eaac324f106070c_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_5c21a48a-920f-4322-b823-22c1874761ff"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3cb23b2f75c46c28a56b7a45b2e8df4_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_cbeef085-5973-4c79-a265-6743dcb6341b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i215fc869cefa46228a13075881587aa5_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNTk0MA_fc53ffa0-a8b3-45aa-9fbb-eae2635c36f4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2Mw_33abb448-ee13-4127-b193-7ca3b42c5c4e">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense was recognized in operating expense as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;387,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;430,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;782,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;888,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,332,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;826,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2,262,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,688,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1,257,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2,577,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec95a18524b84f6cba11d8e830382e5e_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi0xLTEtMS0xMTE_a09c20ab-64b8-4ac7-b99f-5c8e163a3262"
      unitRef="usd">387384</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4297c63d08874f919d86d5021b5f608e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi0zLTEtMS0xMTE_698259d3-be7e-4cd8-9a4a-77ec834c2810"
      unitRef="usd">430638</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d0ce81ed9f94da3af27fc09016adade_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi01LTEtMS0xMTE_64860c0a-5a7a-4c5a-bbcf-d6ff06cf2369"
      unitRef="usd">782876</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc2df3425269455d899f773df3cd67d0_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMi03LTEtMS0xMTE_c5a11293-9635-4a81-b9ed-65e411734ae8"
      unitRef="usd">888673</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f367baf510f4fcaa8c3b3609d892ab8_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy0xLTEtMS0xMTE_ca2906a8-a17b-4f24-8beb-576160c5b7b6"
      unitRef="usd">1332833</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53e4fcf781a84fabbc66e00870f256e2_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy0zLTEtMS0xMTE_27339b1f-8bc4-4cea-aeee-df1fafed0dbd"
      unitRef="usd">826707</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c156f7edfc44816bd94d9a3facde46d_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy01LTEtMS0xMTE_4249c599-8701-49bc-9241-3149e02ec294"
      unitRef="usd">2262153</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58c5083745084ba09e6a766ccd66cc65_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfMy03LTEtMS0xMTE_6efa7fa4-c7ee-4e56-953b-728c7ed51271"
      unitRef="usd">1688673</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC0xLTEtMS0xMTE_7ca35b15-98dd-4ede-b47a-ef7e493d1a05"
      unitRef="usd">1720217</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC0zLTEtMS0xMTE_4ee02877-31e5-4351-aeed-afb0bb9232b4"
      unitRef="usd">1257345</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC01LTEtMS0xMTE_731c3141-e8fd-4723-b717-dcb41a282cb3"
      unitRef="usd">3045029</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3NTNmMDkyZjNiZTQxZTNiZDdhMmY0MGUxODg2ZDgzL3RhYmxlcmFuZ2U6Zjc1M2YwOTJmM2JlNDFlM2JkN2EyZjQwZTE4ODZkODNfNC03LTEtMS0xMTE_c1a87200-77fc-4b95-bb9d-31c922850aa8"
      unitRef="usd">2577346</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU2Ng_ef07d817-5625-4787-9757-e20f7498e483">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,219,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,003,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,520,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,257,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,577,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06df7810437744ac89df59b3071c4620_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi0xLTEtMS0xMTE_7d413c4b-617f-4e37-b57f-f244bc068740"
      unitRef="usd">1700041</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5eb55df39f645e1a8229022112b64af_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi0zLTEtMS0xMTE_51cd7cc0-6fa5-46f6-98fc-6ab822355f06"
      unitRef="usd">1219496</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a447e8d29e345cca3c8dc8bedfbe959_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi01LTEtMS0xMTE_5a010e34-7996-4756-995a-ae913ecb8445"
      unitRef="usd">3003834</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a1bdd56609e4b82a082d20e67eb1ef3_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMi03LTEtMS0xMTE_963855e5-118d-4045-826d-933b2edea175"
      unitRef="usd">2520710</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99f5712bd10f4cb4b4c1c3047f7e03c4_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy0xLTEtMS0xMTE_296fb217-7f0e-47a8-936b-6395632ca710"
      unitRef="usd">20176</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15dbdd9413234e60876544ae84047d70_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy0zLTEtMS0xMTE_b5ce4df2-27f0-4751-a8b2-df6175984e34"
      unitRef="usd">37849</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idda6566951b0490fb0253c079cb5f522_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy01LTEtMS0xMTE_239b6791-22a4-4273-bb61-11282d87a926"
      unitRef="usd">41195</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67836ea5c7334cdca1bd28a16693be9e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfMy03LTEtMS0xMTE_b79cd270-5fff-4f35-8693-7d2742e24074"
      unitRef="usd">56636</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC0xLTEtMS0xMTE_27e93f00-778e-4f20-ad1a-259f7c01d860"
      unitRef="usd">1720217</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC0zLTEtMS0xMTE_24bee972-2f74-4811-ab9e-ccc9863c2ec2"
      unitRef="usd">1257345</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC01LTEtMS0xMTE_7dd179f0-3cc0-45e1-9a2a-fe77bbdf7718"
      unitRef="usd">3045029</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmY3YTkyNTJhNDBkMTQyMDNhN2VhODc5NDcyYjQ3NTA1L3RhYmxlcmFuZ2U6ZjdhOTI1MmE0MGQxNDIwM2E3ZWE4Nzk0NzJiNDc1MDVfNC03LTEtMS0xMTE_45e22ee0-fa18-42ab-9a6f-48e33dc9997c"
      unitRef="usd">2577346</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU1OA_f9d59d90-1228-4e4e-ae89-1dccd36a72b6">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of employee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;86.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;81.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;5.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;3.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of nonemployee options granted during the three and six months ended June&#160;30, 2022 and 2021 was estimated by utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:105%"&gt;Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;80.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;80.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;6.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;1.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:105%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy0xLTEtMS0xMTE_1c60689b-146d-456c-82cc-ed0dbcb0fe85"
      unitRef="number">0.8720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy0zLTEtMS0xMTE_e3a8e75f-9cce-4f96-97a2-51605d64790e"
      unitRef="number">0.8613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy01LTEtMS0xMTE_3173fabd-425a-4c1e-9da5-8d7b4c1831f4"
      unitRef="number">0.8720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfMy03LTEtMS0xMTE_cc650d61-094b-48a8-b093-6f1bc8ee4953"
      unitRef="number">0.8172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC0xLTEtMS0xMTE_fded23a6-d37f-46e3-afde-6bf4fa3c44bd">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC0zLTEtMS0xMTE_f5531443-6d0a-47e8-aafe-3b16c819beed">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC01LTEtMS0xMTE_924d2f30-32e7-49f1-bb82-8c03760c386c">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNC03LTEtMS0xMTE_247fb205-26fb-4997-aafe-a3256cfec3ad">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS0xLTEtMS0xMTE_8cbf9e69-aa3d-4bdd-8400-302f4dd2fb1b"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS0zLTEtMS0xMTE_215b131e-4a6f-4160-8680-fa9382ee75ac"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS01LTEtMS0xMTE_1087caac-b7b3-4f0b-8f5f-1043deb2cd62"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNS03LTEtMS0xMTE_9ceadfed-b276-4920-b282-a4d08cb66f40"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi0xLTEtMS0xMTE_3911094e-c50f-4627-8a78-aa4b02f8fa7b"
      unitRef="number">0.0278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi0zLTEtMS0xMTE_6556a4ad-c5f5-47e6-a0a7-f05ee29e536e"
      unitRef="number">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi01LTEtMS0xMTE_8575e5e5-6955-4f7e-bc86-fd451d41045e"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNi03LTEtMS0xMTE_c9c869e2-83c0-4ddf-9b58-3c24948f7c80"
      unitRef="number">0.0073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy0xLTEtMS0xMTE_7e563618-3b4c-496a-9a27-822da308535d"
      unitRef="usdPerShare">2.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6af9ba2cedea479fb3b1422069fb1751_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy0zLTEtMS0xMTE_4db1471e-9196-4811-a0c7-a3d7a215c85e"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i82778ffdd7a9447e95c4e93b7d7d442f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy01LTEtMS0xMTE_9f68a8d9-8c3e-4ad5-91fc-edba7b57ad5c"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4a90d35c4e9f48f397f928209d4d2a8c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOjRhMDRhOWFhN2QyYjRjM2U5OWVlMGVlZTVkMDI4NzcxL3RhYmxlcmFuZ2U6NGEwNGE5YWE3ZDJiNGMzZTk5ZWUwZWVlNWQwMjg3NzFfNy03LTEtMS0xMTE_6005dd14-8053-42b5-a2de-cc2cd908691d"
      unitRef="usdPerShare">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy0xLTEtMS0yNDEx_2daf5c3c-623b-4122-b35c-ddb6829a4c13"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy0zLTEtMS0yNDEx_47ece13d-899b-4b16-baa0-6e6df7254b3e"
      unitRef="number">0.8043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy01LTEtMS0yNDEx_1d66b13b-347d-4735-9905-1f869baa7dfb"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfMy03LTEtMS0yNDEx_03354792-9d72-4754-8a85-1712cf998839"
      unitRef="number">0.8043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC0xLTEtMS0yNDEx_0f1493a7-2fbb-4b63-b1d0-1e3033002087">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC0zLTEtMS0yNDEx_82cc7b10-cc91-46de-af18-370776f66676">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC01LTEtMS0yNDEx_d2456d7d-a1e1-4e97-b1d5-8b3dcada0db2">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNC03LTEtMS0yNDEx_8141d1b7-6950-4af2-89ca-e862f1eb8c62">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS0xLTEtMS0yNDEx_60294358-5b21-4496-aff5-054cec8fc573"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS0zLTEtMS0yNDEx_099e001e-46a8-4b73-bc47-1b5498aeab19"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS01LTEtMS0yNDEx_02dc4507-7219-4da9-a4ac-d4df5b7a8aac"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNS03LTEtMS0yNDEx_16482988-db7f-40ab-bb85-f66a0d6bef10"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi0xLTEtMS0yNDEx_38ec55a7-aefc-4136-9c7c-26af81580c16"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi0zLTEtMS0yNDEx_cc6197ba-1123-4989-a7c2-b0ab3f67f690"
      unitRef="number">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi01LTEtMS0yNDEx_06b23c70-be1e-4358-af59-b56745eb0ad4"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNi03LTEtMS0yNDEx_48d66202-fe87-4cd8-b856-d4ca0eaa4299"
      unitRef="number">0.0103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e0ccd096afa44e5a35efd87b6a203c7_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy0xLTEtMS0yNDEx_4fab4a5e-4cb5-40d0-a5ac-e1418eda7963"
      unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iacbafcd7f2ee483bb9ef5e5fc81d073f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy0zLTEtMS0yNDEx_918643ba-9380-49d2-ba32-88dc0804ff51"
      unitRef="usdPerShare">2.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia357d7fe5ab540bf9376466560c97767_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy01LTEtMS0yNDEx_d90a4b40-611d-4ffd-80ee-5f90f6bb2eb7"
      unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if6fa5aa1766a4fb295367d0d64506d49_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmI4ODRiNTNlNGZkMzRmNTZhMzllNDVmMzI4NGMxY2FmL3RhYmxlcmFuZ2U6Yjg4NGI1M2U0ZmQzNGY1NmEzOWU0NWYzMjg0YzFjYWZfNy03LTEtMS0yNDEx_30f790ea-fc33-4fac-94fd-77c4176b261b"
      unitRef="usdPerShare">2.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU1OQ_ea6c4ae7-f5d4-47b4-8f59-5316418efd00">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,776,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,389,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,296,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,605,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,451,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,965,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS0xLTEtMS0xMTE_b496d860-8b22-4840-be1f-6f439995e153"
      unitRef="shares">10776758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS0zLTEtMS0xMTE_77239d56-34aa-4b8f-ba4d-bf691104529e"
      unitRef="usdPerShare">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic0fd76e8bb5349d9ab296f99828590c8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS01LTEtMS0xMTE_8a4e806e-6d48-428c-88ea-6b836c54c3bb">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id6a06c63bc824ec19efb5af5e13b7f53_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMS03LTEtMS0xMTE_d8cc91c2-ad35-4a44-b765-20591b8ad7dd"
      unitRef="usd">2389890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMi0xLTEtMS0xMTE_5606ccdb-b547-4c3d-a5b5-7ca83cf4e930"
      unitRef="shares">4296355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMi0zLTEtMS0xMTE_4ad21006-cfc7-4d39-b8bb-084644a43e83"
      unitRef="usdPerShare">2.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMi01LTEtMS0xMTE_23ec2054-a71c-46c0-bad7-4844d6d3e78a">P9Y8M4D</ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMy0xLTEtMS0xMTE_814728ca-2855-4648-b2f4-dfc550284063"
      unitRef="shares">15893</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfMy0zLTEtMS0xMTE_70d7da43-1528-4f61-8bd1-7b52072ceb29"
      unitRef="usdPerShare">1.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNC0xLTEtMS0xMTE_58f80ff5-9292-46bc-99bd-b1d8f0273324"
      unitRef="shares">1605703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNC0zLTEtMS0xMTE_54dd2004-ec5f-4a13-b801-5fccdadd08f8"
      unitRef="usdPerShare">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS0xLTEtMS0xMTE_511fc59f-d33b-4816-b8e0-231e3162b5a6"
      unitRef="shares">13451517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS0zLTEtMS0xMTE_599bdc74-9366-4ab9-b6f4-14c4a7bd24d3"
      unitRef="usdPerShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS01LTEtMS0xMTE_d13e7e0e-b96d-41ea-9e9a-f4210d3405d0">P7Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNS03LTEtMS0xMTE_e54a1d54-f3ca-40eb-b674-176873ea984a"
      unitRef="usd">329651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi0xLTEtMS0xMTE_40b4f299-092b-44b8-806f-fac47f8fe6ee"
      unitRef="shares">5965719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi0zLTEtMS0xMTE_1a101fbd-9a30-432e-8778-f86a43f7064e"
      unitRef="usdPerShare">5.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi01LTEtMS0xMTE_db3bbd16-badc-485a-b789-b919ed6b57a4">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RhYmxlOmNmOWYzNWNhOGZlOTQyNWE5N2NkODk0MDY3NWE1YzA2L3RhYmxlcmFuZ2U6Y2Y5ZjM1Y2E4ZmU5NDI1YTk3Y2Q4OTQwNjc1YTVjMDZfNi03LTEtMS0xMTE_9205a50d-b007-4258-9ccf-c9fb1ee87b4f"
      unitRef="usd">297953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5514b03ea99548678298804a7de4efdb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjM4Mw_aafe08b9-82b7-490b-ac8b-7f20c7a36ac0"
      unitRef="usd">15400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81NS9mcmFnOjYwM2I5ZjIxZGQxNzRhZTNiMGJkMTFmYjQ5NjRjZmU2L3RleHRyZWdpb246NjAzYjlmMjFkZDE3NGFlM2IwYmQxMWZiNDk2NGNmZTZfNjU1Ng_dcfc7aee-233e-476e-85a6-52b5b6924e6b">P2Y6M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81OC9mcmFnOmU2OWNmODQzMTZlNzRjZTJiODE0MWY1YTBmOWM5NDVhL3RleHRyZWdpb246ZTY5Y2Y4NDMxNmU3NGNlMmI4MTQxZjVhMGY5Yzk0NWFfMTYyNA_0fa2836d-8086-432d-a386-1fd8e9e5acee">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of June&#160;30, 2022, the Company was in a pre-tax loss position, and is anticipated to remain so throughout the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2022, the Company did not record a tax provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81OC9mcmFnOmU2OWNmODQzMTZlNzRjZTJiODE0MWY1YTBmOWM5NDVhL3RleHRyZWdpb246ZTY5Y2Y4NDMxNmU3NGNlMmI4MTQxZjVhMGY5Yzk0NWFfMTQ4NDM0MDY5NzY3MTM_2194abc8-f01f-42ec-ab38-1747eaf7e0ae"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV81OC9mcmFnOmU2OWNmODQzMTZlNzRjZTJiODE0MWY1YTBmOWM5NDVhL3RleHRyZWdpb246ZTY5Y2Y4NDMxNmU3NGNlMmI4MTQxZjVhMGY5Yzk0NWFfMTQ4NDM0MDY5NzY3MTM_735648d1-1712-43e6-b7c7-74a3825fa05c"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfNzgwNQ_361641af-da39-4396-ad69-04ee05d8dddc">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;H. Lundbeck A/S License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March 26, 2015, the Company entered into an exclusive agreement with H. Lundbeck A/S (&#x201c;Lundbeck&#x201d;) for a worldwide perpetual licensing right related to the research, development and commercialization of OV101 (gaboxadol). On May 10, 2019, the parties amended the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pursuant to the Lundbeck license agreement, as of the first amendment, the Company agreed to make milestone payments totaling up to $189.0 million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $1.0 million is due upon the successful completion of the first Phase 3 trial for a product in which OV101 is an active ingredient. In addition, the agreement calls for the Company to pay royalties for an initial term based on a low double-digit percentage of sales and provides for the reduction of royalties in certain limited circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter, the Company closed its OV101 program in Angelman syndrome in early 2021. On February 1, 2022, the Company entered into Amendment No. 3 to the Lundbeck agreement, or Amendment No. 3, to permit its performance under the Healx License and Option Agreement. Under the terms of Amendment No. 3, if Healx exercises its option, the Company will owe Lundbeck a share of all milestone and royalty payments received from Healx if the Company chooses not to exercise the Ovid Opt-In Right. If the Company chooses to exercise the Ovid Opt-In Right and to co-develop and co-commercialize the program with Healx, the Company will owe a share of the net profit share to Lundbeck (see further discussion below in Note 11, Healx License and Option Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Northwestern University License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.  The Company is developing OV329 under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3&#160;million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets. The Company&#x2019;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#x2019;s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company&#x2019;s uncured material breach or insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca AB License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On December 30, 2021, the Company entered into an exclusive license agreement with AstraZeneca AB, for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $5.0 million and issued shares of the Company's common stock in an amount that equaled $7.3 million based on the volume-weighted average price of shares of the Company's common stock for the 30 business days immediately preceding the execution date of the transaction. Since the intangibles acquired in the AstraZeneca license agreement do not have an alternative future use, all costs incurred were treated as research and development expense. The Company recorded a total of $12.3 million as research and development expense related to this agreement during December 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $203.0 million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $3.0 million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, none of these contingent payments were considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the terms of their respective employment agreements, certain of our executive officers are eligible to receive severance payments and benefits upon a termination without &#x201c;cause&#x201d; or due to &#x201c;permanent disability,&#x201d; or upon &#x201c;resignation for good reason,&#x201d; contingent upon the executive officer&#x2019;s delivery to the Company of a satisfactory release of claims, and subject to the executive officer&#x2019;s compliance with non-competition and non-solicitation restrictive covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ovid:LicenseAgreementMilestonePayments
      contextRef="i900ec607f0a344bbbf9a2c6f28d71d29_I20150326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyMTg_18ba72a7-f3ef-407d-ab68-0e93288f8f27"
      unitRef="usd">189000000</ovid:LicenseAgreementMilestonePayments>
    <ovid:FirstPaymentDueUponCompletionOfFirstPhase
      contextRef="i89857dab9c4747b59247c78b1c721361_D20150326-20150326"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyMzc_dbb36013-6172-4b75-af5b-a82abfc4fd65"
      unitRef="usd">1000000</ovid:FirstPaymentDueUponCompletionOfFirstPhase>
    <ovid:NumberOfTrial
      contextRef="i89857dab9c4747b59247c78b1c721361_D20150326-20150326"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfNjU0_4f76d4c4-7314-4857-917e-bc7decd8c366"
      unitRef="trial">3</ovid:NumberOfTrial>
    <ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment
      contextRef="ia2be4bda75f94fdd83408349ef2a84a4_D20161201-20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyNTA_cd3b514f-f636-46c2-92ff-da96704633c4"
      unitRef="usd">75000</ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment>
    <ovid:AnnualLicenseMaintenanceFeePayable
      contextRef="i13f4bf2cb6d44b7f9ec70416be17a531_I20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyNjA_eefbfa99-8a03-422e-85eb-a52863d60307"
      unitRef="usd">20000</ovid:AnnualLicenseMaintenanceFeePayable>
    <ovid:ConsiderationPayableForRightsGrant
      contextRef="ia0577fed13974cc79c32e75d6afbf552_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMzczNg_a0b80b61-ddf3-456c-8a7d-78bae7eb8046"
      unitRef="usd">5300000</ovid:ConsiderationPayableForRightsGrant>
    <ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement
      contextRef="ia2be4bda75f94fdd83408349ef2a84a4_D20161201-20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfNDgxMg_3ef38a38-0c80-414a-923c-53949a4947d1"
      unitRef="product">1</ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement>
    <ovid:UpfrontCashPayment
      contextRef="iff1b6990a524490f93ea31b743af4557_D20211230-20211230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyNzU_805a7f97-3249-45e9-8676-ce24d540c530"
      unitRef="usd">5000000</ovid:UpfrontCashPayment>
    <us-gaap:CommonStockSharesIssued
      contextRef="icf2f99c556604fba8747dc92065c5ec1_I20211230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEyOTA_658f8031-bbf4-4324-9711-a12bc18dfd12"
      unitRef="shares">7300000</us-gaap:CommonStockSharesIssued>
    <ovid:CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate
      contextRef="iff1b6990a524490f93ea31b743af4557_D20211230-20211230"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTQ4NDM0MDY5ODM1ODY_d8995be7-e8bc-4387-8bc0-8d55ab19669a">P30D</ovid:CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8e5e3642cc734de5ac47c8a5ccb0a666_D20211201-20211230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEzMDY_9ae864f3-2902-4ac8-aa8c-2420f57946eb"
      unitRef="usd">12300000</us-gaap:ResearchAndDevelopmentExpense>
    <ovid:LicenseAgreementMilestonePayments
      contextRef="id1d5cd62a7c1493a9fde980d2163424c_I20211230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEzMzI_ebd748f5-8591-4d10-9b1a-0b8dc91d3d11"
      unitRef="usd">203000000</ovid:LicenseAgreementMilestonePayments>
    <ovid:FirstPaymentDueUponCompletionOfFirstPhase
      contextRef="ib3e38e7a15e34cceafd124f84ef81706_D20211230-20211230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82MS9mcmFnOjBkNTkyOTYxN2NjYTQ5ZDk4NDZlMTJiN2M2MzA1NmVjL3RleHRyZWdpb246MGQ1OTI5NjE3Y2NhNDlkOTg0NmUxMmI3YzYzMDU2ZWNfMTU5NDI5MTg2MTEzNDc_f6ce67db-a582-43cd-abe3-4059fa538a78"
      unitRef="usd">3000000</ovid:FirstPaymentDueUponCompletionOfFirstPhase>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTM0MjA_0e1e37d4-bd00-486e-87bf-f96454c45d0a">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Angelini Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On July 9, 2020, the Company entered into the Angelini License Agreement, pursuant to which the Company granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABAA receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey (the &#x201c;European Territory&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March 29, 2021, the Company received a notice of termination of the Angelini License Agreement. Subsequently, Angelini and the Company mutually agreed to waive the six month termination notice provisions and the Angelini License Agreement terminated effective March 31, 2021. The Company has been released from its performance obligations and will not be entitled to any future milestone payments under the Angelini License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Angelini License Agreement to determine whether it was a collaborative arrangement for purposes of ASC 808. The Company concluded that because Angelini was not the ultimate decision maker or the legal owner of the license, Angelini was not considered an active participant and therefore the Angelini License Agreement was outside of the scope of ASC 808. The Company concluded that Angelini was a customer with regard to the combined license and research and development activities and as such the Angelini License Agreement should be evaluated under ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company identified the following material promises under the Angelini License Agreement: (1) licensing of intellectual property with respect to OV101; (2) completion of certain ongoing trials; (3) transfer of a specified amount of compound and related information; (4) potential for funding 35% of the cost for Angelini future trials limited to $7.0 million; and (5) completion of the manufacturing process technology transfer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determined that the $7.0 million represented a potential payment to a customer and was deferred. The transfer of compound and related information was considered a contingent milestone payment that will be recognized upon acceptance by Angelini of the milestone. The Company further determined that the license and the completion of ongoing trials were distinct from each other, as each had value without the other. As such, for the purposes of ASC 606, the Company determined that these two material promises, represented distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pursuant to the Angelini License Agreement and during the year ended December 31, 2020, Angelini made an upfront payment to the Company of $20.0 million. Upon the transfer of the specified amount of compound and related information and acceptance by Angelini, Angelini paid the Company an additional $5.0 million. This payment was determined to be variable consideration which was constrained and not considered part of the upfront transaction price allocation. The Company determined the transaction price was equal to the upfront fee of $20.0 million. The transaction price was allocated based on the standalone selling price of the license and the ongoing trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, no revenue was recognized pursuant to the Angelini License Agreement. During the six months ended June 30, 2021 and effective upon termination of the Angelini License Agreement, the Company recognized $12.4 million of revenue consisting of $5.4 million of license revenue related to ongoing trials and the $7.0 million related to the potential 35% funding of the cost for Angelini future trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On January 6, 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into the Takeda License and Termination Agreement, pursuant to which Takeda secured rights to the Company&#x2019;s 50% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company&#x2019;s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the Takeda License and Termination Agreement, all rights in soticlestat were owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including milestone payments or any future development and commercialization costs. On March 29, 2021 upon the closing of the Takeda License and Termination Agreement, the Company received an upfront payment of $196.0 million and, if soticlestat is successfully developed, will be eligible to receive up to an additional $660.0 million upon Takeda achieving developmental, regulatory and sales milestones. In addition, the Company will be entitled to receive tiered royalties beginning in the low double-digits, and up to 20% on sales of soticlestat if regulatory approval is achieved. Royalties will be payable on a country-by-country and product-by-product basis for any indications that soticlestat is approved for and sold during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company identified the following material promises under the Takeda License and Termination Agreement: (1) no later than the second business day prior to the closing of the Takeda License and Termination Agreement (the &#x201c;Closing Date&#x201d;), the Company and Takeda were required to agree on an estimate of the development expenses that accrued, or would accrue, under the original collaboration agreement as of March 31, 2021; (2) on the Closing Date, the Company was required to (i) provide and transfer to Takeda the materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the Takeda License and Termination Agreement, (ii) assign to Takeda certain agreements applicable to the soticlestat program, and (iii) assign to Takeda all of its right, title and interest in, to and under all intellectual property rights developed or created pursuant to the original collaboration agreement and owned jointly by the Company and Takeda as of the Closing Date; (3) within 45 days after March 31, 2021, the Company and Takeda were required to provide a written report to the finance officer designated by the other party setting forth a final total of the development expenses that accrued as of March 31, 2021 and, within 10 business days after receipt of such report, the finance officers shall agree on whether a net settlement payment is due from Takeda to the Company or from the Company to Takeda; and (4) within 75 days after the Closing Date, to the extent not provided on the Closing Date, Ovid shall provide to Takeda (i) any materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the Takeda License and Termination Agreement, (ii) other documents (including all expired agreements and related data developed thereunder) to the extent relating to the soticlestat program that are necessary for the exploitation, development, commercialization and manufacture of soticlestat, as further set forth in the Takeda License and Termination Agreement and (iii) any tangible embodiments of the intellectual property rights controlled by Ovid that are reasonably necessary for, used in or held for use in Takeda&#x2019;s exploitation of the soticlestat program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price is equal to the upfront fee of $196.0 million and is associated with all four performance obligations identified above. It is noted that the incremental effort associated with performance obligations three and four is negligible and not material in the context of the Takeda License and Termination Agreement since all of the information is related to the collaboration period for which the Company already has the information readily available. Therefore, since they are not material in the context of the Takeda License and Termination Agreement, the full upfront fee was allocated to the two performance obligations satisfied at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, no expense was recognized pursuant to the Takeda License and Termination Agreement. During the six months ended June&#160;30, 2021, the Company recognized a credit in research and development expenses of $2.6 million and recognized $0.1 million in general and administrative expenses representing costs which were reimbursed to the Company from Takeda. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Healx License and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On February 1, 2022, the Company entered into the Healx License and Option Agreement. Under the terms of the Healx License and Option Agreement, Healx has secured a one-year option to investigate gaboxadol (OV101) as part of a potential combination therapy for Fragile X syndrome in a Phase 2A clinical trial, as well as a treatment for other indications, for an upfront payment of $0.5 million, and fees to support prosecution and maintenance of our relevant intellectual property rights. At the end of the one-year option period, Healx has the option to secure rights to an exclusive license under our relevant intellectual property rights, in exchange for an additional payment of $2.0 million, development and commercial milestone payments, and low to mid-tier double digit royalties. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Healx will assume all responsibility for, and costs of, both development and commercialization of gaboxadol following the exercise of the option. The Company will retain the option to co-develop and co-commercialize the program with Healx, or the Ovid Opt-In Right, at the end of a positive readout of clinical phase 2B and would share net profits and losses in lieu of the milestones and royalty payments. If the Ovid-Opt-In Right were exercised, the Company would be required to pay Healx 50% of development costs. The Company does not plan to conduct further trials of gaboxadol. The term of the Healx License and Option Agreement will continue until the later of (a) the expiration of all relevant royalty terms, or in the event that Healx does not exercise its option during the option period defined in the Healx License and Option Agreement, or the Option Period, the expiration of such period, or (b) in the event that Healx does exercise its option during the Option Period, and the Company does not exercise the Ovid Opt-In Right during the period of time we have to opt-in, or the Opt-In Period, or the opt-in terms are otherwise terminated, upon the expiration of all payment obligations, or (c) in the event that Healx does exercise the Option during the Option Period, and the Company does exercise the Ovid Opt-In Right during the Opt-In Period, such time as neither Healx nor Ovid is continuing to exploit the gaboxadol. As part of the revised contractual obligations with Lundbeck, Ovid will owe Lundbeck a share of all milestone and royalty payments received from Healx, if we do not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;exercise the Ovid Opt-In Right. If we do exercise the Ovid Opt-In Right to co-develop and co-commercialize the program with Healx, we will owe a share of the net profit share to Lundbeck.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;No revenue was recognized relating to this agreement during the three months ended June&#160;30, 2022. During the six months ended June&#160;30, 2022, the Company recorded revenue of $0.5 million associated with the Healx License and Option Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Marinus Pharmaceuticals Out-License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March 1, 2022, the Company entered into an exclusive patent license agreement with Marinus, or the Marinus License Agreement. Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consist of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory which was received on March 18, 2022, Marinus issued, at the Company's option, 123,255 shares of Marinus common stock, par value $0.001 per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single digits on net sales of each such licensed product sold.&lt;/span&gt;&lt;/div&gt;The Company recorded revenue and an associated investment in equity securities of approximately $0.9 million related to the patent license agreement on March 18, 2022, based on the price of Marinus common stock on March&#160;1, 2022. The Company had an unrealized loss on the Marinus common stock of $0.6&#160;million and $0.3 million for the three and six months ended June&#160;30, 2022, which was recorded as an unrealized loss on equity securities and is reflected in other (expense) income, net in the condensed consolidated statements of operation</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ovid:PotentialFundingCostPercent
      contextRef="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcwNjI_a6d707c4-e939-4224-85cc-16857f3310fe"
      unitRef="number">0.35</ovid:PotentialFundingCostPercent>
    <ovid:CostOfAgreementNet
      contextRef="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcwNzg_217f3550-39cc-416b-9dcb-60e717548715"
      unitRef="usd">7000000</ovid:CostOfAgreementNet>
    <ovid:DeferredUpfrontPaymentCosts
      contextRef="i85d2fb7045cd4ae3b1314624918eb6c0_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcwOTU_584c98c5-ad75-4768-8d1d-dde995098ce2"
      unitRef="usd">7000000</ovid:DeferredUpfrontPaymentCosts>
    <ovid:LicenseAgreementUpfrontPayment
      contextRef="i417dd14e7c28468cbb32aa243f71b4ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxMTE_3c49a874-7f99-4d08-a47c-f80ea2859647"
      unitRef="usd">20000000</ovid:LicenseAgreementUpfrontPayment>
    <ovid:AdditionalUpFrontFeeAmount
      contextRef="i97e6ce3a5011403898de05a7b8a7950e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxMjY_e91c032d-d23e-4896-94ad-39b31012ed69"
      unitRef="usd">5000000</ovid:AdditionalUpFrontFeeAmount>
    <ovid:UpFrontFeeAmount
      contextRef="i97e6ce3a5011403898de05a7b8a7950e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxNDI_701e92dd-1a02-4e16-8563-35bef9e494e7"
      unitRef="usd">20000000</ovid:UpFrontFeeAmount>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxNTg_dd662136-759e-4456-bef2-cd81654404a7"
      unitRef="usd">12400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ovid:LicenseRevenue
      contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxNzM_0d4385a7-efd5-40de-8f0e-cac52edd233b"
      unitRef="usd">5400000</ovid:LicenseRevenue>
    <ovid:AmountForPotentialFutureTrials
      contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxODg_8d934300-08af-4abe-a500-31bc13f51c7d"
      unitRef="usd">7000000</ovid:AmountForPotentialFutureTrials>
    <ovid:PotentialFundingCostPercent
      contextRef="i35f009b554804539856bd0e8035c2fbe_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcxOTQ_1515262f-c4cf-4df5-a264-893640d1ac1b"
      unitRef="number">0.35</ovid:PotentialFundingCostPercent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic5dc9854b22c4401944c1c3f1c81fa35_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyMTY_d61a40d0-34ef-4546-a077-bb60797c41e6"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ovid:UpfrontPaymentReceivable
      contextRef="if4975144823b4b6397ba0954f6522143_I20210329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyMzM_ac42e12d-4ad9-44b7-9f97-a0e8c908c309"
      unitRef="usd">196000000</ovid:UpfrontPaymentReceivable>
    <ovid:AgreementMilestonePayments
      contextRef="if4975144823b4b6397ba0954f6522143_I20210329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyNTA_ae8fd6ff-1cbb-4271-961e-f6ee1106ec07"
      unitRef="usd">660000000</ovid:AgreementMilestonePayments>
    <ovid:AdditionalPaymentReceivableOnSalesPercentage
      contextRef="i76ece08d363143b3a4e48d1512b2d3f2_D20210329-20210329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyNTY_bc060a06-d332-4ab1-b83e-5f897d9d3eaf"
      unitRef="number">0.20</ovid:AdditionalPaymentReceivableOnSalesPercentage>
    <ovid:UpFrontFeeAmount
      contextRef="ie4c8f02f699a46e3be40c5246e96e602_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyNzM_90e62543-8588-4ba5-a6f5-14c9738fd6b8"
      unitRef="usd">196000000</ovid:UpFrontFeeAmount>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ie4c8f02f699a46e3be40c5246e96e602_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfODQ2Mw_c6a3e087-30d9-4060-b57c-2920e607596f"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <ovid:ResearchAndDevelopmentExpenseReimbursementReceived
      contextRef="id97b2a2da582483fb06d8288d746a65f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfODY1MA_0ae3e87c-1fad-4a72-89f2-5ebde0f63494"
      unitRef="usd">2600000</ovid:ResearchAndDevelopmentExpenseReimbursementReceived>
    <ovid:GeneralAndAdministrativeExpenseReimbursementReceived
      contextRef="id97b2a2da582483fb06d8288d746a65f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfODY2OA_883e8b7a-35eb-422e-928c-e10f5d54b949"
      unitRef="usd">100000</ovid:GeneralAndAdministrativeExpenseReimbursementReceived>
    <ovid:UpFrontPayment
      contextRef="ibabba1d2cdfc4be9b9d2d6a75d6c5d4d_D20220201-20220201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTcyODg_57779d46-ea24-4130-91ab-4078ea8a3a4d"
      unitRef="usd">500000</ovid:UpFrontPayment>
    <ovid:DevelopmentAndCommercialMilestonePayments
      contextRef="ibabba1d2cdfc4be9b9d2d6a75d6c5d4d_D20220201-20220201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMDM_82e89ab0-e35d-4ed9-9d4b-ea1d53c7586a"
      unitRef="usd">2000000</ovid:DevelopmentAndCommercialMilestonePayments>
    <ovid:PercentageOfDevelopmentCosts
      contextRef="i3dff19c285cc484e915ef6c61e6e770a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMDk_60a211e2-fdd5-4feb-a3ec-48b491ca0c9b"
      unitRef="number">0.50</ovid:PercentageOfDevelopmentCosts>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9290ae797c984118825406206a94dc50_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTQ4NDM0MDY5ODg4NjI_eae75a64-7487-4856-9e88-3ddb6d946095"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3dff19c285cc484e915ef6c61e6e770a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTE4MTc_d293a3b7-8a78-48a7-b31b-e5d50ccd1564"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i23af69e8e97e4050a2c0ce0556ad29df_I20220301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMTk_b17b6d3f-31cd-46ce-bf21-c669c12603b3"
      unitRef="shares">123255</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i23af69e8e97e4050a2c0ce0556ad29df_I20220301"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMjg_36195260-2eeb-4806-9998-db642cf593c1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i315b0e5db1654ee59132ac7839cdab6b_D20220301-20220301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTMwNDg_aab1a5a5-ffc3-41e4-a77f-a0beee51bb24"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="ib8717ce65ce149a596e214e8657b3b6c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTU5NDI5MTg2MTczMzE_47c122de-d53c-4a8a-8a41-5b53768935cb"
      unitRef="usd">600000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i44bf255bfaca451db24cb2de86760946_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82NC9mcmFnOmNhOTc3ZWYwNzBmYjRlNjI4NDg2NWUzMWU3NGYzZTA4L3RleHRyZWdpb246Y2E5NzdlZjA3MGZiNGU2Mjg0ODY1ZTMxZTc0ZjNlMDhfMTMyMjY_b94c4ef4-be02-4d6a-9e18-428f9c51c178"
      unitRef="usd">300000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV82Ny9mcmFnOjllMjgzNmU3ODNiYjQ2MjM5NGQ0Mzc1NDBhZDRjYjE3L3RleHRyZWdpb246OWUyODM2ZTc4M2JiNDYyMzk0ZDQzNzU0MGFkNGNiMTdfMjEw_b6208652-4afb-4f21-844e-7d036c0bd7e3">RELATED PARTY TRANSACTIONSIn March 2021, the Company entered into the Takeda License and Termination Agreement with Takeda. For a description of the Takeda License and Termination Agreement, see Note 11.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RleHRyZWdpb246ZDVmMjAzNGYxOGM1NDcxZjgzMzM1NTA1ZjQ5MThmZGZfMjEwOA_a093e884-0f43-471a-9c88-393a96a3bf1d">NET (LOSS) INCOME PER SHARE&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding outstanding stock options that have not yet vested. Diluted net income per share is calculated based upon the weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares outstanding during the period resulting from the assumed exercise of outstanding stock options determined under the treasury stock method and the assumed conversion of preferred stock into common shares determined using the if-converted method. Diluted net loss per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The basic and diluted net (loss) income per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For any period in which the Company records net income, undistributed earnings allocated to the participating securities are subtracted from net income in determining net income attributable to common stockholders. The undistributed earnings have been allocated based on the participation rights of preferred stock and common shares as if the earnings for the year have been distributed. For periods in which the Company recognizes a net loss, undistributed losses are allocated only to common shares as the participating securities do not contractually participate in the Company&#x2019;s losses. Basic net (loss) income per share is computed by dividing the net (loss) income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Participating securities are excluded from basic weighted-average common shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,788,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,218,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,824,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,788,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,394,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,788,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,394,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in computing net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,818,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,953,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in computing net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,818,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,565,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,451,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,352,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,103,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,435,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable upon conversion of Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RleHRyZWdpb246ZDVmMjAzNGYxOGM1NDcxZjgzMzM1NTA1ZjQ5MThmZGZfMjEwOQ_a282e849-9c68-4b74-b9fc-ee9e8ed25448">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,788,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160,218,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,824,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,788,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,394,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,788,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,394,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in computing net income (loss) per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,818,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,953,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in computing net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,818,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,565,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi0xLTEtMS0xMTE_a42c263c-c781-42f4-afee-a060e2f70e9a"
      unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi0zLTEtMS0xMTE_5d15fa70-755b-4785-906f-4596197c5347"
      unitRef="usd">-15788427</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi01LTEtMS0xMTE_97f7d0ea-74a7-415f-b77c-395e693a6c52"
      unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMi03LTEtMS0xMTE_9be37e70-fec7-4caa-a3d8-10be71d28383"
      unitRef="usd">160218880</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy0xLTEtMS0xMTE_23823bab-2eff-4e4f-bdba-06b0c33990ee"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy0zLTEtMS0xMTE_c663cfb8-334c-4204-b92b-665c870e89e9"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy01LTEtMS0xMTE_667df96a-029c-4c2b-bf84-768d4556a09e"
      unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMy03LTEtMS0xMTE_86ed7220-8dc0-4a01-bd32-7f6ab8264bfc"
      unitRef="usd">4824587</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC0xLTEtMS0xMTE_a4799c9d-6a0b-44b5-b5c6-e3cea8445993"
      unitRef="usd">-14588414</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC0zLTEtMS0xMTE_f8c47e6f-2c2b-444f-8994-c9fc87e21726"
      unitRef="usd">-15788427</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC01LTEtMS0xMTE_060d8db7-ba56-409a-8b37-a32066b5a2b9"
      unitRef="usd">-30696470</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfNC03LTEtMS0xMTE_1cc946c1-3868-4881-853d-597365e00841"
      unitRef="usd">155394293</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC0xLTEtMS0xMTE_5b564eb9-a362-453b-9da3-ab2f9865f7f0"
      unitRef="usd">-14588414</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC0zLTEtMS0xMTE_30cd0352-1104-4fef-b683-71c5bcb12b9e"
      unitRef="usd">-15788427</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC01LTEtMS0xMTE_3dc0dde7-0a5c-4c0e-ad1b-52e65ea48736"
      unitRef="usd">-30696470</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOC03LTEtMS0xMTE_80ba5f95-62b7-4bb2-b816-cfa033c722f0"
      unitRef="usd">155394293</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS0xLTEtMS0xMTE_94eafe85-1c1f-4815-9c39-ad73debb0cd5"
      unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS0zLTEtMS0xMTE_7416b1c0-4b06-4545-a2e8-c2d33222122d"
      unitRef="shares">67818366</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS01LTEtMS0xMTE_6f91c0fb-10c2-4694-b5fc-fdaffe59ddee"
      unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfOS03LTEtMS0xMTE_e2b593fd-d7cb-4977-a2d7-11dd9b90cf5c"
      unitRef="shares">66953431</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtMS0xLTEtMTEx_e620693d-465f-47e0-8107-32fbc351b100"
      unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtMy0xLTEtMTEx_9e53e7b2-422d-4e65-8733-dafa6d2ea3b2"
      unitRef="shares">67818366</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtNS0xLTEtMTEx_540b0060-b40f-4d01-a7f2-cdb2fbb99a97"
      unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTAtNy0xLTEtMTEx_47e93ebc-5fda-45b7-baff-3637a1cfc38c"
      unitRef="shares">67565761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtMS0xLTEtMTEx_a6283d14-7461-4d4f-afae-d33b46d01c84"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtMy0xLTEtMTEx_e4efbe03-bbdc-4d1d-9339-a6eb4508447f"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtNS0xLTEtMTEx_e481b46b-b596-4783-8535-8645a8394507"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTEtNy0xLTEtMTEx_fb534ce9-3220-46ce-8fb6-a2c7fe438f4e"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItMS0xLTEtMTEx_2ebf5bf8-8722-4c03-b332-b60770743d7f"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i917ff31ed001407db6d68e52b491d9e8_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItMy0xLTEtMTEx_263bd529-a779-41a8-95a1-632a30f53471"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItNS0xLTEtMTEx_9c1df1b1-8913-40f5-a7c3-b2160cd2c34d"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia3d41a7318174686ad00f5bb936b5e64_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOmZjNzJiZDAzOWUwYzQzZGJhYTc5MDkyNjBkMjgwOGFiL3RhYmxlcmFuZ2U6ZmM3MmJkMDM5ZTBjNDNkYmFhNzkwOTI2MGQyODA4YWJfMTItNy0xLTEtMTEx_737c63cb-045a-411a-930c-dcdc3f742ca5"
      unitRef="usdPerShare">2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i416200c53b644f6288c0fb09b2680206_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RleHRyZWdpb246ZDVmMjAzNGYxOGM1NDcxZjgzMzM1NTA1ZjQ5MThmZGZfMjEwNw_d63a565a-52b5-4f75-a005-8a0542ddcd67">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,451,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,352,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,103,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,435,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock issuable upon conversion of Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bc5d022a300431fa15d4be1cb81e3e7_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi0xLTEtMS0xMTE_a6b1abc8-3392-47ac-a85b-f62ebc67c4a6"
      unitRef="shares">13451517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibd93d38c649e4bcf9dc0997d1f36eb7a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi0zLTEtMS0xMTE_70cb5a0c-6d04-46bb-b24a-30eb2820b26a"
      unitRef="shares">10352559</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id20ea80f44894cb98636c41e3d77bcc1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi01LTEtMS00MTg2_891f8f0d-decf-49a6-9807-82038e69c408"
      unitRef="shares">13103587</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff9fd4d2cf174503b125fdaeeb11c6fc_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMi03LTEtMS00MTg2_15e96e34-11c5-426b-bc11-46eb8ab8ab7f"
      unitRef="shares">10435478</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9467652c06534816ba1aa9bc3a888d71_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy0xLTEtMS0xMTE_b783c30a-aff1-4542-85c7-4770a5d8f1cf"
      unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia03f0f7a1a3d450aad2a50ecf43a159f_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy0zLTEtMS0xMTE_0b9be222-f465-4fce-ba57-f7ffb68baa22"
      unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i660cdfd473c24c05b53a1ce7e820084a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy01LTEtMS00MTg2_a9f70815-2af8-422e-b2a7-cd1bb9e08b1d"
      unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09793674d52f4223a7e62a26166fa5e4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmYjg5YzkxYjY4MDQ0ZmU4OTU4NGZhMWFhMmY4Njc5L3NlYzpmZmI4OWM5MWI2ODA0NGZlODk1ODRmYTFhYTJmODY3OV83MC9mcmFnOmQ1ZjIwMzRmMThjNTQ3MWY4MzMzNTUwNWY0OTE4ZmRmL3RhYmxlOjdjZjQ0ZGJkNmZlMTQyMTc5OWRiMmE4MWNlYWRmNDA3L3RhYmxlcmFuZ2U6N2NmNDRkYmQ2ZmUxNDIxNzk5ZGIyYTgxY2VhZGY0MDdfMy03LTEtMS00MTg2_8b322d2b-bd6d-469f-ac49-1780749b4b08"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MGE:':Q9&+"\!<'_)N=B?E .T.[OS_P!02P,$%     @ DD()5<<.!!(S P
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M9*H%$C"!< 8W\=40S@!,]8D4,+F$,W@/B3CY@3B#HVZ)0E5;HJK%J&H)JIK
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MZ%@+3]&QJO/.N!7O6NK@/*(:9N(3 >;@#,BG'. >>(U\ (:C5(0.')8V@MK
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M'NWU.D]CM".$IE-)S7JE&3K5#DV>^/,$R#*3,D !J#H^_HXVRCFF8U.6^N$
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M+;"]-=9@Y-'$7<U:9"@P#!:JA3Z:YHX>JS5-F<.X@S;TN@%( AA^N;S\&-%
M^YB;!DJBMTD%':FD2^JF[X ?5E$P<<<0Q8AI<6D+V&.E'2W<8X>D2&,Q3X]%
M8035.>17##>NA>=@SJXPF+3+=JY;2=&$6;<$-DBK+7U%^_(2 4)W!0G/3Y,V
M:3Y9G]5O]\+HH9HVXIZV7"G*FAK^97<Z;"D.NW->*'82'-VL=4M;@S9790N^
M0*],B!=0@B^PR:*L?T?"Y*$3EEI;MI]I&PXMH@P,@<]W]" ;D*E,5<I:BD9D
MK;*8E[I+0M$\&J_OU+M %Y$?E&#D9O=Y!QE?F_H!3@+C1_DT-J7;&I&2>$U
M65C<&1BD4-_74 Z9S:]^I\J.EJ'=_XR)5C-@Z.+,KX67>,_M74!7[_I.!1ME
MX!6)9;^CH,0;'\]]1@&EZ6E[F%?!IAN\"*!#=$C7F16+%]Q\-QJ\*\%.A,4
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M UY@41@B<N/+CM-I3!I@>[UG?V=CIUB63.&%*/[,4YV-G($#*:Y85>A;L?V
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M1C\D*(T"R5="Z/W&&&A^<<;? 5!+ P04    " "20@E5U_EK\1T#  #:!@
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M4-D >K^5TCPYMD#_.9O\ U!+ P04    " "20@E58(%.)5\%  !2#   &0
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MM \FN9"H2<QL4^B_W]F!E$D4[0LYV_<\]]P==\.]D$\J1]1PJ,I:C9Q<Z^W
M\U228\75K=AB32^9D!77=)0;3VTE\M2"JM)COA][%2]J9SRT=PLY'HJ=+HL:
M%Q+4KJJX?)EB*?8CI^.<+I;%)M?FPAL/MWR#*]2/VX6DD]>RI$6%M2I$#1*S
MD3/I#*:A\;<.WPO<JS,;3"9K(9[,X5,Z<GPC"$M,M&'@]'G&&9:E(2(9?XZ<
M3AO2 ,_M$_L'FSOELN8*9Z+\4:0Z'SD]!U+,^*[42['_B,=\(L.7B%+97]@W
MOD'@0+)36E1',"FHBKKY\L.Q#F> GO\&@!T!S.IN EF5]USS\5"*/4CC36S&
ML*E:-(DK:M.4E9;T6A!.CR=)(G>8POQ ;5:HAIXF5O/F)4>&:</ WF"(X4'4
M.E<PKU-,_\5[I*:5Q$Z2INPJX>==?0N![P+S&;O"%[0I!I8O>(-OP5_XND0%
MO$[!YLM+!;\F:Z4E_2E^7TJY80PO,YI!&:@M3W#DT"0HE,_HC&_>=6+_[HK>
ML-4;7F/_KY9<9;BL;S*;+1_G]S#_N9A_6<U7<(J#QSB0")HUI4%DH'.$3)0T
MLD6]&0"U!&U+[C'!:HT2@HX+5%A)/K:N:U'OJ,)-=>$],+?/(K?3C\D.W&X<
MNG$<PY+$<)GD%I+B,^V$+4VX;H'=;L?UR;'C=OL&[L-"B@R5V0'TG"&^!@GZ
ML1O% ?E&1-^/HC8CS0_DQQASHR"&FW<]UF%W\)62DL!Z@1OV&$1A[(9Q"-^$
MMH)#-^KWW%X8D-UU8]+!NA%<:J=W-FT5RHW=*:9ZNUHW@]?>MFMKTDSKJWNS
M\QZXW!2U@A(S@OJWW<@!V>R1YJ#%UL[N6FC:!-;,:?6B- [TG@FA3P<3H%WF
MX[]02P,$%     @ DD()54+3:,B5!P  "10  !D   !X;"]W;W)K<VAE971S
M+W-H965T,30N>&ULI5C[<]LV$OY7,.KCG!E9HF0[+S]F'-N=I)>T/COMS4VG
M/T D*.), @P 6O']]??M@J(H65+;Z4QBD01V\>WNMP_R;&'=@R^4"N)K51I_
M/BA"J-^.QSXM5"7]R-;*8"6WKI(!MVX^]K53,F.AJAQ/D^3EN)+:#"[.^-FM
MNSBS32BU4;=.^*:JI'MZITJ[.!],!LL'=WI>!'HPOCBKY5S=J_!+?>MP-^ZT
M9+I2QFMKA%/Y^>!R\O;=,>WG#;]JM?"]:T&6S*Q]H)L/V?D@(4"J5&D@#1(_
MC^I*E24I HPOK<Y!=R0)]J^7VG]@VV'+3'IU9<M_ZRP4YX/7 Y&I7#9EN+.+
M]ZJUYX3TI;;T_%<LXMYCG)@V/MBJ%<9]I4W\E5];/_0$7B<[!*:MP)1QQX,8
MY;4,\N+,V85PM!O:Z()-96F TX:"<A\<5C7DPL5]L.E#8<M,.?\/<?.ET>%)
M2).)6WA'.:<RP5O.Q@&GD<PX;36_BYJG.S2_%)^L"847-R93V;K\&"@[J-,E
MU'?3O0I_;,Q('"5#,4VFTSWZCCK3CUC?T0Y]K;&_7<Y\<&#'[]MLC"J.MZN@
MC'GK:YFJ\P%2PBOWJ 87WW\S>9F<[@%XW $\WJ?];\7F#S1__OGJG^]__GA]
M<W?__3>OIY-7I^+F7[]\^/P?<?G3M;B]N_GAYN[NYEKP1O&Y4.+*5K4T3^UN
M+U)9ZR!+ =\U:6B<$JE%JOK@A<UQ757(.4_P&#(6'Y4+>E8J47?PX_K!8,.@
MP8N1N&V<;Z0)(E@1MIPO41G *U8.UP<9<)/2$;E.<4,HM$FMJZV35 "&0G92
MP[Y*H?&\"85U^G_0@?.T]XT234W7D^G),$D2^B]\(7'45OLFR99=&V:-^HX4
M!>!DRNNY8>B3X?0D(2%"UM/60[93,5EFK#E\M$&;N;A73F/?)8Y:.7U3Y( \
M.4U.N\T;&WAY<OHB@FY9^-QTQ%V9H$,9/6>-$D"A!-J%4#(M(FA1J#+;KZF0
MCPI&$#E455.I%E!AX0UJ(3.?.EUS'7=49_V0O4ZKBD% $M!9$GL@Z;5Y(&?D
M#?;5SCYJZB,>Y3441)@:;8$0^V8)TH_$?3/[;_L\DE29%,X)A0PHNDB^NBZ?
M:)4"B!8'VIF,3O'1B\]#,^P;3*'=ZSZG4D66@[%R5C[Q,9E^U!E82VQ)2TF:
MJ9MQP-.F:DK)SD)KTCZZ>.T(D!ONLPXP*2L(>UGNQOO,/]'=2 9H+#5J4-9F
MTT)'TY$F%(H,26/+)KH_[^?77V-0[PP*6ZH4+)=Y  T(^/KR*D3$-SKS669
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MM).SO[;R5K5]2\Z3$577YMOYSQ+;=?TS9*HD__%&!69&\8?V\"4&=3DE9:E
M$;(E"U297_<VPKN9!5(82N>Z-:47V@^E-,'(7%<:VE_02,(KW+54?(S$'"7*
ML+_8L4?"MWL]*+2X MB_A&96DCI'*L/2<*RO03(1>C]"/"TU6?J.X,]-=:!9
M-C;OIA^6AQ5P8.81D)U0KS(N \'C[7QX:+)?#A&H3_]\E8$R#W7T8@@\7#I2
M%[#H:"021%-X,];+P.2EIJ*C-7%#;.8'#(-BYNHJ2^]>TN@S!<+AEL0=A ^5
MELL.F<+8+8OL)-CJ]>\!,&XQVO>(G8%'Y [=*Z.8V<J*.]FY@O%KVC],PM!N
MBM)TD.J\A'2M\R[GQ9H!W\"[9\;LZ&LQX+FAB1!DAQJ]C-3,?$K[1B9A$R[;
MR CP#928=GL^WYZ'/WEO4"J[HJ6OPY]4_(#P(CB?1M8LPMB'B_8=.WIF*#49
MWV(Y4PWJ:T"D-F6FC."*)4U(@A\NM'5MYM"L!58"30$B8P0P]#GG7X6D'A1,
M;017"P522J2NOC7:IH@'2I*C!M JP'O/ZCT;#7IN"()ECLJ R.1!$7Z'^<.Q
M(>JG$0167@<K&:I7%&58,P?DUM1UEW)+Y:NQ:5#SKT'"8 +[*M!XC;WC['48
M.$S'D^;$8%&Q:QLFAD23O13YV87966 G!SW8D7@*?H@NR':$&!!EPW,@_\WH
M._"7&EUL-)R.^LE,\*A<LATHX *]E^)4G_E);1E:@=CN]8G!ST*\K3E-#_LZ
M1(3T-2P[I#=/'FX@CZ)FG6>-@DK7@GH?=B F$29M7<4 X]+4P"FN+I : QX=
M#_^G&M(A!^MEGNAB\9CTR7" I"X#<-\I ,^*]$&BE.%IE 9B'*/0.D$M+]%<
M?3J*T)%/!7'@1ZON+<Y2BB%_*:BV.M!5/>POV-#7-/^+;J1%ZAK6*[F?>]_:
M=2(_S:.B'XI[?$GQ"*TM*&:';GA\_"2O$QO4\"U/\AO8.4KERQ4*J04L3=,C
M4KEO=+?]1(?[]"UY"?N?]Q3)JZFUIL+SV* \&%>^$@B23R<#2(HJX%S:M E5
MO2"C0V(X:@/H_"BB1QSY2U%3R0LQ*F^T6)L@6Y5H*O,>:G=Z8_W3_+ODF6'"
M^3A9[\G >@?0PH3TPPF'AB+!4N5A=+G!LR!4-&D?%@0O?(ST?Q<_O)>5IN@\
M5ISV;)#,G*;)=S(TR:9@S%H?Q7SFP;%_MJ/H(S00G!5Q5"NJ0BF1Q[X+;%1&
MM^&D/'/UT8&*FQCLI]MJOZ/X';27@R7YHZQ]8:S6<\/W1=H$-/<B(,VJ+7#-
MAST[6U(#\-"AG)X#T 8:03)UW.U3:*Q4Y<L\.OG2L<Q.37*NN#3CW-?]=T[W
M] /#O;UF@XM2YPS,1&[#XQ5RKX5!17C7@696F@'V;U&XO6.\0-#F,W8XK%6A
M"5<+LN;>5G?MT*X(IH@_9H1HJV7L<>+0-!6"P47(9/#J[Z[- "I^HMH[1@\5
MVNT.RH;9+A3L9.C]292LZ":4/S3>)4Q/-!UPWTI=40G IO8GDZ/ $]9L?>#]
M?N*&](!.<N =PY%N$)4.&^XRD</_SOM &\OB[QW?AG3XT/CV6-&^8YA[YRQ6
M4KF#9I:T?.<!;$KC/# ?7PTB*A_L3L;3] P$EZI6-HRD9 D!-)T$\#@YD4PG
M.9QP>$@3S@Y\):/7<ZBGMU$Z[>H3]5C\1<GJVT!A-\V.U]_4XJV:6Y[.3J--
M[AU>/DPTGXH14B6H?7CI*+Q#H1)'G!*97YWSD9-IXMBH'PLJL40<?I.EJ<0I
M'Q-3@9P.4/(S3G^^'D9/B#+9^!3VULJE!J3\U^ >CA0?P882L^N=C#_*[^'(
M;.A(M'S"SB8 H]#E'QS[3,:7T3-\@8\@Y*&HZQHN1Y$ 2 ]9XJ1\%8LZ0;!X
MU*!U+*X]'"NJQA?AT&6H5@]BN0GXK:1S;Y!L<CN8#0\GPD<S1H4545G1W9*H
MJFQ6E6MKUF>MT3VCO0-C0:]<FB6![;4NSVGP%.9*@N=*_0PJ'PL1ZOY;(Z'_
M'^J$H8YW*AZS^;GT[SZ6[F&@GQ)YJ>E5EW3L'7I84C%?5OECG8'3%^9\>$!Q
MOG]&$2MD+F98T%&\N,0E(U#N_%TM/OG67 X"D?#):09_J@7HO@"=:4? :3P$
MO?0W,7ADXT]RJ%_#O@L=2GZD7LH;X+_2JMN[$Q'Z G;L;0H+E&R+Q.9YSJ;/
M,U%UY<X8)UXA&G34<AN,3*=.P_.7.&4?5+%&^>M:326#IFMVNEC\AU/+W++A
M)!HYY?B4XFWK+YUT!$^MKK(8 9U3>78@/+Q[!@2+BN-TQL8-CD*'KN'6BF<E
MB97<CBP4_"E#@P'FTOT:KN<#U6,2970P_^!CP.Y].3QRA,=8=#H_NY_Y!QC?
MV7#W_&=?_H-A<  8R:)HS>!Y_M2(T LK:&S5RTH$/O;"!$V>^]/8M0=L3L$;
MWCK=ZQSUYSG[9DXYIB]LO:J*8U65*>8[576\FG:D]Y?]2&%T[5%ICAG/6PW>
MF91VT?%#;Q_Z3::71=6U&UPXL>J6@MYWO]*G[;SH9YQ[CT0_5\77,(/A*#.P
M7?R>$@4C55!RGY0/(5%_0,85; !1O2!O*,T1#L50YE]^0*7_!JAO5"]G)AZ]
MWN-Q^![;1%6,Q8<[+ZD,)R_4AR?@RFSO.^&[^ZCO:KEV>QY;,A^>O9VJ=*]7
M/[8%^$6"G\Y1#8VVL5 H80N"\YNN/=^_7Y:.7Q_N009%9ZAATIV1X0V1P$-"
MBLC3@?L_?<=RYTM#GN)-B?AZSA9UM?5Y/,S@XO$4#U7#AR>(090]KMKVHTT>
MS.GZ;!3CXGRN)-N3JS.?X ?U=3Q&8/?V6G #7UK*6GXS? .KOV,QXEO5(X^O
M=#MO.)_#1SI-,S18I>N#5L\[^INN<(UHAHR-J4+GHI3'1FMN4M*5A% WNHB:
M\8;,5ISZ[C5<98I!$WZSP#^7<5Z_AW_Y,-KY>0/OGOT$XNSP%9!7K__V_I*3
M:Z%576Q)*G)WBUKD[:!(C$7XH2/C,/!_^_IZ6*;OBKTO=7_=+\&;29[^-+IZ
M="&-NI@R52@0@Z?]1TS"(S&=/1K-+B\]P,33 EY*5J2#\-80( /+PQ54A/)D
M,J4,ZQ>-?&N\[7\R<*>[ [1=.B?Q9]M9+]:?V#->1RH[TPCJ'Z#AV&,YDIX/
M&N*!/=^8Y4RVITPZ$Q\?^IG31?9#-KCNDG^NYWR/XG_3EKY-OPB\]C^$ZU_W
M/R<$VVC&G*C4 DLGXR>7)S[BXH?6-/RS.'0AK5GSGRM4Z<K2"WB^, B6\($V
M2+^3?/%/4$L#!!0    ( ))""5427&XZ9 (  '(%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;)5486_3,!#]*Z<@\6EJTK0;TV@CI=T00VQ4;0 A
MQ <WN3;6$CO8UW7[]YR=+!1I*]J7V&>_>WYW\?-DK\V=+1$)'NI*V6E0$C47
M86CS$FMA![I!Q3L;;6I!')IM:!N#HO!)=17&4706UD*J()GXM85))GI'E52X
M,&!W=2W,XPPKO9\&P^!I82FW);F%,)DT8HLKI*_-PG 4]BR%K%%9J148W$R#
M='@Q&SN\!WR3N+<'<W"5K+6^<\%U,0TB)P@KS,DQ"![N<8Y5Y8A8QN^.,^B/
M=(F'\R?V#[YVKF4M+,YU]5T65$Z#\P *W(A=14N]_XA=/:>.+]>5]5_8M]@1
M@_.=)5UWR:R@EJH=Q4/7AX.$\^B%A+A+B+WN]B"O\E*02"9&[\$X-+.YB2_5
M9[,XJ=Q/69'A7<EYE"RQ$H0%+(2A1\B,4%;X?ME)2,SO4&'><<U:KO@%KC.X
MT8I*"U>JP.+?_)!U]>+B)W&S^"CAIYT:P"@Z@3B*XR-\H[[8D><;O;I8^)FN
M+1F.?CU7=TL[?I[6^>;"-B+':<#&L&CN,4C>OAF>1>^/B![WHL?'V%_YA_[#
M=?4YS:XN89$NLQ^0+=/;53K/KK_<KJX5W B3EZ[5PQ.@$F&NZT:H1T!%:%B
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MVY#A? 9,9]70-3^SP^X[,E #G]ZKO 2]=QQ;F'>#]S*H$/>-SFGQB]'GD"M
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MK;HZ78%))&P\?"9CJ86F.D%4H)1^PDU^71ZTEM.=30[GG&55_K8#J0?)I)6
MOK_=&=YPB!:N>R_B;0W?_YL,OX%'QS&IG=Z#(60!&),[#$"YH#BI03<P#W]-
M-.T^F'4J</ KG\>RA$-?!F_M++@=6MUQJ%KZ#G*ZU\9'H3^G-V.B/!<0+"$.
M>PWX*SF9(B$R0+:!(_?@?XGBD'XG&#A]NZGVPB%&R57Z^DC^0<K,W^ :>B=F
MT&<NLE?TH=Q<T1\BH%=<M..W]>.O\8\=W/ K_FDX_Z6$GT6S4M2;6L+4R^E3
M\)2&__@ ?W%F2R_\+XR#VI8^KJ4 =,8!\!S?L@U?<('X)R"N_P]02P,$%
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M3P<]#U2S5AK'R+*6\D(:NQAJ<VTW,2H78.^74IJMXPITNSW]"U!+ P04
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M_F-C&XSAFDLN&N%T$-P*GYL'#+C-@E3R)&<RQ\OI.+^B-$8)#"O3,1$=D_R
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M'U!$X^>,\JSAU!88LEL.3/*6":E,?G&;7ZS-KQJ)*T/\G-P4$N!1JA ,--A
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MTQ%FEFS'PW:C16U'LJ70..#998$3-4AS ;^O!&92MS$*AAE]]B]02P,$%
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MW6X03! 1 ?S]"F/V^B $VJ/WR7]02P,$%     @ DD()53^]<1L_!0  ("8
M !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULO5I=;Z,X%/TK%KM:S4B=
M!)ROIIM$:L-VMJM6JIKI[L-J'USB)%8!9[!)IM+^^+6! =P2-VCOI \-!NZY
MO@?[<@_V9,^39[&A5*)O41B+J;.1<GO1[8I@0R,B.GQ+8W5EQ9.(2-5,UEVQ
M32A99D91V,6N.^Q&A,7.;)*=NT]F$Y[*D,7T/D$BC2*2O%S1D.^GCN=\/_'
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MLL,-)4N:Z!O4]157S!4-O>>GW!0V^P]02P,$%     @ DD()5;(2'<;. P
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M"%,&\OV*4G$W4(?.]D^&^?]02P,$%     @ DD()5;J1J%96 @  7P4  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK511;],P$/XKIR AD,:<I-M
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M2H]4Q>U23[T@3(!^/^=<;19FKJKGZ.@?4$L#!!0    ( ))""54;C_RN0 ,
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M8#FZ(,@@D9H!JY][N( LTT2JC-\5IU6GU,#-YR?VB3F[.LL,"[A@V0^2RN7
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M:B&V*1:V)%8!VBN!]FSJLS\+X+B8\S5)#5()/"-L12)<GQP/GCJ4=DG?(Z]
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M7F>(CG)S;V0:DA7Z)F7)I&29?MP C8&K#OC]BC%Y:*@!RMN[V7]02P,$%
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M- =*HR>^];%U[#MRH>WPH#2&HM6U6MH1MMF.>'6?&P9?UH&_>P5[=\,B8JW
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M6>A8V^^V$T'7NJ&[H4*VAWJX(K@@3 G(YPM*Q?U$&>C_=9C\ E!+ P04
M" "20@E5I^>*K(,#  !L$   &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6RUF&UOVS80Q[\*H0U#"ZP1]6QGMH#84K$.*V#4Z/9BV M&.EM")-$CZ3CY
M]B,I1;44Q4@V]DTL4O?_D7='GWE9G"B[XP6 0 ]UU?"E50AQN+9MGA50$WY%
M#]#(-SO*:B+DD.UM?F! <BVJ*]O%.+1K4C96O-!S&Q8OZ%%490,;AOBQK@E[
M7$%%3TO+L9XFOI3[0J@).UX<R!ZV(+X>-DR.[)Z2ES4TO*0-8K!;6C?.=>I@
M)= 6?Y1PXF?/2+ER2^F=&GS*EQ96.X(*,J$01'[<PQJJ2I'D/O[IH%:_IA*>
M/S_1/VKGI3.WA,.:5G^6N2B6ULQ".>S(L1)?Z.E7Z!P*%"^C%==_T:FSQ1;*
MCES0NA/+'=1ETWZ2ARX09P+)F1:XG< ="_P7!%XG\%Z[@M\)_->N$'0"[;K=
M^JX#EQ!!X@6C)\24M:2I!QU]K9;Q*AMU4+:"R;>EU(EX*VAV]V$E0YVC-:WE
M^>-$9_ #VLI#F1\K0'2';JJ*9NT+.7I1E#ZH9T"WCVA3D0:]2T"0LGHO:5^W
M"7KWX_N%+>2NU=IVUNUPU>[0?6&''OI,&U%PE#8YY!/ZY+(^O*"W9;3ZD+E/
M(5NY%X&_'9LKY.&?D8M==V(_Z]?+G2EW_M_JZ7]>?1 ,KS\_GN9Y;ST_?_TN
M+=$G 37_>RKI+=:?QJKR>,T/)(.E)>L?!W8/5OS3#TZ(?YF*N$E88A*6&H(-
M<N/WN?$OT>-M01CH,IJC[#PWT'Y-I]+2$D--5#\R][$3J:,2+>S[\XA/V+E!
MY/G!T"YY;N=A/\#N?&B7/K>3.,D+>[M!"((^!,'E$*CCB>A!N<VG_+TH?^LQ
M- E+3,)20[!!#L(^!^'W*1&AR=R8A"4F8:DAV" W49^;R'B):(G!H$1@C'UG
M5"(F[%QG[L_#48EX;N=A[,T\?U0BGMNY@8LC!T^7B%D?@MG%$*3UH:*/ .VM
M!FV.+"MD//0%9LK]B[2WGDJ3L,0D+#4$&Z1DWJ=D_GTJQMQD;DS"$I.PU!!L
MD!L'?^L8L/&:T2$'O^_8B4:E8#UAYD4S?W192";,?,>9C^X>Z819$(;>^$IA
MGW5/-;"];ENY=.W8B/8BW,_VK?&-;@A'\ROG>NU,S">JE=;=VC=\VX=_)FQ?
M-AQ5L)-+X:M(5C?6MK;M0-"#[MUNJ9"=H'XL@.3 E(%\OZ-4/ W4 OT_&.)_
M 5!+ P04    " "20@E5OZS<27($  !@%@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6RU6&%OZC84_2M6-DV;]$KL! )T@-22O.U->UO5ZG4?IGWP
M(P:B)C&S#91_/]M) \DS#FVS"I7$W'/L<^]-<N+)GK(GOB9$@.<LS?G460NQ
MN79=OEB3#/,>W9!<_K*D+,-"GK*5RS>,X%B#LM3U( S<#">Y,YOHL3LVF]"M
M2).<W#' MUF&V>&6I'0_=9#S,G"?K-9"#;BSR0:OR ,17S9W3)ZY%4N<9"3G
M"<T!(\NI<X.N(Q0H@(YX3,B>GQP#)>4KI4_JY%,\=:!:$4G)0B@*++]V9$[2
M5#')=?Q;DCK5G IX>OS"_E&+EV*^8D[F-/TKB<5ZZHP<$),EWJ;BGNY_):6@
M@>);T)3K_V!?QD('++9<T*P$RQ5D25Y\X^<R$2< *=0,\$J UP!XYP!^"? O
MG:%? OK-&09G (,2H*6[A7:=N! +/)LPN@=,14LV=:"SK]$R7TFN&N5!,/EK
M(G%B]B#HXNGJ5J8Z!G.:R?[C6%?P"CP4O0/H$MQPV4@;-<[!%Q4JJ([>"@(^
MXH2!1YQNB8K\LXSZA>%<R, ?0R)PDOXD^:)LD](#(4#/64;*\>^!"_@:,\(G
MKI"2U,+<1;G\VV+YWIGE^^ SS<6:@RB/26S AW9\8,&[,I55/KV7?-YZ5L+?
MMGD/^/ #\*#G&=8SOQR.3'+>-WOTYMEKR?"KYO(U7_]<<ZFJELUUAP_R_B+
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M%8)F^G!-<$R8"I"_+RD5+R=J@FI3>?8?4$L#!!0    ( ))""57C9M3@!@4
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ME 6EC^KCMW!D6"HC$I- *!=8/G9D1N)8>9)Y_%LX-<J8RO#X_>#]YPR\!+/
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M#O+_):7B\*$"E%?SX_\!4$L#!!0    ( ))""55KKO6GF@(  -,'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*U5;6_3,!#^*U9 :)-@>5T[2AJI
M;8H8TJ1I8_ !\<%-KJTUQPZVTXY_CU_2T(VLFV!?$M_YGN=\=_9=NN7B5JX!
M%+JK*)-C;ZU4/?)]6:RAPO*$U\#TSI*+"BLMBI4O:P&XM*"*^E$0#/P*$^9E
MJ=5=BBSEC:*$P:5 LJDJ+'Y-@?+MV N]G>**K-;**/PLK?$*KD'=U)="2W['
M4I(*F"2<(0'+L3<)1_/$V%N#KP2V<F^-3"0+SF^-<%Z.O< <""@4RC!@_=O
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M+@ACH/>7G*N=8!QT<SS[#5!+ P04    " "20@E5@G*S;&P(   070  &0
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MQ<[AKN1YV@P61Y#&V?XG_=&\$$<#],4; _1F@'XZX*T(1C/ N#3"53/@ZF2
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M:% 7JGE0S8=J 4J3O^W5-;UU==/[+LMV-&G3O_H**F?9<054==)7 6IX: 5
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M=2TX'.L356LOZ).K%T!8*R?C;4[&1^?DC;(*4^4A7*Q%%9)9N9F79LI*I)O
M=.9%ZI^:%Q(S2,S<8&>[+P+O!@/U65C(*>VCIG3(*=VCIO2.6LHG5RR L%9&
MSK89.7LA(P?>[KQ1;I*WJS19)M5.D=^57\.O8A8JMT58EL7:K/-H6FQC%1E;
MA?%W)8B64=ZYI^*#= 5.#1&)&21FDIA%8C:).23FDIA'8CZ)!1#6"OCY-N#G
MKV./QSD9<Q(S2,PD,8O$;!)S2,PE,8_$?!(+(*P5\\DVYA/IZ_CVP(:2/,8B
MS>ZCU6:[MBNJ4NK4J)*806(FB5DD9I.80V(NB7DDYF^P\H#DSI;YJ+U='D S
MMB*H#IK#CH/_]\:T? U.S2ZJ&:AFHIJ%:C:J.:CFHIJ':CZJ!9363OM.R4!]
M'5O6]7I0F2<U ]5,5+-0S48U!]5<5/-0S4>U@-+:F=>:S&O25_C/J[=W:5($
M^$YT;EG+AY\<55(S4,U$-0O5[%IK';.<C <=1Q@==&(7U3Q4\U$MH+1V#IL:
MCRJM#Q0YW,1P%7ZO7D_7\4RD2II\#Q?Y=R4L7GYSD2ZC>-/H"Y_>''=&%JWJ
MH)I1:T<\D$UT8@O5;%1S4,U%-0_5?%0+**T=V::2H\H[.=?S(H7S,!?*,EJ(
M+$^*;=XZOEEG+M&.#JH9ZGZ%95S'<B^7Y,06JMFHYJ":BVH>JOFH%E!:.Y=-
MF4B5MXD^B441REG9CRA>.O/FC:DBOJW*TGRFI&*:S./H/P=V2:&M(E0S4,U$
M-0O5;'6_W[.WK8L6CU#-0S4?U0)*:P>T:3&I\AK3I\(,T^E]M5D[$P]BD:RJ
MC=XZGT4\H^67=9IM=BT58171PX&HHH4F5#-0S40U"]5L5'-J;3?XVKAC2\1%
MI_50S4>U@-+:@6TJ5:J\4V6+6*3AHLIK."O>A4997N\#_@.11>M3J&:@FHEJ
M%JK9J.;46NMM?6=BT7X4JOFH%E!:.[%-1TJ5=C/H [?%<A_#;]%RO>Q,--J4
M0C4#U4Q4LU#-1C4'U5Q4\U#-1[6 TMJY;TI3ZN25',)%*U>H9J":B6H6JMFH
MYJ":BVH>JOFH%E!:^S0&34E+DY>T=L[Z\'3TJ/R04+@0U:>!IL4-X;SSX*X<
M/C7$J&;4VK-ZW+./=IGHG!:JV:CFH)J+:AZJ^:@64%H[G$VG2I/V-ZX<$2Z^
M;<_64KZ!_OMJ<Q(7V2%<.7IR,-&"%*J9J&:AFHUJ#JJYJ.:AFH]J :6U ]P4
MI#3M=6Q1:VC3"M4,5#-1S4(U&]4<5'-1S4,U']4"2FMGOBEC:?(RUHMG6Y&/
M/SFK:,4*U4QMO[#U_(PKZ(1VQX2CKIXC.JN+:AZJ^:@64%H[6DUI2I.7II[U
M'#O#A?:DM/UF4]?CR4!G-5'-0C4;U1Q4<U'-0S4?U0)*:^>P*4EI\I*4L5.[
M*-^53I/E4J33J'C=.Z[-*/=/3NEH+Z5:5_O00*<U4<U"-1O5'%1S4<U#-1_5
M DIKQ[2I2FGRJM3M=O^MDMRUNE+3)#L03+02A6H&JIFH9J&:76OR3W<[Z)PN
MJGFHYJ-:0&GM5#9]*$W>A_H8IE&\SO9/PEWU)#8_:Q<JLC>*&T\[XXK6H5#-
M0#43U2Q4LU'-0347U3Q4\U$MH+1VK)O2E/9*SBREH84I5#-0S40U"]5L5'-0
MS44U#]5\5 LHK9WYIC"ER4\S]<=//5S#NS5U51MJHV?;>#?R%3@YGFBW"=4L
M5+-1S4$U%]4\5/-1+:"T]L4MFF[3\*434/WH&8_K"5XX_^V-?#U.32FJF:AF
MH9J-:@ZJN:CFH9J/:@&EM5/:E)R&\I+3YS@5X:+\.*VR2+*LK!^*W]91_EW)
MQ'2=1GDD.G=5R=E3MX-1S4 UL]9:GZ_OV+UMH;/:';,.NXZEHK.ZJ.:AFH]J
M :6U8]=4DX;R<S?=AGGYUI/8"R6?Z>0DHN4C5#-1S4(U&]4<5'-1S4,U']4"
M2FNG>N>";J_EBF[L)=W8:[JQ%W5CK^K&7M:-O:X;>V$W]LIN[*7=V&N[_2]:
M4<.F%364MZ)>+!P.]UM,DXXMN1OY/">G$.U$H9J%:C:J.:CFHIJ':CZJ!936
M3F'3B1K*.U'7Q<MH<5NTOT7=&4FT (5J!JJ9J&:AFHUJ#JJYJ.:AFH]J :6U
M@]NTI(;C5[+)C':K4,U -1/5+%2S4<U!-1?5/%3S42V@M';FFP[64-[!NDW*
MG5]E7_EN'<^B>%XU(I\^\-X97K1IA6H&JIFH9J&:76O/BI'#Y\W(XQ9ST77S
M4,U'M8#2VG%KNE%#^0FEK'6^3L4F8\F=_ 3D<NKDH*'U)E0S4<U"-;O6=G<9
MG'5>,0"=UD4U#]5\5 LHK9W(IKDTE#>7#'$GTE3,E/6S2P<<_&2 '#PYEVBO
M"=5,5+-0S1[N]\8.Y!*M+*&:AVH^J@64ULJEWE26='EEZ<5]N?+QI\80U0Q4
M,U'-0C4;U9Q::YT 5=.[3H&*SNNAFH]J :6U<]B4DG1Y*>EI)ZXLB6C_"-4,
M5#-1S4(U&]6<6MM]>1UU!Q&M*:&:CVH!I;6#V-24='E-Z7J9K,L+S"6ILMK9
M:5.]G\S3XIO.C54Y>G(VT482JIFH9J&:C6J.OG\9N\Y-7Q>=UD,U']4"2FMG
MLRD;Z?(S'1T^Y*G\?MQA4/D$)^<4;1&AFHEJ%JK9J.:@FHMJ'JKYJ!906CO,
M38M(UU_'85"=;'W<H)J!:B:J6:AFHYJ#:BZJ>:CFHUI :>W,-YTE7=Y9ZKYN
M[.+I?,/25VZTP(1J!JJ9J&:AFHUJ#JJYJ.:AFH]J@7[P_&/-6Y-V0IMRDBX_
MA=/.Z?G7*V5[L74EK-X6=P83;1FAFH%J)JI9J&;K^Y>A&W4>IT&G=5'-0S4?
MU0)*:^>R*1#I\@+1Y]7;;1@[4XC6A5#-0#43U2Q4L_7]*\OM/3'7,41/NH1J
M'JKYJ!90VB:&_>Q>B-P(\_#J8BG2N;@1BT6F3,O7NO*=Z\ZM2BKNRBM:O;_6
M>OV]VTWUO:5VW&ZK[YWJ]G[#7UVLPKGX&*;SJ'CWNA!WQ52#=V?%4W<:S>^W
MW^3)ZK*G]I0O29XGR^K+>Q$6V\OE L7/[Y(D?_JFG. Q2;]6O\[5?P%02P,$
M%     @ DD()59A_9!J=!   .18  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#@N>&ULQ5A=;]LV%/TKA#8,*=!$WQ_.; -);+DMFB%HT/5AV ,MT3812?1(
M*N[^_2A*EFV)4NQ.V%YLD;KWG$N>RRN2XQVA+VR#$ ??TR1C$VW#^?96UUFT
M02ED-V2+,O%F16@*N6C2M<ZV%,%8.J6);AF&IZ<09]IT+/N>Z'1,<I[@##U1
MP/(TA?3O>Y20W40SM7W'%[S>\*)#GXZW<(V>$?^Z?:*BI=<H,4Y1QC#) $6K
MB79GWBY,Z2 M?L=HQXZ>03&4)2$O1>-C/-&,(B*4H(@7$%#\O:('E"0%DHCC
MKPI4JSD+Q^/G/7HH!R\&LX0,/9#D&X[Y9J(%&HC1"N8)_T)V'U U(+? BTC"
MY"_85;:&!J*<<9)6SB*"%&?E/_Q>3<21@\!1.UB5@]5T<#H<[,K!/M?!J1R<
M<QW<RL$]=PQ>Y>"=R^!7#KX4JYQ=*<T,<C@=4[(#M+ 6:,6#U%=Z"T5P5J3B
M,Z?B+19^?/J;R/:KSX2Q=^!C%I$4@2=$P?,&4@2NP7.9H("LP -,HCR!,G]$
M\QXR' &8Q6"&DYRC&,PAS7"V9GNX;8US-4,<XD3T78.OSS-P]?.[L<Y%\$4(
M>E0%>E\&:G4$:H-'DO$- _,L1K'"/^SW]WK\=3%I]<Q9^YF[MWH!/^79#;"-
M]\ R+$L1ST._^R.DPMWL=)^=SVXJW.?GLZO<PW\W]L4/!W\BA5TGL2WQ[ Z\
M.O4.N?O'W9)Q*@K=GZI4*^$<-5Q1_6_9%D9HHHGRSA!]1=KTEY],S_A5I?.0
M8+,AP>9#@H5#@BT& CO)%J?.%J</O2QYB:Q16)8\58:4$)Z$*#[GK]-KTW&#
MP#&=L?YZ++_*TC.-P'"]4\N9RM+U!:;EGUK.VY:F[QF&;QL-RU"!:1O>R'-\
MX]1RH<#TQ/(+@N!@>3*?;CV?[IOS64XD@)Q3O,PY7"8(< *VD'(<X:WX;&1K
MP%"44\PQ8JH9+TG<H_@:(WCH#>/2A?8FW7Q(NO!-ND7;XMH)+)%SOEH>KY;'
MNRS=6RJ)SE1\U<5>(WK9D"1&5"F0UPZP8TGT!G2I4"I:]:H9DC94T'8LK+:E
MZ;KVR+%&MEHYOU;._V^4\\\N9KT!7:J<BE:MW)"TH8*V0[FVY1O*!;5R0:]R
MW^0)2&R*X2NBXD17"U7L31@01T+&Q=ZY*(HY$V8X*RRVN2R3V:&>5NH76VE6
M;<F7<N-]A?=@RJUTT$I)W[!'A>8-O7N'<:G>;5;/#\S ]AH?POF0K&''6"V[
MP;I0A.>-7-NQ3;78HUKLT?\E=ER=K=Z0>W2NW+T#N53N-FN'W$.RAAUC;<NM
M"L_U7-_KD-LT#D=FX\*Z7&OV_FA]QB1)(&6'E^I3;\D5')<KX\8R&\KUAW2I
M=!VD=D.X04E#-:G3^ 0M%&;6C6UUB'9TSV'^N&C'Z^Q,V<SS9.L-ZF+9U*0M
MV88D#=6D;=G:9D*VAFKZT455BNA:WD$R40[SC)?'_;JWON>\D[=[C?Y[\W9N
M*OK#XEY47HP=X,M+U4=(USAC($$K067<^*(RT/*>LFQPLI779$O".4GEXP9!
ML:4J#,3[%2%\WR@(ZMOBZ3]02P,$%     @ DD()51N:!VNP P  ?0\  !D
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ML#R0Z<_6&M]MO$)>K@-L3U^J$&RF>"5B,\77&A#_N@$C2?R[C>4!!K8+6.U
M?G\>J"D_)XI@5S%OV!.,(TF"(5"+_AJ-8V1U8OCX]P=[2J(H2?P(8'X'480A
M\#3B".8 /&!(%%7OP;WW4=B\I\+-+USC)U!+ P04    " "20@E5EXJ[',
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M>.M.J6,H.]>GAC?[-_?[_SIX_S]02P,$%     @ DD()58YA./J] 0  >AT
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ DD()59E<G",0!@  G"<  !,
M             ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "20@E5/4"S'YT&   T)P  &               @($,"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ DD()58]_V1(-!@  ZA<  !@
M             ("!WPX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( ))""57'OR6&# ,  "8+   8              " @2(5  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "20@E55%_# N8%  #E
M'0  &               @(%D&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ DD()5<<.!!(S P  A0L  !@              ("!@!X
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ))""54,@UTG
ME0L  *YJ   8              " @>DA  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " "20@E5YM9%DR@(  !T(P  &
M@(&T+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ DD()
M5?E#>%BK"@  ;AH  !@              ("!$C8  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( ))""54)A,,I4!0  #H]   8
M      " @?-   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ))""55"TVC(E0<   D4   9              "
M@15E  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ DD()
M5<CA\GM9#0  @"H  !D              ("!X6P  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " "20@E58&\S<L@$  #3"@  &0
M        @(%Q>@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( ))""55-QPP=] P  &\C   9              " @7!_  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ DD()5?5P$0.5$0  ,SD
M !D              ("!FXP  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " "20@E5$EQN.F0"  !R!0  &0              @(%GG@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ))""57^,1-[
M'@8  *02   9              " @0*A  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ DD()5;L3&2.!%   #D(  !D
M ("!5Z<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "2
M0@E5/UX6/UX#  !"#   &0              @($/O   >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ))""569J6,]M (  .<%   9
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M970R-RYX;6Q02P$"% ,4    " "20@E5B.>]Z:,$  "&%P  &0
M    @(%#TP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M ))""54_O7$;/P4  " F   9              " @1W8  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ DD()5;(2'<;. P  <!   !D
M             ("!D]T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " "20@E5NI&H5E8"  !?!0  &0              @(&8X0  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ))""56U\733$ ,
M %,+   9              " @27D  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ DD()51N/_*Y  P  N0L  !D              ("!
M;.<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "20@E5
M:V= 8AP$  #)$P  &0              @('CZ@  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( ))""5412G/ZB0(  ,D&   9
M      " @3;O  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ DD()51H03KI9 @  H@4  !D              ("!]O$  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "20@E5==GV7IP"   &!P
M&0              @(&&]   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( ))""57Q+:Z<W@(  #P(   9              " @5GW  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ DD()5;[I099'
M"   ME(  !D              ("!;OH  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " "20@E52+Z0*>0)  "=8   &0
M@('L @$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ))"
M"55KD&,BB@,  ($0   9              " @0<- 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ DD()5:?GBJR# P  ;!   !D
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M=#0V+GAM;%!+ 0(4 Q0    ( ))""56F71C6L0P  '"M   9
M  " @=PI 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
MDD()59A_9!J=!   .18  !D              ("!Q#8! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " "20@E5&YH':[ #  !]#P  &0
M            @(&8.P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( ))""549T=P+*P,  .X2   -              "  7\_ 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ DD()59>*NQS     $P(   L
M     ( !U4(! %]R96QS+RYR96QS4$L! A0#%     @ DD()56!K6K8K!
M^2    \              ( !OD,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( ))""56.83CZO0$  'H=   :              "  19( 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ))""56<*],/O0$  '<=
M   3              "  0M* 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   Y #D A@\  /E+ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>190</ContextCount>
  <ElementCount>278</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Cash, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Property and Equipment and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets</Role>
      <ShortName>Property and Equipment and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Stockholders' Equity and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockholdersEquityandPreferredStock</Role>
      <ShortName>Stockholders' Equity and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Collaboration And License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration And License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2138112 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2139113 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Property and Equipment and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsTables</Role>
      <ShortName>Property and Equipment and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - Net (Loss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/NetLossIncomePerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Property and Equipment and Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment and Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Leases - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail</Role>
      <ShortName>Leases - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail</Role>
      <ShortName>Leases - Schedule of Components of Operating Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Under the non-cancelable Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail</Role>
      <ShortName>Leases - Schedule of Future Minimum Commitments Under Under the non-cancelable Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Stockholders' Equity and Preferred Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity and Preferred Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Collaboration And License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration And License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Net (Loss) Income Per Share - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails</Role>
      <ShortName>Net (Loss) Income Per Share - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ovid-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Net (Loss) Income Per Share - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>Net (Loss) Income Per Share - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ovid-20220630.htm">ovid-20220630.htm</File>
    <File>ovid-20220630.xsd</File>
    <File>ovid-20220630_cal.xml</File>
    <File>ovid-20220630_def.xml</File>
    <File>ovid-20220630_lab.xml</File>
    <File>ovid-20220630_pre.xml</File>
    <File>ovid-20220630xexx311.htm</File>
    <File>ovid-20220630xexx312.htm</File>
    <File>ovid-20220630xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ovid-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="611">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ovid-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 190,
   "dts": {
    "calculationLink": {
     "local": [
      "ovid-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ovid-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ovid-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ovid-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ovid-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ovid-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 431,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 51,
   "keyStandard": 227,
   "memberCustom": 25,
   "memberStandard": 26,
   "nsprefix": "ovid",
   "nsuri": "http://www.ovidrx.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover page",
     "role": "http://www.ovidrx.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Cash, Cash Equivalents and Marketable Securities",
     "role": "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities",
     "shortName": "Cash, Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Property and Equipment and Intangible Assets",
     "role": "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets",
     "shortName": "Property and Equipment and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Leases",
     "role": "http://www.ovidrx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Accrued Expenses",
     "role": "http://www.ovidrx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Stockholders' Equity and Preferred Stock",
     "role": "http://www.ovidrx.com/role/StockholdersEquityandPreferredStock",
     "shortName": "Stockholders' Equity and Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.ovidrx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Income Taxes",
     "role": "http://www.ovidrx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.ovidrx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Collaboration And License Agreements",
     "role": "http://www.ovidrx.com/role/CollaborationAndLicenseAgreements",
     "shortName": "Collaboration And License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138112 - Disclosure - Related Party Transactions",
     "role": "http://www.ovidrx.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139113 - Disclosure - Net (Loss) Income Per Share",
     "role": "http://www.ovidrx.com/role/NetLossIncomePerShare",
     "shortName": "Net (Loss) Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Property and Equipment and Intangible Assets (Tables)",
     "role": "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsTables",
     "shortName": "Property and Equipment and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Leases (Tables)",
     "role": "http://www.ovidrx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.ovidrx.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.ovidrx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - Net (Loss) Income Per Share (Tables)",
     "role": "http://www.ovidrx.com/role/NetLossIncomePerShareTables",
     "shortName": "Net (Loss) Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Operations - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail",
     "shortName": "Nature of Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EquityMethodInvestments",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquityMethodInvestments",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)",
     "role": "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "investment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "investment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)",
     "role": "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail",
     "shortName": "Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Property and Equipment and Intangible Assets - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Property and Equipment and Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i57c6dc3481c441408bca8588e4b4cd13_I20220310",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i57c6dc3481c441408bca8588e4b4cd13_I20220310",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Leases - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)",
     "role": "http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail",
     "shortName": "Leases - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Leases - Schedule of Components of Operating Lease Cost (Detail)",
     "role": "http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail",
     "shortName": "Leases - Schedule of Components of Operating Lease Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Leases - Schedule of Future Minimum Commitments Under Under the non-cancelable Operating Lease (Detail)",
     "role": "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail",
     "shortName": "Leases - Schedule of Future Minimum Commitments Under Under the non-cancelable Operating Lease (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "role": "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i5514b03ea99548678298804a7de4efdb_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Stockholders' Equity and Preferred Stock - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail",
     "shortName": "Stockholders' Equity and Preferred Stock - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "ovid:CommonStockNumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)",
     "role": "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iec95a18524b84f6cba11d8e830382e5e_D20220401-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)",
     "role": "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
     "shortName": "Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i06df7810437744ac89df59b3071c4620_D20220401-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)",
     "role": "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i4195bb138be34cf897e76ecdeb15529f_D20220401-20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "id6a06c63bc824ec19efb5af5e13b7f53_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)",
     "role": "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail",
     "shortName": "Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "id1d5cd62a7c1493a9fde980d2163424c_I20211230",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ovid:LicenseAgreementMilestonePayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Commitment and Contingencies - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail",
     "shortName": "Commitment and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "ib3e38e7a15e34cceafd124f84ef81706_D20211230-20211230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ovid:FirstPaymentDueUponCompletionOfFirstPhase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Collaboration And License Agreements - Additional Information (Detail)",
     "role": "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration And License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "ic5dc9854b22c4401944c1c3f1c81fa35_I20210331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Net (Loss) Income Per Share - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)",
     "role": "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails",
     "shortName": "Net (Loss) Income Per Share - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i4bc5d022a300431fa15d4be1cb81e3e7_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Net (Loss) Income Per Share - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)",
     "role": "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail",
     "shortName": "Net (Loss) Income Per Share - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i4bc5d022a300431fa15d4be1cb81e3e7_D20220401-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive (Loss) Income",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "iecc248fe62e04067b49ddce214bfdd1f_D20220401-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i8366cf4b4e584ca1933dcff24730eee2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i887eb6a9c32e4c0f81980f21e48951ec_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Operations",
     "role": "http://www.ovidrx.com/role/NatureofOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20220630.htm",
      "contextRef": "i416200c53b644f6288c0fb09b2680206_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]",
        "terseLabel": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]",
        "terseLabel": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail",
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]",
        "terseLabel": "Former Address"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail",
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ovid_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Agreement.",
        "label": "A T M Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_AccretionOfLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of lease liability",
        "label": "Accretion of Lease Liability",
        "terseLabel": "Accretion of lease liability"
       }
      }
     },
     "localname": "AccretionOfLeaseLiability",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development accrual"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AdditionalPaymentReceivableOnSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment receivable on sales percentage.",
        "label": "Additional Payment Receivable On Sales Percentage",
        "terseLabel": "Additional payment on sales percentage"
       }
      }
     },
     "localname": "AdditionalPaymentReceivableOnSalesPercentage",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_AdditionalUpFrontFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AdditionalUpFrontFeeAmount",
        "label": "Additional Up Front Fee Amount",
        "terseLabel": "Additional up front fee amount"
       }
      }
     },
     "localname": "AdditionalUpFrontFeeAmount",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AggregateOfferingPriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price of common stock.",
        "label": "Aggregate Offering Price Of Common Stock",
        "terseLabel": "Net proceeds from offering, value"
       }
      }
     },
     "localname": "AggregateOfferingPriceOfCommonStock",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments.",
        "label": "Agreement Milestone Payments",
        "terseLabel": "Aggregate milestone payments"
       }
      }
     },
     "localname": "AgreementMilestonePayments",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates",
        "label": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates",
        "terseLabel": "Allowable voting right percentage of outstanding common stock holders"
       }
      }
     },
     "localname": "AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period",
        "label": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period",
        "terseLabel": "Allowable voting right percentage of outstanding common stock holders upon notice of days"
       }
      }
     },
     "localname": "AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_AmountForPotentialFutureTrials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for potential future trials.",
        "label": "Amount For Potential Future Trials",
        "terseLabel": "Amount for potential future trials"
       }
      }
     },
     "localname": "AmountForPotentialFutureTrials",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AngeliniLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Angelini License Agreement.",
        "label": "Angelini License Agreement [Member]",
        "terseLabel": "Angelini License Agreement"
       }
      }
     },
     "localname": "AngeliniLicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_AnnualLicenseMaintenanceFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fee payable.",
        "label": "Annual License Maintenance Fee Payable",
        "terseLabel": "Annual license maintenance fee payable"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFeePayable",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock",
        "label": "Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock",
        "terseLabel": "Beneficial ownership limitations, percentage of issued and outstanding common stock"
       }
      }
     },
     "localname": "BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuance , Period Immediately Preceding Execution Date",
        "label": "Common Stock Issuance , Period Immediately Preceding Execution Date",
        "terseLabel": "Days immediately preceding the execution date"
       }
      }
     },
     "localname": "CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Number Of Votes Per Share",
        "label": "Common Stock, Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ovid_ConsiderationPayableForRightsGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration payable for rights grant.",
        "label": "Consideration Payable For Rights Grant",
        "terseLabel": "Consideration payable for rights grant"
       }
      }
     },
     "localname": "ConsiderationPayableForRightsGrant",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_ConvertibleNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note receivable.",
        "label": "Convertible Note Receivable",
        "terseLabel": "Convertible note receivable"
       }
      }
     },
     "localname": "ConvertibleNoteReceivable",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CostOfAgreementNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of agreement net.",
        "label": "Cost Of Agreement Net",
        "terseLabel": "Future cost of agreement"
       }
      }
     },
     "localname": "CostOfAgreementNet",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CowenAndCompanyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and Company, LLC.",
        "label": "Cowen And Company L L C [Member]",
        "terseLabel": "Cowen And Company, LLC"
       }
      }
     },
     "localname": "CowenAndCompanyLLCMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_DeferredUpfrontPaymentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred upfront payment costs.",
        "label": "Deferred Upfront Payment Costs",
        "terseLabel": "Deferred upfront payment costs"
       }
      }
     },
     "localname": "DeferredUpfrontPaymentCosts",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_DevelopmentAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Commercial Milestone Payments",
        "label": "Development and Commercial Milestone Payments",
        "terseLabel": "Development and commercial milestone payments"
       }
      }
     },
     "localname": "DevelopmentAndCommercialMilestonePayments",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_EmployeePerformanceBasedOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee performance based option awards.",
        "label": "Employee Performance Based Option Awards [Member]",
        "terseLabel": "Employee Performance Based Option Awards"
       }
      }
     },
     "localname": "EmployeePerformanceBasedOptionAwardsMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_FirstPaymentDueUponCompletionOfFirstPhase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First payment due upon completion of first phase.",
        "label": "First Payment Due Upon Completion Of First Phase",
        "terseLabel": "First payment due upon completion of first phase"
       }
      }
     },
     "localname": "FirstPaymentDueUponCompletionOfFirstPhase",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_GeneralAndAdministrativeExpenseReimbursementReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative expense reimbursement received.",
        "label": "General And Administrative Expense Reimbursement Received",
        "terseLabel": "General and administrative expense reimbursement received"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseReimbursementReceived",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_HLundbeckASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "H. Lundbeck A/S.",
        "label": "H Lundbeck A S [Member]",
        "terseLabel": "Lundbeck"
       }
      }
     },
     "localname": "HLundbeckASMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_HealxLicenseAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healx License and Option Agreement",
        "label": "Healx License and Option Agreement [Member].",
        "terseLabel": "Healx License and Option Agreement"
       }
      }
     },
     "localname": "HealxLicenseAndOptionAgreementMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_IncomeTaxAccrualCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax accrual, current.",
        "label": "Income Tax Accrual, Current",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "IncomeTaxAccrualCurrent",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in prepaid expense, noncurrent.",
        "label": "Increase Decrease In Prepaid Expense Noncurrent",
        "negatedLabel": "Long-term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseNoncurrent",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incremental borrowing rate",
        "label": "Lease Incremental Borrowing Rate",
        "terseLabel": "Lease incremental borrowing rate"
       }
      }
     },
     "localname": "LeaseIncrementalBorrowingRate",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_LesseeOperatingLeaseFreeRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Free Rent Period",
        "label": "Lessee, Operating Lease, Free Rent Period",
        "terseLabel": "Free rent period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseFreeRentPeriod",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Payments Commencement Following This Period",
        "label": "Lessee, Operating Lease, Rent Payments Commencement Following This Period",
        "terseLabel": "Rent payments commencement following this period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_LicenseAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global commercial and regulatory milestone payments.",
        "label": "License Agreement Milestone Payments",
        "terseLabel": "License agreement milestone payments"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayments",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement upfront payment.",
        "label": "License Agreement Upfront Payment",
        "terseLabel": "Upfront payment under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPayment",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LicenseRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License revenue.",
        "label": "License Revenue",
        "terseLabel": "License revenue"
       }
      }
     },
     "localname": "LicenseRevenue",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_MarinusLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "marinus license agreement member.",
        "label": "Marinus License Agreement [Member]",
        "terseLabel": "Marinus License Agreement"
       }
      }
     },
     "localname": "MarinusLicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_MarinusPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marinus pharmaceuticals, inc [Member]",
        "label": "Marinus Pharmaceuticals, Inc [Member]",
        "terseLabel": "Marinus Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "MarinusPharmaceuticalsIncMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_MarinusTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marinus therapeutics inc member.",
        "label": "Marinus Therapeutics Inc [Member]",
        "terseLabel": "Marinus Therapeutics, Inc"
       }
      }
     },
     "localname": "MarinusTherapeuticsIncMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum allowable owning percentage of outstanding common stock by associates or affiliates.",
        "label": "Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates",
        "terseLabel": "Maximum allowable owning percentage of outstanding common stock by associates or affiliates"
       }
      }
     },
     "localname": "MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum allowable voting right percentage of outstanding common stock holders.",
        "label": "Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders",
        "terseLabel": "Maximum allowable voting right percentage of outstanding common stock holders"
       }
      }
     },
     "localname": "MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of product covered under license agreement",
        "label": "Minimum Number Of Product Covered Under License Agreement",
        "terseLabel": "Minimum number of product covered under license agreement"
       }
      }
     },
     "localname": "MinimumNumberOfProductCoveredUnderLicenseAgreement",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ovid_MoneyMarketFundsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money market funds and short-term investments.",
        "label": "Money Market Funds And Short Term Investments [Member]",
        "terseLabel": "Money Market Funds and Short-term Investments"
       }
      }
     },
     "localname": "MoneyMarketFundsAndShortTermInvestmentsMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_NonEmployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee stock options.",
        "label": "Non Employee Stock Options [Member]",
        "terseLabel": "Nonemployee Stock Options"
       }
      }
     },
     "localname": "NonEmployeeStockOptionsMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash consideration received in licensing agreement transaction.",
        "label": "Noncash Consideration Received in Licensing Agreement Transaction",
        "negatedLabel": "Non-cash consideration received in licensing agreement transaction"
       }
      }
     },
     "localname": "NoncashConsiderationReceivedInLicensingAgreementTransaction",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_NonemployeePerformanceBasedOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee performance based option awards.",
        "label": "Nonemployee Performance Based Option Awards [Member]",
        "terseLabel": "Non-employee Performance Based Option Awards"
       }
      }
     },
     "localname": "NonemployeePerformanceBasedOptionAwardsMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_NorthwesternUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Northwestern University.",
        "label": "Northwestern University [Member]",
        "terseLabel": "Northwestern University"
       }
      }
     },
     "localname": "NorthwesternUniversityMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_NoteReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts of notes currently receivable from customers.",
        "label": "Note receivable",
        "terseLabel": "Note receivable"
       }
      }
     },
     "localname": "NoteReceivable",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_NumberOfTrial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trial.",
        "label": "Number Of Trial",
        "terseLabel": "Number of trial"
       }
      }
     },
     "localname": "NumberOfTrial",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ovid_PatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent license agreement [Member].",
        "label": "Patent License Agreement [Member]",
        "terseLabel": "Patent License Agreement"
       }
      }
     },
     "localname": "PatentLicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_PercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs.",
        "label": "Percentage of Development Costs",
        "terseLabel": "Percentage of development costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCosts",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_PotentialFundingCostPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding cost percent.",
        "label": "Potential Funding Cost Percent",
        "terseLabel": "Potential funding cost percent"
       }
      }
     },
     "localname": "PotentialFundingCostPercent",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, share designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ovid_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes.",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory notes"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party member.",
        "label": "Related Party [Member]",
        "terseLabel": "License revenue - related party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_ResearchAndDevelopmentExpenseReimbursementReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense reimbursement received.",
        "label": "Research And Development Expense Reimbursement Received",
        "terseLabel": "Research and development expense reimbursement received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseReimbursementReceived",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use asset and lease liabilities operating lease table text block.",
        "label": "Right-Of-Use Asset and Lease Liabilities Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease"
       }
      }
     },
     "localname": "RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ovid_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Common stock issuable upon conversion of Series A convertible preferred stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum",
        "terseLabel": "Common stock, reserved for future issuance increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase",
        "terseLabel": "Percentage increase, outstanding stock maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment award options granted contractual life.",
        "label": "Share Based Compensation By Share Based Payment Award Options Granted Contractual Life",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets",
        "label": "Stock Option Exercise Receivables in Prepaid Expenses and Other Current Assets",
        "terseLabel": "Stock option exercise receivables in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options.",
        "label": "Stock Options [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_SummaryOfSignificantAccountingPolicyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policy [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicyLineItems",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ovid_SummaryOfSignificantAccountingPolicyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Table]",
        "terseLabel": "Summary Of Significant Accounting Policy [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicyTable",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ovid_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 employee stock purchase plan.",
        "label": "Two Thousand Seventeen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 ESPP"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities",
        "label": "U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities [Member]",
        "terseLabel": "U.S. Government Treasury Fund, U.S. Government Treasury Bills And Equity Securities"
       }
      }
     },
     "localname": "USGovernmentTreasuryFundUSGovernmentTreasuryBillsAndEquitySecuritiesMember",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial statements.",
        "label": "Unaudited Interim Financial Statements Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Consolidated Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimFinancialStatementsPolicyPolicyTextBlock",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ovid_UpFrontFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front fee amount.",
        "label": "Up Front Fee Amount",
        "terseLabel": "Up-front fee"
       }
      }
     },
     "localname": "UpFrontFeeAmount",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up front Payment.",
        "label": "Up Front Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Cash Payment",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront non-creditable one-time license issuance fee payment.",
        "label": "Upfront Non Creditable One Time License Issuance Fee Payment",
        "terseLabel": "Upfront non-creditable one-time license issuance fee payment"
       }
      }
     },
     "localname": "UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpfrontPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment receivable.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment under royalty and termination agreement"
       }
      }
     },
     "localname": "UpfrontPaymentReceivable",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.ovidrx.com/20220630",
     "presentation": [
      "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r36",
      "r38",
      "r86",
      "r87",
      "r228",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r209",
      "r227",
      "r251",
      "r288",
      "r289",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r472",
      "r474",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r205",
      "r207",
      "r208",
      "r209",
      "r227",
      "r251",
      "r288",
      "r289",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r472",
      "r474",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r150",
      "r207",
      "r208",
      "r277",
      "r278",
      "r440",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r150",
      "r207",
      "r208",
      "r277",
      "r278",
      "r440",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r198",
      "r205",
      "r207",
      "r208",
      "r209",
      "r227",
      "r251",
      "r279",
      "r288",
      "r289",
      "r320",
      "r321",
      "r322",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r472",
      "r474",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r198",
      "r205",
      "r207",
      "r208",
      "r209",
      "r227",
      "r251",
      "r279",
      "r288",
      "r289",
      "r320",
      "r321",
      "r322",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r437",
      "r472",
      "r474",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r37",
      "r38",
      "r86",
      "r87",
      "r228",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26",
      "r406"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees accrual"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r9",
      "r194"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r41",
      "r42",
      "r43",
      "r461",
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r43",
      "r49",
      "r50",
      "r51",
      "r90",
      "r91",
      "r92",
      "r362",
      "r397",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r332",
      "r333",
      "r334",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r291",
      "r335",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation expense",
        "verboseLabel": "Stock-based compensation expense, Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r68",
      "r188",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r11",
      "r83",
      "r138",
      "r142",
      "r148",
      "r175",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r358",
      "r363",
      "r375",
      "r404",
      "r406",
      "r444",
      "r459"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r83",
      "r175",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r358",
      "r363",
      "r375",
      "r404",
      "r406"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r161",
      "r182"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Marketable securities, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r158",
      "r162",
      "r182",
      "r448"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities, Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r160",
      "r182"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r5",
      "r70"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, Amortized cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r71",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "totalLabel": "Fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r70",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r376"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r80",
      "r83",
      "r106",
      "r107",
      "r108",
      "r112",
      "r116",
      "r124",
      "r125",
      "r126",
      "r175",
      "r213",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r249",
      "r250",
      "r254",
      "r258",
      "r266",
      "r375",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r352",
      "r353",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Co-promotion"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r210",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r406"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized; 70,419,388 and 70,364,912 shares issued and outstanding at June\u00a030, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r54",
      "r451",
      "r466"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r16",
      "r17",
      "r261",
      "r267",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of shares issued for each share of convertible preferred stock that is converted"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r82",
      "r88",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r383",
      "r445",
      "r446",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Rate of interest received on convertible promissory note"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r82",
      "r88",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Transaction costs related to purchase of long-term equity investment in accrued expenses"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position for more than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-Sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Change in accrued interest and accretion of discount on marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r68",
      "r136"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r326",
      "r327",
      "r329",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r274",
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r103",
      "r106",
      "r112",
      "r115",
      "r116",
      "r120",
      "r121",
      "r369",
      "r370",
      "r452",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r55",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r106",
      "r112",
      "r115",
      "r116",
      "r120",
      "r121",
      "r369",
      "r370",
      "r452",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and bonus accrual"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r123",
      "r176",
      "r266",
      "r274",
      "r332",
      "r333",
      "r334",
      "r343",
      "r344",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r397",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Agreement ownership share"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r6",
      "r139",
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r63",
      "r174",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Long-Term Equity Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r171",
      "r468"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized loss on equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Unrealized loss on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r371",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r233",
      "r242",
      "r243",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r372",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r233",
      "r280",
      "r281",
      "r286",
      "r287",
      "r372",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r233",
      "r242",
      "r243",
      "r280",
      "r281",
      "r286",
      "r287",
      "r372",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r233",
      "r242",
      "r243",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r372",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r233",
      "r242",
      "r243",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r187",
      "r241",
      "r264",
      "r366",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r189",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r138",
      "r141",
      "r144",
      "r147",
      "r149",
      "r442",
      "r449",
      "r453",
      "r469"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r196",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r340",
      "r341",
      "r342",
      "r345",
      "r347",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r101",
      "r102",
      "r137",
      "r339",
      "r346",
      "r348",
      "r470"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit) provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseDueFromAffiliates": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.",
        "label": "Increase (Decrease) Due from Affiliates",
        "negatedLabel": "Related party receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseDueFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r67",
      "r438"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Land subject to ground leases (sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Operating Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Commitments Under the non-cancelable Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease, liability, to be paid"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofFutureMinimumCommitmentsUnderUnderthenoncancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal option term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r83",
      "r143",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r359",
      "r363",
      "r364",
      "r375",
      "r404",
      "r405"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r83",
      "r175",
      "r375",
      "r406",
      "r447",
      "r463"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Fair value liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License and other revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term equity investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities",
        "verboseLabel": "Cash outflows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r44",
      "r46",
      "r51",
      "r53",
      "r69",
      "r83",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r109",
      "r138",
      "r141",
      "r144",
      "r147",
      "r149",
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r370",
      "r375",
      "r450",
      "r465"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net income loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r103",
      "r104",
      "r111",
      "r116",
      "r138",
      "r141",
      "r144",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net (loss) income attributable to common stockholders",
        "totalLabel": "Net (loss) income attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r141",
      "r144",
      "r147",
      "r149"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r389",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/LeasesScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NatureofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r356",
      "r357",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r41"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Rent lease"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "ATM and other offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r57",
      "r58",
      "r159"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of marketable securities, net of interest earned"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedTerseLabel": "Purchase of long-term equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Payments to Acquire Notes Receivable",
        "negatedTerseLabel": "Issuance of convertible short-term note"
       }
      }
     },
     "localname": "PaymentsToAcquireNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Develop Software",
        "negatedLabel": "Software development and other costs"
       }
      }
     },
     "localname": "PaymentsToDevelopSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based Option Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r17",
      "r80",
      "r254",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Preferred stock, liquidation preference per share"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r406"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r331"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r191",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant, and Equipment and Intangible Assets [Text Block]",
        "terseLabel": "Property and Equipment and Intangible Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r8",
      "r193"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r195",
      "r406",
      "r456",
      "r464"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Note Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transaction expenses recognized"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r398",
      "r399",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r338",
      "r439",
      "r484"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r5",
      "r75",
      "r443",
      "r460"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r274",
      "r406",
      "r462",
      "r478",
      "r480"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r176",
      "r332",
      "r333",
      "r334",
      "r343",
      "r344",
      "r368",
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r140",
      "r145",
      "r146",
      "r150",
      "r151",
      "r152",
      "r276",
      "r277",
      "r440"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NatureofOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r392",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Stock-based Compensation Expense by Plan"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/PropertyandEquipmentandIntangibleAssetsSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r290",
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r297",
      "r312",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Options Outstanding and Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used to Compute Fair Value of Employee Option Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r80",
      "r124",
      "r125",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r258",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r15",
      "r17",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share based compensation, graded vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Share based compensation, percentage of discount from market price on purchase date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares reserved for issuance under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of company's common stock reserved for issuance under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of option on grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Vested and exercisable, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Performance based options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of number of shares of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Share based compensation, number of shares purchased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r290",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share based compensation, term of plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share based compensation, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Unvested stock options, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years, Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r390",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r80",
      "r83",
      "r106",
      "r107",
      "r108",
      "r112",
      "r116",
      "r124",
      "r125",
      "r126",
      "r175",
      "r213",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r249",
      "r250",
      "r254",
      "r258",
      "r266",
      "r375",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r49",
      "r50",
      "r51",
      "r90",
      "r91",
      "r92",
      "r94",
      "r100",
      "r102",
      "r123",
      "r176",
      "r266",
      "r274",
      "r332",
      "r333",
      "r334",
      "r343",
      "r344",
      "r368",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r397",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r123",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r235",
      "r266",
      "r267",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Series A convertible preferred stock to common stock (in shares)",
        "verboseLabel": "Conversion of common stock to series A convertible preferred stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r266",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock from employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r266",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r266",
      "r274",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock from exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/StockBasedCompensationSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r35",
      "r266",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of series A convertible preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r266",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock from employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r266",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r83",
      "r154",
      "r175",
      "r375",
      "r406"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r265",
      "r274",
      "r275",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity and Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/StockholdersEquityandPreferredStockAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r241",
      "r264",
      "r366",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CommitmentandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "US Treasury Bill Securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r110",
      "r113",
      "r114"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedLabel": "Net income attributable to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r391",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/LeasesScheduleofComponentsofOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r105",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average common shares outstanding used in computing net income (loss) per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r103",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding used in computing net income (loss) per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NetLossIncomePerShareSummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2793-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2814-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r486": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r487": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r488": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r489": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r490": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308"
  },
  "r491": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r492": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r493": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r494": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r495": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r496": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r497": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r498": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r499": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r500": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001628280-22-021759-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-021759-xbrl.zip
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M*+7<>&^Y=EQ[QL.M#47SOQXYG46>Q^UZ&E/ZE5(R6&&TH^#L.@2.+BB@2'
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M71NT[9SDIF,CI-4XHB@5BQ9L(D5.,2<"#EB(X=X!FL[8G2V"#'7H1K"=+9B
MHIM^.$*7CT6KD;?;K:)7;77"!,HJ8#D.VV<X W3"!6"5])\F)FCC9!#1>W99
M4&8&)636"#*&\R2;W=27>T[H/(6/PP8>?*(D<3BDS%8,SAS#)FKN"9)<T2!9
ML&J&%>"0O.],7GPQ]6[X9^_RX[^@15.XH]Z'<!;JUS'.Y4-;S=-NIUT^@<<5
M!1CIS'J['?K!@!&6^[SWO@7^?S.-L5:41.J]ZS;]7=?_F=?K[?6F[T.VO>"Z
M!;@]L\RGUU.IHT*",R.U35%"9+4E41/@ (XM,-OLEZF=*\[:!CS? ]-_$CJ)
MH1+C[!VUBDXM%(VMYEEH=]+HYZ6&+J&>1ZLI==@!+@/%Y+1E5#.-*?'8S8%:
MRINFZ7)3OVEZA@]\WAL5] >+]T2YE\R)KO%($$<I)B@*!DA1B6#3D4I$&\JY
M9W/ +B^(6DA'[UA44H%WJ@TQR'&,"%,I@00^OPS+\+S4&F.Y>6292#M-N I,
M1Z1\JMHLJ%0Q1B30RY M.B>R%366G$BB(Z%,::,-CCY*@97UBN,Y.'9C]JDU
MQF/##7<.I1++F(#WI8T2C(-4:>(MD&\.8,Y;TSX"J)G^27[*F:G?L90&-^=$
M?!SRQF ;$ +_EV"N6,(100*!))76+@9!;OH*<T*<: 0Q,@0B#&5$48N(UP81
M9"U3GL^!1SD3TC)&+XTAKRD .,LPB\(K(D&%<<J1,4K1!2'(1*7E2<2YC!/F
MEP[_K5AA&2RX"@@\/F#(I"56$:JH9,YXY6.J:X"-L"8 .)Q]#?FQ:,$T=GH?
MZS"S@_C::6KCG[U:[_3&D>#ON@7,!,P,//@NOTB?YD5=IDQ+1YA0VG%FI5#2
M6*<$V#4D ':(V9?.V:;4^/0HBRY0&K%4!K.@E(5/G(*+Q:DQAL\!ZG@4I3Z
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M7+Y55DO<O#B%UI[A!-/IRRUX]]()ZI%2DD6-=8K?<& ARZ- _<,DYT1N9Y[
MTUD;\0@<%AR\CIH!+C:1R.B0!@H8;WR8(Q@U\P2>"J"RCOA(&>%$:,:Y5UI'
M*2E<<UY(C^;(_9EY D_%$:*1"FE-Y!A%%ITQRE%+!0)5K8FQ:M%L\%ZHU_/F
MX?O0#(6I YG7?2-OYNU.8=+FV0&E%Q)%<QJ PE$J; !N&9MR)@-"2J)(N+C<
M&;TPUG@V2#T5N\P=YB+*X*-C3&%A/9AG;6@TS@<F_*+9Y=D@]50L-%?IN'8J
M&?S-K$$Z"".%<&"?X2\Q3P'*.2+U5&PU$CYI;\2HE(P9I[2//)UK+K%C@J Y
MLM5WA4$6?0N*X<$"A(Y41\%X "M,B(878$RL8&:>*AQ,F7Q3L:G,,":#\D0'
MRKASACKEG;)@9&W0?-ZSQ19]LPDWV'K/!;@V@5E%#%+$$Q2$#!:'2.?(3DY?
M^B9O^[2.7(*B],E/=3:=O((=14P"RD74+<K*SHLH]8.Y!U'4#%-"61#@@0H.
M>"8H!O3T$LVY(7Q1=7V\-X*G*FO8(I;*P"/"J4-2.\LC)V3.K>)\E!\8$RV%
M5%0$PYVDE#GODL5,:ZU 7@H0)\RYB9R/2B'C0JM8<VLQ!7P*M(Q*RR!%<![
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M&8Z1+Y[*]=56T3DZ#VVXW?S<S,]"T8:9>F9F%,G>/<@T]A\=BVG$-#(;B;,
M29F540<G$</"!BP-I[@TC4NVF2VV&;%E8FPGFQO$)7C 'E,MF7-2.TJ"Y%Z8
M:"/G9'8YX?G//5[RV"_SV*7I.RU:ONLZ=QN_C_V;CS9_,6(KM$:&$Y:R9E(U
M)8JM9-1$QOF@6B@P+1IZ1#/G9/^$WNLI(?][: 9GGMVE361&#[ _-Q]]BDL;
M"3BPCJ=\4A:M48"CO=,$">YX<+A?J6=)MQ]4Z+E&BJ<X,X$'*A@!W4^9#]R
M4^.4X<Y99(000UFZBBXL:?)#67I,F&,L*838<^<%,=)AIJG1T0>MD"<PPXPP
M-SE9FA8+6QJH"C*=X40!PP03/28L*A:BPA*)^3<'#_?'Y](<*.Y)M."! ",S
M$ZC%%#-!6*HH;(5#<[ .\S,=! BRGC?SR48ZII1+@J7WF 7IB&)".6LI,88P
M&B6V+(12(:%9=2G&3\1I^!M/0Q=H;.ZEED&X0 U'&#-$53H"$W$CK3)2<S0/
M%4Y>-%-,7YM0'A'2EG.FP#Y0K;BP'@6%*'=@-.8AJWXV;<-TUC(YN'F*,TN(
M8PQAS<J-:!$[A:.A?%"BE<Z>;?B)/ YOOVW5Z\:V^KOI1YX:1WQH#P;LNW5X
M_>:_NV7XIW/4\EO-L]#NE"F,MZZ&</.,4',2O/EX9(J&<:';R9VIOVTU3DVS
M]R%OY)W@G]EM170\AB4R+3EF3!%JF154RU2\@;,H."&8T2$C$3UKC.1#OO8A
M')KZ9MF?<1)GRDP\!MX@>@R\D7;J!*0\%>!&T'3T06#*8XZ))9[&8:4>X(UL
MR20S%%B?//O=-(BC#/@3@SCZZ%.*>#*G(B)1:&V8 -<W,.0X@8]:!('F80/H
M4J'-%&#V8 J)(=ZD\MR*1HN$5T0I+YDP@L<Y ,Q+CIHIT&Z-M09[XE(]-!NT
MU9YX8=(J,>!Y-BR'1H8Z"C[,&D<]Q)O^5S#UBZ$3UAR6CYZ<;_W0I8,;CS[%
MM_8Q8NV(XLXQQ8+&/$3A! XB2(G,'!B?>2#L%$X9(AJ9(+4$9YMAK!3A# D@
MH-',.SY/I<YFF;!3*.5/#4#%H(*6 !0Y,L0A\'4X%^D 1A\'IP[1V=/ ]]OT
M;5/DS6[[NE%O;S7=)$*H@Y=/-+Q.DO> QA$%H9A;%+BW6' 6 M>8$N.DHMIY
M8X4=R#D=ROD,\L5#B/01I*79&7>$??P<.0:50A^N4NAX0(!5$DL7!'<!,VTX
M^)T$LZ $EY9:,0^':K]TW3)]N\12.C'G-AIG&,?>$N8L\<!%4B#-Q!P@R243
M31NU,@ON)#1H*$*,XF@P>)<V8&<5#C3,5=$ :,'G]6Z*#NP%URWR3A[:FQ>N
MWO7!ORM:C12UZ';*"LT[<=,4S;QYV/X8BOY&Q][=#4R[EL14=(OUFGJJG&"I
M]*B+VCNDM?0X4A&L-/.T\7\QV6(ZI1,)"D:AR)C28&RT G(Y!HK"2VF=PW-@
M<A:<+::S 3_JF(H6N8A347]J,>'1FQ LQD[$>:IDM*!L,9T"R R0*"<."4[+
M(ST,-D9;1XU*2R-XB2U&JV'#O,*%MZWF62@ZN:V'CT6(H2B"+]ED$5&&032B
M*($MJ >]88PGAJ/@(J. 0_5<E1=:= :9"MX0 CD/ID52!\XMXI8#8[@@@R((
M*39/BR4+SR!301Y(2TV%9)Z3R BA1@9!#!%8I)I @2V1Q^PPR/-CD-?YQ5H1
MVJUNX4*[__4H&%]VWN=G;_Z$OX:(U2KM-+9"(<9B4)JG ^8 GY"HA-3?4LS^
MZC?M3J\.#-'(F]E1R ^/.FN$O.*GG3_.<]\Y6L,(_=?*]2=-<0@/=UJG:UB=
MIJVX[5/3'-YUK7JK6/L'\!&*\8\(W<^B:>3UWMK_U( QVI5J.*_LMAJF^3^K
M;=-L9VT8\.#!=OX]K&EX=?GMO-\;AM ?];P9AKW#!/W7'VE.,A]<F3#1:JYU
MFS 3Z2GHC9F5KE2.@ 7_6OG'SRDB5][4#/!LI14K;Q/%FYWVGZ\-D"E-[9!:
MMVA6OMK4\\/FF@LI'1Q&WRG;&3Q@6P5T)G,IN>2T'=:&'_[P>?NT;GIK>;,<
M3_FC/P:$M:U.I]582RQ0RI(S]<%+RO?U;U]QQRO4YY .<&+'#]\\N/VJO/6Z
MXV_?T^J51O??1J_PY;W79=O%\('![-.2]^!W,*HT37^MT)4; Q\,!9ZL^%8W
M34SBAC].C?>@7]90!9=M7+WD=3D3=XG'%=-+F)B[9OX>*8#WC8'UY!VLM_+F
M<W6KMKE1V:NMUS;WKC/+3]AD"IW=VWS[>7>KMK6Y5UFO;E0V_^_MO]:K[S<K
M;W>VM[?V]K9VJK,^@J_K>__:JKZO[517*QMO*P1QIF>GSW=IIY4WWW[MS[W#
M&A$$,3N"\&YG=[OR)]C$9JM9[3:@#5<9F,[=I(-SA@7 :L>I%:"!!5'*I=-1
MM"6@DPFZ<T&ITC0)*J6%G(V6ZR9DD%965@;Q0OJE9S=:9Q_([MD^W>[ZX\VS
M@_?Z>*=QT-@_/N3[WT\N]H_WV?;&)W30^,QV:I]9]?W!T?;7=T?;C7U6/7;\
M ZW6][^?PB^VV,[7;;[]=8OL;*PC>*Z^LW&"=S9V&_NU=T?[M;\;.QO[=.>+
MNOA #GK[7YW8/MX\KWY]=PQOX]7:;J/Z'MI\OTGV&_MT_WOU9*>V_7V[]IGN
MUP[/_/LOS/_K[_H!J9_9XU9ON[:.][]6&P?')QA^APZ.#]%^[2 _./;'V^03
MAU]>5&O^:.>=ZE5KZ_Q;#)@2XDBFB: 9\S)DAN*0<4*=-%X+(L3*&XRR3R4R
MN:+"FY<M'].1AM^V37%2V6F&WQ_234P>T\^O8#B3\6P_J8<3$-5/7<#@@,1Z
MN^&T5716*K%5-$P'7G#168OY1?!9I^B^/&G>//_&F9/"<)U);F/&J#"9T=AG
M*;1-'>7<^;CRYN*F*%>&W#0%EO[T>7VWMKG[8;^RN_EQ9[=6^?AY=^_S>K56
MJ>U4 %G4 #Y4,*WL[%8P_\W_7MEY5ZG]:[,R CHN <?ZVUJZC35E#Y$/-D-F
MKE54.D>A\N\A;U?Z[F(%O,C@)V$ /Y;OV^P[K==ERL.5K 'O/$H_R[SI9;U@
MBBPT7YZ,77S##(1,*I81)77&(E&91A$\_^@(DE$C*L%9_;O;#!6*5BMISA]L
M.F>3.7=V']CA!30VM0*ZER?__WYK$TV]_0+-#?X6N:5*,YKA8  \$@"/VBB5
M<>PI,D8)Q.C*F]8LF9O:[GIU;ZLT*A.W-[/D5@WL3>>2O8<&)Q:M1N5N:%SI
MM.ZY,V>C?]MJ-/)VBF17WN7U4 '&M*%8>TXSV\\53&_KO^SEJ0OR+4;,(L8L
M,QCYC$G$TR>>267!V^1:>D_30@7.J$**OS"'<ZP]5@_J<65FY):P:1O\OH#N
MAL,\50%L=E(]C)<GI/2;ER$085&F'7,9LUAD.L(G3@61QEF** %(>);[2NTH
M%.:T3'-N5[::[M7L2NP]X93-"^,ZE43JM$!S1?R*:5?V3H-+JZ.^DC<K>:==
M>7M4^F;WAU[F6P\]21G,S>(4>_CBU#,U.UCSNF^!:[B$14XOTB+6[=F^-3VM
MTW'SV4WK<5-Z-)N$+@:-TBI.!ZNOZ:B?4-;&*GIO6_YZA (&X-+2?"><%JVS
MU,Z<AB;>Y?;]9[%?V_Q>/?YGOIWT]OO/Y_ \VJF=H(/:WT?5[W\?[W\_O-AO
M;++MX_7!;[[ NWCSH'9ZM%W;)MOOMR[VR<')06T==/TGOE/;K6\W-NEVHWJ\
ML_$NAW?UMM^I\P^U]<[V'KKX4-N\V/[T35E' *&)+"JG,J8Y 6].RTPQ&:CV
M)#H#\&PCU,VY*<*]NG[ _TO6_@%KU\S%UB#[QI7L/<=.P:1Y=G.49[U+IUPY
MGU'!8L:459F2@F>8I[-.A">(ZY4WP-.<2*3T_3[%@FCF?E+/;Z6VK("/OP-.
M?E'YNUOD;9^[TL]OQ3]M\?K-->U:/EH<FF;^O?S^^X)(\V ZME[MOMI[51ED
ML!?]\5^3OT$(X/?;_/"0Q)'!0ML2!$T !-5#O#4Y_7FY,YEM,*/HE>23\&-_
MSI!\$O9EW?LBM-N#?SY !_ <VY8#^+?Z%=IZO]6K'M>/JN__/MEN;-&=C4_D
MH%:%=YQ\WS_>8F!C;MJ6D_VO6QC:9G"?['S=1/N-3[W]8\>J&P?U;;(/XZOF
MV\='QSLW\=">1@?_=X1<XTO3?-7=G6.8AZ^;I-K8QSOO-\%O_O2]^OV?>;)K
MU>//%P?OMU 5^G_PM7K\?]\_?]-$.:8BRCAC,F,&D<P(H3/EL99 -"^5 \/$
M<*6:-SM'E?6ST.S> E6KSQ^2O,TJ9,DJ$V25DV_&"$^IDAD6#@&&03Q3SKLL
MH*",2L<.1[GR!C/@DG?U5JMX[&KBBU:!;^'C3E%KG<^S0SA_7+W9^Z:CI<I9
M4'E1F(QQ+3*E,,V4T=$1)C66P-:)F_9;Q<GT-%^)E7>*CT7K+&^ZA0XLS"$?
MD6_*8A6,1ID5#BRIY3:S)II,ILW^@@B)#;^?CVY$-7_-GWDHYGQANO5C"T2C
M?I"?]@-R2['XJ5A<BUU(&XQ#UF62:%"05L3,8BXS'Q0UAEJ+!4JIMRAM/_J1
MR7^6X,4E?T^!@7\;,%A:E#DM0"OGIZ9>"1?!E?O$X#+X[:']+%&*J8X;9*F2
MA.D7XQ 36:K]Z5#*1:BKM;3__H<B6/[1KG1"/9P>M9JATBR#+:L5H&R]F\A3
M,44P0#X?UBJ_/:/Z2FAP'5XUMPKK28N[O6^."- P%F<4"7 UD+49P#22!>TT
MB>E(18M7W@@F;BJ<WY\3CGUH@?A]3)PQQV'P)U&&?=.!>\VUSDBP/F.&V2R=
M@)1)Y:*0)IV][($R F<2_OJ5A%(ZC?RKNU>H?\1+43.*)&6,1LZ 5;4)03K.
ME:9!ZG!GG?N%C7_],E-=5#<.$4#K\^KQ">"8=;Z]_LVY=-1%2N4(D6>,)E\L
M*IMYK6U(YPCXB%.<0:#*/XN6\>>F]SBO[)E(-Y_QJ#&2[M,W;:SS0)Z,<T^!
M=(9F!EN9$66#5$1)&=3*F[UNW@D5S!%CLYN),UV-,.?AH#$RU?DW2JG#F-H,
M:6<!#$29&0=.B.>&*N(5-DC\:H!FG#1[$0&:\5&VNOZ-"4<9UC[3-*J,J6@R
MS1C/-$ ''9PV,.,_"IE,B+#S'S\8(]4.OWD;H[<J9!(F-6.<\Q0P!9B.A0A,
M4LV4+>,!]!8\GQG\]U/G$)=^[CN0X%"4?+%:BC-\,0.?WS3]\%+,V^ 95-)F
M,W 68\4=I;JWOM).>J!2-^U.I2AWY?QT.^Q5O8@_[IJ2O)FR =;XH_8PC=/^
M796^@1$ESSD4,,[3;M'NIG343JL"3Y2)"IC\9G]/@9&T?6/===8>E+=)YRM!
M@:I7F)%?2E#X\3V&Q-C3'K!^11"=D\Z6,_NPSLY'1/%GF=YE0E\M[_1K\ 3C
MCBH.-$?[$;'#:]5DYG?QX*<SE51SK3!I(+/C+]S9R[U>P[;JO[5_?_3JSM-H
M.7.,/=RZ4/)UN.@;R J8B?.C'*Y<V9+')#H.+$.R&R@5#*NT6_7<5X9CF87$
MOY]9U>=.XQW8ZQXFMM0M<XE>^ZM?VV2WL?/U$SXXWLVWR=_UZOMM>E [.MDF
MF[V##7^RL_$%WO?E9.?]IQNK7ZWO!^_W^0'<K[[?^K[?^(SVO_LZ//<=^G92
M)9]8]>O!4?7K)W8 B/=&MKF7.AKO4!:))QEC)&3*.Y))J8) 5NE(97^G)G!S
M6>EOM7)JBLJ9J7=#Y3\3M,!ISVJE??2T;/0':(1Q"\1D%,:D96)@.OJZ>2D0
M#Q"(K5&! )\:7&MN,N<CN'_1H\S(B#/'K0W"!Q086WFS\V5K8\GLTV?VH0'8
M'-C<_G;1FY&I9)'G."@U:7GX-"H/3E+AC->986EK!YB)3"ML,XP]"5XSXR3(
M0PV\X*II>_/OOI&HI I9H5/Y\.'MS_=Z/#2W?U;J%CPJ2G!X/4I0;37#[*#Z
MB9=LFYU0SU;3ITTGH6)[%7<4@&4;J:C;^5$H]^HD@A57&Y%_P[]7CDR[$O,Z
MD-K4ZX.(5^* ?W?S1'\@NPV#!Z#-2Q:@:5=/OX;)@!%&^&>HMQ)SI-NIADG%
MP]WF8?GH:1%<*%,S,*F4M9_:E=^@/=!PE7877(OV42OMAAZ6#>D<F<[-OI^;
MZ[U,7>S_>#"&WU?+:-]OI#]&"WH2[MMC&$%Z/C4'OTF=&#23*O*TRSZ4?4P!
M0(TJWO3:KYX_7_1MMRC@_?TZ0 GH=$RGVYY+Q?ZD9(7OWS".H)2]R3!5H)J)
ME9D**8$]2&.%M Q9L?)F/[2?6OGGL66B[I:XBXG4&[JGQ$:U-9U!MQ99*R9M
M 8JBD7<ZH%I"'11&T6HFT%GO50( T%YE*YDQX\I\P0W3,?U*/S>4YE4;HT9T
MMPM/,L0'-2&Z]?X6P;VL5OGMO_^!A?RC0BAY-7BB<Y2WT\K$::H-\=PJM-_A
M_L^3.FW_/@'%-S*5:28'>O#E*3[^32L:)5,B8PZQC!D: 9U:G?GH B%1!HOM
M4O$M%=^S*3Y0-:92AW&$BG$.%%]ADO9*JJ!(8.K.JQ5@Q.R.&^T&Z$MX1S%$
M-* [&C #O00<H2V 6VG"#BN'1>N\<S2\^PIP9"@[YD/,FV7UN#)5.V7Z$ACC
M/=TK;^,_AH_]](%[NW?Y8 */@X?OZ>OPR;S9U^J8V(P,X? H!GZU-F2;N5DD
M)?27%TE_N(M;O**$C;W99^HM>:7UPUI]IBWGDX]J?2CE:WU$?!*T*9ZV&6(<
M8WRJ_BY'UYK^..8C GE54;)X"UQPV"IZ<PG)AD'&?8!8N_G!QA;;/W:HNN'S
M??+W275CDVP?G]!]\ID=O-^M'VSLWPXR'F_A<L_6\5%>_?X)5<G?Q_N-3VB[
MMM_;J?GC%*P\>/_EI%I/>["N!=VQ,IP313.#G,]8H#2S&/ =5_!98N.TCBMO
M[I"U<18_FAG9NWC,*O'\"&'U!OQ9JLM9I=3> /)=QM@J;_LX;OJC' NUGMT<
ME!/XSVX;7MQN+]3)&!,U$V >MD?-1)".&<-C1J0 YU]*G;;JDBP8&87&1@1/
M[CA78S'5Z>;=KM921!\FHL/I>U_.WD"_+47U5T6U=V-7/2&6"R%<1AAR&4/@
M\*?M;9D74FG"I''"_TQ4IY8..GEA3O%L],>O+8W/4! M_B!>E?:9WQECR^-=
MZPKE:@*@Q&:K7 SHMONQ+AAG_RR>.XY,:!7EN^J]]/+S'%Z=@FA-&%HKA:_.
M\G89XVJ:ILM-/87&4B';]'"[8YK>%+Y=2?N7<G_?<C[]S?Q^5]AJ.B'6Y]>1
M%U?GKO0/)EHH!?FD50CT#:8Q50X)F14D55:*,K-<Z2P$(:B( 7&J?Z3BYD.D
M'Q\7;Q^%>OTRAOT;R'(9H.Y7</])^/?WRCYT?3H+%I,Y#^?NET]KE>;Y/:'$
M##] 5R_ST*9U^BWB"&X+4IG Q*<3/T6FD4(911%99+B.;GIG!-[-+.OE\M)Z
M][#;[O0!"^\?K+9ZVX!?'I;WKERR!N/9;>9]QBHSQ<$KOL9LQCN!N$0Z4L,0
M>'9*I%Q#FLK7<1W8MZV2QQ3B*Z!.7 X.=ONOE;O2@\I4]3()L3S;OKW3[93F
M'63E.@,VNXW,M\JSQ5-S@!H!"H:RT9?$CA?;&R<\':E7/=X^KVZLGW]S'"-I
MC,J<)SICX%5G%E$#UHVJ@"4-@K"5-Q*M,JQ7J5)#'AV2^DU_,T#)+:Z_<Z#=
MWSDPW"]PN8'@<N? :J5U1:=7#SU6=;X/P9BO$]H'[R0D9:/_<=KJP\*U(J2\
MG+-P-1W_=7U#W;#NZ=5/C&VWZMW._3]Y:-[OF[*$^(W-9R-_IR9+48[1*NTT
MMF"YP)8%I;EBT6!C2%1"ZF]R9?B;H^+*>SP$;%<$<Y*9""]=,_5STVNOO+[>
M5^CH8&I8FIB'C$G]",W%^%P:O#^/H.X&Y>;7NH NB_04],;,2E<J1T6R"/]X
M$-%JI:R#GGF;C$FST_[SM;F3(>ZGQ*QDE=\QE(<IP;E2>:\0_[5]V#]J58I7
MFHZ_D#Y&KR36X\QJ>$3,:GYVR#ZLJ.)'T*;/&(AOY-[70U_E3EI\^]5>[U*@
MS_?"6PH4\-=C=">F0)+UW5IEZ]4=*G-L(=4'D64\9N9!LS09B_?(KCR.:N^V
MJNO5MUOK'RI;U7<[N]OKZ:C<1]%P9&LAOK:Q\ >P<!X%]1;P>&Y!O>N%3Q94
ML?)FJQ,:%;PH@OJ@69H2-!V;H +5WEVN-)2ET_J;IG[[W#1=GW>"__TYR3D3
ME4T61O[H/:0:/^I;2NM4I%6G$A=IJ26M$,*GTB2626K_-'63JISM'85PIW>Y
M%-G9$UF]%-E%%UE"[A79$6O;BI6=T]!_S5)XYT)X$V'94G@76GBI% ^4WK1R
M7(0C>"YM(/[M0ZO=_CV=<=]JA*4XSX,XEZ3F2WE>:'DF_('B7"[+'[7J\(KV
MX$":RN:_NWFGMY3F>9#F1&BQ%.;%%F;U4-MLVN51J.=+9#T?P@N$E4OA76CA
MI3CEDG:@2YU6Y3+47+E'GN^*4"]E>1YD.=%9/4V6E^MUST(920?K=62Y7C?M
MKCR.:MNF:0Y+)7AY5N9&WG;==CNE+Z<B-^M-4^^U\Q+]7.G.I%S[&Y'2,[NA
MW:TO0X_S*KH$+[7J#)(&(S10JW2I5J?=E4>2[5/:1IEWRBSQ4D7"A?KP>]*P
M]5:[F[8+K-M6MS.L'+V;MT^6:G-N9),LT>ALTF8(1]FSZLW^V3)+I3D>I4G+
M"%RG +*4"O-CT7+!)QVYU(AS(W6+IQ$7(_$]G:;;SWQ?IKY/O2N/I-M.[5^;
MN[^<][[,;I]!3:F7Z>VSTI5'DNU#.#3U/C8IZ^LOP<G\B!S1BP9.%H,VF S5
MX?I2'TZ[*X^D6XI85=X9UVD52U4X/^*V5(4S2AL^4(5BJ0FGW95'DFWSXBBW
M^3*79(XDC3]*"XJEM,V(M*F5-WLPL:;SR]'AQY> 8L]> &KZ@HR3(.?C*"V%
MT;*VU*QTY:76EMK[N%E6#*GNU#8KNYOOUW<WMJKO*^]V=K_"Q^S#SL[_IN][
MM?7:YO9FM;;WD-I3XOKXCKOM3AY[U^K64C&MNK6U=!SDIZY))SO6>X.3+"JM
M9N5=JP#O&F6?ROJ3)F^6!]F>F\)G]5;K9% ->ICFGJI(Y\VRO&4CF&:ZF[:Q
M#.I!$[E^QYF^5T?YTM6*:5=,HZQ8O5H9G)=[_='^V;N7+>+-!YX2?&?3UVKI
M5M;K]=&QM 85>TM:C";RPU2!SYJL="6"^UHQ11B>YW;_U R/=$M5MT^[!>CV
M?L''SD\G_E5E"WK0:H2*,_"CU4JOU86/3="GT#"PT(\(8GL5:!@4([#18:]_
M B=,Q/ PN[QQZWP[:-+EI]# K3OM=K=QZZH-]3R<W;I<%BMMG-9'VTG7\F;W
MCF>[=7_SH@]MD));5V__.H 8->[H;K@X!2:Y>?6P9>HWK^5)7=WJ0,/T;EYJ
ME6<\Y[='"^.\U=6A]0ZW6CYM)?68W^[(:1%\?KO/IT7K^(ZAM(_NFK=..F;M
MUK/G>?W6V\[3SX?7!@+1#(?]/*/$I?5N 2Q>\F@KE9,'/FKWQ:^=@P8R107F
M&&!4RO=L/Z@&Z4RKP'?W2U'>=/6N#ZL5V^V+>ZJR7X=)Z)3GVZZ./FM25M;:
M0V=C@"JS!/X!J:B?3U VO1DJF45<'KLP\1Y<GRU*7BF>IJ+5+6#6\WK>Z:5M
M')=J,3V<)!"8N-DZ"_T:ZRU -WT[54D*)H^@QYN=LNYN*,K\Y$OQ3(T95YYB
MG.0!J%;/7=H6\D=E2=ZID1=,F .=$[OIT.P[R3-*>%]T#Y.Q].46GG8RK.!%
MM.%> JNE2EM2<]+4')KL=$CX(:C<I&V3N6Z6\"9VDW.>#B ) !8&NC<]DHY'
M*%H]4^^41_TVTD'B'3"PE5/3*W7O*E#Z-.\ V0>'CP\T,EBL9@B^1*ZCS#$X
MVZ1YN&2!*0ITRR:W(K%".K*^58!4GZ9C9?K8(SWL^D>WEX0<<,<-N5X2<.(R
M7,+K_G:=$3%.(/+*@#;ZN>GI?27QRF,/TNDHZ8L/AT4H P:#Q])AEZ>=LGP8
M7"Q=E9MD7E)Y:F(: 3B5TGC>*DI\?)>N7<KA)"F4Q"D')[N<^U(4AQK3#L[2
MK#1:'H!OZ;-UDN0=YJZ2O-6^+;SV:"F32[4Z/7)Z0#SUUND@SE144OWY;D))
MK@4ZL>A'T[H)Z79"/1WWUDW>2M$Z#44?$?4C5NE*D8>. 4M:I'<NR3A-O=D
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MJ#\8_'#VRA]")\#[[2N/TAE.1R_WM>[5VX=43+\^#,V0DJ1.NZ!8W%"QC_@
M9;.C[VD#"[O!NV&,1^:LGTV4)/HTE&(-LW"6A#+O#WUD3%=]Z@T;NI4="(WZ
M5MGDU:0".1((*$W;90_*%L^/<IB9_@3W^YH65^'M9\'/OY;:>@AR2);]!COV
MF; T,^URS@9GKX\\,K S)7_%)&:N7T1V )YVSO+;J7DI; A.!QB06[EXMU(*
MN^U;V8?=8GAEE*%&7G])YO3V2@VZ:DY#MY.[=CH#XM5EA/+\J)5$N'6>A M4
M0SOWN2GRQ$R/UNO71Y_T<Z<P/B3!'&C#UN@5P!6 2H<XJ139%,WLE"_?:]43
MF"GU>*L)NB5/#:_>:C%]+0^R'[R^&&3A7>EU4(*M%)8L.FFU<D0_@)GO]D.G
MZ6C?4H.4^0:@(4J<F"JJ)3K]]S^P9&5:9&V[TNXU;*O>[J?_E>O2(Z,>I@/V
MLTC+GB1A3MH@I"Z5>.'<]%8OL51>#-%HF6D)5"CCI?5ZV0Z %=#/JT-I37E.
M8 9 F%/8MU+FYJ<.)W63<$6)<0:-EHL]Z4L1.JU7E:^7FJ#?MY(ZR<$8K"W!
M!)20M)P85S(FD&%XSL#H++>N434-L'&:LJ\&J!>4WE%^6LY?&2R&=[4&8<+2
M0)VF(LI%^0R\KYNRDE?+:;GQZOL5SHO;23.>K31TN95F5KKR4K?2]$M'E4J%
M_''/6;PWA?Z!W"U6?CX-TQGTH$+/G07C[U!R#QRO?L!X9X7L:76TDJI/K7_<
M_%S;>KL'%'][OWZ?D5X_\%#+!Z%B&$&Y+_3*&)6G2)>KI*?ML#;\\,? %*_E
MS;)#Y8_^&+0UL&!) ]^L()EFK'_[2CF_0GT%/=A_/'CSX/:K\M9PA^NU>Q*_
MTO3^V^@5OO?>CYK%Y!52]__T1\W^^!Y#XGDZ2Q_4['@K75SNS)_PUOO^8@ 6
MZ&HU_I>J#?0%=CJCNET^+XWJ[VXS5"A:_=,6K]\01,@C!OBT(UMF;RXV@@L-
M"RB;XLOYP-?FXR?<;(T[.2S2MIELT&7G0@ ,-5?3L Y>U8CJOI^X]PYWH+]+
M0WL*;F"R#I74[_F:B-^ZEP>J5YXR'8^0ER=,Z6-*3]Y^32S__(@^LZ:/WPYW
M.I3LNO9+!+HQZE\BT'.W,2:=4RG_I3-.TW3N6QDB3Q]2V/#,U/M.W77J/F;P
MJ#('W/R?3QKAZ,C*T-8L#>W/_"+5#7J7\B;3TDVWF7=VDX/?;?N58;BXO)!S
MCIE%-!BM.0-/3A&MP,4ST@<6HK??MA)$08*BE8H/+F^8>ONO%?B28F^IP>S0
MF-.UQ$;K39_^V;SBH?7.6U,4/9BT+Z;>#2N5_BH+O/:BL];L-C+?*@,2J540
M+YB\4+9=NIR>?NG9C=;9![)[MD^WN_YX\^S@O3[>:1PT]H\/^?[WDXO]XWVV
MO?$)'30^LYW:9U9]?W"T_?7=T79CGU6/'?] J_7][Z?PBRVV\W6;;W_=(CL;
MZPB>J^]LG."=C=W&?NW=T7[M[\;.QC[=^:(N=O9TPS7>-7<:[XZJ9(OMU[[4
MM]]7X3Z\Y^N7?/_XZ/C@Z\$)O!OOD^KQ-CDX^4!WC_8;%_6=QGYON[%;W_X.
M_7J_]3VUO_-^FU=KV^?;[^'I[_YHI[9.MK\?' U_ ^_J'I#/XN!XJW?P_O/W
MZO'A^?[Q-HQEG\$8\?;W]?.#XWU:)9M\>V/_>[7Q+F[WT,6'VF9G>P]=;-<V
MORGI..=19-8RE#&M=6:4<1G&VALJI>'&K+R19%5AO"HY__/U=0ZY!VK_BL)[
MA&2,T[(OU=-"JB<O#!).4.L48<%A':+E)O* J961TU(]84PH7JJGF5)/WT?5
M$P-=% 7H(RYDS)@Q*%/&LXP8X@(GVK 85MY@)5>EEJN<DAG23V/"]7,!!ONG
M-?7C@I<%B^Z%^>1QDW"GUIUGW30FZ+0^S,)ZURKV0,5<E8K:"+9S]6W@?2VU
MU+BT5/7M%8BJ'G_J?1,Z$FH1RJ2F*F-"LLP@"KK*"^UT1,I;#2A*KW+.5A%#
M3]52/] 4SX6B'NHZOW39'A/N>))LQ_PB^.Q[*%I+L7Z<6'^_)M9&:JX=E1G0
M462,4)HIS$1&,,4$N<@X)_V=!YC\,4,R_9+"4!]3;F/N+POMC"1%N6M1QU]"
M(P_U >=98XT)C0P(L=FG _A,.XD(_06*)0)Y1@22_"2,L TFFDQZ+S/F,,F4
MM#S#RFH5F=+!R)4W9%5BOHHIFR$O:=SK,R]=FL>$/Y;2/"7@D:29:.N#02H3
M'" '0U)E6H>0X4!H=,@2&UV29J'P*M=RAJ3Y)<4\JJU.RI=W(3]+0'T9[7@>
M?)&*<:REN=Z]G.JEYAF;YMF[CB-X4 '^V$SY"!Y/)#A3%F"%<I)QHX5CU*R\
MP:O 6^G_&?)YEG&,F<(1/Y7:98SB5P7V&E20W#'M*"!]S0 J1!PR147(M %I
M%8IK+>2BAR@(GVV@4&NE>I+CBT8\+&5OX332N%9-EC[,LRBF_ :2L$HHA&G&
MJ;$9PPI\&*)B9@5'3@ ;.Y]6;KE810JMZG3\XEB\F ?GL\Y+M.*%2ONXUE&6
MTOY,TGX-A@2M/(Z!99HCGC&!669C0B4"H6BDP\QAD':-5IG4JWA.I'T 4F[L
MUL6LOPMJ1G*.9Z6-9]AO,6M [D.K>9BEPS7*=.=.KY(WST*[T[@KZWD9D!XO
M;$MS7X.IW[J:\J4Z'Y<ZW[FQG"0$BF!S32:XE!FCD68Z")DAQ9D4@6"7TN[(
M*B%J%:[,4 !ZN9PTDS!L*;W/*[W7P!B*"CD?28:,#AD+V&?*$)<A&;2+E ).
M$RF(*RA>U7H!4V9G&4/L O\7>5E#+&V<6JX:/2]LN)KNE,*_U#ECTSDW%HX"
MTQ8S)#,?J<Z8#SK3SHG,./ #J6>@<Y(#N*HI6I6<SE D>KEP-).(82FXSR:X
MU\""CAIKXVG&4?1IAXW.+)8F4TRY:+7"PKO9%-P7$' 8Y'GW0%#*6F_+(,/S
MHH7A?&_TIWNI=<:VKZ^V7FJ<4O/4-B^^&>,0\H1F45J:,9XV]EGXY+17-*(0
M%;<K;Q1:Q7B9K;JX<CLFL+"4V^>4V]Z(W"J$B)5:9U)XDS$M<6:159E#.O)H
M'<81<+X6JVBFLLQ?0&#AX_#$Q/) OG]W\_)\F-5*,_P:;'@)OLK8MK[TI_YC
MW30[ZTV_.9S]:ECJHC'JHLWK&$)H1Y A,8L6*=!%X+]HY5'F:'"4*>R42RDF
MJX3154S4#+DNRYC#3,*(I1Q/3(Y',84(B",M6(:P$"#'3F?:!)HA)AD1)%HF
MT<H;PLBJY$]>:UP&(!ZU6I$^9ZV8E0=XI5RJ7P<4+\&?&1.@V.D?I]4\_!!,
M.Y1$V(F?VZ',9EMJHO%IHJWKB,(SC6B9P28%R1C&*+-6X8P9+R2F1A*E4]+J
M*J-RE:M9\G"6D8F9A!2/D.3ECIA?%^)1.!%#U%):G'$30L8<2ND/RF=&&ZRH
MDZ"4P]BVQ"QC%(^1OW(3^5-VP+P$9V9<&.)JPWZUU73+#/AQJYWMZ]@!2ZR(
MES:S*MB,<4(S*XS.C#>(4X\1CG'E#24JE2J<(2]F&8N83>"P%-]G%]]1U( (
MI8YIG2$K ?\KR3*-D<JD9"Q:[SV7!*"_8*OHZ2F3LQ>$F*.-M'?#AV?<1C=K
MT_#H L\/'/NB:."Q;A1>JMSQJ=Q/UQ%3##H%>W&&@X\9TUQG&AF?60OFTC*J
MN5"@<J5<I42O*CZN3/6YV"*\U&=+??8<6Z&7^FRL^FP40F(?#$>:9UKBM E:
M (2DU&?:"(:)$X1RFC9!LU7.V#C6LE[D)NB1T5(8DF]U4]7Y^X_7FH,NOHBC
MZC[DQN;ULFAUF:*TUVFYDZ-6'6:J_3^5S7)#];1/;GNV-EY ;'=XQEO]BL[+
M@]X6H<+VNG,PDDZ[<FIZ=Q6Z?/(RX:P->'F TCB]Z 'W?.PSS[(2S]A1Z.&-
M=8AH%=+49(83G3%C8Z9)*L7#' L&86<Y6WG#5@46@$.?O*%K]E(8EOIH(?71
MN+S@I3YZ?GTTZA4'82QXOR837IF,*8TSI2C*;&1<!(.!EF[EC5S%1*XB)F9(
M'[VD8N8@%D4W7!VCLLS.>'98E.9[Q"E>:J*Q:Z*3Z\A("D>U5C2+C*:2I)1D
M5A"148*5MQ1;''E"1ERK5?5T9+3,T9A9(1X?EE@*\02$>!1.<(T12"X#$,%$
MQJ16X.A$D4G$N3)8<D%0@A-"XE4BGWQ>]?@S-9X62)^'8.<R8/K(:J++D.F"
MA4S+9/]+LMZ_K/'2-UD\RW:IH3GN+:WPV*SP\8V-4LAS$A@+F4+<9\Q*D5DL
M6,8%0M9+()VSY48I+<2JED\^*&CVHHQ+&7[.C5+WR/!RB]2OB^^U9&?A*5-<
M9]9'D[%H=:8"PO 5(:P0L&VD"[Q%:HZ2G4>@X5-"<B_T$)%QU9Z_(L(24XQ/
M*=W80"5(,(I8D@4D4<8,TIFAFF0X<"LXYMPPP!2$KV)%5BE_\DK!HT1CCB)W
M+U36QU6I?BGKSR3KHP $-#$AUH3,*QQ UJG,=)0XXUA3@X-6VG/P']BJU&J5
M$CP7LCYK ;Z?CW;:H;]']G#204&?GPW;'C21I>?7,"G[-)4B?R&&H@B)U5ON
M9+7RGS_2D!]#L7=DBC 65$3O."*^WY<RD_?_9^];F]HZMFW_BHISJFYVE:9W
M/V:_G'VI(L;)(;4!/\C.M;^X^FGD@.0C"<?VK[_=2P)+/&Q  I90IV(;$%I:
MJV>/T:-GS\<+.]P?OA[;<0S_L4<G\=MG5YZ\ 4_^,=Y]]HTG\[6.XO^\^O+V
MS_#1,91[VW^0W0.?/__YUS<LOV?[/7F[?7BXFY]S]\-?^2>OCO9_V^%[Q[_G
M:SW/^SRN$V8U)?/*!Y@71C Z94F5"%,Z2I<(__XB>\44NMUB6Z?0ZDTAP4B2
MZ!FXTE8851-.J#4(3'D!1\%):3!,GA!R<9&^\(/.1SOL?"JV_;ESY:P;%9N/
M[JK"W^R$:V;7:.MD?#@89@X.5?"U<A9^_>,=<DG1>@^,6P68I "K\RP,/FB'
M@DGE\3M$=NF46EKQUSJE5G%*19LB$T*!,YX HDI@8XP@LH +Z+F+KM1Z(]W\
M??ES#7:;3+../;/^SYW76>;E'VV5J=?(S)()]O&\BKO9Q*4Z<6^C5(PFY%8:
M3I%Y$8W7,C%F?L"%@T^]<-FLW8ZCK'[+ZELG;1LG;1ZWO&]&M,01T*'LFP5Z
MT%9:8-%2C]Y8EMA->5!&G2A1>55%A20RS37->_!DO+ ! _L!#];IM+K3*9C2
MUI-P4#JP/)TX@RRL##!GD$<EO&?NE .OSW_AS/+WS&S?6Y)W1J.3.A7;.17S
M^_D[XH41%BDD7S8:F7W .4Z!:Y1H(D%:>L[>*[75^;3"\XE+(8U,!(03$K*Q
M"3B;OTW>&:6M3I[?>,MPA_-I_V0\&MM^<3+62=7:2:6(XHS%!(F@R23%&%@F
M A!+F4 1:63FII/J#A>].JE685(%SQC-= 5$6P<H*<OROD3466M098813#5]
M3,0U1-CU95JO6<&:6AR#;_.D8\>=WT_Z<7+ QDFW4RBM^:WMZ..QB\/I2[1Y
MB9Z=P87>IYIJ<G<MAF;1W;C'*VAO"MJY"%9"F)=97V;&1D =(VA1TL*D4<[F
MU5VITCRH1?DC-0FLE0$C%9E+0.9L;(@GS A7"O;;Q %1Y.50>0HV9NYT0F1=
M)-J%S/MN!-2^N(1G@^/C0;\%00F3&ZG'R<M#YYOOBMW=/U\=OOWPG^/=;9_'
MX?!#%KM_O_WMU^,W[&6^YB^';_+][__VZJ\WQV]+:8AW5'FM" D0 EI JBAH
MS-]R+KQ0UI.8R$-&)-3YT^[Y(Z+DD5H.IN0<H2Z9"TYSX#KE5Y00LG1H6I5P
MA)G95@^.5V(*?MUYQS%*(=%#EB<E>48R,-1SH'G[3A.EW)N'BD6H\VD%YY,2
M4G%)\B:4D:QW>>!Y210>I""1:NI9B,7]P\1BD0CMF)#5(]GR&;EW\/*=1H::
M,IJG8 J A-G,<(J %3&@0.&(O_%1W%U-J'H.U^ZY%+TM?K905LN8=_,A@$'I
M0:64]_/"!(-I8U.1+E+3Y?IBE^Z+Y%9\T>V0:Y7-VCX#/SQ_QX@@+,^N/.64
M S1<@B$Q J>"49F$]^)[0?#W.J$JF[5[+B&146B3-YW,AM(6V("UG(".7-KH
MF$.M&S;C$KN&7NQ8<]>G<=U.OMC'F*_]*1Y]6>!L;AU*5RQ?DTS=_Q6^2X3O
MW*F=DB1%E]4$I2JK"2G <.' ,!E)%$E21Z=JHC;G?KS 7?[R6X&[?.#.59P1
MQF,,'A@3-@.79LP:*DN+7"NX%4C\9!O A6D1<->J!'2^Y3+<]JCST?8"]/K@
M[<?>V![58M!W7 SZ;.1?Y('?Z3^;#/L,/55F6AXS^7E)H8T,O)Q#>BPY$%0+
ML,)1""B\$9XSXO+VD OLLBROJ6E3X$$-"6JEKJAXOF<\SQ6(EIXXE %2C.6$
M.$2PVDD044G%3>G"* J>:9=PWLV;^1;A>9UJY&YY?W)\<E3"*SJ#TNP^/_'Q
MQV$\C/U1[U/L' U&MRMYM[(;H)_N0WF4U+S_NP&7E+(_M<9^,<:S65OL]+-I
MXK^S0?;B>#\=V,^5OY;'7S-=*K[^1?9>OC,T*F12@\L;(T#K)6BO+23)+4D\
M!4OTQJ8AI67.!?+Z1_5OM!3>#]*?XO:@KK5V;X_G+W-XYJA0&N> ..8  R:P
MP6M@%BD5E%#A[6.OMKM*:B3$U/.]\7IY/1Y2?+R*8YMO*#RWPWX>M=&,,;8G
MMJAZ8WG\=*Y?*!I4L90!E\Z7DB+<@16$ 45N3;+&L> W-K-!NT3PKM$7^V)=
M7W)4UT=[07UKS5%!W0Y0SSI!K%9..6(A4%[B%*0$6Z*N!*JL-ABBMW)CDRK:
MY4)U!6T)J)?I_UB-^OY-QM3AX"C$X>C_=.+_GBS8+FA-BW\OZ2#F]8PUGC>V
MJ!QU)XZ.YN"%&-3))DA&44#C+&1UD8E*H#5HE'6JY'D*UJ6HNFB6U1JX'07_
ME^@*65/,+\E)4C%_3\Z0@OFDO:.9E(%87@K.I0!:"P9>$N%55#HX++K$=!7*
M+O+5P/PR'25<K8)LF6E+U 2C7D?&7+,YP^3AGO(\'F%P4LJE-G9:@.3:-H3_
M_2 C\UAH?_D]G;;ZH2X"=[@(?-TZU^@IKP",,UG.MW06?J3$ N:O&.<RVY-'
M8VE9!%27,]/-R\-RN[\L!*,'=E=5#JT<VA[I7#GT7CETWL&GE3!:@"=YRXS*
M>]#1Y6^3=\%YX:,OU>L-=@5B5XF+@0*KQZ&-S/[GV.:/.TUIFJF$=&R'[WO]
MR6>S>?+R,<_]X;VCDA54OHZQ8WT);;+]+R6CJS\8YXN/!YWQ81S%C%)[$GKE
MV#$C-,3^:/)5,W3-:63J]6W?]QI?8?[!<7Z6T7Q>U\P@3#\:B^_SXV#41"$^
M'<8C6_+!?OZ[%\:'IVPQ\ZZI-<FWMUB7;^!D?/5;'GYTJ<BWQ,]EN,W\76ZV
MX964G#;>4">S3,04M1$:DZ76LI3UHWG'2LG\R9L.S[JW?;3O([AAM'^!3?GY
MGMJCO^V7T<8_YR==GG&S8W[5<,U.3OV](ETIW=54G  BD^^@]%G.-L[@CL/R
M6_EN;%MNI7,X+"O4?_W8:BKO10L5= :I\ZPL;@TN[.9E,^)J2]P_3:A+:6+_
M/SO;G8/_>?YJZ\7S/PYVGKWN[.P]>W(ESEMRU\_.*.O9+&6]/B.J8IQI9^_\
M"YVV/\]/9VS\CRMO=68"R4EGQV86GE%ILP+F^SVR'T?QZ>D7/X?>Z..1_?*T
MUV\^MGG3S]-K3?FW$,BY!; 9E\G+4VXQ\HFFNM#+U.$T_> I\SQIF.?<:CYY
MC9,G!-F5+Y,G],K7OG=9*IY(Q%M=]ONO(1/U9E?J9L7U;N@'[M(;-!;]3@'-
M"8T\S/[L KDT>N#7P;!S<!CSGV'6A+OY]P]'G>>90,._W/"?FR7-OW.:X7_E
M$7 =IIEAHG68.J][G^<&J5/GT0T&:'X&W7<=WP=P$KV*GV+_)#Z]QL18G[[2
M]0Y;TYM[)8+%_]WS9=<S*=;3I*X-)[!:)&;N<;K='Z7[7/F8I".:.B\P:&;1
M).XIU59Y*:)^M]T<02*A<*VSR"DI_SH<'!=/1KF#/WOCPV<GHSP:<;C3]T<G
M912W1J.8_P\KD*OS9;<W]:I_V/J\R]X>[Q:/]E<OWAR\Y+O;1X>[["7=9;M\
M[\.OQ[L'>\?Y\SY\\ZK_P7=_V\F??72T^_6/KWM?7[+=@^?BS?'SOW=9OL[!
M7[AW\&MO[^L.7O"J'_B_\W.Q_3_S^P[R];???-X]..J].=CZ^O:#I_L'[VF^
M?[[[X3#M]J8>]=<D_\[S=Q&I01,2H-8(Z-" ,5* YT39J(*WR2PM4:=]L?"5
MK1XE6V5R4CK**$((&! M0T4C34$C)N6P82MZRE:TLE5[V>KK+%M1Y8Q4'('0
MP $%4Z -DZ6!=6+::FE%JFQ5V:H%CW8#MM)1&^]XYB>2*2GS4VGX('U0"95/
M&*;:BMZ;MFIIV,*J4!:=I2STEB(-!I1-&M :!4:G_"T-FDC/-=6^=#I$%%TN
M%P[^K:152>M>2,L203,]:2N31FN5L[$T"1%!4"&T#%.)1>]-8E726HBT^!QI
MT> 3HP&48YFT\J($UC,$32*1UFGN%2_].;I<LZY2M9[4PSKEIJZX#G2:N*<8
M2I>GQ9(J'W4:%7(2,1-2XH2B%\*ER+7@PA+'O32F.K-6A+:^S#NS0I;1>2?(
M06>U#$A=UEHA6F"6!A2:9$4MVUAUIM:26C:^T3 3) _>H4%FN!-11Q&3#0X]
MK^Z?E<'WG/M'L2!DY!R4-!RR^5CIB<C!8K0A*TU*DZ_X?OSX-L9%IS1124GD
MAEAC$_76$FY, ?V].TPJOF^+[SE?B5 4@W*E8Y%2@-EB8#B6MD5!>"U4H+3B
M>QWPC=0JG1A2YE&B-B9A7J9U,M1AXJ+Z%E8+Y'.^!1J)C%0@N("E :A7H"GE
MP()UNJ0V*Z=+&I>\LO?GXR@/N1K%FJZ(\KE)#;DUK=42O6=86G2SF'<:4N6=
M2 @^,HHNA4!3=3*L!G_M/9MW,JA$>"2*E+.<_%>4%ISS!I(D)+E@"=%BV6?0
M*Y&H7SGAQ\*&JI0XC8$0BD0%)X/44;#,#328:11==4RL B?,.28<%<(*ER!;
ME&5B8#IKFG+<*YSV1J4@.%9.J)QPJ;.22D:(%]Q)Q"29UCZO(\0X)C7)LJ!&
M?ZP6,<QY-+3+$C 0#::)L4W$@4M20IXU ;E.5@2]_.B/2@V/@QHL#\43PJFF
M"J66-NN&))PS7#H1)58_R&I1PYP?Q'.OA0L<J&.A%*$WX*(VH(Q0V:2:$R9+
M$7J]Y""+EM6%7+U\PFEQA_[[3OS\L<1?C!9*+6Q+\EN]QC6NL4XI?Z_B*-JA
M/VQR_D)>.HX&'TN%D_5J$O.@'K^) ;;Z8?O;\#^?D$Y=F)>V,)]+B0LR$B>"
M <N-RDI=<C":$DAY739(N&>>;6S*+D'9E6KAXXGV16Q70-^9NZX"^GX />>=
MT]EZVK@ *IFLM)7-T)8^ SI)FG?@D>3]U<:FZDK-NU+J"NA'"^CE^]HJH.\'
MT/-Q0IP'$;0"P;P ]$R "=I!\90(*@U/KK1ZXEVM=-?P-J4G5$2WW456$7T_
MB)YSACFI:%;7$="D!,B4 &=1 %4T&]13%)YL;#*>T<RZ0M,6(7J=$HY^B_TX
MM$>-1\"&XUZ_-QH/FT++-=?HGIP"4Q-D?MJ:,T"EJ&53U+GD(L<5Y81R\"X0
M0!(EN,@(V*2ER69UC-F-3=UE(N\DZ,+%YVMX<FLAO6RW0(7T_4%ZSC' HTQ4
MTJ:%1)8>VAO003.0VK$@+#I+;/'T26:Z5"SL&*B0;BVDE^T8J)"^/TC/N0;R
M!I!&M J(DZ1 6H&5.L_EX&(4QOE$2N4"W:5<=35K4W)!Q72[70,5T_>'Z?E(
M&>NRR3P#8E1>IJW*F+8)2\1]X$K1F'^\L<E8EQ'15:1-TGO]$H8&%Z)C:N[0
M@SL-SD*6IEPUJF2U+++:/Y<>9#DR[T($*1T'C(2!426'68CHHS'.%4\FQ2XG
MV&5ZR4WJ:LCOBB-_V;Z%BOR[1/Y\<5KGM,6,=\*= N3.@<T@!^Y3"NA,]$1,
MD$]9WGK48/^*_+MT053DWR7RZ?R:'WD6: FL=@Q0! U6R 0D)4%B)G/*V<8F
M9UU"95>)U8CDK\A?54=%1?Y=(G_.-1&"C=18 0PE!0S$@HU& 6,<=8@<G8P;
MFRB[E.NL]I<56UAS>!9$YT__'HQ&_^CT^GYP'#MI.#@^=5P,^K=S6%R[A=3J
M4-A/]^JQ&.7'_;\;<"69[32V*G:K=+8T.GL][[P@/EB58@!M@@.,F=ALWH&"
M<!2MUY))9[[KO/C'39VL[= P2SQ265<"6-QQ40G@00A@SH>1&3M/!4FRBHEY
M)V.( I?9&WP6.<1$Q[V@W_5A5 )85P)8W']1">!!"&#.E:&T3-XGA+R?"?FO
M+ -LT!1B\%8Q'PDM"H"3KE"TRPVO!/"H": -7HP*^SN!_9P?0Q)C?#!YH6?.
ME\J&%(R)!'C43%D=G0LAK_N2=1EB-TNZ)<58M,R1<7GT19L=&?M-+^:?IK$6
MIQZ-;J<?UZQ.0SN<%<4:YXAKZH3=B^-*7TNK*7VPU5!70V$'SS^_<U;F#2?W
MP(G,_,6H!:.H!R><1X%!49'YBVGL4K:(UZ)F@K87U7?G@:BHOC]4?YE!M;1Y
MMT&B!DNL W0!0:-7H++M2D\GI<IFA'7%)>E6%=./ =-WYU2HF+XW3._-KM0^
M4"I<L$"U-7FE1@=6F0SLZ*37G(006&DM*;I$+>)>K*AN+ZH7=Q545#\\JF=7
MZH#(46B:];?)J-:E!Z-- 4QD2AGKC#89U8)UF;B8<O4@H%Z[( <7\^R/G8_#
MP:?>J  T?WOZVMA^OF6>QB/T>;;"D_#-Z7E:K;G7/\GCN'\6I?)+8\_)[QT4
M^SW_/![:;(=>WPZ_[(SC\6AOT"]W.QP<'35T.([#.*HTN$0:?#[OAL"\S_0L
M6DB"<<CB58')DPJ$EA&-XU($WAR?"JV[2+&>GE0FN6OO166256&264'%;>34
M>0W*:5TZRC P&!$<9Q@CH33&TT ,T>58SV$KD]RYSZ0RR8HPR9S#)0:6UQ4:
M@2@K 55(8)RA((G)MD=G9*E;Q4E7&MG%2^I95R9Y3$SR@!$=E3]6A3]FE8B@
M BTI)78=,L"4)%@J(DA#M;?,6TNGH2'4E/"0&AK2$J2_6*ZG9V4]TP]8=^.,
MR:9.Z%]B/Z;>N/;@7 I1[<P[7X20RA":.8JHO&7RZ$%S+D!$:Z-2>3.5EMZ8
MMQXOM0_$RRZA<2T05\FQ())G)4=BJ>2>:>"DY-,S1- ^&O#2>Q6YL=[&IFNF
MXEVB+WI1*Y8?"Y:7712C+LAW"^,YST,)R;164'""Y@69B+P@9U4%@LI2#0NM
M$'5!7@,0WXT?H2[(=XODV059,8;"RP26*PJHHP-M!0/',64S*F-"LR";O"!S
M^0B[<[1YG[\7QYV?CF9"/>[&TW(I+;5M+/[[CIZ]U53<BH"5/ MKHMY=4/'N
MO)>#24L,.IOW1HF7=DD<;+0,# M>1T_0QG4,,:D<5SGNSD-I*L?='<=]F=\X
MEF,E!LG%!.BX AU<EIL^!,V-)%25&LJBJPK'+9305SFN<EQ;'KH503Z5X^Z,
MX^:<8R$*SCP*L(IIP!@%9-9#\#XE:_*BA8ZM85A.Y;C'S7$/Z#:LS'9WS#;G
M+!2.1L,H*%-:<%DJ06/IY4M%RLI-(4^J! R1+J.ZJ_6R>G#5@*%E.Q(['^.P
M,SJTP]CM.#OJ^07J%/,\[F%PXH[BHZ?K&SY\J_GZNYKT11R^+K-CN3Y&=J4V
M?6Z'_3QLH]//_:7,R4K6-R+KE_/N1".#1FT9$,%*ZP+T8#.=@@O1*L%-HC)L
M;)(G[.*ASHW3=J\)B <^MJV<5CGM(J<MZ%.LG';'G#97C, *(Z5DD&6H!\RK
M#CBB&,2\YY;>26LB:SAMD:RYRFF5TUKTU+?AM 5]B)73[I;3YMR%G!I&M(_
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M/ B#D%?__71@/]>%?WD+_^Z9@WIOV^/>RW<T2*,U.K#6YTT-(0P<R:9'GC5
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MS^^L#4F)O._D+EA XF@I0J> !&E85#;+;+GL$E25TBJE/?A#WR3Y727K!+*
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MN"WU/L< 7^-P4&GMQH4KGY^ZRS_OOGSGF9:4BE1Z6G/ 8#PX[2(0YP5A*OI
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M[4R8[-BQK8R*N?!Z08'@D5$F\LJ.J9(-BT%,<KJFEQ>[ L.X?E\[@ CP-N&
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M^Y75J$78,.Q<%7WJRK+&2B/7NJW!0]H:9'5;@[JMP3W:%"R<W<L8?$,;*24
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MJ7C8P_?O6Q*#G9 .8Y9:AI7/N"6)X)(ZP9R6]]ZWW(QO.?$*MR;5B'7 ^<;
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MOMXD0),HT*OK@VMX[K[M'GS9AK]_3EIPG]:I2>9UK$7^Z;1//]/6U@$_W#)
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M:R5CB024)(XBYJQ "GN&4L&4%4*I-&/ 7T53TL7<LU@T-CH)-6,#Y\J*,0>
M9)=5C(65;#8&;GCAX!Y?7?=JH[$2 /FNFI5:FE8H3>W+(\U8YEQ"D /]14SI
M#&DM-;+6.>' MJM,OWHM>9.)Y,<!1%'+L!(42RP8.%T*D,1SK3.:AJ0B5@ (
MK@'DD9;\NG5YQ!RH63 2B2/ X:RG*.,&9IPD7G(JM#, (#2%)5_T?B< ,NQ\
M^U[XN$^Q:4&("MK"0NU/6?CZQ\!U5;C5M.3GOV>+K@JJF$PO41J(X7BT_)*%
M.HN?SLPPAR%A/#<YE7]/!M,BD6.'],"I,Z0\C/4/U;U45\-7_YIEHT!%J_.W
M[-7G:G.7O[CWCT5)<UX,NMH?1!GX [P -PC?@M&H=1E* VPFH-C_N[L(6KQZ
MO1_+WOJ^$<KP\S0\]?JFQ7V"_L/-%:]W5[!.:YP;*A8YQR!]F*1JGH&J;'4]
MF%2L*#3[M@./<.\!9!8*LY][?.&[34WK]",_2@R6W*<.264$L%-)D4I=BHQB
M5!/!L34>C N1H1O.CQ.*%063ZN7^GN7^3(Y N3D#*H<HI^!_,@G^)\8"P1IX
ME@*Q2WFHA4E9,\D64S"_IU7%+)=HQF^JV"S#=,>!AW1ZC3X0E$$!,1N-ZM;Y
MVD0[JH/:]?-"5TO<C1)W#0!C>2:QU@19J631>5L)#5Y+JL!QS'PB=0"8)ABC
M]8MXU,O^/<L.0)-1Y2GU'E&1.?!3B46:@[/J$P46(#&)\2DL.V]2>4.@:S51
MCY4 R:JC'K5$_;!33'<_'HF$:VZ J%CN+6+@$(-3G()GG%KB,Z.H#;V^9-I,
M:;I^<9!:"'Y4"$S2.CZ2DBK*/0-CDA'$C+$(W#R'*-72*N,]",.KUQEN,G&#
M;5E)9&0A&++09^6>;;C2)]>&B_^L-EPAL]VYW0L7//S><:R:6YM^6^W.I*<=
MWGUWV&F?[W7:U[;3VM_KPO\ZA^^V"8CR=8N$GG8',(X#NMC3[C.#9Y+#=SNT
M37:^M=]]AO_]?7:P?WC2WF]=AYYVAZ?=T_:I]:W][8!_B:!*I9XBHL%Y8^$L
M$XTSBEQF0>JM9A@<^+F658Q*R\"[ S9$F:1&.J\2*QQ55IO,ROF^2.^W-S]M
M?T\OK3L?]"2C*%OC 4A?XY.[&.5=5') &%6ZCL9(9/1I1OV&NE4ON#"I-3 ]
MV# &7%5JHR27TC'-C,6T"'Q0?"]U"-V#=WT(705XFS$@\+;F#SL>7/8'=NAZ
M+TY=0G?@5A(L3/LZC!MT)PO)#XXBX;P [I!(I B72 (WY4+ 7UG(*$O0E5.#
M>?%O=,-\-]0Q,-/8<BN8D<YH"*L[N @Q2-<X<<K^9ZP&( O#QF5G= *B #^?
MPU?.X1(3I*BE!N:D@0O[THQW41<7@_XW,/(CL"W+N]<._^,7.I0^0)ANH27O
MP<Q]&NM3L&_[_7<QMR,'VZ?!2'ZY;&WM')'06H1:@U0B0+8DQRBC0$X3FC(K
MJ+:)" &6K(G9#91D&,3&-;S+HZQ][SL&",J%@G_5J/'OL1V") #: %\9ALA)
M0+:#_N"LV6@?;#1" ^1</$,U><>Z8=%T%,@-2-0 Q#7D7ZNK6&?>Z']U.0/*
MKPDBFM]#AU_#MQLQF%[Y3@?D?#P('\']?J(;A?A"/EGQ%F_[@[U[EU*D+TY"
M/W.02M[:/R;P+KB];XZ44"G()4.9XH$T X=0BF*4"@=_,2S1"B24;-P@GF!3
MNV&=P?0T C9N-,+43P6JP#=WJ^&3BC-8?BR)(PSXKTP<4'4!CI0$4?"ZD 3
M*C1O >,I>S>9OS",4B#>%(,(O[R-W0_A6_LGG>$'&$O?WF@;HX:\.-F81:_=
M_8]'%&,LO#!(9,$R$D$0>%8">9U)G"G@03@<DY<L&,7"?_+E?$?(,)65:-A@
M&0'3)EC2;  T_:V . ZN2D-(\_AP25LC>JT5B0I2_\+EI+V_<^25 W*?*(0=
MMHA1XY&2AB+JK7$N35BFS(UR$N9O7DRBH5F0E0); /W[Y5[!\*?CREL@>1%;
MED-'3:NC4%R?'1EL329IAC E$H$#FB"9.85(RH1T6:9I2'0;7?8+M%@0#D '
M'^*]42" W 3A2 -[!D@0\-\;06:9]%0/@^@,A^.P40W ,P*6$QYDP$WK3)ZB
MSH'K1LKU$$Z#32:LU((2[IAS7'OP=U.+)4]D)KR[>>]ZD<KLN>$()F#D;#@;
MIF8R]V R\+_M(YU0FA!/4.8L!R;C-)(^H\B Q$G&I%%" @IM9,N93&C9/QSV
MR]3(Z*P%@7#?G!G'/U5-UM3K^[/XX[PX 0<Z4>$I;M*!>3!9W?R4ZWXN<EIU
M5:!*PQ,@^QOW;,^\OL&1H&YS[DD^92<P!0HFX5QU>D%GI[Y&F+=;C?L#4D/N
M-NY[Y0@FIKXV\$N<A-/CHPQG!!@4T#]C <NU3I$RV*&,6)8 L5)2NUL,?$#L
MB=%6C2%,>S="M;L$![1_,3D/ ^0T5'V$W^&#GRD-<2BU&-PB!M<@!EQEEFJ.
M:(H!81,2SG7@:=AOL\RKL/4%8L!OEH)9&QP.9.KU1Z58E+:[*A"%,:X@Q.6)
MZP%J=DU(-2LM?OYYMZ-TI]L)9>3#F1@L8'!XS@"^!4*ENU<-XP8C%6^NX/DC
M0/EN-R#\P'2&-PTD'_@% '>@$U]5=SSKN4P=WH#WQ>@ WL=!SH-(PSL.HIF
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M8G5L:CT@Z<"IP?YEOT:BE2'17#"=*D8Y3Q1*F:2(>94@B3.#!$G!H1+48<)
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MJT28\>5),\\_5 @LN5=&K&2'?WOF,EWFMQFRC!;*LBI8J;:H=JBN9G?<,@A
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MGH9K0X*/50'^\;WH'!T2P)TH"$4Q1 "D%"G2SADP4@D8K58(49I. #T2_ "
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MEOK<U84KDQQSA&=L@A^)$N2:U.(&LYX!9BWE'D=F=50B(0,,@'@R$AEE*1(
M1R)(H $< ;/D-F$-9C68M8F8I:G*"0<A*&MRNT4C/(^&.154X)RF:])W&\QZ
M!IBUE-_+B&+).E"QJ+"(>Q*1"58@'51NUZ092;S1LQK,VF#,XM;@P I0):X3
M,RH9JBDV@0=JM;\F1;;!K&> 6<L#);T4.$B"L.$.<6TU<M@P)!-Q7L?(C6"
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M@?.ZJ0L;/JX'S.;U'L$N]O-+7K._99/@^H'[6"EKL$>?,[MU\T.V6S\O**-
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MJ;7SXY^M"^_X[&V;_3XHU$/0U:G,F@X1RTI642M 10+M:@"*7RM^ 6UM5+3
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M'<\N!H.T-P CLFS2=$W_MS\X0_\"KEKQ$IP6!<#/^'6^=I 4%DX\5/'*M:\
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M+9$6"@Z(+DQ,(I4GE2R7+B<762(7I8ZT9@L4+X0*L+_R0U!9DL=3(2N>U]/
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M<K"2=3G#..8<[/,]$K''\S;)/,U<M];-SM[0]F O?OE):V^NF7S*N[3HY]N
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MR!0&G4K*8H->(_U%^.XJ3WXY*R=\6+X4.2>3":;E]K3SK! >N((3,S:N89:
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MTW,+Y@M67><AE*3H]&SCAFI>YT;:\8,U[>Y@']W!/@^WUO<[K^!M4P1R1.S
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M>5HAG1?5YK?PJ.CUUV%*B:*,>9RH) <;"A@"2XGG$1ZM7@/ :E3#H,0"]X"
MEV"[5NS3_E=VOQ]5I7Z]I=![_Y["M%,">BDE>]0G)+=A"9F\N0+Y,H*317K
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MT5V39 B?4('#ETU&$?LG?B&)N6*:O*BO^34FW+ZH.X=;A22(@K!9&A?>L0I
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M1;\074X4BA70+GO!6V?3)9IX(K0<I*[G@V,Z'N2:)^R2A RG%YC77@E=VXD
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M"VM2^=6/+WU269)\ CNNY1(">@VI*B8A=0?V#2,$I<Y/I\;UD%,!H(@Z2^'
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MV)B=IPUP\+^K?/\I1-5R[E.B+B4-<ZBA^N0H0_Q#;J55+\W/_*&NQ2Q V]/
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M5N@!ZFY\&:Y[2T9Q(KCRP.3AIZ3$\@H-,9%$O*P<)A*#E@?"XJ[GPY,I)4+
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M>)](NX\M"I$@B>!;P7)')XHD1)SZE+FBA(4BD4G%$[N$7]3=VG#(^OTI2+$
M05PW<2]%>E'<PPDX047*N?<X2(X>RR:/_*]R,R8$3'9/ "1+V4Q9+K1M-](!
MJ-C3?A_RG>0"G99$.;*=9HC3&0/H$'M1-6,D\&S;N0VX;LY0GEO!,V8+LVAN
M2B9(++IK=KZMVR<DN078F>0F!X;20\+10=V1P,X\G1]O.F$+?8LI-VDST#/F
M_D;%J45DBMY;<DXB,G2RO&R,E?Q\GM:SFE';11?</Q1Y@C%5;]"FGN=Y.NL\
M>5DQ0Z%N@Y1I$Y4"=^]7,IXG[(^>,)$>2U;BR7:NV_PNX\I,1Y22F71MV19_
M7Z_CH+,9ZTA0D998)ZQMU;966AVH]/N(#?U@2IFK#">E0MD6W AVO?=@Q+??
M_O!.P8CSROE8)ADL.K++:4+]D8N,K:1J-:>L)VA2,62>PS//H7-0YZ+J.4?=
M<N8RE9BDO]IB-W 1Y>FG0UYK_B%.7G:]])XAL>;SY)PO3)()&UZ98^$S4Q(+
M>3A17D:MI[[E[A2M VV.(RK$T!67^2SD4LXWUNY I+<L[N^8>_)3:IKR0YLI
M2QF_>OL-,H+B):237=P1R.60#55$W-QQ5Z,PT*@V2U.YXX-PP:@*M 7:"R7)
MZU/ DJTM:ZGM %@R;DVQ<< 8D/ =]UF#44P+'G]OFG7(![]IJ2+J+JN^QM]?
MO/%]#X;D+0L<.DS<VG2,7!.<FE2,AMJT8 @T@;P=ABQ(QI#&=%,2=_>ZX!8X
M58>CH7GUXTO;0=T%D4,A#U36?2T?O:=4X@8]FG>G='^CD546+U?>;#^O2I>%
M5LJ#C&9'-O2D2[@=730)^N4ANN/F%5)83%"8 M=@FF253\T2@@<:D ,]_[X\
MKY1\O@2OQ<1[2BJ&:RDEG1!2@C/7M^_'^&KNQYC[,1X]3T[0TR(S:CK-&9H
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M$+@*.6A+XL[B!+228NCZQ A1Q-"9V97$3;DV^L806:/^V9HF!4(RK/H%J<'
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MBF?6M'K?S(#/\Y*U>I:$.+J.XA=2<&:HC*'_'+,E^&AM1C*==P:%\@+[O3J
M#IDG\1%/HD]D('L%$A/5M@^'FA!2S/-RYLWE-DA]W?NR\&DT(/,LG7>6B/$#
M*4Q?E2I#)OQ4DV?]$E#K.)^$V /A?94K\[MY>L\+#C4IYH8!1C[?N6FD(R_O
MHPH3X9/F?7C^?5B[4\S4U7*FF="V!<G0S<[(XYY&BN'<7]0=0;V?&583P"E
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M7N_D/;N-%X%;?#?E$ARFJ<7M)K>33"VH4TM%11$S!6M0P*%UBX(/KJYQW@%
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M+3!"(G$5E)X^<,(*6),-@HLB.VT3/O"[WAY[BF3&$ML'"";91BHJM\)WO?2
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MLEEZ7,CV>P@;X;Q<166% -C"HX/].G$"!GM,-]HKBXY.9"BX0;&.,BPH"Q@
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M.F1)E5%M&,>=PKG,&NJ:XL;T7D^L=+ AY@&<7!: G$ZNV:[N]5U0+$JW"0/
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MD[E()G$MUJ83<#G1YFE[_+%B7(31QE#'>LLSJR==FTBB&B)4]]!=HP0;S$G
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M7!0CSW($ ;H'4/_IX6]U\P7_@)<+]A/>O;\PP8NDE=&>/CG\"X13'B-&+@P
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M?9<NCW;TTJV\C@L@Y,&\H#QS6^*9O_/WN5#)*WSGET !\,J#\C7."BOY_GM
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M(L&JI\?C-<]](^Y4DM*):3#CE9^01SMOC6Z#QAUU8A?Y!!H'N3/$U307NM0
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M#/EUZ[SF@7D&SL&TNH5)/\S5[<T5]6+(R2GECM[A&^6C!RCG@B(C4W2HRC0
MD(>YO+VY-!X5LGDJ4P>=>:@,3#!?W#*J<)+##-W>#$EQSQ1<9:Z2TCJ==N.R
MMB*$Q61W_><P69]ZLA0>H77R+-38N?\LF<M#%_[MYPC8WY2ZMU$%Q;8J6Z5C
M(YC8Z#O^EC*QM>PMWG^D4-S^+?8D;]>9=:^\V@L:#BG\)M(AY?Q7+\WKD81C
M?E83=Z_@+,IZBGR,0?+(#2UL0?5Z6L.^*PQTTE V>M-%<@$9,U2[45UWH/<V
MLBA6S)>5LOL] (8*C7OQAZCO?'N^B/E(N_>>\W]7,'Z_5BT'N@;[,X3D(90(
MIIQN#%U5 ?105R?:>3%152+T/H"Y9OF:.5P'FM[[OV,(9W.YJ,?>N&]BY<>"
M.C_B'@X!R.X%;I.>/]7QM=?V0/@IJ4N6+<D]+\I_=N54?ZAW9X)@02T)(+H5
M+!NKQ@18=OP%OQJ8KSCS'<+XM*N*Y6I1LPM(F/LV^0+ABCCV;GPEL:N$:8P>
M$J(K_B:T&D6N(](Y@]9-B@6+\'37Q$N^:DA"R3Y49J[M+,^TOJZDMZ<WT&)[
M4A#SZ U'( 1@I<]_(=+4_.C7=XU[@V)T[6(3FD7HCP[/H%Q8UDAR?8;;Q7(H
MV&FJ\AXM+=Z5?L?9Q6#6B#9WRD\E"^8<^E)>WKDBEYOPAM28 <&+[<LN6(!M
M.[_3HGZB2DXHR7F]9!V&Q0;M%.C#<>LT7J4Z(NAL*-%.;U\P(9=8U63QR;\E
MJ&>+#, U 49Q)9'KH*Q?Z%6:%F-\36XM^Y&$ *B[)](8]VJL*8\)\E*5<Q*N
MW ,"J5<T1*"*2W!7N^\7FI8+D//<12#\AX/!FX*E*K5+(%%/>%- F?$%+0PZ
M-4O.GQ:SHFD4Y7K </^^<\9/@2>P"/U!6T0M]ID6WQHCW8O"D)3KM9A5B)*P
M">M'^$F03\E]RMT]'_<-2:OY'D\R@H.P"9)YIOI2*,N^SPSKM]#H-:DO*ZBG
MZD!P1N)X]%NYGM,A RI,0)#XM=B<A_/R0QY3&_B$=?(!;'!IQ03HV!0ZQ52B
MVN*,IYD.LJ,$V&1-3(%Y&U9ZI@J01'MHKK,D$Z$'A"TE\VE[T16--8*T9Z*:
MV?#X:]=>['W>_PW_*ZARK]'1*>T50A SXR:^M>&':4AWHBM"%_8*(JIK[FAE
M-O/K0'ZF95'MSN2&1VK9I5QL4W>7<S4L:!5@[I]D-=2DYTGL#C +/]=7W$!^
M=G)V@IO-H+'G'GA>+&;2TMB(*I\2V-.T?4?=PV^.SD>/?K'?^;D^'IV?GQ^=
M/3TY>?KD"\D1L_@+QVY8K=V*J?-=G'=) /\U4I3_[GYU?#)RL[(0 O-^.T#/
M#*9KW*V\Q^Q6N'7MEK15I*+GC1[WC;Y28,L0<5]N%642)>ZYZ B[=57XIF0"
M:N7:K$UJ??3 _&+__N73^#TB^+XE%4 __I&[W)'8;67R>/'V)R_\J'.F0!0T
M.4#'MW&/&O7^SYTOG0QC4!IA1A&<,%L'PGIO\6N$Z]@7H*NY9PV/]IWWT"RE
MD/=$*^^,JKYIU;,>FBH0F4DC6BA?MJ8)H]^Q+JWG>.LJ.5=#H[I_>N@1YR2I
M:%Q!M]]XH6KKL(L48O@(73/LLV@!4%./P9G$'FM8FM[-W6Y#B_=R_J;&]'%M
MF=MFY7M !#F&BZ6F.0190G&(4S!F<_AYD*&E1B!N1$W[#<)RY0Y?I&!J;D^E
M;5#EGD]:J?9,JZEIS(ZT'476MFRBM@9AD,AD'JEB/"T*\$Z%5AKJ(GK''>K:
MGR-H2<80),=?-G3.F-JQL*3%TW;3CP1CE+$1PUG&,"-RI2#^3# 7JG$[)V3C
MUZ]'XD8ZON%0%%I+=.T.R?]&&M,5G1#QJ3F*=6>9#:$MBG?)HHV.>I$@6;A-
M ?C^58'PCQIG=>%$W^>%RQBK0P^*]J \/?2@''I0/EM+_+ /RGY60P@YMUV=
MBQCDFD'U)T;>@F/@'O;1L$95S[EIS&5(YZ7S)$PRA34G*2'EL_Y0J5>-=(,&
M6=#QTRSW3#F';M?['ZO]G[KS$2A.?>[:Y+9A"EI;S0*ZN-?W#>\5V')NM&@F
M95OTKE"+0.>]CZQ>> F6__BWTV<G7T<Z+.3V#KPU4R@[)SEOBUZT<7J>/7EZ
MFCT]_5*;=0>]'\JI\(-17.0F@23^=+A#X_*_/SD^.Z4*F11*:%).,^>)9VY4
MS VBB\.#A&>^JBNS#CYJ&5#ZIJJM2T/IWG(JGIB4W/:Z5-E&'T.OA+A,F9)H
M%/0ZZ5^"W@)7$:G;QM*68^?:4>1+\%_/RF&]K*AD^S/1J7ZIOQW23E,GU)1X
M_ZMS?@LUS;N0AJF#)#P]/3GZ+^ZI]O.%!W3#H N$G5L[[GOGDVB\=RP<86%0
M3U]+ ][C'V@W#Y[VQS7+)YD^[70WO&*]IQ#F+.HY2@)M>KL0.-B!0/(H_G+*
M&C70@Z^W#,]%_ R@6HW.!W3Z.X]8K^A&T6_AG=WS^A X>^BVG";,?V>-_ZX<
M(!?4-U9IO$ZS;TEN^G:+Z3P14ZK>0$TY*/CW4^?%,V*"SUD7#94K[#,3=M(<
MK1H>3B+Q-M+.E+!2^@&$JP;P&7B5G5=6M@_C]/D&<3?,M&%W&!IX:[?SK6?6
M?A,33<?UO,:<3X6@F;;(T_^ASV!O.[@W_=F7&9M,A:_K2E^G*=QTMX4P&!+P
M_CVZ,MRWGMQ\I_L_R6_S=\4TSYSMND1EN/&#S'/ M7^XPE0V&>;,?51^0>E3
M&B'W;HL%2SBVL'R/2O=AG ^O0,9F(GQ-+03?&U+<,^@^)@M/9MA=UEV7)20H
MJ2/?J;PZF&+H15F[F<;J&;K"0$ZSS/]![&=PYG?Y16YY/BJO^J\#\!$!@KT8
M\JY%HRDQMPJS;8_'(8<<S3Q'HQ^UOXMHY\&IQW;Q!4W.PQ __&%V>U:"<K58
MTY<%+3LD@#;*,^/);:)SVK//@$1'5QAGB)(,IA>QL<EE'-4+:=A@0-92A6[B
M]TLE<$B-FYZ1W-MZ(2<\_!5)P@NK3\1DQG\4 J&V!8:"/,-)>JRZ;<2,2==T
M#UEN0]O9S8-\UVHE@DI+-VRT-Y39D'3O49_ADQ4E3HK32W^P=\IJM<&&PO)G
MSDI8FMXA[5QHZ7P,_B;[BX'A.[XL@6^H#PM[C"L> ]>>EBV,W0/PGMQF&F@*
MU$HXJF:4*'&G'VHJM4HVMH)VL@D+H?_$%M%?JL-NJ&I3*QWHG^S?8\++^V^U
M:$]M@35$!H?24PR&0MHYTZ/#3P&;!)X#%LM4['5$M.^G4F>"YXN137&6_#<@
M'P+O,Q="]'ZH[?&)-0.'ZY@0$4SQNN.^S@E8$%:!:D+7=7@<7)RVU[3)KZN!
MV\@>7>3$5GY=+ CCX$9W[A_4<%)O8CY1U1/A6Z%B95FH]1%\M3):O 2GNW03
M5 CAW.]<L%MOKI*]> KS<QI%4=Y@8A,*W,,&%*[8F(B6#.YX"&VL2TN>6&NW
M(Q>&5A%N.-R?WPCPF-^[Y>Z*<?NFX)<,T)[09DU50N;?WC!>P+T@84:GOKZE
MX$;QQR3NKFG%%CCZ5<]$OTCG<3$I VX;JD>:W&3VNWI!NC*$KZ;%0V#N^V_:
M?A/*YHJ0&5@^.3AX&\Y&[#&Z"?%\ & U!2O0!!]%(![.:%0<5^@X&Q@(\**
M^#+TTW3(RU6"\>LI/WFOVA)B4.DZ5Q?:9P"8-;N3N%\6E'_3*-USTRK9FBG;
ML7)\GJ>_*!_ YGWM_<E -ZD)E,D<F4U/Y*]8;/*I7SI'\IHRS>Y_Q-0)?#;U
M)[L(P#6.<K(#V*TLA=:J&J+W6)VKOURM6Q5AB7Q&+.;5(I^(/[HDYDO+P?*0
M].GWF3OM6Q]OJ,>&_75B+^G("\@&X@$?WT33J/C)P!?K78(9D%7D(O4B ZT
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M'JV=D0903-5&34]\*)</@AO@QM-,N($GF\U8D^A[Z@ 2[&$]3%9S #CL!W"
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M;[ORS0D^O3Y/.IW3C08NX">2P!YI\1L-0L'JSZ0%<!JM=(V.8:BD@ON6X_D
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M?CTQ!S?% R^8,JQAH>XBVN-S)[)M??7NE*[>'D[-SEFI/<1\8( "G*AY22U
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MZ!@SEI=?CTO3V[-YNE"R.Z,Q>.MH2H <9A@\ #,D6+SQ8E8*I:FI<K6;&[:
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M!8R^/! ;N"2H@=H;S;66:1AC> VB,=4!AK$-%252;0QX<U3Z0GID?O:=2,U
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M_=HYG<4_J2B[BMO^ SPZ4VFY4T0'7FZ\ B<A,MR0\(]$G9:)K7.GCD&'*RR
MWE2XC<AJQP31>Q^.+Z>?SJ'QG^%R-HS3-^.X. &X2PJ8L"2%Q(E,I>B&YIH(
MY;4&;UBD]V+3JR(K:T;9WP'<3?"3/J360W;'W:= +4LC358;;0CWI<\>L$@"
M3YIPPX%RM!D,[?=-UHF>J95$WD-OI+N(?O<7<!7KVP!73T&*59@.$W#HJK.U
M%.@H\-Y?<-["ER/G$&4D&@KO\> BP4(F#EB@P"P+LM^]H6\B/.+/[XL'V\BY
M]B'_'F<]G$XGS;?RR.?*OPN6*I5 EM(L0*0 2US 6?N@HP@T [OOBJ\XW9=^
M_/[]ZCJBGU25VSZ*D;STT_/ROW*1]\6/2G# C]/\6L;?:=IR73_C^BIIDLN_
MQ%]_^ &_-I/I](]Q WXT_!>D_YR,$AZ9OZ) RT]+WP68[E[,Y/"@.Q=#.?P4
M[LC]7C$5-&>8D#8Y89C42-(H; *E)/-1Q:P&AX??L0 7#OWB 8*WUZ_B@D/3
M35F/"UZ4?'_IB;79$LNT*JTLE."U@]N/0.I<<FSIQ[^8O?1-\PV%/&\Q;!GS
M5.-&YR(K83LNB'6:$Y,#;GC>9"9JWV=N!.P A:HJ,N1!;;+JNNBCI/52D,M>
M=>-NH6EFFE *%$7!\8CD1A&7>:*<6JOE?DAST)?VAR-.5YWT423["^[1Y2!X
M/6D^(LIB7MV<"2\N2B>N?Y4FZ--9FW<R2,Y0QJ0ARI><](C(;1$-]<X:+56L
M_SAM6XRG1:5>-=1'Z9?U>&]J/]^S(8KQ<-T!;I"\Y3K;3'+0@DB?$O$F)@)*
MIA@$**KH?FFV&?!GQ;T>=-E#^L^ND[C3DG" YSO-VC*BHBXMZ)S#?1K]08A"
M1F^4 G,LA+P#_#LAN^FRA^+B]R=Q,X&[TQE$G5*R/!/!H53A,8FX!)P$9\#2
M4E7W?I'9ZIQ;A>VT:55%([7KY2QQY5$>6Y@' QDA!(GHJ0B)2(LK(,18WDJ
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MFZTQSIK@>:J]*VV*;5_1^)YITHLJCB4FOW)*/W\KE0S:T(R23.4,E @G)/I
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M$.B+=($2G\Y*T9HOL,!Z%0=2$4_4TNE' .@2:Q+$A_+4R<<,$?T)E:K;WML
M/"7R]*>9E?M-_Q&ZA>$WR0NO%;\WR6N#0>%;B7=6#]5U!-)7S*ZF?.X%[Q)C
M%L\T$W.Y.U+:0Z1!!@5"*Y$I7Q6\ZPCIX%&\A&N-2JIQT05?UJ FW@;<;YV/
M+$:3M#B:L@O[CN)!-$*#<L3*XCY%3HEEZ,.!-8S:0#W7M0W$$X[B;<.T':-X
MVRCLJ*-X6I?VZ#$2SZ4D,E$@GC$@2H8$7@+X]/VMY&$I>1AE'TL4[VX"HP,
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MQSH-$E26:<4<GA8>3G<ZQ,]IS=\%H->3YD/).YHG(PVHXLX(QPE/!N<?T.)
MBYNV_ID03$AI-WO!^/A8IZ'RRC)]J'+52>6_H5 O+B^NSJ?WS21=QMG+R1?
M7>H/]*Z:^Z;H #<>&JC1)$J+.Y."0*PQE%C\/R.$SR V:\*S_=BG08F>9?Z0
M(KJ&Q?#23\^OSR4;F-*)$4!#ADC#!7$6#Z=$4W(Y12J\VL8>N/79IZ'BCC)[
MJ$+3-3I9@A^3<7O]V@;&IL7<@#1(''<7GU698O$:.$4_,C,2O5,Y9)L]KWV+
ML0+*D]=\35$_9(#M>+1?8[JR,^=9Q6\N+M <]3,8?7O?0,2OQV>_?(5XV8;
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ME+8D#Z]S";GY1<E'B)<-J@6FK[_\/OQCW( ?#?\%J;R(&SCA:':"$C!HA$F
M2*S2BK@,.FH7)>.U'P _CNH9TZJRRI:PJGOSMNLFEA6DMGB%"4;Y9,M[6F^(
MU*5X;_8:9>>M9#26;-;*+*P_BWT51#P:KAZ8"$=;?M$9=&.M8H1)A]N^*HU\
M8Z0D)BH%-32CS"N\ SRF\HN'IL)CI1NW4<G!BO%M O(9EV[<2H<[5>7;10$'
M8XO5*GO%\-R7V95K;$YL6_^>,J&5=S*Z&D5>GUCIQOY)LHW<J]> P]T2?S!<
M45 D48V@F"" _XY(RQ&DLXEHDU$&.3*O-\PG63O.L5:'VTHSDW[$VD/CV^7%
MB)@KA1-H>2G/<;(4?<N0 [H"QHMD7 J:U^Z+?%2EXH[$XJBGI",H,[<)W.]E
MYCHIN6-9L%TT= 1EYD2,03%=NDN7!$P/EN">*4F2(0B=>-*B=KK141!JIS)S
M^^33-HK94YDY'O"L3L&2)!Q%2)21H!+*0"07#*<JB<TNSPYMO.Q%)QN4F=M&
MH#V8+ZN.YZO&\$E*S9@F.J92!(][/'0-$$VS-L$G .\K;PWK$9TF07K01O6Z
M].!'7Z\X/$[O/K=2OT=F;9S '=$3RUE&&Q_G;DMGYJ2#-=1DF\6&I>HW&.TT
MJ="/L&O7D?C--\/QY735G@:*6P&1B(C;F73E"5G0 >$YXYVPTHK-R@NM'>:$
M]5]/O+7K1+SWY<W@"F#6X]#6"\*LM40R .*S582J$&CB63JU69F =:.<L-JK
M";=B08@$P\%;./.C7\:SX>Q;:P,+:S@#2XDI#T-E=#A5:BB)46:(CE)S_XW<
M':M@"O%O9Y,O/^%'SPT"_.+&#E@RX#./8G150<4]H$"9HUA$]3;!L4%0XG%*
MW!YUO_&%SN*?5)1=1;/N 1Z-^Y(.0A'(!O<M30&]D!"(EHPY&F5D:YL7'H,.
M5[CTO:EP&Y'5ML@_^3\A^??GOKGP$2YGP^A'+R<7G_WXV]OAQ7 &Z2HL19D
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M*/G_EI+_S!AM7!!IHB\B'X0O(!).##0T=#14#'0T=$P,#$PL0FQ$CH%%@D^
M0TA.0DE!3D).1D7+\HB*AIF&C)R!FX&9E8V#DX.2GD> AYV?A9V#_3<($@8F
M)M8#+&)L;&)V:G)J]O]I@K<#A)C(@JBD*$@, #(A$@HA$KP;H , )#2DO^@_
M$F8D9!14-'0,S =8V B&6@( &0D%!1D5!0T-%16Q&HQ8!U )T8@>\<FB/]2P
MP&!P)^9_'9^#R?BTJH-$<_R$2<#2(_0!%BD9.04E\V,65C9V02%A$5$Q<;EG
M\@J*2LK/M;1U=/7T#0RMK&UL[>Q!#IY>WCZ^?OX!;]Z&A;]['Q&9D/@Q*3GE
M4VI:;EY^06%1<<F7;]4UM77U#=\;.[NZ>WK[^@<&)R:GIF=F?\[-KZUO;&YM
M[^SN[4-.S\XO+J^@US>__4("4)#^@_YW_2)$^(6,BHJ"BO';+R1DW]\,A*AH
MC_C0B60U,"S<'S+PO\8D?AJ?4]7Q@%% \X3$TF,<BY1)<(T9\MNUOSS['W,L
M]/^49_]R[#_]F@=P4) 0FX="",@ -PJ1K)^1_W_><,S(]D4HU<)X>)SR3XNB
M;&?G\?CW\3%BPYL#CM??1:R/#&O171Z3P8&'ICD0<36.M9%B6)8>+.;Y=1H,
M#E0(_5H%/?5:2&C-KYX/(?7[90(1B3IR\@Z$ S5&?=:G7_SY"LG% 8\O^ I"
M"_M9#--DW5KVK3039:[E9<Z,30TB]<,..=9VVH2'D4]W^*0]B/%3$I3[HD)&
M9Z5]NP,ALY3&[^  0X]IV4:F])5.:F[ER?#4S4=>OHG:!94&RUOJD=(V,7[.
MUTCS!CK6NJ9?^K;*C9T8L68B*\?'%J'5776&.9,\0O?<RW<$A1-&_3/&'\AQ
MW^[D8!0]98WJR:+)5DC7>V,VL3G)M3*4=L'#R-N[&%2Z>HBQ;?H ]NB7L5U$
M,UGQ?A8-I*!QK])XZ1=EYL>J[/B021R->?21[34Y16&2N'*!C*19+S4BV0U<
M.\UQKRO'P#E._&R'NE$W5/<1)K]G!P1*#R)$9$ZJS8GXC.6$:T??"QLZD<Z*
M:R[L7Z:(!U\<^ K//K=RK69/R/G(*\84O1/M)=1R7VN'_@:OK&11MFB^6:/_
MU/@%(>-*-'(?RE>D(Z4*YMH3D<C-R>.0R:)%P<3R!JO;%Y?+H%MM]VNCNUP"
M =Z@PVO94=$.Z3?ENWKBV:\%#YG+B-8F=E1%",0T"T7++?P]$T.1&:E]>]$]
MGY"90^K#7$SGN)I5\P9G/?QUAVCN7M@&O:[E7>$;0$')DC?([I['+:^BC?<N
MVQO;UR1Y8,.\Z"B0O(O\L&&GGGKVP;H,NL/L^)UBH)2PV..9B<D#W%9>._L<
MC:DLX4K1I3@-E6(HV,@5WR^N\P3J>8A?ND]&1NB([/<,\_$'<15Z;F:B9[R
MML5M\8G_]1/QKSQ4(.?"%;-?OL)I0BWE1=)9S$U-VLJ4(NQXV^UH=8GUV;T5
M9M"\)Q.EA^47JIZJW^J:3&;.C$WZ*%_PXFE\>M6%2BLE[[\((X P9U7CE3FC
MYTIFJNF8IUDG*ZQIKFO[;6EXX/AQ4&@--BSS]:[IG>,BPX&.@'RR9&GJ::%
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M4E*$,+]*&8PLZ9*3]+'_<RB^NGQ@ BB$AI:_=5*H"1_W2'R1</<R^8/1=8?
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MC$?KT]';W*E_>9&=0Z/25;]"Z*V5O_RC]W:T.L(Y(_T; X *V+QVX>=(!*-
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M9N&[5ODW+_(<J8>A,[P%P*H-'V>@<->(&VATI@HT&KUK%'4M,HYRW0C$@#^
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MKMMEX3CO9 A+[I/>)H$0Q>BCBF\#VD/VMEC)1Y]9GF\]V:4VX3BLN8I_(8U
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M)&@QOQ(TGKN/Y&:,MZX0LXY#CJE4+=,/-NDB%DY92&[3/AY_"62?!R%TV?
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MU]->1*H+(*?_%Y"9%&/$)& +*"U6^QEF">> 51Y@T7&8C'*H0N'<+*$M2-3
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M]@?R)7<4]NN<4#%YN@;="7(:\SB.=B()2\M#ESBS;=P['['%7"UV8@B:A0$
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M5[&]VQ/2W]4]L.NW4:%1C1O UX9TV;$T+8@K\F#>-!<TF1[DPSS!A +X>,?
MN].W'^5+* /Q;\'=*B'F_U.?R[-\LTAQBS>0*:EP<5+M14?DK.0'TM3)L'5V
MNKL?3XVO?06H;P"PJ3> ^2Q8HX V*-O:FX4.6=:$3DGP;J>]7U()0E.(E%!I
MZ+97&TYS 'YM_AX.<^V0TLI%TR,"W/X.PLC%MA7TE?[[??/B>@V^!8<";B^J
MV*: G"\G.6/M !5B^W,3,AY?X6'P.]9JP/9)?R[[YY*OTO53<980]],S&OR[
M5UG6.>/J$X"I((O\.-@GTQD%"!WF[U[T1V!%B'P%X.+GZ!!!F#3Z&AU/- R'
M+-*GM5#"V>^+&7?9@B.'#(+(-#9O ',LNWU7J*[RUPCB-X!6Q1L 4J@O:%5_
M$+3+RW1-&Z(O&>"ZUG#&<?Y9*  T]VC8G%]4WPZ]$,(2P<<GRV>(NR\:&CWQ
M+*V((F>1>/>^3MV0)6.M,L9Q6W">=(:I".$(#;V.>&62%6L1\6M7FJ.._-SK
MAV2H-X#^]K0;P*R][J4RV1\(9Q\@C$2#NZ[X0.&=6N+6UW15HY2ZF!KJZYSA
M]+KZ%5?S[(;OI!\"65?(O2&1JOQ/DD$&I]EI7KW[1/*;'T>X:@'5-7(4Q0]J
MC9<18"<J_@F_6!;6E@H\[-KZK1!8Z7X'-*97FA?#(PP,:9H?84WW+)U#)](<
MIN+5M@SU1& K!')?-#\'H0/C'*MP?,$"[_NU* =Z\&/F9]0I,6I3'<T="0B6
MJ_M.G[NSW0!$22-O .\&0'NO0$WZ<TGG^(=)E^B!-X" S&ZMHHC(84L]LXG>
M(J<LM5+.ZK;X-%EBGYF1'IVY132?^U+ZA.&]4@BC.'9?54:K0;X[,?LCRT]O
M *6,AE+;-G7>@K/2Q,0K6?.E_X1<QHN]XOZ>T1?$ 52VXDYNCH/?->2Y3EY&
MW:M&$[!\\-VB!8B/@)@C(7S2CB/Z3VS)_=9HF(O")>A$=5)7=C2XLT-;_W18
MJS:;XG^C%4<AHO\KY1E/+6KX[RAY\FC^./MI4S_U$]>MRQW# '>"@JW43S.;
MU^&WG.3(;OM#VXK?V?+RTE%</^A#!_6#9*'PQZ!W0T]E^7EN ")73%"D]&\
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M&F>3$)M5^$5JDZ-<FF^CRA3^O5*8[V:)) ,.#4P70,G"(?>4#]>C9A&;MY1
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M>^\@J!V_%5#0O%BUV_09IZP=0[(/E%34QY%)GD;_TNE6[!"ESL?+JC2^A
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MA!^P<S"3/["YK48^GU(H,>@-Z5'D:<#VA*6P/9Q OA1>"N]*P7RS$Q4R^-U
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MUWDO$PM^]3   2$Q 3BN];)M)8H $)RFE[X,CD"P\(H@A\ON!\N]9=*/>!G
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M)A+;,:B=GEUT'1O06:_SE:@*Z5N)D2V<[T*)C[SL9#7*#()<G#U-XTU!C])
M6&P,GP:E:[W->7PCQB??Y;I(%\#S-0.A?F%=^B+7F%TD\M%EX9VBX=(5P-W7
M,+65R=^\H1I=4U_7ECPSFE2VC##ET=",>J0JNJS!0N&.THDWVK#R):(./Z;&
MF_GZFP9&>.SD.[VT3I,K?)U$,_RUISX)]Z#W:=W7E>IFN15MJ"GD#TIBWFC$
M<-PY"72L(A_C8-UDM*!&ZJT]3,;YEJ3!\IWX7@ 3P6*\'+0Q;CTNM%[K='(
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M    ;W9I9"TR,#(R,#8S,%]L86(N>&ULW+WIDMPXEB[X_SX%)N='9YD%*KF
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MC5,.><1XK/Z7^F:YTL-%F-NKKH7797/U%[9KV-:!$:(16_^V_G%>ZS,\+'_
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M_!V&,:2(!I %?N#'A.#(I\:[;OMCS^W%U](UE63,>T>=PLQ@\VLX$B._VLY
ML-B#&@[&1+M+RK4%Y>9)GZ&0:O.[.B33%85*P#:%#D1:OG10:P[5-N4Z?U(/
MKJL-IM,X]6X='=PRW:;0:5GWMGO.7&+?Y:0VC'X1Z\><?UA]$^5:B$]J.1NC
MFV"9IE12Z$D<0"2\ )( *S)+4!A$D0QB%)HV/NF?:FZ,5DM8EVW24EKVC3+
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MM7T!=H7*;R_#;$WW]H@Y^A983#SIA\(>D,.OR( 1!FZ$G^XD^:9N8+.0@O*
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M*:+9CXM)%<TS(TQ>1K-?DU-U-"_<,:3YUNI!J-]EYQY;A.( X0!R[@<0"9)
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M8G23"U2R 24<J*6[!@PK&VLX*)/95KM'!)!*2G=&U6GM+QA3!S=-:42=EO?
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MNQYY9V>:VVN\%73;AL"RG<EY3,W>:2=(C?QZ[T!JA1SE5;\(A:.W_OP\DQ+
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MYD:,K=R@$1QL)0<=T<''3 IEEH+_5D^?,F9J/"IJ$#L,!E2WF\6:V%3/FX7
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MNS57A'SMR*S''7?7Y0K'R<[*^0$]L\#EVNS4#FFS&L]'4J[B* 0,DQC A"&
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MJ:U^28'U_A=?;(44'[0R;\L2\G()NE?OZ7JIQ2F:YBA[#CD>X3#B60A4E!$
M0QP#1B4&VAVC J91Q*!3"I)_$:=FMMJ4CE]6&[U(Y'2Q>*EJP<V9\U[9H-$V
M,*]7T-*W,'?7-<?!2='Y::EYWX9]WMX3.R/ZNK,_L.%M3WQ;/:L)-S<U2NY[
M2[G01][0S,_W9'AOYN=-P%=JYN<;X,O-_+R/U+<&:[7>F/SZLKSK[:K8S$VC
M*X49 S%+(8"*Q(!&N#SF("')5(R%4SK\Z1"36PF,A* L>*JX1;D6TK7DZ01'
M2TM[$SI#6\H2&"-=4W;YM@N9'@5!EY3W5LAS,L#(!3B7%#PMG+EXI8_3R\H3
MN=OE"<V9H@0C&@&4B0A O44%+"02F.8?4&*($N;$Q=4]W-2^^).VG">)5/VI
MF*X W^?H\Q8XQST$G34^[U[8H8Y#+X$RR,'HR6"O>$1Z2?'NP]*+=_5,TZ3%
M3_,_0\;Q3!<FY_RK+#;KW!3LF5_<+<7A#UI7SA-*H(QI!M+0'*BF) &41R9T
M!F.J?Q?*C,\KVHEO&[K>V-F@FV1R^::.)1ON\S)"S@*N_PSD7M8R+7.]TZ3Z
M/=T$3/[(E\9/-+L4%]8./[,JXP3J_XM!B% *("89($G$ $F)4$A @558S^K[
MI26[U<ASVL@UE1F5)DOW->;2;ID:;78&7L6J23%_!BT!9\%>]J"ZQ$S3T0_;
M=WC,]?6!K*_$X)MD&3>+V =L)RG'7A[:IY^/+*2^PSS_G7R6BU5)>U6'H;_*
M_)%MM:]L?O95<ID_:_<R2LMX;P(01.8@7D: <"I %DM%$X%CD5KY]3W'GYJC
MWVA0?KABKT-0GU9IF]O20O^K4L.E]XO['%D<] ^+_,#6= ?Z75D]L@>]EC\X
M4"#X.@KH+DUV!@5_K,8Z_=Y\;VUT>F/8W3K'_;$CMLOIK?-ABYS^C^E?<I=O
MFKKA T:%=WG!%ZMBVSY"2D,2JM1TB#-5O3",0T!CF0)B DI$$ @SYX(\^^&G
MML*TI"\_M0/YW<OB'.;!TD4?#-VA??(N8(.][,'W04[=^N'FL13/8?#1"_7<
M@3E7QM?C*3W)G_;=Q>I\L#NFW77*-W.>,IQPA$#"10Q@FC+ ,.4@DAAG/-:^
M=$B=R)\N#C4YPU6)UVZR]V^.C$^78;6S37[ &M@.M83<I;(&WQM!?3(^747#
M%^/3Y8'&97RZJO )X]/U._I9B,]R4^5X&4ZINV>:+\J^@ZM6M?'/U4(_KWA#
MBYS/(:-)E'(!$E,65%8'4X$SD,"4I"@1#,EHOEEMZ,+.;#B.[V1+=E(,]XUH
M\9NV)G63$[K9K'.VK;MTKG:]4EJ:N!D;UQGBJ2+:G". 8,@ C'$$L$HI("Q+
MXBAAC%$G"M@A9VB,FJ[IS9#=&C$@[@,O' ;R)JGW4XG\3GR#=YLRHM9@%I0Z
M^%M2>H+G:9UQ'7W4Q:<G-,<K4M_']$WJ6'$I16'RP\IGWS=,J7+-\\*$N2!+
M,<(01 1* *-06[R4,A!C26.NO5E"K)H66(\X-4/7"%QE;LI:3'.(MJHD=\WF
MN(:XG1GSBN/ ANL0PJJXO18WV,GK,ZW#$AIOF1W7QALYN<-2_=/\#ML;;V;B
MJI)'*CZC.9>8$QJG@$>F+IZD,6 \R@"%C(0X3-*,.#'C7!AG:H:ES<MUQ*75
M.U?L$L3VH;T;@1LAAK>GQ:J$')07ZQP._NFQ#D9Y+9:L<ZIVD&6=O;R?83"G
MVZ:8?/-S)3XNGV51Q?'FL218)4P!',H$P(1QH"V"_EN<RB2)M65 3H;APCA3
M,PR5F'I;M9/0S0A<@M/."'@ :6 C4.-3B1A\M(#)V0)< <&3!;@TRJ@6X(JJ
MQQ;@VN5]LS^?\@U=E&>2(M]LC659EC7KXLUV\WFU^4^Y^4)S,4]3!&6J$D 2
MO0F!:<0!5I@#@3.%(>,HA$YIYK8#3\U&[)K%FV2^NI]=>:HEFV9VIM<.Y7RU
M->==3_3%;"-=$_XL)\72NQ@ ZJ'=C4KDH"UST @=L.TFT&('+W(3&,%])NNY
M0>4M+\]RV)%3\-S .,VV<[R_GPFKHC;?-G13IE)\,I-LFE!6!)51@A-$0P*R
MB&, :08!AH@ 3J2*D$ X=.OHT#G:U(Q5';3<21LTXKK9HVZ$[8R0-]P&MCP7
M(1N "]0*$T\FIGNL4>V*E=K'QL3NIAZIN7\LZ59;)ZF=*OU)YH\?\B5=\IPN
M=F,57U:+G+]4?^ZS=EB(*6.* 15A"F"(3&M"HCVB&$*24BDD%]8)NGVEF)K%
MV>D1U(J8;!]A\MW*O)]"2R_*SM,[!?>?F@OU5N]9Z[96H\W%P%;L=!K.X1U4
M"@3?Z__:I%]YG J'1-XQIF2D=-[]U.3UU*C=U!0[;7QE[]X*7&<.;^^'CY?)
M>ZO^!_F\-S^L]UGA^;;I^N]:$OURY7J+>5<4<E/LOZX$4A8F0H&$4@1@'"I
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M!W?78>Z30.Z(F+_<<=N!QTX;=P3D3,:XZQ-ZDM8?6,F2DU(( E.6Q"")LP1
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M"G:];=B>9%'1G9@?5HOE2@5"^X.&+3;0_WRDZW_**K^TV*'@ZI XSJ2M<S+
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MMMF[*XKM8_6EO?_U)/E&BG^L%OHQBWSS\I5NY%Q$"&81@0!%80H@81$@<<:
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M@G,QD=SU.?TLW]<J6KGGR8SB+,51ID!81D9PC &E80RP"C..%90I#ETLV_$
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M!\U)QY6>C^EY,I7_6.8JYZ:[2U6N8LC+3 :U?O[^- 2'*$%QG &>"*H]&X$
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ML8XU "?5-O9WCES>6?[Q#[USV_7AC>9$QG$BM;%!*M1;+8($H)G ($,\2J#
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M]](*EDYWLOL)X[F/5IH<N(MV=[C7%[]?;K1Y?O^K3*DH(Q%5:$+_,H%92"A
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M9>T];5;/###JUO*R@L<;P8XKIYJ&O6O4^'&Y6>MM9\XK.MDL%FD&];8/4L@
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M1QRI"&21_@-&$NGE(Q1 KQT$PDS23#(G"FSKH:>V(+3I.&K9R]/M9>&Z"#C
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MU\O35XM,/K0H0@K48'R@2#TG!<Z3(UU8MC((J6-I@9$'B=@),O890::=R+M
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M+_]V7B%A?19"<H3(1*Q=410Y=XXVIM4,BXR2I]C:4#V-Q'%:%@T'NR$UU $
MWR_Q6YCF7WY\JUXK[:]WZR^XO";&2?(4B@0A08I-*VIB+BCD$+B5G$7ATX/-
M5?<!W0YDC=,!:3B@M=;$B."J0='D]\6:(KZ$9*EK3T%O0BX^!@@Q$^E&4W";
M24A2<BFUB8S?K,J^'<+=\;GC=#IJCX)#1=:!*;D.59:53H:\QYQU >6X@"A#
M[2:)/$@>*?QH'6P^W3PTOZ8>\!S:6[K[0V.Q#K,FT'B[F'_^A,NOO\Z_XVI=
MH]/5Q+/,?>$,=-8("H4'5T@V+B6#WB696>LX_0XR>G!7FD1<AXJX P/R@0A?
M3M,:-T[^I"2F>"3S9ZQ11'U]BE1WBXP^NU"[ YK6 +E.00\>1A-L'"#8#F!Q
M_@SE-7ZK>:Q),)P\'?)_G"MD^TI]@:*UI8C/9^^U)R8>:ARP5QKS.@D].!U-
M@'&(:#M QOOEXALNUZ?O9X%.V7FN>8%OU?3]CNM)9B6EY"V0#!@H'S)4]Q@X
M+T$G.B.+>^@F>K^HY7YZ>O!'FF"FF= [ - [XB34YTIO,:SP0YW:]*[\0=%7
M%=<D!J*X#E[*%('46L ,]']5.](6+;1@X<'*VWT0]"!!X_1L' !"[<3> X8N
MP_3?%_-T'JE++:1- <BM]V1)-7UE60+);##%J!Q#ZT/J3D+&:=HX!&8.%G,'
M6-G2/[%&5PD(J 7%1+5@4",VR-%F%4361K8V+-N5QVG&.-C]TI,$V4,8/ UQ
M.MNDB^G@W%00?UG,2.BK>HBN3R]$HW+!$A$A:1E!124)UKIV#"1G719OT3]4
M)+57;+PC;>,&S(/?;@^BH@XLSQ6^;F:EO#39UC2CY9ILJ.4&(C%%[*A(WC_S
M1K9VE.^G9MQ;RV&T?S_$#E%%!Z!ZD5)MF+QZ'TYKPOH\.<D9F6-79Y5F).&4
M8L C28@LM27+'#&YAQZ][G6\W4E)-V Z2,\WC[[#A=X'=)8GM.HM&4TP&&><
MCY!2[9'+/5EO4:VW)&_.F< D:UU/<2\QXQYVPP&H@>@[P- 5#BY#@@L1659W
M0B#IH'5DHD.L=Z42& 60%"S(Z,V Q]IM@KK!TE%.M@,5T@&ZKB<ISED[K2^&
MDTM<UO1$J9=X%')R]&"R\#PS7LR#7>8.SPI=D-+-\7:HLA],#^TG^0X =$5
M$\6*"=H%LJRU:U8L%+(Z&R!F*WGF9%E#Z]OP*\N/>Y%U;-/S)&%WD!5X0"*^
M>F^F9$!O&2CC!41'B*]S)@CNR:C8VI,^,/(?[-;K*"AJI(H.C,_[\W4W+&UK
M8XVWQBNC "UM"<60G$:E+' 3D]!D0X5O73QZ!QEC/X]HH^';Q7L'B;L#Q%QI
M:["EGWQ^&P1:2*$>X8D7<'1\0W$43'(17'IPZ.E>A>TW:!@[V3@(5@X2= =
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M\4$)HTA\0[P+? J)G9Q>>R+B]GO!P=33 ?JNM>!GCL0B4B($8!U\GC,$"B!
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MYW;O1MFX9K8;X ZHSBY@^AKC^DH#S^]A.JL9\#>+Y<<PPSLXU!)]SL2<]"*
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MKI-,O!. R97@?5 AMNZDOQ-AO;VA/Q("#U51![C;/5,Z<9LVK")#B;8^^,(
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MK3)T/C>("^02:_%G=3><(VY$*J!$22B$(2'JH[F %V1U:MWVA<+.7N!^>ND
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MXQ=\K0YW62 YX[ZU5;Y.P>$)> (>OB/$ASJ'9_OAEU5*SFI&X84 QI'X*R:
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M6+1;%O.S-]HB)EL;/R2K$RC!L+Y#S(#&\1BR*9&WOKI\G*JQ/>F&(-@ABC]
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M+RTC%FZ,TZIU+\F'*1KW(K\]E!K*?^SH^PY67N-J^GE>'W5/0A0DF*# &!]
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M#T/E"[_A&%UL4^-R>X5S?6G,%!.F!F+.UC$7SFI2J2SJ58XNRBB*^Y]M//[
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MZ\?&7%O@[P& \?/1VQ_4?V*XP/_[O_X_4$L#!!0    ( ))""5763"8^9 @
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MM]K>Q>V*&H@6Q"6>D8=$325G(U[TX=,^:$R!"8D"K@ C4)$0FLQ(EEB=<?
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M!-CGE!P"PB%1&RP$\!?)^7Q9\M\S >:[)9@EH3O=./K_?NY+$H2V!+H'DR4
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M &]V:60M,C R,C V,S N>'-D4$L! A0#%     @ DD()5=6!IL=2%P  %=D
M !4              ( !'I<" &]V:60M,C R,C V,S!?8V%L+GAM;%!+ 0(4
M Q0    ( ))""561D';L7DL  /P< P 5              "  :.N @!O=FED
M+3(P,C(P-C,P7V1E9BYX;6Q02P$"% ,4    " "20@E5026-&8DD 0!@>0$
M%               @ $T^@( ;W9I9"TR,#(R,#8S,%]G,2YJ<&=02P$"% ,4
M    " "20@E5X2MF7['+  !><0@ %0              @ 'O'@0 ;W9I9"TR
M,#(R,#8S,%]L86(N>&UL4$L! A0#%     @ DD()5;-?Q6:/=   U3D% !4
M             ( !T^H$ &]V:60M,C R,C V,S!?<')E+GAM;%!+ 0(4 Q0
M   ( ))""5763"8^9 @  "XI   8              "  95?!0!O=FED+3(P
M,C(P-C,P>&5X>#,Q,2YH=&U02P$"% ,4    " "20@E5[1SB1FL(  !3*0
M&               @ $O: 4 ;W9I9"TR,#(R,#8S,'AE>'@S,3(N:'1M4$L!
M A0#%     @ DD()54+QG&T_!0  'Q8  !@              ( !T' % &]V
L:60M,C R,C V,S!X97AX,S(Q+FAT;5!+!08     "@ * )X"  !%=@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
